<SEC-DOCUMENT>0001104659-23-125049.txt : 20231211
<SEC-HEADER>0001104659-23-125049.hdr.sgml : 20231211
<ACCEPTANCE-DATETIME>20231211172043
ACCESSION NUMBER:		0001104659-23-125049
CONFORMED SUBMISSION TYPE:	N-CSR
PUBLIC DOCUMENT COUNT:		29
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231211
DATE AS OF CHANGE:		20231211
EFFECTIVENESS DATE:		20231211

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			abrdn World Healthcare Fund
		CENTRAL INDEX KEY:			0001635977
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			PA
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		N-CSR
		SEC ACT:		1940 Act
		SEC FILE NUMBER:	811-23037
		FILM NUMBER:		231479020

	BUSINESS ADDRESS:	
		STREET 1:		1900 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		(617) 772-8515

	MAIL ADDRESS:	
		STREET 1:		1900 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tekla World Healthcare Fund
		DATE OF NAME CHANGE:	20150306
</SEC-HEADER>
<DOCUMENT>
<TYPE>N-CSR
<SEQUENCE>1
<FILENAME>tm2325133d1_ncsr.htm
<DESCRIPTION>N-CSR
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL-->
<!-- Assembled by CompSci Transform  (tm) - http://www.compsciresources.com - version 1.2 -->
<!-- Created: Mon Dec 11 21:59:24 UTC 2023 -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:ck0001635977="http://www.teklacap.com/20230930" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2023">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
  <title>Tekla World Healthcare Fund - 1635977 - 2023</title>
</head>
<body><!-- BannerFile="tm2325133d1_regite1ar25133-2.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2325133-1/tm2325133-1_ncsrseq1" -->
<div style="display:none">
<ix:header>
  <ix:hidden>
    <ix:footnote id="FN20231202141707772" xml:lang="en-US">If Common Shares are sold to or through underwriters, a prospectus or prospectus supplement will set forth any applicable sales load and the estimated offering expenses borne by the Fund.</ix:footnote>
    <ix:footnote id="FN20231202141718378" xml:lang="en-US">Offering expenses payable by the Fund will be deducted from the proceeds, before expenses, to the Fund.</ix:footnote>
    <ix:footnote id="FN20231202141728748" xml:lang="en-US">The expenses of administering the Fund's Dividend Reinvestment and Stock Purchase Plan are included in "Other Expenses." You will pay brokerage charges if you direct your broker or the plan agent to sell your Shares that you acquired pursuant to the Fund's Dividend Reinvestment and Stock Purchase Plan. You may also pay a pro rata share of brokerage commissions incurred in connection with open-market purchases pursuant to the Fund's Dividend Reinvestment and Stock Purchase Plan. For more details about the Dividend Reinvestment and Stock Purchase Plan, see "Dividend Reinvestment and Stock Purchase Plan" in the Fund's Prospectus.</ix:footnote>
    <ix:footnote id="FN20231202141747132" xml:lang="en-US">The Advisory fee is charged as a percentage of the Fund's average daily Managed Assets, as opposed to net assets. If leverage is used, Managed Assets will be greater in amount than net assets, because Managed Assets includes borrowings for investment purposes.</ix:footnote>
    <ix:footnote id="FN20231202141759866" xml:lang="en-US">The percentage in the table is based on total borrowings of $120,000,000 (the balance outstanding under the Fund's Credit Facility as of September 30, 2023, representing approximately 21.2% of the Fund's Managed Assets) and an average interest rate during the fiscal year ended September 30, 2023, of 5.77%. There can be no assurances that the Fund will be able to obtain such level of borrowing (or to maintain its current level of borrowing), that the terms under which the Fund borrows will not change, or that the Fund's use of leverage will be profitable. The Fund currently intends during the next twelve months to maintain a similar proportionate amount of borrowings but may increase such amount to 33 1/3% of the average daily value of the Fund's total assets.</ix:footnote>
    <ix:footnote id="FN20231202141817796" xml:lang="en-US">As of the close of business on October 27, 2023, the Adviser has entered into a written contract with the Fund to limit the total ordinary operating expenses of the Fund (excluding leverage costs, interest, taxes, brokerage commissions, acquired fund fees and expenses and any non-routine expenses) from exceeding 1.51% of the average daily net assets of the Fund on an annualized basis for twelve months (the "Expense Limitation Agreement").The Expense Limitation Agreement may not be terminated before October 27, 2025, without the approval of the Fund's trustees who are not "interested persons" of the Fund (as defined in the 1940 Act).The Fund may repay any such reimbursement from the Adviser, within three years of the reimbursement, provided that the following requirements are met: the reimbursements do not cause the Fund to exceed the lesser of the applicable expense limitation in the contract at the time the fees were limited or expenses are paid or
                    the applicable expense limitation in effect at the time the expenses are being recouped by the Adviser. Because interest expenses and investment related expenses are not subject to the reimbursement agreement, interest expenses and investment related expenses are included in the "Total annual expenses after expense reimbursement" line item.</ix:footnote>
    <ix:footnote id="FN20231202141602793" xml:lang="en-US">The examples above should not be considered representations of future expenses. Actual expenses may be higher or lower than those shown. The examples assume that all dividends and distributions are reinvested at net asset value. The Fund's actual rate of return may be greater or less than the hypothetical 5% return shown in the examples. For more complete descriptions of certain of the Fund's costs and expenses, see "Management of the Fund&#8212;Advisory Agreements" in the Fund's Prospectus.</ix:footnote>
    <ix:footnote id="FN20231202141541386" xml:lang="en-US">Notwithstanding this assumption, in actuality, these fees will be indirectly borne by all holders of Common Shares.</ix:footnote>
    <ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20221001to20230930" id="F20231202043944553_0" >false</ix:nonNumeric>
    <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20221001to20230930" id="F20231202043944554_1" >0001635977</ix:nonNumeric>
    <ix:footnote id="FN20231204153347876" xml:lang="en-US">The closing price at which the Fund's shares were traded on the exchange.</ix:footnote>
    <ix:footnote id="FN20231204153401745" xml:lang="en-US">Per-share dollar value of the Fund, calculated by dividing the total value of all the securities in its portfolio, plus any other assets and less liabilities, by the number of Fund shares outstanding.</ix:footnote>
    <ix:footnote id="FN20231202124019444" xml:lang="en-US">Beginning with the year ended September 30, 2023, the Fund's financial statements were audited by KPMG LLP. Previous years were audited by a different independent registered public accounting firm.</ix:footnote>
    <ix:footnote id="FN20231202132818615" xml:lang="en-US">Data presented are with respect to a short period of time and are not indicative of future performance.</ix:footnote>
    <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="C_20221001to20230930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2023Member" id="Fxbrl_20231202144904787_121" unitRef="USD_Per_Share" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="C_20211001to20220930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2022Member" id="Fxbrl_20231202144904787_221" unitRef="USD_Per_Share" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="C_20201001to20210930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2021Member" id="Fxbrl_20231202144904787_321" unitRef="USD_Per_Share" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="C_20191001to20200930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2020Member" id="Fxbrl_20231202144904787_421" unitRef="USD_Per_Share" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="C_20181001to20190930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2019Member" id="Fxbrl_20231202144904787_521" unitRef="USD_Per_Share" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="C_20171001to20180930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2018Member" id="Fxbrl_20231202144904787_621" unitRef="USD_Per_Share" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="C_20161001to20170930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2017Member" id="Fxbrl_20231202144904787_721" unitRef="USD_Per_Share" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="C_20151001to20160930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2016Member" id="Fxbrl_20231202144904787_821" unitRef="USD_Per_Share" xsi:nil="true"></ix:nonFraction>
    <ix:footnote id="FN20231202150552498" xml:lang="en-US">The asset coverage ratio for the Loan Facility is calculated by dividing net assets plus the amount of any borrowings for investment purposes by the amount of any senior securities, which includes the Loan Facility, and then multiplying by $1,000.</ix:footnote>
    <ix:footnote id="FN20231202150602254" xml:lang="en-US">Not applicable because the senior securities are not registered for public trading.</ix:footnote>
    </ix:hidden>
  <ix:references> <link:schemaRef xlink:type="simple" xlink:href="ck0001635977-20230930.xsd"/>
    </ix:references>
  <ix:resources>
    <xbrli:context id="C_20221001to20230930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977PortfolioMarketRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:PortfolioMarketRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleDoesNotIncludeSalesLoadMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001635977:ExampleDoesNotIncludeSalesLoadMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001635977:ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977SecurityMarketRiskDiscountToNetAssetValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:SecurityMarketRiskDiscountToNetAssetValueMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977EquitySecuritiesRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:EquitySecuritiesRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977ConvertibleSecuritiesRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:ConvertibleSecuritiesRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977SelectionRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:SelectionRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977ConcentrationInHealthcareIndustriesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:ConcentrationInHealthcareIndustriesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977PharmaceuticalSectorRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:PharmaceuticalSectorRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977BiotechnologyIndustryRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:BiotechnologyIndustryRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977ManagedCareSectorRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:ManagedCareSectorRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977LifeScienceAndToolsIndustryRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:LifeScienceAndToolsIndustryRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareTechnologySectorRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:HealthcareTechnologySectorRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareServicesSectorRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:HealthcareServicesSectorRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareSuppliesSectorRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:HealthcareSuppliesSectorRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareFacilitiesSectorRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:HealthcareFacilitiesSectorRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareEquipmentSectorRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:HealthcareEquipmentSectorRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareDistributorsSectorRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:HealthcareDistributorsSectorRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977RisksAssociatedWithRegulatoryAndPolicyChangesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:RisksAssociatedWithRegulatoryAndPolicyChangesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977ForeignSecuritiesRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:ForeignSecuritiesRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977ForwardContractRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:ForwardContractRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977DerivativesRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:DerivativesRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977RisksAssociatedWithFundsOptionStrategyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:RisksAssociatedWithFundsOptionStrategyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977InterestRatesRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:InterestRatesRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977ReitRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:ReitRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977CreditDefaultRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:CreditDefaultRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977NonInvestmentGradeSecuritiesRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:NonInvestmentGradeSecuritiesRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977CounterpartyRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:CounterpartyRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977RegulationAsCommodityPoolMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:RegulationAsCommodityPoolMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977LiquidityRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:LiquidityRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977EquityLinkedNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:EquityLinkedNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977PrivateInvestmentInPublicEquityRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:PrivateInvestmentInPublicEquityRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977VentureCapitalInvestmentsRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:VentureCapitalInvestmentsRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977ExchangeTradedFundsRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:ExchangeTradedFundsRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977LeverageRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:LeverageRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977RestrictedSecuritiesAndValuationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:RestrictedSecuritiesAndValuationRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977KeyPersonnelRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:KeyPersonnelRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977AntiTakeoverProvisionsRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:AntiTakeoverProvisionsRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977RelatedPartyTransactionsRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:RelatedPartyTransactionsRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977GovernmentInterventionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:GovernmentInterventionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977MarketDisruptionAndGeopoliticalRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:MarketDisruptionAndGeopoliticalRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977PotentialConflictsOfInterestRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:PotentialConflictsOfInterestRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_cefRiskAxis_ck0001635977SpecialPurposeAcquisitionCompanyRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:SpecialPurposeAcquisitionCompanyRiskMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20200930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20190930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2019-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20180930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2018-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211001to20220930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201001to20210930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20191001to20200930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20181001to20190930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201001to20201231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20210331">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210401to20210630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210701to20210930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211001to20211231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20220331">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220401to20220630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220701to20220930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20221231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230331">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230701to20230930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231124">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-11-24</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231124to20231124">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-24</xbrli:startDate>
        <xbrli:endDate>2023-11-24</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221001to20230930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2023Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2023Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211001to20220930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2022Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2022Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201001to20210930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2021Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2021Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20191001to20200930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2020Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20200930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2020Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20181001to20190930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2019Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20190930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2019Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2019-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20171001to20180930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2018Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20180930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2018Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2018-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20161001to20170930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2017Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20170930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2017Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2017-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20151001to20160930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2016Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20160930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2016Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2016-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="USD_Per_Share"><xbrli:divide>
      <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator>
      <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide>
      </xbrli:unit>
    <ix:relationship fromRefs="Fxbrl_20231202131712153" toRefs="FN20231202141707772"/>
    <ix:relationship fromRefs="Fxbrl_20231202131721229" toRefs="FN20231202141718378"/>
    <ix:relationship fromRefs="Fxbrl_20231202131724023" toRefs="FN20231202141728748"/>
    <ix:relationship fromRefs="Fxbrl_20231202131857489" toRefs="FN20231202141747132"/>
    <ix:relationship fromRefs="Fxbrl_20231202131859366" toRefs="FN20231202141759866"/>
    <ix:relationship fromRefs="Fxbrl_20231202131906133" toRefs="FN20231202141817796"/>
    <ix:relationship fromRefs="Fxbrl_20231202141040228" toRefs="FN20231202141602793"/>
    <ix:relationship fromRefs="Fxbrl_20231202141045406" toRefs="FN20231202141602793"/>
    <ix:relationship fromRefs="Fxbrl_20231202141048194" toRefs="FN20231202141602793"/>
    <ix:relationship fromRefs="Fxbrl_20231202141050909" toRefs="FN20231202141602793"/>
    <ix:relationship fromRefs="Fxbrl_20231202141100037" toRefs="FN20231202141541386"/>
    <ix:relationship fromRefs="Fxbrl_20231202141102284" toRefs="FN20231202141541386"/>
    <ix:relationship fromRefs="Fxbrl_20231202141104669" toRefs="FN20231202141541386"/>
    <ix:relationship fromRefs="Fxbrl_20231202141106886" toRefs="FN20231202141541386"/>
    <ix:relationship fromRefs="Fxbrl_20231202152128342" toRefs="FN20231204153347876"/>
    <ix:relationship fromRefs="Fxbrl_20231202152137130" toRefs="FN20231204153401745"/>
    <ix:relationship fromRefs="Fxbrl_20231202121140788" toRefs="FN20231202124019444"/>
    <ix:relationship fromRefs="Fxbrl_20231202122222386" toRefs="FN20231202124019444"/>
    <ix:relationship fromRefs="Fxbrl_20231202122420675" toRefs="FN20231202124019444"/>
    <ix:relationship fromRefs="Fxbrl_20231202122946590" toRefs="FN20231202124019444"/>
    <ix:relationship fromRefs="Fxbrl_20231202125337432" toRefs="FN20231202132818615"/>
    <ix:relationship fromRefs="Fxbrl_20231202131545225_323" toRefs="FN20231202132818615"/>
    <ix:relationship fromRefs="Fxbrl_20231202131545225_423" toRefs="FN20231202132818615"/>
    <ix:relationship fromRefs="Fxbrl_20231202131545225_523" toRefs="FN20231202132818615"/>
    <ix:relationship fromRefs="Fxbrl_20231202131545225_723" toRefs="FN20231202132818615"/>
    <ix:relationship fromRefs="Fxbrl_20231202131545225_823" toRefs="FN20231202132818615"/>
    <ix:relationship fromRefs="Fxbrl_20231202131545225_923" toRefs="FN20231202132818615"/>
    <ix:relationship fromRefs="Fxbrl_20231202131545225_1023" toRefs="FN20231202132818615"/>
    <ix:relationship fromRefs="Fxbrl_20231202131545225_1223" toRefs="FN20231202132818615"/>
    <ix:relationship fromRefs="Fxbrl_20231202131545225_1323" toRefs="FN20231202132818615"/>
    <ix:relationship fromRefs="Fxbrl_20231202131545225_1423" toRefs="FN20231202132818615"/>
    <ix:relationship fromRefs="Fxbrl_20231202131545225_1523" toRefs="FN20231202132818615"/>
    <ix:relationship fromRefs="Fxbrl_20231202144904787_117" toRefs="FN20231202150552498"/>
    <ix:relationship fromRefs="Fxbrl_20231202144904787_121" toRefs="FN20231202150602254"/>
    <ix:relationship fromRefs="Fxbrl_20231202144904787_221" toRefs="FN20231202150602254"/>
    <ix:relationship fromRefs="Fxbrl_20231202144904787_321" toRefs="FN20231202150602254"/>
    <ix:relationship fromRefs="Fxbrl_20231202144904787_421" toRefs="FN20231202150602254"/>
    <ix:relationship fromRefs="Fxbrl_20231202144904787_521" toRefs="FN20231202150602254"/>
    <ix:relationship fromRefs="Fxbrl_20231202144904787_621" toRefs="FN20231202150602254"/>
    <ix:relationship fromRefs="Fxbrl_20231202144904787_721" toRefs="FN20231202150602254"/>
    <ix:relationship fromRefs="Fxbrl_20231202144904787_821" toRefs="FN20231202150602254"/>
    </ix:resources>
  </ix:header></div>

<div>

<div style="display:none"></div>

<div >

<div style="margin:8pt 0pt 8pt 0pt">

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 13pt 0pt;text-align:left;vertical-align:bottom;width:305">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 13pt 0pt;text-align:left;vertical-align:bottom;width:100"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">OMB
        APPROVAL</span><br /><span style="font-size:9pt;font-family:Times New Roman, Times, serif">OMB Number: 3235-0570</span><br /><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Expires:
        September 30, 2025</span><br /><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Estimated average burden hours per
        response 7.8</span></td>
    <td colspan="1">&#160;</td> </tr>
  </table>

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:12pt;font-family:Times New Roman, Times, serif">UNITED STATES<br />SECURITIES
AND EXCHANGE COMMISSION<br />Washington, D.C. 20549</span></p>

<p style="margin:15pt 0pt 0pt 0pt;text-align:center"><span style="font-size:14pt;font-family:Arial, Helvetica"><strong>FORM <ix:nonNumeric id="Fxbrl_20231202101255345" name="dei:DocumentType" contextRef="C_20221001to20230930">N-CSR</ix:nonNumeric></strong></span></p>

<p style="margin:13pt 0pt 13pt 0pt;text-align:center"><span style="font-size:11pt;font-family:Times New Roman, Times, serif"><strong>CERTIFIED
SHAREHOLDER REPORT OF REGISTERED<br />MANAGEMENT INVESTMENT COMPANIES</strong></span></p>

<p style="margin:0pt 0pt 12pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Investment Company
Act file number 811-23037</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:14pt;font-family:Times New Roman, Times, serif"><ix:nonNumeric id="Fxbrl_20231202101303401" name="dei:EntityRegistrantName" contextRef="C_20221001to20230930">abrdn
World Healthcare Fund</ix:nonNumeric></span></p>

<p style="margin:0pt 0pt 12pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(Exact name
of registrant as specified in charter)</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:21">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:190">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">1900 Market Street, Suite 200,
        Philadelphia</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">13103</span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 12pt 0pt;text-align:left;vertical-align:bottom;width:21">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 12pt 0pt;text-align:left;vertical-align:bottom;width:190">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(Address of principal executive
        offices)</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 12pt 0pt;text-align:left;vertical-align:bottom;width:73">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(Zip code)</span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  </table>

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Sharon Ferrari,
abrdn Inc.,<br />1900 Market Street, Suite 200, Philadelphia, PA 19103</span></p>

<p style="margin:0pt 0pt 12pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(Name and
address of agent for service)</span></p>

<p style="margin:0pt 0pt 12pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Registrant's
telephone number, including area code: 1-800-522-5465</span></p>

<p style="margin:0pt 0pt 12pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Date of fiscal
year end: September 30</span></p>

<p style="margin:0pt 0pt 12pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Date of reporting
period: October 1, 2022 to <ix:nonNumeric id="Fxbrl_20231202161342701" name="dei:DocumentPeriodEndDate" contextRef="C_20221001to20230930" format="ixt:date-monthname-day-year-en">September
30, 2023</ix:nonNumeric></span></p> </div> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><strong>ITEM 1.
REPORTS TO STOCKHOLDERS.</strong></span></p>

<p style="margin:18pt 0pt 0pt 0pt;text-align:left"><img alt="j23251332_ab001.jpg" src="j23251332_ab001.jpg" /></p> </div> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<p style="margin:12pt 0pt 12pt 0pt"><img alt="j23251332_ac002.jpg" src="j23251332_ac002.jpg" /></p>

<p style="margin:12pt 0pt 12pt 0pt"><img alt="j23251332_ac003.jpg" src="j23251332_ac003.jpg" /></p>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:16pt;font-family:Times New Roman, Times, serif"><strong>abrdn
World Healthcare Fund (THW)</strong></span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:12pt;font-family:Times New Roman, Times, serif"><strong>(Formerly
Tekla World Healthcare Fund)</strong></span></p>

<p style="margin:5.60001pt 0pt 0pt 0pt;text-align:left"><span style="font-size:12pt;font-family:Times New Roman, Times, serif"><strong>Annual
Report</strong></span><br /><span style="font-size:12pt;font-family:Times New Roman, Times, serif">September 30, 2023</span></p> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:18pt;font-family:Times New Roman, Times, serif"><strong>abrdn.com</strong></span></p>
</div> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 6pt 0pt;text-align:left"><span style="font-size:19pt;font-family:Arial, Helvetica">abrdn World Healthcare Fund</span></p>
</div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Distribution policy:</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
The Fund has implemented a managed distribution policy (the Policy) that provides for monthly distributions at a rate set by the Board
of Trustees. Under the current Policy, the Fund intends to make monthly distributions at a rate of $0.1167 per share to shareholders of
record. The Policy would result in a return of capital to shareholders, if the amount of the distribution exceeds the Fund's net investment
income and realized capital gains. A return of capital may occur, for example, when some or all of the money that you invested in the
Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund's investment performance and should not
be confused with "yield" or "income."</span></p>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The amounts and sources of
distributions reported in the Fund's notices pursuant to Section 19(a) of the Investment Company Act of 1940 are only estimates and are
not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon
the Fund's investment experience during its fiscal year and may be subject to changes based on tax regulations. The Fund will send you
a Form 1099-DIV for the calendar year that tells you how to report distributions for federal income tax purposes.</span></p>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">During the last fiscal year
ended September 30, 2023, the Fund made monthly distributions totaling $1.40 per share, which were characterized as $0.82 per share of
net realized long-term capital gains and $0.58 per share of return of capital. Final determination of the tax character of the distributions
paid by the Fund in 2023 will be reported to shareholders in January 2024.</span></p>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">You should not draw any conclusions
about the Fund's investment performance from the amount of distributions pursuant to the Policy or from the terms of the Policy. The Policy
has been established by the Trustees and may be changed or terminated by them without shareholder approval. The Trustees regularly review
the Policy and the frequency and rate of distributions considering the purpose and effect of the Policy, the financial market environment,
and the Fund's income, capital gains and capital available to pay distributions. The suspension or termination of the Policy could have
the effect of creating a trading discount or widening an existing trading discount. At this time there are no reasonably foreseeable circumstances
that might cause the Trustees to terminate the Policy.</span></p>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Consider these risks
before investing:</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> As with any investment company that invests
in equity securities, the Fund is subject to market risk&#8212;the possibility that the prices of equity securities will decline over
short or extended periods of time. As a result, the value of an investment in the Fund's shares will fluctuate with the market generally
and market sectors in particular. You could lose money over short or long periods of time. Political and economic news can influence market-wide
trends and can cause disruptions in the U.S. or world financial markets. Other factors may be ignored by the market as a whole but may
cause movements in the price of one company's stock or the stock of companies in one or more industries. All of these factors may have
a greater impact on initial public offerings and emerging company shares. Different types of equity securities tend to shift into and
out of favor with investors, depending on market and economic conditions. The performance of funds that invest in equity securities of
healthcare companies may at times be better or worse than the performance of funds that focus on other types of securities or that have
a broader investment style.</span></p> </div> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 6pt 0pt;text-align:left"><span style="font-size:19pt;font-family:Arial, Helvetica">Welcome to abrdn</span></p>
</div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Dear Shareholder,</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Effective close of regular
business on October 27, 2023, abrdn, Inc. is your new investment adviser. abrdn Inc. assumed responsibility for the management of four
former Tekla Capital Management, LLC closed-end funds: abrdn Healthcare Investors (Ticker: HQH), formerly Tekla Healthcare Investors,
abrdn Life Sciences Investors (Ticker: HQL), formerly Tekla Life Sciences Investors, abrdn Healthcare Opportunities Fund (Ticker: THQ),
formerly Tekla Healthcare Opportunities Fund and abrdn World Healthcare Fund (Ticker: THW), formerly Tekla World Healthcare Fund.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Two existing trustees of the
Funds, Jeffrey Bailey and Kathleen Goetz, were joined by four newly elected trustees of the Funds, who were approved by shareholders of
HQL on October 3, 2023, by shareholders of HQH on October 13, 2023, and by shareholders of THQ and THW on October 25, 2023, with each
approval being contingent upon abrdn's appointment as adviser. The new trustees are Stephen Bird, Rose DiMartino, C. William Maher, and
Todd Reit, who will serve as Chair of the Boards.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Upon the close of business
on October 27, 2023, nearly all of the investment team responsible for the management of the Funds joined abrdn. The Funds will continue
to be managed in accordance with their existing investment objectives and strategies by the same team of Boston-based investment professionals
pursuing the same investment philosophy and employing the same investment process that has served the Funds well through the years. abrdn
is one of the largest closed-end fund managers globally and is dedicated to creating long-term value for our clients.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">As of June 30, 2023, we managed
over $602 billion in assets on behalf of institutional and retail clients worldwide. We believe that our global footprint ensures that
we are always close to our clients and the challenges they face. Should you have any questions about the recent change in management of
the funds, or our U.S. registered fund products, please don't hesitate to contact us. We look forward to serving you.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>An introduction to
abrdn</strong></span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">We invest to help our clients
create more. More opportunity. More potential. More impact. We offer investment expertise across all key asset classes and markets so
that our clients can capture investment potential wherever it arises. By combining market and economic insight with technology and diverse
perspectives, we look for optimal ways to help investors navigate the future and reach their financial goals. As a leading global asset
manager, abrdn is dedicated to creating long-term value for our clients. Closed-end funds have been a longstanding and important part
of our firm's business, and we believe in their long-term value in helping to meet investors' needs. Visit our Investor Center to learn
more about abrdn and our entire suite of 16 U.S. closed-end funds across a variety of asset classes.</span></p> </div> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Shareholder Information</strong></span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">As part of abrdn's commitment
to shareholders, we invite you to visit the Funds on the web at www.abrdnhqh.com, www.abrdnhql.com, www.abrdnthq.com and www.abrdnthw.com.
Here, you can view monthly fact sheets, quarterly commentary, distribution and performance information, and other Fund literature.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Contact us:</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">&#8226; Visit: https://www.abrdn.com/en-us/cefinvestorcenter</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">&#8226; Email: Investor.Relations@abrdn.com;
or</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">&#8226; Call: 1-800-522-5465
(toll free in the U.S.).</span></p>

<p style="margin:9pt 0pt 6pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Yours sincerely,</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><img alt="j23251332_ac004.jpg" src="j23251332_ac004.jpg" /></p>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Christian Pittard<br />President</span></p>
</div> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 6pt 0pt;text-align:center"><span style="font-size:19pt;font-family:Arial, Helvetica">Letter to Shareholders</span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>
(Unaudited)</i></span></p> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Dear Shareholders,</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare continues to be
a unique and differentiated sector of the economy. The sector contains relatively non-cyclical defensive components, in the pharmaceutical
and payor subsectors, for example. Healthcare also includes highly innovative, capital intensive subsectors like biotechnology that can
perform in line with or in contrast to the more defensive market sectors. The overall consequence is that the healthcare sector, as a
whole, can perform better or worse than the broad market, depending on a combination of fundamentals and macroeconomic conditions.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare materially outperformed
the broad market in 2022 at a time when interest rates moved much higher quickly and there were heightened recession fears. Outperformance
was presumably due to the defensive nature of such healthcare subsectors as Pharmaceuticals and Managed Care. So far in 2023, this trend
has reversed. That is, the broad market has materially outperformed healthcare. Part of that outperformance was undoubtedly the result
of the AI "craze" earlier in the year, but we believe that a lessening of inflation and a slowing in the rate of interest rate increase,
conditions which can favor such sectors as tech, were at least as helpful to broad market advancement.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">It is important to note that
our faith in the long-term future of healthcare remains strong. We continue to believe in the underlying demographics. The population
is aging. People spend more on healthcare as they get older. And innovation moves ahead unbowed. We believe that the combination of these
things will 1) continue to help us address unmet medical needs for patients, 2) reduce side effects and extend the lives of patients and
3) reward healthcare investors.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">There can be no better example
of this than the recent development of the so-called GLP-1 class of incretin drugs being used to treat diabetes and obesity. Results in
this area have been truly remarkable. Advancement in A1c control and weight loss for diabetics as well as profound weight loss for individuals
battling obesity have been, in our experience, without precedent. Who would have thought, just a few years ago, that a weekly dose of
a drug could, over just months, produce weight loss of 20% of body weight. And this class of drugs has the potential to have much broader
impact. Initial studies suggest that, simultaneous with weight loss, incretin therapy could provide cardiovascular and renal benefit.
Moreover, initial studies suggest that these agents could have potential impact in a wide array of diseases, including but not limited
to obstructive sleep apnea, chronic obstructive pulmonary disease (COPD), cancer and CNS diseases like Alzheimer's. There are sure to
be bumps in the road during clinical and other evaluation of GLP-1 drugs (which may or may not be represented in your Fund's portfolio
at this or other times), but their potential is impressive. Some Wall Street analysts are projecting market size for this class of drugs
in excess of $100B. Sales at this level would likely make this class of drugs among the most successful (and arguably the most effective)
drugs of all time.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 1</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Separately, we note that Tekla
has announced that its investment capabilities and management of your Fund have been acquired by abrdn Inc., a prominent U.K. based asset
manager. We think this is a win-win-win situation. We believe that Tekla has a highly competent healthcare investment capability; the
Company has managed your Fund since its inception. Nearly the entire Tekla team will be joining abrdn. This firm is one of the largest
and most well-known closed-end fund (CEF) sponsors in the world and possesses premier CEF sponsor capabilities. We expect that with the
addition of the Tekla Funds (which have been re-named as abrdn Funds), abrdn will become the third largest CEF sponsor worldwide. We look
forward to working with abrdn and believe that the combination of the capabilities of these two fine firms will significantly benefit
shareholders. I can tell you personally that it has been both a rewarding experience and a privilege to serve your Fund.</span></p>

<p style="margin:9pt 0pt 1pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Be well,</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Daniel R. Omstead<br />Vice
President and Portfolio Manager</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">2 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:11pt;font-family:Arial, Helvetica"><strong>Fund Essentials
</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>(Unaudited)</i></span></p> <ix:nonNumeric id="Fxbrl_20231212021220033" name="cef:InvestmentObjectivesAndPracticesTextBlock" contextRef="C_20221001to20230930" continuedAt="F20231212021409974" escape="true">

<div>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Objective of the Fund</strong></span></p>

<p style="margin:2pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">The Fund's investment objective is to seek
current income and long-term capital appreciation.</span></p> </div> </ix:nonNumeric> </div>

<div style="width:48%;float:left;margin-top:10pt;margin-right:3%">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Description of the
Fund</strong></span></p>

<p style="margin:2pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">abrdn World Healthcare Fund ("THW") is a diversified
closed-end fund traded on the New York Stock Exchange under the ticker THW. THW employs a versatile growth and income investment strategy
investing across all healthcare subsectors and across a company's full capital structure. THW invests at least 40% of AUM in ex-U.S. companies
or those with substantial ex-U.S. revenues.</span></p>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Investment Philosophy</strong></span></p>

<p style="margin:2pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">The Investment Adviser to the Fund, believes
that:</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8226;&#160;&#160;Aging demographics
and adoption of new medical products and services may provide long-term tailwinds for healthcare companies</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8226;&#160;&#160;Opportunities
outside the United States may be underappreciated and timely</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8226;&#160;&#160;Investment
opportunity spans the globe including biotechnology, healthcare technology, life sciences and medical devices</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8226;&#160;&#160;The potential
for value creation may exist in companies both inside and outside the United States that are commercializing novel technologies</span></p>
</div>

<div style="width:48%;float:left;margin-top:10pt;margin-right:0%">

<p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Fund Overview and
Characteristics </strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">as of 9/30/23</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Market Price<sup>1</sup></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255)"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20231202152128342" name="us-gaap:SharePrice" contextRef="C_20230930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">11.72</ix:nonFraction></strong></span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">NAV<sup>2</sup></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20231202152137130" name="us-gaap:NetAssetValuePerShare" contextRef="C_20230930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">11.73</ix:nonFraction></strong></span></td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Premium/(Discount)</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255)"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>-<ix:nonFraction id="Fxbrl_20231202152140915" name="cef:LatestPremiumDiscountToNavPercent" contextRef="C_20221001to20230930" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">0.09</ix:nonFraction></strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>%</strong></span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Average 30 Day Volume</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>131,452</strong></span></td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net Assets</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255)"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>447,117,624</strong></span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Managed Assets</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>567,117,624</strong></span></td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Leverage Outstanding</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255)"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>120,000,000</strong></span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Total Leverage Ratio<sup>3</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>21.16</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>%</strong></span></td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Ticker</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:99;background-color:#cceeff">
        <p style="margin:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>THW</strong></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">NAV Ticker</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:99">
        <p style="margin:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>XTHWX</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:85;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">Commencement
        of</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">Operations Date</span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:99;background-color:#cceeff">
        <p style="margin:0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>6/30/15</strong></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:85"><span style="font-size:8pt;font-family:Arial, Helvetica">Fiscal
        Year to Date</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">Distributions per Share</span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20231202152157339" name="cef:AnnualDividendPayment" contextRef="C_20221001to20230930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">1.40</ix:nonFraction></strong></span></td>
    <td colspan="1">&#160;</td> </tr>
  </table>

<p style="margin:4pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><i><sup>1</sup></i><i>
The closing price at which the Fund's shares were traded on the exchange.</i></span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><i><sup>2</sup></i><i>
Per-share dollar value of the Fund, calculated by dividing the total value of all the securities in its portfolio, plus any other assets
and less liabilities, by the number of Fund shares outstanding.</i></span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><i><sup>3</sup></i><i>
As a percentage of managed assets</i></span></p> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Holdings of the Fund
</strong></span><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><i>(Data is based on net assets)</i></span></p>
</div>

<div style="width:48%;float:left;margin-top:10pt;margin-right:3%">

<p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Asset Allocation as of 9/30/23</span></p>

<p style="margin:0pt 0pt 0pt 0pt"><img alt="j23251332_ba007.jpg" src="j23251332_ba007.jpg" /></p> </div>

<div style="width:48%;float:left;margin-top:10pt;margin-right:0%">

<p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sector Diversification as of 9/30/23</span></p>

<p style="margin:0pt 0pt 0pt 0pt"><img alt="j23251332_ba008.jpg" src="j23251332_ba008.jpg" /></p> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:7pt;font-family:Times New Roman, Times, serif"><i>This data
is subject to change on a daily basis.</i></span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 3</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />
</div>

<div >

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:11pt;font-family:Arial, Helvetica"><strong>Largest Holdings by
Issuer </strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>(Unaudited)</i></span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>(Excludes Short-Term
Investments)</strong></span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>As of September
30, 2023</i></span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:11pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:225"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Issuer</strong></span><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><i>
        &#8211; Sector</i></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:11pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:76"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>%
        of Net</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Assets</strong></span></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Johnson
        &#38; Johnson</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">7.9</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>UnitedHealth
        Group, Inc.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Health Care Providers &#38;
        Services</i></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">7.7</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Eli
        Lilly &#38; Co.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">6.3</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>AstraZeneca
        plc ADR</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">4.7</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Pfizer,
        Inc.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">4.4</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Thermo
        Fisher Scientific, Inc.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Life Sciences
        Tools &#38; Services</i></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">4.3</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Roche
        Holding AG ADR</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">4.3</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Novo
        Nordisk A/S ADR</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">4.0</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Merck
        &#38; Co., Inc.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.7</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Abbott
        Laboratories</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Health Care Equipment &#38;
        Supplies</i></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.6</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>AbbVie,
        Inc.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Biotechnology</i></span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.6</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Amgen,
        Inc.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Biotechnology</i></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.4</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Danaher
        Corp.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Medical Devices and Diagnostics</i></span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.0</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Elevance
        Health, Inc.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Health Care Providers &#38;
        Services</i></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.0</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Sanofi
        ADR</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">2.5</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Boston
        Scientific Corp.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Medical Devices and
        Diagnostics</i></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">2.0</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Humana,
        Inc.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Health Care Providers &#38; Services</i></span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.9</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Bayer
        AG</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Pharmaceuticals</i></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.9</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>CSL
        Ltd.</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Biotechnology</i></span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.8</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225"><span style="font-size:9pt;font-family:Arial, Helvetica"><strong>Lonza
        Group AG</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> &#8211; Life Sciences Tools &#38; Services</i></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.7</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  </table>

<p style="margin:0pt 0pt 0pt 0pt;height:18pt">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:7pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:169"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>COUNTRY
        DIVERSIFICATION</strong></span><br /><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><i>As of September 30, 2023</i></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:7pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:76"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>%
        of Net</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Assets</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:7pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:96"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>%
        of Managed</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Assets</strong></span></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:169;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">United States</span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">68.2</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:65;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">53.7</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:169">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">United States (with substantial ex-U.S revenue)</span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">29.7</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:65">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">23.4</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:169;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">Switzerland</span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">7.6</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:65;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">6.0</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:169">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">United Kingdom</span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">5.7</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:65">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">4.5</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:169;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">Denmark</span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">4.4</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:65;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.5</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:169">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">France</span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.1</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:65">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">2.5</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:169;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">Germany</span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.8</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:65;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.4</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:169">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">Australia</span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.8</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:65">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.4</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:169;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">Japan</span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.7</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:65;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.4</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:169">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">Netherlands</span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.5</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:65">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.2</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:169;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">Ireland</span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">0.8</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:65;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">0.6</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:169">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">China</span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">0.2</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:65">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">0.2</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:169;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">Israel</span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">0.2</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:65;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">0.1</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:169">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">Canada</span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:45">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">0.0</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:65">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">0.0</span></p></td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:23">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">%</span></p></td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  </table></div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">4 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p><hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:11pt;font-family:Arial, Helvetica"><strong>Fund Performance
</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>(Unaudited)</i></span></p>

<p style="margin:12pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Fund and Benchmark
Performance and Other Influencing Factors</strong></span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">THW is a closed-end fund which
invests predominantly in healthcare companies. Subject to regular consideration, the Trustees of THW have instituted a policy of making
monthly distributions to shareholders.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund invests in equity
and debt of healthcare companies. The Fund seeks to benefit from the earnings growth of the healthcare industry while capturing income.
Income is derived from multiple sources including equity dividends, fixed income coupons, real estate investment trust distributions,
convertible securities coupons and selective equity covered call writing premiums. In order to accomplish its objectives, THW often holds
a majority of its assets in equities. Allocation of assets to various healthcare sectors can vary significantly, as can the percentage
of the portfolio which is overwritten. Under normal market conditions, the Fund expects to invest at least 40 percent of its managed assets
in companies organized or located outside of the U.S. or companies that do a substantial amount of business outside the U.S. (Foreign
Issuers).</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund may invest up to
20 percent of managed assets, measured at the time of investment, in non-convertible debt of healthcare companies. It may also invest
up to 20 percent of managed assets in healthcare REITs. The Fund may also hold up to 30 percent of managed assets in convertible securities
and may invest a portion of its assets in restricted securities. In order to generate additional "current" income, THW often sells (or
writes) calls against a material portion of its equity assets. The portion of equity assets overwritten can vary, but usually represents
less than 20 percent of managed assets. At times, the overwritten portion of assets is materially less than 20 percent of managed assets.
The use of covered calls is intended to produce "current" income but may limit upside in bullish markets. The Fund may also use leverage
to enhance yield. The Fund may incur leverage up to 20 percent of managed assets at the time of borrowing. "Managed Assets" means the
total assets of the Fund (including any assets attributable to borrowings for investment purposes) minus the sum of the Fund's accrued
liabilities (other than liabilities representing borrowings for investment purposes).</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">There is no commonly published
index which matches the investment strategy of THW. With respect to the Fund's equity investments, THW often holds 10-25% of its assets
in biotechnology. By contrast, the S&#38;P Global 1200 Healthcare Index<sup>&#174;</sup>* (SGH) consists of approximately 110 global companies
representing most or all of the healthcare subsectors in which THW typically invests; biotechnology often represents up to 20% of this
index. By contrast, the NASDAQ Biotechnology Index<sup>&#174;</sup>* (NBI) which contains approximately 260 constituents, is much more
narrowly constructed. The vast majority of this index is comprised of biotechnology, pharmaceutical and life science tools companies.
In recent years, biotechnology has often represented 72-82% of the NBI. Neither the SGH nor NBI indices contain any material amount of
pre-public company assets.</span></p></div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 5</span></p><hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The S&#38;P 500<sup>&#174;</sup>
Health Care Corporate Bond Index* (SP5HCBIT) measures the performance of U.S. corporate debt issued by constituents in the healthcare
sector of the SPX. This index is generally reflective of the debt assets in which THW invests though the Fund invests in the SPX index
debt components as well as those of smaller capitalization companies.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The S&#38;P Composite 1500<sup>&#174;</sup>
Health Care REITs Index* (S15HCRT) is comprised of U.S. publicly traded REITs in the healthcare sector. This index is generally reflective
of the REITs in which THW invests.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Given the circumstances, we
present both NAV and stock price returns for the Fund in comparison to several commonly published indices. We note that THW is a dynamically
configured multi-asset class global healthcare growth and income fund. There is no readily available index comprised of similar characteristics
to THW and to which THW can directly be compared. Therefore, we provide returns for a number of indices representing the major components
of THW's assets. Having said this, we note that there are no readily available indices representing the covered call strategy employed
by THW or the restricted security components of THW.</span></p>

<p style="margin:12pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Fund Performance
for the Period Ended September 30, 2023</strong></span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">For the 12-month period ended
September 30, 2023, the return on the Fund's net asset value was up 8.1% and market value was up 1.7%, including reinvestment of dividends
and distributions. Over the same period the SGH was up 11.2%, the SP5HCBIT was up 3.0%, and the S15HCRT was up 6.5%, including reinvestment
of dividends.</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:46">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Period</strong></span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:71">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>THW NAV %</strong></span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:72">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>THW MKT %</strong></span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:51">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>NBI %</strong></span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:54">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>SGH %</strong></span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>SPX %</strong></span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:72">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>SP5HCBIT %</strong></span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:69">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>S15HCRT %</strong></span></p></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:46;background-color:#cceeff"><span style="font-size:9pt;font-family:Arial, Helvetica">6
        </span><span style="font-size:9pt;font-family:Arial, Helvetica">month</span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:55;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">-1.86</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:56;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">-9.80</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">-3.75</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:38;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">-0.09</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:36;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">5.18</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:56;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">-4.25</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">2.90</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:46"><span style="font-size:9pt;font-family:Arial, Helvetica">1
        </span><span style="font-size:9pt;font-family:Arial, Helvetica">year</span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:55">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">8.09</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:56">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.70</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">5.79</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:38">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">11.15</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:36">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">21.59</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:56">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">2.96</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">6.52</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:46;background-color:#cceeff"><span style="font-size:9pt;font-family:Arial, Helvetica">5
        </span><span style="font-size:9pt;font-family:Arial, Helvetica">year</span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:55;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">5.18</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:56;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">6.90</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.31</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:38;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">7.60</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:36;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">9.90</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:56;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">1.11</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">0.79</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:46">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Arial, Helvetica">inception</span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:55">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">4.22</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:56">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">3.60</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">0.77</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:38">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">7.22</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:36">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">11.04</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:56">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">2.05</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Arial, Helvetica">2.45</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  </table>

<p style="margin:3pt 0pt 9pt 0pt"><span style="font-size:6pt;font-family:Times New Roman, Times, serif"><i>Inception date June 26, 2015</i></span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><img alt="j23251332_ba009.jpg" src="j23251332_ba009.jpg" /></p></div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">6 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p><hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Change in the value
of a $10,000 investment</strong></span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Cumulative total return from
6/26/2015 to 9/30/2023</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><img alt="j23251332_ba010.jpg" src="j23251332_ba010.jpg" /></p>

<p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><i>All performance over one-year
has been annualized. Performance data quoted represents past performance, which is no guarantee of future results, and current performance
may be lower or higher than the figures shown. The NAV total return takes into account the Fund's total annual expenses and does not reflect
transaction charges. If transaction charges were reflected, NAV total return would be reduced. All distributions are assumed to be reinvested
either in accordance with the dividend reinvestment plan (DRIP) for market price returns or NAV for NAV returns. Until the DRIP price
is available from the Plan Agent, the market price returns reflect the reinvestment at the closing market price on the last business day
of the month. Once the DRIP is available around mid-month, the market price returns are updated to reflect reinvestment at the DRIP price.
The graph and table do not reflect the deduction of taxes a shareholder would pay on fund distributions or the sale of fund shares.</i></span></p>

<p style="margin:12pt 0pt 0pt 0pt;text-align:left"><span style="font-size:11pt;font-family:Arial, Helvetica"><strong>Portfolio Management
Commentary</strong></span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's performance benefited
from company stock selection as well as the presence of leverage. Company selection was strongest in biotechnology stocks. Company selection
was also strong in equipment stocks led by a Fund investment in Dexcom, Inc. (DXCM), a leading maker of continuous glucose monitors or
CGMs for diabetes patients. The Fund had positive performance contribution from its use of leverage due to positive returns for equities,
bonds and REITs in the period.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Fund performance was negatively
affected by its allocation to pharmaceuticals and foreign currency hedging. A low allocation to pharmaceuticals detracted from performance
as this defensive industry was up 20% in the period. Company selection in healthcare REITs negatively impacted performance mainly due
to the Fund's small position in Welltower Inc. (WELL), the largest company in the space, which outperformed its smaller peers. The Fund
also saw negative performance from its hedging of foreign currency exposure due to strength in the Euro vs the U.S. Dollar in the period.</span></p></div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 7</span></p><hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:11pt;font-family:Arial, Helvetica"><strong>Portfolio Highlights
as of September 30, 2023</strong></span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Among other investments, abrdn
World Healthcare Fund's performance benefitted in the past year by the following:</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>CVS Health
Corp. (CVS)</i></span><span style="font-size:10pt;font-family:Arial, Helvetica"> is a large vertically integrated managed care organization
and is one of the largest retail pharmacies and pharmacy benefit managers (PBMs) in the U.S. Stock underperformance has come on the heels
of growing PBM political scrutiny and ongoing retail pharmacy reimbursement pressure. Additionally, the loss of a large PBM customer and
step down in the company's Medicare Advantage (MA) Star ratings represent a headwind to the Company's 2024 growth outlook. The Fund benefited
from owning a relatively small position in this stock.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Dexcom, Inc.
(DXCM)</i></span><span style="font-size:10pt;font-family:Arial, Helvetica"> is a leading global continuous glucose monitor (CGM) manufacturer.
Its latest model, the G7, allows diabetes patients to better maintain glucose levels in a healthy range and lower risk of complications.
DXCM rose in the period most notably due to expanded Medicare coverage of Dexcom's device for more type 2 diabetes patients in April 2023.
The Fund benefited from its ownership of Dexcom.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Horizon Therapeutics
plc (HZNP)</i></span><span style="font-size:10pt;font-family:Arial, Helvetica"> is a specialty pharmaceuticals company transitioning to
a focused orphan disease business model. With 12 marketed therapies, including first-in-class Tepezza for thyroid eye disease, and a pipeline
of over 20 programs in development, Horizon was recently acquired by Amgen for $28 billion. The Fund benefited during the period from
its ownership of Horizon which had a strong positive return following Amgen's acquisition offer in December 2022.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Among other examples, abrdn
World Healthcare Fund's performance was negatively impacted by the following investments:</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Roche Holding
AG (ROG SW)</i></span><span style="font-size:10pt;font-family:Arial, Helvetica"> is a leading global developer of pharmaceuticals and
diagnostics that primarily serve cancer patients. The Company's stock price declined in the six-month period and lagged its peers while
the Fund held a position in the stock. Weakness was partly due to a sales decline of its cancer fighting therapies Avastin and Herceptin
which face generic competition. In addition, an experimental treatment in Roche's pipeline for Alzheimer's proved unsuccessful.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Illumina,
Inc. (ILMN)</i></span><span style="font-size:10pt;font-family:Arial, Helvetica"> is the leading global provider of genomic sequencing
equipment. During the period, Illumina's stock price declined mainly due to two factors. First, sales revenue missed company forecasts
due to faltering demand from China as well as lower domestic biotech which has negatively impacted the life sciences tools and diagnostics
space this past year. Second, the Company acquired Grail, a private liquid biopsy cancer diagnostic company it founded, without approval
from the Federal Trade Commission and at what appears to be an expensive valuation. Fund performance during the period was negatively
affected by its ownership of ILMN.</span></p></div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">8 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p><hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Guardant Health,
Inc. (GH)</i></span><span style="font-size:10pt;font-family:Arial, Helvetica"> is a leading precision oncology company focused on using
liquid biopsy for cancer detection and diagnostics through its proprietary blood tests, vast data sets, and advanced analytics. Despite
this, the stock performed poorly during the period due to disappointing results from its colorectal cancer or CRC screening product. While
the accuracy of the Guardant CRC screening test is not best in class, it did meet the bar needed for reimbursement and may see clinical
adoption due to its convenience. The Fund's performance was negatively affected by its position in GH stock, which declined during the
period.</span></p>

<p style="margin:12pt 0pt 0pt 0pt;text-align:center"><span style="font-size:11pt;font-family:Arial, Helvetica"><strong>Distributions </strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>(Unaudited)</i></span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund intends to make monthly
distributions at a rate of $0.1167 per share. The Fund intends to use net realized capital gains when making monthly distributions, if
available, but would make return of capital distributions if the amount of the distribution exceeds the Fund's net investment income and
realized capital gains. During the last fiscal year, the Fund made monthly distributions totaling $1.40 per share, which were characterized
as $0.82 per share of net realized long-term capital gains and $0.58 per share of return of capital. Final determination of the tax character
of the distributions paid by the Fund in 2023 will be reported to shareholders in January 2024.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Distributions of return of
capital decrease the Fund's total assets and total assets per share and, therefore, could have the effect of increasing the Fund's expense
ratio. In general, the policy of making monthly distributions at a fixed value does not affect the Fund's investment strategy. However,
in order to make these distributions, the Fund might need to sell portfolio securities at a less than opportune time.</span></p>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund is covered under
exemptive relief received by the Fund's investment adviser from the U.S. Securities and Exchange Commission (SEC) that allows the Fund
to distribute long-term capital gains as frequently as monthly in any one taxable year.</span></p></div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">*The trademarks NASDAQ Biotechnology
Index<sup>&#174;</sup>, S&#38;P Global 1200 Health Care Index<sup>&#174;</sup>, S&#38;P Composite 1500<sup>&#174;</sup> Health Care REITs
Index, S&#38;P 500<sup>&#174;</sup> Health Care Corporate Bond Index, SPDR<sup>&#174;</sup> S&#38;P<sup>&#174;</sup> Biotech ETF and S&#38;P
500<sup>&#174;</sup> Index referenced in this report are the property of their respective owners. These trademarks are not owned by or
associated with the Fund or its service providers, including abrdn Inc.</span></p></div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 9</span></p><hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" /></div>

<div >

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 6pt 0pt;text-align:left"><span style="font-size:19pt;font-family:Arial, Helvetica">Schedule of Investments</span></p>
</div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>September 30, 2023</strong></span></p>
</div>

<div style="margin:8pt 0pt 8pt 0pt">

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:227">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:154">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Principal Amount</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:97">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Value</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 6pt 0pt;text-align:left;vertical-align:bottom;width:486;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Non-Convertible Notes 18.5%</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>France 0.5%</i></strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sanofi, 3.63% due 06/19/28</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,600,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>2,449,435</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Ireland 0.4%</i></strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Endo Dac/Endo Finance LLC/Endo Finco, Inc.,
        9.50% due 07/31/27 <sup>(a) (e)</sup></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">516,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">36,120</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Endo Dac/Endo Finance LLC/Endo Finco, Inc.,
        6.00% due 06/30/28 <sup>(a) (e)</sup></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">789,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">55,230</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Mallinckrodt International Finance S.A., 10.00%
        due 06/15/29 <sup>(a) (e)</sup></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">997,897</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">70,421</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Shire Acquisitions Investments Ireland DAC,
        3.20% due 09/23/26</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,500,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,401,165</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:227;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>1,562,936</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>United Kingdom 1.1%</i></strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">AstraZeneca plc, 3.38% due 11/16/25</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,000,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>4,794,712</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>United States 16.5%</i></strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Abbott Laboratories, 4.75% due 11/30/36</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,652,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,372,250</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">AbbVie, Inc., 4.50% due 05/14/35</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,200,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,892,292</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">AbbVie, Inc., 4.45% due 05/14/46</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,705,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,392,343</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Amgen, Inc., 3.63% due 05/22/24</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,000,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,972,069</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Amgen, Inc., 2.00% due 01/15/32</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,555,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,180,440</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Baxalta, Inc., 4.00% due 06/23/25</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">831,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">805,952</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Becton, Dickinson and Co., 3.73% due 12/15/24</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">328,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">319,911</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Bristol-Myers Squibb Co., 3.40% due 07/26/29</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,400,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,268,463</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">CVS Health Corp., 1.88% due 02/28/31</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,448,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,867,453</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">DH Europe Finance II Sarl, 3.25% due 11/15/39</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">985,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">739,052</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Elevance Health, Inc., 2.55% due 03/15/31</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,200,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,592,776</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">EMD Finance LLC, 3.25% due 03/19/25 <sup>(a)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,000,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,857,963</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">GlaxoSmithKline Capital plc, 3.00% due 06/01/24</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,400,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,375,590</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">GlaxoSmithKline Capital plc, 3.38% due 06/01/29</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,000,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">912,952</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">HCA, Inc., 5.38% due 02/01/25</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,250,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,236,807</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">HCA, Inc., 5.25% due 04/15/25</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">600,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">592,620</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">IQVIA, Inc., 5.00% due 05/15/27 <sup>(a)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">710,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">669,246</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Johnson &#38; Johnson, 2.45% due 03/01/26</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,300,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,039,417</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Johnson &#38; Johnson, 2.90% due 01/15/28</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,400,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,292,124</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Johnson &#38; Johnson, 3.70% due 03/01/46</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,470,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,256,812</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Laboratory Corporation of America Holdings,
        3.60% due 02/01/25</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,400,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,355,633</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Medtronic, Inc., 4.38% due 03/15/35</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,675,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,517,682</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Merck &#38; Co., Inc., 2.75% due 02/10/25</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,463,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,412,487</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Novartis Capital Corp., 3.40% due 05/06/24</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,115,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,086,438</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Par Pharmaceutical, Inc., 7.50% due 04/01/27
        <sup>(a) (e)</sup></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">193,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">137,030</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Pfizer, Inc., 3.45% due 03/15/29</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,300,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,881,733</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Pfizer, Inc., 4.00% due 12/15/36</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,800,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,555,386</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  </table> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE
AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">10 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:227">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:154">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Principal Amount</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:97">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Value</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>United States (continued)</i></strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Senior Housing Properties Trust, 4.75% due
        05/01/24</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,750,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,653,570</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">The Cigna Group, 3.50% due 06/15/24</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,785,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,739,062</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">The Cigna Group, 2.38% due 03/15/31</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,200,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,556,722</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Thermo Fisher Scientific, Inc., 5.40% due 08/10/43</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,500,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,342,172</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">UnitedHealth Group, Inc., 3.88% due 12/15/28</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,560,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,404,582</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">UnitedHealth Group, Inc., 4.20% due 05/15/32</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,060,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,533,014</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Zimmer Biomet Holdings, Inc., 4.25% due 08/15/35</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,000,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,055,967</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:227;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>73,868,010</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total Non-Convertible Notes (Cost $92,331,615)</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>82,675,093</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:9pt .7pt 0pt 0pt;vertical-align:bottom;width:227">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:154">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Shares</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:9pt .7pt 0pt 0pt;vertical-align:bottom;width:97">&#160;</td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 6pt 0pt;text-align:left;vertical-align:bottom;width:486;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Convertible Preferreds (Restricted)
        </strong><strong><sup>(b) (c)</sup></strong><strong> 1.5%</strong></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>France 0.7%</i></strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Amolyt Pharma SAS Series C</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">981,328</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,220,270</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Flamingo Therapeutics, Inc. Series A3</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">136,337</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">880,709</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:227;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>3,100,979</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Ireland 0.3%</i></strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Priothera Ltd. Series A, 6.00%</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">194,134</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>1,436,737</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>United States 0.5%</i></strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Endeavor Biomedicines, Inc. Series B, 8.00%</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">424,079</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,999,999</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">IO Light Holdings, Inc. Series A2</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">101,839</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">154,673</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:227;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>2,154,672</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total Convertible Preferreds (Cost
        $10,054,471)</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>6,692,388</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:6pt .7pt 6pt 0pt;text-align:left;vertical-align:bottom;width:486;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Common Stocks 102.3%</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Australia 1.8%</i></strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">CSL Ltd.</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">49,945</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>8,053,724</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Canada 0.0%</i></strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Fusion Pharmaceuticals, Inc. <sup>(b)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,378</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">19,183</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Fusion Pharmaceuticals, Inc. (restricted) <sup>(b)
        (c)</sup></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,689</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,632</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:227;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>27,815</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>China 0.2%</i></strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">BeiGene Ltd. ADR <sup>(b)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,114</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">739,985</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">I-Mab ADR <sup>(b)</sup></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">38,848</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">51,280</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:227;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>791,265</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Denmark 4.4%</i></strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">MorphoSys AG ADR <sup>(b)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">296,191</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,990,404</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Novo Nordisk A/S ADR</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">194,358</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">17,674,916</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:227;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>19,665,320</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  </table> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE
AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 11</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:227">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:154">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Shares</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:97">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Value</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>France 1.9%</i></strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Abivax S.A. <sup>(b)</sup></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,827</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">139,985</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sanofi ADR</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">158,645</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,509,718</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:227">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>8,649,703</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Germany 1.9%</i></strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Affimed N.V. <sup>(b)</sup></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,779</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Bayer AG</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">173,684</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,345,866</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:227">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>8,350,645</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Ireland 0.1%</i></strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Perrigo Co. plc</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15,882</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>507,430</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Israel 0.2%</i></strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Teva Pharmaceutical Industries Ltd. ADR <sup>(b)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">90,281</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>920,866</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Japan 1.7%</i></strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Astellas Pharma, Inc.</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">44,419</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">616,468</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Daiichi Sankyo Co., Ltd.</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">54,075</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,485,760</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Eisai Co., Ltd.</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,830</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">379,526</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Hoya Corp.</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">9,682</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">992,884</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">M3, Inc.</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,436</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">135,146</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Olympus Corp.</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">28,940</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">375,984</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Ono Pharmaceutical Co., Ltd.</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">11,330</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">217,441</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Otsuka Holdings Co., Ltd.</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">20,808</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">739,781</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Shionogi &#38; Co., Ltd.</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,707</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">344,814</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Takeda Pharmaceuticals Co., Ltd.</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">9,600</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">298,137</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Takeda Pharmaceuticals Co., Ltd. ADR</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">105,073</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,625,479</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Terumo Corp.</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">17,288</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">458,461</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:227">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>7,669,881</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Netherlands 1.5%</i></strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">argenx SE ADR <sup>(b)</sup></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,681</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,267,840</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Koninklijke Philips N.V. <sup>(b)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">114,765</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,288,414</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:227">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>6,556,254</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Switzerland 7.6%</i></strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Lonza Group AG</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16,011</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,444,455</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Novartis AG ADR</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">38,071</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,877,912</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Oculis Holding AG <sup>(b)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">304,333</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,451,136</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Roche Holding AG ADR</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">562,829</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">19,096,788</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:227">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>33,870,291</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:3pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>United Kingdom 4.6%</i></strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">AstraZeneca plc ADR <sup>(d)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">240,450</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16,283,274</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Smith &#38; Nephew plc ADR</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">181,710</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,500,957</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:227">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>20,784,231</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  </table> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE
AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">12 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:227">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:154">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Shares</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:97">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Value</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>United States 76.4%</i></strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Abbott Laboratories <sup>(d)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">111,065</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10,756,645</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">AbbVie, Inc.</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">77,903</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">11,612,221</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Acadia Healthcare Co., Inc. <sup>(b)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">25,973</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,826,162</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Agilent Technologies, Inc. <sup>(d)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">19,531</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,183,956</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Amgen, Inc. <sup>(d)</sup></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">45,424</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12,208,154</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Ardelyx, Inc. <sup>(b)</sup></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">454,742</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,855,347</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Avantor, Inc. <sup>(b)</sup></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">180,484</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,804,603</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Baxter International, Inc. <sup>(d)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">86,526</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,265,491</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Becton, Dickinson and Co.</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,521</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,685,874</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Biogen, Inc. <sup>(b)</sup></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15,208</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,908,608</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Boston Scientific Corp. <sup>(b) (d)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">172,145</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">9,089,256</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Bristol-Myers Squibb Co. <sup>(d)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">100,088</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,809,107</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Catalent, Inc. <sup>(b)</sup></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">26,200</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,192,886</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Centene Corp. <sup>(b) (d)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">57,666</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,972,034</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Charles River Laboratories International, Inc.
        <sup>(b) (d)</sup></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">21,364</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,186,917</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Community Health Systems, Inc. <sup>(b)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,700</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">25,230</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Community Healthcare Trust, Inc.</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14,900</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">442,530</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Danaher Corp.</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">54,909</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13,622,923</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">DexCom, Inc. <sup>(b) (d)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">42,866</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,999,398</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Diversified Healthcare Trust REIT</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">63,841</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">123,852</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Edwards Lifesciences Corp. <sup>(b) (d)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">50,982</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,532,033</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Elevance Health, Inc. <sup>(d)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">24,573</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10,699,576</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Eli Lilly &#38; Co.</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">52,523</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">28,211,679</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Galera Therapeutics, Inc. <sup>(b)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">161,709</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">28,315</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Gilead Sciences, Inc. <sup>(d)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">87,662</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,569,390</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Global Medical REIT, Inc.</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">143,229</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,284,764</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">GSK plc ADR</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">41,852</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,517,135</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Guardant Health, Inc. <sup>(b)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">53,333</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,580,790</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">HCA Healthcare, Inc.</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12,213</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,004,154</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Healthcare Realty Trust, Inc.</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">149,567</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,283,888</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Healthpeak Properties, Inc.</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">83,601</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,534,914</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Humana, Inc.</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">17,385</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,458,150</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">IDEXX Laboratories, Inc. <sup>(b)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12,104</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,292,716</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Illumina, Inc. <sup>(b) (d)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">26,735</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,670,181</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Incyte Corp. <sup>(b) (d)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12,302</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">710,687</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Insulet Corp. <sup>(b)</sup></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12,441</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,984,215</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Intuitive Surgical, Inc. <sup>(b) (d)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">20,041</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,857,784</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">IQVIA Holdings, Inc. <sup>(b) (d)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16,311</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,209,189</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Johnson &#38; Johnson <sup>(d)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">164,139</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">25,564,649</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">LTC Properties, Inc.</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">46,903</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,506,993</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  </table> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE
AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 13</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:227">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:154">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Shares</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:97">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Value</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>United States (continued)</i></strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Mallinckrodt plc <sup>(b)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">35,048</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,990</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">McKesson Corp. <sup>(d)</sup></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10,401</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,522,875</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Medical Properties Trust, Inc.</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">145,186</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">791,264</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Medtronic plc</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">79,482</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,228,209</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Merck &#38; Co., Inc. <sup>(d)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">144,900</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14,917,455</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Moderna, Inc. <sup>(b) (d)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14,416</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,489,029</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Molina Healthcare, Inc. <sup>(b) (d)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,047</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,310,641</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">National Health Investors, Inc.</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,442</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">228,141</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Omega Healthcare Investors, Inc.</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">71,075</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,356,847</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Pfizer, Inc. <sup>(d)</sup></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">392,775</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13,028,347</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Physicians Realty Trust</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">291,309</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,551,057</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">R1 RCM, Inc. <sup>(b)</sup></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">124,297</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,873,156</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Regeneron Pharmaceuticals, Inc. <sup>(b)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,151</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,062,027</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">ResMed, Inc.</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10,104</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,494,078</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sabra Health Care REIT, Inc.</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">90,781</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,265,487</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Stryker Corp.</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16,321</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,460,040</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">The Cigna Group <sup>(d)</sup></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">858,210</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Thermo Fisher Scientific, Inc.</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">31,366</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15,876,528</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">UnitedHealth Group, Inc. <sup>(d)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">52,619</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">26,529,974</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Universal Health Realty Income Trust</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,183</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">330,839</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Ventas, Inc.</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">66,681</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,809,271</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Veradigm, Inc. <sup>(b)</sup></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">90,363</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,187,370</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Vertex Pharmaceuticals, Inc. <sup>(b)</sup></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">17,979</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,252,017</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Welltower, Inc.</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">41,484</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,398,369</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">West Pharmaceutical Services, Inc.</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,370</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,264,458</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Zimmer Biomet Holdings, Inc.</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">23,986</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,691,709</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Zoetis, Inc. <sup>(d)</sup></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">27,301</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,749,828</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:227;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>341,602,612</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total Common Stocks (Cost $492,439,317)</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>457,450,037</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:9pt .7pt 0pt 0pt;vertical-align:bottom;width:227">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:154">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Principal Amount</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:9pt .7pt 0pt 0pt;vertical-align:bottom;width:97">&#160;</td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 6pt 0pt;text-align:left;vertical-align:bottom;width:486;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Short-Term Investments 4.4%</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227"><span style="font-size:8pt;font-family:Arial, Helvetica">Repurchase
        Agreement, Fixed Income Clearing Corp., </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">repurchase value $19,871,649,
        1.60%, dated 09/29/23, </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">due 10/02/23 (collateralized by U.S. Treasury
        Note 3.625%, </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">due 05/15/26, market value $20,266,411)</span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">19,869,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">19,869,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total Short-Term Investments (Cost
        $19,869,000)</strong></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>19,869,000</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:9pt .7pt 6pt 0pt;text-align:left;vertical-align:bottom;width:486">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Milestone Interest (Restricted) </strong><strong><sup>(b)
        (c)</sup></strong><strong> 0.0%</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Rainier Therapeutics Milestone Interest</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:85;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:50;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total Milestone Interest (Cost $143,115)</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>0</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  </table> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE
AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">14 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<div>

<div>

<div style="margin:8pt 0pt 8pt 0pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:100%" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:227">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:154"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Number
        of Contracts</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(100 shares each)/</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Notional
        Amount ($)</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:97">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Value</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 6pt 0pt;text-align:left;vertical-align:bottom;width:486;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Option Contracts Written (0.0)%</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:486">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Call Option Contracts
        Written 0.0%</i></strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Abbott Laboratories Oct23 105 Call</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:8%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">167/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(1,753,500)</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(4,676</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Agilent Technologies, Inc. Oct23 120 Call</span></p>
        </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:8%">
        <p style="margin:0pt 7pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">50/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(600,000)</span></p>
        </td>
    <td colspan="1" style="width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(2,850</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Amgen, Inc. Oct23 280 Call</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:8%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">68/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(1,904,000)</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(7,140</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">AstraZeneca plc Oct23 72.5 Call</span></p>
        </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:8%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">362/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(2,624,500)</span></p>
        </td>
    <td colspan="1" style="width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(4,706</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Baxter International, Inc. Oct23 41 Call</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:8%">
        <p style="margin:0pt 7pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">43/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(176,300)</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(537</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Boston Scientific Corp. Oct23 56 Call</span></p>
        </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:8%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">258/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(1,444,800)</span></p>
        </td>
    <td colspan="1" style="width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(2,580</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Bristol-Myers Squibb Co. Oct23 61 Call</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:8%">
        <p style="margin:0pt 7pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">100/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(610,000)</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,000</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Centene Corp. Oct23 70 Call</span></p> </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:8%">
        <p style="margin:0pt 7pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">87/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(609,000)</span></p>
        </td>
    <td colspan="1" style="width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(11,310</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Charles River Laboratories International, Inc.
        Oct23 220 Call</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:8%">
        <p style="margin:0pt 7pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">21/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(462,000)</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,260</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">DexCom, Inc. Oct23 105 Call</span></p> </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:8%">
        <p style="margin:0pt 7pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">21/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(220,500)</span></p>
        </td>
    <td colspan="1" style="width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,512</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Edwards Lifesciences Corp. Oct23 75 Call</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:8%">
        <p style="margin:0pt 7pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">49/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(367,500)</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(2,205</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Elevance Health, Inc. Oct23 460 Call</span></p>
        </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:8%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">37/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(1,702,000)</span></p>
        </td>
    <td colspan="1" style="width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(16,280</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Gilead Sciences, Inc. Oct23 80 Call</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:8%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">132/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(1,056,000)</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,716</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Illumina, Inc. Oct23 150 Call</span></p> </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:8%">
        <p style="margin:0pt 7pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">35/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(525,000)</span></p>
        </td>
    <td colspan="1" style="width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(5,250</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Incyte Corp. Oct23 62.5 Call</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:8%">
        <p style="margin:0pt 7pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">17/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(106,250)</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,020</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Intuitive Surgical, Inc. Oct23 320 Call</span></p>
        </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:8%">
        <p style="margin:0pt 7pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">20/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(640,000)</span></p>
        </td>
    <td colspan="1" style="width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(5,600</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">IQVIA Holdings, Inc. Oct23 220 Call</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:8%">
        <p style="margin:0pt 7pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(352,000)</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(600</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Johnson &#38; Johnson Oct23 170 Call</span></p>
        </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:8%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">165/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(2,805,000)</span></p>
        </td>
    <td colspan="1" style="width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,485</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">McKesson Corp. Oct23 455 Call</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:8%">
        <p style="margin:0pt 7pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(455,000)</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,800</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Merck &#38; Co., Inc. Oct23 113 Call</span></p>
        </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:8%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">145/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(1,638,500)</span></p>
        </td>
    <td colspan="1" style="width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,015</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Moderna, Inc. Oct23 115 Call</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:8%">
        <p style="margin:0pt 7pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">21/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(241,500)</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(2,247</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Molina Healthcare, Inc. Oct23 350 Call</span></p>
        </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:8%">
        <p style="margin:0pt 7pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(245,000)</span></p>
        </td>
    <td colspan="1" style="width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(945</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Pfizer, Inc. Oct23 35 Call</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:8%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">600/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(2,100,000)</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(10,800</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">The Cigna Group Oct23 300 Call</span></p> </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:8%">
        <p style="margin:0pt 7pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(120,000)</span></p>
        </td>
    <td colspan="1" style="width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(600</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">UnitedHealth Group, Inc. Oct23 500 Call</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:8%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">79/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(3,950,000)</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(118,105</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:80%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Zoetis, Inc. Oct23 190 Call</span></p> </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:3%">&#160;</td>
    <td colspan="2" rowspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:8%">
        <p style="margin:0pt 7pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">27/</span><span style="font-size:8pt;font-family:Arial, Helvetica">(513,000)</span></p>
        </td>
    <td colspan="1" style="width:0.5%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(675</span></p> </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong><i>Total
        Call Option Contracts Written</i></strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(Premiums received
        ($246,001))</strong></span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:154;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(207,914</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:9pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total Investments 126.7% (Cost $614,591,517)</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:9pt .7pt 0pt 0pt;vertical-align:bottom;width:154">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>566,478,604</strong></span></p>
        </td>
    <td colspan="1" style="padding:9pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:3pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Other Liabilities in Excess of Assets
        (26.7)%</strong></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:3pt .7pt 0pt 0pt;vertical-align:bottom;width:154;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:3pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:3pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(119,360,980</strong></span></p>
        </td>
    <td colspan="1" style="padding:3pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:3pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:227">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net Assets 100%</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:3pt .7pt 0pt 0pt;vertical-align:bottom;width:154">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:3pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:3pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>447,117,624</strong></span></p>
        </td>
    <td colspan="1" style="padding:3pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  </table>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(a) Security exempt from registration
under Rule 144A of the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration, normally
to qualified institutional buyers.</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(b) Non-income producing security.</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(c) Security fair valued using
significant unobservable inputs. See Investment Valuation and Fair Value Measurements.</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(d) A portion of security is
pledged as collateral for call options written.</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(e) Security is in default.</span></p>
</div> </div> </div> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE
AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 15</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 6pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">The following forward contracts were held as
of September 30, 2023</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:64">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Description</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:77">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Counterparty</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:52"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Settlement</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Date</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:84">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Currency</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:90"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Settlement</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Value
        (in USD)</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:81"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Current</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Value</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:90"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Unrealized</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Gain/(Loss)</strong></span></td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="27" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:562;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Contracts Sold:</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:64">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Australian Dollar</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:77">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Goldman Sachs Bank</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">10/31/23</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:68">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,572,304 AUD</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:63">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,936,069</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,942,478</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(6,409</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:64;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">British Pound</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:77;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Goldman Sachs Bank</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:52;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">10/31/23</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:68;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">9,440,375 GBP</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:63;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">11,514,681</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">11,520,184</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(5,503</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:64">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Danish Krone</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:77">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Goldman Sachs Bank</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">10/31/23</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:68">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">53,401,650 DKK</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:63">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,592,484</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,580,889</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">11,595</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:64;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Euro</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:77;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Goldman Sachs Bank</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:52;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">10/31/23</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:68;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14,561,683 EUR</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:63;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15,438,151</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15,413,059</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">25,092</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:64">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Israeli Sheqel</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:77">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Goldman Sachs Bank</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">11/01/23</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:68">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,457,647 ILS</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:63">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,168,360</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,170,222</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,862</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:64;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Japanese Yen</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:77;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Goldman Sachs Bank</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:52;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">10/31/23</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:68;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">523,322,125 JPY</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:63;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,531,896</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,517,563</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14,333</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:64">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Swiss Franc</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:77">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Goldman Sachs Bank</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">10/31/23</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:68">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16,668,832 CHF</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:63">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">18,318,263</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">18,264,461</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">53,802</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:64;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:77;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:52;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:84;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:90;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:53;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>60,408,856</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:52;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>91,048</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  </table> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE
AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">16 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 6pt 0pt;text-align:left"><span style="font-size:19pt;font-family:Arial, Helvetica">Financial statements</span></p>
</div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 18pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>STATEMENT OF ASSETS
AND LIABILITIES</strong></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>&#160;</i></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>SEPTEMBER
30, 2023</i></span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="7" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:387;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>ASSETS</strong></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Investments, at value (cost $614,694,403)</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:21">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">566,686,518</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Milestone interests, at value (cost $143,115)</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total investments (cost $614,837,518)</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>566,686,518</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Cash</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,143</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Foreign currency, at value (cost $234)</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">234</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Dividends and interest receivable</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,623,591</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Prepaid expenses</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">50,549</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Prepaid offering expenses (see Note 5)</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">271,108</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Unrealized appreciation on forward currency
        contracts</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">104,822</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total assets</strong></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>569,738,965</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="7" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:387">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>LIABILITIES</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Payable for investments purchased</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">140,218</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Unrealized depreciation on forward currency
        contracts</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13,774</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Accrued advisory fee</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">503,112</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Accrued investor support service fees</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">25,156</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Accrued shareholder reporting fees</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">55,366</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Accrued trustee fees</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">30,736</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Loan payable</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">120,000,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Options written, at value (premium received
        $246,001)</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">207,914</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Interest payable</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,444,667</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Accrued other</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">200,398</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total liabilities</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>122,621,341</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Commitments and Contingencies (see Notes 1
        and 4)</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:98">&#160;</td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>NET ASSETS</strong></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:21;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>447,117,624</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="7" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:387">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>SOURCES OF NET ASSETS CONSIST OF</strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">Shares
        of beneficial interest, par value $.01 per share, unlimited number of shares authorized, </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">amount
        paid in on 38,113,338 shares issued and outstanding</span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:21;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">381,133</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Additional paid-in-capital</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">503,456,766</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Total distributable earnings (loss)</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(56,720,275</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total
        net assets (equivalent to $11.73 per share based on <ix:nonFraction id="Fxbrl_20231202101640763" name="cef:OutstandingSecurityHeldShares" contextRef="C_20221001to20230930" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">38,113,338</ix:nonFraction></strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>shares
        outstanding)</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:21">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>447,117,624</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  </table> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE
AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 17</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 18pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>STATEMENT OF OPERATIONS
</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>YEAR ENDED SEPTEMBER 30, 2023</i></span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="7" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:387;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>INVESTMENT INCOME</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Dividend income (net of foreign tax of $365,095)</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:21">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10,275,085</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Interest and other income</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,494,665</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Securities lending</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,488</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total investment income</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>12,776,238</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="7" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:387">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>EXPENSES</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Interest expense</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,987,726</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Advisory fees</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,008,776</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Investor support service fees</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">300,439</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Trustees' fees and expenses</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">143,328</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Custodian fees</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">138,915</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Legal fees</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">128,850</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Shareholder reporting</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">127,322</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Administration fees</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">111,761</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Auditing fees</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">85,610</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Transfer agent fees</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">31,168</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Other (see Note 2)</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">328,083</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total expenses</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>14,391,978</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net investment loss</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(1,615,740</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="7" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:387">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>REALIZED AND UNREALIZED GAIN (LOSS)</strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net realized gain (loss) on</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:98;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Investments</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">33,596,773</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Closed or expired option contracts written</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,880,207</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Foreign currency transactions</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13,698</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Forward contracts</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(3,268,828</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net realized gain</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>33,221,850</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net change in unrealized appreciation
        (depreciation) on</strong></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:98;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Investments</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,569,715</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Milestone interests</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(138,520</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Option contracts written</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(200,688</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Foreign currency</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">20,997</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Forward contracts</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">760,369</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net change in unrealized appreciation
        (depreciation)</strong></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>6,011,873</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net realized gain and change in unrealized
        appreciation (depreciation)</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>39,233,723</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net increase in net assets resulting
        from operations</strong></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:21;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>37,617,983</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  </table> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE
AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">18 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 18pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>STATEMENTS OF CHANGES
IN NET ASSETS</strong></span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:8pt .7pt 0pt 0pt;vertical-align:bottom;width:225">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:8pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:96"><span style="font-size:8pt;font-family:Arial, Helvetica">Year
        ended</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">September 30,</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">2023</span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:8pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:97"><span style="font-size:8pt;font-family:Arial, Helvetica">Year
        ended</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">September 30,</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">2022<sup>(1)</sup></span></td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:426;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>INCREASE (DECREASE) IN NET ASSETS FROM
        OPERATIONS</strong></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net investment income gain (loss)</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:21">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">($</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,615,740</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,947,208</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net realized gain</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">33,221,850</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">25,964,884</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Change in net unrealized appreciation (depreciation)</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,011,873</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(90,748,168</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net increase (decrease) in net assets
        resulting from operations</strong></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>37,617,983</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(62,836,076</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:426">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>DISTRIBUTIONS TO SHAREHOLDERS (See
        Note 1)</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Distributions</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(30,951,311</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(31,069,521</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Return of capital</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(22,034,793</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(21,264,321</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total distributions</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(52,986,104</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(52,333,842</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:426">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>CAPITAL SHARE TRANSACTIONS</strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">Proceeds
        from at-the-market offering (274,984 and 0 shares, </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">respectively)</span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,950,593</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Expenses in connection with the at-the-market
        offering ( See Note 5)</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(7,478</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">Reinvestment
        of distributions (318,084 and 265,352 shares, </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">respectively)</span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,199,880</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,830,775</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total capital share transactions</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>8,142,995</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>3,830,775</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net decrease in net assets</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(7,225,126</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(111,339,143</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="11" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:426">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>NET ASSETS</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Beginning of year</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">454,342,750</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:59;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">565,681,893</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:225">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>End of year</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:21">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>447,117,624</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:59">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>454,342,750</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  </table>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(1)&#160;&#160;Audited by a
different independent registered public accounting firm.</span></p> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE
AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 19</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 18pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>STATEMENT OF CASH
FLOWS</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i> YEAR ENDED SEPTEMBER 30, 2023</i></span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="7" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:387;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Purchases of portfolio securities</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:21">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">($</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">236,845,841</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Securities lending income</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,969</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net maturities of short-term investments</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(6,644,531</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sales of portfolio securities</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">288,889,329</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Proceeds from option contracts written</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,841,646</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Interest income received</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,959,275</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Dividend income received</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">9,922,042</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Other operating receipts (expenses paid)</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(14,015,794</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net realized gain (loss) on forward contracts</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(3,268,828</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net cash provided from operating activities</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>44,844,267</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="7" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:387">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Cash distributions paid</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(48,786,224</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net proceeds from at-the-market offering</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,950,593</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Expenses in connection with the at-the-market
        offering</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(7,478</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net cash used for financing activities</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(44,843,109</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>NET INCREASE IN CASH</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>1,158</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>CASH AT BEGINNING OF YEAR</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>985</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>CASH AT END OF YEAR</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:21;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>2,377</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:left;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>*</strong></span></p>
        </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="7" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:387"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>RECONCILIATION
        OF NET INCREASE IN NET ASSETS</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>RESULTING FROM OPERATIONS
        TO NET CASH</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>PROVIDED FROM OPERATING ACTIVITIES</strong></span></td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net increase in net assets resulting from operations</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:21;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">37,617,983</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Purchases of portfolio securities</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(236,845,841</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net maturities of short-term investments</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(6,644,531</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sales of portfolio securities</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">288,889,329</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Proceeds from option contracts written</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,841,646</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Amortization of premium</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">529,818</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net realized gain on investments, options,
        foreign currencies and forwards</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(36,490,678</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289"><span style="font-size:8pt;font-family:Arial, Helvetica">Increase
        in net unrealized (appreciation) depreciation on investments, options and foreign </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">currencies</span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(6,011,873</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Non-cash dividend income received</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(418,590</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Decrease in dividends and interest receivable</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">339</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Decrease in securities lending income receivable</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">481</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Decrease in accrued other expenses</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(246,230</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Increase in interest payable</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">688,242</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Increase in prepaid expenses and other assets</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(65,828</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net cash provided from operating activities</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:21;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>44,844,267</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:289">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Supplemental disclosure: Cash paid for interest</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:21">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,299,484</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  </table>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">*&#160;&#160;Includes: $234
foreign currency.</span></p> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE
AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">20 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 6pt 0pt;text-align:left"><span style="font-size:19pt;font-family:Arial, Helvetica">Financial highlights</span></p>
</div>

<div style="margin:8pt 0pt 8pt 0pt">

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 1.5pt 0pt;vertical-align:bottom;width:170">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="19" style="padding:0pt .7pt 1.5pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:424">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>For the years ended September 30,</strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:1.5pt .7pt 0pt 0pt;vertical-align:bottom;width:170">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:1.5pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:81">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>2023</strong><strong><sup>(1)</sup></strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:1.5pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:79">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>2022</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:1.5pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:76">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>2021</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:1.5pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:78">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>2020</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:1.5pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:78">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>2019</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="23" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:594;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>OPERATING PERFORMANCE FOR A SHARE </strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net asset value per share, beginning
        of year</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:37">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20231202121140788" name="us-gaap:NetAssetValuePerShare" contextRef="C_20220930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">12.11</ix:nonFraction></strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20231202122204823" name="us-gaap:NetAssetValuePerShare" contextRef="C_20210930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">15.18</ix:nonFraction></strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20231202122207946" name="us-gaap:NetAssetValuePerShare" contextRef="C_20200930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.14</ix:nonFraction></strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20231202122211075" name="us-gaap:NetAssetValuePerShare" contextRef="C_20190930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">13.51</ix:nonFraction></strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20231202122215152" name="us-gaap:NetAssetValuePerShare" contextRef="C_20180930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">15.24</ix:nonFraction></strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net investment income (loss) <sup>(2)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:37;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.04</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.05</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.08</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.10</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.06</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net realized and unrealized gain (loss)</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:37">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.05</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(4.52</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2.36</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.93</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.40</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total
        increase (decrease) from investment</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>operations</strong></span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:37;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>1.01</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:24;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(4.47</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>2.44</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>2.03</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:24;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(0.34</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Distributions to shareholders from</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:81">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:79">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:76">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:78">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:78">&#160;</td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net investment income</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:37;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.33</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.14</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.05</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.19</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net realized capital gains</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:37">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.82</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.50</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Return of capital (tax basis)</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:37;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.58</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.57</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1.26</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1.35</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1.21</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total distributions</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:37">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(<ix:nonFraction id="Fxbrl_20231202122420675" name="cef:AnnualDividendPayment" contextRef="C_20221001to20230930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">1.40</ix:nonFraction></strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(<ix:nonFraction id="Fxbrl_20231202122524761" name="cef:AnnualDividendPayment" contextRef="C_20211001to20220930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">1.40</ix:nonFraction></strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(<ix:nonFraction id="Fxbrl_20231202122528993" name="cef:AnnualDividendPayment" contextRef="C_20201001to20210930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">1.40</ix:nonFraction></strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(<ix:nonFraction id="Fxbrl_20231202122532689" name="cef:AnnualDividendPayment" contextRef="C_20191001to20200930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">1.40</ix:nonFraction></strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>(<ix:nonFraction id="Fxbrl_20231202122536477" name="cef:AnnualDividendPayment" contextRef="C_20181001to20190930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">1.40</ix:nonFraction></strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Increase resulting from shares repurchased
        </strong><strong><sup>(2)</sup></strong></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:37;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><sup>(3)</sup></strong></span></p>
        </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>0.01</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Increase
        resulting from At-the-market</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>offering </strong><strong><sup>(2)</sup></strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:37">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>0.01</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Net asset value per share, end of year</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:37;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20231202122222386" name="us-gaap:NetAssetValuePerShare" contextRef="C_20230930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">11.73</ix:nonFraction></strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:24;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20231202122231928" name="us-gaap:NetAssetValuePerShare" contextRef="C_20220930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">12.11</ix:nonFraction></strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:24;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20231202122236013" name="us-gaap:NetAssetValuePerShare" contextRef="C_20210930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">15.18</ix:nonFraction></strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20231202122240267" name="us-gaap:NetAssetValuePerShare" contextRef="C_20200930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.14</ix:nonFraction></strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:24;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong><ix:nonFraction id="Fxbrl_20231202122244532" name="us-gaap:NetAssetValuePerShare" contextRef="C_20190930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">13.51</ix:nonFraction></strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:24;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Per share market value, end of year</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:37">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202122946590" name="us-gaap:SharePrice" contextRef="C_20230930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">11.72</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202123346350" name="us-gaap:SharePrice" contextRef="C_20220930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">12.86</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202123354810" name="us-gaap:SharePrice" contextRef="C_20210930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">16.45</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202123359044" name="us-gaap:SharePrice" contextRef="C_20200930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.33</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202123402921" name="us-gaap:SharePrice" contextRef="C_20190930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">13.44</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Total investment return at market value</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:37;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.70</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(13.65</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">26.00</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">18.14</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6.80</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Total investment return at net asset value</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:37">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8.09</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(11.94</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">17.91</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15.97</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1.10</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="23" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:594;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>RATIOS</strong></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net investment income (loss) to average net
        assets</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:37">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(0.34</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.37</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.53</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.68</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.45</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Expenses to average net assets</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:37;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2.99</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.91</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.74</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2.16</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2.53</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170"><span style="font-size:8pt;font-family:Arial, Helvetica">Expenses,
        excluding interest expense, to average </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">net assets</span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:37">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.54</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.53</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.51</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.57</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.59</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="23" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:594;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>SUPPLEMENTAL DATA</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net assets at end of year (in millions)</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:37">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">447</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">454</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">566</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">427</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">407</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Portfolio turnover rate</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:37;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">40.12</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">43.87</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">69.37</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">48.11</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">55.17</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170"><span style="font-size:8pt;font-family:Arial, Helvetica">Senior
        securities (loan facility) outstanding </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">(in millions)</span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:37">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">120</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">120</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">120</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">120</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">120</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">Asset
        coverage ratio on revolving credit facility </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">at year end</span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:37;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">473</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">479</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">571</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">455</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">440</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:170"><span style="font-size:8pt;font-family:Arial, Helvetica">Asset
        coverage per $1,000 on revolving credit </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">facility at year end</span></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:37">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,726</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,786</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5,714</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,554</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:34">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,396</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:24">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  </table>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(1)&#160;&#160;Beginning with
the year ended September 30, 2023, the Fund's financial statements were audited by KPMG LLP. Previous years were audited by a different
independent registered public accounting firm.</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(2)&#160;&#160;Computed using
average shares outstanding.</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">(3)&#160;&#160;Amount represents
less than $0.005 per share.</span></p> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:6pt;font-family:Arial, Helvetica">THE ACCOMPANYING NOTES ARE
AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 21</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />
</div>

<div >

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 6pt 0pt;text-align:left"><span style="font-size:19pt;font-family:Arial, Helvetica">Notes to financial statements</span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>
SEPTEMBER 30, 2023</i></span></p> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>(1)&#160;&#160;Organization
and Significant Accounting Policies</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">abrdn World Healthcare Fund
(the Fund) is a Massachusetts business trust formed on March 5, 2015 and registered under the Investment Company Act of 1940 as a diversified
closed-end management investment company. The Fund commenced operations on June 30, 2015. <ix:continuation id="F20231212021409974" continuedAt="F20231212021433901"><span>The
Fund's investment objective is to seek current income and long-term capital appreciation. The Fund invests primarily in equity and debt
securities of public and private U.S. and non-U.S. companies believed by the Fund's Investment Adviser, abrdn Inc. (as of October 27,
2023) (prior to October 27, 2023, Tekla Capital Management, LLC) (the Investment Adviser or the Adviser), to have significant potential
for above-average growth.</span></ix:continuation></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The preparation of these financial
statements requires the use of certain estimates by management in determining the Fund's assets, liabilities, revenues and expenses. Actual
results could differ from these estimates and such differences could be material. The following is a summary of significant accounting
policies followed by the Fund, which are in conformity with accounting principles generally accepted in the United States of America (GAAP).
The Fund is an investment company and follows accounting and reporting guidance in the Financial Accounting Standards Board Accounting
Standards Codification 946. Events or transactions occurring after September 30, 2023, through the date that the financial statements
were issued, have been evaluated in the preparation of these financial statements.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The market value of the Fund's
investments will move up and down, sometimes rapidly and unpredictably, based upon political, regulatory, market, economic and social
conditions, as well as developments that impact specific economic sectors, industries or segments of the market, including conditions
that directly relate to the issuers of the Fund's investments, such as management performance, financial condition and demand for the
issuers' goods and services. The Fund is subject to the risk that geopolitical events will adversely affect global economies and markets.
War, terrorism and related geopolitical events have led, and in the future may lead, to increased short-term market volatility and may
have adverse long-term effects on global economies and markets. Likewise, natural and environmental disasters and epidemics or pandemics
may be highly disruptive to economies and markets. This means that the Fund may lose money on its investment due to unpredictable drops
in a security's value or periods of below-average performance in a given security or in the securities market as a whole.</span></p>

<p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Investment Valuation</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Shares of publicly traded
companies listed on national securities exchanges or trading in the over-the-counter market are typically valued at the last sale price
as of the close of trading, generally 4 p.m. Eastern Time. The Fund holds securities, currencies and other assets that are denominated
in a foreign currency. The Fund will normally use the currency exchange rates as of 4:00 p.m. (Eastern Time) when valuing such assets.
The Board of Trustees of the Fund (the Trustees) has established and approved fair valuation policies and procedures with respect to securities
for which quoted prices may not be available or which do not reflect fair </span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">22 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">value. Convertible, corporate
and government bonds are valued using a third-party pricing service. Puts and calls generally are valued at the close of regular trading
on the securities or commodities exchange on which they are primarily traded. Options on securities generally are valued at their last
sale price in the case of exchange traded options or, in the case of OTC-traded options, the average of the last sale price as obtained
from two or more dealers unless there is only one dealer, in which case that dealer's price is used. Forward foreign currency contracts
are valued on the basis of the value of the underlying currencies at the prevailing forward exchange rates. Restricted securities of companies
that are publicly traded are typically valued based on the closing market quote on the valuation date adjusted for the impact of the restriction
as determined in good faith by the Adviser also using fair valuation policies and procedures approved by the Trustees described below.
Short-term investments with a maturity of 60 days or less are generally valued at amortized cost, which approximates fair value. See also
Subsequent Event Note 6.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Convertible preferred shares,
warrants or convertible note interests in private companies, milestone interests and other restricted securities, as well as shares of
publicly traded companies for which market quotations are not readily available, such as stocks for which trading has been halted or for
which there are no current day sales, or which do not reflect fair value, are typically valued in good faith, based upon the recommendations
made by the Adviser pursuant to fair valuation policies and procedures approved by the Trustees.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Adviser has a Valuation
Sub-Committee comprised of senior management which reports to the Valuation Committee of the Board at least quarterly. Each fair value
determination is based on a consideration of relevant factors, including both observable and unobservable inputs. Observable and unobservable
inputs considered may include (i) the existence of any contractual restrictions on the disposition of securities; (ii) information obtained
from the company, which may include an analysis of the company's financial statements, products, intended markets or technologies; (iii)
the price of the same or similar security negotiated at arm's length in an issuer's completed subsequent round of financing; (iv) the
price and extent of public trading in similar securities of the issuer or of comparable companies; or (v) a probability and time value
adjusted analysis of contractual terms. Where available and appropriate, multiple valuation methodologies are applied to confirm fair
value. Significant unobservable inputs identified by the Adviser are often used in the fair value determination. A significant change
in any of these inputs may result in a significant change in the fair value measurement. Significant unobservable inputs identified by
the Adviser are often used in the fair value determination. Additionally, changes in the market environment and other events that may
occur over the life of the investments may cause the gains or losses ultimately realized on these investments to be different from the
valuations used at the date of these financial statements.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 23</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Milestone Interests</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund holds financial instruments
which reflect the current value of future milestone payments the Fund may receive as a result of contractual obligations from other parties.
The value of such payments are adjusted to reflect the estimated risk based on the relative uncertainty of both the timing and the achievement
of individual milestones. A risk to the Fund is that the milestones will not be achieved and no payment will be received by the Fund.
The milestone interests were received as part of the proceeds from the sale of one private company. Any payments received are treated
as a reduction of the cost basis of the milestone interests with payments received in excess of the cost basis treated as a realized gain.
The contractual obligations with respect to the milestone interests provide for payments at various stages of the development of Rainier
Therapeutics' principal product candidate as of the date of the sale.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following is a summary
of the impact of the milestone interests on the financial statements as of and for the year ended September 30, 2023:</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 2pt 0pt;text-align:left;vertical-align:bottom;width:233;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Statement of Assets and Liabilities, Milestone
        interests, at value</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;vertical-align:bottom;width:21;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;vertical-align:bottom;width:40;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 2pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 2pt 0pt;text-align:left;vertical-align:bottom;width:233">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Statement of Assets and Liabilities, Total
        distributable earnings</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;vertical-align:bottom;width:21">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">($</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;vertical-align:bottom;width:40">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">143,115</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:left;vertical-align:bottom;width:18">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 2pt 0pt;text-align:left;vertical-align:bottom;width:233;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">Statement
        of Operations, Change in unrealized appreciation (depreciation) </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">on
        milestone interests</span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;vertical-align:bottom;width:21;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">($</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:right;vertical-align:bottom;width:40;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">138,520</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 2pt 0pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  </table>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Options on Securities</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">An option contract is a contract
in which the writer (seller) of the option grants the buyer of the option, upon payment of a premium, the right to purchase from (call
option) or sell to (put option) the writer a designated instrument at a specified price within a specified period of time. Certain options,
including options on indices, will require cash settlement by the Fund if the option is exercised.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's obligation under
an exchange traded written option or investment in an exchange traded purchased option is valued at the last sale price or in the absence
of a sale, the mean between the closing bid and asked prices. Gain or loss is recognized when the option contract expires, is exercised
or is closed.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">If the Fund writes a covered
call option, the Fund foregoes, in exchange for the premium, the opportunity to profit during the option period from an increase in the
market value of the underlying security above the exercise price. If the Fund writes a put option it accepts the risk of a decline in
the market value of the underlying security below the exercise price. Over-the-counter options have the risk of the potential inability
of counterparties to meet the terms of their contracts. The Fund's maximum exposure to purchased options is limited to the premium initially
paid. In addition, certain risks may arise upon entering into option contracts including the risk that an illiquid secondary market will
limit the Fund's ability to close out an option contract prior to the expiration date and that a change in the value of the option </span></p>
</div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">24 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">contract may not correlate
exactly with changes in the value of the securities or currencies hedged.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">All options on securities
and securities indices written by the Fund are required to be covered. When the Fund writes a call option, this means that during the
life of the option the Fund may own or have the contractual right to acquire the securities subject to the option or may maintain with
the Fund's custodian in a segregated account appropriate liquid securities in an amount at least equal to the market value of the securities
underlying the option. The prices provided by a pricing service take into account broker dealer market price quotations for institutional
size trading in similar groups of securities, yields or securities with similar characteristics, security quantity, maturity, coupon and
other security characteristics as well as any developments related to the specific securities. The pricing service may use a matrix approach,
regarding securities with similar characteristics to determine the valuation for a security. When the Fund writes a put option, this means
that the Fund will maintain with the Fund's custodian in a segregated account appropriate liquid securities in an amount at least equal
to the exercise price of the option.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The average number of outstanding
call options written for the year ended September 30, 2023 was 2,751.</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:left;vertical-align:bottom">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Derivatives not accounted<br />for
        as hedging instruments<br />under ASC 815</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="7" style="padding:0pt 0.7pt 0pt 0pt;vertical-align:bottom">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="7" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Statement of Assets and<br />Liabilities
        Location</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="7" style="padding:0pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Statement of Operations Location</strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Equity Contracts</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="7" style="padding:0pt 0.7pt 0pt 0pt;text-align:center;background-color:rgb(204, 238, 255);vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">&#160;</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Liabilities, options<br />written, at value</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:middle">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">$207,914</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net realized gain (loss) on<br />closed or
        expired option<br />contracts written</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">$2,880,207</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td> </tr>
  <tr>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;text-align:left;vertical-align:bottom;width:0%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">&#160;</span></p> </td>
    <td colspan="1" style="width:1%">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;text-align:left;vertical-align:bottom;width:0%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">&#160;</span></p> </td>
    <td colspan="1" style="width:1%">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;text-align:left;vertical-align:bottom;width:0%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">&#160;</span></p> </td>
    <td colspan="1" style="width:1%">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;text-align:left;vertical-align:bottom;width:0%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">&#160;</span></p> </td>
    <td colspan="1" style="width:1%">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;text-align:left;vertical-align:bottom;width:0%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">&#160;</span></p> </td>
    <td colspan="1" style="width:1%">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;text-align:left;vertical-align:bottom;width:0%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Change in unrealized<br />appreciation (depreciation)<br />on
        option contracts written</span></p> </td>
    <td colspan="1" style="width:1%">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;text-align:left;vertical-align:bottom;width:0%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">($200,688)</span></p> </td>
    <td colspan="1" style="width:1%">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td> </tr>
  <tr>
    <td colspan="3" style="padding:0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Forward Currency<br />Contracts</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="7" style="padding:0pt;text-align:center;background-color:rgb(204, 238, 255);vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">&#160;</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Unrealized appreciation<br />on forward currency<br />contract</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">$104,822</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net realized gain (loss)<br />on forward contracts</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);padding-top:0pt;vertical-align:top">&#160;
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">($3,268,828)</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td> </tr>
  <tr>
    <td colspan="3" style="padding:0pt;text-align:left;width:0%;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">&#160;</span></p> </td>
    <td colspan="1" style="width:1%;padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt;text-align:left;width:0%;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">&#160;</span></p> </td>
    <td colspan="1" style="width:1%;padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt;text-align:left;width:0%;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">&#160;</span></p> </td>
    <td colspan="1" style="width:1%;padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt;text-align:left;width:0%;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Unrealized depreciation<br />on forward currency<br />contracts</span></p>
        </td>
    <td colspan="1" style="width:1%;padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt;text-align:left;width:0%;vertical-align:bottom">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">($13,774)</span></p> </td>
    <td colspan="1" style="width:1%;padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt;text-align:left;width:0%;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Change in unrealized<br />appreciation (depreciation)<br />on
        forward contracts</span></p> </td>
    <td colspan="1" style="width:1%;padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt;text-align:left;width:0%;vertical-align:bottom">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">$760,369</span></p> </td>
    <td colspan="1" style="width:1%;padding-top:0pt;vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt">&#160;</p> </td> </tr>
  </table> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 25</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund has transactions
that may be subject to enforceable master netting agreements. A reconciliation of the gross amounts on the Statement of Assets and Liabilities
as of September 30, 2023 to the net amounts by broker and derivative type, including any collateral received or pledged, is included in
the following tables:</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;vertical-align:bottom;width:69">
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td colspan="1">
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td colspan="15" style="padding:0pt 0pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;height:10px">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Gross Amounts Not Offset
        in the</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Statement of Assets and&#160; Liabilities</strong></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;height:10px">
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td colspan="15" style="padding:0pt 0pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;height:10px">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Gross Amounts Not Offset
        in the</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Statement of Assets and&#160; Liabilities</strong></span></p>
        </td>
    <td colspan="1">
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> </td> </tr>
  <tr>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;vertical-align:bottom;width:69">
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td colspan="1">
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Gross
        Amounts</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>of Assets</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Presented
        in</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Statement of</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Assets
        and</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Liabilities</strong></span></p> </td>
    <td colspan="1" style="vertical-align:bottom">
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Financial</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Instruments</strong></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom">
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Collateral</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Received</strong><strong><sup>(1)</sup></strong></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom">
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Net</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Amount</strong><strong><sup>(2)</sup></strong></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom">
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Gross
        Amounts</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>of Liabilities</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Presented
        in</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Statement of</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Assets
        and</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Liabilities</strong></span></p> </td>
    <td colspan="1" style="vertical-align:bottom">
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Financial</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Instruments</strong></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom">
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Collateral</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Pledged</strong><strong><sup>(1)</sup></strong></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom">
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Net</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Amount</strong><strong><sup>(2)</sup></strong></span></p>
        </td>
    <td colspan="1">
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> </td> </tr>
  <tr>
    <td colspan="3" style="padding:0pt 0pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:69">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Description</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="15" style="padding:0pt 0pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:324">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Assets</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="15" style="padding:0pt 0pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:324">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Liabilities</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="35" style="padding:4pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-bottom:1pt solid windowtext;text-align:left;vertical-align:bottom"><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Foreign
        Currency Exchange</strong></span><br /><span style="font-size:6pt;font-family:Arial, Helvetica"><strong>Contracts</strong><strong><sup>(3)</sup></strong></span></td>
    <td colspan="1" style="padding-top:4pt">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:4pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:52.5%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">Goldman Sachs Bank</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:3%;padding-top:4pt">&#160;</td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">104,822</span></p> </td>
    <td colspan="1" style="padding:4pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%;padding-top:4pt">&#160;</td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">(13,774</span></p> </td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:0.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%;padding-top:4pt">&#160;</td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:4pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%;padding-top:4pt">&#160;</td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">91,048</span></p> </td>
    <td colspan="1" style="padding:4pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%;padding-top:4pt">&#160;</td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">13,774</span></p> </td>
    <td colspan="1" style="padding:4pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%;padding-top:4pt">&#160;</td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">(13,774</span></p> </td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:0.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%;padding-top:4pt">&#160;</td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:4pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:0.5%">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%;padding-top:4pt">&#160;</td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:4pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:3.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:4pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%;padding-top:4pt">&#160;</td> </tr>
  </table>

<p style="margin:4pt 0pt 4pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">Amounts listed as "&#8212;"
are $0 or round to $0.</span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(1) In some instances, the
actual collateral received and/or pledged may be more than the amount shown here due to overcollateralization.</span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(2) Net amounts represent the
net receivables/(payable) that would be due from/to the counterparty in the event of default. Exposure from financial derivative instruments
can only be netted across transactions governed under the same master netting agreement with the same legal entity.</span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(3) Includes financial instrument
which are not subject to a master netting arrangement across funds, or another similar arrangement.</span></p>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Forward Contracts</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Forward contracts involve
the purchase or sale of a specific quantity of a commodity, government security, foreign currency, or other asset at a specified price,
with delivery and settlement at a specified future date. Because it is a completed contract, a purchase forward contract can be a cover
for the sale of a futures contract. The Fund may enter into forward contracts for hedging purposes and non-hedging purposes (i.e., to
increase returns). Forward contracts may be used by the Fund for hedging purposes to protect against uncertainty in the level of future
foreign currency exchange rates, such as when the Fund anticipates purchasing or selling a foreign security. Forward contracts may also
be used to attempt to protect the value of the Fund's existing holdings of foreign securities. <ix:continuation id="F20231212021433901" continuedAt="F20231212021501221"><span>Forward
contracts may also be used for non-hedging purposes to pursue the Fund's investment objective. There is no requirement that the Fund hedge
all or any portion of its exposure to foreign currency risks.</span></ix:continuation></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Average notional amount of
forward contracts purchased and sold for the year ended September 30, 2023 was $61,878,109 and $317,381, respectively.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">26 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Investment Transactions
and Income</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Investment transactions are
recorded on a trade date basis. Gains and losses from sales of investments are recorded using the "identified cost" method. Interest income
is recorded on the accrual basis, adjusted for amortization of premiums and accretion of discounts. Dividend income is recorded on the
ex-dividend date, less any foreign taxes withheld. Upon notification from issuers, some of the dividend income received may be redesignated
as a reduction of cost of the related investment if it represents a return of capital. Stock dividends are reflected as non-cash dividend
income on the Statement of Operations.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The aggregate cost of purchases
and proceeds from sales of investment securities (other than short-term investments) for the year ended September 30, 2023 totaled $232,618,289
and $278,435,387, respectively.</span></p>

<p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Securities Lending</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The securities lending arrangement
was terminated on July 18, 2023. Prior to July 18, 2023, the Fund may have lended its securities to approved borrowers to earn additional
income. The Fund received cash collateral from the borrower and the initial collateral received by the Fund was required to have a value
of at least 102% of the current value of the loaned securities traded on U.S. exchanges, and a value of at least 105% for all other securities.
The Fund invested its cash collateral in State Street Institutional U.S. Government Money Market Fund (SAHXX), which is registered with
the Securities and Exchange Commission (SEC) as an investment company. SAHXX invests substantially all of its assets in the State Street
U.S. Government Money Market Portfolio. The Fund received the benefit of any gains and bear any losses generated by SAHXX with respect
to the cash collateral.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund had the right to
recall loaned securities on demand. If a borrower failed to return loaned securities when due, then the lending agent was responsible
and indemnified the Fund for the lent securities. The lending agent used the collateral received from the borrower to purchase replacement
securities of the same issue, type, class and series of the loaned securities. If the value of the collateral was less than the purchase
cost of replacement securities, the lending agent was responsible for satisfying the shortfall but only to the extent that the shortfall
was not due to any decrease in the value of SAHXX.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Although the risk of loss
on securities lent was mitigated by receiving collateral from the borrower and through lending agent indemnification, the Fund could have
experienced a delay in recovering securities or could have experienced a lower than expected return if the borrower failed to return the
securities on a timely basis. The Fund received compensation for lending its securities by retaining a portion of the return on the investment
of the collateral and compensation from fees earned from borrowers of the securities. Securities lending </span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 27</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">income received by the Fund
was net of fees retained by the securities lending agent. Net income received from SAHXX was a component of securities lending income
as recorded on the Statement of Operations.</span></p>

<p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Repurchase Agreements</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">In managing short-term investments
the Fund may from time to time enter into transactions in repurchase agreements. In a repurchase agreement, the Fund's custodian takes
possession of the underlying collateral securities from the counterparty, the market value of which is at least equal to the principal,
including accrued interest, of the repurchase transaction at all times. In the event of default or bankruptcy by the other party to the
agreement, realization and/or retention of the collateral by the Fund may be delayed. The Fund may enter into repurchase transactions
with any broker, dealer, registered clearing agency or bank. Repurchase agreement transactions are not counted for purposes of the limitations
imposed on the Fund's investment in debt securities.</span></p>

<p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Distribution Policy</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Pursuant to a Securities and
Exchange Commission exemptive order the Fund may make periodic distributions that include capital gains as frequently as 12 times in any
one taxable year in respect of its common shares, and the Fund has implemented a managed distribution policy (the Policy) providing for
monthly distributions at a rate set by the Trustees. Under the current Policy, the Fund intends to make monthly distributions at a rate
of $0.1167 per share to shareholders of record. If taxable income and net long-term realized gains exceed the amount required to be distributed
under the Policy, the Fund will at a minimum make distributions necessary to comply with the requirements of the Internal Revenue Code.
The Policy has been established by the Trustees and may be changed by them without shareholder approval. The Trustees regularly review
the Policy and the frequency and distribution rate considering the purpose and effect of the Policy, the financial market environment,
and the Fund's income, capital gains and capital available to pay distributions.</span></p>

<p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Share Repurchase Program</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">In March 2023, the Trustees
approved the renewal of the repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares in the open market
for a one-year period ending July 14, 2024. Prior to this renewal, in March 2022, the Trustees approved the renewal of the share repurchase
program to allow the Fund to repurchase up to 12% of its outstanding shares for a one-year period ending July 14, 2023. The share repurchase
program is intended to enhance shareholder value and potentially reduce the discount between the market price of the Fund's shares and
the Fund's net asset value.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">During the years ended September
30, 2023 and September 30, 2022, the Fund did not repurchase any shares through the repurchase program.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">28 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Federal Taxes</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">It is the Fund's policy to
comply with the requirements of the Internal Revenue Code applicable to regulated investment companies and to distribute to its shareholders
substantially all of its taxable income and its net realized capital gains, if any. Therefore, no Federal income or excise tax provision
is required.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">As of September 30, 2023,
the Fund had no uncertain tax positions that would require financial statement recognition or disclosure. The Fund's federal tax returns
are subject to examination by the Internal Revenue Service for a period of three years.</span></p>

<p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Distributions</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund records all distributions
to shareholders on the ex-dividend date. Such distributions are determined in conformity with income tax regulations, which may differ
from GAAP. These differences include temporary and permanent differences from losses on wash sale transactions, distribution re-designations,
return of capital distributions, passive foreign investment company transactions, foreign currency gains and losses, distributions from
real estate investment trusts, ordinary loss netting reduce short term capital gains, net operating loss, forward contracts mark-to-market,
premium amortization accruals and book to tax difference due to merger. Reclassifications are made to the Fund's capital accounts to reflect
income and gains available for distribution under income tax regulations. At September 30, 2023, the Fund reclassified ($28,386,254) from
accumulated net realized gain on investment and $28,932,091 to undistributed net investment income, with a net impact of ($545,837) to
paid in capital, for current period book/tax differences.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The tax basis components of
distributable earnings and the tax cost as of September 30, 2023 were as follows:</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:152;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Cost of investments for tax purposes</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:21;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:54;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">620,402,749</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:152">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Gross tax unrealized appreciation</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:21">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:54">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">47,525,528</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:152;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Gross tax unrealized depreciation</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:21;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">($</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:54;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">101,358,625</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:152">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Net tax unrealized appreciation on investments</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:21">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">($</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:54">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">53,833,097</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:152;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Late-year ordinary loss deferrals</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:21;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">($</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:54;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,865,740</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  </table>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund has designated the
distributions for its taxable years ended September 30, 2023 and 2022 as follows:</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:6pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:161">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Distributions paid from:</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:6pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:77">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>2023</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:6pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:77">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>2022</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:161;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Ordinary income (includes short-term capital
        gain)</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:50;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:50;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12,307,296</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:161">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Long-term capital gain</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:50">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">30,951,311</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:50">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">18,762,225</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:161;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Return of Capital</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:50;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">22,034,793</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:50;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">21,264,321</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  </table> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 29</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Statement of Cash
Flows</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The cash amount shown in the
Statement of Cash Flows is the amount included in the Fund's Statement of Assets and Liabilities and represents cash deposits at September
30, 2023.</span></p>

<p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Commitments and Contingencies</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Under the Fund's organizational
documents, its officers and Trustees may be indemnified against certain liabilities and expenses arising out of the performance of their
duties to the Fund. Additionally, in the normal course of business, the Fund enters into agreements with service providers that may contain
indemnification clauses. The Fund's maximum exposure under these agreements is unknown as this would involve future claims that may be
made against the Fund that have not yet occurred. However, based on experience, the Fund expects the risk of loss to be remote.</span></p>

<p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Loan Payable</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund maintains a $125,000,000
line of credit with the Bank of Nova Scotia (the Line of Credit) which expires on January 26, 2024. As of September 30, 2023, the Fund
had drawn down $120,000,000 from the Line of Credit, which was the maximum borrowing outstanding during the period. Between October 1,
2022 through January 27, 2023, the Fund was charged interest at the rate of 0.75% plus a SOFR Adjustment plus the relevant SOFR rate.
Starting January 28, 2023, the Fund is charged interest at the rate of 0.95% plus a SOFR Adjustment plus the relevant SOFR rate. The Fund
is also charged a commitment fee on the daily unused balance of the line of credit at the rate of 0.10% (per annum). Per the Line of Credit
agreement, the Fund paid an upfront fee of 0.05% on the total line of credit balance, which is being amortized through January 27, 2024.
The Fund pledges its investment securities as the collateral for the line of credit per the terms of the agreement. The weighted average
interest rate and the average outstanding loan payable for the period from October 1, 2022 to September 30, 2023 were 5.77% and $120,000,000,
respectively. The stated carrying amount of the line of credit approximates its fair value based upon the short term nature of the borrowings
and the interest rates being based upon the market terms. The borrowings under the line of credit would be considered as Level 2 in the
fair value hierarchy (See Note 3) at September 30, 2023.</span></p>

<p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Investor Support Services</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Destra Capital Advisors LLC
(Destra) provide the Fund investor support services in connection with the ongoing operation of the Fund. The Fund paid Destra a fee in
an annual amount equal to 0.05% of the average aggregate daily value of the Fund's Managed Assets pursuant to the investor support services
agreement.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">30 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>(2)&#160;&#160;Investment
Advisory and Other Affiliated Fees</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund entered into an Investment
Advisory Agreement (the Advisory Agreement) with the Adviser. Pursuant to the terms of the Advisory Agreement, the Fund paid the Adviser
a monthly fee at the rate when annualized of 1.00% of the average daily value of the Fund's Managed Assets. Managed Assets means the total
assets of the Fund minus the Fund's liabilities other than the loan payable.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund entered into a Services
Agreement (the Agreement) with the Adviser. Pursuant to the terms of the Agreement, the Fund reimbursed the Adviser for certain services
related to a portion of the payment of salary and provision of benefits to the Fund's Chief Compliance Officer. During the year ended
September 30, 2023, these payments amounted to $65,706 and are included in the Other category of expenses in the Statement of Operations,
together with insurance and other expenses incurred to unaffiliated entities. Expenses incurred pursuant to the Agreement as well as certain
expenses paid for by the Adviser are allocated to the Fund in an equitable fashion as approved by the Trustees or officers of the Fund
who are also officers of the Adviser. See also Subsequent Event Note 6.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund pays compensation
to Independent Trustees in the form of a retainer, attendance fees and additional compensation to Board and Committee chairpersons. The
Fund does not pay compensation directly to Trustees or officers of the Fund who are also officers of the Adviser.</span></p>

<p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>(3)&#160;&#160;Fair
Value Measurements</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund uses a three-tier
hierarchy to prioritize the assumptions, referred to as inputs, used in valuation techniques to measure fair value. The three-tier hierarchy
of inputs is summarized in the three broad levels. Level 1 includes quoted prices in active markets for identical investments. Level 2
includes prices determined using other significant observable inputs (including quoted prices for similar investments, interest rates,
credit risk, etc.). The independent pricing vendor may value bank loans and debt securities at an evaluated bid price by employing methodologies
that utilize actual market transactions, broker-supplied valuations, and/or other methodologies designed to identify the market value
for such securities and such securities are considered Level 2 in the fair value hierarchy. Level 3 includes prices determined using significant
unobservable inputs (including the Fund's own assumptions in determining the fair value of investments). These inputs or methodology used
for valuing securities are not necessarily an indication of the risk associated with investing in those securities. See also Subsequent
Event Note 6.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">For the year ended September
30, 2023, the total amount of transfers between Level 3 and Level 1 was $1,711,411. The investment was transferred due to an initial public
offering and the value is being supported by the market price.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 31</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following is a summary
of the levels used as of September 30, 2023 to value the Fund's investments.</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:96">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Assets at Value</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:97">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Level 1</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:95">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Level 2</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:88">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Level 3</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:98">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="19" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:498;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Non-convertible Notes</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">France</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,449,435</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,449,435</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Ireland</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,562,936</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,562,936</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">United Kingdom</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,794,712</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4,794,712</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">United States</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">73,868,010</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">73,868,010</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="19" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:498">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Convertible Preferreds</strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">France</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,100,979</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,100,979</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Ireland</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,436,737</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,436,737</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">United States</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,154,672</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,154,672</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="19" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:498">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Common Stocks</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Australia</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,053,724</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,053,724</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Canada</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">19,183</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,632</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">27,815</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">China</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">791,265</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">791,265</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Denmark</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">19,665,320</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">19,665,320</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">France</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,649,703</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,649,703</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Germany</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,350,645</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,350,645</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Ireland</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">507,430</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">507,430</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Israel</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">920,866</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">920,866</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Japan</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,669,881</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7,669,881</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Netherlands</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,556,254</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,556,254</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Switzerland</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">33,870,291</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">33,870,291</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">United Kingdom</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">20,784,231</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">20,784,231</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">United States</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">341,602,612</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">341,602,612</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Short-term Investments</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">19,869,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">19,869,000</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Milestone Interest</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">*</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">*</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>457,441,405</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>102,552,725</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>6,692,388</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>566,686,518</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="19" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:498;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Other Financial Instruments</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="19" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:498">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Assets</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Forward Currency Contracts</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">104,822</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">104,822</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="19" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:498">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Liabilities</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Forward Currency Contracts</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(13,774</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(13,774</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Options Contracts Written</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(207,914</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(207,914</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:96;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total</strong></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>($</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>207,914</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>91,048</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>&#8212;</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>($</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>116,866</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:left;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  </table>

<p style="margin:4pt 0pt 6pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">* Represents security valued
at zero.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">32 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following is a reconciliation
of Level 3 assets for which significant unobservable inputs were used to determine fair value.</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:60"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Investments
        in </strong></span><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Securities</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:88"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Balance
        as of</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>September 30,</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>2022</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:100"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Net
        realized</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>gain (loss) and</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>change
        in</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>unrealized</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>appreciation</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>(depreciation)</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:94"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Cost
        of</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>purchases</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>and</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>conversions</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:98"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Proceeds</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>from</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>sales
        and</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>conversions</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:89"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Net</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>transfers</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>into</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>(out
        of)</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Level 3</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:101"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Balance</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>as
        of</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>September 30,</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>2023</strong></span></td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="27" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:670;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Convertible Preferred</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">France</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">960,713</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">($</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">166,621</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,306,887</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:21">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,100,979</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Ireland</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,902,611</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(466,074</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">200</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,436,737</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Switzerland</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,047,583</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(336,172</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,711,411</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">United States</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,943,709</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(189,215</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">182</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1,600,004</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,154,672</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="27" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:670">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Milestone Interest</strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">United States</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">138,520</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(138,520</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:18;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Total</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>8,993,136</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>($</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>1,296,602</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:left;vertical-align:bottom;width:18">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>2,307,269</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>($</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>1,600,004</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:left;vertical-align:bottom;width:18">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>($</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>1,711,411</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:left;vertical-align:bottom;width:18">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>)</strong></span></p>
        </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:21">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>6,692,388</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="23" style="padding:2.5pt .7pt 3pt 0pt;text-align:left;vertical-align:bottom;width:561;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">Net
        change in unrealized appreciation (depreciation) from </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">investments
        still held as of September 30, 2023</span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2.5pt .7pt 3pt 0pt;text-align:right;vertical-align:bottom;width:21;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">($</span></p> </td>
    <td colspan="1" style="padding:2.5pt .7pt 3pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">960,430</span></p> </td>
    <td colspan="1" style="padding:2.5pt .7pt 3pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  </table>

<p style="margin:6pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following is a quantitative
disclosure about significant unobservable inputs used in the determination of the fair value of Level 3 assets.</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:6pt 0.7pt 2pt 0pt;vertical-align:bottom;height:15px">&#160;</td>
    <td colspan="1" style="height:15px">&#160;</td>
    <td colspan="3" style="padding:6pt 0.7pt 2pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt;height:15px">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Fair
        Value at</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">September
        30,</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">2023</strong></span></p>
        </td>
    <td colspan="1" style="height:15px">&#160;</td>
    <td colspan="3" style="padding:6pt 0.7pt 2pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;height:15px">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Valuation Technique</strong></span></p>
        </td>
    <td colspan="1" style="height:15px">&#160;</td>
    <td colspan="3" style="padding:6pt 0.7pt 2pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;height:15px">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Unobservable Input</strong></span></p>
        </td>
    <td colspan="1" style="height:15px">&#160;</td>
    <td colspan="3" style="padding:6pt 0.7pt 2pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;height:15px"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Range</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>(Weighted
        Average)</strong></span></td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:91;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Convertible Preferreds</strong></span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">6,692,388</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:75;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Transaction price</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:74;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">(a)</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:88;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">N/A</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:91">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Milestone Interest</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:75"><span style="font-size:8pt;font-family:Arial, Helvetica">Probability
        adjusted </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">value</span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:90"><span style="font-size:8pt;font-family:Arial, Helvetica">Probability
        of events</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">Timing of events</span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:88"><span style="font-size:8pt;font-family:Arial, Helvetica">0.00%-10.00%
        (0.00%)</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">0.75-12.25 years (0.00)</span></td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:91;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>6,692,388</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:75;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:90;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:104;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  </table>

<p style="margin:4pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(a) The valuation technique
used as a basis to approximate fair value of these investments is based on a transaction price or subsequent financing rounds.</span></p>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>(4)&#160;&#160;Private
Companies and Other Restricted Securities</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund may invest in private
companies and other restricted securities if these securities currently comprise 10% or less of Managed Assets. The value of these securities
represented 2% of the Fund's Managed Assets at September 30, 2023.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">At September 30, 2023, the
Fund had commitments of $1,966,585 relating to additional investments in two private companies.</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 33</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following table details
the acquisition date, cost, carrying value per unit, and value of the Fund's private companies and other restricted securities at September
30, 2023. The Fund on its own does not have the right to demand that such securities be registered.</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:146">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Security</strong><strong><sup>#</sup></strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:107"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Acquisition</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Date</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:81">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Cost</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:85"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Carrying
        Value</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>per Unit</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt .7pt 2pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:77">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Value</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:146;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Amolyt Pharma SAS Series C Cvt. Pfd</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:107;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">01/25/23</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,306,755</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2.26</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,220,270</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:146">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Endeavor Biomedicines, Inc. Series B Cvt. Pfd</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:107">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">01/21/22</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,002,482</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4.72</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,999,999</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:146;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Flamingo Therapeutics, Inc. Series A3 Cvt.
        Pfd</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:107;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">04/21/20, 10/28/20</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">3,142,774</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5.46</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">880,709</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:146">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Fusion Pharmaceuticals, Inc. Common</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:107">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">09/20/22</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2.34</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">8,632</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:146;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">IO Light Holdings, Inc. Series A2 Cvt. Pfd</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:107;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">04/30/20, 05/17/21, 09/15/21&#8224;</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">337,063</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.52</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">154,673</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:146">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Priothera Ltd. Series A Cvt. Pfd</span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:107">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">10/07/20</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,265,398</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7.40</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,436,737</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:146;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Rainier Therapeutics Milestone Interest</span></p>
        </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:107;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">09/28/21</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:53;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">143,115</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:19;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.00</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:146">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:107">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:53">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>10,197,587</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:85">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>$</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>6,701,020</strong></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;border:none;border-top:solid windowtext 1pt;border-bottom:double windowtext 2.25pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  </table>

<p style="margin:4pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">#&#160;&#160;See Schedule of
Investments and corresponding footnotes for more information on each issuer.</span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8224;&#160;&#160;Interest
received as part of a corporate action for a previously owned security.</span></p> <ix:continuation id="F20231212021501221" continuedAt="F20231212021548999">

<div>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>(5)&#160;&#160;At-the-Market
Offering</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund has a registration
statement on file with the SEC, initially effective on December 6, 2022, authorizing the Fund to issue shares through an At-the-Market
Offering (ATM) having an aggregate value of up to $150,000,000. The offering costs associated with the Fund's ATM offering are approximately
$278,586 of which $7,478 were charged to paid-in-capital upon the issuance of associated shares and $271,108 remains in prepaid expenses.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">On December 14, 2022, the
Fund entered into a distribution agreement with Foreside Fund Services, LLC (Foreside), pursuant to which the Fund may offer and sell
up to $150,000,000 of shares from time to time, through Foreside as its agent, in transactions deemed to be at the market as defined in
Rule 415 under the Securities Act of 1933, as amended (the Offering). Under the Distribution Agreement, Foreside may enter into sub-placement
agent agreements with one or more selected dealers. Foreside has entered into a sub-placement agent agreement, dated December 14, 2022
(the Sub-Placement Agent Agreement), with UBS Securities LLC (UBS) relating to the shares to be offered under the Distribution Agreement.
During the year ended on September 30, 2023, 274,984 shares were sold under this agreement for $3,950,593 (net of commissions to Foreside
and UBS of $39,906).</span></p> </div> </ix:continuation>

<p style="margin:0pt 0pt 3pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>(6)&#160;&#160;Subsequent
Event</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Effective at the close of
business on October 27, 2023, the Adviser assumed responsibility for management of the Fund from Tekla Capital Management, LLC (TCM).
On the same date, the investment team at TCM joined abrdn and continues to manage the Fund. Also effective upon abrdn's appointment as
adviser, four Trustees resigned from the Fund's Board, and Stephen Bird, Rose DiMartino, C. William Maher and Todd Reit, who were elected
by </span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">34 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">shareholders, joined Jeffrey
Bailey and Kathleen Goetz on the Fund's Board. Mr. Reit began serving as Chair of the Board on the same date.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Also effective upon abrdn's
appointment as adviser, the Fund's assets are valued pursuant to the valuation procedures for funds advised by abrdn, as approved by the
Board after the new Trustees began their term. Pursuant to the new valuation procedures, foreign equity securities that trade on a market
that closes prior to the Fund's valuation time are valued by applying daily valuation factors to the last quoted sale price. Additionally,
the new valuation procedures generally value forward foreign currency contracts based on the daily spot exchange rates and the forward
exchange rate points (e.g. 1-month, 3-month).</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Services Agreement terminated
on October 27, 2023.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Effective upon the close of
business on October 27, 2023, the Adviser as Adviser of the Fund, entered into a written contract with the Fund to limit the total ordinary
operating expenses of the Fund (excluding leverage costs, interest, taxes, brokerage commissions, acquired fund fees and expenses and
any non-routine expenses) from exceeding 1.51% of the average daily net assets of the Fund on an annualized basis for twelve months (the
"Expense Limitation Agreement").The Expense Limitation Agreement may not be terminated before October 27, 2025, without the approval of
the Fund's trustees who are not "interested persons" of the Fund (as defined in the 1940 Act).</span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 35</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />
</div>

<div >

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 6pt 0pt;text-align:left"><span style="font-size:19pt;font-family:Arial, Helvetica">REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</span></p></div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>To the Shareholders
and Board of Trustees abrdn World Healthcare Fund:</strong></span></p>

<p style="margin:4pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong><i>Opinion on the Financial
Statements</i></strong></span></p>

<p style="margin:0pt 0pt 6pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">We have audited the accompanying
statement of assets and liabilities of abrdn World Healthcare Fund (formerly, Tekla World Healthcare Fund) (the Fund), including the schedule
of investments, as of September 30, 2023, the related statements of operations, changes in net assets, and cash flows for the year then
ended, and the related notes (collectively, the financial statements) and the financial highlights for the year then ended. In our opinion,
the financial statements and financial highlights present fairly, in all material respects, the financial position of the Fund as of September
30, 2023, the results of its operations, the changes in its net assets, its cash flows and the financial highlights for the year then
ended, in conformity with U.S. generally accepted accounting principles. The statement of changes in net assets for the year ended September
30, 2022 and financial highlights for each of the years in the four-year period ended September 30, 2022 were audited by other independent
registered public accountants whose report, dated November 21, 2022, expressed an unqualified opinion on that financial statement and
those financial highlights.</span></p>

<p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong><i>Basis for Opinion</i></strong></span></p>

<p style="margin:0pt 0pt 6pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">These financial statements
and financial highlights are the responsibility of the Fund's management. Our responsibility is to express an opinion on these financial
statements and financial highlights based on our audit. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Fund in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="margin:0pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">We conducted our audit in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements and financial highlights are free of material misstatement, whether due to error or fraud. Our
audit included performing procedures to assess the risks of material misstatement of the financial statements and financial highlights,
whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the financial statements and financial highlights. Such procedures also included confirmation
of securities owned as of September 30, 2023, by correspondence with custodians and brokers; when replies were not received from brokers,
we performed other auditing procedures. Our audit also included evaluating the accounting principles used and significant estimates made
by management, as well as evaluating the overall presentation of the financial statements and financial highlights. We believe that our
audit provides a reasonable basis for our opinion.</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:center"><img alt="j23251332_ga011.jpg" src="j23251332_ga011.jpg" /></p>

<p style="margin:0pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">We have served as the auditor
of one or more abrdn investment companies since 2009.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Philadelphia, Pennsylvania<br />November
29, 2023</span></p></div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">36 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p><hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 6pt 0pt;text-align:left"><span style="font-size:19pt;font-family:Arial, Helvetica">TRUSTEES AND OFFICERS</span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>
(AS OF OCTOBER 30, 2023, Unaudited)</i></span></p></div>

<div style="margin:8pt 0pt 8pt 0pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:100%" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt 0.7pt 3.5pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:left;vertical-align:bottom;width:36%"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Name,
        Address</strong><strong><sup>1</sup></strong><strong>, Date of Birth,</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Length
        of Time Served, Principal Occupation(s)</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>During Past
        5 Years, at Minimum, and</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Other Directorship Held</strong></span></td>
    <td colspan="1" style="width:0.2%">&#160;</td>
    <td colspan="3" style="padding:0pt 0.7pt 3.5pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;width:31.3%"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Position(s)
        Held with Fund,</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Term of Office</strong><strong><sup>2</sup></strong></span></td>
    <td colspan="1" style="width:0.2%">&#160;</td>
    <td colspan="3" style="padding:0pt 0.7pt 3.5pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;width:31.3%"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Number
        of Registered</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Investment Companies</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>("Registrants")
        consisting</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>of Investment Portfolios</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>("Portfolios")</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>in
        Fund Complex</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Overseen by Trustee</strong><strong><sup>4</sup></strong></span></td>
    <td colspan="1" style="width:1%"><br />&#160;</td></tr>
  </table>

<p style="margin:9pt 0pt 6pt 0pt;text-align:left"><span style="font-size:12pt;font-family:Arial, Helvetica"><strong>INDEPENDENT TRUSTEES</strong></span></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top;width:36%"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Jeffrey
        A. Bailey, Born: 1962</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"> &#160;</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.2%">&#160;</td>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:31.3%"><span style="font-size:8pt;font-family:Arial, Helvetica">Trustee
        since 2020</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">&#160;</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.2%">&#160;</td>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:31.3%"><span style="font-size:8pt;font-family:Arial, Helvetica">Registrants
        consisting</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">of 4 Portfolios</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td></tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:1456">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">CEO, IlluminOss, Inc. (2018-2020); Board Chairman,
        Aileron Therapeutics Inc. (since 2017); Director, Madison Vaccines, Inc. (since 2018); Director, Aurinia Pharmaceuticals, Inc. (since
        August 2023); Director and CEO, BioDelivery Systems, Inc. (since 2020-2022).</span></p></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top;width:36%"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Kathleen
        Goetz, Born: 1966</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"> &#160;</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.2%">&#160;</td>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:31.3%"><span style="font-size:8pt;font-family:Arial, Helvetica">Trustee
        since 2021</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">&#160;</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.2%">&#160;</td>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:31.3%"><span style="font-size:8pt;font-family:Arial, Helvetica">Registrants
        consisting</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">of 4 Portfolios</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td></tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:1456">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Independent Consultant (since 2020); Novartis
        Pharmaceuticals: Vice President and Head of Sales (2017-2019), Executive Director of Strategic Account Management (2015-2016).</span></p></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top;width:36%"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Rose
        DiMartino, Born: 1952</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"> &#160;</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.2%">&#160;</td>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:31.3%"><span style="font-size:8pt;font-family:Arial, Helvetica">Trustee
        since 2023</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">&#160;</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.2%">&#160;</td>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:31.3%"><span style="font-size:8pt;font-family:Arial, Helvetica">5
        Registrants consisting </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">of 7 Portfolios</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td></tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:1456">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Retired since 2019. Partner (1991-2017) and
        Senior Counsel (2017-2019) at the law firm of Willkie Farr &#38; Gallagher LLP.</span></p></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top;width:36%"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>C.
        William Maher, Born: 1961</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"> &#160;</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.2%">&#160;</td>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:31.3%"><span style="font-size:8pt;font-family:Arial, Helvetica">Trustee
        since 2023</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">&#160;</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.2%">&#160;</td>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:31.3%"><span style="font-size:8pt;font-family:Arial, Helvetica">7
        Registrants consisting </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">of 7 Portfolios</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td></tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:1456">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Mr. Maher is a Co-founder of Asymmetric Capital
        Management LLC from May 2018 to September 2020. Formerly Chief Executive Officer of Santa Barbara Tax Products Group from October 2014
        to April 2016.</span></p></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top;width:36%"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Todd
        Reit, Born: 1968</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"> &#160;</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.2%">&#160;</td>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:31.3%"><span style="font-size:8pt;font-family:Arial, Helvetica">Trustee
        since 2023</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">&#160;</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.2%">&#160;</td>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:31.3%"><span style="font-size:8pt;font-family:Arial, Helvetica">9
        Registrants consisting </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">of 9 Portfolios</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td></tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:1456">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Mr. Reit is a Managing Member of Cross Brook
        Partners LLC, a real estate investment and management company since 2017. Mr. Reit is also Director and Financial Officer of Shelter Our
        Soldiers, a charity to support military veterans, since 2016. Mr. Reit was formerly a Managing Director and Global Head of Asset Management
        Investment Banking for UBS AG, where he was responsible for overseeing all the bank's asset management client relationships globally,
        including all corporate security transactions, mergers and acquisitions. Mr. Reit retired from UBS in 2017 after an over 25-year career
        at the company and its predecessor company, PaineWebber Incorporated (merged with UBS AG in 2000).</span></p></td>
    <td colspan="1">&#160;</td></tr>
  </table>

<p style="margin:9pt 0pt 6pt 0pt;text-align:left"><span style="font-size:12pt;font-family:Arial, Helvetica"><strong>INTERESTED TRUSTEE</strong></span></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top;width:36%"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Stephen
        Bird</strong><strong><sup>3</sup></strong><strong>, Born: 1967</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica">
        &#160;</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.2%">&#160;</td>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:31.3%"><span style="font-size:8pt;font-family:Arial, Helvetica">Trustee
        since 2023</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">&#160;</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.2%">&#160;</td>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:31.3%"><span style="font-size:8pt;font-family:Arial, Helvetica">15
        Registrants consisting</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">of 33 Portfolios</span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td></tr>
  <tr>
    <td colspan="11" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:1456">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Mr. Bird joined the Board of SLA plc in July
        2020 as Chief Executive-Designate, and was formally appointed Chief Executive Officer in September 2020. Previously, Mr. Bird served as
        chief executive officer of global consumer banking at Citigroup from 2015, retiring from the role in November 2019. His responsibilities
        encompassed all consumer and commercial banking businesses in 19 countries, including retail banking and wealth management, credit cards,
        mortgages, and operations and technology supporting these businesses. Prior to this, Mr. Bird was chief executive for all of Citigroup's
        Asia Pacific business lines across 17 markets in the region, including India and China. Mr. Bird joined Citigroup in 1998, and during
        his 21 years with the company he held a number of leadership roles in banking, operations and technology across its Asian and Latin American
        businesses. Before this, he held management positions in the UK at GE Capital&#8212;where he was director of UK operations from 1996 to
        1998&#8212;and at British Steel.</span></p></td>
    <td colspan="1">&#160;</td></tr>
  </table>

<p style="margin:0pt 0pt 1pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica"><sup>1&#160;&#160;</sup>The
Address for each Trustee is: c/o abrdn Inc., 1900 Market Street, Suite 200, Philadelphia, PA 19103.</span></p>

<p style="margin:0pt 0pt 1pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica"><sup>2&#160;&#160;</sup>Each
Trustee currently is serving a three year term.</span></p></div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT37</span></p><hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 1pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica"><sup>3&#160;&#160;</sup>Trustee
considered to be an "interested person" within the meaning of the Investment Company Act of 1940, as amended (the "1940 Act"), through
position or affiliation with the Adviser.</span></p>

<p style="margin:0pt 0pt 1pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica"><sup>4</sup>&#160;&#160;As
of October 30, 2023, the Fund Complex has a total of 18 Registrants with each Board member serving on the Boards of the number of Registrants
listed. Each Registrant in the Fund Complex has one Portfolio except for two Registrants that are open-end funds, abrdn Funds and abrdn
ETFs, which each have multiple Portfolios. The Registrants in the Fund Complex are as follows: abrdn Asia-Pacific Income Fund, Inc., abrdn
Global Income Fund, Inc., abrdn Australia Equity Fund, Inc., abrdn Emerging Markets Equity Income Fund, Inc., The India Fund, Inc., abrdn
Japan Equity Fund, Inc., abrdn Income Credit Strategies Fund, abrdn Global Dynamic Dividend Fund, abrdn Global Premier Properties Fund,
abrdn Total Dynamic Dividend Fund, abrdn Global Infrastructure Income Fund, abrdn National Municipal Income Fund, abrdn Healthcare Investors,
abrdn Life Sciences Investors, abrdn Healthcare Opportunities Fund, abrdn World Healthcare Fund, abrdn Funds (19 Portfolios), and abrdn
ETFs (3 Portfolios).</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:7pt .7pt 3.5pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:560"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Name,
        Address</strong><strong><sup>1</sup></strong><strong>, Date of Birth,</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Principal
        Occupation(s)</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>During Past 5 Years</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:7pt .7pt 3.5pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:527"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Position(s)
        Held with</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Fund, Term of Office</strong><strong><sup>2</sup></strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>and
        Length of Time Served</strong></span></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Joseph
        Andolina*, Born: 1978</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"> &#160;&#160;</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">&#160;&#160;</span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 5pt 0pt;text-align:left;vertical-align:bottom;width:527;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">Chief
        Compliance Officer and </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">Vice President Compliance </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">since
        2023</span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="7" style="padding:0pt .7pt 5pt 0pt;text-align:left;vertical-align:bottom;width:1087">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Currently, Chief Risk Officer&#8212;Americas
        for abrdn Inc. and serves as the Chief Compliance Officer for abrdn Inc. Prior to joining the Risk and Compliance Department, he was a
        member of abrdn Inc.'s Legal Department, where he served as US Counsel since 2012.</span></p></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Sharon
        Ferrari*, Born: 1977</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"> &#160;&#160;</span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 5pt 0pt;text-align:left;vertical-align:bottom;width:527;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">Treasurer
        and Chief Financial </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">Officer since 2023</span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="7" style="padding:0pt .7pt 5pt 0pt;text-align:left;vertical-align:bottom;width:1087">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Currently, Director Product Management&#8212;US
        for abrdn Inc. Ms. Ferrari joined abrdn Inc. as a Senior Fund Administrator in 2008.</span></p></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Alan Goodson*, Born: 1974</strong></span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 5pt 0pt;text-align:left;vertical-align:bottom;width:527;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Vice President since 2023</span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="7" style="padding:0pt .7pt 5pt 0pt;text-align:left;vertical-align:bottom;width:1087">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Currently, Director, Vice President and Head
        of Product &#38; Client Solutions&#8212;Americas for abrdn Inc., overseeing Product Management &#38; Governance, Product Development and
        Client Solutions for registered and unregistered investment companies in the U.S., Brazil and Canada. Mr. Goodson is Director and Vice
        President of abrdn Inc. and joined abrdn Inc. in 2000.</span></p></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Megan
        Kennedy*, Born: 1974</strong></span><span style="font-size:8pt;font-family:Arial, Helvetica"> &#160;&#160;</span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 5pt 0pt;text-align:left;vertical-align:bottom;width:527;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">Secretary
        and Vice President </span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">since 2023</span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="7" style="padding:0pt .7pt 5pt 0pt;text-align:left;vertical-align:bottom;width:1087">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Currently, Senior Director, Product Governance
        for abrdn Inc. Ms. Kennedy joined abrdn Inc. in 2005.</span></p></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Daniel R. Omstead, Ph.D., Born: 1953</strong></span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 5pt 0pt;text-align:left;vertical-align:bottom;width:527;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Vice President since 2023</span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="7" style="padding:0pt .7pt 5pt 0pt;text-align:left;vertical-align:bottom;width:1087">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Currently Head of Healthcare Investments at
        abrdn. Previously, President of HQH and HQL (from 2001 to October 2023), THQ (from 2014 to October 2023) and THW (from 2015 to October
        2023); President, Chief Executive Officer and Managing Member of Tekla Capital Management, LLC from 2002 to October 2023).</span></p></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 5pt 0pt;text-align:left;vertical-align:bottom;width:560;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Christian Pittard*, Born:1973</strong></span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 5pt 0pt;text-align:left;vertical-align:bottom;width:527;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">President since 2023</span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="7" style="padding:0pt .7pt 5pt 0pt;text-align:left;vertical-align:bottom;width:1087">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Currently, Director of Corporate Finance and
        Head of Listed Funds. Mr. Pittard joined abrdn from KPMG in 1999.</span></p></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Lucia Sitar*, Born: 1971</strong></span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 5pt 0pt;text-align:left;vertical-align:bottom;width:527;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Vice President since 2023</span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="7" style="padding:0pt .7pt 5pt 0pt;text-align:left;vertical-align:bottom;width:1087">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Currently, Vice President and Head of Product
        Management and Governance for abrdn Inc. since 2020. Previously, Ms. Sitar was Managing U.S. Counsel for abrdn Inc. She joined abrdn Inc.
        as U.S. Counsel in July 2007.</span></p></td>
    <td colspan="1">&#160;</td></tr>
  </table></div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">38 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p><hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 3.5pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:560"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Name,
        Address</strong><strong><sup>1</sup></strong><strong>, Date of Birth,</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Principal
        Occupation(s)</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>During Past 5 Years</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 3.5pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:527"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Position(s)
        Held with</strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Fund, Term of Office</strong><strong><sup>2</sup></strong></span><br /><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>and
        Length of Time Served</strong></span></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:0pt 0.7pt 5pt 0pt;text-align:left;background-color:rgb(204, 238, 255);vertical-align:top">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica"><strong>Laura Woodward, Born: 1968</strong></span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:0pt .7pt 5pt 0pt;text-align:left;vertical-align:bottom;width:527;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Vice President 2023</span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="7" style="padding:0pt .7pt 5pt 0pt;text-align:left;vertical-align:bottom;width:1087">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Currently Vice President of Fund Administration
        at abrdn. Previously Chief Compliance Officer, Secretary and Treasurer of HQH and HQL (from 2009 to October 2023), THQ (from 2014 to October
        2023) and THW (from 2015 to October 2023); Chief Compliance Officer and Vice President of Fund Administration, Tekla Capital Management,
        LLC (from 2009 to October 2023).</span></p></td>
    <td colspan="1">&#160;</td></tr>
  </table>

<p style="margin:0pt 0pt 2pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica"><sup>1&#160;&#160;</sup>The
Address for each officer is: c/o abrdn Inc., 1900 Market Street, Suite 200, Philadelphia, PA 19103.</span></p>

<p style="margin:0pt 0pt 2pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica"><sup>2&#160;&#160;</sup>Each
officer serves in such capacity for an indefinite period of time at the pleasure of the Trustees.</span></p>

<p style="margin:0pt 0pt 2pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">*&#160;&#160;Each officer may
hold officer position(s) in one or more other funds which are part of the Fund Complex.</span></p>

<p style="margin:4pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">The Fund's Statement of Additional
Information includes additional information about the Fund's Trustees and is available without charge, upon request.</span></p>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">Contact us:</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8226; Visit: https://www.abrdn.com/en-us/cefinvestorcenter</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8226; Email: Investor.Relations@abrdn.com;
or</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:8pt;font-family:Arial, Helvetica">&#8226; Call: 1-800-522-5465
(toll free in the U.S.)</span></p></div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 39</span></p><hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" /></div>

<div >

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 6pt 0pt;text-align:left"><span style="font-size:19pt;font-family:Arial, Helvetica">Additional Information</span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>
(unaudited)</i></span></p> </div>

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Summary of Fund Expenses</strong></span></p>
<ix:nonNumeric id="Fxbrl_20231202141321175" name="cef:PurposeOfFeeTableNoteTextBlock" contextRef="C_20221001to20230930" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The purpose of the following
table and the example below is to help you understand the fees and expenses that holders of Common Shares ("Common Shareholders") would
bear directly or indirectly. The expenses shown in the table under "Other expenses," "Interest expenses on bank borrowings," "Total annual
expenses" and "Total annual expenses after expense reimbursement" are based on the Fund's capital structure as of September 30, 2023.
As of September 30, 2023, the Fund had $120,000,000 of leverage outstanding through bank borrowings which represented 21.2% of the Managed
Assets as of September 30, 2023. The table reflects Fund expenses as a percentage of net assets attributable to Common Shares. The following
table should not be considered a representation of the Fund's future expenses. Actual expenses may be greater or less than those shown
below.</span></p> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20231202141330946" name="cef:ShareholderTransactionExpensesTableTextBlock" contextRef="C_20221001to20230930" continuedAt="F20231202141846309" escape="true">

<div>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:8pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:182">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Shareholder transaction expenses</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:8pt .7pt 0pt 0pt;vertical-align:bottom;width:133">&#160;</td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:182;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sales load (<ix:nonNumeric id="Fxbrl_20231202144737369" name="cef:BasisOfTransactionFeesNoteTextBlock" contextRef="C_20221001to20230930" escape="true">as
        a percentage of offering price</ix:nonNumeric>)<sup>(1)</sup></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:103;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202131712153" name="cef:SalesLoadPercent" contextRef="C_20221001to20230930" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.00</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:182">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Offering expenses (<ix:nonNumeric id="Fxbrl_20231202144758996" name="cef:BasisOfTransactionFeesNoteTextBlock" contextRef="C_20221001to20230930" escape="true">as
        a percentage of offering price</ix:nonNumeric>)<sup>(2)</sup></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:103">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202131721229" name="cef:OtherTransactionExpensesPercent" contextRef="C_20221001to20230930" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.19</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:182;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Dividend reinvestment and Stock Repurchase
        Plan Fees<sup>(3)</sup></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:103;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202131724023" name="cef:DividendReinvestmentAndCashPurchaseFees" contextRef="C_20221001to20230930" unitRef="USD" scale="0" decimals="0" format="ixt-sec:numwordsen">None</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20231202141339022" name="cef:AnnualExpensesTableTextBlock" contextRef="C_20221001to20230930" continuedAt="F20231202141858013" escape="true">

<div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%" width="100%">
  <tr>
    <td colspan="3" style="padding:8pt .7pt 0pt 0pt;vertical-align:bottom;width:182">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:8pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:133"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Annual
        expenses</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>(as a percentage of net<br />assets</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>attributable
        to</strong></span><br /><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Common Shares)</strong></span></td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:90%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Advisory fee<sup>(4)</sup></span></p> </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:6%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202131857489" name="cef:ManagementFeesPercent" contextRef="C_20221001to20230930" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.24</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:90%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Interest expenses on bank borrowings<sup>(5)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:6%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202131859366" name="cef:InterestExpensesOnBorrowingsPercent" contextRef="C_20221001to20230930" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.45</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:90%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Other expenses</span></p> </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:6%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202131901664" name="cef:OtherAnnualExpensesPercent" contextRef="C_20221001to20230930" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.30</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:90%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Total annual expenses</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:6%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202131904127" name="cef:TotalAnnualExpensesPercent" contextRef="C_20221001to20230930" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.99</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:90%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Less: expense reimbursement<sup>(6)</sup></span></p>
        </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:6%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202131906133" name="cef:WaiversAndReimbursementsOfFeesPercent" contextRef="C_20221001to20230930" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.03</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:90%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Total annual expenses after expense reimbursement</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:6%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202131908324" name="cef:NetExpenseOverAssetsPercent" contextRef="C_20221001to20230930" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.96</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric> <ix:continuation id="F20231202141846309">

<div>

<p style="margin:4pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(1) If Common Shares are sold
to or through underwriters, a prospectus or prospectus supplement will set forth any applicable sales load and the estimated offering
expenses borne by the Fund.</span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(2) Offering expenses payable
by the Fund will be deducted from the proceeds, before expenses, to the Fund.</span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(3) <ix:nonNumeric id="Fxbrl_20231202144846957" name="cef:OtherTransactionFeesNoteTextBlock" contextRef="C_20221001to20230930" escape="true">The
expenses of administering the Fund's Dividend Reinvestment and Stock Purchase Plan are included in "Other Expenses." You will pay brokerage
charges if you direct your broker or the plan agent to sell your Shares that you acquired pursuant to the Fund's Dividend Reinvestment
and Stock Purchase Plan. You may also pay a pro rata share of brokerage commissions incurred in connection with open-market purchases
pursuant to the Fund's Dividend Reinvestment and Stock Purchase Plan. For more details about the Dividend Reinvestment and Stock Purchase
Plan, see "Dividend Reinvestment and Stock Purchase Plan" in the Fund's Prospectus.</ix:nonNumeric></span></p> </div> </ix:continuation>
<ix:continuation id="F20231202141858013" continuedAt="F20231202141904131">

<div>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(4) The Advisory fee is charged
as a percentage of the Fund's average daily Managed Assets, as opposed to net assets. If leverage is used, Managed Assets will be greater
in amount than net assets, because Managed Assets includes borrowings for investment purposes.</span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(5) The percentage in the table
is based on total borrowings of $120,000,000 (the balance outstanding under the Fund's Credit Facility as of September 30, 2023, representing
approximately 21.2% of the Fund's Managed Assets) and an average interest rate during the fiscal year ended September 30, 2023, of 5.77%.
There can be no assurances that the Fund will be able to obtain such level of borrowing (or to maintain its current level of borrowing),
that the terms under which the Fund borrows will not change, or that the Fund's use of leverage will be profitable. The Fund currently
intends during the next twelve months to maintain a similar proportionate amount of borrowings but may increase such amount to 33 1/3%
of the average daily value of the Fund's total assets.</span></p> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">40 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202141904131">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(6) As of the close of business
on October 27, 2023, the Adviser has entered into a written contract with the Fund to limit the total ordinary operating expenses of the
Fund (excluding leverage costs, interest, taxes, brokerage commissions, acquired fund fees and expenses and any non-routine expenses)
from exceeding 1.51% of the average daily net assets of the Fund on an annualized basis for twelve months (the "Expense Limitation Agreement").The
Expense Limitation Agreement may not be terminated before October 27, 2025, without the approval of the Fund's trustees who are not "interested
persons" of the Fund (as defined in the 1940 Act).The Fund may repay any such reimbursement from the Adviser, within three years of the
reimbursement, provided that the following requirements are met: the reimbursements do not cause the Fund to exceed the lesser of the
applicable expense limitation in the contract at the time the fees were limited or expenses are paid or the applicable expense limitation
in effect at the time the expenses are being recouped by the Adviser. Because interest expenses and investment related expenses are not
subject to the reimbursement agreement, interest expenses and investment related expenses are included in the "Total annual expenses after
expense reimbursement" line item.</span></p> </ix:continuation> <ix:nonNumeric id="Fxbrl_20231202142243683" name="cef:ExpenseExampleTableTextBlock" contextRef="C_20221001to20230930" escape="true">

<div>

<p style="margin:11pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Example</strong></span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following examples illustrate
the expenses you would pay on a $1,000 investment in common shares assuming that (i) all dividends and other distributions are reinvested
at NAV (ii) the percentage amounts listed under "Total annual expenses" above remain the same in the years shown and (iii) a 5% annual
portfolio total return.<sup>(1)</sup></span></p>

<div>

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following example does
not include the sales load:</span></p>

<table border="0" cellpadding="0" cellspacing="0">
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:60"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>1
        Year</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:63">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>3 Years</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:63">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>5 Years</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:67">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>10 Years</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:33;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202141040228" name="cef:ExpenseExampleYear01" contextRef="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleDoesNotIncludeSalesLoadMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:36;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202141050909" name="cef:ExpenseExampleYears1to3" contextRef="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleDoesNotIncludeSalesLoadMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:36;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202141048194" name="cef:ExpenseExampleYears1to5" contextRef="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleDoesNotIncludeSalesLoadMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">157</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:40;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202141045406" name="cef:ExpenseExampleYears1to10" contextRef="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleDoesNotIncludeSalesLoadMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">330</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  </table>

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following example assumes
a transaction fee of 1.19%, as a percentage of the offering price, as if it were borne solely by you, as purchaser<sup>(2)</sup>:</span></p>

<table border="0" cellpadding="0" cellspacing="0">
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:60"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>1
        Year</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:63">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>3 Years</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:63">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>5 Years</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:67">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>10 Years</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:33;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202141100037" name="cef:ExpenseExampleYear01" contextRef="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:36;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202141102284" name="cef:ExpenseExampleYears1to3" contextRef="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:36;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202141104669" name="cef:ExpenseExampleYears1to5" contextRef="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">167</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:40;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202141106886" name="cef:ExpenseExampleYears1to10" contextRef="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">338</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  </table>

<p style="margin:4pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(1) </span><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>The
examples above should not be considered representations of future expenses. Actual expenses may be higher or lower than those shown.</strong></span><span style="font-size:7pt;font-family:Arial, Helvetica">
The examples assume that all dividends and distributions are reinvested at net asset value. The Fund's actual rate of return may be greater
or less than the hypothetical 5% return shown in the examples. For more complete descriptions of certain of the Fund's costs and expenses,
see "Management of the Fund&#8212;Advisory Agreements" in the Fund's Prospectus.</span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(2) Notwithstanding this assumption,
in actuality, these fees will be indirectly borne by all holders of Common Shares.</span></p> </div> </div> </ix:nonNumeric> </div> </div>

<div >

<div style="margin:8pt 0pt 8pt 0pt"> <ix:nonNumeric id="Fxbrl_20231202144429534" name="cef:SeniorSecuritiesNoteTextBlock" contextRef="C_20221001to20230930" continuedAt="F20231202144438011" escape="true">

<div>

<p style="margin:11pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Senior Securities</strong></span></p>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following table sets forth
information about the Fund's outstanding senior securities as of the end of each of the Fund's last eight fiscal years. The Fund's senior
securities during this time period are comprised of borrowings which constitutes a "senior security" as defined in the 1940 Act. The information
in this table for the fiscal years ended 2022, 2021, 2020, 2019 and 2018 has been audited by a predecessor, independent registered public
accounting firm, and fiscal year ended 2023 has been audited by KPMG LLP, independent registered</span></p> </div> </ix:nonNumeric> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 41</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202144438011">

<div>

<p style="margin:0pt 0pt 8pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">public accounting firm. The Fund's
audited financial statements, including the report of KPMG LLP thereon, and accompanying notes thereto, are included in this Annual Report.</span></p>
<ix:nonNumeric id="Fxbrl_20231202144536403" name="cef:SeniorSecuritiesTableTextBlock" contextRef="C_20221001to20230930" escape="true">

<div>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:67"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Fiscal
        Period&#160;</strong></span><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Ended</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Title of Security</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Total
        Principal</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Amount</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Outstanding</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Aggregate</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Liquidation</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Preference</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Liquidation</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Preference</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Per
        Share</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Asset
        Coverage</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Per
        $1,000</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">of
        Principal</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Amount</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Average</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Market
        Value</strong><strong style="margin-top:0pt;margin-bottom:0pt"><sup style="margin-top:0pt;margin-bottom:0pt">(2)</sup></strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2023</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonNumeric id="Fxbrl_20231202144904787_12" name="cef:SecurityTitleTextBlock" contextRef="C_20221001to20230930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2023Member" escape="true">Loan
        Facility 2023</ix:nonNumeric></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_15" name="cef:SeniorSecuritiesAmt" contextRef="C_20230930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2023Member" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">120,000,000</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_113" name="us-gaap:PreferredStockLiquidationPreference" contextRef="C_20230930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2023Member" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_117" name="cef:SeniorSecuritiesCvgPerUnit" contextRef="C_20230930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2023Member" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,726</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><sup>(1)</sup></span></p>
        </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_121">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2022</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonNumeric id="Fxbrl_20231202144904787_22" name="cef:SecurityTitleTextBlock" contextRef="C_20211001to20220930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2022Member" escape="true">Loan
        Facility 2022</ix:nonNumeric></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_25" name="cef:SeniorSecuritiesAmt" contextRef="C_20220930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2022Member" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">120,000,000</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_213" name="us-gaap:PreferredStockLiquidationPreference" contextRef="C_20220930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2022Member" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_217" name="cef:SeniorSecuritiesCvgPerUnit" contextRef="C_20220930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2022Member" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,786</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_221">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2021</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonNumeric id="Fxbrl_20231202144904787_32" name="cef:SecurityTitleTextBlock" contextRef="C_20201001to20210930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2021Member" escape="true">Loan
        Facility 2021</ix:nonNumeric></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_35" name="cef:SeniorSecuritiesAmt" contextRef="C_20210930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2021Member" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">120,000,000</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_313" name="us-gaap:PreferredStockLiquidationPreference" contextRef="C_20210930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2021Member" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_317" name="cef:SeniorSecuritiesCvgPerUnit" contextRef="C_20210930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2021Member" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">5,714</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_321">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2020</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonNumeric id="Fxbrl_20231202144904787_42" name="cef:SecurityTitleTextBlock" contextRef="C_20191001to20200930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2020Member" escape="true">Loan
        Facility 2020</ix:nonNumeric></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_45" name="cef:SeniorSecuritiesAmt" contextRef="C_20200930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2020Member" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">120,000,000</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_413" name="us-gaap:PreferredStockLiquidationPreference" contextRef="C_20200930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2020Member" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_417" name="cef:SeniorSecuritiesCvgPerUnit" contextRef="C_20200930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2020Member" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,554</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_421">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2019</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonNumeric id="Fxbrl_20231202144904787_52" name="cef:SecurityTitleTextBlock" contextRef="C_20181001to20190930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2019Member" escape="true">Loan
        Facility 2019</ix:nonNumeric></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_55" name="cef:SeniorSecuritiesAmt" contextRef="C_20190930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2019Member" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">120,000,000</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_513" name="us-gaap:PreferredStockLiquidationPreference" contextRef="C_20190930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2019Member" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_517" name="cef:SeniorSecuritiesCvgPerUnit" contextRef="C_20190930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2019Member" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,396</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_521">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2018</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonNumeric id="Fxbrl_20231202144904787_62" name="cef:SecurityTitleTextBlock" contextRef="C_20171001to20180930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2018Member" escape="true">Loan
        Facility 2018</ix:nonNumeric></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_65" name="cef:SeniorSecuritiesAmt" contextRef="C_20180930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2018Member" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">120,000,000</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_613" name="us-gaap:PreferredStockLiquidationPreference" contextRef="C_20180930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2018Member" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_617" name="cef:SeniorSecuritiesCvgPerUnit" contextRef="C_20180930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2018Member" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,861</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_621">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2017</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonNumeric id="Fxbrl_20231202144904787_72" name="cef:SecurityTitleTextBlock" contextRef="C_20161001to20170930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2017Member" escape="true">Loan
        Facility 2017</ix:nonNumeric></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_75" name="cef:SeniorSecuritiesAmt" contextRef="C_20170930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2017Member" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">120,000,000</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_713" name="us-gaap:PreferredStockLiquidationPreference" contextRef="C_20170930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2017Member" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_717" name="cef:SeniorSecuritiesCvgPerUnit" contextRef="C_20170930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2017Member" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,999</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_721">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2016</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonNumeric id="Fxbrl_20231202144904787_82" name="cef:SecurityTitleTextBlock" contextRef="C_20151001to20160930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2016Member" escape="true">Loan
        Facility 2016</ix:nonNumeric></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_85" name="cef:SeniorSecuritiesAmt" contextRef="C_20160930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2016Member" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">120,000,000</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_813" name="us-gaap:PreferredStockLiquidationPreference" contextRef="C_20160930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2016Member" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202144904787_817" name="cef:SeniorSecuritiesCvgPerUnit" contextRef="C_20160930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2016Member" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">5,160</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_821">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  </table>

<p style="margin:4pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(1) The asset coverage ratio
for the Loan Facility is calculated by dividing net assets plus the amount of any borrowings for investment purposes by the amount of
any senior securities, which includes the Loan Facility, and then multiplying by $1,000.</span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(2) Not applicable because
the senior securities are not registered for public trading.</span></p> </div> </ix:nonNumeric> </div> </ix:continuation> </div> </div>

<div >

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:11pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Net Asset Value and
Market Price Information</strong></span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Net Asset Value</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's currently outstanding
Common Shares are listed on the NYSE. The Common Shares commenced trading on the NYSE on June 30, 2015.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Common Shares have traded
both at a premium and at a discount to the Fund's NAV per Common Share. There can be no assurance that this will continue after an offering
of Common Shares or that the Common Shares will not trade at a discount in the future. Shares of closed-end investment companies frequently
trade at a discount to NAV. The Fund's NAV will be reduced immediately following an offering of Common Shares due to the costs of such
offering, which will be borne entirely by the Fund. The sale of Common Shares by the Fund (or the perception that such sales may occur)
may have an adverse effect on prices of Common Shares in the secondary market. An increase in the number of Common Shares available may
result in downward pressure on the market price for Common Shares. The Fund cannot predict whether its Common Shares will trade in the
future at a premium to or discount from NAV, or the level of any premium or discount.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Market Price Information</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's Common Shares are
publicly held and are listed and traded on the NYSE (trading symbol "THW"). The following table sets forth for the fiscal quarters indicated
the highest and lowest daily prices during the applicable quarter at the close of market on the NYSE per Common Share along with (i) the
highest and lowest closing NAV and (ii) the highest and </span></p> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">42 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">lowest premium or discount
from NAV represented by such prices at the close of the market on the NYSE.</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:4pt 0.7pt 2pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:left;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Quarter</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Ending</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt 0.7pt 2pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Market</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Price</strong><strong style="margin-top:0pt;margin-bottom:0pt"><sup style="margin-top:0pt;margin-bottom:0pt">(1)</sup></strong><strong style="margin-top:0pt;margin-bottom:0pt">
        High</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt 0.7pt 2pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Corresponding</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Net
        Asset</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Value</strong><strong style="margin-top:0pt;margin-bottom:0pt"><sup style="margin-top:0pt;margin-bottom:0pt">(2)</sup></strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt 0.7pt 2pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Market</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Premium/</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">(Discount)</strong><strong style="margin-top:0pt;margin-bottom:0pt"><sup style="margin-top:0pt;margin-bottom:0pt">(2)</sup></strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt 0.7pt 2pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Corresponding</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Price</strong><strong style="margin-top:0pt;margin-bottom:0pt"><sup style="margin-top:0pt;margin-bottom:0pt">(1)</sup></strong><strong style="margin-top:0pt;margin-bottom:0pt">
        Low</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt 0.7pt 2pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Net
        Asset</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Value</strong><strong style="margin-top:0pt;margin-bottom:0pt"><sup style="margin-top:0pt;margin-bottom:0pt">(2)</sup></strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:4pt 0.7pt 2pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Premium/</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">(Discount)</strong><strong style="margin-top:0pt;margin-bottom:0pt"><sup style="margin-top:0pt;margin-bottom:0pt">(2)</sup></strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="27" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:670;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Fiscal 2021</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Dec. 31</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16.07</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14.68</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">9.47</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13.43</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13.25</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202125337432" name="cef:LatestPremiumDiscountToNavPercent" contextRef="C_20201001to20201231" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.36</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Mar. 31</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">17.92</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15.29</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">17.20</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14.29</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14.63</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">-<ix:nonFraction id="Fxbrl_20231202131545225_323" name="cef:LatestPremiumDiscountToNavPercent" contextRef="C_20210101to20210331" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">2.32</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">June 30</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16.69</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15.56</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7.26</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14.86</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15.15</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">-<ix:nonFraction id="Fxbrl_20231202131545225_423" name="cef:LatestPremiumDiscountToNavPercent" contextRef="C_20210401to20210630" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">1.91</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sept. 30</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">17.38</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16.22</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">7.15</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16.13</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15.45</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202131545225_523" name="cef:LatestPremiumDiscountToNavPercent" contextRef="C_20210701to20210930" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.40</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="27" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:670">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Fiscal 2022</span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Dec. 31</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">17.08</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15.63</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">9.28</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15.51</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14.75</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202131545225_723" name="cef:LatestPremiumDiscountToNavPercent" contextRef="C_20211001to20211231" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.15</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Mar. 31</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">16.34</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15.63</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4.54</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13.29</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13.86</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">-<ix:nonFraction id="Fxbrl_20231202131545225_823" name="cef:LatestPremiumDiscountToNavPercent" contextRef="C_20220101to20220331" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">4.11</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">June 30</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10.39</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14.49</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">9.70</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14.00</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12.40</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202131545225_923" name="cef:LatestPremiumDiscountToNavPercent" contextRef="C_20220401to20220630" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">12.90</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sept 30</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15.72</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13.74</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14.41</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12.85</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12.02</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202131545225_1023" name="cef:LatestPremiumDiscountToNavPercent" contextRef="C_20220701to20220930" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">6.91</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="27" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:670;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Fiscal 2023</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Dec. 31</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15.76</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13.65</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15.46</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12.60</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12.17</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202131545225_1223" name="cef:LatestPremiumDiscountToNavPercent" contextRef="C_20221001to20221231" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.53</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Mar. 31</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">15.27</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13.34</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14.47</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13.34</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12.36</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202131545225_1323" name="cef:LatestPremiumDiscountToNavPercent" contextRef="C_20230101to20230331" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">7.93</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">June 30</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14.76</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13.09</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12.76</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">13.74</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12.76</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202131545225_1423" name="cef:LatestPremiumDiscountToNavPercent" contextRef="C_20230401to20230630" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">7.76</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sept. 30</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:20;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">14.11</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:60;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">12.77</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:20;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:52;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10.49</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">11.69</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">11.78</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:18;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:21;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:58;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">-<ix:nonFraction id="Fxbrl_20231202131545225_1523" name="cef:LatestPremiumDiscountToNavPercent" contextRef="C_20230701to20230930" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">0.76</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  </table>

<p style="margin:4pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(1) Source: Bloomberg L.P.</span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(2) Data presented are with
respect to a short period of time and are not indicative of future performance.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The NAV per Share as of the
close of business on November 24, 2023 was $<ix:nonFraction id="Fxbrl_20231202132832075" name="us-gaap:NetAssetValuePerShare" contextRef="C_20231124" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">11.44</ix:nonFraction>
and the last reported sales price of a Common Share on the NYSE that day was $<ix:nonFraction id="Fxbrl_20231202132839890" name="us-gaap:SharePrice" contextRef="C_20231124" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">11.28</ix:nonFraction>
representing a [premium/discount] to NAV of <ix:nonFraction id="Fxbrl_20231202132847426" name="cef:LatestPremiumDiscountToNavPercent" contextRef="C_20231124to20231124" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">1.42</ix:nonFraction>%.</span></p>
</div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 43</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />
</div>

<div >

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>ANNUAL MEETING REPORT
(unaudited)</strong></span></p>

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">An Annual Meeting of Shareholders
was held on June 8, 2023. Shareholders voted to elect Trustees of the Fund to hold office for a term of three years or until their respective
successors have been duly elected and qualified. The following votes were cast with respect to each of the nominees:</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:95">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:66">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>For</strong></span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Withheld</strong></span></p></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:95;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Rakesh Jain, Ph.D.</span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:50;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">26,898,088</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:46;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">556,943</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:95">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Daniel Omstead, Ph.D.</span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:50">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">26,952,589</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:46">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">502,442</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  </table>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Rakesh Jain, Ph.D.* and Daniel
Omstead, Ph.D.* were elected to serve until the 2026 Annual Meeting.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Trustees serving until the
2024 Annual Meeting are Jeffrey Bailey and Thomas M. Kent, CPA*.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Trustees serving until the
2025 Annual Meeting are Kathleen Goetz and W. Mark Watson, CPA*.</span></p>

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Shareholders ratified the
appointment of Deloitte &#38; Touche LLP** as the independent registered public accountants of the Fund for the fiscal year ending September
30, 2023, by the following votes:</span></p>

<table border="0" cellpadding="0" cellspacing="0">
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:95"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>For</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:66">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Against</strong></span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Abstain</strong></span></p></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:79;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">26,960,455</span></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:50;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">248,950</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:46;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">245,626</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  </table>

<p style="margin:4pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">&#160;&#160;*&#160;&#160;Resigned
effective October 27, 2023.</span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">&#160;&#160;**&#160;&#160;Resigned
effective September 6, 2023.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">On September 7, 2023, upon
the recommendation of the Audit Committee of the Board, the Board approved the engagement of KPMG LLP ("KPMG") as the independent registered
public accounting firm for the Fund for the fiscal year ending September 30, 2023. During the Fund's two most recent fiscal years (ended
September 30, 2022 and September 30, 2021) and the subsequent interim period prior to the engagement of KPMG, neither the Fund, nor anyone
on the Fund's behalf consulted with KPMG regarding (1) the application of accounting principles to a specified transaction, either completed
or proposed; (2) the type of audit opinion that might be rendered on the Fund's financial statements; or (3) the subject of any "disagreement,"
as defined in Item 304(a)(1)(iv) of Regulation S-K under the Exchange Act and the instructions thereto, or a "reportable event," as defined
in Item 304(a) (1)(v) of Regulation S-K under the Exchange Act.</span></p>

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>SPECIAL MEETINGS REPORTS
(unaudited)</strong></span></p>

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">At a Special Meeting of Shareholders
held on August 14, 2023, shareholders voted to elect four new Trustees of the Fund to hold office for a term of three years or until their
respective successors have been duly elected and qualified. The following votes were cast with respect to each of the nominees:</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:95">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:66">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>For</strong></span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Withheld</strong></span></p></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:95;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Stephen Bird</span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:50;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">26,314,267</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:46;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,041,552</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:95">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Rose DiMartino</span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:50">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">26,224,473</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:46">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,131,347</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:95;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">C. William Maher</span></p></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:50;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">26,245,256</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:46;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,110,563</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:95">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Todd Reit</span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:50">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">26,270,482</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:46">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1,085,337</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td></tr>
  </table></div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">44 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p><hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">C. William Maher was elected
to serve until the 2024 Annual Meeting.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Stephen Bird was elected to
serve until the 2025 Annual Meeting.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Todd Reit and Rose DiMartino
were elected to serve until the 2026 Annual Meeting.</span></p>

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Subsequent to the reporting
period, at a Special Meeting of Shareholders held on October 25, 2023 (as adjourned from August 14, August 29, September 12 and October
3), shareholders voted to approve a new investment advisory agreement between the Fund and abrdn Inc. The October 25, 2023 results of
the voting on this matter were as follows:</span></p>

<table border="0" cellpadding="0" cellspacing="0">
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:95"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>For</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:66">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Against</strong></span></p></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Abstain</strong></span></p></td>
    <td colspan="1">&#160;</td></tr>
  <tr>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:79;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">17,393,643</span></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:50;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">924,485</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:46;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2,137,165</span></p></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr>
  </table>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>FOR MORE INFORMATION
(unaudited):</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> A description of the Fund's proxy voting policies
and procedures and information on how the Fund voted proxies relating to portfolio securities during the most recent 12-month period ended
June 30 is available (i) without charge, upon request by calling 1-800-451-2597; (ii) by writing to abrdn Inc. at 1900 Market Street,
Suite 200, Philadelphia, PA 19103; (iii) on the Fund's website at www.abrdnthw.com; and (iv) on the SEC's website at www.sec.gov.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's complete Schedule
of Investments for the first and third quarters of its fiscal year will be filed with the SEC on Form N-PORT. These will also be available
on the Fund's website at www.abrdnthw.com or the SEC's website at www.sec.gov.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">You can find information regarding
the Fund at the Fund's website, www.abrdnthw.com. The Fund regularly posts information to its website, including information regarding
daily share pricing, distributions, press releases, and links to the Fund's SEC filings. The Fund currently publishes and distributes
quarterly fact cards, which include performance, portfolio holdings and sector information for each fiscal quarter. These fact cards will
be available on the Fund's website and by request from the Fund's marketing and investor support services agent, Destra Capital Advisors
LLC, at 1-877-855-3434.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>FEDERAL TAX INFORMATION</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
</span><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>(unaudited):</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Certain information for the Fund is required to be provided to shareholders based on the Fund's income and distributions for the taxable
year ended December 31, 2023. In February 2024, shareholders will receive Form 1099-DIV, which will include their share of qualified dividends
and capital gains and return of capital distributed during the calendar year 2023. Shareholders are advised to check with their tax advisors
for information on the treatment of these amounts on their individual tax returns.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>DISTRIBUTION POLICY
(unaudited):</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund has a managed distribution policy as described
in the Notes to Financial Statements. For more information contact your financial adviser.</span></p></div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 45</span></p><hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>SHARE REPURCHASE PROGRAM
(unaudited):</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> In March 2023, the Trustees reauthorized the share
repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares for a one-year period ending July 14, 2024.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>PORTFOLIO MANAGEMENT
(unaudited):</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Daniel Omstead, Ph.D., Jason Akus, M.D./M.B.A.,
Timothy Gasperoni, M.B.A., Ph.D., Ashton L. Wilson, Christopher Abbott, Robert Benson, Kelly Girskis, Ph.D., Richard Goss, Christopher
Seitz, M.B.A., and Loretta Tse, Ph.D. are members of a team that analyzes investments on behalf of the Fund. Dr. Omstead exercises ultimate
decision making authority with respect to investments.</span></p>

<p style="margin:11pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>DIVIDEND REINVESTMENT
AND STOCK PURCHASE PLAN (unaudited)</strong></span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Reinvestment of Distributions.
</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">Under the Dividend Reinvestment and Stock Purchase Plan, dividends
and/or distributions to a Shareholder will automatically be reinvested in additional Shares of the Fund. Each registered Shareholder may
elect to have dividends and distributions distributed in cash (i.e., "opt-out") rather than participate in the Dividend Reinvestment and
Stock Purchase Plan. For any registered Shareholder that does not so elect, dividends and/or distributions on such Shareholder's Shares
will be reinvested by Computershare Trust Company, N.A. (the "Plan Agent"), as agent for Shareholders in additional Shares, as set forth
below. Participation in the Dividend Reinvestment and Stock Purchase Plan is completely voluntary, and may be terminated or resumed at
any time without penalty by internet, telephone or notice if received and processed by the Plan Agent prior to the dividend record date;
otherwise such termination or resumption will be effective with respect to any subsequently declared dividend or other distribution. Participants
who hold their Shares through a broker or other nominee and who wish to elect to receive any dividends and distributions in cash must
contact their broker or nominee.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Plan Agent's fees for
the handling of the reinvestment of dividends and distributions will be paid by the Fund. Each participant will pay a per Share fee (currently
$0.05 per Share) incurred in connection with open market purchases. If a participant elects to have the Plan Agent sell all or a part
of his or her Shares and remit the proceeds to the participant, the Plan Agent is authorized to deduct a $15 sales fee per trade and a
per Share fee of $0.12 from such proceeds. All per Share fees include any applicable brokerage commissions the Plan Agent is required
to pay. The automatic reinvestment of Dividends will not relieve Participants of any federal, state or local income tax that may be payable
(or required to be withheld) on such dividend.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Plan Agent will acquire
shares for participants' accounts by purchasing either newly issued shares from the Fund or outstanding shares in the open market, depending
upon the circumstances. If on the payment date of a dividend or distribution the NAV per share is equal to or less than the closing market
price (plus estimated per share fees in connection </span></p></div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">46 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p><hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" /></div>

<div >

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">with the purchase of shares),
the Plan Agent will invest the dividend or distribution in newly issued shares. The number of newly issued shares to be credited to each
participant's account will be determined by dividing the amount of the participant's cash dividend or distribution by the greater of the
NAV per share on the payment date or 95% of the closing market price per share on the payment date. If on the payment date the NAV per
share is greater than the closing market price per share (plus per share fees), the Plan Agent will invest the dividend or distribution
in shares acquired in open-market purchases. The per share price for open-market purchases will be the weighted average price of the shares
on the payment date.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Stock Purchase Plan.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
All registered shareholders can voluntarily purchase additional shares in the Fund at any time through the Plan Agent. The minimum investment
under this option is $50. Participants can make an investment online or by sending a check to the Plan Agent. Each investment will entail
a transaction fee of $5.00 plus $0.05 per share purchased. Shareholders can also authorize the Plan Agent to make automatic withdrawals
from a bank account.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Each automatic transaction
will entail a fee of $2.50 plus $0.05 per share purchased. There is a $25 charge for each returned check or rejected electronic funds
transfer.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Amendment or Termination
of Plan.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund reserves the right to amend or terminate the
Plan upon notice in writing to each participant at least 30 days prior to any record date for the payment of any dividend or distribution
by the Fund.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Plan Agent.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
You can contact the Plan Agent at www.computershare.com/investor, at P.O. Box 30170, College Station, TX 77842-3170 or at 1-800-426-5523.</span></p>

<p style="margin:11pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>INVESTMENT OBJECTIVE,
POLICIES AND RISK FACTORS </strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><i>(Unaudited)</i></span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following information
in this annual report is a summary of certain information about the Fund and changes since September 30, 2022. This information may not
reflect all of the changes that have occurred since you purchased the Fund.</span></p>

<div> <ix:continuation id="F20231212021548999" continuedAt="F20231212021558342">

<div>

<p style="margin:11pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Investment Objective
and Policies</strong></span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">There have been no changes
in the Fund's investment objective and policies since September 30, 2022 that have not been approved by shareholders.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's investment objective
is to seek current income and long-term capital appreciation.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Under normal market conditions,
the Fund expects to invest at least 80% of its Managed Assets in U.S. and non-U.S. companies engaged in the healthcare industries including
equity securities and debt securities. "Managed Assets" means the total assets of the Fund (including any assets attributable to borrowings
for investment purposes) minus the sum of</span></p> </div> </ix:continuation> </div> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 47</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<div> <ix:continuation id="F20231212021558342" continuedAt="F20231212021617766">

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">the Fund's accrued liabilities
(other than liabilities representing borrowings for investment purposes). The Fund's 80% policy may only be changed with 60 days' prior
notice to the Fund's shareholders (the "Shareholders"). The Fund will concentrate its investments in the healthcare industries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">A company will be deemed to
be a healthcare company if, at the time the Fund makes an investment in the company, 50% or more of such company's sales, earnings or
assets arise from or are dedicated to healthcare products or services or medical technology activities. healthcare companies may include
companies in one or more of the following sub-sectors: pharmaceuticals, biotechnology, managed care, life science and tools, healthcare
technology, healthcare services, healthcare supplies, healthcare facilities, healthcare equipment, healthcare distributors and Healthcare
REITs (as defined herein). The Investment Adviser determines, in its discretion, whether a company is a healthcare company.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Under normal market conditions,
the Fund expects to invest at least 40% of its Managed Assets in companies organized or located outside the United States or companies
that do a substantial amount of business outside the United States. The Fund may invest up to 5% of its Managed Assets in securities of
issuers located in emerging market countries ("Emerging Markets"). While the Fund may hedge its non-U.S. dollar exposure, it is currently
expected to do so from time to time rather than continuously. The Investment Adviser may hedge its non-U.S. dollar exposure from 0%-100%
at any given time, though it typically expects to do so between 0% and 50% of such exposure.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund expects to invest
60-90% of its Managed Assets in equity securities (which may include common stock, preferred stock and warrants or other rights to acquire
common or preferred stock). The Fund will invest in foreign securities and may buy and sell currencies for the purpose of settlement of
transactions in foreign securities. The Fund may invest up to 30% of its Managed Assets in convertible securities, which may include securities
that are noninvestment grade. The Fund may invest up to 20% of its Managed Assets as measured at the time of investment in non-convertible
debt securities, including corporate debt obligations and debt securities that are rated noninvestment grade (that is, rated Ba1 or lower
by Moody's Investors Service, Inc. ("Moody's"), BB+ or lower by Standard &#38; Poor's Ratings Group ("S&#38;P"), or BB+ by Fitch, Inc.
("Fitch") or comparably rated by another nationally recognized statistical rating organization ("NRSRO"), or, if unrated, determined by
the Investment Adviser to be of comparable credit quality) and not including convertible securities. The Fund may invest up to 15% of
its Managed Assets in non-convertible debt securities that are, at the time of investment, rated Caa1 or lower by Moody's and CCC+ or
lower by S&#38;P or Fitch, or comparably rated by another nationally recognized statistical rating organization, or, if unrated, determined
by the Investment Adviser to be of comparable credit quality. Such securities are subject to a very high credit risk. The Fund's investments
in noninvestment grade investments and those deemed to be of similar quality are considered</span></p> </div> </ix:continuation> </div>
</div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">48 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<div> <ix:continuation id="F20231212021617766">

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">speculative with respect to
the issuer's capacity to pay interest and repay principal and are commonly referred to as "junk" or "high yield" securities.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund may invest in derivatives,
including but not limited to options, futures, options on futures, forwards, swaps (including credit default, index, basis, total return,
volatility and currency swaps), options on swaps and other derivatives. Initially, the Fund intends to employ a strategy of writing (selling)
covered call options on a portion of the common stocks in its portfolio, writing (selling) put options on a portion of the common stocks
in its portfolio and, to a lesser extent, writing (selling) covered call and writing (selling) put options on indices of securities and
sectors of securities generally within the healthcare industry. This option strategy is intended to generate current income from option
premiums as a means to enhance distributions payable to the Fund's shareholders and will be limited to 30% of the Fund's Managed Assets.
These option strategies are not always profitable. The sale of a covered call option exposes the Fund during the term of the option to
possible loss of opportunity to realize appreciation in the market price of the underlying security or to possible loss due to continued
holding of a security that might otherwise have been sold to protect against depreciation in the market price of the security. Therefore,
the Investment Adviser may choose to decrease its use of the option writing strategy to the extent that it may negatively impact the Fund.
Other than the Fund's option strategy and use of derivatives for hedging purposes, the Fund may invest up to 10% of its Managed Assets
in derivatives.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund may invest up to
10% of its Managed Assets in restricted securities, including private investments in public equity ("PIPEs") and venture capital investments.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund may invest up to
20% of its Managed Assets in healthcare REITs.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund may from time-to-time
lend its portfolio securities but has terminated its Securities Lending program effective July 18, 2023.</span></p> </div> </ix:continuation>
</div>

<p style="margin:11pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Changes to Risk Factors
During the Prior Fiscal Year</strong></span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">There have been no material
changes to the Fund's Risk Factors since September 30, 2022.</span></p> <ix:nonNumeric id="Fxbrl_20231202102330071" name="cef:RiskFactorsTableTextBlock" contextRef="C_20221001to20230930" continuedAt="F20231202102933236" escape="true">

<div>

<p style="margin:11pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Risk Factors</strong></span></p>

<p style="margin:8pt 0pt 10pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Investing in any investment company
security involves risk, including the risk that you may receive little or no return on your investment or even that you may lose part
or all of your investment. Investors should consider the following Risk Factors and special considerations associated with investing in
the Fund's shares.</span></p> <ix:nonNumeric id="Fxbrl_20231202103347060" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977PortfolioMarketRiskMember" continuedAt="F20231202103507212" escape="true"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Portfolio</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
</span><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Market Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
As with any investment company that invests in equity securities, the Fund is subject to market risk&#8212;the possibility that the prices
of equity securities will</span></ix:nonNumeric> </div> </ix:nonNumeric> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 49</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />
</div>

<div >

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202102933236" continuedAt="F20231202102939431">

<div> <ix:continuation id="F20231202103507212">

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">decline over short or extended
periods of time. As a result, the value of an investment in the Fund's shares will fluctuate with the market. You could lose some or all
of your investment over short or long periods of time.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Political and economic news
can influence market-wide trends and can cause disruptions in the U.S. or world financial markets. Other factors may be ignored by the
market as a whole but may cause movements in the price of one company's stock or the stock of companies in one or more industries. All
of these factors may have a greater impact on initial public offerings and emerging company shares.</span></p> </div> </ix:continuation>
<ix:nonNumeric id="Fxbrl_20231202103529052" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977SecurityMarketRiskDiscountToNetAssetValueMember" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Security Market Risk&#8212;Discount
to NAV.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Shares of closed-end investment companies frequently
trade at a discount from their NAV. This characteristic is a risk separate and distinct from the risk that the Fund's NAV per share could
decrease as a result of its investment activities and may be greater for investors expecting to sell their shares in a relatively short
period of time following completion of this offering. Although the value of the Fund's net assets is generally considered by market participants
in determining whether to purchase or sell shares, whether investors will realize gains or losses upon the sale of the shares will depend
entirely upon whether the market price of the shares at the time of sale is above or below the investor's purchase price for the shares.
Because the market price of the shares will be determined by supply of and demand for the shares which will be affected by factors such
as (i) NAV, (ii) dividend and distribution levels and their stability (which will in turn be affected by levels of dividend and interest
payments by the Fund's portfolio holdings, the timing and success of the Fund's investment strategies, regulations affecting the timing
and character of Fund distributions, Fund expenses and other factors), (iii) trading volume of the shares, (iv) general market, interest
rate and economic conditions and (v) other factors that may be beyond the control of the Fund. The Fund cannot predict whether the shares
will trade at, below or above NAV or at, below or above the initial public offering price.</span></p> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20231202103605676" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977EquitySecuritiesRiskMember" continuedAt="F20231202104526214" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Equity Securities
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund expects to invest 60-90% of its Managed Assets
in equity securities. Equity risk is the risk that equity securities held by the Fund will fall due to general market or economic conditions,
perceptions regarding the industries in which the issuers of securities held by the Fund participate, changes in interest rates, and the
particular circumstances and performance of particular companies whose securities the Fund holds. The price of an equity security of an
issuer may be particularly sensitive to general movements in the stock market, or a drop in the stock market may depress the price of
most or all of the equity securities held by the Fund. In addition, equity securities held by the Fund may decline in price if the issuer
fails to make anticipated distributions or dividend payments because, among other reasons, the issuer experiences a decline in its financial
condition. The Fund's expected investments in preferred stocks carries its own unique risks. Preferred stocks are typically subordinated
to bonds and other debt instruments in a company's capital structure, in terms of priority to corporate income, and therefore will be
subject to greater credit risk than those debt instruments. In addition, unlike interest payments on debt securities,</span></p> </ix:nonNumeric>
</div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">50 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202102939431" continuedAt="F20231202102946624">

<div> <ix:continuation id="F20231202104526214">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">preferred stock dividends
are payable only if declared by the issuer's board of directors. The prices of preferred stock also tend to move upwards slower than common
stock prices and the preferred stock may be substantially less liquid than common stock or other securities.</span></p> </ix:continuation>
<ix:nonNumeric id="Fxbrl_20231202103613296" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977ConvertibleSecuritiesRiskMember" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Convertible Securities
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Convertible Securities generally offer lower interest
or dividend yields than nonconvertible debt securities of similar quality. The market value of convertible securities tends to decline
as interest rates increase and, conversely, tends to increase as interest rates decline. In addition, because of the conversion feature,
the market value of convertible securities tends to vary with fluctuations in the market value of the underlying common stock. When the
market price of the underlying common stock approaches or is greater than the convertible security's conversion price, the prices of the
convertible securities tend to rise as a reflection of the value of the underlying common stock. The conversion prior is defined as the
predetermined price at which the convertible security could be exchanged for the associated stock. Consequently, a unique feature of convertible
securities is that as the market price of the underlying common stock declines, convertible securities tend to trade increasingly on a
yield basis, and so may not experience market value declines to the same extent as the underlying common stock. Investments in convertible
securities generally entail less risk than investments in common stock of the same issuer but more risk than the issuer's debt obligations.</span></p>
</ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20231202103619535" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977SelectionRiskMember" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Selection Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Different types of equity securities tend to shift into and out of favor with investors, depending on market and economic conditions.
The performance of funds that invest in healthcare industry equity securities may at times be better or worse than the performance of
funds that focus on other types of securities or that have a broader investment style.</span></p> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20231202103624052" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977ConcentrationInHealthcareIndustriesMember" continuedAt="F20231202104601040" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Concentration in the
Healthcare Industries.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Under normal market conditions, the Fund
expects to invest at least 80% of its Managed Assets in securities of healthcare companies. As a result, the Fund's portfolio will likely
be more sensitive to, and possibly more adversely affected by, regulatory, economic or political factors or trends relating to the healthcare,
agricultural and environmental technology industries than a portfolio of companies representing a larger number of industries. The risk
is in addition to the risks normally associated with any strategy seeking capital appreciation by investing in a portfolio of equity securities.
As a result of its concentration policy, the Fund's investments may be subject to greater risk and market fluctuation than a fund that
has securities representing a broader range of investments. The healthcare industries can be volatile. The Fund may occasionally make
investments in a company with the objective of controlling or influencing the management and policies of that company, which could potentially
make the Fund more susceptible to declines in the value of the company's stock. The Investment Adviser may seek control in public companies
only occasionally and most often in companies with a small capitalization.</span></p> </ix:nonNumeric> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 51</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202102946624" continuedAt="F20231202102953211">

<div> <ix:continuation id="F20231202104601040" continuedAt="F20231202104609418">

<div>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare companies have in the
past been characterized by limited product focus, rapidly changing technology and extensive government regulation. In particular, technological
advances can render an existing product, which may account for a disproportionate share of a company's revenue, obsolete. Obtaining governmental
approval from U.S. governmental agencies such as the Food and Drug Administration (the "FDA"), and from non-U.S. governmental agencies
for new products can be lengthy, expensive and uncertain as to outcome. Such delays in product development may result in the need to seek
additional capital, potentially diluting the interests of existing investors such as the Fund. In addition, governmental agencies may,
for a variety of reasons, restrict the release of certain innovative technologies of commercial significance. These various factors may
result in abrupt advances and declines in the securities prices of particular companies and, in some cases, may have a broad effect on
the prices of securities of companies in particular healthcare industries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">A concentration of investments
in any healthcare industry or in healthcare companies generally may increase the risk and volatility of an investment company's portfolio.
Such volatility is not limited to the biotechnology industry, and companies in other industries may be subject to similar abrupt movements
in the market prices of their securities. No assurance can be given that future declines in the market prices of securities of companies
in the industries in which the Fund may invest will not occur, or that such declines will not adversely affect the NAV or the price of
the shares.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Intense competition exists
within and among certain healthcare industries, including competition to obtain and sustain proprietary technology protection, including
patents, trademarks and other intellectual property rights, upon which healthcare companies can be highly dependent for maintenance of
profit margins and market exclusivity. The complex nature of the technologies involved can lead to patent disputes, including litigation
that may be costly and that could result in a company losing an exclusive right to a patent.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">With respect to healthcare
industries, cost containment measures already implemented by national governments, state or provincial governments and the private sector
have adversely affected certain sectors of these industries. The implementation of the Affordable Care Act ("ACA") has created increased
demand for healthcare products and services, but potential changes to the ACA and future healthcare laws and regulations may impact demand
for healthcare products and services and has had or may have an adverse effect on some companies in the healthcare industries. Increased
emphasis on managed care in the United States and a shift toward value based payment models may put pressure on the price and usage of
products sold by healthcare companies in which the Fund may invest and may adversely affect the sales and revenues of healthcare companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Product development efforts
by healthcare companies may not result in commercial products for many reasons, including, but not limited to, failure to achieve acceptable
clinical trial results, limited effectiveness in treating the specified condition or illness, harmful side effects,</span></p> </div>
</ix:continuation> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">52 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202102953211" continuedAt="F20231202103001647">

<div> <ix:continuation id="F20231202104609418">

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">failure to obtain regulatory
approval, and high manufacturing costs. Even after a product is commercially released, governmental agencies may require additional clinical
trials or change the labeling requirements for products if additional product side effects are identified, which could have a material
adverse effect on the market price of the securities of those healthcare companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Certain healthcare companies
in which the Fund may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing
and sale of pharmaceuticals, medical devices or other products. A product liability claim may have a material adverse effect on the business,
financial condition or securities prices of a company in which the Fund has invested.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">All of these factors as well
as others may cause the value of the Fund's shares to fluctuate significantly over relatively short periods of time.</span></p> </div>
</ix:continuation> <ix:nonNumeric id="Fxbrl_20231202103631700" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977PharmaceuticalSectorRiskMember" continuedAt="F20231202110715328" escape="true">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Pharmaceutical Sector
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The success of companies in the pharmaceutical sector
is highly dependent on the development, procurement and marketing of drugs. The values of pharmaceutical companies are also dependent
on the development, protection and exploitation of intellectual property rights and other proprietary information, and the profitability
of pharmaceutical companies may be significantly affected by such things as the expiration of patents or the loss of, or the inability
to enforce, intellectual property rights.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The research and other costs
associated with developing or procuring new drugs and the related intellectual property rights can be significant, and the results of
such research and expenditures are unpredictable. There can be no assurance that those efforts or costs will result in the development
of a profitable drug. Pharmaceutical companies may be susceptible to product obsolescence. Pharmaceutical companies also face challenges
posed by the increased presence of counterfeit pharmaceutical products, which may negatively impact revenues and patient confidence. Many
pharmaceutical companies face intense competition from new products and less costly generic products. Moreover, the process for obtaining
regulatory approval by the FDA or other U.S. and non-U.S. governmental regulatory authorities is long and costly and there can be no assurance
that the necessary approvals will be obtained or maintained.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The pharmaceutical sector
is also subject to rapid and significant technological change and competitive forces that may make drugs obsolete or make it difficult
to raise prices and, in fact, may result in price discounting. Companies in the pharmaceutical sector may also be subject to expenses
and losses from extensive litigation based on intellectual property, product liability and similar claims. Failure of pharmaceutical companies
to comply with applicable laws and regulations can result in the imposition of civil and criminal fines, penalties and, in some instances,
exclusion of participation in government sponsored programs such as Medicare and Medicaid.</span></p> </div> </ix:nonNumeric> </div> </ix:continuation>
</div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 53</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103001647" continuedAt="F20231202103008427">

<div> <ix:continuation id="F20231202110715328">

<div>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Companies in the pharmaceutical
sector may be adversely affected by government regulation and changes in reimbursement rates. The ability of many pharmaceutical companies
to commercialize and monetize current and any future products depends in part on the extent to which reimbursement for the cost of such
products and related treatments are available from third party payors, such as Medicare, Medicaid, private health insurance plans and
health maintenance organizations. Third-party payors are increasingly challenging the price and cost-effectiveness of many medical products.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Significant uncertainty exists
as to the reimbursement status of health care products, and there can be no assurance that adequate third-party coverage will be available
for pharmaceutical companies to obtain satisfactory price levels for their products.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The international operations
of many pharmaceutical companies expose them to risks associated with instability and changes in economic and political conditions, foreign
currency fluctuations, changes in foreign regulations and other risks inherent to international business. Additionally, a pharmaceutical
company's valuation can often be based largely on the potential or actual performance of a limited number of products. A pharmaceutical
company's valuation can also be greatly affected if one of its products proves unsafe, ineffective or unprofitable. Such companies also
may be characterized by thin capitalization and limited markets, financial resources or personnel, as well as dependence on wholesale
distributors. The stock prices of companies in the pharmaceutical industry have been and will likely continue to be extremely volatile.</span></p>
</div> </ix:continuation> <ix:nonNumeric id="Fxbrl_20231202103640523" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977BiotechnologyIndustryRiskMember" continuedAt="F20231202110739405" escape="true">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Biotechnology Industry
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The success of biotechnology companies is highly dependent
on the development, procurement and/or marketing of drugs. The values of biotechnology companies are also dependent on the development,
protection and exploitation of intellectual property rights and other proprietary information, and the profitability of biotechnology
companies may be significantly affected by such things as the expiration of patents or the loss of, or the inability to enforce, intellectual
property rights.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The research and other costs
associated with developing or procuring new drugs, products or technologies and the related intellectual property rights can be significant,
and the results of such research and expenditures are unpredictable. There can be no assurance that those efforts or costs will result
in the development of a profitable drug, product or technology. Moreover, the process for obtaining regulatory approval by the FDA or
other U.S. and non-U.S. governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals
will be obtained or maintained.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The biotechnology sector is
also subject to rapid and significant technological change and competitive forces that may make drugs, products or technologies obsolete
or make it difficult to raise prices and, in fact, may result in price discounting. Companies in the biotechnology sector may also be
subject to expenses and losses from extensive litigation</span></p> </div> </ix:nonNumeric> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">54 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103008427" continuedAt="F20231202103016176">

<div> <ix:continuation id="F20231202110739405">

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">based on intellectual property,
product liability and similar claims. Failure of biotechnology companies to comply with applicable laws and regulations can result in
the imposition of civil and/or criminal fines, penalties and, in some instances, exclusion of participation in government sponsored programs
such as Medicare and Medicaid.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Companies in the biotechnology
sector may be adversely affected by government regulation and changes in reimbursement rates. Healthcare providers, principally hospitals,
that transact with companies in the biotechnology industry, often rely on third party payors, such as Medicare, Medicaid, private health
insurance plans and health maintenance organizations to reimburse all or a portion of the cost of healthcare related products or services.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Biotechnology companies will
continue to be affected by the efforts of governments and third party payors to contain or reduce health care costs. For example, certain
foreign markets control pricing or profitability of biotechnology products and technologies. In the United States, there has been, and
there will likely continue to be, a number of federal and state proposals to implement similar controls.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">A biotechnology company's
valuation could be based on the potential or actual performance of a limited number of products and could be adversely affected if one
of its products proves unsafe, ineffective or unprofitable. Such companies may also be characterized by thin capitalization and limited
markets, financial resources or personnel. The stock prices of companies involved in the biotechnology sector have been and will likely
continue to be extremely volatile.</span></p> </div> </ix:continuation> <ix:nonNumeric id="Fxbrl_20231202103647195" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977ManagedCareSectorRiskMember" continuedAt="F20231202110756720" escape="true">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Managed Care Sector
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Companies in the managed care sector often assume the
risk of both medical and administrative costs for their customers in return for monthly premiums. The profitability of these products
depends in large part on the ability of such companies to predict, price for, and effectively manage medical costs. Managed care companies
base the premiums they charge and their Medicare bids on estimates of future medical costs over the fixed contract period; however, many
factors may cause actual costs to exceed what was estimated and reflected in premiums or bids. These factors may include medical cost
inflation, increased use of services, increased cost of individual services, natural catastrophes or other large-scale medical emergencies,
epidemics, the introduction of new or costly treatments and technology, new mandated benefits (such as the expansion of essential benefits
coverage) or other regulatory changes and insured population characteristics. Relatively small differences between predicted and actual
medical costs or utilization rates as a percentage of revenues can result in significant changes in financial results.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Managed care companies are
regulated at the federal, state, local and international levels. Insurance and Health Maintenance Organization ("HMO") subsidiaries must
be licensed by and are subject to the regulations of the jurisdictions in which they conduct business. U.S. health plans and insurance
companies are also regulated under state insurance holding</span></p> </div> </ix:nonNumeric> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 55</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103016176" continuedAt="F20231202103022414">

<div> <ix:continuation id="F20231202110756720">

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">company regulations, and some
of their activities may be subject to other health care-related regulations. The health care industry is also regularly subject to negative
publicity, including as a result of governmental investigations, adverse media coverage and political debate surrounding industry regulation.
Negative publicity may adversely affect stock price, damage the reputation of managed care companies in various markets or foster an increasingly
active regulatory environment, which, in turn, could further increase the regulatory burdens under which such companies operate and their
costs of doing business.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The evolution of the ACA and
other regulatory reforms could materially and adversely affect the manner in which U.S. managed care companies conduct business and their
results of operations, financial position and cash flows. The ACA includes guaranteed coverage and expanded benefit requirements, eliminates
pre-existing condition exclusions and annual and lifetime maximum limits, restricts the extent to which policies can be rescinded, establishes
minimum medical loss ratios, creates a federal premium review process, imposes new requirements on the format and content of communications
(such as explanations of benefits) between health insurers and their members, grants to members new and additional appeal rights, and
imposes new and significant taxes on health insurers and health care benefits.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">New laws or regulations could
drive substantial change to the way healthcare products and services are currently delivered and paid for in the United States. Health
plans and insurance companies could face meaningful disruption or disintermediation if the U.S. migrates to a single payer healthcare
system where the government acts as the sole payer of healthcare services for the entire population. A transformative overhaul of the
U.S. healthcare system could impact the financial viability of managed care companies in which the Fund may invest.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Managed care companies contract
with physicians, hospitals, pharmaceutical benefit service providers, pharmaceutical manufacturers, and other health care providers for
services. Such companies' results of operations and prospects are substantially dependent on their continued ability to contract for these
services at competitive prices. Failure to develop and maintain satisfactory relationships with health care providers, whether in-network
or out-of-network, could materially and adversely affect business, results of operations, financial position and cash flows.</span></p>
</div> </ix:continuation> <ix:nonNumeric id="Fxbrl_20231202103654176" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977LifeScienceAndToolsIndustryRiskMember" continuedAt="F20231202110816654" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Life Science and Tools
Industry Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Life sciences industries are characterized by
limited product focus, rapidly changing technology and extensive government regulation. In particular, technological advances can render
an existing product, which may account for a disproportionate share of a company's revenue, obsolete. Obtaining governmental approval
from agencies such as the FDA, U.S. Department of Agriculture and other U.S. and non-U.S. governmental agencies for new products can be
lengthy, expensive and uncertain as to outcome. Such delays in product development may result in the need to seek additional capital,
potentially diluting the interests of existing investors such as the Fund. In addition,</span></p> </ix:nonNumeric> </div> </ix:continuation>
</div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">56 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103022414" continuedAt="F20231202103030239">

<div> <ix:continuation id="F20231202110816654">

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">governmental agencies may,
for a variety of reasons, restrict the release of certain innovative technologies of commercial significance, such as genetically altered
material. These various factors may result in abrupt advances and declines in the securities prices of particular companies and, in some
cases, may have a broad effect on the prices of securities of companies in particular life sciences industries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Intense competition exists
within and among certain life sciences industries, including competition to obtain and sustain proprietary technology protection. Life
sciences companies can be highly dependent on the strength of patents, trademarks and other intellectual property rights for maintenance
of profit margins and market share. The complex nature of the technologies involved can lead to patent disputes, including litigation
that could result in a company losing an exclusive right to a patent. Competitors of life sciences companies may have substantially greater
financial resources, more extensive development, manufacturing, marketing and service capabilities, and a larger number of qualified managerial
and technical personnel. Such competitors may succeed in developing technologies and products that are more effective or less costly than
any that may be developed by life sciences companies in which the Fund invests and may also prove to be more successful in production
and marketing. Competition may increase further as a result of potential advances in health services and medical technology and greater
availability of capital for investment in these fields.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">With respect to healthcare,
cost containment measures already implemented by national governments, state or provincial governments, international organizations and
the private sector have adversely affected certain sectors of these industries. Increased emphasis on managed care in the United States
may put pressure on the price and usage of products sold by life sciences companies in which the Fund may invest and may adversely affect
the sales and revenues of life sciences companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Product development efforts
by life sciences companies may not result in commercial products for many reasons, including, but not limited to, failure to achieve acceptable
clinical trial results, limited effectiveness in treating the specified condition or illness, harmful side effects, failure to obtain
regulatory approval, and high manufacturing costs. Even after a product is commercially released, governmental agencies may require additional
clinical trials or change the labeling requirements for products if additional product side effects are identified, which could have a
material adverse effect on the market price of the securities of those life sciences companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Certain life sciences companies
in which the Fund may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing
and sale of pharmaceuticals, medical devices or other products. There can be no assurance that a product liability claim would not have
a material adverse effect on the business, financial condition or securities prices of a company in which the Fund has invested.</span></p>
</div> </ix:continuation> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 57</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103030239" continuedAt="F20231202103037598">

<div> <ix:nonNumeric id="Fxbrl_20231202103703595" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareTechnologySectorRiskMember" continuedAt="F20231202110843175" escape="true">

<div>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Technology
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Companies in the healthcare technology sector may
incur substantial costs related to product-related liabilities. Many of the software solutions, health care devices or services developed
by such companies are intended for use in collecting, storing and displaying clinical and health care-related information used in the
diagnosis and treatment of patients and in related health care settings such as admissions, billing, etc. The limitations of liability
set forth in the companies' contracts may not be enforceable or may not otherwise protect these companies from liability for damages.
Healthcare technology companies may also be subject to claims that are not covered by contract, such as a claim directly by a patient.
Although such companies may maintain liability insurance coverage, there can be no assurance that such coverage will cover any particular
claim that has been brought or that may be brought in the future, that such coverage will prove to be adequate or that such coverage will
continue to remain available on acceptable terms, if at all.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare technology companies
may experience interruption at their data centers or client support facilities. The business of such companies often relies on the secure
electronic transmission, data center storage and hosting of sensitive information, including protected health information, financial information
and other sensitive information relating to clients, company and workforce. In addition, such companies may perform data center and/or
hosting services for certain clients, including the storage of critical patient and administrative data and support services through various
client support facilities. If any of these systems are interrupted, damaged or breached by an unforeseen event or actions of a third party,
including a cyber-attack, or fail for any extended period of time, it could have a material adverse impact on the results of operations
for such companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The proprietary technology
developed by healthcare technology companies may be subject to claims for infringement or misappropriation of intellectual property rights
of others, or may be infringed or misappropriated by others. Despite protective measures and intellectual property rights, such companies
may not be able to adequately protect against theft, copying, reverse-engineering, misappropriation, infringement or unauthorized use
or disclosure of their intellectual property, which could have an adverse effect on their competitive position. In addition, these companies
are routinely involved in intellectual property infringement or misappropriation claims and it is expected that this activity will continue
or even increase as the number of competitors, patents and patent enforcement organizations in the healthcare technology market increases,
the functionality of software solutions and services expands, the use of open-source software increases and new markets such as health
care device innovation, health care transactions, revenue cycle, population health management and life sciences are entered into. These
claims, even if not meritorious, are expensive to defend and are often incapable of prompt resolution.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The success of healthcare
technology companies depends upon the recruitment and retention of key personnel. To remain competitive, such companies must attract,
motivate and retain</span></p> </div> </ix:nonNumeric> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">58 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103037598" continuedAt="F20231202103044186">

<div> <ix:continuation id="F20231202110843175">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">highly skilled managerial,
sales, marketing, consulting and technical personnel, including executives, consultants, programmers and systems architects skilled in
healthcare technology, health care devices, health care transactions, population health management, revenue cycle and life sciences industries
and the technical environments in which solutions, devices and services are needed. Competition for such personnel in the healthcare technology
sector is intense in both the United States and abroad. The failure to attract additional qualified personnel could have a material adverse
effect on healthcare technology companies' prospects for long-term growth.</span></p> </ix:continuation> <ix:nonNumeric id="Fxbrl_20231202103711415" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareServicesSectorRiskMember" continuedAt="F20231202110904111" escape="true">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Services
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The operations of healthcare services companies
are subject to extensive federal, state and local government regulations, including Medicare and Medicaid payment rules and regulations,
federal and state anti-kickback laws, the physician self-referral law ("Stark Law") and analogous state self-referral prohibition statutes,
Federal Acquisition Regulations, the False Claims Act and federal and state laws regarding the collection, use and disclosure of patient
health information and the storage, handling and administration of pharmaceuticals. The Medicare and Medicaid reimbursement rules related
to claims submission, enrollment and licensing requirements, cost reporting, and payment processes impose complex and extensive requirements
upon dialysis providers as well. A violation or departure from any of these legal requirements may result in government audits, lower
reimbursements, significant fines and penalties, the potential loss of certification, recoupment efforts or voluntary repayments. If healthcare
services companies fail to adhere to all of the complex government regulations that apply to their businesses, such companies could suffer
severe consequences that would substantially reduce revenues, earnings, cash flows and stock prices.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">A substantial percentage of
a healthcare services company's service revenues may be generated from patients who have state Medicaid or other non-Medicare government-based
programs, such as coverage through the Department of Veterans Affairs ("VA"), as their primary coverage. As state governments and other
governmental organizations face increasing budgetary pressure, healthcare services companies may in turn face reductions in payment rates,
delays in the receipt of payments, limitations on enrollee eligibility or other changes to the applicable programs.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Adverse economic conditions
could adversely affect the business and profitability of healthcare services companies. Among other things, the potential decline in federal,
non-U.S. government and state revenues that may result from such conditions may create additional pressures to contain or reduce reimbursements
for services from Medicare, Medicaid and other government sponsored programs. Increasing job losses or slow improvement in the unemployment
rate in the United States and elsewhere as a result of adverse or recent economic conditions may result in a smaller percentage of patients
being covered by an employer group health plan and a larger percentage being covered by lower paying Medicare and Medicaid programs. Employers
may also select more restrictive commercial plans with</span></p> </div> </ix:nonNumeric> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 59</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103044186" continuedAt="F20231202103051430">

<div> <ix:continuation id="F20231202110904111">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">lower reimbursement rates.
To the extent that payors are negatively impacted by a decline in the economy, healthcare services companies may experience further pressure
on commercial rates, a further slowdown in collections and a reduction in the amounts they expect to collect. In addition, uncertainty
in the financial markets could adversely affect the variable interest rates payable under credit facilities or could make it more difficult
to obtain or renew such facilities or to obtain other forms of financing in the future, if at all. Any or all of these factors, as well
as other consequences of the adverse economic conditions which cannot currently be anticipated, could have a material adverse effect on
a healthcare services company's revenues, earnings and cash flows and otherwise adversely affect its financial condition.</span></p> </ix:continuation>
<ix:nonNumeric id="Fxbrl_20231202103718987" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareSuppliesSectorRiskMember" escape="true">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Supplies
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> If healthcare supplies companies are unable to
successfully expand their product lines through internal research and development and acquisitions, their business may be materially and
adversely affected. In addition, if these companies are unable to successfully grow their businesses through marketing partnerships and
acquisitions, their business may be materially and adversely affected.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Consolidation of healthcare
providers has increased demand for price concessions and caused the exclusion of suppliers from significant market segments. It is expected
that market demand, government regulation, third-party reimbursement policies, government contracting requirements and societal pressures
will continue to change the worldwide healthcare industry, resulting in further business consolidations and alliances among customers
and competitors. This may exert further downward pressure on the prices of healthcare supplies companies' products and adversely impact
their businesses, financial conditions or results of operations.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Quality is extremely important
to healthcare supplies companies and their customers due to the serious and costly consequences of product failure. Quality certifications
are critical to the marketing success of their products and services. If a healthcare supplies company fails to meet these standards or
fails to adapt to evolving standards, its reputation could be damaged, it could lose customers, and its revenue and results of operations
could decline.</span></p> </div> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20231202103723901" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareFacilitiesSectorRiskMember" continuedAt="F20231202110930023" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Facilities
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> A healthcare facility's ability to negotiate favorable
contracts with HMOs, insurers offering preferred provider arrangements and other managed care plans significantly affects the revenues
and operating results of such healthcare facilities. In addition, private payers are increasingly attempting to control health care costs
through direct contracting with hospitals to provide services on a discounted basis, increased utilization reviews and greater enrollment
in managed care programs, such as HMOs and Preferred Provider Organizations ("PPOs"). The trend toward consolidation among private managed
care payers tends to increase their bargaining power over prices and fee structures. Non-government payers may increasingly demand reduced
fees. If a healthcare facility is unable to enter into and maintain managed care contractual arrangements on acceptable</span></p> </ix:nonNumeric>
</div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">60 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103051430" continuedAt="F20231202103057938">

<div> <ix:continuation id="F20231202110930023">

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">terms, if it experiences material
reductions in the contracted rates received from managed care payers, or if it has difficulty collecting from managed care payers, its
results of operations could be adversely affected.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Further changes in the Medicare
and Medicaid programs or other government health care programs could have an adverse effect on a healthcare facility's business. In addition
to the changes affected by the ACA, the Medicare and Medicaid programs are subject to other statutory and regulatory changes, administrative
rulings, interpretations and determinations concerning patient eligibility requirements, funding levels and the method of calculating
payments or reimbursements, among other things, requirements for utilization review, and federal and state funding restrictions. All of
these could materially increase or decrease payments from government programs in the future, as well as affect the cost of providing services
to patients and the timing of payments to facilities, which could in turn adversely affect a healthcare facility's overall business, financial
condition, results of operations or cash flows.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare facilities are
adversely affected by uninsured and underinsured patients, as well as a growing mix of Medicare and Medicaid patients that typically have
lower reimbursement rates than commercial managed care patients As a result, healthcare facilities continue to experience a shift in payer
mix and a high level of uncollectible accounts, which could worsen if there is an increase in unemployment. Healthcare facilities may
continue to experience significant levels of bad debt expense and may have to provide uninsured discounts and charity care for undocumented
immigrants who are not permitted to enroll in a health insurance exchange or government health care program. The trend of higher co-pays
and deductibles and a focus on migrating healthcare utilization to lower cost sites of care, may also pressure volumes and revenue at
certain healthcare facilities which could adversely impact the financial condition of hospitals and facilities with high fixed cost structures.</span></p>
</div> </ix:continuation> <ix:nonNumeric id="Fxbrl_20231202103729901" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareEquipmentSectorRiskMember" continuedAt="F20231202110949911" escape="true">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Equipment
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The medical device markets are highly competitive
and a healthcare equipment company many be unable to compete effectively. These markets are characterized by rapid change resulting from
technological advances and scientific discoveries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Development by other companies
of new or improved products, processes, or technologies may make a healthcare equipment company's products or proposed products less competitive.
In addition, these companies face competition from providers of alternative medical therapies such as pharmaceutical companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Medical devices and related
business activities are subject to rigorous regulation, including by the FDA, U.S. Department of Justice ("DOJ"), and numerous other federal,
state, and foreign governmental authorities. These authorities and members of Congress have been increasing their scrutiny of the healthcare
equipment industry. In addition, certain states have</span></p> </div> </ix:nonNumeric> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 61</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103057938" continuedAt="F20231202103104570">

<div> <ix:continuation id="F20231202110949911">

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">passed or are considering
legislation restricting healthcare equipment companies' interactions with health care providers and requiring disclosure of certain payments
to them. It is anticipated that governmental authorities will continue to scrutinize this industry closely, and that additional regulation
may increase compliance and legal costs, exposure to litigation, and other adverse effects to operations.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare equipment companies
are substantially dependent on patent and other proprietary rights and failing to protect such rights or to be successful in litigation
related to such rights may result in the payment of significant monetary damages and/or royalty payments, may negatively impact the ability
of healthcare equipment companies to sell current or future products, or may prohibit such companies from enforcing their patent and other
proprietary rights against others.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Quality problems with the
processes, goods and services of a healthcare equipment company could harm the company's reputation for producing high-quality products
and erode its competitive advantage, sales and market share. Quality is extremely important to healthcare equipment companies and their
customers due to the serious and costly consequences of product failure. Quality certifications are critical to the marketing success
of goods and services. If a healthcare equipment company fails to meet these standards, its reputation could be damaged, it could lose
customers, and its revenue and results of operations could decline.</span></p> </div> </ix:continuation> <ix:nonNumeric id="Fxbrl_20231202103736565" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareDistributorsSectorRiskMember" continuedAt="F20231202111007131" escape="true">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Distributors
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Companies in the healthcare distribution sector
operate in markets that are highly competitive. Because of competition, many of these companies face pricing pressures from customers
and suppliers. If these companies are unable to offset margin reductions caused by pricing pressures through steps such as effective sourcing
and enhanced cost control measures, the financial condition of such companies could be adversely affected. In addition, the healthcare
industry has continued to consolidate. Further consolidation among customers and suppliers (including branded pharmaceutical manufacturers)
could give the resulting enterprises greater bargaining power, which may adversely impact the financial condition of companies in the
healthcare distribution sector.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Fewer generic pharmaceutical
launches or launches that are less profitable than those previously experienced may have an adverse effect on the profits of companies
in the healthcare distribution sector. Additionally, prices for existing generic pharmaceuticals generally decline over time, although
this may vary. Price deflation on existing generic pharmaceuticals may have an adverse effect on company profits. With respect to branded
pharmaceutical price appreciation, if branded manufacturers increase prices less frequently or by amounts that are smaller than have been
experienced historically, healthcare distribution companies may profit less from branded pharmaceutical agreements.</span></p> </div>
</ix:nonNumeric> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">62 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103104570" continuedAt="F20231202103111802">

<div> <ix:continuation id="F20231202111007131">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The healthcare industry is
highly regulated, and healthcare distribution companies are subject to regulation in the United States at both the federal and state level
and in foreign countries. If healthcare distribution companies fail to comply with these regulatory requirements, the financial condition
of such companies could be adversely affected.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Due to the nature of the business
of healthcare distribution companies, such companies may from time to time become involved in disputes or legal proceedings. For example,
some of the products that these companies distribute may be alleged to cause personal injury or violate the intellectual property rights
of another party, subjecting such companies to product liability or infringement claims. Litigation is inherently unpredictable, and the
unfavorable resolution of one or more of these legal proceedings could adversely affect the cash flows and balance sheets of healthcare
distribution companies. Pharmaceutical distributors currently face lawsuits related to the abuse of opioid medications in the United States.
The allegations include that pharmaceutical distributors failed to provide effective controls around the quantities of opioid medications
distributed to certain pharmacies, failed to properly prevent the diversion of medications and failed to report suspicious orders. Pharmaceutical
distributors are in discussions with federal, state and local jurisdictions related to their role in the distribution of opioid pharmaceuticals
and it is possible that they will be required to pay multi-billion dollar settlements related to the ongoing litigation.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare distribution companies
depend on the availability of various components, compounds, raw materials and energy supplied by others for their operations. Any of
these supplier relationships could be interrupted due to events beyond the control of such companies, including pandemics, epidemics or
natural disasters, or could be terminated. A sustained supply interruption could have an adverse effect on business.</span></p> </div>
</ix:continuation> <ix:nonNumeric id="Fxbrl_20231202103742613" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977RisksAssociatedWithRegulatoryAndPolicyChangesMember" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Risks Associated with
Regulatory and Policy Changes.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> At any time after the date hereof,
U.S. and non-U.S. governmental agencies and other regulators may implement additional regulations and legislators may pass new laws that
affect the investments held by the Fund, the strategies used by the Fund or the level of regulation or taxation applying to the Fund.
These regulations and laws impact the investment strategies, performance, costs and operations of the Fund, as well as the way investments
in, and shareholders of, the Fund are taxed. In particular, changes to U.S. healthcare policy could affect the Fund and its investments.
The affordability of healthcare in the U.S. will remain a topic of debate, and proposals, laws and regulations to reduce the costs of
healthcare products and services could adversely impact healthcare companies that the Fund invests in.</span></p> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20231202103747126" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977ForeignSecuritiesRiskMember" continuedAt="F20231202111033713" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Foreign Securities
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Foreign investments involve special risks that are not
typically associated with U.S. dollar denominated or quoted securities of U.S. issuers. Foreign investments may be affected by changes
in currency rates, changes in foreign or U.S. laws or restrictions applicable to such investments and changes in exchange control regulations
(e.g., currency blockage). A decline in the exchange rate of the currency (i.e., weakening of</span></p> </ix:nonNumeric> </div> </ix:continuation>
</div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 63</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103111802" continuedAt="F20231202103118184">

<div> <ix:continuation id="F20231202111033713" continuedAt="F20231202111043753">

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">the currency against the U.S.
dollar) in which a portfolio security is quoted or denominated relative to the U.S. dollar would reduce the value of the portfolio security.
In addition, if the currency in which the Fund receives dividends, interest or other payments declines in value against the U.S. dollar
before such income is distributed as dividends to Shareholders or converted to U.S. dollars, the Fund may have to sell portfolio securities
to obtain sufficient cash to pay such dividends.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund may invest in foreign
securities which take the form of sponsored and unsponsored American depositary receipts ("ADRs"), global depositary receipts ("GDRs"),
European depositary receipts ("EDRs") or other similar instruments representing securities of foreign issuers (together, "Depositary Receipts").
ADRs represent the right to receive securities of foreign issuers deposited in a domestic bank or a correspondent bank. ADRs are traded
on domestic exchanges or in the U.S. over-the-counter ("OTC") market and, generally, are in registered form. EDRs and GDRs are receipts
evidencing an arrangement with a non-U.S. bank similar to ADRs and are designed for use in the non-U.S. securities markets. EDRs and GDRs
are not necessarily quoted in the same currency as the underlying security. To the extent the Fund acquires Depositary Receipts through
banks which do not have a contractual relationship with the foreign issuer of the security underlying the Depositary Receipts to issue
and service such unsponsored Depositary Receipts, there is an increased possibility that the Fund will not become aware of and be able
to respond to corporate actions, such as stock splits or rights offerings, involving the foreign issuer in a timely manner. In addition,
the lack of information may result in inefficiencies in the valuation of such instruments. Investment in Depositary Receipts does not
eliminate all the risks inherent in investing in securities of non-U.S. issuers. The market value of Depositary Receipts is dependent
upon the market value of the underlying securities and fluctuations in the relative value of the currencies in which the Depositary Receipts
and the underlying securities are quoted. However, by investing in Depositary Receipts, such as ADRs, which are quoted in U.S. dollars,
the Fund may avoid currency risks during the settlement period for purchases and sales. The issuers of Depositary Receipts may discontinue
issuing new Depositary Receipts and withdraw existing Depositary Receipts at any time, which may result in costs and delays in the distribution
of the underlying assets to the Fund and may negatively impact the Fund's performance.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Brokerage commissions, custodial
services and other costs relating to investment in international securities markets generally are more expensive than in the United States.
In addition, clearance and settlement procedures may be different in foreign countries and, in certain markets, such procedures have been
unable to keep pace with the volume of securities transactions, thus making it difficult to conduct such transactions.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Foreign issuers are not generally
subject to uniform accounting, auditing and financial reporting standards comparable to those applicable to U.S. issuers. There may be
less publicly available information about a foreign issuer than about a U.S. issuer. In addition, there is generally less government regulation
of foreign markets, companies and securities dealers</span></p> </div> </ix:continuation> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">64 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103118184" continuedAt="F20231202103125136">

<div> <ix:continuation id="F20231202111043753" continuedAt="F20231202111051418">

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">than in the United States,
and the legal remedies for investors may be more limited than the remedies available in the United States. Foreign securities markets
may have substantially less volume than U.S. securities markets and securities of many foreign issuers are less liquid and more volatile
than securities of comparable domestic issuers. Furthermore, with respect to certain foreign countries, there is a possibility of nationalization,
expropriation or confiscatory taxation, imposition of withholding or other taxes on dividend or interest payments (or, in some cases,
capital gains distributions), limitations on the removal of funds or other assets from such countries, and risks of political or social
instability or diplomatic developments which could adversely affect investments in those countries. At any time after the date hereof,
U.S. and non-U.S. governmental agencies and other regulators may implement additional regulations and legislators may pass new laws that
affect the investments held by the Fund, the strategies used by the Fund or the level of regulation or taxation applying to the Fund.
These regulations and laws impact the investment strategies, performance, costs and operations of the Fund, as well as the way investments
in, and shareholders of, the Fund are taxed. In particular, changes to U.S. healthcare policy could affect the Fund and its investments.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund may invest in securities
of issuers located in Emerging Markets. The risks of foreign investment are heightened when the issuer is located in an emerging country.
Emerging Markets are generally located in Africa, Asia, the Middle East, Eastern Europe and Central and South America. Investments in
securities of issuers located in Emerging Markets may be subject to heightened risks, including relative illiquidity, price volatility
and potential restrictions on repatriation of investment capital and income. The Fund's purchase and sale of portfolio securities in Emerging
Markets may be constrained by limitations relating to daily changes in the prices of listed securities, periodic trading or settlement
volume and/or limitations on aggregate holdings of foreign investors. Such limitations may be computed based on the aggregate trading
volume by or holdings of the Fund, the Investment Adviser, or its affiliates and respective clients and other service providers. The Fund
may not be able to sell securities in circumstances where price, trading or settlement volume limitations have been reached.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Foreign investment in the
securities markets of certain Emerging Markets is restricted or controlled to varying degrees which may limit investment in such countries
or increase the administrative costs of such investments. For example, certain Asian countries require governmental approval prior to
investments by foreign persons or limit investment by foreign persons to only a specified percentage of an issuer's outstanding securities
or a specific class of securities which may have less advantageous terms (including price) than securities of the issuer available for
purchase by nationals. In addition, certain countries may restrict or prohibit investment opportunities in issuers or industries deemed
important to national interests. Such restrictions may affect the market price, liquidity and rights of securities that may be purchased
by the Fund. The repatriation of both investment income and capital from</span></p> </div> </ix:continuation> </div> </ix:continuation>
</div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 65</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103125136" continuedAt="F20231202103131143">

<div> <ix:continuation id="F20231202111051418" continuedAt="F20231202111102273">

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">certain Emerging Markets is
subject to restrictions such as the need for governmental consents. In situations where a country restricts direct investment in securities
(which may occur in certain Asian and other countries), the Fund may invest in such countries through other investment funds in such countries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Many Emerging Markets have
experienced currency devaluations and substantial (and, in some cases, extremely high) rates of inflation. Other Emerging Markets have
experienced economic recessions. These circumstances have had a negative effect on the economies and securities markets of those Emerging
Markets.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Economies in Emerging Markets
generally are dependent heavily upon commodity prices and international trade and, accordingly, have been and may continue to be affected
adversely by the economies of their trading partners, trade barriers, exchange controls, managed adjustments in relative currency values
and other protectionist measures imposed or negotiated by the countries with which they trade.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Many Emerging Markets are
subject to a substantial degree of economic, political and social instability. Governments of some emerging countries are authoritarian
in nature or have been installed or removed as a result of military coups, while governments in other Emerging Markets have periodically
used force to suppress civil dissent. Disparities of wealth, the pace and success of democratization, and ethnic, religious and racial
disaffection, among other factors, have also led to social unrest, violence and/or labor unrest in some Emerging Markets. Unanticipated
political or social developments may result in sudden and significant investment losses. Investing in Emerging Markets involves greater
risk of loss due to expropriation, nationalization, confiscation of assets and property or the imposition of restrictions on foreign investments
and on repatriation of capital invested. As an example, in the past, some Eastern European governments have expropriated substantial amounts
of private property, and many claims of the property owners have never been fully settled. There is no assurance that similar expropriations
will not occur in other countries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's investment in Emerging
Markets may also be subject to withholding or other taxes, which may be significant and may reduce the return to the Fund from an investment
in issuers in such countries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Settlement procedures in Emerging
Markets are frequently less developed and reliable than those in the United States and may involve the Fund's delivery of securities before
receipt of payment for their sale. In addition, significant delays may occur in certain markets in registering the transfer of securities.
Settlement or registration problems may make it more difficult for the Fund to value its portfolio securities and could cause the Fund
to miss attractive investment opportunities, to have a portion of its assets uninvested or to incur losses due to the failure of a counterparty
to pay for securities the Fund has delivered or the Fund's inability to complete its contractual obligations because of theft or other
reasons.</span></p> </div> </ix:continuation> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">66 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103131143" continuedAt="F20231202103137092">

<div> <ix:continuation id="F20231202111102273">

<div>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The creditworthiness of the local
securities firms used by the Fund in Emerging Markets may not be as sound as the creditworthiness of firms used in more developed countries.
As a result, the Fund may be subject to a greater risk of loss if a securities firm defaults in the performance of its responsibilities.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The small size and inexperience
of the securities markets in certain Emerging Markets and the limited volume of trading in securities in those countries may make the
Fund's investments in such countries less liquid and more volatile than investments in countries with more developed securities markets
(such as the United States, Japan and most Western European countries). The Fund's investments in Emerging Markets are subject to the
risk that the liquidity of a particular investment, or investments generally, in such countries will shrink or disappear suddenly and
without warning as a result of adverse economic, market or political conditions or adverse investor perceptions, whether or not accurate.
Because of the lack of sufficient market liquidity, the Fund may incur losses because it will be required to effect sales at a disadvantageous
time and only then at a substantial drop in price. Investments in Emerging Markets may be more difficult to value precisely because of
the characteristics discussed above and lower trading volumes. In addition, the impact of the economic and public health crisis in emerging
market countries may be greater due to their generally less established healthcare systems and capabilities with respect to fiscal and
monetary policies, which may exacerbate other pre-existing political, social and economic tasks.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's use of foreign
currency management techniques in Emerging Markets may be limited. A significant portion of the Fund's currency exposure in Emerging Markets
may not be covered by these techniques.</span></p> </div> </ix:continuation> <ix:nonNumeric id="Fxbrl_20231202103822878" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977ForwardContractRiskMember" continuedAt="F20231202111127449" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Forward Contract Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Forward contracts involve the purchase or sale of a specific quantity of a commodity, government security, foreign currency, or other
asset at a specified price, with delivery and settlement at a specified future date. Because it is a completed contract, a purchase forward
contract can be a cover for the sale of a futures contract. The Fund may enter into forward contracts for hedging purposes and non-hedging
purposes (i.e., to increase returns). Forward contracts may be used by the Fund for hedging purposes to protect against uncertainty in
the level of future foreign currency exchange rates, such as when the Fund anticipates purchasing or selling a foreign security. For example,
this technique would allow the Fund to "lock in" the U.S. dollar price of the security. Forward contracts may also be used to attempt
to protect the value of the Fund's existing holdings of foreign securities. There may be, however, an imperfect correlation between the
Fund's foreign securities holdings and the forward contracts entered into with respect to those holdings. Forward contracts may also be
used for non-hedging purposes to pursue the Fund's investment objective, such as when the Investment Adviser anticipates that particular
foreign currencies will appreciate or depreciate in value, even though securities denominated in</span></p> </ix:nonNumeric> </div> </ix:continuation>
</div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 67</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103137092" continuedAt="F20231202103143328">

<div> <ix:continuation id="F20231202111127449">

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">those currencies are not then
held in the Fund's portfolio. There is no requirement that the Fund hedge all or any portion of its exposure to foreign currency risks.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Forward contracts, unlike
futures contracts, are not traded on exchanges and are not standardized; rather, banks and dealers act as principals in these markets,
negotiating each transaction on an individual basis. The principals who deal in the forward markets are not required to continue to make
markets in the currencies or commodities they trade and these markets can experience periods of illiquidity, sometimes of significant
duration. There have been periods during which certain participants in these markets have refused to quote prices for certain currencies
or commodities or have quoted prices with an unusually wide spread between the price at which they were prepared to buy and that at which
they were prepared to sell. Disruptions can occur in any market traded by the Investment Adviser due to unusually high trading volume,
political intervention or other factors. Arrangements to trade forward contracts may be made with only one or a few counterparties, and
liquidity problems therefore might be greater than if such arrangements were made with numerous counterparties. The imposition of controls
by governmental authorities might also limit such forward (and futures) trading to less than that which the Investment Adviser would otherwise
recommend, to the possible detriment of the Fund. Market illiquidity or disruption could result in major losses to the Fund. In addition,
the Fund will be exposed to credit risks with regard to counterparties with whom they trade as well as risks relating to settlement default.
Such risks could result in substantial losses to the Fund.</span></p> </div> </ix:continuation> <ix:nonNumeric id="Fxbrl_20231202103828359" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977DerivativesRiskMember" continuedAt="F20231202111149233" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Derivatives Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
The Fund may invest in derivative instruments including options, futures, options on futures, forwards, swaps (including credit default,
index, basis, total return, volatility and currency swaps), options on swaps and other derivatives, although suitable derivative instruments
may not always be available to the Investment Adviser for these purposes. The Fund intends to employ a strategy of writing (selling) covered
call options on a portion of the common stocks in its portfolio, writing (selling) put options on a portion of the common stocks in its
portfolio and, to a lesser extent, writing (selling) covered call and writing (selling) put options on indices of securities and sectors
of securities generally within the healthcare industry. This option strategy is intended to generate current income from option premiums
as a means to enhance distributions payable to the Fund's shareholders and will be limited to 30% of the Fund's Managed Assets. These
option strategies are not always profitable. The sale of a covered call option exposes the Fund during the term of the option to possible
loss of opportunity to realize appreciation in the market price of the underlying security or to possible loss due to continued holding
of a security that might otherwise have been sold to protect against depreciation in the market price of the security. To the extent the
Fund writes a covered put option, the Fund has assumed the obligation during the option period to purchase the security or securities
from the put buyer at the option's exercise price if the put buyer exercises its option, regardless of whether the value of the underlying
investment falls below the exercise price. This means that a Fund that writes a</span></p> </ix:nonNumeric> </div> </ix:continuation>
</div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">68 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103143328" continuedAt="F20231202103153200">

<div> <ix:continuation id="F20231202111149233" continuedAt="F20231202111155806">

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">put option may be required
make payment for such investment at the exercise price. This may result in losses to the Fund and may result in the Fund holding securities
for some period of time when it is disadvantageous to do so. Therefore, the Investment Adviser may choose to decrease its use of the option
writing strategy to the extent that it may negatively impact the Fund. Other than the Fund's option strategy and use of derivatives for
hedging purposes, the Fund may invest up to 10% of its Managed Assets in derivatives. Derivative instruments can be illiquid, may disproportionately
increase losses, and may have a potentially large adverse impact on Fund performance.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Although both OTC and exchange-traded
derivatives markets may experience a lack of liquidity, OTC nonstandardized derivative transactions are generally less liquid than exchange-traded
instruments. The illiquidity of the derivatives markets may be due to various factors, including congestion, disorderly markets, limitations
on deliverable supplies, the participation of speculators or their withdrawal from the markets, government regulation and intervention,
and technical and operational or system failures. In addition, daily limits on price fluctuations and speculative position limits on exchanges
on which the Fund may conduct its transactions in derivative instruments may prevent the Fund from liquidating these positions at an advantageous
time or price, subjecting the Fund to the potential of greater losses. Losses from investments in derivative instruments can result from
a lack of correlation between changes in the value of derivative instruments and the portfolio assets (if any) being hedged, the potential
illiquidity of the markets for derivative instruments, the failure of the counterparty to perform its contractual obligations, or the
risks arising from margin requirements and related leverage factors associated with such transactions. Losses may also arise if the Fund
receives cash collateral under the transactions and some or all of that collateral is invested in the market. To the extent that cash
collateral is so invested, such collateral will be subject to market depreciation or appreciation, and the Fund may be responsible for
any loss that might result from its investment of the counterparty's cash collateral. The use of these derivatives trading techniques
also involves the risk of loss if the Investment Adviser is incorrect in its expectation of the timing or level of fluctuations in securities
prices, interest rates or currency prices. Investments in derivative instruments may be harder to value, subject to greater volatility
and more likely subject to changes in tax treatment than other investments. For these reasons, the Investment Adviser's attempts to hedge
portfolio risks through the use of derivative instruments may not be successful. Trading in derivative instruments can increase the Fund's
exposure to leverage. Thus, the leverage offered by trading in derivative instruments will magnify the gains and losses experienced by
the Fund and could cause the Fund's net asset value to be subject to wider fluctuations than would be the case if the Fund did not use
the leverage feature in derivative instruments.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Derivatives markets have been
subject to increased regulation over the past several years, which may continue, and consequently, may make derivatives trading more costly,
may limit the availability of and reduce the liquidity of derivatives or may otherwise adversely affect the</span></p> </div> </ix:continuation>
</div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 69</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103153200" continuedAt="F20231202103200063">

<div> <ix:continuation id="F20231202111155806">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">value or performance of derivatives.
Such potential adverse future developments could increase the risks reduce the effectiveness of the Fund's derivative transactions, and
cause the Fund to lose value. For instance, the SEC has adopted new regulations related to a registered investment company's use of derivatives
and related instruments. These regulations impose limits on the amount of derivatives a fund can enter into, eliminate the asset segregation
framework formerly used by funds to comply with Section 18 of the 1940 Act. These regulations may significantly impact the Fund's ability
to invest in derivatives and other instruments, limit the Fund's ability to employ certain strategies that use derivatives and/or adversely
affect the Fund's performance, efficiency in implementing its strategy, liquidity and/or ability to pursue its investment objectives.</span></p>
</ix:continuation> <ix:nonNumeric id="Fxbrl_20231202103835215" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977RisksAssociatedWithFundsOptionStrategyMember" continuedAt="F20231202111217464" escape="true">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Risks Associated with
the Fund's Option Strategy.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The ability of the Fund to achieve
its investment objective is partially dependent on the successful implementation of its option strategy. There are several risks associated
with transactions in options on securities used in connection with the Fund's option strategy. For example, there are significant differences
between the securities and options markets that could result in an imperfect correlation between these markets, causing a given transaction
not to achieve its objectives. A decision as to whether, when and how to use options involves the exercise of skill and judgment, and
even a well-conceived transaction may be unsuccessful to some degree because of market behavior or unexpected events.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">As the writer of a call option
covered with a security held by the Fund, the Fund forgoes, during the option's life, the opportunities to profit from increases in the
market value of the security covering the call option above the sum of the premium and the strike price of the call but retains the risk
of loss should the price of the underlying security decline. As the Fund writes such covered calls over more of its portfolio, its ability
to benefit from capital appreciation becomes more limited. To the extent the Fund writes call options that are not fully covered by securities
in its portfolio (such as calls on an index or sector), it will lose money if the portion of the security or securities underlying the
option that is not covered by securities in the Fund's portfolio appreciate in value above the exercise price of the option by an amount
that exceeds the premium received on the option plus the exercise price of the option. The amount of this loss theoretically could be
unlimited. The writer of an option has no control over the time when it may be required to fulfill its obligations as a writer of the
option.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">When the Fund writes put options,
it bears the risk of loss if the value of the underlying stock declines below the exercise price minus the put premium. If the option
is exercised, the Fund could incur a loss if it is required to purchase the stock underlying the put option at a price greater than the
market price of the stock at the time of exercise plus the put premium the Fund received when it wrote the option. While the Fund's potential
gain as the writer of a</span></p> </div> </ix:nonNumeric> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">70 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103200063" continuedAt="F20231202103206632">

<div> <ix:continuation id="F20231202111217464">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">covered put option is limited
to the premium received from the purchaser of the put option, the Fund risks a loss equal to the entire exercise price of the option minus
the put premium.</span></p> </ix:continuation> <ix:nonNumeric id="Fxbrl_20231202103841443" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977InterestRatesRiskMember" escape="true">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Interest Rate Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Prices of fixed-income securities generally rise and fall in response to interest rate changes. Generally, the prices of fixed-rate instruments
held by the Fund will tend to fall as interest rates rise. Conversely, when interest rates decline, the value of fixed-rate instruments
held by the Fund can be expected to rise. Changing interest rates may have unpredictable effects on the markets, may result in heightened
market volatility and may detract from Fund performance. In addition, changes in monetary policy may exacerbate the risks associated with
changing interest rates. The longer the duration, or price sensitivity to changes in interest rates, of the security, the more sensitive
the security is to this risk. In typical market interest rate environments, the prices of longer-term fixed-rate instruments tend to fluctuate
more in price in response to changes in market interest rates than prices of shorter-term fixed-rate instruments. A 1% increase in interest
rates would reduce the value of a $100 note by approximately one dollar if it had a one-year duration. It is difficult to predict the
magnitude, timing or direction of interest rate changes and the impact these changes will have on the Fund's investments and the markets
where it trades.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The risks attendant to changing
interest rate environments have been, and continue to be, magnified in the current economic environment. To combat rising inflation, the
Board of Governors of the Federal Reserve System increased the federal funds rate several times in 2022 and 2023.</span></p> </div> </ix:nonNumeric>
<ix:nonNumeric id="Fxbrl_20231202103847054" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977ReitRiskMember" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>REIT Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
REITs whose underlying properties are concentrated in a particular industry, such as the healthcare industry, or geographic region are
subject to risks affecting such industries or regions. The securities of REITs involve greater risks than those associated with larger,
more established companies and may be subject to more abrupt or erratic price movements because of interest rate changes, economic conditions
and other factors. Securities of such issuers may lack sufficient market liquidity to enable the Fund to effect sales at an advantageous
time or without a substantial drop in price.</span></p> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20231202103851303" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977CreditDefaultRiskMember" continuedAt="F20231202111503395" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Credit/Default Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Loans and other debt obligation investments are subject to the risk of non-payment of scheduled principal and interest. Changes in economic
conditions or other circumstances may reduce the capacity of the party obligated to make principal and interest payments on such instruments
and may lead to defaults. Such non-payments and defaults may reduce the value of the shares and income distributions. The value of loans
and other income investments also may decline because of concerns about the issuer's ability to make principal and interest payments.
In addition, the credit ratings of loans or other income investments may be lowered if the financial condition of the party obligated
to make payments with respect to such instruments changes. Because the Fund will invest in non-investment grade securities, it will be
exposed to a greater amount of credit risk than a fund which invests solely in investment grade securities. The prices of lower grade</span></p>
</ix:nonNumeric> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 71</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103206632" continuedAt="F20231202103212968">

<div> <ix:continuation id="F20231202111503395">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">instruments are generally
more sensitive to negative developments, such as a decline in the issuer's revenues or a general economic downturn, than are the prices
of higher grade instruments. Credit ratings assigned by rating agencies are based on a number of factors and do not necessarily reflect
the issuer's current financial condition or the volatility or liquidity of the security. In the event of bankruptcy of the issuer of loans
or other income investments, the Fund could experience delays or limitations with respect to its ability to realize the benefits of any
collateral securing the instrument. In order to enforce its rights in the event of a default, bankruptcy or similar situation, the Fund
may be required to retain legal or similar counsel and incur additional costs.</span></p> </ix:continuation> <ix:nonNumeric id="Fxbrl_20231202103857346" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977NonInvestmentGradeSecuritiesRiskMember" continuedAt="F20231202111521282" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Non-Investment Grade
Securities Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund may invest in securities that are
rated, at the time of investment, non-investment grade quality (rated "Ba/BB+/BB+" or below by Moody's, S&#38;P or Fitch, respectively),
or securities that are unrated but determined to be of comparable quality by the Investment Adviser. The Fund may invest up to 15% of
its Managed Assets in non-convertible debt securities that are, at the time of investment, rated Caa1 or lower by Moody's and CCC+ or
lower by S&#38;P or Fitch, or comparably rated by another nationally recognized statistical rating organization, or, if unrated, determined
by the Investment Adviser to be of comparable credit quality. Such securities are subject to a very high credit risk. Securities of non-investment
grade quality are regarded as having predominantly speculative characteristics with respect to the issuer's capacity to pay interest and
repay principal, and are commonly referred to as "junk bonds." Non-investment grade securities and unrated securities of comparable credit
quality are subject to the increased risk of an issuer's inability to meet principal and interest payment obligations. The value of high
yield, lower quality bonds is affected by the creditworthiness of the issuers of the securities and by general economic and specific industry
conditions. These securities may be subject to greater price volatility due to such factors as specific corporate or municipal developments,
interest rate sensitivity, negative perceptions of the junk bond markets generally and less secondary market liquidity. Issuers of high
yield bonds are not as strong financially as those with higher credit ratings. These issuers are more vulnerable to financial setbacks
and recession than more creditworthy issuers, which may impair their ability to make interest and principal payments. Non-investment grade
securities may be particularly susceptible to economic downturns, specific corporate or municipal developments, interest rate sensitivity,
negative perceptions of the junk bond markets generally and less secondary market liquidity. An economic recession could disrupt severely
the market for such securities and may have an adverse impact on the value of such securities. In addition, any such economic downturn
could adversely affect the ability of the issuers of such securities to repay principal and pay interest thereon and increase the incidence
of default for such securities. Non-investment grade securities, though higher yielding, are characterized by high risk. They may be subject
to certain risks with respect to the issuing entity and to greater market fluctuations than certain lower yielding, higher rated securities.
The retail secondary market for non-investment grade securities may be less liquid than that for higher rated securities. Adverse conditions</span></p>
</ix:nonNumeric> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">72 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103212968" continuedAt="F20231202103219715">

<div> <ix:continuation id="F20231202111521282">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">could make it difficult at
times for the Fund to sell certain securities or could result in lower prices than those used in calculating the Fund's NAV. Because of
the substantial risks associated with investments in non-investment grade securities, you could lose money on your investment in shares
of the Fund, both in the short-term and the long-term.</span></p> </ix:continuation> <ix:nonNumeric id="Fxbrl_20231202103903478" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977CounterpartyRiskMember" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Counterparty Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Many of the protections afforded to participants on some organized exchanges, such as the performance guarantee of a clearing house, might
not be available in connection with uncleared OTC transactions. Therefore, in those instances in which the Fund enters into uncleared
OTC transactions, the Fund will be subject to the risk that its direct counterparty will not perform its obligations under the transactions
and that the Fund will sustain losses. If a counterparty becomes bankrupt, the Fund may experience significant delays in obtaining recovery
(if at all) under the derivative contract in bankruptcy or other reorganization proceeding; if the Fund's claim is unsecured, the Fund
will be treated as a general creditor of such prime broker or counterparty and will not have any claim with respect to the underlying
security. The Fund may obtain only a limited recovery or may obtain no recovery in such circumstances. The counterparty risk for cleared
derivatives is generally lower than for uncleared OTC derivatives since generally a clearing organization becomes substituted for each
counterparty to a cleared derivative and, in effect, guarantees the parties' performance under the contract as each party to a trade looks
only to the clearing house for performance of financial obligations. However, there can be no assurance that the clearing house, or its
members, will satisfy its obligations to the Fund.</span></p> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20231202103908123" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977RegulationAsCommodityPoolMember" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Regulation as a "Commodity
Pool".</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Investment Adviser has claimed an exclusion from
the definition of the term "commodity pool operator" with respect to the Fund pursuant to Regulation 4.5 promulgated by the U.S. Commodity
Futures Trading Commission (the "CFTC"). For the Investment Adviser to continue to qualify for the exclusion under CFTC Regulation 4.5
with respect to the Fund, the aggregate initial margin and premiums required to establish our positions in derivative instruments subject
to the jurisdiction of the Commodity Exchange Act of 1936, as amended ("CEA") (other than positions entered into for hedging purposes)
may not exceed five percent of the Fund's liquidation value or, alternatively, the net notional value of the Fund's aggregate investments
in CEA-regulated derivative instruments (other than positions entered into for hedging purposes) may not exceed 100% of the Fund's liquidation
value. In the event the Investment Adviser fails to qualify for the exclusion with respect to the Fund and is required to register as
a "commodity pool operator," it will become subject to additional disclosure, recordkeeping and reporting requirements with respect to
the Fund, which may increase the Fund's expenses.</span></p> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20231202103913035" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember" continuedAt="F20231202111555326" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Failure of Futures
Commission Merchants and Clearing Organizations.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund may
deposit funds required to margin open positions in derivative instruments subject to the CEA with a clearing broker registered as a "futures
commission merchant" ("FCM"). The CEA requires an FCM to segregate all funds received from customers with respect to any orders for the
purchase or sale of U.S. domestic futures contracts and cleared swaps from the FCM's</span></p> </ix:nonNumeric> </div> </ix:continuation>
</div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 73</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103219715" continuedAt="F20231202103226543">

<div> <ix:continuation id="F20231202111555326">

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">proprietary assets. Similarly,
the CEA requires each FCM to hold in a separate secure account all funds received from customers with respect to any orders for the purchase
or sale of foreign futures contracts and segregate any such funds from the funds received with respect to domestic futures contracts.
However, all funds and other property received by a clearing broker from its customers are held by the clearing broker on a commingled
basis in an omnibus account and may be freely accessed by the clearing broker, which may also invest any such funds in certain instruments
permitted under the applicable regulation. There is a risk that assets deposited by the Fund with any swaps or futures clearing broker
as margin for futures contracts or cleared swaps may, in certain circumstances, be used to satisfy losses of other clients of the Fund's
clearing broker. In addition, the assets of the Fund may not be fully protected in the event of the clearing broker's bankruptcy, as the
Fund would be limited to recovering only a pro rata share of all available funds segregated on behalf of the clearing broker's combined
domestic customer accounts.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Similarly, the CEA requires
a clearing organization approved by the CFTC as a derivatives clearing organization to segregate all funds and other property received
from a clearing member's clients in connection with domestic futures, swaps and options contracts from any funds held at the clearing
organization to support the clearing member's proprietary trading. Nevertheless, with respect to futures and options contracts, a clearing
organization may use assets of a non-defaulting customer held in an omnibus account at the clearing organization to satisfy payment obligations
of a defaulting customer of the clearing member to the clearing organization. As a result, in the event of a default or the clearing broker's
other clients or the clearing broker's failure to extend its own funds in connection with any such default, the Fund would not be able
to recover the full amount of assets deposited by the clearing broker on its behalf with the clearing organization.</span></p> </div>
</ix:continuation> <ix:nonNumeric id="Fxbrl_20231202103919110" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977LiquidityRiskMember" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Liquidity Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Illiquid securities include securities the disposition of which is subject to substantial legal or contractual restrictions. The sale
of illiquid securities often requires more time and results in higher brokerage charges or dealer discounts and other selling expenses
than does the sale of securities eligible for trading on national securities exchanges or in the over-the-counter markets. Restricted
securities may sell at a price lower than similar securities that are not subject to restrictions on resale. The continued liquidity of
such securities may not be as well assured as that of publicly traded securities. During certain periods the liquidity of particular issuers
or industries, or all securities within particular investment categories, may shrink or disappear suddenly and without warning as a result
of adverse economic, market or political events, or adverse investor perceptions, whether or not accurate.</span></p> </ix:nonNumeric>
<ix:nonNumeric id="Fxbrl_20231202103923782" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977EquityLinkedNotesMember" continuedAt="F20231202111618706" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Equity-Linked Notes.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Equity-linked notes ("ELNs") are hybrid securities with characteristics of both fixed income and equity securities. An ELN is a debt instrument,
usually a bond, that pays interest based upon the performance of an underlying equity, which can be a single stock, basket of stocks or
an equity index. The interest payment on an ELN may in some cases be leveraged so that, in percentage terms, it exceeds the relative performance
of the market.</span></p> </ix:nonNumeric> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">74 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103226543" continuedAt="F20231202103232880">

<div> <ix:continuation id="F20231202111618706">

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">ELNs generally are subject to
the risks associated with the securities of equity issuers, default risk and counterparty risk. Additionally, because the Fund may use
ELNs as an alternative or complement to its options strategy, the use of ELNs in this manner would expose the Fund to the risk that such
ELNs will not perform as anticipated, and the risk that the use of ELNs will expose the Fund to different or additional default and counterparty
risk as compared to a similar investment executed in an options strategy.</span></p> </ix:continuation> <ix:nonNumeric id="Fxbrl_20231202103930930" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977PrivateInvestmentInPublicEquityRiskMember" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>PIPEs Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
PIPE transactions typically involve the purchase of securities directly from a publicly traded company or its affiliates in a private
placement transaction, typically at a discount to the market price of the company's common stock. In a PIPE transaction, the Fund may
bear the price risk from the time of pricing until the time of closing. Equity issued in this manner is often subject to transfer restrictions
and is therefore less liquid than equity issued through a registered public offering. In a PIPE transaction, the Fund may bear the price
risk from the time of pricing until the time of closing. The Fund may be subject to lock-up agreements that prohibit transfers for a fixed
period of time. In addition, because the offering of the securities in a PIPE transaction is not registered under the Securities Act,
the securities are "restricted" and cannot be immediately resold by the investors into the public markets. The Fund may enter into a registration
rights agreement with the issuer pursuant to which the issuer commits to file a resale registration statement allowing the Fund to publicly
resell its securities. Accordingly, PIPE securities may be deemed illiquid. However, the ability of the Fund to freely transfer the shares
is conditioned upon, among other things, the Commission's preparedness to declare the resale registration statement effective covering
the resale of the shares sold in the private financing and the issuer's right to suspend the Fund's use of the resale registration statement
if the issuer is pursuing a transaction or some other material non-public event is occurring. Accordingly, PIPE securities may be subject
to risks associated with illiquid securities.</span></p> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20231202103936730" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977VentureCapitalInvestmentsRiskMember" continuedAt="F20231202111644182" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Venture Capital Investments
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund may occasionally invest in venture capital opportunities.
While these securities offer the opportunity for significant capital gains, such investments also involve a degree of risk that can result
in substantial losses. Some of the venture capital opportunities in which the Fund may invest are expected to be companies that are in
a "start-up" stage of development, have little or no operating history, operate at a loss or with substantial variations in operating
results from period to period, have limited products, markets, financial resources or management depth, or have the need for substantial
additional "follow-on" capital to support expansion or to achieve or maintain a competitive position. Such additional investments may
dilute the interests of prior investors, such as the Fund. Some of these companies may be emerging companies at the research and development
stage with no marketable or approved products or technology. There can be no assurance that securities of start-up or emerging growth
companies will, in the future, yield returns commensurate with their associated risks.</span></p> </ix:nonNumeric> </div> </ix:continuation>
</div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 75</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103232880" continuedAt="F20231202103239823">

<div> <ix:continuation id="F20231202111644182">

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">These investments, which are considered
Restricted Securities, will be made primarily in convertible preferred stock. The Fund may also purchase non-convertible debt securities
in connection with its venture capital investments, and otherwise when the Investment Adviser believes that such investments would be
consistent with the Fund's investment objective. While these debt investments typically will not be rated, the Investment Adviser believes
that, in light of the risk characteristics associated with investments in emerging growth companies, if such investments were to be compared
with investments rated by S&#38;P or Moody's, they may be rated as low as "C" in the rating categories established by S&#38;P and Moody's.
Such securities are commonly referred to as "junk bonds" and are considered, on balance, as predominantly speculative.</span></p> </ix:continuation>
<ix:nonNumeric id="Fxbrl_20231202103942470" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977ExchangeTradedFundsRiskMember" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>ETFs Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
An investment in an ETF generally presents the same primary risks as an investment in a conventional fund (i.e., one that is not exchange-traded)
that has the same investment objectives, strategies and policies. In addition, an ETF may fail to accurately track the market segment
or index that underlies its investment objective. The price of an ETF can fluctuate, and the Fund could lose money investing in an ETF.
Moreover, ETFs are subject to the following risks that do not apply to conventional open-end funds: (i) the market price of the ETF's
shares may trade at a premium or a discount to their NAV; (ii) an active trading market for an ETF's shares may not develop or be maintained;
and (iii) there is no assurance that the requirements of the exchange necessary to maintain the listing of an ETF will continue to be
met or remain unchanged.</span></p> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20231202103947774" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977LeverageRiskMember" continuedAt="F20231202111712170" escape="true">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Leverage Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
The Fund intends to use financial leverage for investment purposes. The Fund may issue preferred shares, borrow money and/or issue debt
securities ("traditional leverage"). The Fund intends to use traditional leverage through a credit facility representing up to 20% of
the Fund's Managed Assets as measured at the time when leverage is incurred. In addition, the Fund may enter into reverse repurchase agreements,
swaps, futures, forward contracts, securities lending, short sales, and other derivative transactions, that have similar effects as leverage
(collectively referred to as "effective leverage"). Furthermore, at no time will the Fund's use of leverage, either through traditional
leverage or effective leverage, exceed 30% of the Fund's Managed Assets as measured at the time when leverage is incurred. Notwithstanding
the foregoing, effective leverage incurred through the Fund's option strategy and use of derivatives for hedging purposes will not be
counted toward the Fund's limit on the use of effective leverage or in the overall 30% leverage limitation.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's leveraged capital
structure creates special risks not associated with unleveraged funds having a similar investment objective and policies. These include
the possibility of greater loss and the likelihood of higher volatility of the NAV, market price and distributions of the Fund and the
asset coverage for preferred shares, if any. Such volatility may increase the likelihood of the Fund having to sell investments in order
to meet its obligations to make distributions on the preferred shares, or to redeem preferred shares when it may be disadvantageous to
do so. Also, if the Fund is utilizing leverage, a decline in NAV could affect</span></p> </div> </ix:nonNumeric> </div> </ix:continuation>
</div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">76 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103239823" continuedAt="F20231202103246203">

<div> <ix:continuation id="F20231202111712170">

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">the ability of the Fund to
make distributions and such a failure to pay dividends or make distributions could result in the Fund ceasing to qualify as a regulated
investment company under the Code, as amended.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Other risks and special considerations
include the risk that fluctuations in interest rates on borrowings and short-term debt or in the interest or dividend rates on any leverage
that the Fund must pay will reduce the return to the shareholders; the effects of leverage in a declining market, which are likely to
cause a greater decline in the NAV of the shares than if the Fund were not leveraged, which may result in a greater decline in the market
price of the shares. If the Fund uses leverage, the amount of fees paid to the Investment Adviser for its services will be higher than
if the Fund did not use leverage because the fees paid are calculated based on Managed Assets, which includes assets purchased with leverage.
Therefore, the Investment Adviser has a financial incentive to use leverage, which creates a conflict of interest between the Investment
Adviser and common shareholders, as only the Fund's common shareholders would bear the fees and expenses incurred through the Fund's use
of leverage, including the issuance of Preferred shares, if any. Leverage may increase operating costs, which may reduce total return.</span></p>
<ix:nonNumeric id="Fxbrl_20231202112444499" name="cef:EffectsOfLeverageTextBlock" contextRef="C_20221001to20230930" escape="true">

<div>

<p style="margin:11pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Effects of Leverage</strong></span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Assuming that leverage will
represent approximately 20% of Managed Assets and that the Fund will bear expenses relating to that leverage at an annual cost of 1.00%,
Fund performance before leverage (net of expenses) must exceed .2% in order to cover the expenses specifically related to the Fund's use
of leverage. Actual leverage expenses will vary frequently and may be significantly higher or lower than the rate estimated above.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">As of September 30, 2023 and
the most recently signed line of credit agreement, the Fund projects an annual leverage expense of 6.57%. The Fund had $120,000,000 of
funds drawn on its line of credit which was 21.2% of Managed Assets as of September 30, 2023.</span></p> <ix:nonNumeric id="Fxbrl_20231202112644218" name="cef:EffectsOfLeverageTableTextBlock" contextRef="C_20221001to20230930" escape="true">

<div> <ix:nonNumeric id="Fxbrl_20231202113204920" name="cef:EffectsOfLeveragePurposeTextBlock" contextRef="C_20221001to20230930" escape="true">

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following table is furnished
in response to requirements of the SEC. It is designed to illustrate the effects of leverage on total returns from an investment in the
Fund assuming investment portfolio returns before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage
representing 20% of the Fund's Managed Assets and the Fund's currently projected annual leverage expense of 6.57%.</span></p> </ix:nonNumeric>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:143;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">Assumed
        Fund Return Before Leverage</span><br /><span style="font-size:8pt;font-family:Arial, Helvetica">(Net of Expenses) </span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(10.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(5.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:29;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:33;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:143">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Assumed Fund Return Inclusive of Leverage </span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(<ix:nonFraction id="Fxbrl_20231202112722028_13" name="cef:ReturnAtMinusTenPercent" contextRef="C_20221001to20230930" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">14.14</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(<ix:nonFraction id="Fxbrl_20231202112722028_17" name="cef:ReturnAtMinusFivePercent" contextRef="C_20221001to20230930" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">7.89</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(<ix:nonFraction id="Fxbrl_20231202112722028_111" name="cef:ReturnAtZeroPercent" contextRef="C_20221001to20230930" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">1.64</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:29">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202112722028_115" name="cef:ReturnAtPlusFivePercent" contextRef="C_20221001to20230930" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.61</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:33">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica"><ix:nonFraction id="Fxbrl_20231202112722028_119" name="cef:ReturnAtPlusTenPercent" contextRef="C_20221001to20230930" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">10.89</ix:nonFraction></span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  </table>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Assumed Fund performance before
and inclusive of leverage are hypothetical and are provided to assist investors in understanding the effects of leverage. Actual performance
experienced by the Fund may be lesser or greater than that shown above.</span></p> </div> </ix:nonNumeric> </div> </ix:nonNumeric> </div>
</ix:continuation> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 77</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103246203" continuedAt="F20231202103252387">

<div> <ix:nonNumeric id="Fxbrl_20231202104054873" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977RestrictedSecuritiesAndValuationRiskMember" escape="true">

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Restricted Securities
and Valuation Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Some of the Fund's investments are subject
to restrictions on resale and generally have no established trading market or are otherwise illiquid with little or no trading activity.
The valuation process requires an analysis of various factors. The Fund's fair value methodology includes the examination of, among other
things, (i) the existence of any contractual restrictions on the disposition of the securities; (ii) information obtained from the issuer
which may include an analysis of the company's financial statements, the company's products or intended markets, or the company's technologies;
and (iii) the price of a security sold at arm's length in an issuer's subsequent completed round of financing. As there is typically no
readily available market value for some of the Restricted Securities in the Fund's portfolio, such Restricted Securities in the Fund's
portfolio are valued at fair value as determined in good faith by or under the direction of the Board pursuant to the Fund's valuation
policy and a consistently applied valuation process. Because of the inherent uncertainty of determining the fair value of investments
that do not have a readily available market value, the fair value of the Fund's investments determined in good faith by the Board may
differ significantly from the values that would have been used had a ready market existed for the investments, and the differences could
be material. There is no single standard for determining fair value in good faith. As a result, determining fair value requires that judgment
be applied to the specific facts and circumstances of each portfolio investment, while employing a consistently applied valuation process
for the types of investments the Fund makes.</span></p> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20231202104059334" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977KeyPersonnelRiskMember" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Key Personnel Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
There may be only a limited number of securities professionals who have comparable experience to that of the Fund's existing portfolio
management team in the area of healthcare companies. If one or more of the team members dies, resigns, retires or is otherwise unable
to act on behalf of the Investment Adviser, there can be no assurance that a suitable replacement could be found immediately.</span></p>
</ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20231202104107262" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977AntiTakeoverProvisionsRiskMember" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Anti-Takeover Provisions
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund's Amended and Restated Declaration of Trust ("Declaration
of Trust"), dated March 5, 2015, as amended, has provisions that could have the effect of limiting the ability of other entities or persons
to (1) acquire control of the Fund, (2) cause it to engage in certain transactions, or (3) modify its structure. The By-Laws also contain
provisions regarding qualifications for nominees for Trustee positions, advance notice of Shareholder proposals, and requirements for
the call of special Shareholder meetings. These provisions may be considered "anti-takeover" provisions.</span></p> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20231202104111657" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977RelatedPartyTransactionsRiskMember" continuedAt="F20231202111754522" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Related Party Transactions
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The majority of the Board is unaffiliated with the Investment
Adviser; nevertheless, the Fund may be subject to certain potential conflicts of interest. Although the Fund has no obligation to do so,
it may place brokerage orders with brokers who provide supplemental investment research and market and statistical information about healthcare
companies and the healthcare industries. In addition, other investment companies advised by the Investment Adviser may concurrently invest
with the Fund in restricted securities under certain conditions. The Fund also may invest, subject to</span></p> </ix:nonNumeric> </div>
</ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">78 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103252387" continuedAt="F20231202103300579">

<div> <ix:continuation id="F20231202111754522">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">applicable law, in companies
in which the principals of the Investment Adviser or Trustees of the Fund have invested, or for which they serve as directors or executive
officers. The Investment Company Act prohibits the Fund from engaging in certain transactions involving its "affiliates," including, among
others, the Fund's Trustees, officers and employees, the Investment Adviser and any "affiliates" of such affiliates except pursuant to
an exemptive order or the provisions of certain rules under the Investment Company Act. In the view of the staff of the Commission, other
investment companies advised by the Investment Adviser may, in some instances, be viewed to be affiliates of the Fund. Such legal restrictions
and delays and costs involved in obtaining necessary regulatory approvals may preclude or discourage the Fund from making certain investments
and no assurance can be given that any exemptive order sought by the Fund will be granted.</span></p> </ix:continuation> <ix:nonNumeric id="Fxbrl_20231202104119954" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977GovernmentInterventionMember" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Government Intervention.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Instability in the financial markets has led the U.S. government and certain foreign governments to take a number of unprecedented actions
designed to support certain financial institutions and segments of the financial markets that have experienced extreme volatility, and
in some cases a lack of liquidity, including through direct purchases of equity and debt securities. Federal, state, and foreign governments,
their regulatory agencies or self-regulatory organizations may take actions that affect the regulation of the issuers in which the Fund
invests in ways that are unforeseeable. Legislation or regulation may also change the way in which the Fund is regulated. Such legislation
or regulation could limit or preclude the Fund's ability to achieve its investment objective.</span></p> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20231202104126191" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977MarketDisruptionAndGeopoliticalRiskMember" continuedAt="F20231202111822390" escape="true">

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Market Disruption
and Geopolitical Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The value of your investment in the Fund
is based on the market prices of the securities the Fund holds. These prices change daily due to economic and other events that affect
markets generally, as well as those that affect particular regions, countries, industries, companies or governments. These price movements,
sometimes called volatility, may be greater or less depending on the types of securities the Fund owns and the markets in which the securities
trade. The increasing interconnectivity between global economies and financial markets increases the likelihood that events or conditions
in one region or financial market may adversely impact issuers in a different country, region or financial market. Securities in the Fund's
portfolio may underperform due to inflation (or expectations for inflation), interest rates, global demand for particular products or
resources, natural/environmental disasters, pandemics, epidemics, terrorism, cyber-attacks, regulatory events and governmental or quasi-governmental
actions. The occurrence of global events similar to those in recent years, such as terrorist attacks around the world, natural disasters,
social and political discord or debt crises and downgrades, among others, may result in market volatility and may have long term effects
on both the U.S. and global financial markets. A disruption of financial markets or other terrorist attacks could adversely affect Fund
service providers and/or the Fund's operations as well as interest rates, secondary trading, credit risk, inflation and other factors
relating to the shares. The Fund cannot predict the effects or likelihood of similar events in the future on the U.S. and world economies,
the value of the shares or the NAV of the Fund.</span></p> </ix:nonNumeric> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 79</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103300579" continuedAt="F20231202103308451">

<div> <ix:continuation id="F20231202111822390" continuedAt="F20231202111828194">

<div>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Social, political, economic
and other conditions and events, such as natural/environmental disasters, health emergencies (e.g., epidemics and pandemics such as COVID-19,
avian influenza and HINI/09), cyber-attacks, terrorism, actual or threatened wars or other armed conflicts (such as the Russia/Ukraine
and Israel/Hamas conflicts), may occur and could significantly impact issuers, industries, governments and other systems, including the
financial markets. These impacts could negatively affect the Fund's investments in securities and instruments that are economically tied
to the applicable region, and include (but are not limited to) declines in value and reductions in liquidity. In addition, to the extent
new sanctions are imposed or previously relaxed sanctions are reimposed, complying with such restrictions may prevent the Fund from pursuing
certain investments, cause delays or other impediments with respect to consummating such investments or divestments, require divestment
or freezing of investments on unfavorable terms, render divestment of underperforming investments impracticable, negatively impact the
Fund's ability to achieve its investment objective, prevent the Fund from receiving payments otherwise due it, increase diligence and
other similar costs to the Fund, render valuation of affected investments challenging, or require the Fund to consummate an investment
on terms that are less advantageous than would be the case absent such restrictions. As global systems, economies and financial markets
are increasingly interconnected, events that once had only local impact are now more likely to have regional or even global effects. Events
that occur in one country, region or financial market will, more frequently, adversely impact issuers in other countries, regions or markets.
These impacts can be exacerbated by failures of governments and societies to adequately respond to an emerging event or threat. These
types of events quickly and significantly impact markets in the U.S. and across the globe leading to extreme market volatility and disruption.
The extent and nature of the impact on supply chains or economies and markets from these events is unknown, particularly if these types
of events persist for an extended period of time. These types of events, could reduce consumer demand or economic output, result in market
closures, travel restrictions or quarantines, and generally have a significant impact on the economies and financial markets and the Investment
Adviser's investment advisory activities and services of other service providers, which in turn could adversely affect the Fund's investments
and other operations. The value of the Fund's investments may decrease as a result of such events, particularly if these events adversely
impact the operations and effectiveness of the Investment Adviser or key service providers or if these events disrupt systems and processes
necessary or beneficial to the investment advisory or other activities on behalf the Fund.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">In March 2023, several financial
institutions experienced a larger-than-expected decline in deposits and two banks, Silicon Valley Bank ("SVB") and Signature Bank, were
placed into receivership. Given the interconnectedness of the banking system, the Federal Reserve invoked the systemic risk exception,
temporarily transferred all deposits-both insured and uninsured-and substantially all the assets of the two banks into respective bridge
banks and</span></p> </div> </ix:continuation> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">80 abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt"> <ix:continuation id="F20231202103308451">

<div> <ix:continuation id="F20231202111828194">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">guaranteed depositors' full
access to their funds. This type of systemic risk event and/or resulting government actions can negatively impact the Funds, for example,
through less credit being available to issuers or uncertainty regarding safety of deposits at other institutions. These risks also may
adversely affect financial intermediaries, such as clearing agencies, clearing houses, banks, securities firms, and exchanges, with which
the Fund interacts.</span></p> </ix:continuation> <ix:nonNumeric id="Fxbrl_20231202104134933" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977PotentialConflictsOfInterestRiskMember" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Potential Conflicts
of Interest Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Investment Adviser's investment team is
responsible for managing the Fund as well as three other closed-end investment companies. In the future, the investment team may manage
other funds and accounts, including proprietary accounts, separate accounts and other pooled investment vehicles, such as unregistered
hedge funds. In the future, a portfolio manager may manage a separate account or other pooled investment vehicle which may have materially
higher fee arrangements than the Fund and may also have a performance-based fee. The side-by-side management of these funds or accounts
may raise potential conflicts of interest relating to cross trading, the allocation of investment opportunities and the aggregation and
allocation of trades.</span></p> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20231202104141560" name="cef:RiskTextBlock" contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977SpecialPurposeAcquisitionCompanyRiskMember" escape="true">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Special Purpose Acquisition
Company Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund may invest in SPACs. SPACs are collective
investment structures that pool funds in order to seek potential acquisition opportunities. Unless and until an acquisition is completed,
a SPAC generally invests its assets (less an amount to cover expenses) in U.S. Government securities, money market fund securities and
cash. SPACs and similar entities may be blank check companies with no operating history or ongoing business other than to seek a potential
acquisition. Certain SPACs may seek acquisitions only in limited industries or regions. If an acquisition that meets the requirements
for the SPAC is not completed within a predetermined period of time, the invested funds are returned to the entity's shareholders, unless
such shareholders approve alternative arrangements. Investments in SPACs may be illiquid and/or be subject to restrictions on resale.</span></p>
</ix:nonNumeric> </div> </ix:continuation> </div>

<p style="text-align:center"><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">abrdn WORLD HEALTHCARE
FUND | ANNUAL REPORT 81</span></p> <hr style="page-break-after:always;height:3px;text-align:center;width:100%;background-color:gray" />

<div style="margin:8pt 0pt 8pt 0pt">

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:19pt;font-family:Arial, Helvetica">abrdn World Healthcare Fund</span></p>

<p style="margin:7pt 0pt 6pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">New York Stock Exchange Symbol:
THW<br />NAV Symbol: XTHWX</span></p>

<p style="margin:7pt 0pt 6pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">1900 Market Street, Suite
200<br />Philadelphia. PA 19103<br />866-354-4005<br />www.abrdnthw.com</span></p>

<p style="margin:5pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Trustees</strong></span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Jeffrey Bailey<br />Stephen
Bird<br />Rose DiMartino<br />Kathleen Goetz<br />C. William Maher<br />Todd Reit, Chair</span></p>

<p style="margin:5pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Investment Adviser</strong></span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">abrdn Inc.</span></p>

<p style="margin:5pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Administrator &#38;
Custodian</strong></span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">State Street Bank and Trust
Company</span></p>

<p style="margin:5pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Transfer Agent</strong></span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Computershare, Inc.</span></p>

<p style="margin:5pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Independent Registered
Public Accounting Firm</strong></span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">KPMG LLP</span></p>

<p style="margin:5pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Legal Counsel</strong></span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Dechert LLP</span></p>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Shareholders with questions
regarding share transfers may call </span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:14pt;font-family:Arial, Helvetica"><strong>1-800-426-5523</strong></span></p>

<p style="margin:7pt 0pt 20pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Daily net asset value may
be obtained from<br />our website </span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>www.abrdnthw.com</i></span></p>
</div> <hr style="page-break-after:avoid;height:3px;text-align:center;width:100%;background-color:gray" /> </div></div>

<div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2325133d1_item2-13.htm" BannerFilePath="/apps/files/files/jms2files/gofiler/tm2325133-1/tm2325133-1_ncsrseq1" --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 2. CODE OF ETHICS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 34.3pt"><span style="font-family: Times New Roman, Times, Serif">(a)</span></td><td>As
                                            of the end of the period covered by this report, the Registrant has adopted a code of ethics
                                            that applies to the Registrant&#x2019;s principal executive officer, principal financial officer,
                                            principal accounting officer or controller, or persons performing similar functions, regardless
                                            of whether these individuals are employed by the Registrant or a third party.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 34.3pt"><span style="font-family: Times New Roman, Times, Serif">(b)</span></td><td>No
                                            disclosures are required by this Item.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 34.3pt"><span style="font-family: Times New Roman, Times, Serif">(c)</span></td><td>During
                                            the period covered by this report, the Registrant did not make any substantive amendment
                                            to the code of ethics.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 34.3pt"><span style="font-family: Times New Roman, Times, Serif">(d)</span></td><td>During
                                            the period covered by this report, the Registrant did not grant any waiver, including any
                                            implicit waiver, from any provision of the code of ethics.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 34.3pt"><span style="font-family: Times New Roman, Times, Serif">(e)</span></td><td>Not
                                            applicable.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 34.3pt"><span style="font-family: Times New Roman, Times, Serif">(f)</span></td><td>A
                                            copy of the Registrant&#x2019;s Code will be made available, free of charge, upon request,
                                            by writing or calling abrdn Inc., 1900 Market Street, Suite&#xa0;200, Philadelphia, PA, 19103,
                                            1-800-522-5465.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 3. AUDIT COMMITTEE FINANCIAL EXPERT.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Registrant&#x2019;s Board of Trustees has determined that the Registrant
has at least one audit committee financial expert serving on its audit committee. As of the period ended September&#xa0;30, 2023 the
audit committee financial expert was Thomas M. Kent. As of October&#xa0;27, 2023, the audit committee financial expert is C. William
Maher. The financial expert is &#x201c;independent&#x201d; for the purposes of Item 3.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4. PRINCIPAL ACCOUNTANT FEES AND SERVICES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 34.3pt"><span style="font-family: Times New Roman, Times, Serif">(a)</span></td><td>Audit
                                            Fees. The aggregate fees billed for each of the last two fiscal years for professional services
                                            rendered by the principal accountant for the audit of the Registrant&#x2019;s annual financial
                                            statements or services that are normally provided by the accountant in connection with statutory
                                            and regulatory filings or engagements for those fiscal years were $85,000 for the fiscal
                                            year ended September&#xa0;30, 2023 and $72,930 for the fiscal year ended September&#xa0;30,
                                            2022.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 34.3pt"><span style="font-family: Times New Roman, Times, Serif">(b)</span></td><td>Audit
                                            Related Fees. The Registrant was not billed any fees in each of the last two fiscal years
                                            ended September&#xa0;30 for assurance and related services by the principal accountant that
                                            are reasonably related to the performance of the audit of the Registrant&#x2019;s financial
                                            statements and not otherwise included above.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 34.3pt"><span style="font-family: Times New Roman, Times, Serif">(c)</span></td><td>Tax
                                            Fees. The aggregate fees billed in each of the last two fiscal years for professional services
                                            rendered by the principal accountant for tax compliance, tax advice, and tax planning were
                                            $0 for the fiscal year ended September&#xa0;30, 2023 and $14,170 for the fiscal year
                                            ended September&#xa0;30, 2022. The nature of the services comprising the fees disclosed under
                                            this category was tax compliance.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 34.3pt"><span style="font-family: Times New Roman, Times, Serif">(d)</span></td><td>All
                                            Other Fees. The Registrant was not billed any fees in each of the last two fiscal years ended
                                            September&#xa0;30 for products and services provided by the principal accountant, other than
                                            the services reported in paragraphs (a)&#xa0;through (c)&#xa0;of this Item.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 34.3pt"><span style="font-family: Times New Roman, Times, Serif">(e)</span></td><td>(1)&#xa0;Pre-approval
                                            Policies and Procedures.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Pursuant to the Registrant&#x2019;s Audit Committee Charter
(&#x201c;Charter&#x201d;), the Audit Committee is responsible for approving in advance the firm to be employed as the Registrant&#x2019;s
independent auditor. In addition, the Charter provides that the Audit Committee is responsible for approving any and all proposals by
the Registrant, its investment adviser or their affiliated persons or any entity controlling, controlled by, or under common control
with the adviser that provides services to the Registrant to employ the independent auditor to render permissible non-audit services
related directly to the operations and financial reporting of the Registrant. In determining whether to pre-approve non-audit services,
the Audit Committee considers whether such services are consistent with the independent auditor&#x2019;s independence. The Charter further
permits the Audit Committee to delegate to one or more of its members authority to pre-approve permissible non-audit services to the
registrant, provided that any pre-approval determination of a delegate is for services with an estimated budget of less than $15,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
</span><span style="font-size: 10pt">None of the services described in each of paragraphs (b)&#xa0;through (d)&#xa0;of this Item were
approved by the Audit Committee pursuant to paragraph (c)(7)(i)(C)&#xa0;of Rule&#xa0;2-01 of Regulation S-X. All services described in
paragraphs (b)&#xa0;through (d)&#xa0;of the NCSR were approved in advance by the Audit Committee of each Fund.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 34.3pt"><span style="font-family: Times New Roman, Times, Serif">(f)</span></td><td>Not
                                            applicable.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 34.3pt"><span style="font-family: Times New Roman, Times, Serif">(g)</span></td><td>None.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 34.3pt"><span style="font-family: Times New Roman, Times, Serif">(h)</span></td><td>Not
                                            applicable.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 34.3pt"><span style="font-family: Times New Roman, Times, Serif">(i)</span></td><td>Not
                                            applicable.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 34.3pt"><span style="font-family: Times New Roman, Times, Serif">(j)</span></td><td>Not
                                            applicable.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 5. AUDIT COMMITTEE OF LISTED REGISTRANTS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The Registrant has a separately-designated standing
Audit Committee established in accordance with Section 3(a)(58)(A) of the Securities Exchange Act (15 U.S.C. 78c(a)(58)(A)). As of
the period ended, September 30, 2023, the members of the Audit Committee are Kathleen Goetz, Thomas Kent and W. Mark Watson. As of
October 27, 2023, the members of the Audit Committee are Jeffrey Bailey, Rose DiMartino, Kathleen Goetz, C. William Maher and Todd
Reit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 6. INVESTMENTS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Registrant&#x2019;s Schedule of Investments is included as part
of the Report to Shareholders filed under Item 1 of this form.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 7. DISCLOSURE OF PROXY VOTING POLICIES AND PROCEDURES FOR
CLOSED-END MANAGEMENT INVESTMENT COMPANIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Registrant has adopted the following proxy voting policies and
procedures through the period ended September&#xa0;30, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROXY VOTING POLICIES AND PROCEDURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">Polic</span></b></span><b>y</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following are the policies and procedures adopted and implemented
by Tekla Capital Management LLC (&#x201c;TCM&#x201d;) (the predecessor Adviser) for voting proxies with respect to portfolio securities
held by abrdn Healthcare Investors (formerly Tekla Healthcare Investors), abrdn Life Sciences Investors (formerly Tekla Life Sciences
Investors), abrdn Healthcare Opportunities Fund (formerly Tekla Healthcare Opportunities Fund) and abrdn World Healthcare Fund (formerly
Tekla World Healthcare Fund) (each a &#x201c;Fund&#x201d; and collectively the &#x201c;Funds&#x201d;) as of the period ended September&#xa0;30,
2023. The policies and procedures are reasonably designed to ensure that proxies are voted in the best interest of the Funds and the
Funds&#x2019; shareholders, in accordance with TCM&#x2019;s fiduciary duties and Rule&#xa0;206(4)-6 under the Investment Advisers Act of
1940 (the &#x201c;Investment Advisers Act&#x201d;). TCM considers the &#x201c;best interests&#x201d; of the Funds and their shareholders
to mean their best long-term economic interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TCM shall vote proxies for the exclusive benefit, and in the best
economic interest, of the Funds and their shareholders. Such exercise of voting rights shall be subject to the same standard of care
as is generally applicable to TCM&#x2019;s performance of its duties, as set forth in the advisory agreements with the Funds. The policies
and procedures contained herein are designed to be guidelines, however each vote is ultimately cast on a case-by-case basis, taking into
consideration the relevant facts and circumstances at the time of the vote. Any material conflicts that may arise will be resolved in
the best interests of the Funds and their shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A proxy committee has been designated and is responsible for administering
and overseeing the proxy voting process. The committee consists of the President of TCM, TCM&#x2019;s Chief Compliance Officer (&#x201c;CCO&#x201d;),
and the analyst responsible for oversight of the company that is the subject of the proxy. The committee considers proxy questions and
determines the vote on behalf of the Funds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">Procedures</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#xa0;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Logistics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TCM&#x2019;s CCO shall be responsible for maintaining the proxy log,
monitoring corporate actions and confirming the timely voting of proxies. The proxy log shall contain the following information, in accordance
with Form&#xa0;N-PX:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 19.5pt"></td><td style="width: 17.25pt"><span style="font-family: Times New Roman, Times, Serif">&#x25cf;</span></td><td>the
                                            name of the issuer;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 19.5pt"></td><td style="width: 17.25pt"><span style="font-family: Times New Roman, Times, Serif">&#x25cf;</span></td><td>the
                                            exchange ticker symbol, if available;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 19.5pt"></td><td style="width: 17.25pt"><span style="font-family: Times New Roman, Times, Serif">&#x25cf;</span></td><td>the
                                            CUSIP number, if available;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 19.5pt"></td><td style="width: 17.25pt"><span style="font-family: Times New Roman, Times, Serif">&#x25cf;</span></td><td>the
                                            shareholder meeting date;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 19.5pt"></td><td style="width: 17.25pt"><span style="font-family: Times New Roman, Times, Serif">&#x25cf;</span></td><td>a
                                            brief identification of the matter voted on;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 19.5pt"></td><td style="width: 17.25pt"><span style="font-family: Times New Roman, Times, Serif">&#x25cf;</span></td><td>whether
                                            the matter was proposed by the issuer or a security holder;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 19.5pt"></td><td style="width: 17.25pt"><span style="font-family: Times New Roman, Times, Serif">&#x25cf;</span></td><td>whether
                                            TCM cast its vote on the matter;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 19.5pt"></td><td style="width: 17.25pt"><span style="font-family: Times New Roman, Times, Serif">&#x25cf;</span></td><td>how
                                            TCM cast its vote on the matter (for, against, abstain; for or withhold regarding the election
                                            of directors); and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 19.5pt"></td><td style="width: 17.25pt"><span style="font-family: Times New Roman, Times, Serif">&#x25cf;</span></td><td>whether
                                            TCM cast its vote for or against management;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TCM&#x2019;s CCO shall also record whether any conflicts of interest
have been identified and, if so, what action was taken to resolve the conflict with respect to each vote cast and each abstention.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Substantive Voting Decisions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TCM&#x2019;s substantive voting decisions turn on the particular facts
and circumstances of each proxy vote. The following is a list of common proxy vote issues and TCM&#x2019;s standard considerations when
determining how to vote such proxies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Routine
Matters/Corporate Administrative Items</i></span>. After an initial review, TCM generally votes with management on routine matters related
to the operation of the issuer that are not expected to have a significant economic impact on the issuer and/or its shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Potential
for Major Economic Impact</i></span>. TCM may review and analyze on a case-by-case basis, non-routine proposals that are more likely
to affect the structure and operation of the issuer and to have a greater impact on the value of the investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Corporate
Governance</i></span>. TCM may review and consider corporate governance issues related to proxy matters and generally supports proposals
that foster good corporate governance practices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Special
Interest Issues</i></span>. TCM may consider: (i)&#xa0;the long-term benefit to shareholders of promoting corporate accountability and
responsibility on social issues; (ii)&#xa0;management&#x2019;s responsibility with respect to special interest issues; (iii)&#xa0;any
economic costs and restrictions on management; and (iv)&#xa0;the responsibility of TCM to vote proxies for the greatest long-term shareholder
value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Limitations
on Director Tenure and Retirement</i></span>. TCM may consider: (i)&#xa0;a reasonable retirement age for directors, <i>e.g. </i>70 or
72; (ii)&#xa0;the introduction of new perspectives on the board; and (iii)&#xa0;the arbitrary nature of such limitations and the possibility
of detracting from the board&#x2019;s stability and continuity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Directors&#x2019;
Minimum Stock Ownership </i></span>. TCM may consider: (i)&#xa0;the benefits of additional vested interest; (ii)&#xa0;the ability of
a director to serve a company well regardless of the extent of his or her share ownership; and (iii)&#xa0;the impact of limiting the
number of persons qualified to be directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>D&amp;O
Indemnification and Liability Protection</i></span>. TCM may consider: (i)&#xa0;indemnifying directors for acts conducted in the normal
course of business; (ii)&#xa0;limiting liability for monetary damages for violating the duty of care; (iii)&#xa0;expanding coverage beyond
legal expenses to acts that represent more serious violations of fiduciary obligation than carelessness (<i>e.g. </i>negligence); and
(iv)&#xa0;providing expanded coverage in cases when a director&#x2019;s legal defense was unsuccessful if the director was found to have
acted in good faith and in a manner that he or she reasonably believed was in the best interests of the issuer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Director
Nominations in Contested Elections</i></span>. TCM may consider: (i)&#xa0;long-term financial performance of the issuer relative to its
industry; (ii)&#xa0;management&#x2019;s track record; (iii)&#xa0;background to proxy contest; (iv)&#xa0;qualifications of both slates
of nominees; (v)&#xa0;evaluations of what each side is offering shareholders as well as the likelihood that the proposed objectives and
goals can be met; and (vi)&#xa0;stock ownership positions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Cumulative
Voting</i></span>. TCM may consider: (i)&#xa0;the ability of significant stockholders to elect a director of their choosing; (ii)&#xa0;the
ability of minority shareholders to concentrate their support in favor of a director or directors of their choosing; and (iii)&#xa0;the
potential to limit the ability of directors to work for all shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Classified
Boards</i></span>. TCM may consider: (i)&#xa0;providing continuity; (ii)&#xa0;promoting long-term planning; and (iii)&#xa0;guarding against
unwanted takeovers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Poison
Pills</i></span>. TCM may consider: (i)&#xa0;TCM&#x2019;s position on supporting proposals to require a shareholder vote on other shareholder
rights plans; (ii)&#xa0;ratifying or redeeming a poison pill in the interest of protecting the value of the issuer; and (iii)&#xa0;other
alternatives to prevent a takeover at a price demonstrably below the true value of the issuer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Fair Price
Provisions</i></span>. TCM may consider: (i)&#xa0;the vote required to approve the proposed acquisition; (ii)&#xa0;the vote required
to repeal the fair price provision; (iii)&#xa0;the mechanism for determining fair price; and (iv)&#xa0;whether these provisions are bundled
with other anti-takeover measures (<i>e.g.</i>, supermajority voting requirements) that may entrench management and discourage attractive
tender offers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Equal
Access</i></span>. TCM may consider: (i)&#xa0;the opportunity for significant shareholders of the issuer to evaluate and propose voting
recommendations on proxy proposals and director nominees, and to nominate candidates to the board; and (ii)&#xa0;the added complexity
and burden.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Charitable
Contributions</i></span>. TCM may consider: (i)&#xa0;the potential benefits to shareholders; (ii)&#xa0;the potential to detract the issuer&#x2019;s
resources from more direct uses of increasing shareholder value; and (iii)&#xa0;the responsibility of shareholders to make individual
contributions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Stock
Authorizations</i></span>: TCM may consider: (i)&#xa0;the need for the increase; (ii)&#xa0;the percentage increase with respect to the
existing authorization; (iii)&#xa0;voting rights of the stock; and (iv)&#xa0;overall capitalization structures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Preferred
Stock</i></span>. TCM may consider: (i)&#xa0;whether the new class of preferred stock has unspecified voting, conversion, dividend distribution,
and other rights; (ii)&#xa0;whether the issuer expressly states that the stock will not be used as a takeover defense or carry superior
voting rights; (iii)&#xa0;whether the issuer specifies the voting, dividend, conversion, and other rights of such stock and the terms
of the preferred stock appear reasonable; and (iv)&#xa0;whether the stated purpose is to raise capital or make acquisitions in the normal
course of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Director
Compensation</i></span>. TCM may consider: (i)&#xa0;whether director shares are at the same market risk as those of the shareholders;
and (ii)&#xa0;how option programs for outside directors compare with the standards of internal programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Golden
and Tin Parachutes</i></span>. TCM may consider: (i)&#xa0;whether they will be submitted for shareholder approval; and (ii)&#xa0;the
employees covered by the plan and the quality of management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Compensation.
</i></span>TCM may consider: (i)&#xa0;Whether the company has an independent compensation committee; (ii)&#xa0;whether the compensation
committee engaged independent consultants; (iii)&#xa0;whether the compensation committee has lapsed or waived equity vesting restrictions;
and (iv)&#xa0;whether the company has adopted or extended a Golden Parachute without shareholder approval. TCM will generally support
annual advisory votes on executive compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Limitations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TCM may abstain from voting a proxy if it concludes that the effect
on shareholders&#x2019; economic interests or the value of the portfolio holding is indeterminable or insignificant. TCM may abstain from
voting a proxy if it concludes that the cost of voting is disproportionate to the economic impact the vote would have on the portfolio
holdings. With respect to certain privately held companies, TCM may not have the opportunity to vote or may have a limitation on its
ability to vote. For example, in certain cases a company may be permitted by its charter or other governing documents to take action
without a shareholder meeting and with written consent of fewer than all shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Conflicts of Interest</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Proxy Committee identifies any potential conflicts of interest.
Each potential conflict must be addressed in a manner which will be in the best interest of the Funds and their shareholders. If any
potential conflict is identified the Proxy Committee consults with the Funds&#x2019; counsel. Where conflicts of interest arise between
clients and TCM, TCM may convene an ad-hoc committee to debate the conflict and to give a ruling on a preferred course of action. If
the ad- hoc committee determines that TCM has a conflict of interest in any instance, TCM&#x2019;s CCO shall disclose the conflict to
the Board and seek voting instructions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TCM may cause the proxies to be voted in accordance
with the recommendations of an independent third party service provider that TCM may use to assist in voting proxies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Disclosure</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following disclosure shall be provided in connection with these
policies and procedures:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#x25cf;</span></td><td>TCM
                                            shall provide a description or a copy of these policies and procedures to the Boards of Trustees
                                            of the Funds annually and upon request.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#x25cf;</span></td><td>TCM
                                            shall make available to the Funds its proxy voting records, for inclusion on the Funds&#x2019;
                                            Form&#xa0;N-PX.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#x25cf;</span></td><td>TCM
                                            shall include its proxy voting policies and procedures in its annual filing on Form&#xa0;N-CSR.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#x25cf;</span></td><td>TCM
                                            shall cause the Funds&#x2019; shareholder reports to include a statement that a copy of these
                                            policies and procedures is available upon request (i)&#xa0;by calling a toll-free number;
                                            (ii)&#xa0;on the Funds&#x2019; website, (if the Funds choose); and (iii)&#xa0;on the SEC&#x2019;s
                                            website.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#x25cf;</span></td><td>TCM
                                            shall cause the Funds&#x2019; annual and semi-annual reports to include a statement that information
                                            is available regarding how the Funds voted proxies during the most recent twelve-month period
                                            (i)&#xa0;without charge, upon request, either by calling a toll-free number or on or through
                                            the Funds&#x2019; website, or both; and (ii)&#xa0;on the SEC&#x2019;s website.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recordkeeping</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TCM shall maintain records of proxies voted in accordance with Section&#xa0;204-2
of the Advisers Act, including proxy statements, a record of each vote cast, and a copy of any document created by the Adviser that was
material to making a decision of how to vote the proxy, or that memorializes the basis for the Adviser&#x2019;s decision on how to vote
the proxy. TCM shall also maintain a copy of its policies and procedures and each written request from a client for proxy voting records
and the Adviser&#x2019;s written response to any client request, either written or oral, for such records. Proxy statements that are filed
on EDGAR shall be considered maintained by TCM. All such records shall be maintained for a period of five years in an easily accessible
place, the first two years in the offices of TCM.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 8. PORTFOLIO MANAGERS OF CLOSED-END MANAGEMENT INVESTMENT
COMPANIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) (1) As of December 11, 2023, Daniel
Omstead, Ph.D., Jason Akus, M.D./M.B.A., Timothy Gasperoni, M.B.A., Ph.D., Ashton Wilson, Christopher Abbott, Robert Benson, Kelly
Girskis, Ph.D., Richard Goss, Christopher Seitz, M.B.A. and Loretta Tse, Ph.D. are members of a team that analyzes investments on
behalf of the Registrant. As of September 30, 2023, Dr. Omstead exercised ultimate decision-making authority with respect to
investments. Dr. Omstead also made investments on behalf of abrdn Healthcare Investors (&#x201c;HQH&#x201d;), abrdn Life Sciences
Investors (&#x201c;HQL&#x201d;) and abrdn Healthcare Opportunities Fund (&#x201c;THQ&#x201d;). The date each team member joined the
portfolio management team and each team member&#x2019;s business experience for at least the last five years is included below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Daniel R. Omstead, Ph.D. is Vice President of the Registrant and Head
of Healthcare Investments of the investment adviser. Previously he was President of the Registrant and Chief Executive Officer of the
predecessor investment advisor for the Registrant, where he was employed for over 40 years. He is also Vice President of the Registrant,
HQH, HQL and THQ. He joined abrdn Inc. in October 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jason Akus, M.D./M.B.A. is Senior Investments Director of the investment
adviser and is responsible for investment research and due diligence in the biotechnology, medical device, and diagnostic areas. He joined
the predecessor investment adviser in 2001, where he was Senior Vice President, Research. Dr.&#xa0;Akus joined abrdn Inc. in October&#xa0;2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Timothy Gasperoni, M.B.A., Ph.D. is Senior Investments Director of
the investment adviser. He joined the predecessor investment adviser in 2015, where he was Senior Vice President, Research. He was also
previously a Senior Analyst and Founding Member of Sabby Capital. He joined abrdn Inc. in October&#xa0;2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ashton Wilson is Senior Investments Director of the investment adviser.
He joined the predecessor investment adviser in 2018, where he was Senior Vice President. He was previously a Vice President in equity
derivative trading at Goldman Sachs and Co. and was an equity derivative trader at Bank of America Merrill Lynch. He joined abrdn Inc.
in October&#xa0;2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Christopher Abbott is Investment Director of the investment adviser.
He joined the predecessor investment adviser in 2016, where he was Vice President, Research. Previously, Mr.&#xa0;Abbott was at Leerink
Partners where he was a Vice President on the Equity Research Team. He joined abrdn Inc. in October&#xa0;2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 5 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert Benson is Investment Director of the investment
adviser. He joined the predecessor investment adviser in 2016, where he was Vice President. Previously, Mr. Benson was at State Street
Global Advisors (SSgA) where he performed quantitative research for asset allocation, equities, and alternatives teams. He joined abrdn
Inc. in October 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.05pt 0pt 5.65pt">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kelly Girskis, Ph.D. is Investment Director of the
investment adviser. She joined the predecessor investment adviser in 2021, where she was Vice President, Research. Previously, Dr. Girskis
was an Equity Research Associate at SVB Leerink. She joined abrdn Inc. in October 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Richard Goss is Investment Director of the investment
adviser. He joined the predecessor investment adviser in 2018, where he was Vice President, Research. Previously, Mr. Goss was at Leerink
Partners where he was a Vice President on the Large Pharma and Biotech Equity Research Teams and a Healthcare Analyst at Datamonitor.
He joined abrdn Inc. in October 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Christopher Seitz, M.B.A. is Investment Director of
the investment adviser. He joined the predecessor investment adviser in 2021, where he was Vice President, Research. Previously, Mr. Seitz
was a Healthcare Analyst Intern at Nantahala Capital Management and an Associate at Excel Venture Management. He joined abrdn Inc. in
October 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.05pt 0pt 5.65pt">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Loretta Tse, Ph.D. is Investment Director of the investment
adviser. She joined the predecessor investment adviser in 2015, where she was Vice President. She previously ran a biotech consulting
business and worked at various venture funds and start-up companies and was Managing Director at Fred Hutchinson Cancer Research Center.
She joined abrdn Inc. in October 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)(2)&#xa0;The following table lists the number
and types of other accounts and assets under management in those accounts advised by the Registrant&#x2019;s portfolio management team
as of the end of the Registrant&#x2019;s fiscal year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 6 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTERED</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PORTFOLIO</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMPANY</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ASSETS</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>POOLED</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ASSETS</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ASSETS</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANAGER</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ACCOUNTS</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANAGED</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ACCOUNTS</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANAGED</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ACCOUNTS</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANAGED</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel
    Omstead</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 11%; text-align: right">2,391 million</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jason
    Akus</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">2,391 million</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
    Gasperoni</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">2,391 million</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ashton
    Wilson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">2,391 million</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Abbott</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">2,391 million</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Benson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">2,391 million</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kelly
    Girskis</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">2,391 million</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Richard Goss</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">3</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">2,391
                                            million</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">0</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">0</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">0</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">0</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#xa0;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Seitz</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">2,391 million</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Loretta Tse</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">3</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">2,391 million</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">0</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">0</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">0</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">0</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#xa0;</td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None of the funds or other accounts is subject to a performance-based
advisory fee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each member of the portfolio management team may perform investment
management services for other accounts similar to those provided to the Registrant and the investment action for each account may differ.
The portfolio management team may discover an investment opportunity that may be suitable for more than one account. However, the investment
opportunity may be limited so that all accounts may not be able to fully participate or an investment opportunity or investment allocation
may be allocated to just one account or may be allocated between accounts at different levels based on an investment decision made by
the investment team. The investment team may subsequently make investment decisions that result in investment levels that make the accounts
more differentiated or, conversely, more closely or completely aligned. Such investment decisions may occur within a day or two. In addition,
the investment adviser may receive different compensation from each account. In that case, the portfolio management team may have an
incentive to direct investments to an account that could result in higher fees for the investment adviser. The registrant has adopted
procedures designed to allocate investments fairly across multiple accounts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, a portfolio manager may be perceived to have a conflict
of interest if he has other executive management responsibilities. In addition to managing the Registrant, HQH, HQL and THQ, Dr. Omstead
is the President of the investment adviser of the Registrant. Dr. Omstead periodically discusses the amount of time he allocates to each
of his responsibilities with the Registrant&#x2019;s Board of Trustees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The portfolio management team&#x2019;s management of personal accounts
may also present certain conflicts of interest. The Registrant has adopted a code of ethics designed to address these potential conflicts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(a)(3)&#xa0;As of September&#xa0;30, 2023, portfolio manager
compensation is comprised of a base salary and discretionary compensation as described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Base
Salary Compensation</i></span>. The team members receive a base salary compensation linked to individual experience and responsibilities.
The amount of base salary is reviewed annually.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Discretionary
Compensation</i></span>. Discretionary Compensation is in the form of a cash bonus, paid annually, which may be 50% or more of the team
member&#x2019;s base salary. Several factors affect discretionary compensation, which can vary by team member and circumstances. The discretionary
compensation component is determined based on factors including investment performance of accounts managed by the team predominantly
relative to the S&amp;P 500 Index and a blended consideration of appropriate healthcare indices and related performance metrics during
the Fund&#x2019;s fiscal year, performance of specific investments proposed by the individual, financial performance of the investment
adviser and a qualitative assessment of the individual overall contribution to the investment team and to the investment adviser. Discretionary
compensation is evaluated annually after the completion of the Registrant&#x2019;s fiscal year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 7 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)(4)&#xa0;As of September&#xa0;30, 2023, the
dollar range of Registrant&#x2019;s shares beneficially owned by the portfolio managers are as follows as of the end of the Registrant&#x2019;s
fiscal year:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; width: 21%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PORTFOLIO&#xa0;MANAGER</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; width: 77%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DOLLAR&#xa0;RANGE&#xa0;OF&#xa0;SHARES&#xa0;BENEFICIALLY&#xa0;OWNED</b></span></td>
    </tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel R. Omstead</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$100,001-$500,000</span></td>
    </tr>
<tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jason
    Akus</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">none</span></td>
    </tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
    Gasperoni</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10,001-$50,000</span></td>
    </tr>
<tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ashton
    Wilson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">none</span></td>
    </tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Abbott</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">none</span></td>
    </tr>
<tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Benson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">none</span></td>
    </tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Kelly Girskis</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">none</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    Goss</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">none</span></td>
    </tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Seitz</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">none</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loretta
    Tse</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">none</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(b)&#xa0;N/A.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 9. PURCHASES OF EQUITY SECURITIES BY CLOSED-END MANAGEMENT
INVESTMENT COMPANY AND AFFILIATED PURCHASERS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)&#xa0;Total&#xa0;No.<br />
    of&#xa0;Shares<br />
    Purchased&#xa0;(1)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#xa0;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)&#xa0;Average<br />
    Price&#xa0;Paid&#xa0;per<br />
    Share</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)&#xa0;Total&#xa0;No.<br />
    of&#xa0;Shares<br />
    Purchased&#xa0;as<br />
    Part&#xa0;of<br />
    Publicly<br />
    Announced&#xa0;Plans<br />
    or&#xa0;Programs</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)&#xa0;Maximum&#xa0;No.<br />
    of&#xa0;Shares&#xa0;that<br />
    May&#xa0;Yet&#xa0;Be<br />
    Purchased&#xa0;Under<br />
    the&#xa0;Plans&#xa0;or<br />
    Programs</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Month
    #1 (Oct.&#xa0;1, 2022 &#x2014; Oct.&#xa0;31, 2022)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">4,493,657</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Month
    #2 (Nov.&#xa0;1, 2022 &#x2014; Nov.&#xa0;30, 2022)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">4,493,657</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Month
    #3 (Dec.&#xa0;1, 2022 &#x2014; Dec.&#xa0;31, 2022)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">4,493,657</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Month
    #4 (Jan.&#xa0;1, 2023 &#x2014; Jan.&#xa0;31, 2023)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">4,493,657</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Month
    #5 (Feb.&#xa0;1, 2023 &#x2014; Feb.&#xa0;28, 2023)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">4,493,657</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Month
    #6 (Mar.&#xa0;1, 2023 &#x2014; Mar.&#xa0;31, 2023)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">4,493,657</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Month
    #7 (Apr.&#xa0;1, 2023 &#x2014; Apr.&#xa0;30, 2023)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">4,493,657</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Month
    #8 (May&#xa0;1, 2023 &#x2014; May&#xa0;31, 2023)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">4,493,657</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Month
    #9 (Jun.&#xa0;1, 2023 &#x2014; Jun.&#xa0;30, 2023)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">4,493,657</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Month
    #10 (Jul.&#xa0;1, 2023 &#x2014; Jul.&#xa0;31, 2023)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">4,563,005</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Month
    #11 (Aug.&#xa0;1, 2023 &#x2014; Aug.&#xa0;31, 2023)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">4,563,005</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Month
    #12 (Sep.&#xa0;1, 2023 &#x2014; Sep.&#xa0;30, 2023)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: right"><span style="font-style: normal; font-weight: normal">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">4,563,005</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 41%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; border-bottom: black 1pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#x2014;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#xa0;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; border-bottom: black 1pt solid; width: 1%">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>&#x2014;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; border-bottom: black 1pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#xa0;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1pt solid">&#xa0;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 19.5pt"></td><td style="width: 17.25pt"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="text-align: left">On
                                            December 3, 2015, the share repurchase program was announced, which
has been subsequently reviewed and approved by the Board of Trustees. On March 17, 2022, the Trustees approved the renewal of the share
repurchase program allowing the Registrant to repurchase up to 12% of its outstanding shares in the open market for a one year period
ending July 14, 2023. On March 16, 2023, the Trustees approved the renewal of the share repurchase program allowing the Registrant to
repurchase up to 12% of its outstanding shares in the open market for a one year period ending July 14, 2024.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 10. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There have been no material changes, to the procedures by which the
shareholders may recommend nominees to the Registrant&#x2019;s Board of Trustees, where those changes were implemented after the Registrant
last provided disclosure in response to the requirements of Item 407(c)(2)(iv)&#xa0;of Regulation S-K (17 CFR229.407)(as required by
Item 22(b)(15) of Schedule 14A (17 CFR240.14a-101)), or this Item.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 8 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 11. CONTROLS AND PROCEDURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 37.7pt"></td><td style="width: 17.15pt"><span style="font-family: Times New Roman, Times, Serif">(a)</span></td><td style="text-align: left">In
                                            the opinion of the principal executive officer and principal financial officer, based on
                                            their evaluation which took place within 90 days of this filing, the Registrant&#x2019;s disclosure
                                            controls and procedures are adequately designed and are operating effectively to ensure (i)&#xa0;that
                                            material information relating to the Registrant, including its consolidated subsidiaries,
                                            is made known to them by others within those entities, particularly during the period in
                                            which this report is being prepared; and (ii)&#xa0;that information required to be disclosed
                                            by the registrant on Form&#xa0;N-CSR is recorded, processed, summarized and reported within
                                            the time period specified in the Securities and Exchange Commission&#x2019;s rules&#xa0;and
                                            forms.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 37.7pt"></td><td style="width: 17.15pt"><span style="font-family: Times New Roman, Times, Serif">(b)</span></td><td style="text-align: left">There
                                            were no changes in the Registrant&#x2019;s internal control over financial reporting that
                                            occurred during the Registrant&#x2019;s most recent fiscal half- year that have materially
                                            affected or that are reasonably likely to materially affect the Registrant&#x2019;s internal
                                            control over financial reporting.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 12. DISCLOSURE OF SECURITIES LENDING ACTIVITIES FOR CLOSED-END
MANAGEMENT INVESTMENT COMPANIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 37.7pt"></td><td style="width: 17.15pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="text-align: left"><span style="font-size: 10pt">&#x202f;The following table shows
the dollar amounts of income, and dollar amounts of fees and/or compensation paid, relating to the Fund&#x2019;s securities lending activities
during the fiscal year ended September&#xa0;30, 2022.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#x202f;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left; text-indent: -12pt; padding-left: 12pt">(1)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 83%; text-align: left; text-indent: -12pt; padding-left: 12pt">Gross
    income from securities lending activities</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#xa0;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><b>64,267</b></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">(2)</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Fees and/or
    compensation for securities lending activities and related services</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="font-size: 10pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-size: 10pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.2in; text-align: left">(a)&#xa0;&#xa0; Fees paid for services as securities lending agent</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,146</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-size: 10pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.2in; text-align: left">(b) &#xa0;&#xa0;Collateral management expenses not
    included in (a)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-size: 10pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.2in; text-align: left">(c) &#xa0;&#xa0;Administrative fees not included
    in (a)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-size: 10pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.2in; text-align: left">(d) &#xa0;&#xa0;Indemnification fees not included
    in (a)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-size: 10pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.2in; text-align: left">(e) &#xa0;&#xa0;Rebate (paid to borrowers)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.85pt">56,626</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-size: 10pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.2in; text-align: left">(f) &#xa0;&#xa0;Other fees not included in (a)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">(3)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Aggregate
    fees/compensation for securities lending activities</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><b>$</b></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b>57,772</b></p></td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">(4)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Net
    income from securities lending activities</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6,494.86</b></p></td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 37.7pt"></td><td style="width: 17.15pt; text-align: left">(b)</td><td style="text-align: left">Goldman Sachs Bank USA, doing business as Goldman Sachs Agency
Lending (&#x201c;GSAL&#x201d;) serves as securities lending agent for the Fund and in that role administers the Fund&#x2019;s securities
lending program pursuant to the terms of a securities lending agency agreement entered into between the Fund and GSAL.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 13. EXHIBITS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.5pt 0pt 0in; text-indent: 0.5in"><a href="tm2325133d1_ex99-cert.htm">(a)&#x202f;&#x202f;&#x202f;(2) Separate certifications of the Principal Executive and Financial Officers as required by Rule 30a-2(a) under the 1940 Act and Section 302 of the Sarbanes-Oxley Act of 2002 are attached hereto (Exhibit 1 and 2).</a></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36.7pt"></td><td style="width: 18.15pt"><a href="tm2325133d1_ex99-sec19xa.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></a></td><td><a href="tm2325133d1_ex99-sec19xa.htm">(3)
                                            Notice to Fund&#x2019;s shareholders in accordance with Investment Company Act Section 19(a)
                                            and Rule 19a-1 (Exhibit 3).</a></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36.7pt"></td><td style="width: 18pt"><a href="tm2325133d1_ex99-indpubacct.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></a></td><td><a href="tm2325133d1_ex99-indpubacct.htm">(4)
                                            Change in Registrant&#x2019;s independent public accountant (Exhibit 4)</a></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 36.7pt"></td><td style="width: 18pt; text-align: left"><a href="tm2325133d1_ex99-906cert.htm" style="-sec-extract: exhibit">(b)</a></td><td style="text-align: justify"><a href="tm2325133d1_ex99-906cert.htm" style="-sec-extract: exhibit">Certifications
                                            pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 are attached hereto (Exhibit 5).</a></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#xa0;</td><td style="text-align: left">&#xa0;</td><td style="text-align: justify">&#xa0;</td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td>&#xa0;</td><td style="text-align: left"><a href="tm2325133d1_ex99-indpubacc.htm" style="-sec-extract: exhibit">(c)</a></td><td style="text-align: justify"><a href="tm2325133d1_ex99-indpubacc.htm" style="-sec-extract: exhibit">Consent of Independent Registered Public Accounting Firm (Exhibit 6 and 7)</a></td></tr>
     </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #0000ed"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 9; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div></div><div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2325133d1_sigpage.htm" BannerFilePath="/apps/files/files/jms2files/gofiler/tm2325133-1/tm2325133-1_ncsrseq1" --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by
the undersigned, there unto duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">abrdn World Healthcare Fund</p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
    (Signature and Title)*</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">/s/ Christian Pittard</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">Christian Pittard,</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">Principal Executive Officer of abrdn World Healthcare Fund</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/11/23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By (Signature and
    Title)*</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt"><span style="font-size: 10pt">/s/ Sharon Ferrari</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt">&#xa0;</td>
    <td colspan="2" style="font-size: 10pt">Sharon Ferrari,</td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt">&#xa0;</td>
    <td colspan="2" style="font-size: 10pt">Treasurer and Chief Financial Officer</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#xa0;</td>
    <td colspan="2" style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt">&#xa0;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt">12/11/23</td>
    <td style="font-size: 10pt">&#xa0;</td></tr>
<tr>
    <td style="width: 8%">&#xa0;</td>
    <td style="width: 11%">&#xa0;</td>
    <td>&#xa0;</td>
    <td style="width: 50%">&#xa0;</td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#xa0;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Print the name and title of each signing officer under
his or her signature.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.CERT
<SEQUENCE>2
<FILENAME>tm2325133d1_ex99-cert.htm
<DESCRIPTION>EXHIBIT 99.CERT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2325133d1_ex99-cert.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2325133-1/tm2325133-1_ncsrseq1/users" -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;99.CERT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;1: CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">I, Christian Pittard, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">1.</TD><TD>I have reviewed this report on Form N-CSR of abrdn World Healthcare Fund;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required
to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.</FONT></TD><TD>The registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Rule&nbsp;30a-3(c)&nbsp;under the Investment Company Act of 1940) and internal control over financial reporting
(as defined in Rule&nbsp;30a-3(d)&nbsp;under the Investment Company Act of 1940) for the Registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report
based on such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the period
covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control
over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.</FONT></TD><TD>The registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed to the registrant&rsquo;s auditors and the audit committee
of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize, and report financial information;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 41%"> <FONT STYLE="font-size: 10pt">12/11/23</FONT></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 50%"><FONT STYLE="font-size: 10pt">/s/ Christian Pittard</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD>Name: Christian Pittard</TD></TR>

<TR STYLE="vertical-align: top">
  <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD>Title: Principal Executive Officer of abrdn World Healthcare Fund</TD></TR>

</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Sharon Ferrari, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5pt"></TD><TD STYLE="width: 35.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.</FONT></TD><TD>I have reviewed this report on Form N-CSR of abrdn World Healthcare Fund;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5pt"></TD><TD STYLE="width: 35.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5pt"></TD><TD STYLE="width: 35.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required
to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5pt"></TD><TD STYLE="width: 35.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.</FONT></TD><TD>The registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Rule&nbsp;30a-3(c)&nbsp;under the Investment Company Act of 1940) and internal control over financial reporting
(as defined in Rule&nbsp;30a-3(d)&nbsp;under the Investment Company Act of 1940) for the Registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report
based on such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the period
covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control
over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5pt"></TD><TD STYLE="width: 35.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.</FONT></TD><TD>The registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed to the registrant&rsquo;s auditors and the audit committee
of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize, and report financial information;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Date: </FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 41%"><FONT STYLE="font-size: 10pt">12/11/23</FONT></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 50%"><FONT STYLE="font-size: 10pt">/s/ Sharon Ferrari</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-size: 10pt">Name: Sharon Ferrari</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-size: 10pt">Title: Treasurer and Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.SECTION 19(A)
<SEQUENCE>3
<FILENAME>tm2325133d1_ex99-sec19xa.htm
<DESCRIPTION>EXHIBIT 99.SECTION 19(A)
<TEXT>
<!-- Assembled by CompSci Transform  (tm) - http://www.compsciresources.com - version 1.2 -->
<!-- Created: Mon Dec 11 21:59:25 UTC 2023 -->
<html>
<head>
     <title></title>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2325133d1_ex99-sec19a63023.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2325133-1/tm2325133-1_ncsrseq1" -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Exhibit&#xa0;99.Section&#xa0;19(a)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXHIBIT&#xa0;3: SECTION&#xa0;19(a)&#xa0;NOTICE
TO FUND&#x2019;S SHAREHOLDERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="font-size: 10pt; font-variant: small-caps">Tekla
World Healthcare Fund</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Notification of Sources of Distribution</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif">Distribution
Paid Date: June</font>&#xa0;<font style="font-family: Times New Roman, Times, Serif">30, 2023</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif">Distribution
Amount Per Common Share:&#xa0;&#xa0;</font>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<font style="font-family: Times New Roman, Times, Serif">$0.1167</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The following table sets
forth the estimated amounts of the current distribution, paid June&#xa0;30, 2023, and the cumulative distributions paid this fiscal
year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term
capital gains and return of capital or other capital source. The Fund estimates that it has distributed more than its income and net
realized capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for
example, when some or all the money that you invested in the Fund is paid back to you. A return of capital distribution does not
necessarily reflect the Fund&#x2019;s investment performance and should not be confused with &#x2018;yield&#x2019; or
 &#x2018;income&#x2019;. All amounts are expressed per common share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; font-size: 10pt">&#xa0;</td><td style="white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Current<br>
 Distribution</td><td style="white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Percentage<br>
                                                                                                                                              Breakdown<br> of Current</b></p> <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Distribution</b></p></td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Total Cumulative</b></p> <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Distributions for the<br>
 Fiscal Year to Date<sup>1</sup></b></p></td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Percentage Breakdown<br>
 of the Total Cumulative<br>
 Distributions for the</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Fiscal Year to Date<sup>1</sup></b></p></td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left">Net Investment Income</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.0172</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized ST Cap Gains</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized LT Cap Gains</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Return of Capital or Other Capital Source</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1.0331</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">98</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">TOTAL (per common share):</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1.0503</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left">The table below includes information relating to the Fund&#x2019;s performance based on its NAV for certain periods.</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="font-size: 10pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="font-size: 10pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Average annual total return at NAV for the period from May 31, 2018 through May 31, 2023</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">7.91</td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Annualized current distribution rate expressed as a percentage of NAV as of May 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">11.28</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative total return at NAV for the fiscal year, through May 31, 2023<sup>2</sup></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">10.23</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of May 31, 2023<sup>1</sup></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">8.46</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">You should not draw any conclusions about the Fund&#x2019;s
investment performance from the amount of this distribution or from the terms of the Fund&#x2019;s managed distribution policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The composition of this and subsequent distributions may vary from
month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized
appreciation of portfolio securities and net realized losses on sale of securities is $3,645,487, of which $6,728,320 represents net unrealized
appreciation of portfolio securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The amounts and sources of distributions reported in this
19(a)&#xa0;Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts
for tax reporting purposes will depend upon the Fund&#x2019;s investment experience during the remainder of its fiscal year and may be
subject to changes based on tax regulations. The Fund will send you a Form&#xa0;1099-DIV for the calendar year that will tell you how
to report these distributions for federal income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 10.2pt">1</td><td>The Fund&#x2019;s current fiscal year began on October&#xa0;1, 2022.</td></tr>
<tr style="vertical-align: top">
<td style="width: 10.15pt">2</td><td>Cumulative total return at NAV is the percentage change in the Fund&#x2019;s NAV and includes all distributions and assumes the reinvestment
of those distributions for the period of September&#xa0;30, 2022 through May&#xa0;31, 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Tekla World Healthcare Fund</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">CUSIP: 87911L108</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="text-decoration:underline">www.teklacap.com</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></p>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#xa0;</p>

</div><div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2325133d1_ex99-sec19a73123.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2325133-1/tm2325133-1_ncsrseq1" -->
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="font-size: 10pt; font-variant: small-caps">Tekla
World Healthcare Fund</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Notification of Sources of Distribution</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif">Distribution
Paid Date: July</font>&#xa0;<font style="font-family: Times New Roman, Times, Serif">31, 2023</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif">Distribution
Amount Per Common Share:&#xa0;&#xa0;&#xa0;</font>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<font style="font-family: Times New Roman, Times, Serif">$0.1167</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The following table sets
forth the estimated amounts of the current distribution, paid July&#xa0;31, 2023, and the cumulative distributions paid this fiscal
year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term
capital gains and return of capital or other capital source. The Fund estimates that it has distributed more than its income and net
realized capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for
example, when some or all the money that you invested in the Fund is paid back to you. A return of capital distribution does not
necessarily reflect the Fund&#x2019;s investment performance and should not be confused with &#x2018;yield&#x2019; or
 &#x2018;income&#x2019;. All amounts are expressed per common share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; font-size: 10pt">&#xa0;</td><td style="white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Current<br> Distribution</td><td style="white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Percentage<br>
                                                                                                                                              Breakdown<br> of Current</b></p> <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Distribution</b></p></td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Total Cumulative</b></p> <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Distributions for the<br> Fiscal Year to Date<sup>1</sup></b></p></td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Percentage Breakdown<br> of the Total Cumulative<br> Distributions for the</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Fiscal Year to Date<sup>1</sup></b></p></td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left">Net Investment Income</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.0172</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized ST Cap Gains</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized LT Cap Gains</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0323</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">28</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0323</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Return of Capital or Other Capital Source</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0844</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1.1175</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">96</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">TOTAL (per common share):</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1.1670</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">The table below includes information relating to the Fund&#x2019;s performance based on its NAV for certain periods.</td><td style="font-size: 10pt">&#xa0;</td>
    <td colspan="2" style="font-size: 10pt">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td colspan="2" style="font-size: 10pt">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 87%; text-align: left">Average annual total return at NAV for the period from June 30, 2018 through June 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">8.34</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Annualized current distribution rate expressed as a percentage of NAV as of June 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">11.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative total return at NAV for the fiscal year, through June 30, 2023<sup>2</sup></font></td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">13.48</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of June 30, 2023<sup>1</sup></font></td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">9.21</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">You should not draw any conclusions about the Fund&#x2019;s
investment performance from the amount of this distribution or from the terms of the Fund&#x2019;s managed distribution policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The composition of this and subsequent distributions may vary from
month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized
appreciation of portfolio securities and net realized gains on sale of securities is $16,581,322, of which $3,936,118 represents net unrealized
appreciation of portfolio securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The amounts and sources of distributions reported in this
19(a)&#xa0;Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts
for tax reporting purposes will depend upon the Fund&#x2019;s investment experience during the remainder of its fiscal year and may be
subject to changes based on tax regulations. The Fund will send you a Form&#xa0;1099-DIV for the calendar year that will tell you how
to report these distributions for federal income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: left; width: 10.2pt">1</td><td style="text-align: left">The Fund&#x2019;s current fiscal year began on October&#xa0;1, 2022.</td></tr>
<tr style="vertical-align: top">
<td style="text-align: left; width: 10.15pt">2</td><td style="text-align: left">Cumulative total return at NAV is the percentage change in the Fund&#x2019;s NAV and includes all distributions and assumes the reinvestment
of those distributions for the period of September&#xa0;30, 2022 through June&#xa0;30, 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Tekla World Healthcare Fund</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">CUSIP: 87911L108</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="text-decoration:underline">www.teklacap.com</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

</div><div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2325133d1_ex99-sec19a83123.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2325133-1/tm2325133-1_ncsrseq1" -->
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="font-size: 10pt; font-variant: small-caps">Tekla
World Healthcare Fund</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Notification of Sources of Distribution</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif">Distribution
Paid Date: August</font>&#xa0;<font style="font-family: Times New Roman, Times, Serif">31, 2023</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif">Distribution
Amount Per Common Share:&#xa0;&#xa0;&#xa0;</font>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<font style="font-family: Times New Roman, Times, Serif">$0.1167</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The following table sets forth the estimated amounts of
the current distribution, paid August&#xa0;31, 2023, and the cumulative distributions paid this fiscal year-to-date from the following
sources: net investment income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other
capital source. The Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of
your distribution may be a return of capital. A return of capital may occur, for example, when some or all the money that you invested
in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund&#x2019;s investment performance
and should not be confused with &#x2018;yield&#x2019; or &#x2018;income&#x2019;. All amounts are expressed per common share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-bottom: 1pt; text-align: center; font-size: 10pt">&#xa0;</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Current<br>
 Distribution</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Percentage<br>
 Breakdown<br>
 of Current</b></p> <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Distribution</b></p></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Total Cumulative</b></p> <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Distributions for the <br>
Fiscal Year to Date<sup>1</sup></b></p></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Percentage Breakdown <br>
of the Total Cumulative<br>
 Distributions for the</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Fiscal Year to Date<sup>1</sup></b></p></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left">Net Investment Income</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.0172</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized ST Cap Gains</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized LT Cap Gains</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0803</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">69</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1126</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Return of Capital or Other Capital Source</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0364</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">31</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1.1539</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">90</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">TOTAL (per common share):</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1.2837</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">The table below includes information relating to the Fund&#x2019;s performance based on its NAV for certain periods.</td><td style="font-size: 10pt">&#xa0;</td>
    <td colspan="2" style="font-size: 10pt">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td colspan="2" style="font-size: 10pt">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 2.45pt">Average annual total return at NAV for the period from July 31, 2018 through July 31, 2023</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">7.24</td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 2.45pt">Annualized current distribution rate expressed as a percentage of NAV as of July 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">11.05</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 2.45pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative total return at NAV for the fiscal year, through July 31, 2023<sup>2</sup></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">14.53</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 2.45pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of July 31, 2023<sup>1</sup></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">10.13</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">You should not draw any conclusions about the Fund&#x2019;s
investment performance from the amount of this distribution or from the terms of the Fund&#x2019;s managed distribution policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The composition of this and subsequent distributions may vary from
month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized
depreciation of portfolio securities and net realized gains on sale of securities is $4,134,124, of which $20,510,339 represents net unrealized
depreciation of portfolio securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The amounts and sources of distributions reported in this
19(a)&#xa0;Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts
for tax reporting purposes will depend upon the Fund&#x2019;s investment experience during the remainder of its fiscal year and may be
subject to changes based on tax regulations. The Fund will send you a Form&#xa0;1099-DIV for the calendar year that will tell you how
to report these distributions for federal income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: left; width: 10.2pt">1</td><td style="text-align: left">The Fund&#x2019;s current fiscal year began on October&#xa0;1, 2022.</td></tr>
<tr style="vertical-align: top">
<td style="text-align: left; width: 10.15pt">2</td><td style="text-align: left">Cumulative total return at NAV is the percentage change in the Fund&#x2019;s NAV and includes all distributions and assumes the reinvestment
of those distributions for the period of September&#xa0;30, 2022 through July&#xa0;31, 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Tekla World Healthcare Fund</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">CUSIP: 87911L108</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="text-decoration:underline">www.teklacap.com</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

</div><div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2325133d1_ex99-sec19a92923.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2325133-1/tm2325133-1_ncsrseq1" -->
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="font-size: 10pt; font-variant: small-caps">Tekla
World Healthcare Fund</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Notification of Sources
of Distribution</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif">Distribution
Paid Date: September</font>&#xa0;<font style="font-family: Times New Roman, Times, Serif">29, 2023</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif">Distribution
Amount Per Common Share:&#xa0;&#xa0;</font>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<font style="font-family: Times New Roman, Times, Serif">$0.1167</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The following table sets forth
the estimated amounts of the current distribution, paid September&#xa0;29, 2023, and the cumulative distributions paid this fiscal year-to-date
from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains and return
of capital or other capital source. The Fund estimates that it has distributed more than its income and net realized capital gains; therefore,
a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all the money that
you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund&#x2019;s investment
performance and should not be confused with &#x2018;yield&#x2019; or &#x2018;income&#x2019;. All amounts are expressed per common share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; text-align: center; font-size: 10pt">&#xa0;</td><td style="padding-bottom: 1pt; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Current<br>
    Distribution</td><td style="padding-bottom: 1pt; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#xa0;</td><td style="padding-bottom: 1pt; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Percentage<br>
                                            Breakdown<br>
                                            of Current</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Distribution</b></p></td><td style="padding-bottom: 1pt; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center">&#xa0;</td><td style="padding-bottom: 1pt; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Total
                                            Cumulative</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Distributions
                                            for the <br>
                                            Fiscal Year to Date<sup>1</sup></b></p></td><td style="padding-bottom: 1pt; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center">&#xa0;</td><td style="padding-bottom: 1pt; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Percentage
                                            Breakdown <br>
                                            of the Total Cumulative<br>
                                            Distributions for the</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Fiscal
                               Year to Date<sup>1</sup></b></p></td><td style="padding-bottom: 1pt; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left">Net Investment Income</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.0172</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized ST Cap Gains</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized LT Cap Gains</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0883</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">76</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2009</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Return of Capital or Other Capital Source</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0284</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">24</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1.1823</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">85</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">TOTAL (per common share):</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1.4004</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">The table below includes information relating to the Fund&#x2019;s performance based on its NAV for certain
    periods.</td><td style="font-size: 10pt">&#xa0;</td>
    <td colspan="2" style="font-size: 10pt">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td colspan="2" style="font-size: 10pt">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Average annual total return
    at NAV for the period from August 31, 2018 through August 31, 2023</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">6.15</td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Annualized current distribution rate
    expressed as a percentage of NAV as of August 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">11.28</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative
    total return at NAV for the fiscal year, through August 31, 2023<sup>2</sup></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">13.32</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative
    fiscal year-to-date distribution rate expressed as a percentage of NAV as of August 31, 2023<sup>1</sup></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">11.28</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">You should not draw any conclusions
about the Fund&#x2019;s investment performance from the amount of this distribution or from the terms of the Fund&#x2019;s managed distribution
policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The composition of this and
subsequent distributions may vary from month to month because it may be materially impacted by future realized gains and losses on securities.
The aggregate of the net unrealized depreciation of portfolio securities and net realized gains on sale of securities is $-10,617,112,
of which $41,882,448 represents net unrealized depreciation of portfolio securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The amounts and sources of
distributions reported in this 19(a)&#xa0;Notice are only estimates and are not being provided for tax reporting purposes. The actual
amounts and sources of the amounts for tax reporting purposes will depend upon the Fund&#x2019;s investment experience during the remainder
of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form&#xa0;1099-DIV for the calendar
year that will tell you how to report these distributions for federal income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: left; width: 10.2pt">1</td><td style="text-align: left">The Fund&#x2019;s current fiscal year began on October&#xa0;1,
                                            2022.</td></tr>
<tr style="vertical-align: top">
<td style="text-align: left; width: 10.15pt">2</td><td style="text-align: left">Cumulative total return at NAV is the percentage change
                                            in the Fund&#x2019;s NAV and includes all distributions and assumes the reinvestment of those
                                            distributions for the period of September&#xa0;30, 2022 through August&#xa0;31, 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Tekla World Healthcare Fund</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">CUSIP: 87911L108</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="text-decoration:underline">www.teklacap.com</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

</div><div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2325133d1_ex99-se19a103123.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2325133-1/tm2325133-1_ncsrseq1" -->
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="font-size: 10pt; font-variant: small-caps">Tekla
World Healthcare Fund</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Notification of Sources of Distribution</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif">Distribution
Paid Date: October</font>&#xa0;<font style="font-family: Times New Roman, Times, Serif">31, 2023</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif">Distribution
Amount Per Common Share:&#xa0;&#xa0;&#xa0;</font>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<font style="font-family: Times New Roman, Times, Serif">$0.1167</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The following table sets forth the estimated amounts of
the current distribution based on generally accepted accounting principles, paid October&#xa0;31, 2023, and the cumulative distributions
paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term
capital gains and return of capital or other capital source. The Fund estimates that it has distributed more than its income and net realized
capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when
some or all the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect
the Fund&#x2019;s investment performance and should not be confused with &#x2018;yield&#x2019; or &#x2018;income&#x2019;. All amounts are expressed
per common share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; font-size: 10pt">&#xa0;</td><td style="white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Current<br>
 Distribution</td><td style="white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Percentage<br>
 Breakdown<br>
 of Current</b></p> <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Distribution</b></p></td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Total Cumulative</b></p> <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Distributions for the <br>
Fiscal Year to Date<sup>1</sup></b></p></td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Percentage Breakdown<br>
 of the Total Cumulative<br>
 Distributions for the</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Fiscal Year to Date<sup>1</sup></b></p></td><td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left">Net Investment Income</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized ST Cap Gains</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Realized LT Cap Gains</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Return of Capital or Other Capital Source</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">TOTAL (per common share):</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">The table below includes information relating to the Fund&#x2019;s performance based on its NAV for certain periods.</td><td style="font-size: 10pt">&#xa0;</td>
    <td colspan="2" style="font-size: 10pt">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td colspan="2" style="font-size: 10pt">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 2.45pt">Average annual total return at NAV for the period from September 30, 2018 through September 30, 2023</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">5.18</td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 2.45pt">Annualized current distribution rate expressed as a percentage of NAV as of September 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">11.94</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 2.45pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative total return at NAV for the fiscal year, through September 30, 2023<sup>2</sup></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">8.09</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 2.45pt">Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of September 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">11.94</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">You should not draw any conclusions about the Fund&#x2019;s
investment performance from the amount of this distribution or from the terms of the Fund&#x2019;s managed distribution policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The composition of this and subsequent distributions may vary from
month to month because it may be materially impacted by future realized gains and losses on securities. As of October 26, 2023, the aggregate
of the net unrealized depreciation of portfolio securities and net realized losses on sale of securities is $-68,841,789, of which $64,762,451
represents net unrealized depreciation of portfolio securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The amounts and sources of distributions reported in this
19(a)&#xa0;Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts
for tax reporting purposes will depend upon the Fund&#x2019;s investment experience during the remainder of its fiscal year and may be
subject to changes based on tax regulations. The Fund will send you a Form&#xa0;1099-DIV for the calendar year that will tell you how
to report these distributions for federal income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: left; width: 10.2pt">1</td><td style="text-align: left">The Fund&#x2019;s current fiscal year began on October&#xa0;1, 2023.</td></tr>
<tr style="vertical-align: top">
<td style="text-align: left; width: 10.15pt">2</td><td style="text-align: left">Cumulative total return at NAV is the percentage change in the Fund&#x2019;s NAV and includes all distributions and assumes the reinvestment
of those distributions for the period of September&#xa0;30, 2022 through September&#xa0;30, 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Tekla World Healthcare Fund</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CUSIP: 87911L108</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="text-decoration:underline">www.abrdnthw.com</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#xa0;</p>

</div><div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2325133d1_ex99-se19a113023.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2325133-1/tm2325133-1_ncsrseq1" -->
<p style="margin: 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>abrdn Global Infrastructure Income Fund</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif"><b>NYSE:
ASGI Cusip: </b></font><b>00326W106</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>abrdn Healthcare Opportunities
Fund</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif"><b>NYSE
American: THQ Cusip: </b></font><b>879105104</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>abrdn World Healthcare Fund</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif"><b>NYSE
American: THW Cusip: </b></font><b>87911L108</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The abrdn U.S. Closed-End Funds (the &#x201c;Funds&#x201d; or individually
the &#x201c;Fund&#x201d;), today announced that the Funds paid the distributions noted in the table below on November&#xa0;30, 2023, on
a per share basis to all shareholders of record as of November&#xa0;22, 2023 (ex-dividend date November&#xa0;21, 2023).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Ticker</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exchange</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fund</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; padding-bottom: 1pt">ASGI</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; padding-bottom: 1pt">NYSE</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: left; padding-bottom: 1pt">abrdn Global Infrastructure Income Fund</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">0.1200</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">THQ</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">NYSE American</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Healthcare Opportunities Fund</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1125</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">THW</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">NYSE American</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn World Healthcare Fund</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each Fund has adopted a distribution policy to provide investors with
a stable distribution out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under applicable U.S. tax rules, the amount and character of distributable
income for each Fund&#x2019;s fiscal year can be finally determined only as of the end of the Fund&#x2019;s fiscal year. However, under
Section&#xa0;19 of the Investment Company Act of 1940, as amended (the &#x201c;1940 Act&#x201d;) and related rules, the Funds may be required
to indicate to shareholders the estimated source of certain distributions to shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following tables set forth the estimated amounts of the sources
of the distributions for purposes of Section&#xa0;19 of the 1940 Act and the rules&#xa0;adopted thereunder. The tables have been computed
based on generally accepted accounting principles. The tables include estimated amounts and percentages for the current distributions
paid this month as well as for the cumulative distributions paid relating to fiscal year to date, from the following sources: net investment
income; net realized short-term capital gains; net realized long-term capital gains; and return of capital. The estimated compositions
of the distributions may vary because the estimated composition may be impacted by future income, expenses and realized gains and losses
on securities and currencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Funds&#x2019; estimated sources of the current distribution paid
this month and for its current fiscal year to date are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="37" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Estimated Amounts of Current Distribution per Share</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fund</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Distribution <br> Amount</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Net Investment<br> Income</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Net Realized Short-<br> Term Gains**</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Net Realized Long-<br> Term Gains</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Return of Capital</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 19%; text-align: center; padding-bottom: 1pt">ASGI</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">0.1200</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">0.1200</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">100</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">THQ</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1125</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1125</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">THW</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1167</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="37" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Estimated Amounts of Fiscal Year* to Date Cumulative Distributions per Share</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fund</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Distribution <br> Amount</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Net Investment <br> Income</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Net Realized Short-<br> Term Gains **</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Net Realized Long-<br> Term Gains</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Return of Capital</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; width: 19%">ASGI</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 6%; text-align: right">0.2400</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 6%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 6%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 6%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 6%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 6%; text-align: right">0.2400</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 6%; text-align: right">100</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 6%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 6%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">THQ</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">0.2250</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">0.2250</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">100</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">THW</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">0.2334</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">0.2334</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">100</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* ASGI, THQ and THW have a 9/30 fiscal year end.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">**includes currency gains</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where the estimated amounts above show a portion of the distribution
to be a &#x201c;Return of Capital,&#x201d; it means that Fund estimates that it has distributed more than its income and capital gains;
therefore, a portion of your distribution may be a return of capital. A return of capital may occur for example, when some or all the
money that you invested in a Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund&#x2019;s
investment performance and should not be confused with &#x201c;yield&#x201d; or &#x201c;income.&#x201d;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of November&#xa0;7, 2023, after giving effect to this payment,
ASGI estimates it has a net deficit of $16,675,000.00. A net deficit results when the Fund has net unrealized losses that are in
excess of any net realized gains that have not yet been distributed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The amounts and sources of distributions reported in this notice
are only estimates and are not being provided for tax reporting purposes. The final determination of the source of all distributions for
the current year will only be made after year-end. The actual amounts and sources of the amounts for tax reporting purposes will depend
upon the Fund&#x2019;s investment experience during the remainder of the fiscal year and may be subject to change based on tax regulations.
After the end of each calendar year, a Form&#xa0;1099-DIV will be sent to shareholders for the prior calendar year that will tell you
how to report these distributions for federal income tax purposes.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table provides the Funds&#x2019; total return performance
based on net asset value (NAV) over various time periods compared to the Funds&#x2019; annualized and cumulative distribution rates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom">
    <td colspan="17" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fund Performance and Distribution Rate Information</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fund</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Average <br> Annual Total <br> Return on NAV <br> for the 5 Year <br> Period Ending <br> 10/31/2023&#xb9;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Current Fiscal<br> Period&#x2019;s <br> Annualized <br> Distribution<br> Rate on NAV</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Cumulative <br> Total Return <br> on NAV&#xb9;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Cumulative<br> Distribution <br> Rate on NAV&#xb2;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: center; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI<b>&#xb3;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">4.74</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%<sup>3</sup>&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">7.76</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">-2.23</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.65</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">THQ</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">6.93</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">7.06</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-4.34</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.59</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">THW</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">5.45</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">12.71</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-4.97</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">1.06</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1
</sup></font>Return data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices
obtained under the Fund&#x2019;s dividend reinvestment plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>2
</sup></font>Based on the Fund&#x2019;s NAV as of October&#xa0;31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>3</sup></font>
The Fund launched within the past 5 years; the performance and distribution rate information presented reflects data from inception (July&#xa0;29,
2020) through October&#xa0;31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Shareholders should not draw any conclusions about a Fund&#x2019;s
investment performance from the amount of the Fund&#x2019;s current distributions or from the terms of the distribution policy (the &#x201c;Distribution
Policy&#x201d;).</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While NAV performance may be indicative of the Fund&#x2019;s investment
performance, it does not measure the value of a shareholder&#x2019;s investment in the Fund. The value of a shareholder&#x2019;s investment
in the Fund is determined by the Fund&#x2019;s market price, which is based on the supply and demand for the Fund&#x2019;s shares in the
open market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to an exemptive order granted by the Securities and Exchange
Commission, the Funds may distribute any long-term capital gains more frequently than the limits provided in Section&#xa0;19(b)&#xa0;under
the 1940 Act and Rule&#xa0;19b-1 thereunder. Therefore, distributions paid by the Funds during the year may include net income, short-term
capital gains, long-term capital gains and/or a return of capital. Net income dividends and short-term capital gain dividends, while generally
taxable at ordinary income rates, may be eligible, to the extent of qualified dividend income earned by the Funds, to be taxed at a lower
rate not to exceed the maximum rate applicable to your long-term capital gains. Distributions made in any calendar year in excess of investment
company taxable income and net capital gain are treated as taxable ordinary dividends to the extent of undistributed earnings and profits,
and then as a return of capital that reduces the adjusted basis in the shares held. To the extent return of capital distributions exceed
the adjusted basis in the shares held, capital gain is recognized with a holding period based on the period the shares have been held
at the date such amount is received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The payment of distributions in accordance with the Distribution Policy
may result in a decrease in the Fund&#x2019;s net assets. A decrease in the Fund&#x2019;s net assets may cause an increase in the Fund&#x2019;s
annual operating expense ratio and a decrease in the Fund&#x2019;s market price per share to the extent the market price correlates closely
to the Fund&#x2019;s net asset value per share. The Distribution Policy may also negatively affect the Fund&#x2019;s investment activities
to the extent that the Fund is required to hold larger cash positions than it typically would hold or to the extent that the Fund must
liquidate securities that it would not have sold, for the purpose of paying the distribution. Each Fund&#x2019;s Board has the right to
amend, suspend or terminate the Distribution Policy at any time. The amendment, suspension or termination of the Distribution Policy may
affect the Fund&#x2019;s market price per share. Investors should consult their tax advisor regarding federal, state and local tax considerations
that may be applicable in their particular circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><font style="text-decoration:underline">Circular
230 disclosure</font></font>: To ensure compliance with requirements imposed by the U.S. Treasury, we inform you that any U.S. tax advice
contained in this communication (including any attachments) is not intended or written to be used, and cannot be used, for the purpose
of (i)&#xa0;avoiding penalties under the Internal Revenue Code or (ii)&#xa0;promoting, marketing or recommending to another party any
transaction or matter addressed herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the United States, abrdn is the marketing name for the following
affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, abrdn Asia Limited, abrdn Private Equity (Europe) Limited,
and abrdn ETFs Advisors LLC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Closed-end funds are traded on the secondary market through one
of the stock exchanges. A Fund&#x2019;s investment return and principal value will fluctuate so that an investor&#x2019;s shares may
be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net
asset value (NAV) of the fund&#x2019;s portfolio. There is no assurance that a Fund will achieve its investment objective. Past
performance does not guarantee future results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.IND PUB ACCT
<SEQUENCE>4
<FILENAME>tm2325133d1_ex99-indpubacct.htm
<DESCRIPTION>EXHIBIT 99.IND PUB ACCT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2325133d1_ex99-indpubacct.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2325133-1/tm2325133-1_ncsrseq1/users" -->
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit&nbsp;99.<FONT STYLE="text-transform: none">IND PUB ACCT</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;13.(a)(4)</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Changes in Registrant&rsquo;s Certifying Accountant.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There was a change in the registrant&rsquo;s independent public accountant
during the reporting period. Below is the information called for by Item 4 of Form&nbsp;8-K, which was included in the Fund&rsquo;s current
report on Form&nbsp;8-K filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) on September&nbsp;12, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 4.01</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Changes in Registrant&rsquo;s Certifying Accountant.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>(a)&nbsp;Resignation of independent registered public accounting
firm</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September&nbsp;6, 2023, Deloitte&nbsp;&amp; Touche LLP (&ldquo;D&amp;T&rdquo;),
the independent registered public accounting firm for the Tekla World Healthcare Fund (the &ldquo;Fund&rdquo;), resigned due to an anticipated
independence issue arising as a result of a pending transaction between Tekla Capital Management LLC and abrdn Inc. On September&nbsp;7,
2023, the Audit Committee of the Board of Trustees (the &ldquo;Board&rdquo;) of the Fund approved D&amp;T&rsquo;s resignation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The reports of D&amp;T on the Fund&rsquo;s financial statements as
of and for the two most recent fiscal years ended September&nbsp;30, 2022 and September&nbsp;30, 2021 did not contain an adverse opinion
or a disclaimer of opinion, nor were such reports qualified or modified as to uncertainties, audit scope or accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the Fund&rsquo;s two most recent fiscal years (ended September&nbsp;30,
2022 and September&nbsp;30, 2021) and the subsequent interim period through September&nbsp;6, 2023, there were no &ldquo;disagreements&rdquo;
(within the meaning of Item 304(a)(1)(iv)&nbsp;of Regulation S-K and the related instructions under the Securities Exchange Act of 1934,
as amended (the &ldquo;Exchange Act&rdquo;)) between the Fund and D&amp;T on any matter of accounting principles or practices, financial
statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of D&amp;T, would have caused
D&amp;T to make reference to the subject matter of the disagreements in its reports on the financial statements of the Fund for such years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Also during this same period, there were no &ldquo;reportable events&rdquo;
(within the meaning of Item 304(a)(1)(v)&nbsp;of Regulation S-K and the related instructions under the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Fund has provided D&amp;T with a copy of the foregoing disclosures
under Item 4.01 on Form&nbsp;8-K prior to filing it with the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;) and has requested
that D&amp;T furnish to the Fund with a letter addressed to the SEC stating whether it agrees with the statements made by the Fund in
this Item 4.01 on Form&nbsp;8-K. A copy of D&amp;T&rsquo;s letter, dated September&nbsp;12, 2023, is attached as Exhibit&nbsp;16.1 to
this report on Form&nbsp;8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-indent: 0.5in"><B><I>(b)&nbsp;Engagement of new independent registered
public accounting firm</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">On September&nbsp;7, 2023, upon the recommendation
of the Audit Committee of the Board, the Board approved the engagement of KPMG LLP (&ldquo;KPMG&rdquo;) as the independent registered
public accounting firm for the Fund for the fiscal year ending September&nbsp;30, 2023. During the Fund&rsquo;s two most recent fiscal
years (ended September&nbsp;30, 2022 and September&nbsp;30, 2021) and the subsequent interim period prior to the engagement of KPMG, neither
the Fund, nor anyone on the Fund&rsquo;s behalf consulted with KPMG regarding (1)&nbsp;the application of accounting principles to a specified
transaction, either completed or proposed; (2)&nbsp;the type of audit opinion that might be rendered on the Fund&rsquo;s financial statements;
or (3)&nbsp;the subject of any &ldquo;disagreement,&rdquo; as defined in Item 304(a)(1)(iv)&nbsp;of Regulation S-K under the Exchange
Act and the instructions thereto, or a &ldquo;reportable event,&rdquo; as defined in Item 304(a)&nbsp;(1)(v)&nbsp;of Regulation S-K under
the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*********</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit&nbsp;16.1 of Form&nbsp;8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September&nbsp;12, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, DC 20549-7561</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Sirs/Madams:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have read Item 4.01 of Tekla World Healthcare Form&nbsp;8-K dated
September&nbsp;12, 2023, and we agree with the statements made therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yours truly,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Deloitte&nbsp;&amp; Touche LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*********</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.906 CERT
<SEQUENCE>5
<FILENAME>tm2325133d1_ex99-906cert.htm
<DESCRIPTION>EXHIBIT 99.906 CERT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2325133d1_ex99-906cert.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2325133-1/tm2325133-1_ncsrseq1/users" -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;99.906CERT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT 5: CERTIFICATION PUSUANT TO SECTION&nbsp;906
OF THE SARBANES-OXLEY ACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.05pt 0pt 5.65pt; text-indent: 22.4pt">Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, each of the undersigned officers of abrdn World Healthcare Fund, do hereby certify, to such officer&rsquo;s
knowledge, that the report on Form N-CSR of abrdn World Healthcare Fund for the period ended September 30, 2023 fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as applicable, and information contained in the Form N-CSR
fairly presents, in all material respects, the financial condition and results of operations of abrdn World Healthcare Fund for the stated
period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Dated:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 41%"><FONT STYLE="font-size: 10pt">12/11/23</FONT></TD>
  <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 41%"><FONT STYLE="font-size: 10pt">/s/ Christian Pittard</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 50%"><FONT STYLE="font-size: 10pt">/s/ Sharon Ferrari</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Christian Pittard</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-size: 10pt">Name: Sharon Ferrari</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Principal Executive Officer of abrdn World Healthcare Fund</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-size: 10pt">Title: Treasurer and Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">A signed original of this written statement required by Section 906
has been provided to abrdn World Healthcare Fund and will be retained by abrdn World Healthcare Fund and furnished to the SEC or its staff
upon request. This statement accompanies this report on Form N-CSR pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.IND PUB ACCT
<SEQUENCE>6
<FILENAME>tm2325133d1_ex99-indpubacc.htm
<DESCRIPTION>EXHIBIT 99.IND PUB ACCT
<TEXT>
<!-- Assembled by CompSci Transform  (tm) - http://www.compsciresources.com - version 1.2 -->
<!-- Created: Mon Dec 11 21:59:26 UTC 2023 -->
<html>
<head>
     <title></title>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2325133d1_exhibt6.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2325133-1/tm2325133-1_ncsrseq1" -->
<p style="text-align: right; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></p>

<p style="margin: 0pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 99.IND
PUB ACCT</b></font></p>

<p style="margin: 0pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></p>

<p style="margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="tm2325133d1_ex6-001a.jpg" alt="">&#xa0;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">KPMG
LLP</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1601
Market Street<br>
Philadelphia, PA 19103-2499</font></p>

<p style="margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><b>Consent
of Independent Registered Public Accounting Firm</b></font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">We
consent to the incorporation by reference in the Registration Statement (No. 333-267555) on Form N-2 of our report dated November&#xa0;28,&#xa0;2023,
with respect to the financial statements and financial highlights of abrdn World Healthcare Fund, and to the references to our firm under
the heading &#x201c;Additional Information&#x201d;.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 20%; padding-top: 3pt; font: 10pt Arial, Helvetica, Sans-Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="width: 20%; padding-top: 3pt; font: 10pt Arial, Helvetica, Sans-Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="width: 20%"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="tm2325133d1_ex6-img001b.jpg" alt="" style="height: 28px; width: 132px"></font></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></p></td>
    <td style="width: 20%; padding-top: 3pt; font: 10pt Arial, Helvetica, Sans-Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="width: 20%; padding-top: 3pt; font: 10pt Arial, Helvetica, Sans-Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Philadelphia,
Pennsylvania<br>
December&#xa0;8,&#xa0;2023</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 2pt">&#xa0;</font></p>


<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="width: 30%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="width: 40%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-left: 0in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KPMG
                                            LLP, a Delaware limited liability partnership and a member firm of<br>
                                            the KPMG global organization of independent member firms affiliated with <br>
                                            KPMG International Limited, a private English company limited by guarantee.</font></p>


</td><td style="width: 30%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  </table>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

</div><div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2325133d1_exhibit7.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2325133-1/tm2325133-1_ncsrseq1" -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the incorporation by reference in
Registration Statement No. 333-267555 on Form N-2 of our report dated November 21, 2022, relating to the financial statements and financial
highlights of Tekla World Healthcare Fund (the &#x201c;Fund&#x201d;), appearing in the Annual Report on Form N-CSR of the Fund for the year
ended September 30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ DELOITTE &amp; TOUCHE LLP</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Boston, Massachusetts</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">December 11, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>

<p style="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&#xa0;</p>

<p style="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&#xa0;</p>

</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ck0001635977-20230930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:ck0001635977="http://www.teklacap.com/20230930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:cef-pre="http://xbrl.sec.gov/cef-pre/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" targetNamespace="http://www.teklacap.com/20230930" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://xbrl.sec.gov/cef/2023" schemaLocation="https://xbrl.sec.gov/cef/2023/cef-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/cef-pre/2023" schemaLocation="https://xbrl.sec.gov/cef/2023/cef-2023_pre.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.teklacap.com/role/Cover" id="Cover">
        <link:definition>0000 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.teklacap.com/role/FinancialHighlights" id="FinancialHighlights">
        <link:definition>0000 - Disclosure - Senior Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.teklacap.com/role/FeeTable" id="FeeTable">
        <link:definition>0000 - Disclosure - Summary of Fees &amp; Expenses And Example Table</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.teklacap.com/role/GeneralDescriptionOfRegistrant" id="GeneralDescriptionOfRegistrant">
        <link:definition>0000 - Disclosure - General Description of Registrant</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.teklacap.com/role/CapitalStockLongTermDebtAndOtherSecurities" id="CapitalStockLongTermDebtAndOtherSecurities">
        <link:definition>0000 - Disclosure - Capital Stock Long Term Debt And Other Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ck0001635977-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ck0001635977-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ck0001635977-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AntiTakeoverProvisionsRiskMember" id="ck0001635977_AntiTakeoverProvisionsRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BiotechnologyIndustryRiskMember" id="ck0001635977_BiotechnologyIndustryRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConcentrationInHealthcareIndustriesMember" id="ck0001635977_ConcentrationInHealthcareIndustriesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConvertibleSecuritiesRiskMember" id="ck0001635977_ConvertibleSecuritiesRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CounterpartyRiskMember" id="ck0001635977_CounterpartyRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CreditDefaultRiskMember" id="ck0001635977_CreditDefaultRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DerivativesRiskMember" id="ck0001635977_DerivativesRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EquityLinkedNotesMember" id="ck0001635977_EquityLinkedNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EquitySecuritiesRiskMember" id="ck0001635977_EquitySecuritiesRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember" id="ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExampleDoesNotIncludeSalesLoadMember" id="ck0001635977_ExampleDoesNotIncludeSalesLoadMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExchangeTradedFundsRiskMember" id="ck0001635977_ExchangeTradedFundsRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember" id="ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ForeignSecuritiesRiskMember" id="ck0001635977_ForeignSecuritiesRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ForwardContractRiskMember" id="ck0001635977_ForwardContractRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentInterventionMember" id="ck0001635977_GovernmentInterventionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HealthcareDistributorsSectorRiskMember" id="ck0001635977_HealthcareDistributorsSectorRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HealthcareEquipmentSectorRiskMember" id="ck0001635977_HealthcareEquipmentSectorRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HealthcareFacilitiesSectorRiskMember" id="ck0001635977_HealthcareFacilitiesSectorRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HealthcareServicesSectorRiskMember" id="ck0001635977_HealthcareServicesSectorRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HealthcareSuppliesSectorRiskMember" id="ck0001635977_HealthcareSuppliesSectorRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HealthcareTechnologySectorRiskMember" id="ck0001635977_HealthcareTechnologySectorRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InterestRatesRiskMember" id="ck0001635977_InterestRatesRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="KeyPersonnelRiskMember" id="ck0001635977_KeyPersonnelRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LeverageRiskMember" id="ck0001635977_LeverageRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LifeScienceAndToolsIndustryRiskMember" id="ck0001635977_LifeScienceAndToolsIndustryRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LiquidityRiskMember" id="ck0001635977_LiquidityRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LoanFacility2016Member" id="ck0001635977_LoanFacility2016Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LoanFacility2017Member" id="ck0001635977_LoanFacility2017Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LoanFacility2018Member" id="ck0001635977_LoanFacility2018Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LoanFacility2019Member" id="ck0001635977_LoanFacility2019Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LoanFacility2020Member" id="ck0001635977_LoanFacility2020Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LoanFacility2021Member" id="ck0001635977_LoanFacility2021Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LoanFacility2022Member" id="ck0001635977_LoanFacility2022Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LoanFacility2023Member" id="ck0001635977_LoanFacility2023Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ManagedCareSectorRiskMember" id="ck0001635977_ManagedCareSectorRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MarketDisruptionAndGeopoliticalRiskMember" id="ck0001635977_MarketDisruptionAndGeopoliticalRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonDiversificationRiskMember" id="ck0001635977_NonDiversificationRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonInvestmentGradeSecuritiesRiskMember" id="ck0001635977_NonInvestmentGradeSecuritiesRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PharmaceuticalSectorRiskMember" id="ck0001635977_PharmaceuticalSectorRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PortfolioMarketRiskMember" id="ck0001635977_PortfolioMarketRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PotentialConflictsOfInterestRiskMember" id="ck0001635977_PotentialConflictsOfInterestRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PrivateInvestmentInPublicEquityRiskMember" id="ck0001635977_PrivateInvestmentInPublicEquityRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RegulationAsCommodityPoolMember" id="ck0001635977_RegulationAsCommodityPoolMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ReitRiskMember" id="ck0001635977_ReitRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RelatedPartyTransactionsRiskMember" id="ck0001635977_RelatedPartyTransactionsRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RestrictedSecuritiesAndValuationRiskMember" id="ck0001635977_RestrictedSecuritiesAndValuationRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RisksAssociatedWithFundsOptionStrategyMember" id="ck0001635977_RisksAssociatedWithFundsOptionStrategyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RisksAssociatedWithRegulatoryAndPolicyChangesMember" id="ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecurityMarketRiskDiscountToNetAssetValueMember" id="ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SelectionRiskMember" id="ck0001635977_SelectionRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SpecialPurposeAcquisitionCompanyRiskMember" id="ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="VentureCapitalInvestmentsRiskMember" id="ck0001635977_VentureCapitalInvestmentsRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>ck0001635977-20230930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <link:roleRef roleURI="http://xbrl.sec.gov/cef/role/RiskOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/cef/2023/cef-2023.xsd#RiskOnly"/>
  <link:roleRef roleURI="http://xbrl.sec.gov/cef/role/SecurityOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/cef/2023/cef-2023.xsd#SecurityOnly"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/SecurityOnly">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_0"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ExampleDoesNotIncludeSalesLoadMember" xlink:label="loc_ck0001635977_ExampleDoesNotIncludeSalesLoadMember_1"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember" xlink:label="loc_ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2023Member" xlink:label="loc_ck0001635977_LoanFacility2023Member_3"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2022Member" xlink:label="loc_ck0001635977_LoanFacility2022Member_4"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2021Member" xlink:label="loc_ck0001635977_LoanFacility2021Member_5"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2020Member" xlink:label="loc_ck0001635977_LoanFacility2020Member_6"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2019Member" xlink:label="loc_ck0001635977_LoanFacility2019Member_7"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2018Member" xlink:label="loc_ck0001635977_LoanFacility2018Member_8"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2017Member" xlink:label="loc_ck0001635977_LoanFacility2017Member_9"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2016Member" xlink:label="loc_ck0001635977_LoanFacility2016Member_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0" xlink:to="loc_ck0001635977_ExampleDoesNotIncludeSalesLoadMember_1" order="1" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0" xlink:to="loc_ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember_2" order="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0" xlink:to="loc_ck0001635977_LoanFacility2023Member_3" order="1" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0" xlink:to="loc_ck0001635977_LoanFacility2022Member_4" order="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0" xlink:to="loc_ck0001635977_LoanFacility2021Member_5" order="3" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0" xlink:to="loc_ck0001635977_LoanFacility2020Member_6" order="4" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0" xlink:to="loc_ck0001635977_LoanFacility2019Member_7" order="5" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0" xlink:to="loc_ck0001635977_LoanFacility2018Member_8" order="6" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0" xlink:to="loc_ck0001635977_LoanFacility2017Member_9" order="7" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0" xlink:to="loc_ck0001635977_LoanFacility2016Member_10" order="8" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/RiskOnly">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cef/2023/cef-2023.xsd#cef_AllRisksMember" xlink:label="loc_cef_AllRisksMember_0"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_PortfolioMarketRiskMember" xlink:label="loc_ck0001635977_PortfolioMarketRiskMember_3"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember" xlink:label="loc_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_4"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_NonDiversificationRiskMember" xlink:label="loc_ck0001635977_NonDiversificationRiskMember_5"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_EquitySecuritiesRiskMember" xlink:label="loc_ck0001635977_EquitySecuritiesRiskMember_6"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ConvertibleSecuritiesRiskMember" xlink:label="loc_ck0001635977_ConvertibleSecuritiesRiskMember_7"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_SelectionRiskMember" xlink:label="loc_ck0001635977_SelectionRiskMember_8"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ConcentrationInHealthcareIndustriesMember" xlink:label="loc_ck0001635977_ConcentrationInHealthcareIndustriesMember_9"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_PharmaceuticalSectorRiskMember" xlink:label="loc_ck0001635977_PharmaceuticalSectorRiskMember_10"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_BiotechnologyIndustryRiskMember" xlink:label="loc_ck0001635977_BiotechnologyIndustryRiskMember_11"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ManagedCareSectorRiskMember" xlink:label="loc_ck0001635977_ManagedCareSectorRiskMember_12"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LifeScienceAndToolsIndustryRiskMember" xlink:label="loc_ck0001635977_LifeScienceAndToolsIndustryRiskMember_13"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareTechnologySectorRiskMember" xlink:label="loc_ck0001635977_HealthcareTechnologySectorRiskMember_14"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareServicesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareServicesSectorRiskMember_15"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareSuppliesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareSuppliesSectorRiskMember_16"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareFacilitiesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareFacilitiesSectorRiskMember_17"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareEquipmentSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareEquipmentSectorRiskMember_18"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareDistributorsSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareDistributorsSectorRiskMember_19"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember" xlink:label="loc_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_20"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ForeignSecuritiesRiskMember" xlink:label="loc_ck0001635977_ForeignSecuritiesRiskMember_21"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ForwardContractRiskMember" xlink:label="loc_ck0001635977_ForwardContractRiskMember_22"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_DerivativesRiskMember" xlink:label="loc_ck0001635977_DerivativesRiskMember_23"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RisksAssociatedWithFundsOptionStrategyMember" xlink:label="loc_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_24"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_InterestRatesRiskMember" xlink:label="loc_ck0001635977_InterestRatesRiskMember_25"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ReitRiskMember" xlink:label="loc_ck0001635977_ReitRiskMember_26"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_CreditDefaultRiskMember" xlink:label="loc_ck0001635977_CreditDefaultRiskMember_27"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_NonInvestmentGradeSecuritiesRiskMember" xlink:label="loc_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_28"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_CounterpartyRiskMember" xlink:label="loc_ck0001635977_CounterpartyRiskMember_29"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RegulationAsCommodityPoolMember" xlink:label="loc_ck0001635977_RegulationAsCommodityPoolMember_30"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember" xlink:label="loc_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_31"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LiquidityRiskMember" xlink:label="loc_ck0001635977_LiquidityRiskMember_32"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_EquityLinkedNotesMember" xlink:label="loc_ck0001635977_EquityLinkedNotesMember_33"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_PrivateInvestmentInPublicEquityRiskMember" xlink:label="loc_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_34"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_VentureCapitalInvestmentsRiskMember" xlink:label="loc_ck0001635977_VentureCapitalInvestmentsRiskMember_35"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ExchangeTradedFundsRiskMember" xlink:label="loc_ck0001635977_ExchangeTradedFundsRiskMember_36"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LeverageRiskMember" xlink:label="loc_ck0001635977_LeverageRiskMember_37"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RestrictedSecuritiesAndValuationRiskMember" xlink:label="loc_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_38"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_KeyPersonnelRiskMember" xlink:label="loc_ck0001635977_KeyPersonnelRiskMember_39"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_AntiTakeoverProvisionsRiskMember" xlink:label="loc_ck0001635977_AntiTakeoverProvisionsRiskMember_40"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RelatedPartyTransactionsRiskMember" xlink:label="loc_ck0001635977_RelatedPartyTransactionsRiskMember_41"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_GovernmentInterventionMember" xlink:label="loc_ck0001635977_GovernmentInterventionMember_42"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_MarketDisruptionAndGeopoliticalRiskMember" xlink:label="loc_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_43"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_PotentialConflictsOfInterestRiskMember" xlink:label="loc_ck0001635977_PotentialConflictsOfInterestRiskMember_44"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember" xlink:label="loc_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_45"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_PortfolioMarketRiskMember_3" order="1" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_4" order="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_NonDiversificationRiskMember_5" order="3" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_EquitySecuritiesRiskMember_6" order="4" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_ConvertibleSecuritiesRiskMember_7" order="5" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_SelectionRiskMember_8" order="6" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_ConcentrationInHealthcareIndustriesMember_9" order="7" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_PharmaceuticalSectorRiskMember_10" order="8" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_BiotechnologyIndustryRiskMember_11" order="9" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_ManagedCareSectorRiskMember_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_LifeScienceAndToolsIndustryRiskMember_13" order="11" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_HealthcareTechnologySectorRiskMember_14" order="12" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_HealthcareServicesSectorRiskMember_15" order="13" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_HealthcareSuppliesSectorRiskMember_16" order="14" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_HealthcareFacilitiesSectorRiskMember_17" order="15" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_HealthcareEquipmentSectorRiskMember_18" order="16" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_HealthcareDistributorsSectorRiskMember_19" order="17" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_20" order="18" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_ForeignSecuritiesRiskMember_21" order="19" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_ForwardContractRiskMember_22" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_DerivativesRiskMember_23" order="21" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_24" order="22" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_InterestRatesRiskMember_25" order="23" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_ReitRiskMember_26" order="24" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_CreditDefaultRiskMember_27" order="25" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_28" order="26" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_CounterpartyRiskMember_29" order="27" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_RegulationAsCommodityPoolMember_30" order="28" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_31" order="29" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_LiquidityRiskMember_32" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_EquityLinkedNotesMember_33" order="31" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_34" order="32" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_VentureCapitalInvestmentsRiskMember_35" order="33" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_ExchangeTradedFundsRiskMember_36" order="34" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_LeverageRiskMember_37" order="35" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_38" order="36" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_KeyPersonnelRiskMember_39" order="37" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_AntiTakeoverProvisionsRiskMember_40" order="38" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_RelatedPartyTransactionsRiskMember_41" order="39" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_GovernmentInterventionMember_42" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_43" order="41" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_PotentialConflictsOfInterestRiskMember_44" order="42" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_45" order="43" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ck0001635977-20230930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_AntiTakeoverProvisionsRiskMember" xlink:label="loc_ck0001635977_AntiTakeoverProvisionsRiskMember_1"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_AntiTakeoverProvisionsRiskMember" xlink:label="loc_ck0001635977_AntiTakeoverProvisionsRiskMember_2"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_BiotechnologyIndustryRiskMember" xlink:label="loc_ck0001635977_BiotechnologyIndustryRiskMember_3"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_BiotechnologyIndustryRiskMember" xlink:label="loc_ck0001635977_BiotechnologyIndustryRiskMember_4"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ConcentrationInHealthcareIndustriesMember" xlink:label="loc_ck0001635977_ConcentrationInHealthcareIndustriesMember_5"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ConcentrationInHealthcareIndustriesMember" xlink:label="loc_ck0001635977_ConcentrationInHealthcareIndustriesMember_6"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ConvertibleSecuritiesRiskMember" xlink:label="loc_ck0001635977_ConvertibleSecuritiesRiskMember_7"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ConvertibleSecuritiesRiskMember" xlink:label="loc_ck0001635977_ConvertibleSecuritiesRiskMember_8"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_CounterpartyRiskMember" xlink:label="loc_ck0001635977_CounterpartyRiskMember_9"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_CounterpartyRiskMember" xlink:label="loc_ck0001635977_CounterpartyRiskMember_10"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_CreditDefaultRiskMember" xlink:label="loc_ck0001635977_CreditDefaultRiskMember_11"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_CreditDefaultRiskMember" xlink:label="loc_ck0001635977_CreditDefaultRiskMember_12"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_DerivativesRiskMember" xlink:label="loc_ck0001635977_DerivativesRiskMember_13"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_DerivativesRiskMember" xlink:label="loc_ck0001635977_DerivativesRiskMember_14"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_EquityLinkedNotesMember" xlink:label="loc_ck0001635977_EquityLinkedNotesMember_15"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_EquityLinkedNotesMember" xlink:label="loc_ck0001635977_EquityLinkedNotesMember_16"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_EquityLinkedNotesMember" xlink:label="loc_ck0001635977_EquityLinkedNotesMember_17"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_EquitySecuritiesRiskMember" xlink:label="loc_ck0001635977_EquitySecuritiesRiskMember_18"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_EquitySecuritiesRiskMember" xlink:label="loc_ck0001635977_EquitySecuritiesRiskMember_19"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember" xlink:label="loc_ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember_20"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember" xlink:label="loc_ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember_21"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember" xlink:label="loc_ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember_22"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ExampleDoesNotIncludeSalesLoadMember" xlink:label="loc_ck0001635977_ExampleDoesNotIncludeSalesLoadMember_23"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ExampleDoesNotIncludeSalesLoadMember" xlink:label="loc_ck0001635977_ExampleDoesNotIncludeSalesLoadMember_24"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ExampleDoesNotIncludeSalesLoadMember" xlink:label="loc_ck0001635977_ExampleDoesNotIncludeSalesLoadMember_25"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ExchangeTradedFundsRiskMember" xlink:label="loc_ck0001635977_ExchangeTradedFundsRiskMember_26"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ExchangeTradedFundsRiskMember" xlink:label="loc_ck0001635977_ExchangeTradedFundsRiskMember_27"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ExchangeTradedFundsRiskMember" xlink:label="loc_ck0001635977_ExchangeTradedFundsRiskMember_28"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember" xlink:label="loc_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_29"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember" xlink:label="loc_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_30"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ForeignSecuritiesRiskMember" xlink:label="loc_ck0001635977_ForeignSecuritiesRiskMember_31"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ForeignSecuritiesRiskMember" xlink:label="loc_ck0001635977_ForeignSecuritiesRiskMember_32"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ForwardContractRiskMember" xlink:label="loc_ck0001635977_ForwardContractRiskMember_33"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ForwardContractRiskMember" xlink:label="loc_ck0001635977_ForwardContractRiskMember_34"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_GovernmentInterventionMember" xlink:label="loc_ck0001635977_GovernmentInterventionMember_35"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_GovernmentInterventionMember" xlink:label="loc_ck0001635977_GovernmentInterventionMember_36"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareDistributorsSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareDistributorsSectorRiskMember_37"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareDistributorsSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareDistributorsSectorRiskMember_38"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareEquipmentSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareEquipmentSectorRiskMember_39"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareEquipmentSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareEquipmentSectorRiskMember_40"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareFacilitiesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareFacilitiesSectorRiskMember_41"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareFacilitiesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareFacilitiesSectorRiskMember_42"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareServicesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareServicesSectorRiskMember_43"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareServicesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareServicesSectorRiskMember_44"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareSuppliesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareSuppliesSectorRiskMember_45"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareSuppliesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareSuppliesSectorRiskMember_46"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareTechnologySectorRiskMember" xlink:label="loc_ck0001635977_HealthcareTechnologySectorRiskMember_47"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareTechnologySectorRiskMember" xlink:label="loc_ck0001635977_HealthcareTechnologySectorRiskMember_48"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_InterestRatesRiskMember" xlink:label="loc_ck0001635977_InterestRatesRiskMember_49"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_InterestRatesRiskMember" xlink:label="loc_ck0001635977_InterestRatesRiskMember_50"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_KeyPersonnelRiskMember" xlink:label="loc_ck0001635977_KeyPersonnelRiskMember_51"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_KeyPersonnelRiskMember" xlink:label="loc_ck0001635977_KeyPersonnelRiskMember_52"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LeverageRiskMember" xlink:label="loc_ck0001635977_LeverageRiskMember_53"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LeverageRiskMember" xlink:label="loc_ck0001635977_LeverageRiskMember_54"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LifeScienceAndToolsIndustryRiskMember" xlink:label="loc_ck0001635977_LifeScienceAndToolsIndustryRiskMember_55"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LifeScienceAndToolsIndustryRiskMember" xlink:label="loc_ck0001635977_LifeScienceAndToolsIndustryRiskMember_56"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LiquidityRiskMember" xlink:label="loc_ck0001635977_LiquidityRiskMember_57"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LiquidityRiskMember" xlink:label="loc_ck0001635977_LiquidityRiskMember_58"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2016Member" xlink:label="loc_ck0001635977_LoanFacility2016Member_59"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2016Member" xlink:label="loc_ck0001635977_LoanFacility2016Member_60"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2017Member" xlink:label="loc_ck0001635977_LoanFacility2017Member_61"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2017Member" xlink:label="loc_ck0001635977_LoanFacility2017Member_62"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2018Member" xlink:label="loc_ck0001635977_LoanFacility2018Member_63"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2018Member" xlink:label="loc_ck0001635977_LoanFacility2018Member_64"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2019Member" xlink:label="loc_ck0001635977_LoanFacility2019Member_65"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2019Member" xlink:label="loc_ck0001635977_LoanFacility2019Member_66"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2020Member" xlink:label="loc_ck0001635977_LoanFacility2020Member_67"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2020Member" xlink:label="loc_ck0001635977_LoanFacility2020Member_68"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2021Member" xlink:label="loc_ck0001635977_LoanFacility2021Member_69"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2021Member" xlink:label="loc_ck0001635977_LoanFacility2021Member_70"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2022Member" xlink:label="loc_ck0001635977_LoanFacility2022Member_71"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2022Member" xlink:label="loc_ck0001635977_LoanFacility2022Member_72"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2023Member" xlink:label="loc_ck0001635977_LoanFacility2023Member_73"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2023Member" xlink:label="loc_ck0001635977_LoanFacility2023Member_74"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ManagedCareSectorRiskMember" xlink:label="loc_ck0001635977_ManagedCareSectorRiskMember_75"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ManagedCareSectorRiskMember" xlink:label="loc_ck0001635977_ManagedCareSectorRiskMember_76"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_MarketDisruptionAndGeopoliticalRiskMember" xlink:label="loc_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_77"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_MarketDisruptionAndGeopoliticalRiskMember" xlink:label="loc_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_78"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_NonDiversificationRiskMember" xlink:label="loc_ck0001635977_NonDiversificationRiskMember_79"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_NonDiversificationRiskMember" xlink:label="loc_ck0001635977_NonDiversificationRiskMember_80"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_NonInvestmentGradeSecuritiesRiskMember" xlink:label="loc_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_81"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_NonInvestmentGradeSecuritiesRiskMember" xlink:label="loc_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_82"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_PharmaceuticalSectorRiskMember" xlink:label="loc_ck0001635977_PharmaceuticalSectorRiskMember_83"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_PharmaceuticalSectorRiskMember" xlink:label="loc_ck0001635977_PharmaceuticalSectorRiskMember_84"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_PortfolioMarketRiskMember" xlink:label="loc_ck0001635977_PortfolioMarketRiskMember_85"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_PortfolioMarketRiskMember" xlink:label="loc_ck0001635977_PortfolioMarketRiskMember_86"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_PotentialConflictsOfInterestRiskMember" xlink:label="loc_ck0001635977_PotentialConflictsOfInterestRiskMember_87"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_PotentialConflictsOfInterestRiskMember" xlink:label="loc_ck0001635977_PotentialConflictsOfInterestRiskMember_88"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_PrivateInvestmentInPublicEquityRiskMember" xlink:label="loc_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_89"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_PrivateInvestmentInPublicEquityRiskMember" xlink:label="loc_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_90"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RegulationAsCommodityPoolMember" xlink:label="loc_ck0001635977_RegulationAsCommodityPoolMember_91"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RegulationAsCommodityPoolMember" xlink:label="loc_ck0001635977_RegulationAsCommodityPoolMember_92"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ReitRiskMember" xlink:label="loc_ck0001635977_ReitRiskMember_93"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ReitRiskMember" xlink:label="loc_ck0001635977_ReitRiskMember_94"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RelatedPartyTransactionsRiskMember" xlink:label="loc_ck0001635977_RelatedPartyTransactionsRiskMember_95"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RelatedPartyTransactionsRiskMember" xlink:label="loc_ck0001635977_RelatedPartyTransactionsRiskMember_96"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RestrictedSecuritiesAndValuationRiskMember" xlink:label="loc_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_97"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RestrictedSecuritiesAndValuationRiskMember" xlink:label="loc_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_98"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RisksAssociatedWithFundsOptionStrategyMember" xlink:label="loc_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_99"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RisksAssociatedWithFundsOptionStrategyMember" xlink:label="loc_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_100"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember" xlink:label="loc_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_101"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember" xlink:label="loc_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_102"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember" xlink:label="loc_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_103"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember" xlink:label="loc_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_104"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember" xlink:label="loc_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_105"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_SelectionRiskMember" xlink:label="loc_ck0001635977_SelectionRiskMember_106"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_SelectionRiskMember" xlink:label="loc_ck0001635977_SelectionRiskMember_107"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember" xlink:label="loc_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_108"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember" xlink:label="loc_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_109"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_VentureCapitalInvestmentsRiskMember" xlink:label="loc_ck0001635977_VentureCapitalInvestmentsRiskMember_110"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_VentureCapitalInvestmentsRiskMember" xlink:label="loc_ck0001635977_VentureCapitalInvestmentsRiskMember_111"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_112"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_113"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_AntiTakeoverProvisionsRiskMember_0" xml:lang="en-US">This member stands for Anti-Takeover Provisions Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_AntiTakeoverProvisionsRiskMember_1" xml:lang="en-US">Anti Takeover Provisions Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_BiotechnologyIndustryRiskMember_0" xml:lang="en-US">Biotechnology Industry Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_BiotechnologyIndustryRiskMember_1" xml:lang="en-US">This member stands for Biotechnology Industry Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_ConcentrationInHealthcareIndustriesMember_0" xml:lang="en-US">This member stands for Concentration in the Healthcare Industries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_ConcentrationInHealthcareIndustriesMember_1" xml:lang="en-US">Concentration In Healthcare Industries [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_ConvertibleSecuritiesRiskMember_0" xml:lang="en-US">Convertible Securities Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_ConvertibleSecuritiesRiskMember_1" xml:lang="en-US">This member stands for Convertible Securities Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_CounterpartyRiskMember_0" xml:lang="en-US">This member stands for Counterparty Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_CounterpartyRiskMember_1" xml:lang="en-US">Counterparty Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_CreditDefaultRiskMember_0" xml:lang="en-US">This member stands for Credit/Default Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_CreditDefaultRiskMember_1" xml:lang="en-US">Credit Default Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_DerivativesRiskMember_0" xml:lang="en-US">This member stands for Derivatives Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_DerivativesRiskMember_1" xml:lang="en-US">Derivatives Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_EquityLinkedNotesMember_0" xml:lang="en-US">This member stands for Equity-Linked Notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001635977_EquityLinkedNotesMember_1" xml:lang="en-US">Equity-linked Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_EquityLinkedNotesMember_2" xml:lang="en-US">Equity Linked Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_EquitySecuritiesRiskMember_0" xml:lang="en-US">Equity Securities Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_EquitySecuritiesRiskMember_1" xml:lang="en-US">This member stands for Equity Securities Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember_0" xml:lang="en-US">Example Assumes Transaction Fee Of As Percentage Of Offering Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember_1" xml:lang="en-US">It represents as a example assumes transaction fee of as percentage of offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember_2" xml:lang="en-US">Example assumes transaction fee of percentage of offering price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_ExampleDoesNotIncludeSalesLoadMember_0" xml:lang="en-US">Example Does Not Include Sales Load [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_ExampleDoesNotIncludeSalesLoadMember_1" xml:lang="en-US">It represents as a example does not include the sales load.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001635977_ExampleDoesNotIncludeSalesLoadMember_2" xml:lang="en-US">Example does not include the sales load [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_ExchangeTradedFundsRiskMember_0" xml:lang="en-US">This member stands for ETFs Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001635977_ExchangeTradedFundsRiskMember_1" xml:lang="en-US">Exchange-Traded Funds Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_ExchangeTradedFundsRiskMember_2" xml:lang="en-US">Exchange Traded Funds Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_0" xml:lang="en-US">Failure Of Futures Commission Merchants And Clearing Organizations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_1" xml:lang="en-US">Represents information of failure of futures commission merchants and clearing organizations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_ForeignSecuritiesRiskMember_0" xml:lang="en-US">Foreign Securities Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_ForeignSecuritiesRiskMember_1" xml:lang="en-US">This member stands for Foreign Securities Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_ForwardContractRiskMember_0" xml:lang="en-US">This member stands for Forward Contract Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_ForwardContractRiskMember_1" xml:lang="en-US">Forward Contract Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_GovernmentInterventionMember_0" xml:lang="en-US">This member stands for Government Intervention.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_GovernmentInterventionMember_1" xml:lang="en-US">Government Intervention [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_HealthcareDistributorsSectorRiskMember_0" xml:lang="en-US">Healthcare Distributors Sector Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_HealthcareDistributorsSectorRiskMember_1" xml:lang="en-US">This member stands for Healthcare Distributors Sector Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_HealthcareEquipmentSectorRiskMember_0" xml:lang="en-US">Healthcare Equipment Sector Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_HealthcareEquipmentSectorRiskMember_1" xml:lang="en-US">This member stands for Healthcare Equipment Sector Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_HealthcareFacilitiesSectorRiskMember_0" xml:lang="en-US">Healthcare Facilities Sector Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_HealthcareFacilitiesSectorRiskMember_1" xml:lang="en-US">This member stands for Healthcare Facilities Sector Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_HealthcareServicesSectorRiskMember_0" xml:lang="en-US">This member stands for Healthcare Services Sector Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_HealthcareServicesSectorRiskMember_1" xml:lang="en-US">Healthcare Services Sector Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_HealthcareSuppliesSectorRiskMember_0" xml:lang="en-US">This member stands for Healthcare Supplies Sector Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_HealthcareSuppliesSectorRiskMember_1" xml:lang="en-US">Healthcare Supplies Sector Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_HealthcareTechnologySectorRiskMember_0" xml:lang="en-US">Healthcare Technology Sector Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_HealthcareTechnologySectorRiskMember_1" xml:lang="en-US">This member stands for Healthcare Technology Sector Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_InterestRatesRiskMember_0" xml:lang="en-US">Interest Rates Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_InterestRatesRiskMember_1" xml:lang="en-US">Interest Rates Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_KeyPersonnelRiskMember_0" xml:lang="en-US">This member stands for Key Personnel Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_KeyPersonnelRiskMember_1" xml:lang="en-US">Key Personnel Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_LeverageRiskMember_0" xml:lang="en-US">This member stands for Leverage Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_LeverageRiskMember_1" xml:lang="en-US">Leverage Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_LifeScienceAndToolsIndustryRiskMember_0" xml:lang="en-US">This member stands for Life Science and Tools Industry Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_LifeScienceAndToolsIndustryRiskMember_1" xml:lang="en-US">Life Science And Tools Industry Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_LiquidityRiskMember_0" xml:lang="en-US">This member stands for Liquidity Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_LiquidityRiskMember_1" xml:lang="en-US">Liquidity Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_LoanFacility2016Member_0" xml:lang="en-US">Loan Facility 2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_LoanFacility2016Member_1" xml:lang="en-US">Loan Facility 2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_LoanFacility2017Member_0" xml:lang="en-US">Loan Facility 2017 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_LoanFacility2017Member_1" xml:lang="en-US">Loan Facility 2017 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_LoanFacility2018Member_0" xml:lang="en-US">Loan Facility 2018 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_LoanFacility2018Member_1" xml:lang="en-US">Loan Facility 2018 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_LoanFacility2019Member_0" xml:lang="en-US">Loan Facility 2019 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_LoanFacility2019Member_1" xml:lang="en-US">Loan Facility 2019 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_LoanFacility2020Member_0" xml:lang="en-US">Loan Facility 2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_LoanFacility2020Member_1" xml:lang="en-US">Loan Facility 2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_LoanFacility2021Member_0" xml:lang="en-US">Loan Facility 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_LoanFacility2021Member_1" xml:lang="en-US">Loan Facility 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_LoanFacility2022Member_0" xml:lang="en-US">Loan Facility 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_LoanFacility2022Member_1" xml:lang="en-US">Loan Facility 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_LoanFacility2023Member_0" xml:lang="en-US">Loan Facility 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_LoanFacility2023Member_1" xml:lang="en-US">Loan Facility 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_ManagedCareSectorRiskMember_0" xml:lang="en-US">This member stands for Managed Care Sector Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_ManagedCareSectorRiskMember_1" xml:lang="en-US">Managed Care Sector Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_0" xml:lang="en-US">This member stands for Market Disruption and Geopolitical Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_1" xml:lang="en-US">Market Disruption And Geopolitical Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_NonDiversificationRiskMember_0" xml:lang="en-US">Non Diversification Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_NonDiversificationRiskMember_1" xml:lang="en-US">This member stands for Non-Diversification Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_0" xml:lang="en-US">This member stands for Non-Investment Grade Securities Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_1" xml:lang="en-US">Non Investment Grade Securities Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_PharmaceuticalSectorRiskMember_0" xml:lang="en-US">This member stands for Pharmaceutical Sector Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_PharmaceuticalSectorRiskMember_1" xml:lang="en-US">Pharmaceutical Sector Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_PortfolioMarketRiskMember_0" xml:lang="en-US">Portfolio Market Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_PortfolioMarketRiskMember_1" xml:lang="en-US">This member stands for Portfolio Market Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_PotentialConflictsOfInterestRiskMember_0" xml:lang="en-US">This member stands for Potential Conflicts of Interest Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_PotentialConflictsOfInterestRiskMember_1" xml:lang="en-US">Potential Conflicts Of Interest Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_0" xml:lang="en-US">Private Investment In Public Equity Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_1" xml:lang="en-US">This member stands for private investments in public equity ("PIPEs") Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_RegulationAsCommodityPoolMember_0" xml:lang="en-US">Represents information of regulation as commodity pool.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_RegulationAsCommodityPoolMember_1" xml:lang="en-US">Regulation As Commodity Pool [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_ReitRiskMember_0" xml:lang="en-US">REIT Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_ReitRiskMember_1" xml:lang="en-US">This member stands for REIT Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_RelatedPartyTransactionsRiskMember_0" xml:lang="en-US">This member stands for Related Party Transactions Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_RelatedPartyTransactionsRiskMember_1" xml:lang="en-US">Related Party Transactions Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_0" xml:lang="en-US">This member stands for Restricted Securities and Valuation Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_1" xml:lang="en-US">Restricted Securities And Valuation Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_0" xml:lang="en-US">This member stands for Risks Associated with the Fund's Option Strategy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_1" xml:lang="en-US">Risks Associated With Funds Option Strategy [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_0" xml:lang="en-US">Risks Associated With Regulatory And Policy Changes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_1" xml:lang="en-US">This member stands for Risks Associated with Regulatory and Policy Changes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_0" xml:lang="en-US">Security Market Risk Discount To Net Asset Value [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_1" xml:lang="en-US">Security Market Risk-discount To Net Asset Value [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_2" xml:lang="en-US">This member stands for security market risk-discount to net asset value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_SelectionRiskMember_0" xml:lang="en-US">Selection Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_SelectionRiskMember_1" xml:lang="en-US">This member stands for Selection Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_0" xml:lang="en-US">This member stands for Special Purpose Acquisition Company Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_1" xml:lang="en-US">Special Purpose Acquisition Company Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_VentureCapitalInvestmentsRiskMember_0" xml:lang="en-US">This member stands for Venture Capital Investments Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_VentureCapitalInvestmentsRiskMember_1" xml:lang="en-US">Venture Capital Investments Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain_0" xml:lang="en-US">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_0" xml:lang="en-US">Debt Instrument Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_AntiTakeoverProvisionsRiskMember_1" xlink:to="lab_ck0001635977_AntiTakeoverProvisionsRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_AntiTakeoverProvisionsRiskMember_2" xlink:to="lab_ck0001635977_AntiTakeoverProvisionsRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_BiotechnologyIndustryRiskMember_3" xlink:to="lab_ck0001635977_BiotechnologyIndustryRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_BiotechnologyIndustryRiskMember_4" xlink:to="lab_ck0001635977_BiotechnologyIndustryRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ConcentrationInHealthcareIndustriesMember_5" xlink:to="lab_ck0001635977_ConcentrationInHealthcareIndustriesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ConcentrationInHealthcareIndustriesMember_6" xlink:to="lab_ck0001635977_ConcentrationInHealthcareIndustriesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ConvertibleSecuritiesRiskMember_7" xlink:to="lab_ck0001635977_ConvertibleSecuritiesRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ConvertibleSecuritiesRiskMember_8" xlink:to="lab_ck0001635977_ConvertibleSecuritiesRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_CounterpartyRiskMember_9" xlink:to="lab_ck0001635977_CounterpartyRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_CounterpartyRiskMember_10" xlink:to="lab_ck0001635977_CounterpartyRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_CreditDefaultRiskMember_11" xlink:to="lab_ck0001635977_CreditDefaultRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_CreditDefaultRiskMember_12" xlink:to="lab_ck0001635977_CreditDefaultRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_DerivativesRiskMember_13" xlink:to="lab_ck0001635977_DerivativesRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_DerivativesRiskMember_14" xlink:to="lab_ck0001635977_DerivativesRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_EquityLinkedNotesMember_15" xlink:to="lab_ck0001635977_EquityLinkedNotesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_EquityLinkedNotesMember_16" xlink:to="lab_ck0001635977_EquityLinkedNotesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_EquityLinkedNotesMember_17" xlink:to="lab_ck0001635977_EquityLinkedNotesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_EquitySecuritiesRiskMember_18" xlink:to="lab_ck0001635977_EquitySecuritiesRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_EquitySecuritiesRiskMember_19" xlink:to="lab_ck0001635977_EquitySecuritiesRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember_20" xlink:to="lab_ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember_21" xlink:to="lab_ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember_22" xlink:to="lab_ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ExampleDoesNotIncludeSalesLoadMember_23" xlink:to="lab_ck0001635977_ExampleDoesNotIncludeSalesLoadMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ExampleDoesNotIncludeSalesLoadMember_24" xlink:to="lab_ck0001635977_ExampleDoesNotIncludeSalesLoadMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ExampleDoesNotIncludeSalesLoadMember_25" xlink:to="lab_ck0001635977_ExampleDoesNotIncludeSalesLoadMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ExchangeTradedFundsRiskMember_26" xlink:to="lab_ck0001635977_ExchangeTradedFundsRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ExchangeTradedFundsRiskMember_27" xlink:to="lab_ck0001635977_ExchangeTradedFundsRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ExchangeTradedFundsRiskMember_28" xlink:to="lab_ck0001635977_ExchangeTradedFundsRiskMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_29" xlink:to="lab_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_30" xlink:to="lab_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ForeignSecuritiesRiskMember_31" xlink:to="lab_ck0001635977_ForeignSecuritiesRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ForeignSecuritiesRiskMember_32" xlink:to="lab_ck0001635977_ForeignSecuritiesRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ForwardContractRiskMember_33" xlink:to="lab_ck0001635977_ForwardContractRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ForwardContractRiskMember_34" xlink:to="lab_ck0001635977_ForwardContractRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_GovernmentInterventionMember_35" xlink:to="lab_ck0001635977_GovernmentInterventionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_GovernmentInterventionMember_36" xlink:to="lab_ck0001635977_GovernmentInterventionMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareDistributorsSectorRiskMember_37" xlink:to="lab_ck0001635977_HealthcareDistributorsSectorRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareDistributorsSectorRiskMember_38" xlink:to="lab_ck0001635977_HealthcareDistributorsSectorRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareEquipmentSectorRiskMember_39" xlink:to="lab_ck0001635977_HealthcareEquipmentSectorRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareEquipmentSectorRiskMember_40" xlink:to="lab_ck0001635977_HealthcareEquipmentSectorRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareFacilitiesSectorRiskMember_41" xlink:to="lab_ck0001635977_HealthcareFacilitiesSectorRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareFacilitiesSectorRiskMember_42" xlink:to="lab_ck0001635977_HealthcareFacilitiesSectorRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareServicesSectorRiskMember_43" xlink:to="lab_ck0001635977_HealthcareServicesSectorRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareServicesSectorRiskMember_44" xlink:to="lab_ck0001635977_HealthcareServicesSectorRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareSuppliesSectorRiskMember_45" xlink:to="lab_ck0001635977_HealthcareSuppliesSectorRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareSuppliesSectorRiskMember_46" xlink:to="lab_ck0001635977_HealthcareSuppliesSectorRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareTechnologySectorRiskMember_47" xlink:to="lab_ck0001635977_HealthcareTechnologySectorRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_HealthcareTechnologySectorRiskMember_48" xlink:to="lab_ck0001635977_HealthcareTechnologySectorRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_InterestRatesRiskMember_49" xlink:to="lab_ck0001635977_InterestRatesRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_InterestRatesRiskMember_50" xlink:to="lab_ck0001635977_InterestRatesRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_KeyPersonnelRiskMember_51" xlink:to="lab_ck0001635977_KeyPersonnelRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_KeyPersonnelRiskMember_52" xlink:to="lab_ck0001635977_KeyPersonnelRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LeverageRiskMember_53" xlink:to="lab_ck0001635977_LeverageRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LeverageRiskMember_54" xlink:to="lab_ck0001635977_LeverageRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LifeScienceAndToolsIndustryRiskMember_55" xlink:to="lab_ck0001635977_LifeScienceAndToolsIndustryRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LifeScienceAndToolsIndustryRiskMember_56" xlink:to="lab_ck0001635977_LifeScienceAndToolsIndustryRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LiquidityRiskMember_57" xlink:to="lab_ck0001635977_LiquidityRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LiquidityRiskMember_58" xlink:to="lab_ck0001635977_LiquidityRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacility2016Member_59" xlink:to="lab_ck0001635977_LoanFacility2016Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacility2016Member_60" xlink:to="lab_ck0001635977_LoanFacility2016Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacility2017Member_61" xlink:to="lab_ck0001635977_LoanFacility2017Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacility2017Member_62" xlink:to="lab_ck0001635977_LoanFacility2017Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacility2018Member_63" xlink:to="lab_ck0001635977_LoanFacility2018Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacility2018Member_64" xlink:to="lab_ck0001635977_LoanFacility2018Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacility2019Member_65" xlink:to="lab_ck0001635977_LoanFacility2019Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacility2019Member_66" xlink:to="lab_ck0001635977_LoanFacility2019Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacility2020Member_67" xlink:to="lab_ck0001635977_LoanFacility2020Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacility2020Member_68" xlink:to="lab_ck0001635977_LoanFacility2020Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacility2021Member_69" xlink:to="lab_ck0001635977_LoanFacility2021Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacility2021Member_70" xlink:to="lab_ck0001635977_LoanFacility2021Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacility2022Member_71" xlink:to="lab_ck0001635977_LoanFacility2022Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacility2022Member_72" xlink:to="lab_ck0001635977_LoanFacility2022Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacility2023Member_73" xlink:to="lab_ck0001635977_LoanFacility2023Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacility2023Member_74" xlink:to="lab_ck0001635977_LoanFacility2023Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ManagedCareSectorRiskMember_75" xlink:to="lab_ck0001635977_ManagedCareSectorRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ManagedCareSectorRiskMember_76" xlink:to="lab_ck0001635977_ManagedCareSectorRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_77" xlink:to="lab_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_78" xlink:to="lab_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_NonDiversificationRiskMember_79" xlink:to="lab_ck0001635977_NonDiversificationRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_NonDiversificationRiskMember_80" xlink:to="lab_ck0001635977_NonDiversificationRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_81" xlink:to="lab_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_82" xlink:to="lab_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_PharmaceuticalSectorRiskMember_83" xlink:to="lab_ck0001635977_PharmaceuticalSectorRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_PharmaceuticalSectorRiskMember_84" xlink:to="lab_ck0001635977_PharmaceuticalSectorRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_PortfolioMarketRiskMember_85" xlink:to="lab_ck0001635977_PortfolioMarketRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_PortfolioMarketRiskMember_86" xlink:to="lab_ck0001635977_PortfolioMarketRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_PotentialConflictsOfInterestRiskMember_87" xlink:to="lab_ck0001635977_PotentialConflictsOfInterestRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_PotentialConflictsOfInterestRiskMember_88" xlink:to="lab_ck0001635977_PotentialConflictsOfInterestRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_89" xlink:to="lab_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_90" xlink:to="lab_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RegulationAsCommodityPoolMember_91" xlink:to="lab_ck0001635977_RegulationAsCommodityPoolMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RegulationAsCommodityPoolMember_92" xlink:to="lab_ck0001635977_RegulationAsCommodityPoolMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ReitRiskMember_93" xlink:to="lab_ck0001635977_ReitRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_ReitRiskMember_94" xlink:to="lab_ck0001635977_ReitRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RelatedPartyTransactionsRiskMember_95" xlink:to="lab_ck0001635977_RelatedPartyTransactionsRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RelatedPartyTransactionsRiskMember_96" xlink:to="lab_ck0001635977_RelatedPartyTransactionsRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_97" xlink:to="lab_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_98" xlink:to="lab_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_99" xlink:to="lab_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_100" xlink:to="lab_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_101" xlink:to="lab_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_102" xlink:to="lab_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_103" xlink:to="lab_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_104" xlink:to="lab_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_105" xlink:to="lab_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_SelectionRiskMember_106" xlink:to="lab_ck0001635977_SelectionRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_SelectionRiskMember_107" xlink:to="lab_ck0001635977_SelectionRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_108" xlink:to="lab_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_109" xlink:to="lab_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_VentureCapitalInvestmentsRiskMember_110" xlink:to="lab_ck0001635977_VentureCapitalInvestmentsRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_VentureCapitalInvestmentsRiskMember_111" xlink:to="lab_ck0001635977_VentureCapitalInvestmentsRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_112" xlink:to="lab_us-gaap_ClassOfStockDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_113" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ck0001635977-20230930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <link:roleRef roleURI="http://xbrl.sec.gov/cef/role/N2" xlink:type="simple" xlink:href="https://xbrl.sec.gov/cef/2023/cef-2023.xsd#N2"/>
  <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/N2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_0"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ExampleDoesNotIncludeSalesLoadMember" xlink:label="loc_ck0001635977_ExampleDoesNotIncludeSalesLoadMember_1"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember" xlink:label="loc_ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2023Member" xlink:label="loc_ck0001635977_LoanFacility2023Member_3"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2022Member" xlink:label="loc_ck0001635977_LoanFacility2022Member_4"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2021Member" xlink:label="loc_ck0001635977_LoanFacility2021Member_5"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2020Member" xlink:label="loc_ck0001635977_LoanFacility2020Member_6"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2019Member" xlink:label="loc_ck0001635977_LoanFacility2019Member_7"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2018Member" xlink:label="loc_ck0001635977_LoanFacility2018Member_8"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2017Member" xlink:label="loc_ck0001635977_LoanFacility2017Member_9"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LoanFacility2016Member" xlink:label="loc_ck0001635977_LoanFacility2016Member_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cef/2023/cef-2023.xsd#cef_AllRisksMember" xlink:label="loc_cef_AllRisksMember_0"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_PortfolioMarketRiskMember" xlink:label="loc_ck0001635977_PortfolioMarketRiskMember_3"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember" xlink:label="loc_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_4"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_NonDiversificationRiskMember" xlink:label="loc_ck0001635977_NonDiversificationRiskMember_5"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_EquitySecuritiesRiskMember" xlink:label="loc_ck0001635977_EquitySecuritiesRiskMember_6"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ConvertibleSecuritiesRiskMember" xlink:label="loc_ck0001635977_ConvertibleSecuritiesRiskMember_7"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_SelectionRiskMember" xlink:label="loc_ck0001635977_SelectionRiskMember_8"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ConcentrationInHealthcareIndustriesMember" xlink:label="loc_ck0001635977_ConcentrationInHealthcareIndustriesMember_9"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_PharmaceuticalSectorRiskMember" xlink:label="loc_ck0001635977_PharmaceuticalSectorRiskMember_10"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_BiotechnologyIndustryRiskMember" xlink:label="loc_ck0001635977_BiotechnologyIndustryRiskMember_11"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ManagedCareSectorRiskMember" xlink:label="loc_ck0001635977_ManagedCareSectorRiskMember_12"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LifeScienceAndToolsIndustryRiskMember" xlink:label="loc_ck0001635977_LifeScienceAndToolsIndustryRiskMember_13"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareTechnologySectorRiskMember" xlink:label="loc_ck0001635977_HealthcareTechnologySectorRiskMember_14"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareServicesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareServicesSectorRiskMember_15"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareSuppliesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareSuppliesSectorRiskMember_16"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareFacilitiesSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareFacilitiesSectorRiskMember_17"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareEquipmentSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareEquipmentSectorRiskMember_18"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_HealthcareDistributorsSectorRiskMember" xlink:label="loc_ck0001635977_HealthcareDistributorsSectorRiskMember_19"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember" xlink:label="loc_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_20"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ForeignSecuritiesRiskMember" xlink:label="loc_ck0001635977_ForeignSecuritiesRiskMember_21"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ForwardContractRiskMember" xlink:label="loc_ck0001635977_ForwardContractRiskMember_22"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_DerivativesRiskMember" xlink:label="loc_ck0001635977_DerivativesRiskMember_23"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RisksAssociatedWithFundsOptionStrategyMember" xlink:label="loc_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_24"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_InterestRatesRiskMember" xlink:label="loc_ck0001635977_InterestRatesRiskMember_25"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ReitRiskMember" xlink:label="loc_ck0001635977_ReitRiskMember_26"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_CreditDefaultRiskMember" xlink:label="loc_ck0001635977_CreditDefaultRiskMember_27"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_NonInvestmentGradeSecuritiesRiskMember" xlink:label="loc_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_28"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_CounterpartyRiskMember" xlink:label="loc_ck0001635977_CounterpartyRiskMember_29"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RegulationAsCommodityPoolMember" xlink:label="loc_ck0001635977_RegulationAsCommodityPoolMember_30"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember" xlink:label="loc_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_31"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LiquidityRiskMember" xlink:label="loc_ck0001635977_LiquidityRiskMember_32"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_EquityLinkedNotesMember" xlink:label="loc_ck0001635977_EquityLinkedNotesMember_33"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_PrivateInvestmentInPublicEquityRiskMember" xlink:label="loc_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_34"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_VentureCapitalInvestmentsRiskMember" xlink:label="loc_ck0001635977_VentureCapitalInvestmentsRiskMember_35"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_ExchangeTradedFundsRiskMember" xlink:label="loc_ck0001635977_ExchangeTradedFundsRiskMember_36"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_LeverageRiskMember" xlink:label="loc_ck0001635977_LeverageRiskMember_37"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RestrictedSecuritiesAndValuationRiskMember" xlink:label="loc_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_38"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_KeyPersonnelRiskMember" xlink:label="loc_ck0001635977_KeyPersonnelRiskMember_39"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_AntiTakeoverProvisionsRiskMember" xlink:label="loc_ck0001635977_AntiTakeoverProvisionsRiskMember_40"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_RelatedPartyTransactionsRiskMember" xlink:label="loc_ck0001635977_RelatedPartyTransactionsRiskMember_41"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_GovernmentInterventionMember" xlink:label="loc_ck0001635977_GovernmentInterventionMember_42"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_MarketDisruptionAndGeopoliticalRiskMember" xlink:label="loc_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_43"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_PotentialConflictsOfInterestRiskMember" xlink:label="loc_ck0001635977_PotentialConflictsOfInterestRiskMember_44"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20230930.xsd#ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember" xlink:label="loc_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_45"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0" xlink:to="loc_ck0001635977_ExampleDoesNotIncludeSalesLoadMember_1" order="1" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0" xlink:to="loc_ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember_2" order="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0" xlink:to="loc_ck0001635977_LoanFacility2023Member_3" order="1" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0" xlink:to="loc_ck0001635977_LoanFacility2022Member_4" order="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0" xlink:to="loc_ck0001635977_LoanFacility2021Member_5" order="3" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0" xlink:to="loc_ck0001635977_LoanFacility2020Member_6" order="4" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0" xlink:to="loc_ck0001635977_LoanFacility2019Member_7" order="5" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0" xlink:to="loc_ck0001635977_LoanFacility2018Member_8" order="6" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0" xlink:to="loc_ck0001635977_LoanFacility2017Member_9" order="7" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0" xlink:to="loc_ck0001635977_LoanFacility2016Member_10" order="8" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_0" order="999" priority="1" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_PortfolioMarketRiskMember_3" order="1" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember_4" order="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_NonDiversificationRiskMember_5" order="3" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_EquitySecuritiesRiskMember_6" order="4" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_ConvertibleSecuritiesRiskMember_7" order="5" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_SelectionRiskMember_8" order="6" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_ConcentrationInHealthcareIndustriesMember_9" order="7" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_PharmaceuticalSectorRiskMember_10" order="8" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_BiotechnologyIndustryRiskMember_11" order="9" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_ManagedCareSectorRiskMember_12" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_LifeScienceAndToolsIndustryRiskMember_13" order="11" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_HealthcareTechnologySectorRiskMember_14" order="12" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_HealthcareServicesSectorRiskMember_15" order="13" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_HealthcareSuppliesSectorRiskMember_16" order="14" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_HealthcareFacilitiesSectorRiskMember_17" order="15" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_HealthcareEquipmentSectorRiskMember_18" order="16" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_HealthcareDistributorsSectorRiskMember_19" order="17" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember_20" order="18" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_ForeignSecuritiesRiskMember_21" order="19" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_ForwardContractRiskMember_22" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_DerivativesRiskMember_23" order="21" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_RisksAssociatedWithFundsOptionStrategyMember_24" order="22" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_InterestRatesRiskMember_25" order="23" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_ReitRiskMember_26" order="24" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_CreditDefaultRiskMember_27" order="25" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_NonInvestmentGradeSecuritiesRiskMember_28" order="26" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_CounterpartyRiskMember_29" order="27" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_RegulationAsCommodityPoolMember_30" order="28" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember_31" order="29" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_LiquidityRiskMember_32" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_EquityLinkedNotesMember_33" order="31" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_PrivateInvestmentInPublicEquityRiskMember_34" order="32" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_VentureCapitalInvestmentsRiskMember_35" order="33" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_ExchangeTradedFundsRiskMember_36" order="34" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_LeverageRiskMember_37" order="35" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_RestrictedSecuritiesAndValuationRiskMember_38" order="36" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_KeyPersonnelRiskMember_39" order="37" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_AntiTakeoverProvisionsRiskMember_40" order="38" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_RelatedPartyTransactionsRiskMember_41" order="39" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_GovernmentInterventionMember_42" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_MarketDisruptionAndGeopoliticalRiskMember_43" order="41" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_PotentialConflictsOfInterestRiskMember_44" order="42" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllRisksMember_0" xlink:to="loc_ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember_45" order="43" use="optional"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>j23251332_ab001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j23251332_ab001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@  @+T P$1  (1 0,1 ?_$ :(    & @,!
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MU[_T_P">_=>Z]_Z?\]^Z]U[_ -/^>_=>Z]_Z?\]^Z]U[_P!/^>_=>Z]_Z?\
M/?NO=>_]/^>_=>Z]_P"G_/?NO=>_]/\ GOW7NO?^G_/?NO=>_P#3_GOW7NO?
M^G_/?NO=>_\ 3_GOW7NO?^G_ #W[KW7O_3_GOW7NO?\ I_SW[KW7O_3_ )[]
MU[KW_I_SW[KW7O\ T_Y[]U[KW_I_SW[KW7O_ $_Y[]U[KW_I_P ]^Z]U[_T_
MY[]U[KW_ *?\]^Z]U[_T_P">_=>Z]_Z?\]^Z]U[_ -/^>_=>Z]_Z?\]^Z]U[
M_P!/^>_=>Z]_Z?\ /?NO=>_]/^>_=>Z]_P"G_/?NO=>_]/\ GOW7NO?^G_/?
MNO=>_P#3_GOW7NO?^G_/?NO=>_\ 3_GOW7NO?^G_ #W[KW7O_3_GOW7NO?\
MI_SW[KW7O_3_ )[]U[KW_I_SW[KW7O\ T_Y[]U[KW_I_SW[KW7O_ $_Y[]U[
MKW_I_P ]^Z]U[_T_Y[]U[KW_ *?\]^Z]U[_T_P">_=>Z]_Z?\]^Z]U[_ -/^
M>_=>Z]_Z?\]^Z]U[_P!/^>_=>Z]_Z?\ /?NO=>_]/^>_=>Z]_P"G_/?NO=>_
M]/\ GOW7NO?^G_/?NO=>_P#3_GOW7NO?^G_/?NO=>_\ 3_GOW7NO?^G_ #W[
MKW7O_3_GOW7NO?\ I_SW[KW7O_3_ )[]U[KW_I_SW[KW7O\ T_Y[]U[KW_I_
MSW[KW7O_ $_Y[]U[KW_I_P ]^Z]U[_T_Y[]U[KW_ *?\]^Z]U[_T_P">_=>Z
M]_Z?\]^Z]U[_ -/^>_=>Z]_Z?\]^Z]U[_P!/^>_=>Z]_Z?\ /?NO=>_]/^>_
M=>Z]_P"G_/?NO=>_]/\ GOW7NO?^G_/?NO=>_P#3_GOW7NO?^G_/?NO=>_\
M3_GOW7NO?^G_ #W[KW7O_3_GOW7NO?\ I_SW[KW7O_3_ )[]U[KW_I_SW[KW
+7O\ T_Y[]U[K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>j23251332_ac002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j23251332_ac002.jpg
M_]C_X0AK17AI9@  34T *@    @ #0$   ,    ! 1T   $!  ,    ! 1T
M  $"  ,    #    J@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    L $;  4    !    N $H  ,    !  (   $Q  (
M   A    P $R  (    4    X0$[  (    @    ]8=I  0    !   !&
M 5  "  (  @ +<;    G$  MQL   "<0061O8F4@4&AO=&]S:&]P(#(R+C4@
M*$UA8VEN=&]S:"D ,C R,SHQ,3HS," P,CHR,#HQ-0!!9&]B92!);D1E<VEG
M;B Q."XU("A-86-I;G1O<V@I       $D   !P    0P,C,QH $  P    '_
M_P  H ( !     $   ##H , !     $   ##          8! P #     0 &
M   !&@ %     0   9X!&P %     0   :8!*  #     0 "   " 0 $
M 0   :X" @ $     0  !K4         2     $   !(     ?_8_^T #$%D
M;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5
M#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  O "\# 2(  A$! Q$!_]T
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M;Z'T_P!<_P"5?U5=S]?:^BLZ7T*OI9QOV<Q^2,<U'"=3 IL#MC^H.]-_Z?\
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M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! !+     $  0$L     0 !.$))300F       .
M     #^    X0DE- _(       H  /_______P  .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #3P    8              ,,   ##    #0!A &( <@!D &X
M7P!K &\ 7P!, &\ 9P!O     0                         !
M      ##    PP                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG    PP    !29VAT;&]N9P   ,,    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ,,
M4F=H=&QO;F<   ##     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    !.$))300,      ;1     0   "\    O    D   &G
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M_M.S[3_Z4L_RXDI__]D .$))300A      !7     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    % !! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ #( ,  R #$    ! #A"24T$!@      !P (     0$
M_^$6^6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E
M9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z
M>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O
M8F4@6$U0($-O<F4@-RXP+6,P,# @-SDN9&%B86-B8BP@,C R,2\P-"\Q-"TP
M,#HS.3HT-" @(" @(" @(CX@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O
M=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX@/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L
M+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIP9&8](FAT=' Z+R]N<RYA
M9&]B92YC;VTO<&1F+S$N,R\B('AM;&YS.G!D9G@](FAT=' Z+R]N<RYA9&]B
M92YC;VTO<&1F>"\Q+C,O(B!X;6QN<SIP9&9X:60](FAT=' Z+R]W=W<N;G!E
M<RYO<F<O<&1F>"]N<R]I9"\B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIS=$5V=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E
M;G0C(B!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO
M=&]S:&]P+S$N,"\B(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@<&1F.E!R;V1U
M8V5R/2)!9&]B92!01$8@3&EB<F%R>2 Q-RXP(B!P9&8Z5')A<'!E9#TB1F%L
M<V4B('!D9G@Z1U137U!$1EA#;VYF;W)M86YC93TB4$1&+U@M,6$Z,C P,R(@
M<&1F>#I'5%-?4$1&6%9E<G-I;VX](E!$1B]8+3%A.C(P,#,B('!D9GAI9#I'
M5%-?4$1&6%9E<G-I;VX](E!$1B]8+3%A.C(P,#,B('AM<#I#<F5A=&5$871E
M/2(R,#(S+3$Q+3,P5# Q.C0T.C P+3 V.C P(B!X;7 Z0W)E871O<E1O;VP]
M(D%D;V)E($EL;'5S=')A=&]R(#(U+C0@*$UA8VEN=&]S:"DB('AM<#I-971A
M9&%T841A=&4](C(P,C,M,3$M,S!4,#(Z,C Z,34M,#8Z,# B('AM<#I-;V1I
M9GE$871E/2(R,#(S+3$Q+3,P5# R.C(P.C$U+3 V.C P(B!X;7!-33I$;V-U
M;65N=$E$/2)X;7 N9&ED.F$Y9&8V.38X+31B9C$M-&8U,2UB-6,S+6)E-S,Q
M.#9D9#!D-2(@>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#IB,C!E.3$S,"TT
M868R+30U,&8M.65D."UA8V9F.3,V.3<W-C(B('AM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#TB>&UP+F1I9#I",#(Q.#)#1D-%,C V.#$Q.# X,SDU1$(Q0D8Q
M-D(Q,B(@>&UP34TZ4F5N9&ET:6]N0VQA<W,](G!R;V]F.G!D9B(@>&UP34TZ
M5F5R<VEO;DE$/2(Q(B!P:&]T;W-H;W Z3&5G86-Y25!40T1I9V5S=#TB0D(Q
M1# T1#4P1CA$-S1%,D-&,S$V0SDR0D4V13 R-$$B('!H;W1O<VAO<#I#;VQO
M<DUO9&4](C,B('!H;W1O<VAO<#I)0T-0<F]F:6QE/2(B('!H;W1O<VAO<#I(
M:7-T;W)Y/2(R,#(S+3$Q+3,P5# Q.C0W.C,W+3 V.C P)B-X.3M&:6QE(&%B
M<F1N7VMO7TQO9V\N:G!G(&]P96YE9"8C>$$[3W!E;B8C>#D[9F%L<V4F(WA!
M.W1R=64F(WA!.R]7;W)K+V%B<F1N7VMO7TQO9V\N:G!G)B-X03LR-S<F(WA!
M.R8C>$$[4V5L96-T('!R979I;W5S(&1O8W5M96YT)B-X.3LR-C@F(WA!.R8C
M>$$[4V5L96-T('!R979I;W5S(&1O8W5M96YT)B-X.3LR-C@F(WA!.R8C>$$[
M4V5L96-T('!R979I;W5S(&1O8W5M96YT)B-X.3LR-C@F(WA!.R8C>$$[0W)O
M<"8C>$$[26UA9V4@4VEZ928C>$$[26UA9V4@4VEZ928C>#D[5VED=&@Z(#$N
M-#$W($EN8VAE<R8C>$$[5VET:"!#;VYS=')A:6X@4')O<&]R=&EO;G,F(WA!
M.TEN=&5R<&]L871I;VXZ(&%U=&]M871I8R8C>$$[)B-X03M396QE8W0@<')E
M=FEO=7,@9&]C=6UE;G0F(W@Y.S(V."8C>$$[)B-X03M396QE8W0@<')E=FEO
M=7,@9&]C=6UE;G0F(W@Y.S(V."8C>$$[)B-X03M396QE8W0@<')E=FEO=7,@
M9&]C=6UE;G0F(W@Y.S(V."8C>$$[)B-X03M396QE8W0@<')E=FEO=7,@9&]C
M=6UE;G0F(W@Y.S(V."8C>$$[)B-X03M396QE8W0@<')E=FEO=7,@9&]C=6UE
M;G0F(W@Y.S(V."8C>$$[)B-X03LR,#(S+3$Q+3,P5# Q.C4T.C4S+3 V.C P
M)B-X.3M&:6QE(&%B<F1N7VMO7TQO9V\N:G!G('-A=F5D)B-X03LB/B \9&,Z
M8W)E871O<CX@/')D9CI397$^(#QR9&8Z;&D^061O8F4@26Y$97-I9VX@,3@N
M-2 H36%C:6YT;W-H*3PO<F1F.FQI/B \+W)D9CI397$^(#PO9&,Z8W)E871O
M<CX@/&1C.FQA;F=U86=E/B \<F1F.D)A9SX@/')D9CIL:3YE;BU'0CPO<F1F
M.FQI/B \<F1F.FQI/F5N+4="/"]R9&8Z;&D^(#PO<F1F.D)A9SX@/"]D8SIL
M86YG=6%G93X@/&1C.G1I=&QE/B \<F1F.D%L=#X@/')D9CIL:2!X;6PZ;&%N
M9STB>"UD969A=6QT(CY35$$P.3(S,S,R,3$V+3 P,5]A8G)D;B!,:69E(%-C
M:65N8V5S($EN=F5S=&]R<R H2%%,*5]#;W9E<BYI;F1D/"]R9&8Z;&D^(#PO
M<F1F.D%L=#X@/"]D8SIT:71L93X@/'AM<$U-.D1E<FEV961&<F]M('-T4F5F
M.FEN<W1A;F-E240](GAM<"YI:60Z,C W9&1F-S<M8V4W8BTT9&9A+3@S.&,M
M960X.#EE,&%B,V4R(B!S=%)E9CID;V-U;65N=$E$/2)X;7 N9&ED.C(P-V1D
M9C<W+6-E-V(M-&1F82TX,SAC+65D.#@Y93!A8C-E,B(@<W12968Z;W)I9VEN
M86Q$;V-U;65N=$E$/2)X;7 N9&ED.D(P,C$X,D-&0T4R,#8X,3$X,#@S.35$
M0C%"1C$V0C$R(B!S=%)E9CIV97)S:6]N240](C$B('-T4F5F.G)E;F1I=&EO
M;D-L87-S/2)P<F]O9CIP9&8B+SX@/'AM<$U-.DAI<W1O<GD^(#QR9&8Z4V5Q
M/B \<F1F.FQI('-T179T.F%C=&EO;CTB8V]N=F5R=&5D(B!S=$5V=#IC:&%N
M9V5D/2(O(B!S=$5V=#IP87)A;65T97)S/2)F<F]M(&%P<&QI8V%T:6]N+W@M
M:6YD97-I9VX@=&\@87!P;&EC871I;VXO<&1F(B!S=$5V=#IS;V9T=V%R94%G
M96YT/2)!9&]B92!);D1E<VEG;B Q."XU("A-86-I;G1O<V@I(B!S=$5V=#IW
M:&5N/2(R,#(S+3 Y+3$T5#$T.C$Q.C,R*S Q.C P(B\^(#QR9&8Z;&D@<W1%
M=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HR
M,#=D9&8W-RUC93=B+31D9F$M.#,X8RUE9#@X.64P86(S93(B('-T179T.G=H
M96X](C(P,C,M,3 M,C94,3,Z,3,Z,30M,#4Z,# B('-T179T.G-O9G1W87)E
M06=E;G0](D%D;V)E($EL;'5S=')A=&]R(#(U+C0@*$UA8VEN=&]S:"DB('-T
M179T.F-H86YG960](B\B+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](F-O;G9E
M<G1E9"(@<W1%=G0Z<&%R86UE=&5R<STB9G)O;2!A<'!L:6-A=&EO;B]P;W-T
M<V-R:7!T('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YI;&QU<W1R871O<B(O
M/B \<F1F.FQI('-T179T.F%C=&EO;CTB<V%V960B('-T179T.FEN<W1A;F-E
M240](GAM<"YI:60Z83ED9C8Y-C@M-&)F,2TT9C4Q+6(U8S,M8F4W,S$X-F1D
M,&0U(B!S=$5V=#IW:&5N/2(R,#(S+3$Q+3,P5# Q.C0T+3 V.C P(B!S=$5V
M=#IS;V9T=V%R94%G96YT/2)!9&]B92!);&QU<W1R871O<B R-2XT("A-86-I
M;G1O<V@I(B!S=$5V=#IC:&%N9V5D/2(O(B\^(#QR9&8Z;&D@<W1%=G0Z86-T
M:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#IB,C!E.3$S
M,"TT868R+30U,&8M.65D."UA8V9F.3,V.3<W-C(B('-T179T.G=H96X](C(P
M,C,M,3$M,S!4,#(Z,C Z,34M,#8Z,# B('-T179T.G-O9G1W87)E06=E;G0]
M(D%D;V)E(%!H;W1O<VAO<" R,BXU("A-86-I;G1O<V@I(B!S=$5V=#IC:&%N
M9V5D/2(O(B\^(#PO<F1F.E-E<3X@/"]X;7!-33I(:7-T;W)Y/B \+W)D9CI$
M97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" \/WAP86-K970@96YD/2)W(C\^_^X #D%D;V)E &1
M     ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$! @(! @(#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,#_\  $0@ PP## P$1  (1 0,1 ?_=  0 &?_$ :(    & @,!
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M#&G(-2S1Y+^-O(_NO=$[_P"$]?R/_EQ?'G^8/L/>GS<ZJR0@?.5[=*]S[B[
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M_K]^Z]U__]7?X]^Z]T!WR%^2_0'Q.ZWR';_R3[?V%TIUKC:NEQT^[>P=P46
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M &:2W\,_AWF_V6W_ $9_[]K^^_E\'\6_R_[7Q?Y/[]U[K__6W^/?NO=?.O\
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M9-U#;'^C63HL8^ADWC%\>S2LN[%^4K1QQ?P]IF6I\!(Q9!^^)]U[JG?XW/\
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M_P"##$";[KR_M>#5J]-_?NO=?$\^5I_EEM\\<RWQ?7Y0+\ 3ON+^)KDVV/\
MZ9#MP9BL_O,>H#N!1CTVR]+H_NR-U*<NM)H_BEZCR>_=>ZN&_G^S?R39NGO@
MR/Y?O^D)N[XOBSU+'C&VH=J?Z/$Z/5\H<#%\FEJ!_>,_*1:MJXU9HS]T$)_B
MEX?X7;W7NEK_ "ZY?Y!Z?R6OG#'\G6[X_P!F'DR72W^E:,-U\O<,N^4R6YVZ
M3_V2DU*M@1M%<G_%_P"\G\7#52T_W'\6_P B.*O[KW1 ?Y!C?RVT_F3]/O\
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M@J9LJL"&?"*N/BKECFEDCI_=>Z1/\K3^1G\UOYFNR>].TNH<-7;%ZYZ\ZN[
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M% ^;A[BQN5W#5X3:6ZNOZS'-4PY[%[PDA62G 9:B)W,51'#.DD:>Z]UL8?\
M0-Y_,Y_T#?W$_P!'E;_>C_AI;R_PO^]FTOX!_IY_X<D_V8__ &4G[S^\.O\
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MOAGJ4E]U[H4?Y!'RF^27QV_FD_$'$=#[IW6N+[I[TZ\ZC[8Z\Q]7DZS;&_\
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M_O[O[L_8:_V_MO?NO='-^3'^A7_H'(^-GWO_  QO_HO_ -->Y?X%_"/]G_\
M]'_W/\/S/\-_T+?P#_G,+_9NOXAJ_OC_ 'C_ ,D_AGF^_P#\BT>_=>Z"#_A+
MK_HI_OI\H/[D?\-)_P!Y_P#97.W?[P_WK_V=#_9@OX?HQ?\ #O[U_P"S"?\
M&(/]E5UZ_P"_G]U_]R?VOV?WWH\?OW7NJ/.J/]EK_P!GYH_LO^&.O#_?V/\
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*_7]_OW[]U[K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>j23251332_ac003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j23251332_ac003.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[ $91'5C:WD  0 $    9  " (     ^
M $, ;P!P 'D <@!I &< : !T "@ 0P I #( ,  P #  +0 R #  ,  V "
M00!D &\ 8@!E "  4P!Y ', = !E &T <P L "  20!N &, +@ @ $$ ; !L
M "  4@!I &< : !T ', ( !2 &4 <P!E '( =@!E &0 +@ # (     ^ $,
M;P!P 'D <@!I &< : !T "@ 0P I #( ,  P #  +0 R #  ,  V "  00!D
M &\ 8@!E "  4P!Y ', = !E &T <P L "  20!N &, +@ @ $$ ; !L "
M4@!I &< : !T ', ( !2 &4 <P!E '( =@!E &0 +@  _^X #D%D;V)E &3
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MG(/]+$C\@_\ %/?NO=/%+2'@#@G\"_/T)N?S>_O?6NE9C<<3(BLI8GBP4F[
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M 'CW[KW39DE)1N"K6 Y'U<$:!8$$J=/%P!_KV/OW7NBZ]A@>"I*DD!9#J 4
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M %%^+#CC\>]U_;UJG2"RFW5L3X5TW+<*;H1>U]7((MR?K[M7K1Z#'+X!0#Z
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M5?\ I[]U[I/U$P+<FY&KZD,=)L +$BY_UA_O/OW6QTV2D-]/J+'CEK:>1^>
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MPZ,'MJFC.B]M8N%TC6VFY !]&AQ=C;U&W/'O?5.ARP5#':, <V_590S$\*0
M7LPMQ8_3W[KW0TX''(-&D)RH4$7L;:BQ_4#=0?\ 6M:WY]UZWT-.$HDM&0 #
M9+ ?D7M?4%L+?[V/=3U8="9CZ)- NO/U;CD"Y(_'!%^+^Z]6Z44=#&>1IO\
M[U>][7&JY'O5>O=<9J&,C]*V_''T!_P(LOJ_UO?NO=,U10+SZ01SQ87_ !QS
M>P-S_MO>^O=)3(4",&XN1_6P.GC^EC_OO\/>^M=!]E:%0&('^L/[5C?^G /^
ML?KS[L.M=!7G*0$'TK8*XY L!R-/UU<L+?Z_YM[V.JGH"-UTQ$<IMS^K2;CZ
MWY! /TOQ?Z7_  ;>[=:Z*;O:!5$UPJA7OI 6ZEK#@$:N%-^!S<_X^]=6'11M
MY4Y8N  ?J+II.B[%3S_74W YN/=3U;H!LC"=9^A.KU'@W%N+_P")M]?\.?=>
MM])J:$V/XY7D@W]*K_:Y)N>/]<G@?0:Z]TW2H38%19A?_'ZDCZ7/]FW'U]^Z
MWTSU41NP/&H@<BYY'"V )-@/Z?GW[KPZ;606#<C2./[) )^BL.?H/]YX/]?=
M>ZAR"W&KD <:N?J+:@2;?7Z\_P#$>_=>ZALU@5-K\FQ!_)_M7OJ//^-C[]UO
MK() P)'^\:;W)_V N&/^V_/OW7NLZRJ.+M86_'T.DD\$CZ,?]C_O'OW6NLJR
M"[6N21_06Y( ^O%@?H/Q[]U[J2C"W)%RI%@2001R";D<G_6'_$^Z]U(6Q//'
MJ/UO8GFX 'TN/ZG_ %O?NO=95^B_4\VMQ<!@!=20 OZ0?I[]U[Y].$ #6N
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M^A;Q+ Z?]8<_6_T_PO\ 3W4];''I?T+< ?4BW/U^@/!X_'O1X=>Z4T!)5?\
M$\?[;Z_['W4<>MCCU-M;\_3\<\\_[$#Z^[=6ZY<\&Q_U_P#'_#W[KW75O]?D
M\?[:X L/?NO=>86!!_H0?K<?C^G/OW7NFBJ%U-O]]^/]A]?=>J=(W**?6?\
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MM #KMS<M_K EB3=;$D<\^[=5Z"S.P:K\#^T2#I-CS_M-S8FW'/\ @?=AU4]
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M9B 1<$VL?]>WXM[MU?K,RWN;G@V*V&D<6)4?@V(]^Z]UT  UK'TG\GZG3]+
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M92P8$DFS+:_)YX/OW7NNR+ABOU'UO] UP38CZ?X_ZW^!]^IU[K&4.GD7-O\
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MI)/!NIM_MO\ 6YUU[I/5]W##]1+7)]/UN.5L0ZCZ+^!8?[;W6^@FW#$#J '
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M5+:A>YNK6_/^OS86M[]U[KRH !]#:_U4$V/^-_H"??NO=<) =  !XL3_ $
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M@^RN:'-G_+7)*V^I N0+7-K?D>]TZT:=!?F<U&-0+J#9OK>]]+<?X\@?TO\
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M^/NO=1:L#0U[@'4#ZKJ?S=AZC?0#8_U!M:]O?NO= AOD?Y/46LMPY*@BQ])
M:S7864<C^@Y_-M=;'5:W;Z%9I;_B3CC_ %.H,%  L;_FY^H_URVW3@Z+P"+B
MP^AX_5>W MS^1[UU:O2MVU_P,A%CI:1">2#:X^K!0."??NM='NZUOXZ,*MR
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M:Z;JS-C0Q5@;W(8D$?I^C6^HCX/^'XN;6]U[I Y3-"SV86  )-EU L"38#@
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M<V!*FWU^@Y_WKPZUT.6"V\LT41%B38_@L6X).GZZSJ/!X^O^PMUHGH0J';8
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MZJ>CS["8+'&6N;>,C\ BR_3Z7 (Y/^/(^GNW5.C8[58&.$'\V+6N2I+ BRD
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MO6^@WR!8EK:B";:3P/TA3]; LUO]:W'O77NDZ]R^KU:F)%[BX(-KDMR;6_V
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M^Z]T".X:@J)-(N 6L&90P_421:_)7^IO;_;>]=;Z+INVN8"0:_IJU:M.DDW
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MU'\* ?\ 6_WCW[KW3C3OH(4"WUOQ<>HD"PO8EB?Q_P 4/OW6NE'#/& K*%N
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M_P")]V'IUKHJ/9,@-/4?3G5:]K$>K4#?CBW^-K>[KUH]$HB4?WBK_P!-OO\
M$+:W]KQ9L7M^&]N_YNJ=$!\QO<'ZV7U>A;#ZK8\6 O>_%K?4^_=>ZAU$Q(<$
M%2UO2&O=3ZKZ!=E%U!_P_P!O[]U[I,5S&S?UO<\>G@R:25TV6^D?D7/T-R??
MNM](^N1B6^K7!OI)]-BRWO<7(8"_Y%Q_L?=;Z#_*I( _T)):X*OJ)^H]/J+$
M@?FW!/YN/>NM]!AEU8ZK7-BOUNLAL& YN""?Z_CZ\>Z]>Z#3*1E2_JN;D'FP
MO?66!MP2I_P^O'XMKK?2#K8O4WT(!M] .2;$ FYTB_U_!]ZZW_AZ3LL1N>0!
MP;$7MR1<$M8$D6]^Z]U$:-FL3?EEY-P/S?4.2#_3\FWOW7AUC*?4\<@ #4 M
M[7%C<Z22>+^_=;ZP/&?R23;C@_EA_B#]??NM=1C$2>+DWN+<$W YN+F_^\^_
M=;ZX&$FY)'/-N;\_4VN""2;_ /%>/?NO>?7'QVL+V%[FUK@  @_0F]_I];>_
M=:ZX$6O8BX/'^(M]./K<'@_\:]^ZWUX<?4\<_6Q"BUSZ;'E?]Z_UO?NO=9$M
M<@F]N+#^R!=?I8<W'Y/OW7OLZGQ-:_X;\V(NI!L1?BX(O<_@"WOW7N/3G3D<
M #Z6X%B6XL+?G4>/Z<_U]^ZUTH*5@+'4#8 DWY^I)N1P1_L?]?W[K72OQU2%
MO9C<L2>-)!(#^JQ*D*+?X#_#WOKW0D8>N.I#=3PI-].BQLH;^MOZ<7_Q]['6
MNA=P5=9@;K:Q77>X+#Z@7_M CD D#_8>]BO7NA?PM:2J D@BP-U<K8E7^@-@
M6O\ 3^MN3[MUKH5,/6,?'ZC]003R?]?4S$\'Z$\_GCW[JO0K8BL(TVMP>1J4
M7*W&DEB%)#(#^ ?KQ[WUKH2L55,;"]SJ%[_VM7TX)!N+?T%_]N/?NO="-C:@
MD+ZOPH;@L";7YTFX8_[<_3WKKW2HBD) !-S8L$XU6'Z@% 8$&PY'TO\ X^]=
M;ZXREBMM1-Q^EN?HJWMR006_P/'Y]^Z]TE,A]'%[<$W')NOJ'T)+7_P)X_'O
M?6N@^RS>ASJYOZ>&/()"V(0FXXX'^%A]?>^O=!!GF'K)N6(]2L#=0H(4%@!;
M3;BW'].>#[KW0';A5OW>#9C< DMIU6]);0A8*%'^]?X^]=;'1>MTT[E20--[
MFP%KCGBX4DLP'^'T_P!A[J>K] %GJ5]3FQU:C;A@OY%S>UK$W%N1:W^'NIZW
MT&U="RL^JXY)!'YMZB.6M;_'Z+]/>NO=,$P Y^G%@0+#TIZ;@K;Z@?4\^_=;
MZ;) "/2?J;?X@+?FW%K_ .\#W[KW45@ 22">00;?4<>H'\?\3?W[KW6$_3Z$
M_D 'B_"_@  \D>]=;ZCE+F]SZA]?PMQ<<\6 (/\ KCWOK77#0P-K#GFUK6^I
MM]+?0?[;W[KW7()8W'^) ^O] /R+<+^;V_I]??NM]9Q&!SS<_@G^BF_%N;D_
MZ_OW6N/4E5(4W  ^IO8@V('UO9O5];GD>_=;ZDA;\?X7/^N.1<BWJ-_Q_K^_
M=:ZSJG-A]+ _6UK"_P"/4>5(-K'G_#W[KW4A$'%K7^I+"YYU?0 '@Z2/?NO=
M2D6Q%_KZ 2P-K@ M<7M?21<"XM_A[]UKIQADL02#>Y OZ01?_'DD6 _UO]Y]
MU[I^I*C2%YMJ_KSP;L+DE1?GFU^/?NO=/L$ZD DA#Q<"0@FXM^KD+I^G-_\
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M;,"W]JQ)52-(%V]/X-[V]^'7NCY;+73CZ<<7T *U_I9%TF]R"  /I:UK_P"
MMU3H3(PH 5B;:0!;2PTJ1>X 6QXM];<_6_UWUKJ5&27X-R 39;J2&'XO?GZ$
M@WO?W[KW7=2248'C5:_)!N"66W%P2 /\;'_;^Z]T$^\E)I)BP+:0S'E=)U$@
M<A5*'U?FW!M>WO76QQZKA[F2TDI L-36;BP//]D @#ZV -[&WNAZN.BOA22P
M/I''%[V)X&D@L5LP(_V)_P!C7J_'I4;=L:N,M]"RD@'Z68$\G41:UC:W'^V'
MNM'H]75&N2"G0MJL03:VJWI!*M=2?IJ)!/TM_KN#JIZ/7L74J1_T!^G)-["Y
MTFVOQL2!<"]_Q[MU3HU^TVM'%:_"K<\@VX%FY52+<_C^I]Z/7NA]PANJCZB_
M("J/P/Q<@A@0?]?W7K8Z&[;<EE6Q_I^ +D#Z_4V_K_O/^M0]7Z&7$R$Z/R;+
M]?QS;GCW4]>Z$_%-].?]?BX_I_L#S_L?=3U[I<43FP_V'_$#G_8^_#K9X]*:
MGN1_L%/^PYX_U_\ BGNAX]>Z<0;B_P#Q/T]ZZ]UR]^Z]U[W[KW4:H/I/UX'^
M]\#_ 'OW[KW26R(_40/P?^)_WOVYY=>''H+]PQW23CZAA>W]/Z?3F_O8]>M=
M%4[%I-=-4<#U:_Q]2 P/^'-_=UZT>'1)XL:?[PUYXYK\3_9]=@F:%M6K5JYO
M:_\ A?VYU3Y=$5%&&'I ''X]1LI+<A;JIU WTWL3^?=NO=<6I ?\+@<?T<E;
MKZB%#?2WX/\ L#[]U[J#/1WO<<$7 6YU>K4#<%;J-(()/TL;<>]=>Z3%?1+I
M8!;W6SWU$Z/U D\*H*GZ6_P//OW6QTA\E0GZ%$N"1Q9;D:N"?KJU<7O>Y!]^
MZ]T'.5QHLZVL"R@6 O;D6%AS=0.#;WKJW0<93&?K(6S&^H ,1Z6 !L5X7U#\
M_@>ZTZ]T'=?CAR0I!L0/PHXO:X7U&_\ 4"XX//O5//K?2/K*,#657CZ74 :;
M !C=Y ;DGFPY]^Z]TGJBG.HA;@@<W'T N3<ZB+%;WM_O7O77NH#16)%OTC\?
MX^K1P!:__&_?NM]8WCM_CS^#^193:PMZ6-SR;>_=>ZC2Q_2X('UXM<D 7(N;
M@V-_R1_3W[KW#J X)OP.!]";+RS,+7'&K5_AR;?CW[K?GUBM<#\@@V8_X<>H
MD _3\GZ'W[KW45T^@(O8\WN=5E)L!P?7;\^_=:ZC:;$7N+VM<_UY_!Y/I_ Y
M_P!X]^Z]7KP N#;G\\$V_3R ;$FY^@^O]/?NO=2XEX(/TY'I%A];G5SP>/Z>
M_=;^73M!'].+ @ZK&Y/!O:X'Y!_U_P#>O=:Z>:6( _0*?K;@@<BP%E-P;VOQ
M8_3W[KW2NQT!.@VNU])N?23<7']+D*#^0?\ 6 !WUKH3,+2"Z$H5OP% M=B1
MJM8/8D_FQ%_=J>G6NAHP..9K>DDBY(L?JUB%-[&]SQ:XY^I^GO=.O=#1@\8]
MHSH8V L-)N#8<:@&47+<7M<_X^]]5Z%K#8QCX[J+\>D6.KDAR7"CD<_0$?X^
M]]5Z%?"XI[1GQLUP OI8\6#WN+G60W(L+#Z?T]^Z]T*F(Q$EE'C8CTDV7TK>
MZCC38B_^%O\ 8>]=>Z$F@P\I53X[!0"?]?3H#:K:^0?^(_K[UUNG3\F(DL/V
MC^2"1_J?H2 /J%/Y%^/]8'W6^L$^*EO?0WI&HVO_ $N;#BYY^O\ OA[KQZ35
M;BY?4H0DL+_CU6%R5N/K]/H!S_A[WCK72#R>)D-]49(0V_)O;ZW 4$@M^?Z^
M_=:Z#?*X9V+'1S^/3;E5]18$+>Q''YY_H.-]>Z#++X5B\@,=^#SH]1]1LWK
M!O?C_C7.NM]!9G,0;,!'R;AN"&+'\^NRV 6XM86 /OW6QT ^ZL05$MH1>P)'
M^TJ3;5<?IXX'TM]?H/>CUL=%RW%1F-I38CDD?3BRA02;7]-C]?J+?[&G5N@P
MJX3=_P"@LI-OJ2M[FZ\@6L?ZCZ7^OO77NF:2(JQ!4#DJ>.!8V_UC8K8 ?C^O
MT]^ZWU%>,6XL.+@7+\-8FQ^O&KZ?4>_=>ZA^(WM8VX!%R!:U@MS86!'^PO\
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MUL #_K7^GNO=30Y 'JNEOIS] HM]5 -E)L;_ /%?>^O=9AROX-SQ?CZ!M7T
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MWX(9A?\ J!R";6/UY)(%CS]>/=AUKH1\>MU4:2OZ20UB+%3RMM7/ %^0;W_
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M]??NO=.$-."!8@D?0'^I/T'Z?I_6PX_UK^_=>Z=(J$7X!MR;D FQU >JZLI
MO^1;W[KW4T4-_J+ @"]K76_/UO9B;7-_SS]/>^O=8WH[B_\ 0$-]/^#?@?32
MUN>/\/?NO=8/M;$DBY_KIY)%EMJL"!8?U/%N+?3W7NO"-N#>[,?RK _4/?AN
M.>+$GT_GW[KW64Q,O)) ^IN6+ W.H'22=7]#?Z>_=>ZQ,K79C8\6Y'TMR+_1
MK$FWX'^'OW7NO7TZ+6%KFS_7EKCZ<L?]\??NO=98I%!4@>H&P(YN-7/!()XY
MX-[V^OOW7NE)CY@-()^@7@AK<DCD(;@#G](YMP+>]]>Z=GFLH(<>H7(O_3\
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M:F=FB;4ZV(:+'E"O/'(_U_S[]4=:^74ZMZR[!PL3R9;8^\,<H)9VK]N9NC1
M!^H&>DC54%S?\_U/]?=:Z3E10U-$^BNI:JED*A@M9334S,C %2RRK -) N.
M+'CBUM]>ZQH@L+W(OIY56)))/)92../J!<\>_=>ZX^$!KMI?U"P0N+VU'D\_
M73_3\W_U_=>ZZ5!=6-@/^0ASJOQ]2&( / OQ_7W[K?6;0+6^OZ3R#I.G0I%C
M<DA6OR0 ??NM5Z9LA$A# @,"J,"5YLI"BVH6;FUC_M[@D#W6^@CW"ED?]-OP
M+E;7&KBY)Y!N"+W!_//O76^F#;H09*,$_P"[..+D+>,7T^H?0< \&]C]?>AU
M[H\.S&5:" DV]/Y :PMI O8Z@#R/H?Q:WNW5#T(BLH4CU@@FRH&OJ6S6 L ?
M2>2+7%K6_&^M=<(C;5:W]H:0;\*P']KA3P/K_7W[KW669B8V.I"!=E(!/J6P
MUV< Z=-[D_ZW//OW7N@LW:2::8_I.@CBZDM;ZD+?AB;?0?7CWKK?5>O<8N9E
M  !)-OZ"QXN+"S?['Z<<<^Z-TX.BMA3J8@!2Q-N/R3<@&PO_ ('CW7K9STI,
M&K"JC9?IK0\*WU^G ]/)O]!;Z>_=>/1QNLW"O"2?5];$$D6;ZF]A9M-KCZG^
MA]W'53U87U].LE/"K6UH1;4""1R5("\*H'Y_V'X]VZH>C6[90A(CP+J!Z25%
M_P"GJX)8_P!;B_T_K[]U[H=L(!Z18<\'@&UK'ZBP4 _2_P"/\/=3U;/Y]##@
M?[)!)!_UR/I?\\<?F_X_K[H>K=#-A;V3^OI!O^2/Z?7_ 'OCW4]>Z%/$_5+?
MFW-_IR"">?K[UY=>Z7]#^/I?D_C\+_O7O0ZV>E32\Z;W^A_P_'_%?=6X]>Z<
MT'U/Y^GNO7NN?OW7NN_?NO=8)1Q^.?K<7^GOW7ND[6B]_K]#^/K?_B![N.'7
MND#F8[HW%P01]/\ B1;WL=>/'H ]XTQ:*7C^OTO;Z'_>;_[;W<=:Z++'C3_&
MJLZ/^4O''38VX7*'@Z;$$&]K_P"Q]W\NJ^?5;\5.J@, HNRC5<6-[$#2^DD,
M2/\ >?S[<ZIUS>!/'>Q=C=;W,8MI720&&@%@;<6M8?GZ>Z]TV54"A6LH!]%^
M%7Z EAI TEUM]";@^_=>Z1M=$J 7"@M87N!<#D@GT_7^GU_UB/>NM](2NB6S
MA0#S;@*/P=+#TV*@J?P!]?Z'W[KW2*R$0LQ4+92UKVMP% L&'-N!^/\ $6O[
M]UOI#Y*)?5^1<H>/H" I+&0E@.3]+FPM8\>]'K?0:Y. ,SDL!8FY8 <*""ME
MNWU6YXOQ]/K[U]G6^@^RL096(Y4\Z@6%[$A2=5_U?2Y'X-OS[UUOI"5=.?*S
M%3R$'/T86+<  +<CG\C_ 'CWKKW32T0!(%M)4_D'^R;, =+6_P!A8_7\CW[K
MW4*2+^@O]%N01KN#P!PQ_7^/K_L1[UU[IOEC-_U'@&PX/ YL2>5L?K[]U[IM
MFCM<7T^FPMK_ *V/(;U$6'^]>_=;ZA%;'\'@!;<$6#6_(M>W/^\^_=>ZQ.@L
M3>X+ $,>>>0W-C<'ZWXN/Z^_=;^749HQJ!!_)-[ZOU'@6O;Z?6_]??NM9ZZ6
M,^DVOP; VXXM^2+<_P"\>_=>Z=((P#]3]3>Y-_K87)'T(^H/OW7NG^EC%@3_
M +'BUE4W-[6+ _[#B]OR??NM=*>BAL1=>>!8 &_JY'J %R/Z7N>/\?>^O="#
MA*?48R5NWI^IOPI)+ E=-KC\'C\?3WL=:Z'C;%,K-&Q4$V X87(#*>--B2VF
MX''''!]VZ]T8O;-$#I)3Z$@@Z@;LH8$W-VOJ)XXX-OI[WU3HP.W**,JG _L\
M7TD:K<W#+'<7XY_WGWOK70TX7'+>.Q%^%/ X;40 2P]0Y_P_I_3WH]>Z%K#8
MY%"@*H 6X4!22/JITWX /^]?7WH];IT*>'H0--U]-P!;E186/T/ %_\ 7]UZ
MMT(E#11A4L.#P.+"_-[$\BWY_'NO5NGD42&Y*C\"UCQ]!<'Z!?S_ *_OW7NH
M=10H!]+?UYY%P+$?T!_P]^Z]TEJZB6Y.@7-_H!;Z7(L;\V'/]?>^M4Z0F3HT
MTL;<>JW%M0N+6!^O)(Y'_$'WOK70<9>D50UE'Y -KV7U&P XO<?C_8_CW8=5
M/05YJGC)EMI(]7%@-)M8:@JF]K$6][ZUT".Z- 206-SZB6+<"Q+7NU@Y"W^@
ML.?]??7NBQ[P.H2_4-Q>]]5PW*@%EY-@/P;<#Z^]=6'14-V*GED O:Q4>M6)
M(#@E38ZM 8WYL3S[J?EU;H'ZZ-"7(4<<DDB[ 7(LA;4R_2_^O_MJ];Z8Y8@6
M/+$< D%0HOJL!;@W3^G!^GOW7NFZ6-?H#QZN;6'U-R +FX)/].1[UU[J(R@W
MYMJ!(M?G5^5'X(O]/\?\??NO=1W5;GG@$W-QQ?D?XCD7^A_K_3W[KW6'3<$<
MV/YU"XXYX!)(U?X?3W[K?73)<\'BP])N;V^FF_X-K?@DW^G/OW7NNBG N; B
MYM?G_&QL?K_@??NM=<E4AEL;@?4\\"X'%K<$_0?3GW[K?4N)0O\ 9MP/]BMK
M"Y T\V-QR/\ >/?NO=.<,8U6/T-A^JX) M^H@ DV'(X^G^!]^ZUT]TT/()M<
M\V7BPTD#Z?7\'ZV(_KS;?7NGVGI@=)L!8M]/Z$!O2;6U:;<#D6M[]U[IU6B!
MXMI8@BRD,%(]0!&K58#^M_Z<\^_=>ZX24MV-R2#JN/HQ-FO:]VOS;\BWT-OK
MOKW33-2^-QQQ<_EOT@@V&D?55_'U_K^/>NO=85IKV 'Y91;BUP+<&P#V)/%_
M]AS[]U[J8*+4%N@('U^@^@U64L""5U<CZ 'G\GWOKW4.:D"#T_6VD$G_ (*2
M2>=9L#_6P/TO]==>Z;IZ=E-AJ%[ >G^R;D<@D#2.;'FY]^Z]U@4F][GZ#GEB
M!^K6?\+_ $_XGGWKKW4^GF,;*>186_I^054\"UOZ?U][Z]TZ+5!E'*_T7CD$
M#U$ D:0H(O\ T']/?NO=0WJ-)N;$@DD"Q*"Q!U#\#4H!MRO^M[]U[J')+J(L
M0&M<'F]EYN6-_I8_[U]/?NO=+W8.4--DX#?^U;TJ!]=*G5<*NEB3_7_>C[V.
MM=6R=(9ORTM+&7U,%B5;6:ZL;AB %TVU<\"WT^ON_5#QZ._BJM6A0:A].6"E
M002+\&_''%_S_C[UUL=/+R:E)OR#<FW%@0;"WYLHM^/>NO=)^O:X8*2HYYXX
MU* 1<'Z"W^-O]Y][Z]_AZ"[<!!!X*_[3:]N2&(-[Z1<\GZ6_I:^^J]%)[4@#
MTL_U(,<@-M7JU!AJ!(^I*_ZP'U_I[]UL=5&=OT?CKJD *"LLFJP L;H#;D<'
M\6_J+V^GML\>G!T74$:R#8$$@6X_%OS;ZFY^@'O75NGNB<@@@#Z@@LPN!:W(
M+"_UY]^Z]3I;X]M3+^"5-@3_ &B!_6YN?]C:_P#MO=5Z'KJ3K7>W:VZ,=L_8
M. K,_G<@R"*EID8K#"71355<M_'3TT7]MV( ^GUL/>QU[K97^*/\EK;<.)QN
MZOD)G,AE*^58JEMLXFJ;'XB)2BOXZB?QC(5;DL02LD26X"GZFADI@=;"UR>K
M>MG=!]!],T<-#L#KC:5+)1HD<9&.HTJI#$@0&6L%.\\LC!>7?4Q)N3S[;+,>
M)ZW0#/0DP[R@@ID2#"8RAFM9Z:-(F2(AK69T10]O\ /?J=>KU!DW0M2S+/C<
M9*"#<M112* PL;HU]2\\_3W[2>O5]>@]W+M+KS><$^-W9LC;]?25",ACJ<;2
M5-!*C:E-J:IBFI .3P4_V'O8)' ]>P>/1+.ROY;/0&Z_+5[<Q61VC7S:I%7:
M.;2CC>1E;2JXZOI<OB:>,$C4L-/%_A;W<2'JI4=4W?(;XI=H]!YJNER.W<MD
M=C*R/CMV0QI74H@D7QLF6>BBC..E2<%5>:&%)0%*$DD!T,&X<>JD$=%:292
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MW3KA)'P;7-K?[S^?];WHCK1'3%5PGD?['^GUN/Z?B_T][4^76ND/E*>ZN/\
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MGWL=:Z>8O4H9M=K6+*%# D!?J%8@-;_C0]^Z]UF=E(T :B2!9$)))O8*0?\
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MTS5! +7_ -B.?JUK:?KR?S^;6_QO[K=.H'XO_:^AY/TM8V '(TK[]UX]<6)
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M:]S_ %/%M1#$B]OI_O'O76^G,S>G]1_U1_/Y%SS_ ,;]ZZWTTU50>?K8@?\
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MR21=ENI-R0S?X#Z_7W[KW2DI+A5M8FXL2K-P"%'%G!N+V_U^?>^O=/\ 3^D
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ML&_UC^/>NM]1:N<%;6L"7 )L?T^KZ$V(&DCDV][SU[I 9J2ZM]23=;W/)_M
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M$#W?JIZ$4&ZW)"^DL+ZN6N+D<'GFP_'-_KQ[WUKKH&\EO21<!@#9K,001J
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MD'D?T]^ZWTGJV?TM=N ">&!6VGFYMS]?I_A^+>]CK72(R=2VE^?ZWY)OQR;
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M(L #8'3R;_[#VIZ9Z,/MTW""_'&D KS:_-P+_P"]D^Z'JW0Q80BZW-_Z#Z
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M:W ]^Z]U"7\@GD$:;W!T_P!.+DGCW[KW#KCJN>+WYN"X;D@K<66UM(YM^/\
M8>_=>Z[6_P"+$$V%[<WY_43R0!86M<_GW[KW6=-+?GZ_6UC8<CU?I 'T_K[]
MU[IXIM)46M_:N"+7/!M;@#U#FWT/^O[]U[CT_4Q!TBQL;WOI;Z6-['0O]?\
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M^H 7X_Q]^Z]_AZ\K<&_^P!:S$<#ZD@B_Y_K_ +;W[KW7)0. ?Z'^C W*VO\
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M3[.B%[RV1E=I9":GKZ&HIK2D*)HRMT.JS*63ZW'U_'^MS[H13JU>DY1FS*2
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M*=,LTB?J"Z;<'_8VM]0.?>P.M=<EJ4=5\FA@#87M?_>/Z^_4/EU[J3IB8+R
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M#Z\_ZK_??[[\^]#CU3I#Y2Y#_P"QN?\ $^[>?7O+I!*G[LW'/FI3_P FU?\
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MZJ>AAQ,EHU4'2#]+"_'X_M$G4MQ;^@_/O?6NE[CYA>,?0MRPOJ])L+DZKN
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M[L#NB7M/8TM6<SCZE\G4TRM46F,$GF CT@A-03\<$GVZK _;U0X^SH??BO\
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MZ\L;L "6"JR^FQ >(JSV4\C\?ZPM[M7K6D]#YLSLZGS*@QU:@$K8.RMI&E=
M8ZK@_CD?G\>]]5Z-CL^7%[TPU9@,E!%64U?320ZV59$5OT$@L>"I!_WU[5(I
MD=6&>A]ZJ[JQG7.R:K8FZ*ZG@R.V*MZ2CIS*AGJ\23$*654)5GO&^G_&WNC+
M4U'6PU!0]49_/['XN#Y(5&X\0(UIMW8JCRDOC10IGC?PEVTE0SO#H+&_X_P]
M[X<>M]!SM"3]J%B+%KF_TN U](%V ]'];$?C_&_6CT-6-J;(@!MR%M>U]5B
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M<=5UTLRN\<Y2*ENWCX M8J-1Y^G-[#VX0>O*0/MZ+2N.DHF0."&7]0%U]0/
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M-BME_I_QKW7NIB)P>.6))! )(M;5].3_ (<W ]^Z]U+51;^O];*1?^U91?\
MU5OI]??NM=94(47N/4%MZA<@7])MZ> /P?I^/Z>Z]UE/T.G\L>1]?H./QS?_
M (BQM[]U[K [@$W"\E>+BY-@;_4%0M_S_P :]^Z]U#D86]2FXXN/Z>DBY4,/
MQ;_&_)/'OW7NFZ7BS<_[$GG1S^HCBQ _I[]UOIGG )-KG@_GZ7X%N>03R/\
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MU 6-Q^?]C[]U[I#92KL&+-96N""P-C:P ;ZM8#Z?X^_=:Z"S-U=VE4/_ &"
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MKK4;\"]B?Q_0\VL3QJ'X^OOW7NN2O_0FX)/T')XT\$_47_)]^ZUUEC87_!Y
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MA:W/Y^MB+VO9K_6PY]^ZWUR5[FXO?D\?D$ FUR">?]YM]??NO=9D<W)M>]B
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MI_-S]/H/S?C\_3W[KW45A:Y^@^K<V!%B!8<D'TBWTY]^Z]_@ZX6^EB..!<7
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MO[L>/7APZ+[Y+@"Y///_  4ISZA:]FN/>NM]8V8&X5@;'_#3:U[EA:WI:_\
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M;GZCU:5 >U_58J0+6^G'^Q]ZZWT>GX3.]1W3LV_D$:;6[ +%&(_YAN</(%)
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MUS;U"Q4!0%U V9C]2%-_\;7]Z/7N@WS^H(Z\7!^G^/(L?J01IYL;#_>]=;Z
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MS^&8R%5*@V+V'! )_I<^W1UHC'1C*GL.NSV$-?41O%3Q1$U$TER\K%-3VO\
M75IM_47'^PWU3HG6U-ZY+?G;M50!Y$I<=7K$L-V3P11R*1&4#>D6%R#<:OZ^
M]5J>K$4'5_73E.#LJ@4J1J1?P;D!%!^O-[?UYM[;;CU8<.AQW!N:#I[H?L/?
M<+4])G]Q1S;>VS42Z5=IYJ>:DI9O6OJ6BG>JJC8'5$@/NM-3@>0ZM6BU\^BG
M="[YH=Q;:QDE!*LM+34\%/#*LGD::&- D4S,S&1O,/4222Q-R;GW=AY]5!\N
MH'RAVI#N/9E3+H#R)')9@!]!%(1R?Q:YY_/T]^0]:;AT1CX&];C<?R(FSV4*
M?8]5[>R&7^WE:R'-YQI<-C)W4ZDU8^CAJG4$^DR*U^![VYH*=>&>DK\Z]ZQ[
MG[GR6.I91+0[8H(L>C(RLHK<C--E:GUK)(C2015L-,UD0:J?3S;6^UX=>/56
M/8[+]O+]+$7U6(N1=>%7TBQ%K6'^O]?>CUL=$\JS_E4H_K*X8CZFYY_U_P#?
M<>Z]6Z6FQ,!E-U;FV_MC"4QK,UN3-8S 8>D1;R5&4S%?#CL;3+<$:YJFI15'
M')]^Z]UN@=T-C?BY_+ERFU=OB#$3MM'%['Q0@M3S3U.<$6U35H=(,E7((ZRO
M9N6;6SDDDM[J.Y^O'"]4.=>1&H>CIUTAJB>"&-;GEI72%5!4,UF8BU@3Q_C[
M?Z:/6Q%#D8>L^@=WY^1A2T^R.J,C/$[L(O'-C=MRZ!ZK-&QFBX_-_;)RWY].
M<!UJ@=M=X9#*M-34E9*TCLRNRN3IUDDER"Q/J/\ 3GC^A]N$]5 IT6S#T.3W
M'F8[+45M542KP TK6.G^S9V](^O/ ]U''JW5N'QLZ)WQ#10[@VQEJW;N\*6&
M&LP=:DM12TKUE.//!09)(5,KXVJD],FD:D#%U]8'N^ .J5J>KK/CAW;_ *8\
M77;8WI0MA^XNO&_AVXJ*M^W%=64E,8HWCGEA.FIDI!4Q2K+^B2&5)4],OMIA
M3(X=6!KCSZ./BR- Y%N"+?G_ (T+>Z'JPX]+J@)LMO\  C^GY^O^O[T>'7NE
M/3\@?X"W/^(_WGD^]#JPZ>EY4&UK@6']!_O'O?6^N7OW7NO>_=>ZPS6T<_6X
MM_K_ )_WCW[KW3/..&'X'_%/]Z]U/'JIX])3(?0W_P 3_O/U'^W]W'#K0X])
MI2=4O'^[(/\ ;::@7M?WKK?G^?6@94S$,Y:PY^A-R5_595!M<L; ?U_UK%[J
MO3#42FS?GBY N.5)!TGU$W%_];WKKW3/,X/U) /(L+V5OJ=5KVM8VM_Q/OW6
M_P#!TVNY Y&KF[?7G2+WU']-A]/Q_L??NO=1F"BX)4BXXO<$:E_!N + _FP]
M^Z]U)C7019?Z#_$6-_I86X!_J?Z^_=>Z4E'2D@EKCFXN38LP -CQ<Z1>_P!/
M\03[]UKJ2T)323;C@C2 ;<VUBYX)^IM_CS[WU[K@L893^1_4\6*\C4.;W4?6
MX'^'O77NNGCN!< ?6X!7]7!L+B]B.3^.?\+^_=>Z;)DO87XL-)+&PL3]0!K'
M^WO_ +;W[KW4 Q--(D:@EY"%  Y)_JVD?B]K_P!/IQ?W[KW3_!M#(U8UE#<J
M6^A-EMJOP ./]:UO>Z=>Z;,EM6KI Q>)M %[M?ZD:0.5)^OX//X_'/J=;KTB
MYHI*=RC@@@67ZGDDFR@@D7_W@'WKK8ZCEB !JX6US]?I;G^M[J1S<_3W[KW7
M8<@+8\<?6P'-V6Y!!_'U^G^Q]^Z]U(C)!7TEOH?]8Z18$<V!_/\ 6UOQ[]U[
M_#T[T[\K^HC^FBY]5N VE3<7MQ?GW[K73_ SKI/J MIOR!:XM^2;<BQ/TO\
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M]:; I-NTM*HB6,(L8LJA1QI_2".. #:W ]T)KU8"G0([XR@ZR^;_ %AFMO\
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M0W164Z:@Y3'T<>/I"X4A61ILJY((_L_X<57.?GUOHIGQ.^-1\M)E,C1M-6U
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MS4Q (.BWUL-%R;CZCZ?0C^H_Q]N=:Z3\S#\'GA; W%K68&P/)_'X/T]^ZWU
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M2#>_]!_O?O76^D!E)@2X'U^ME) T@<+SS<,3_A<7'O77N@UR<HU,+F]M7/\
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M?#K>BVIDL!\>OC%O"J9(8L7UOU_4JL5.X=:3;>P-L"DQ^,CD5477%24;K9>
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MKW3]3U=K:K!;K<<'3;D\<L!8_6W 'OV3U[I54%7I()(_1;4.> 38KZB3RQX
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MT\\MA%#)(3_J59A<'Z<"]['CW[KW3W1[9SU9;P8NLD4D'5X'TD<"Y)]( /\
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M][ZT>C);4H*VLT"GIGG*E6OH8CU$#3S]5 4?4_["W/NPZIT,%%M#/S@,*:5
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ML8S=B0;*5//] /\ 8^[]-]%Y[BWXF%VYF:MYPAAHIR@++<S/&R@7)U:@UO\
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M45*GFQ8K;GZV_P!N.?>@*=:R>IO4W=FW<A7QA*R!I SDEI$LI8BYTZF)M_K
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M?1!431K1)1B..0JC_N_J8$7'O8TGAUZI\^BSR]#U+1#10HME5D]#*"M[-J(
MLGT%[_C\<6MIZUJ'20R71V54D"DU ?AA=M-]-R&N4!MQ>UN 1<V/M/6Z]).N
MZER,6J].1I MI#V'I(!9F0$73^OX]ZT]>KTWQ==U$4@O";*VK4?2?K8LP87;
MAO\ $DGZ^]4ZWTM-H25.SNQ]MZ7>.GJJH4C_ -E )RI1K:=17T@@C\_3G@[&
M#UHY'6S%\3-PF&"AHYY+BKIH$-BKC4J*!J(9@; GG\_[#WYQZ=:7HA?\Y;I)
MZS;^#[*Q])&SX^M"5DBK=Q320NKEN+$( /\ "X_/NHROV=;\^M;YX""0$X%R
M23S<#ZE;FX(X/OW5O+I\H24]1+ 6MZ;7Y(-CZ;_I/^P(]^Z]GIY29P0I(-N3
M=3P .;D-:YM;^A^M_?NO=96EO8 CD<_4 6^BEE^AM_2X-N?I[]UKI1[-VEE]
M\YU,%@Z&MR50F,SF;J*7&PM/7RXO;>%K\]EQ0P!6\]>V-QLBT\9L))V12>21
M[K?5UGP7^,V^M[=<;M[%VI#MK9F+W;L&NV5BMK9^7)U4]/BY\90-'NROSK5\
MZ-DMP5]5/5RT(BCAITG3Q2*A$45J@<>JD=74[;^(%1383I],AOBA.X>J-CXK
M#XMZ7$SQ8S)+2X''X2I^Z>;(-+]W,E&[I$H"KKOK>UO=-?'K=*Y\^C 8*J%3
M@ "59OMM!*MK36BZ7TG2"RZE(!_(]U/'KW6O/_-&ZXK]UL\%''8FL28/I+,R
M /J56T-8J>1_4"W^/MT"JTZKP;HO'Q/^*U-%%0UU711S3R/$Y>6)G8#]IS8_
MBS,1_@";CW8"G'KQ-30=7N=4],T&*HJ-11Q 11Q*H$=BNDCD$H&!/))_KS]?
M=&;K8%.C:8C8=/'&EH$%@+ +;C_DG\_\5_K[;KUOIUK=FPB)@(4(M_J>?H>?
MI^/?J];IT7G?^Q!)#4-'"I;1(3Z>?H3:X^H/^^%_=P>M$=5W]I[12ICJZ"LI
M5(N>#'_12;@Z;VYX%CJ/XY]NCIL]5!=]]5UN#KI\ICH2\3%VD"1D(0-=B$"B
M[6-S]?\ ;BWO1'5@:]%SP'4>Y=ZU"R+220TS-:[DEFL0&L;,P%EYL>?J+#Z5
M"D];)IT9+:7Q4J$"L]%>32MV"Z>1J(#?ML547(OS<<C\>]A>M:NAMV'T_7;$
MW109J.'2M')'(2BD#Q.'@<"XL+&0'@6O]#>X][ IUHFO5X>PLE39[IW#U%._
MD,..EHYOJ2K1!@$()U$!?Z_CW0X;JPX=:R_RLPQ@[NWE(5%C7*;A6O9D5QI5
M;CZ,1;\_4"PM[VW'KR\.@ I*5'T^DFY(("@DVTK92JD*Q L;VM;_ %_>NM]"
M[MO;OW!B.DFY51< WNHT:@JWL00 ?Z$_CZ6IUKH9L?L,5$04PJ1I#@C2;_0L
M?RH)X!M;CZ?DC=.M5ZE;=ZMC&Y:9S$JK;BZ7%U<?3@WL>!^2?]@??J=>KCHS
MV1V8U)CRRPKZ(0#I4AK>,*.0#Z3^/J+?T/ MU3JL+Y#4IIL]( ;:7:Y8:B;H
MQ'^/ZC_MQ?\ (]MMQZ='3;\8'#=JXO\ I=#8_3_/):Y -K$W_P "!?WY>/7F
MX=;@OQ<D$=?2K]->%H6L"O\ QS _!M^/]?W5^M+T7KY0U0I=_9]KA5E-,Q/Y
M_;68D7M:Q"_ZU_S[NGP]5;CT3?K?)LN>W!8ZM2AR"66PT1D'22"#9OH!Q_MO
M=NJ]"G@HWK=ZTC_5U96/IN0;C4-0XN!>XO<GGGWX]>Z=_EO528_HK//JT^E0
M"./I0UI_4;68\6_)/'UM[J./5SUJV8@M596<78^6LDL ;</*;D:22;$_T_VW
MNG5^C X'%I(:6)%0W"+]"/Z$LV@$_P"-N+D^]CK75FOQY5<=B-^58M']OA88
M?*24\;4>UXX VC26+*4*G@ZN.;7/MP=4/1+>U,I/3YRLD2=T>66"0^LK9I*6
M)N-)4$#7^!:WU/X%6ZL.'0;#)/4>)FF9PRKJNY-B5" L&^CW/-_\>/I[U7KW
M2YVSO.OVM,M3#++XQ?THQ))3@A5U+<B_YY /O8QU[JWWX/\ :#[XSM4S51#8
MO"R,?,0/'-62PT<2D%BCN[2$*2/KS;GWYLCJH%#U:9VQ6P0].==^=V8)NZMA
M8JH!-1!19A;,1I4.S1$\V'NBCN/V=6/#H&(LT:/;6:R,\K0HF-K#=#J=%,#J
MI47L7^H'(O;WNF>O5QT&?P3D0-W]N(G_ (#28S'^8@ZO'28^JJE4EA] *J]K
MGZ_CCWN3RZTO2NWCW(M,DT8J-( =;AA_9N=7XOR!<?\ &_?@O7BW1:-T=VTZ
MQ3!JES)ZE]+'421]/4Q&H7%KD+_O'NX '52>B0]G[YR6\U7$Q-,T-;E,3#+&
M1K:1/XM3-IT-K2\B \VO?^OOW7AZ]')[[JIMO=>]![1D;2*+%[@RL@T$AIJG
M(Q!4%K0VB1P";F^H$ B_O0XD];/ =8>LMX/C)J5VE;Q_37J)(!.E=5SZ0 ?Z
M?X?3Z;.>M#'1QJ'LB!J<,'N0@8@-8GC@C_4W O;\^Z:>K ]![OSM)(,?4H)R
MK%6 57'J33JN?62;@W^OT_V/O87KQ/14MC;@?<?9D9$C-'&1(5U7(UO91<,2
M!J)Y)Y/']/=CU4=75]4I;'T@'T\<9L+#^PH^M@+6''''MANG!T:[$7\<5O\
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M! /U#6!^OTYO[]U7J54Q:8OI9?\  $BP  Y%^2!]>+@#_"WNO=!M-"9Z^2-
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M/C,GF<*T!#VLS2Q $6%S^0/;HX]5/#JW/XXROLSYS;OP$B?;46\MI)E8$=M
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M1H]L8YQ1PD?I9(^!SJ"JE[II-KZN21<W'NXZKT[Y3'E(920?TM_6Q8+:UK$
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MU*R0H;@67Z6/U_V'/MLCKW7%Y])Y('^VM_K6L;<^]@5Z]UB9@Z^D_P!>./\
M8&_O8%.O=--1,R$WY/\ Q2Q_K_0>]]> KU -:NH@_7_7O]>/Z^_5Z]0=9#4J
M5 %N>?S;_>/?J];ITPY)$DC-[6.JU_K?_"W^/OPZ\>@YJZ'QSM(HXU7-OZ7
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M9I//M*OBTA@U$XLU^;QGC_;>VAU8]4*8_;$5-ELY1,+/!N;.JP50 0N1FD
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M39%.K0^E^RZ+(I$JSB1M*6/(')2W)(N23]+?7\>Z,.K UZL!VGEDJ($.H$D
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M O;@7N+?GWOJO21W/,\=++=F7T?VKW]1-FL;,"!^/P!;\\:/6QT%5-*5G#W
M]>JY_P #8?[3<'_>/?NMXZ-YT#O0T.Y<?35,[+&\B(NIR%(#J "-1+$KZ1^/
M^(LISU5AULU?&K<U--MZBTS+ZHX@27L;&-"5OSJLW L?]Y^GGZJOIT=C'5;3
M-&58D<?UYN;6^MB+>V^K="+25*1(IU 6 O;_ )'>W ]Z^77NG>/)K<:&OP+_
M .O_ (<\^_4Z]T])E$6/U'FU_J+_ $^EO\?>J=;KTCMQUXGIR$;_ %7T-O\
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M\M:WT]T*GJP->AD;=\#0:HY1<A;"XY^H-[#^GNE.M]<\5NB3RVE# :N"!<<
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M5#[<J:J*FS4 ,T--*RQO41Z0C:=1]5S_ $N1]?S[]0C/EU[I![@C>GF*!6"
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MIZF=/1$QU+<%%9PO(TV"IS^+@?6_/^.NM]!/OO$5(:"H-/*@U,C.T?'*AA]
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MJD*#9?H?]YX]J>(Z:ZN2Z9[+HL[A:.452.S01EU\@/J('%OJ#<_\5]LLN>G
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M)X4JW:,V%HSK21M+6%R6-P&4"PY_I?WZO6R.K#^K^[Z6>.!?,J\JINY)-U4
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MV/\ 3CWKJW^#JQ+8O1M#LWL_IO?=13BDIMK;+H\W$)B8&CJ\;L;>F?HFF@D
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M$ZDV]7(_ Y/^'_%/>NM].$M+#ILQ%V!^@' //^M:_O77NF:MPL$T3-I7GDW
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M4P57(6/2+V.GU'TCZ?UV!U4GJ_;XYT<N,W-L.@TKJQVP\_(=)NK,E;AH&(#
M7NTAYO\ Z_NC\#]O5EZK$^/^K</S<^5TSQ &3*[AJ7 #,JM+V=N/7ZOH19@+
M@6)!_P ?>_+K7'/1G/ALLL_:7=.XP%$&-VSGX(9 URD<61EJG">IB->I#>Q
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MQ*@*M$X%P#P5)%A:_ML<>K=:K'\P+8=/CNP9L[CXDC6HB*5(1>"5DD(:URI
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MZT?Y]&\VQ1F.EC2P8@)8 'DW&DDBW)X^@O<_Z_NPZJ>E!7*5IV]7X?4U_2>
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M[:&QMP$0&&&6KHZFZAV,<M&K16((-A+ >3Z1?_7]TCXGJS=:UG:V*FQ>?S=
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MNID4-/\ <B1HV=K@A0+V(L+<<<6M_B??NO=&UZ)Q9R&X\3%5VIX)Y8T"L+\
M@V9B;-9 >!Q<_P"/NR\>J'JZ_&]28O\ @]'DX(FD=H "[:&NP4 ,2D8L5'/X
MO>WU]N=-=-,] V(HZF'R(@@29E72$T6B8JHL5TZK \?CZV][Z]T0NEJ2F>WJ
M&NVNHR<R@@DC7/(=0(L&NQ^I/)%K@#FOGU?RZ3FT,W-A\PE3"WC#2 #]0NNH
M!@38* ;<W-A^;?3WKK?3U3[OJJKL>E-48V091+$@MZ&G!8L&,A87-_\ #^O/
MOU<]:ICJ[KJOL*+!;0IV#K&STT9U BYNA(N 0#_M_P#;^]D5/6@:#J))WKF,
MQF!14-3IBC+"207*BQTZ%=2UF"CD#\_X^_:1U[4>A_Z_[:R\571T\M0KW>,7
MN_TN0."Y47'^\$?3W4J.M@]'FH-Z5,V"$S-ZFB!')Y])/Y:P]M4SU?H"\;D!
MFMT35$M5+'X:E@4 .DG2W^N2MKW]VX#K75!_>F17*]P]OL^FIA'R-S5*;N0W
M@Q68QN!C#A(SJAB^P<6]6HBQL."XO#JIX]60]Z[@Q>7ZNAR=,].:J<4\;GCS
M.CN%E.NZK^Y+&#8"Q%K>_**'K1R.JILQ++_%)-,4AC?2 P16UL"0#95(&E3^
M0&MQ;GW;KP^?2@PC/(IA\;V=0OZ9B;D6XTC4Y(*\<\?X6M[K1ZS[3Q<]%V-M
MJH$4C-3Y^@J2OC"^F.J26Q-KBT27'/ YO_7W6_+K8!^)%?4UFU.W\_/)%_Q?
M*J.GD3A?#0;?HB@NS']+,W-_;,G$#JR^O5$V^-V28^DR&%IW61MT8/8&V:R=
M9;L\-%FQ)(DC%R TJU_JX(((OS]'NJ]''^15?4XSX>;'PJOJI][=M]1[7JP)
M9&5:?'=@MG9V+1N!+K3;*JP.H%%^B\6IQ;K8^'JN'Y)R34?:>PL'"-7DZ;ZS
MH--K2ALICY*^978N09'DR#$WL-)M;\^]^?7O+I6[&TXS*;H*^850@CI$8:5"
M!*<L]Y'1D&A6/U_V%_=NJGHMW:K),]#!2'R2S5U0Y:98VBC:/]L2RF0V\;?4
MFU_R0/J-'JPZL ^%.*2DPJRU#>8R/D*CR%(TC=I'1%:,H.;B,@'^@M] 1[]Y
M=:\^K$8:W"4<>N1@SA0.6'!'!(#"]K$_ZY_V'NN>MXZ;,AO['P'Q4[B]M-OQ
M8DC23<$E2"/SP/>]/7J]9*3(U>80LGE97L;J++8@FXN3]/\ 6_!]ZIUX=)'<
MWW-''(R^B15+#2"6/T)!8D6O8?[ZX-A3K1Z!D]BY&AK#!+2O-I;0)-9!O:W]
MD6!+C\6N./>Z=:Z%[9F2J=R&.6H:WXCCC' 4VNU_S< 'Z#Z<_P!?>C@=;!KU
M6U_,SV&N(W5L#=AAE%-N';F1QU0P8+Y:G!U"S!!)XV <T^60#@\+[KY=6ZJA
MI&B>>3QHT<7I55:0>D(027)6^K@G_'_6]ZZWTKZ:6<1@H!I4<LY8LJJP1%X.
MG@<#_#CWOK72^VDF=EI\K%BYY8<<\4,>5<.L=.8B]X8YGD*6C\K?X?7_ !N=
MCKW0C[)KI&K8X_*&TR%=3 :6LVDDDL.#;B_TL+6^OO8ZT>'1O:>;_C'67.LZ
M_P"\6W?1=O*&_A.Z9+WMR[6_I^/I^?>^JYX>?58O1-2D&<C$KV#RKH%B#^.;
MVNKB]Q^+_3W1>KG/5Y/24R5-!2>)3Z5A!.D"P&D%M)^AYO\ BUO\?=SPZIT:
M?(5,T6$G327!%["YL"I (OR/Z6_!]UQU;[>JG?E+EX#0Y6$D*S02@:@4Y;RV
MT\(-=P1>W-K6^@%CPZTO'JJ7;<.J>H*<WGE('TY\G%M5Q<W/XY!_/ML=7Z,-
MM%3'32:."P( %R.0?21:^GGZ?T_V-[#K73AGJ.6H=5*N0MQ$;EN$N S$</P_
MI%P3_O7N/7N@>W-M%YYM;*0OA<K8>FZK8#T@$\'Z_P"!)!!]U(ZWUAZVQ"15
MB)H 99=)&E3?2R@@'ZV)'U%^?]8>]@9Z\>K)]ATRQ8M%%E("W( 'J(%AR&-V
M!O>]KC_;7Z;/'I+]IN(<956:RVD!()5;MR=!TWL/S_O7OQZV.JKNSY/+52 F
MY#\-P/I<6^A_L_T/U_V'ML].#H)(E+* ;FUK\6X^GTY_)OQ_7WKK?1M>JL*M
M5A8)-)):,$D*!QP#8@*M[J.">=7NP'53QZ,!1[8B*<1*-2B,D+IX<6]+$$$V
M'TL;"X][IUKH ^XMM"@AI9EBT^21PX ;BQ0 \<#E3:_^M[JP_9UL'HL-?2PH
M3] +DD7O^!:WI'X-_IS;WKJW2HV!11RY12 "WH('%CZP3?\ U]-OZ6]^'6CT
M::GH]%DTD*$#'@WL!9C<<6LP^@M^?=NJ]1<]1D8JH8W75%(18 GA7.H%M%KD
M6_)XYM[]UOHK^3P_ED<6YU-] #S^225M8*.;C_'W7K=>D14XB;SGTE57D@"X
M)!N+"WYO^/>NMCJ7% 8AI/!4$#\?[U^/]\/>^O=<Y?K8$_U!N/Z_ZD$7'I_Y
M'[]U[IDK93"A?425'/X_5:P''O76^FC$!IJU6)) ;6;D6^MP!8'^T>+^_=>/
MSZ%2!5>,.U[Z5-BPN5! !-[D_C_8GZ^]]5_P]<2B$VXL"NE0=7-V)/\ 4DL?
MR/\ >/?NMYZ8LM411E(U<:F/)N.1Q86_%CR+_CW[KPZBT]?XA=7 L/I<<\<@
M7_UCQ[]U[J<N6E9KE[7_ *$WN3P"3_K?CGCW[KW3_35<@C_66# ?7EB/I8WO
MZ1:XXO[]UKKC45+N?42W/TU73FX)_P!8VM_7\^_=>Z2E>Q64N";_ )MR"PL2
M1>PN3[]U[I_VQ45$=0'BEE1]2*N@E6+$@66W!X_I_M_?NO'HP>VJC+4S1R3U
M=0L7I8,SE5'Z?QQ<_7^I/^'-]BO6NC(;3W9+3%%EK6"DJJEWMZ..-9L 5L>?
MH01_A[O7JM.AXV_NX5\HBIY/(0Z1D*4/J]+ @W  =2+6)'];_3WOK70\8FDJ
MJN%8Y*75&46[@!R%<'3<<EOJ2.+ GZ<^]]5Z6^'ZZH<G4*9(4U7Y4QJ/RH-U
M%AI4IP+_ $%K_P!==>Z@[\^,N S=%4//BZ>21HV*2>! VIT(NC!"XY'/(_P/
MOV#UNI'1 ]\?&6OVI5S9'%15,<=/(S1@:UTA0SJ4<G5<-8_4@#\_GW73Z=6#
M5QT/OQH^2-5L2MBVWN2I*P1RI'%)*^DH$"(5<7(N-/\ A<>]X.#UZE,CJ[78
M7;.*SU!1U<-;$RR)$PD69&X9;BY4G]7UMS;W0KUL&O1@:3.T69QL]$S1S15=
M/+3S(2KJ\<T922-@Q(974FX(]TH0>M]:RGPOHALOMWNWJFM$PGP-7GL.U+I9
MA]YLG=$^)L*==4DLJH9  IOIO]?;J]5;JSC<M+DL724N4EJF3&!6F9'+I41@
MQZV@D+GTF)E*A;&P'TL/=NJ]<-M;CB6I"-(TGW*+% [RJ40R)'>,MJ.IF9B#
M:X'T'OQZ\.C*=(Y[[+L/"4<A56KX<GB90K?MLLM*,A".;,PUX\*HM^?H?='&
M.K#H*ZNF:/N7*T\<,<8HMW9+E(!'+J\TK,99E75+$OB1AP; G^OO?X>M?BZ,
ME\B*%\AU''XXQ(*"HIYQ^AM/[4L37U@ DK+>P('%B1]11./5FX=:[GR%VXB]
M@9A@C".O2@R4;JITR_>T=-+-)<?JO4.PO8@L#?\ /MP]:'#HO57M$",V#Z54
M7-A?45O<+I51;5^;<?3Z7%3UOI*3;4T":1([C01R'6Z@JVH$@6 -SR?I_0VM
MZG7NB8[NILE#F<A2?;3#15/_ &38K]?K_2UO]\/=.KCATK.NMH[CW76&@Q%/
M*\L9C+Z4=RI9@JEM()7U$?X_GWL GK1H.CP=8?'O=38K/;DKYEA3:\$F0J*:
M;T-(M)/2N8P""6:4%@O!N?\ 87L!U4GK''22K7KK81B2>M".JZ6,8DD5?W"7
M)9BO! (Y _!][Z]T8SXB8^.J^0^W \J(L.4Q%9K:-!XY/N9#$8V8:M/ETDE1
M?_6) ]^]>M'JU#IO;V0R.=W37>.'["?=&:+M!%5QSB=*YFBCGD@:6">1M>J1
MI7O$1I&J]QLGK0%>C ;SPR4%-24L;*:X5M%3.2!4R1>5HW<L"6(C6)P23Z1;
MZ<<5&>K'H)M^>/#T67R+5;:X,3VC1/\ M&,.\.-PJ+4-4K4+I>_$,5M10DAE
MY V.M=5'_%VN@H]A;^S"QO&*W?KTFHR-(90L62F1C(RL\B/<E3>R\ 6MI&UZ
MTW0KX;<:1;D$WET1,KB]U%B2 1SQI93];?[?WOK71A<CO2BGQ<4!F!9Z>-5Y
M!97*C@@\ >J_/'^%_?NM= IO/!093"5NND$_D0N6T.Q4LFLB^D@D_C4;\_X6
M]^ZV.B 9[:L>)R-2T4"H#(&"E+:F;UD$Z4%PW-P!8?X>ZTSU<'IUVSOFIQ,\
M4/F*(K *MSS<V  #+]+#GB_OU>O$=&CV?WA+1"/76LBK900]C_326L651R;6
M_/\ @/=J]4IT:C9WR8I*9HHYL@OU%QY0#<6^BAKGZ_D>_4'7L]&[V3\E\34"
M!#D("QTW3SQ@D%;_ );CZGZC_>Q[H4ZMJ]>C3[8[HQ>0C0K5QL3:Y\J_X<W!
M'NA4];J.A J^Q<?-BZ@B=2/$UO6#]%/UY)-P?Q[U3UZWU3=\F\RF=W?,]*X#
MB*M"NC#4OHF(LBW8$M]?IR+^WQ@=-GCUKN?); U>+WGD*J>25EJ9F8ZFU*59
MW"^HVN2A!_/^]V;;CTZO#HNM'5BG<$CTDV//T!L3<@?@?7Z?Z_NO5NE/_&J.
MD"R1P(\C6YTC\#^S8G^O^'O?6J="/LG>633.8>M2=X%I*VFE$<3%=0$JDKZ"
M+KHN!;Z_['WX=:('6R+UGN6+*]6XF>&:'SM3*Q!L\B2-%$61M _3QS]/ZV'X
M=Z:^706;DVONG-)D*JDF<1-'*7%B%T:" =*!. H)L.3_ %_/O?6NB$I3O!G-
MS4[K>1FKDD8<M?[A]1 *JHLP-AR./S?FO3GETBXXE1Z9T&DK(XD.KZLND@ \
M%@#]"1^#^0?>NO=-M'_Q]V/E/#25\0_4#_NT%KD C\<?U_'UY]Y]>ZM-PN8D
M3:]-$)6#+2(?SZ3I&LW(4&Q_WK^GN_3?6+KI7>JJYV).NH;2Q]7^!(T7(N0H
M/YO_ % ]^Z]T;;:$9%52N"P;S0E?J"?4#8@W "_[[Z^ZGAUL='UHJTP[7C.H
MBT(/U O9/IP?Q_L/;7GTYT%&-WGAZ&NE74K5 8LT:E/(9"&2Q)YN+>[4ZU4=
M4.;\JERG8.\*N.9RF8[JS>6F)/D4193?CY0QJA8EXO#67(4\%]1%A?W?JIZ,
M%6[BW)DMEUM#6%_M:*.GDI3,)-<I>OH(DET'ZQM!*S #]0YY ).^M=)C8NP=
MY=@9.6BVOMZNW#44^DU%/C:)J@QJPE*"0A25+B)PH/ZP#8\<>K3CU[[.AH7J
M#?>U@6W#USNO#Q*6=I<AMK+TL%HBZ.1-+1+&5UAA?5I)'U]^!!X'KU#U!I\=
M14V=HYFI%2:.=&56B6-P\37U$,@-E!O_ %6U^/>^M=6S=,UU)@OCAV[EET1B
M@Q.[:YY(AH3R4VU%F>Q !%GX^M_;#UUCIQ>'5!6Z*7'9#+[ZQ<SK%487LO9>
MW(@;,].L--BLC,%DLK'4:5P2+'DBUK'V]U7(Z.A\J 8/B%\9I%!?7VK2[IJ5
M)T'P;>ZO[BW=+>/2S.(ZG'*0"&(/YXU>V_Q_+K?X>@C[6Z5CR>4VSOC(PROE
M(]@]6PH\D8C^WBAZ^VY*5XTJ"9G8D,?JUK\W-P!UHGHM-)E?L<]N.D^\DC;[
MO[<")6&HZ2I4 'R:S&]K?7_B-]>(Z+YV)9]PT,<?E"ARTJQHI8R23?I:5PQ1
M#I'I"Z;7/O1SUL=6S?"K;,-1MJMR%7 LUJ-8(E<Q(L?FE\A940"^I?SP2+_Z
MWO3''7AD]&GW)L^FD#7JS$OJ]$$FEA>_%U8$D<#\^] ]>(Z2&*V%C/NT9Q)(
MRN#JE=FN1_P>XXL>+_X>[$]:IT9G:6T<:E'8E02MQR 1Q_4_E;_X^VR<]6'#
MINW%UQ05_E4@^K4"0Q_!M>_/U_QO_7WX'KQ /01UG16.FG:4M<@DJ"21S;Z@
MFY)4#ZW'^W]VU=:T]"]L'K3%X:-7D:.X/-R+ V7Z#_$_[?W4D]; IT1_^:KM
MG&93HK;V7HHX9*K:F\8-3*J:XZ#+T%52U*^0>J-'JH:>]CS8?FWOR_/K?6N;
M1BTSBVHAF4E2I U2-]"#IL2UC_C_ +?WOKW2THJ6MJXM5-3SR0PJ_EEBA,H1
M5TF\I4%0!J_(^GOW7NGBDDK:4-2L:F&*0JTE/^[$LJK?2)8R5UVXM<7_ *7M
M[WUKH4-EU,<=?!KN526,FW"GU J";"WX/U-[^[#KQZ.;3XBL&R,O7:H?X8^?
MV[6?>^=+ 18S=":"-=]31S7 _58'WOSZI_AZJ=ZCJ&3<5&5)TB9;^KU6N/4O
M]DZ5%[<?3\^VQQZ</6P-\>H8Y<+16LS"*,M;3]1H'%@W X^GTY^G/MP\.J<3
MT<"IQ;'%51(N/$Q*Z18^@FUM('K!^I]T\^M]5%_+7:TU;'D5@C;UQ2!CZO79
MFU!F)]1L . ?K]?H?=CPZT./56&$I#23U,3^B6*61&53S=9-=AZ@0UA];W _
M'NG5^AZV1$LH7@@M,JK<DAE%OU"W  4?Z_'NPZUT*M3MXLR%$)N$*ECP=(6P
M)NVHFS#^G!/O?6NDMN';Y\<RA5L*9]1TZFX0J';_ %'U!_/]?Z^_'KPZ"+9=
M*E%EW1](M/\ 2QLOJ4 <:;>G^H! -P/I[J.K='RV?7P0XZ)?*MV5>+ *-*@<
M CZE3?ZD$#_7!OTV?GT'';>4B^RF74IUHY !( +(>2JVN2WU/U(]^/#K:]5@
M]A RU+L#P9>/3_9YXO>]B".+<C_6]MGIP=(G&XJ6I^OI%K7<-]+6O;CZ'^I]
MZZV>CP=&XD3801&2-FBDL5YOI 9AR1<@W/ _K:W]++U0]&2BHH:=%NR752B$
MJY?D+R#PW(^OU_Q(!]WZKT7GO2%*O"DP\FG=G&E@Q6^H$*!JT_6_U-@+?U]U
M;JR]$1KP[-<7N"> ?H;D\?J/T']>3[IU;H1.MZ;_ "A93;]0OJY-K@_TLUKV
M-[?7WL=:/1I,<@D=-+6UZ@. 66Y*BZL1]#]#Q_O7NV>M=2MUT*Q84LK#4ZV<
MJOU%P5N$8J+_ $%A8 6]^/7N@#?%QM(Q&ABH/(U$$#Z6_4O]KZ_CCW3K?22K
M\6?(28[\_J + V(N > /I?\ Q''OW7NDK6T#I<JMBOT()(MQI+?@\?[U_A[]
MUOI-SED^H7@D-;\?3GDD6N?I[]U[I*YF;7HB4_CU$?7GZ"Q^@_I[UU;K-@(]
M+&2W/ 'UM:_YM?\ 2>?>^M="+&]D %P!I^O(-K_T-KJ#;_8_CW[K74"JG* E
MF)/YN;&ZW OZK"_'^O[]U[H+\Q6RR5K&.0@( !:_YL?Z\CGGCWKJW6*')3BP
M;D#_  "D6_)^G//]![]U[IXIJO4P8,;7OZ[W^@^G-_K_ (\V]^Z]TM*2KU0J
M5(%D_P +@CF_^N6_'O?5?EUDDG/UN23^ 2?R+B[&PM>W_%??NM],57)Y6T+8
M$DGZ<@6)X)_''OW7NECMF%(IJ?R'DRJ2;WO8\6L&%_I?\C^GOW6CT8)I?%#'
MI_2(^"+:;6N!;4Q"@BW]& ]VZUTGLAN*KQJ'[>9_K:S Z3JM^D'Z$D?7_ ?T
M]ZK^SKW0Q]8=DIA&AEJR[!S%Y%8W5V_4&5M>C5P3]1^/]CL'K1'5AO6O;6'S
M:1(E2&E=%5XBR J RKK\=^$ ^EN+_3Z'W>O5"*=&SP.6HY'@J4(TR'U-<+R3
M8']6FY/^'^Q]^ZUT+4F<IZF$4[E> %!](+"[$<7N0+#\?[SS[UU:O2*SF.P^
M1CFIJR"&2.9674X4CD$74D\6!(_/^]6WGK1ZKK[IZ'I:?(39G;D\:-S(:>P5
MM0UN  I6X(_(Y^HMQ[\1UL'UZ!K:'RAW)U!D(\'E9*B2BII?"8I5<%(E>P92
M9 PY46(OQQ?W6M./6Z5X=6R_'GY983>]-"(:]3(8P/"6C#*#X0-6F0M]#]>>
M3Q_CZ@.1UZM,'JONFK:;9/\ ,JWA%#J3';VS]3D81')XXI9-Z;:I<O.SDC3X
M3G*J12!^5XO]/>A@];.1U:ONFB7*T24JQ"54>1V60*$+\*A.IO5&S,/Q8_GD
M^[#JIZ"VKVNR9*"01NBTZ)4DH0L**S2!0EE36ROR0#:W^\[KU7I2;,W ^"WG
MA\HU0\QQ>6Q^0<+&1Y8!5_:UCN?J=5-,3P+6'U]Z.13K8P>EKF(ZE/D5N >1
MXHVSL_B1D4\U]+#+"=;7!21ZD?0%KGZBWO0^#K?XNC?=FXZ3,]69VD0*J4^/
MBJ5D55\RRT_BD8(IL& ?4?KRH(]MK\75CPZH>[MP:Y?.8^O6'Q:,1!22@B[$
MT]35$/*"$8,8Y0".;$$\7 ]O4ZI7H"VVXA0K;2RA=/&O0/2/U,1I8'Z'_8\>
M_=;KU(P>PAEL@D-D*L]V6QM</P"Q$@0L&-_U<D^_4Z]7HIOR#VE2[4WC]HU%
M!&DL<<S2Z03(DQ.EF;]3./4+W-K>Z,*'JP-1T'73^X/[J]B1QPR+'#DRD0)(
M"EY&XCU70 ZFO_06]Z&#ULYZL<>//;?PFY96E23&;GHXJ50K,2&JJRC$BWNA
MOI!N5%S8 VX]N=4_P] +D($CJZ%%4,6@JI'N%TEWGD  %P!(21P#;GBY]ZZM
MT87X:P(_R!I%E0F.# UU:S760>6#'9:>%A=S9?(4N ?T$VO<@^ZT>K9-H9*'
M:$&26>%3)6YC+U-,:E$E54FJWDDF@E(J?(K:KQBZ,-0)0W++JE3UH=.>(W!5
M[IS+&2P$$M.A* !9&>6+RR>G4ZLYB_3J6P4 CWZE!UX&IZA]I8:#)[<WM42R
M^-<;V -OPG7HD6@W+A<%/.\8*)#*'JL/*21=C<CD,WO0X_EUX_Y>J8^C:Y<+
MLOLC U</CFINRH"0S*P$51CLLL<;A!HM(("0H^@ _-_=AUYN/2EDIO$U140L
M=5G*,K'4!JNMCR2IM^3;C\7/O?7NIN RM=65M)1RN0OFC# NY4<@D,I91<"Y
MY N/?NO$=6Y=1;&VSD,31155%1U<4M/'?R(KK(#I5C=_JS7)Y^MO=6/6P!TH
MMV_%KI_<DDQFVCB;R_K>*%(^6'-M L '_' X]UU'SZW3HM^Y/@UU!&)7I<*E
M(X!:\534+>_(L#*572?Z6XL/IQ[L".M9Z!C)_#C:-*Q^QJ)X"?3_ ,"'/^IL
MH,BV;A+_ ))_-[^]]:STB:GXH+#+_D>4<V=; L!?DJ+F,<J;"]C?_>+[Z]4]
M*O!_';<6.>-H*MG0'5R\JV!/UY4L +_T'%OI[]UK)Z'O$;>W!L^D$\]5(PC'
M'J+ D M;0R*P-Q^ 1S]??JCKW2:RG>U5B8ZBEJ*XW\956;00H;BQ]:6+?ZWO
M5!UZIZ+I-NNDWAN*-A/]U4/))?\ M:1)>X(NUG)3D<7^GO?6NJR_G+L7*8>J
MAR1I"M,\X5Y EE8 2:9+!"0&6Q^OT'U]T8>?3B'JMIV-K<V^GUN3_CR3^/=.
MG.G&*$U$2!+$W'Y_-OP+W)(_U_?NO="3L^B,<T3%@RHRLQ_'# Z?KSRW']?]
MM[WUH]7:]&]G8"@V1CZ6IKQ$52-?%*]BC&./^PQ(TLHOQ>]K'\^W1PZ:(ST8
MG&=F;<JZ/(4T61I :BF=48RHGK(#7(-C]+?V;BQ_V/NJ]$(JJ>^]MS,I0B;^
M*R"U])C$\@+"RVTR+S_K#FX-O>NK^700AK#22#XZJ5/21Z )#P2/KH(^MS;_
M !X]Z^WK?4/%Q&?<N,M^HUL.D%>.'.KU$W6P_P =/U/XX\./7NK$,=4O'A5C
M%[B#C4QOP%*L-3J2I*@?0'CW?IOH2.M85CI&8W):4DV()(8G2?II'I%_Q?B_
M-[:Z]T:W:!4U-%8@7FBN5'UY^OY'T;C_ %^/>CPZV./1TZIS!M9+?BGYL>+B
M/BY)M]/][]M^?3G1:<-30+6YO+5**XA=_P!5K 1*2?3I ]/)M_AS]/=SPIU0
M>O50_;^W9-H;VI**;Q"N_O%M!JHTA'C>HF3#RU!E,G/E><%7%CIDU#ZJ#[WC
MKW0Y?'KJ?<&2ZN[!W'N=JN>??/8V3JZ*MJ8JV*1Z'%9.7&T=/%%5*QHZ6AIL
M<M'!'&?3!2H/IP/#CUX]*S)=.=DXQJ:NZLWO6[,S-)-YVFHZBK@6M>-2(EED
M@TO"HC=U/I=2'(((-O>SUH=")A^^OY@W7E.$K$V_V13P*D1:2EHI3]I$QU:9
M*<[9KI:HKI4%TG-@3ZF/NFE3U:O2L@^76^NU*',;([!Z%Q^W]R5]'>FW"^&E
MTX^26<J9UJ\KB(YXY)XD*Q2Q3.-5]))%QX+0U'7B<=&VV],^#^%';M561R!J
M_!;MIY$5@-#5F*@Q][ZA959[BWX^@/O1_M!UX?#U1YOR*:@AWCN*CQ]0:7._
M)#KW'4V4BIRU/!556(WU7S0S5+H(6J:E,3$%5F#E5-A91:YZT!CH]?S#HQ7=
M-?'G:-+4PQST=/GJCP*Q#R5F4FV]US2PB,:I@[T&^JV6]@/'"XYOQ4#)/5O+
MH:^U8A/M+&3P0H](]'BL<3*VB0KAZ"FQ$846Y244?'(L+ <^]KQZJ>'5+E=.
MU1N3=]5$1H3+U_A96)53!)H!+7<%B8K@G@V_K?W;K?0?YL/-F,:9;^)=#32!
MH!Y&&JR/KE9[?0_BY_V_O76^K4OC[N*OVKL]:>DH*^LCJ6BG,E*L>E L**%T
MJ . _P!/S;_8MLBO5*TZ&>?LJKED!?!9)M5@I-F/)#$Z0+6N2+<G_6'O5.O5
MZ4V+WI4,5=\-7HO'UC#7Y_#*QX_PY^@_V&J=;KT(V+WM7+81XW(H3H',8L .
M+WUB]@.3Q_Q75.M@G\^GNI[&>F98JJGJ4=P#R+%2#8ZB>!P?K[U3K=?+IIK.
MS\+2(TM95+%IU636K,6(.D %OK^;?X<>]Z3UZOGT'6<[@W+6PE=KXS)/')?Q
MS>"18R&+*'N+G1J(Y -_]A;WO2//JI)\NBU_(/9G9V^^E>Q)\V*DT>/P<^?2
M JXXP97*NQU!V81P4K6 ]5_>\4IU[-<]4#QTY2M\/Z 9 K7NUF9F&J]U'I53
M8_3Z_P"PIU?I=ME*NEB>AP=9/2XZ$1F4HS+]W/"59GD"*+H746!-K <7^N^M
M=.];N_*9A*>/,Q4<TZZ4%5!21P5!' 6_@(C<A6_()M_M_?J^O7J4Z7](M#0G
M'0T[R>:6F2IG#JB@ARRI9TF9P&4W^HM^!]![MPZ]T9.FR4G^C/,1^:33_>+;
M;?VM'D_A.ZP'"?ZJW!YO]!;W[JN.JY.FUB?<E+&Q%C,@L;7T%TU%;^GT!1;_
M %O]C[H./5SUL"_'>F$=!02"5@GBA!6_%U"+]!8!2@%K_2UO\!<]-CCT?&G%
M'58FH@"CF,C5:Y%EN0M[W!4\?TO[IY].>75=OR(VU0&#(2$"4A&!NJ_1K\\+
MJ# $WL?Q_K>W!PZ;/'JC^LH?#N7,0D$!:ZLMJX#+Y"NJ^D (;\\#CCCW3J_0
MO;$IB&@TDG5.%%S_ &S8GZ?J*_2U@ ?\1[L!UX]&OH<":U8RL=@;6(!)86*\
MKS=@S"Y_K_MO>^J=1<_M"-X6TJ2S4[@&]F4E6Y])/)N./I8_Z_OW7@>BCKMR
M>BW#*BC1=[CEOJK'BQLQL>?R+ V/]*YZOT8S:T4L="!(5!01FPU*/R+VX=EU
MF_\ A]/]>W53T%G:\THCJ([LI"M;ZDD$,&LM[V)N3^+?7WH];'1"MTWEG92.
M1(W-[\*UM5K<#42>!^1[;ZOUGQ-*IC72@^E^5-[E18_VB>1_3W[KU>AYZLS$
MV-KVHU)7S21$7;U+H9BP6UP"RV)/Y]V'6CT:R=S/2AU:Y>,$@,0H)6[$CDZ5
M!^G//]/S?JO'CT7/M+[A*2I!/H=&5HQ>Y5A:QN?J#_0VN1_3W4];'1,,B560
M@FS:C^#J()#"]_H3?W3J_0J]=1!%1CI ?DJ/Z$_0_4?4?7_#_"WO8ZJ<]&0Q
MC7;TJ + "X!"F_%P?20-?)/UM[M\^M=9MXU5J"*%;@M:ZDZKE54<MR#ZK&P^
MI_V_OQZ]T%T=&)-;"X) :[:0+MJ-[ \L=)/^)^ONN.M])G(45G<BY/UX^FGE
MFL/3:X/^^_'NO=):OH4T,Q5N0Q/!%P%-[$@ <\6_KS]1[UU[H+\E&(W9+?6]
MQ<_@7L?P1_O0]^ZMQ^SI UD#O,Q(X^EQ;Z7)_I]![UUOI[Q$!CC1B#:XL+<G
M\<WL.?\ 6]^Z\?Y=*?[E0E@1Q_4VN;<&XYL/>^M=-60J1H<A@; W4%1^#].;
M<V_V_P#K^_=>Z#-V,DSESSKN2?K]0?\ #^OO76^I<4:V!-OS:_\ 6WUXX(]^
MZ]TXPI]#8"UK<WYXY_K^??NO=.D4[0@:3?5>UVY-P!<V8$#F_P#K^_=>ZSO7
MR. %')O].+WY('U'))^IOQ[]U[J11P&4ZV/^!%S]?J!<W^FK^GO?6NEC2WB5
M62UXV#+^/IZM0'X O?Z_Z_'OW6CTNZ+=2_;)!5V'C6VNX_LA;7]0O?\ UK_Z
M_P!/?NM=)3<&XZ46\;W>]_ZWTFP](/!/%[?G_8^_=; Z==K;A2N@6"1BLD9T
MA3<L "#=0#=R>#_A_C^/=>/0K87=.5V_4)6454\#PFX =K%;JQ ]3&1;'ZW)
MX'^'O8-.J]&?V1\QZG%U=+CLM$DRKXT\L&I9 >+.R&1TD7B_]>/Z^[:NM:?3
MJPG8_=FV,_24=<F3C_R@(PBDD"N/(FK])8 *-0'U Y]VZK0]"O7[GQ%=1%HJ
ME%<JP66*12KL1]" 26#$@,#]#QS[]U[HG/96[JY:JHIDG#QC6%<D@$:F *^J
M_-_S_L/?NO#JO+MFB&9JWG<_OM(?45N=99R#SR+CZ\:3?W1N/5QTT[)W/N+8
M%9#68*MFIYHBNH+(UN"KVLA'!7^H/^L2??@:=>(Z7K]LY/-=_P#7G8V4"QY'
M$OMJ.METV\HQ.5J&+M8ZF=J654+7X _'OU:FO7J8H.MAAIWR\])X9%1*B@>2
M.1!P[RQJX(8N0!>.W'X((][ZKTD<U32A M3,Q-ZE-<)*_13("7N[$"0"UB#8
M\7/NPZT>@ZQD=34[F2DFF*">E\=.RA@\IU,K,B%0=/K46//'X]^ZUT8G<E4!
MV;MW/S1N9LUB]G9.*-&!8L]%3JZ6%C=IH"!<$F_]/=1\)'5O/HYM37TN3VIE
M\;XV=FQ54H%T.H&F9E#?6R!C:YYX_P ;>V^!ZOU3ON+ _P >&;33>?#9VN2I
M)/K$=53T\</[;"Z*32MZ0"W!N;@ /=-]%RW3ASBC*SC0UG])TD_TTD\7<V^G
MUM_O/NO#I_Z@H_XOE)(0+$&_(]=@58II:YY/(XL+<?3W[KQZ#_YP='ULF!Q.
M_**D:88^-:#),BZCXPSR4\CZ1<C42I/'!_V]6SUM>JE<+2R5N[\="K>*99]8
M M$4:.3QJ+\:2& _-^/]C[J./3G =6 +EM[5%+C<+F)2V-I)L8OFTN6DCDGI
MU4-(CJ6+,]M7')^ON_5,<>N.9Q<D I:EI97#BK"B2/2$+3,0%8Z=2HE@!:Q-
M[WX]^Z]T._PZJ(:7Y$;=20&>'(T/\,E1%$:H*DU4.A"Q D\@E5!J^C$7/T U
MY=>/^7JQ/MNIW )/#!#X,>KU44,A8"G\)EG$QCCCD@C2-)A9 4N6Y+7TCWL4
MZJ>G;I!)4UEY'D-57+4*Y'^:6011HD: >I0RE0 MM-N3]!YNMKTY[NI*JMW9
MN+$K+,:"L;L'>;1L_D\M7M7;NW:.E*LP;3(IW*U]) "VT_5K:!QUZGEU6ME.
MI*VMZ?RV\-F*:BLRG=F*BJ_MP&DFI1M/=$LDDB7)94E55 N0JBW%C??R'7NN
M\'UQV')0F&?$SEEA*6\3+]022"0>3>]OSP18>]]>KZ=+38_2F]Y:Y9IL-4):
MHB8 1E6-E##]8TD$#^ILQY_'OW6OLZ&/>.YN]NH<:M3M*@GJ8X_+Y*:>F^YC
MN"&!6(2*P#'^A!X//(OK!ZV*CHNM-_,/^2.,J):;*;(QA5&*O+-A\E"+*2&L
M8JJQ%A]0;7/U]UI\NK?GU(?^8=VKE2()MG8J2HELOC@AR2NSM]-*?<R :F(/
M^N?\??L5X=>ST-777:O<_8DL;UFR!CJ6:S&:1JJ,!";#_.%SSS_L0?=NJ_+H
MY^WTQ>'HEJ]Q>-:@ .PDE4VL 38V(%BI'%O>C7RZ\* 9Z3VY.[MK8]9(,4L=
M3*EU58+$$@60$KJ )?Z"P_J/\?!>MD^G17]_=F[YW)3U%/A\<RJY=5"1N6"G
M58DI9B.18?C\'W:E.JUKQZ)]G>KNW]QSU-1.E2R2![(#,O!+$ZB&N6^I+?7_
M &'OV>MU'3-L#%Y_9.>CH,ZKPU,=8B-(^KFTK74EE!!" _4\W_UO>AUXYZ;/
MG;EZ?([$ID>!#*E-#%'+XQ^DP^E]0L  3_O/^/OS<.MIQZI!TOY'0\@'@_[$
MVX]-B;^VNG?GTHZ"CDF5?$54'ZWN.?T_B]@#_A[]U[H8MF1T% ^JOJ!P#<,0
M %('#6(8?X\D6_V_O?53U;E\+-G;(['QE4E7%'6Z:FH@G\A4E-"J8^"0=%B"
MI //'^LX*4J.J'C3H_+_ !9V2OGFHL=42/I9D6#2-10$@>@!E' 'U_WOWZO6
MJ'JN+L7;LFS>QLKC_MC11-35GCA9VD:)/(VD7)!\@*6Y%P1]3[]Y]>!J,]%C
M-1HDG"VO]T[ C4; L3HM]+,#_47'Y]ZZMUGVIJJ-UXM%/Z:Q&-M3?1EMS9;
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MDBY_-O>^M='&^&NQ.H^P-_Y9NUJN"/$8'&#*T6-J:^"ABRTD3V:E*R M4,J
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M 7YMQ?Z?['W3JPZ%OK^B*T\0 /J525 LI-KG]1M<_B_ ^I(]['6CT87%PZ
M%-@195N#^#PW)X#?@<W!%OI[OUKIBWI)JG2(C4(DM^H"Q8G@ LUKDW-C<6_Q
M]U/7ND;!(BQDD L.  ?S8%ORU["QM_6]S^/?NM]0):&KJ?\ -P2E2>"R,"
M21QP; \VN#:][^_=:Z362Q57&CJT)#,KK^6 (U6 ;QH"= /TY_UQ[U3K?009
M*B(GD++RQO\ D"YORM]2W(!N?Z^]=;\J=)BIH+LS:3]+@KS^1R?Q^?\ 7_P]
M^ZWU,HZ9?&$L+ 6X!/.H?I ^@]7XY/OW7NLM32NHTV]0MIMJX#6L+?I('^P]
M^ZUTFZZ&70Y8G38_U%R-5^3:Q9OH?Z>]=6Z1+HPE)(/U)_/]?S_A;W[KW4VG
M^G/'TM>YXL>2;?FW^\>_=>ZGI8?[ K<\@_CDDA0+'W[KW64D&YU V_(L.?\
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MSNB3QU,^!K(JMCJUF Q.K'Z>M5U$ C\ #C_$^_:AU[2>A/I_C-OY%5X(ZP!
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MU>C*="=/[0_O-V%A-_[KV^/[I;JR^(*8^L2H@J(DJDR%/D:>3U)-05F/J4*
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M!U!9Y89G'[8%@38CGF_O8KY\>O'Y<.JJ=R8O["OKTT@-Y=1M9CJL;FY6YO<
MCZ<_2_O1ZL.L'7\9.YJ?2J^@W4E;WL2WT/ 4E^0/Z?4CZ^'6CPZ,[F:R6"C#
M(006B6UV]5V%CH]0Y:W!L!_3\^[=5 Z'OKUI9:"G'U4Q@@,0;<#D^K@E5^A'
M)_U_>^O'HVO6Z%<KC@S6)J8C<$$\-8V')%RW^O8_[:IX=>''HTF^\C)28>*6
M,L)$"E2H^C!;CZMZ;$?U-A[H.KGATG]V[LEKNA=]T%9DZ3%Y/(;'W+1X7&I*
ME=F,AE*K#U4&.BJ$B(AHX9:J1 UG9@+DZ??J=U>O5QGJG3I^LV'MGN3:M%VH
MFFBI,-O;(K,\?-%N!=^86*&1UE$,E/+&F-J%N0I0,1IL2/=_\/5<4^75Y>VZ
M+KGM3%THVCN6ER%-$%R$U-!-&\D5.BA?)*A8RJ@\P O_ %_J?;9JO'JV#TV[
M_P"NZ.BQ$\&#^XEJ3$P0T],[C623J7059C?Z_P!?>P37KQ&,=5:[YVYWGMK)
MU\^#VWN.O59)'2H3'3N&2[Z-&GU*HXM]#;_6]N5'5*>O3#U[N+LF7,4G^DC#
M93#A,H5H%RE-)1FJ"QZ9?'YQ:4(9PA8$D VYY/OW7CT?GYTH:3XM=,;;EE\:
MY;>6%IQ%('(J)H]OYR2GI]"JS-KJV0F_"*";BU_;:_$>KG ZI\ZGZHW5L_Y<
M_&';^2H!C<[1;(CW>RR-!54HGK]P[C>&N$](\T%3"G@!)1W!6,K<Z2/>_/\
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MU3?_ #&^PJ7M;MO;O85/A*O"29/:5+C*V&MB,,M15XJIK1K((!D_R2I1;_T
M%^/>R-/6P:]$2Q]V/XX]2D*#I L018CFY_K^/P?>NM]+"C4\$_4@"X47T76Q
M_239"W^\#_8;X]:Z$?'3TM6M/%/3FD$%-*[RP EYY4%D5UYY8A5U?06O]/>Z
M]>Z$:FG_ -^!FXK?NG<NUQX_3<$8O=Z\FWYC;@7O8'\<>_=:Z+1V?@XMK]C)
M0H@CBCJ8R!]"?W&) X/I!_ _'O1X];'#JUSXMUE.*3'%E4@0TPL21=O2QL
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MY01J2ECA0_T/O?'K7#I1=B?+C%=;9**J[8ZWQF$RCGS'+44D+3*SMZ9GJJ"
MS1,TE^21]+W_ #[]@=>I7IVV?_,[Z=01:MZ5-& 4$,=3E/+%%J"KI=*]&U(
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MWI7-@]FG-X+&Y"1X*'"[:FR%1FJBGJ&=(OO\C&[5<@=6L0A1>;<\^ZU/EU8
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MQ] >+6_V_OW6^G"F1" &7CZ?0\FY) X^O^L#?W[KP^73KX(-.HWU)I%K ?@
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MIAIYIG:%8YW=0L4K3QE &-[CWK1UO5TI,!WQM/>%=%0[8@AR#NP'EIQ#/'^
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M_%; CK1KTN=V?&G/[_P<.#S^-]"IX6C6D@@UHZ$'5*D0=N6/)^GY_I[]4=:
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M0+4U\3>210Q!O918$'^@))_VUO;9H.K]8-Q9NFPOJJFCB5P;EV%@4)_3<WX
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MV]5H3]G2@H?CC@7B59:&(RL@#SZ;RM^6+,8R>2?>M9Z]I'3M'\5]O3BYUQW
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MMN[9*XSF*-@3<:01];N.0H5AIL/K8 <_TOHBG6^@=K,=*LI C;@D*0K<$L+
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M"RB*_P#2Z\'Z?[Q[]]O7ND1O;KO;6\J2&DR%+3SK!,9(]21M9K,IX(^GJ/\
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MN""+GG_6]ZJ.O4Z*UO+L.IR<L[^:FCCN2D8DUA?U  FZ_4_4W'^'/NI/5J=
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M4>M4'4['=2X;'D-#0TZ$&X(B7_"UK \FWU]^+$];ITN,+MFDQM0)%AC0C\A
M">1?_$?3WHGKW0NQ*DU*J @IIM8-_OAS[H<'K?ET$F^-G8RIC:JEIXFE4%@V
MA2QL2W)Y_/\ 7W<'K7577=G6T&0[JZSSM)&&EP^X\#D"BI_NS'92GG1K+8>C
MQ_7\\_Z_MT?#U4\<=6YT?4V#WIB,-+G<1C\FU-)-4PK4TM/4)"\T:(60>-E#
M%1:XY]LEB.'5Z5Z!_N'X3=9[PP-0@VOBJ:K/E99J>@IT;4\21M>T5V4K$HM?
MD#WM9#Y\.M%>@FZ9^-^&ZGD2EAHD6DIGJ&CA:(>(R3-S)XR"-9/Y_ ]V9J\.
MM 4Z-32;5PE6N@4T$)(_L*(S]?J-%O="?/K?22[)ZGHLKL;=%#$NHY##5M)$
MP!+)-4T[PQ,MKW82.+>]J<_+KQ'00=<]#T>U^CMY[<JIJI:O-XK-4GW:N_W,
M9KH_MX5A=M3#0'MP.1^/=BU6ZT!0=%AZL^(K[=RE14Y'*;ER%,U+40Q193<+
M99"T@T?MXQ:7P0W1C9C+^T0+>KGW<MUH+Z]6([!V]3;;W4DHC I33Q0'3&@O
M-J8F5D0!5 U-J/\ CQ]/;))(^?5NC7-78ZFH_+YX2 GX<7'%_P!(Y_V_NG^'
MJ^ .B5]SYS.U%54/A!(2R$1Z+CFYM<_XCVXH]>J=5\Y/JSN3>V[::6JRE9!B
M16>1H%\B JKZO4PNPN%X^I/'T_#H( QU2A/0JT'P]WME\C)72;AD@@F"Z(A%
M,VA;6MJ=M36!_J/]A^->(!UO2>A?Q'PLW3!&K1[G.H  !H) O*D:;!R"+?7W
M4RCKVCH0\;\0]TQA5FW%'(!R;Q3 D&Q-_5S:WT_WPKX@ZMI/2B7XL96E9;YA
MY"#8A1*H_P!<>H?0?X>_>(.O:3T_4GQMK5%GRT_^(O)P!_K..>1^+^]:QUO2
M>N=5\:\@X*QYVMC^MO&#<$G\'5?\_7W[6.O:3TE<C\8\ZR'Q[IR<;\\HOTO?
M\Z[_ )_-A[V''IUHJ>D++\8]W02M(N\\U8 Z546M:QY!N#:W^\>]ZQUK3UDC
MZ6WICU(&>R505N%+EM5@  3_ *H6]^U#K=#U#DZUWZA(&3K#SQJ+M<'DW XO
M_0_X_P"V]J7KV>L<G6O8!C<Q96M5@IT@M+;^MCZAQQ_A[WJ7KU.LN.Z_[%4
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M4W#E*VH6/S21J7/HC:P4"UCI-AP#^/K[K7JW0H8W&/+"C.6ED])(9SI.L@H
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M.US9<QLJN=0MKCRFFW'.-5R=0TL .3_CZ@]>M5/IU#/16ULD\IH/D-M:=@[
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MS8K(5&.F\A5O$KAZ:Q(-M0X-_=1UOH;\;*-*!"."GZB21I#64AN++?B]B/\
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MFDK&@5?H(S-35]/"%9?J OU-O=#3JPZA[?Z'W=N=42;<-5C ZBR5&6RLC+<
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M1-?B-FR$ZKT-.;_4W:-3?Z7/U_XGWYO/K2UZ'_Y,$KT_G2M[_9FUR5 ]!O\
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MZH.K2NH 5EF4BUF>UO\ 4^20*/J;<?\ %/Q[9;JXZ$WLF/R=?;IYM:BG8DV
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M_L??O+KQX]6U4DZU>+C+7(*@?U()6_UL3<\_0_CW0]6Z@TE#2))Y&5GE=A8
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M519F!UN00H/]>"/];WN@ZU4]#YB?C1\0.I88ZC>>X]O9.HIA&LE.]93SZY5
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M2R[Z_P#9G_\ &W^BJWU'TU>K]-_K^;^Z]WRZWCY]-7_.$VGU_P"S16LWZ?\
M1+>UQ_J>;:OK^;>_9^77L=*?;7^R#>1?O?\ 9H+?V_/_ *,=&GTZ+_:\VU_6
MWJU6_'OPK\NO'\^C7;$_X;GU4_B_TTVUQZOXC_<+3>_.KQ_[#_B?Q[N*_+JI
MZ/UUQ_LCWC@_@W]][671]S_=&W^/^:XT_P"OQ]?\/>^[RI3JN/.O1LL5_H0^
MQ_WZ/]Y;ZAH\7]U-?DT^J_D].O\ XW[T==>MBGET"7;7\:_AM7]E_IR^QT2W
M_NS_ *.//X]#?YK[CG]'^P_WGWX5\J=>QYUZJ;W_ /Z%?XG/_?#_ &;7[_SM
M]S]]_HUO:YU:M?/CO>]O3_L/>CKKU8:>@]E_V4[PM]Q_LSGV]A>W^B^UO5?5
M_:M;Z_X^]=U/+KV.@^W)_LEO@?[G_9F]/&KP?Z*[WO+:]_S?5>_Y_P!A[\=7
MG3K?2.VS_LE'W#?;?[-'^HW\O^B?3:QU7T<_3ZW]Z[OEULTZ'_ ?[)[XD\?^
MS&V]-_+_ *,=/XM?5S_M_P W_P /=N[Y=5QTH:W_ &3W4GG_ -F"_P US?\
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MMZM-^;V^G_%?=3J^76\=%5W'_LCOGJ?N?]FAU7>_A_T3?2W/Z^?]>_\ C?\
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MV[OEU3'SZ,%\%/\ 1-_HXWO_ '&_TC>3^%TFO^\G]VOO;?P*?[;P?8?Y/?\
M5JU?V_\ "WMMZXK3IP4Z(_T]_LM?^D>+[#^_G]\?XA6_Q#1_<[^+_P 0^X_R
MSP?<>KRZ]5_M>--[<>[]WRZKCY]"M1?Z#O\ 2EN[[O\ TN^/^\TVCS?W._@/
MWWV%/]]_P%]?]XOL?%Y?NO\ +/!J\/[>OW[N\J=:-/GU7A\NO]EG_P!F(?\
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3]/@\?DU7YOIMZ=7O6?EU;K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>j23251332_ac004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j23251332_ac004.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ /P!! P$1  (1 0,1 ?_$ :(    & @,!
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>j23251332_ba007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j23251332_ba007.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ K@#A P$1  (1 0,1 ?_$ :(    & @,!
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M'LW9^Z^S*NHEGCIZL20[.VW(8-!(.2R=-D,[&\@>Z@XJQ //X]NB%CQQU0R
M<.B$[F_G!]]5\TB[5Z^ZMVW1LY,8R5+N;<>2B0.K(GWB[@PE YT@AB:/U7N
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M8Z>TT<4M.>P\W$,DRC7'-CJ/&S(UW90TYJ:=748KUL%^V^K=%CWI\.OCUO\
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MR>R]V9?;&!I=IXK/9;'4>Z*6#%YM<6U5-!*^/K<D'7W7NAJZGS.UNK_CCU?
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#O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>j23251332_ba008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j23251332_ba008.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!#0#J P$1  (1 0,1 ?_$ :(    & @,!
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M9=)ITX#7H\_NO6^O>_=>Z+/7=(Y^JK:RI3+8=4J*JHG56-;J59I7D4-:E(U
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MCFC@JL5CJZ&6$U5*M0X2HE5I 3J01G@,LY/# ZN%'GT8@ * J@     6  X
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MZ]UGIJ:IK:FGHZ.GGJZRKGBIJ6EIHI)ZFIJ9Y%B@IZ>")7EFGFE<*B*"S,0
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M(?Z0O[\;J_TA_P!Y/O/O/[V?WN_BG\4_CGC_ ,@TZOL?X%_N%^W_ (-_N/\
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M:I\_1S9S.8&FWAEMG/0OFX\97U>)H,P]3#C)7H8Z<GW7ND'V[U/O_<W<#Y7
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:=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>j23251332_ba009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j23251332_ba009.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ H0'* P$1  (1 0,1 ?_$ :(    & @,!
M      <(!@4$"0,* @$ "P$   8# 0$!            !@4$ P<"" $)  H+
M$  " 0,$ 0,# @,# P(&"74! @,$$042!B$'$R( "#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL? F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M  (! P($! ,%! 0$!@8%;0$" Q$$(1(%,08 (A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M  P# 0 "$0,1 #\ W2OA-F<QG_CIMO*9W*Y+-9.7?7>=/+D<M7562KI*?'=\
M=EX['P25=9+-4/#0X^DB@A4L5BAB1% 50![KW1KO?NO=>]^Z]T6+Y/\ ;.\^
MJ<9U3_<FIH:&MW]VE4[)R>0JNFNS.^ZNBQ5+U%VQV"),-UMU-N3:^[\KDJC+
M["I(#*E0\%-2S3/(G DC]U[H%=N_/."KQ\V(S72_8DW9&$CV;MO<. VV=MU&
MWI>TLIV9U1TGO/9N(W3E-PT.&I:?:_:_:8Q]/49"HIOXC3X/*U4(:GIH9:KW
M7NG6@^4.^,!V/\A<%NWKC=V??9&ZLZVS-G[2RO7<XINK.L.G^D-][XW@V0S%
M?M>:IW%E\SW=0Q04$]?.934TD,<=+'3U]8WNO=9LS\Y<;0X?*;GPW2G9FZMI
MXS'_ "!W.,[B<MUK1+D=@?&C<F'VUV5OG&4&?WOAZR;'SY#,QTV(HY5AR-;6
M@K+!34@-:ONO=*'*?,O;>VLCMC;^\-B;@VKN[+]R;:Z7SVSLAN?KRLW'MO.;
MSR?4>.VSF(*##[KR+;KV_,O>>VJBNJL89Z?%Q5,L=3(E4*:GJ_=>ZA;-^9U/
MO:CV[%C^E>R*#=._\/UEN+K+:^4RW7,+[OV_VO@>W=R[<R]3F*7>=9C=M4]'
MM[HW<&4K8ZL_<IC11^&*?(5+XZG]U[H0.I/D]M?M[L/=_76'VEO3$5^SZC>E
M#5YG*T%#+@*C)]<[NH]A;TQIR6+KZ^&AK*+=M1+3T25!C;)PT5344X:&(L?=
M>Z,Q[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB;=W]U]N;/[N
MZ]ZTZUQ.)SE/G\#AMP9/"U/4_9&\ZW,P3]DX#;6>BF[)VKN?$[*Z9QN)VE55
MM:,GN&BKX9IX@L$4\B?;3>Z]TG.L_G5M[N2#87^C;J/LS+UG9&G(;<&6&V<!
MAX=KU6SJS?&,W'F-P56<FH(ON,91?:5&/HOO\G0Y*>G6>!:*HBKV]U[IBZ>^
M8N3DZ0V)O[L[9F\LC+-M7K[(=K[UQ\^P7VWLSLCN;;N!WYLKKRAQM!D,'G<A
MB30;]P-!35,&.K#0QYS$1UM973+FJ^@]U[I34GS+SF3RVT<#B?C9VG5YG>M/
MLJ+$T4^ZNG: 4FX.P-A;V[2PNWLQ-/V&8Z2HV]U_L&MKL]40_<TU+)+3TV.?
M+3/*L'NO=0,Q\_>N<=#CJK&[)WEN49WIG&]O;?PN!RW7=5N^ODRN!V)NJ@V#
MD\ ^]8Z;:6[LGM[L.AFH_P"+UE%13M%.QGCIC2559[KW2VI?EOBY8]SI6=;;
MPQM9U7B]S;B[X6IRFSY:#J3;.VLON7$QYFHKJ3/U$V\_[UP[0R>1Q%/B(*F9
ML;CYS7C'UIIZ&I]U[H3NAN[\7WSM3+;HQFT]W;-.$W%_=NOQ.[Z*DIJHUK[;
MVWNM)*"KQU;D,7EZ6GQ^Z8*6IFI9YJ>'*4]72I)**?RO[KW0W>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JN;>OS!W_UOW%W;29[;B[GZ@ZIW
M]M;8-10[=ZCW]@,]BY-\]6]#YK9N7E[OW+O ]1;XRV>[:[?BP3;>Q^/H:VBQ
MM8N1GJ%CQ=4*WW7NI6^_F/NW<6V:ZAZ=ZJWQ2YV:CZ :;<^Y:C9VW8,.>]/D
M]N+XX?8[?HMP5.6ER6Y,6=C9C+4-;5XN; S4T^,J;UD,\M.ONO="'FOF#C,%
MC:::FZM[(W#-G\QC\+UH8JSKVED[-IW[\ZW^.62W)!(^ZZ6GVSB\;O#M+$96
M7^(QT<TV J?/! U6DV/A]U[INHOFBM3N^;;=1T7V;CL3'V=4]=1[OJ<WU9+B
MJBGI_DO6_%*/=$>-HM_56X%H:[LF&"NAIGI5J1MZ9JB58JZ/^&O[KW6(?-S#
MY3<,>SMD=5;N[%W;6=C8W9&)QNS]V]65N)K\/FNM^YNRL/O3^]]5O>CVHN-K
M:3HK-XMJ6*KGJH,N]+'*JT\DM5![KW4BN^;VSEV'5]J878.]LUUM+5;!V_M;
M=/GVSCSNW>?8J;'J<5A:'!SYN3.X[$X*@WOYLOD*NGA-.,1D%IJ>K=*1:SW7
MNC5=?[TQ_8VR-J[[Q6.SF(Q^[,'C\Y38G<V-;$;@Q:U].DS8[,8XR3QT^0HI
M"8I/%+/3NRZX998F21O=>Z6'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>ZJFZZ_F";NQ&P]H[R[GV/FMUP=@=<[2[ VQ/UGTIV#U?5M)%M%]S]
MO8+&;0[5WEG\_O\ QNR!F-M4^(SN'D:BW+D-S14E+$%H:ZKB]U[H5]]_+7=-
M#E]O9VBZ_P!W;:ZEVOO+Y1#L+<?\0V!5;BW-M[XL4>[\9GAMS;]55Y=UP.ZM
MS[:J13^63&962.D0AJ6*;R/[KW2TW1\QZ':<VZL;D^H>POX]L# ]N;FW]BX<
MEL*6+:^$Z>Z^ZG[,S60?)1;MDILM#F=O=S82"A2C$TYR,SQ31PPQO4K[KW7*
MF^8"466S^-W]TUOCK*FVWF,_M/*YO=V\>F4P5+OC#]+M\AH=KUF7QW95;C<9
M'-U*#55.6K):?"461CDIFJWB5:I_=>Z9-H_.7;^\YMOOA^J>P*K#U>8VGM_=
MFXZ;(;';$[.S.\_DKOKXI82G>.MW/C\OGZ>J[/V#650EHZ5A_=^.2J8+5B''
MS^Z]UESWSCVQMG#=?;BRW5O97\([8P.<WYUT,9'MG.9K<76&WJ':M96;R_@.
M'S];7TM=D!O;%?P_" 29:I6OB#Q0S)404_NO='B]^Z]U[W[KW7O?NO=>]^Z]
MT3_X(?\ 9,VU_P#Q('?_ /\ !"]I^_=>Z.![]U[KWOW7N@9[[W9MOK3K3<'<
M6X-N+N>JZ;QN=W_M7&AJV.JEW4NU\_M:AI*"HQ^/R]51U6=HMT5.+,Z4=688
MJ]W\+D6]^Z]T4?-YFEH>G>P.Y-M[1VKV3W3DNVNG=O5VQZG"=P]*;5'9^9[2
MZ8@V4NY.LNS\_P#>;9WMC:C*8#(_W@GQ^,J<W1TN.JI42D:*-?=>Z3NZ>Z.@
M>S.UL9A?]&U'NWJ_?70=?WWNK>-(^>QN[MW]A;^J/CEU?U[T;!BZ&MQ5/E,A
MV!UQN_#4VYMLYBIAIJN"OVW%5TTM/4R.GNO=+[,=S] )E9]AY[H?L**NFQ/9
MVW^V,;/AMG5%-U-@^[NP]DS]ET?9-70]AU-+-2]BY[>&&SLJ;?DSLM5C)Q60
MCPQRZ/=>Z".+M3K/L/L[&;M[-^+>ZMLP1;NW3NC/5L^3P&6R>W=Y=)_)?:O2
M&UNP^QJK:G9XV9G<+BLSU)MK*46-C@SF0QE?BC4444Z4CUDGNO=+[Y(Y#:74
M.XMA[7?X_P!9G>KH]E['V[#F]HX7?46Z5J-A#?U)U+L_K7LS;E=AMN=0[XV5
MN3,4N/P?\9S&(R&YJW>L5#A:EJNGJ(I/=>Z,E\<*/K+-[.Q_9FP<IM7,Y+=V
M)H$WG7=<[UW/N/K.3>D-/32;RK-IXC+9FMQ..FS.>#5-7D(Z6#)9O]FJKY:F
M5EE/NO=&.]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3/_ '?P
MW\?_ +T_PZG_ +P_P?\ N_\ Q:S?=?P;[W^(_P .U:M/V_WW[EK7U?GW[KW1
M9=A;7P&Q^^*CK'#==X'![.VSU[%OSKG,Q[TW;N'*8F?*UL>S<_MO#;5SD38'
MK?9.+QM+3TV,Q6(J7H(HD?Q4U(MD;W7NBQ;][!ZKZDWKD,7V3T?@]NXSH6CV
M[MW-;E3,Y'$]?5'1?8=97=-?$U-LU>YLMMKKRO[(W/NS>=9M7RY^JIX]HPX?
M=$TE?08W(XR?*^Z]TO<C\I_B5M*79F\1MR:6*HV#NSMC:&;P55L;-Y5JGI3J
MGMBBSVW\)M'%[^J]^9S-8'J_;.YJ.FRM!B:S:=8C>"GR\T]13J_NO=0>]=D;
M-ZJV#L3M'87Q?J,KN6L_AFV<CLO+XS=V[)]B[4PW5$T]-B*K"];9W=FU]HY#
M<O\ H?VILRKW*DSXK%!L=792>LH\5'3O[KW0E=(5?0_R+FR78&.Q6T?[V8'=
M6Y,Y2T.V-P9*BW;0[(WYE57#MV4,)G89<MB>UTV'!F,AMW)PC&T]?0ICJ^A.
M5PE0T?NO=&DV)L#:W6N BVOLZCKL=@J>9I:2@KL]N#< H(Q!3TE/C\=4;CRF
M6J\=A<;14D5/14$$D=%0TT20T\442*@]U[I9>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[I#Y?K;8N=QN\\1EMM8^LH.P<I1YW=\3">*7+YW&X
MC;N#Q6=^Z@FBJZ#.8?';1Q8HJREDAJ:*;'P30/'-$L@]U[HI_P >5Q_8=+V!
MA]VXO%T^_P#;/^CT+M'=G67=6U]X;9PVQ.Q>P=T]+9G>6[.W-Y9G-=UT8WMB
MZ_)T>Y,<:6EK<A!77DED#"+W7NBZ8_Y*]#[*W#69+N7J#']8U=;D*F?=M+E=
MPM*^.[OZJWYANS^_JOK.FW_FMFXS,]:;'[%RFV,Y!4[/I*G,]B9[,_>4^%J*
MF@JV/NO=#OF>Y_C;B.PMV]<Q=5YC/[_VMOS8L$> VM4]=;ARN>W'V!W7EM_8
MK/4U)C>RYJC:U/C^Y,-+FJT[F3 S0R$5*Q24PD9/=>Z3':=7L[XJ=G;$KMI?
M'VLR>T?M\?DI-QXG#[[W1FJ_<5'M_M/9&QMC;+W=5U\G7O7.0VK!O%-M[>P>
MXZ_&TF;AWI2X?;JH] :8>Z]T+O3757QX[.ZMPVXMNX[8N8I=R;1V'@=W2].[
MTW;3]=R[MZVQ^QZ7"Y[;<>*S]$L&[MAU77N$BV[NHQQ[IH,=AL8(*Y(Z>G"^
MZ]T;;$XNCPF*QF%QXJ%H,1CZ+%T*U==79.J6CH*:.DIA4Y+)U%9DLA4"&)=<
M]1++/*UVD=F)8^Z]TX>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@?[PWQNKK
M[8YW!M3#R9"?^,8W'Y?+IM3<_8*;*P=<9HZO>53UULB6FWKORCQ52(8Y<?BY
M8*@1U!J9)8J:GGD3W7N@+R/S.V9MBHR=%68W<'9M/@]O[DWKFMY]28; 56Q\
M9UUL'JKH'LK>O8QR6;[!7^-;;./[]Q=7C8,1)D\K7TLCQ4E+6/3/--[KW2)[
M1[F^-6T-E;0H-Y]?;JV]UUL#LZ;I/IG<\&[ME=98S*;UZ_P?8."W;M;8NYZ[
MN#8^X<-B=K[<ZPW#C\E%FY,31Y^EHWHZ1<J*F"&?W7NE%VEV3TSLY.LQ_HK_
M -)/7W:6Q^R=Y8/&[?P<.0SNX\QWGW!T-UY_"J/;V[:_ 888_M//_)R6HS+9
M::D@I8=;SF*(2A?=>Z8:'?WQGI\!O&6IZCWLV!P?6/<N1^0.XMTR8[.5W7&Q
MILQN7KKL^B[5W#G.P\KNC?,V9RGQCK,,C;?EW4QH]L4PAECQWV4DGNO=)O-_
M)/XI=A86LR%9U9NK>V.R\W:O:?9E?MC^XVZ:'KN+JKK'JKKWL/L+<F\-E]F9
M';N4R6#ZA[IP,$$.S\EGLX:9ZB.FI?XACJN*G]U[K#UWV'TQM[$8C&M\<]R;
M&KMU]@=PX;#]?3Y#;&\=[[^WA\>_F924^W]SQ;I3L>JPLF4R?=/;63W75MEJ
MX2QU]57U535M34WW-9[KW3EAMW?&.?>N&V?B>H.VL##C,MM'+9+=&-R]?@-E
M]0;L[4[<[)Z0I>JV.%[2I\ABL;N7N3J')8G/;>VIC\ALZJK'I*O(B2FJHZH^
MZ]TM/D+\J=]=']A5V"_N!#5[.EV33S8#<F9Q>Y\3M^7=V5H]W5,.?S?:$\4'
M6>+V;LZKVY3IN'#?=MNFBPE35[C^W7#8NHED]U[HXVT-U8'>VV\3N?;.=Q>Y
M<+E:=GILSAGU4%5-2S2T60C2,S3RT=119&FF@GII6,])41/#*!+&X'NO=*3W
M[KW7O?NO=$_^"'_9,VU__$@=_P#_ ,$+VG[]U[HX'OW7NO>_=>Z9=R;=PV[M
MOYS:NXJ)<E@=QXG(8/,T#35%.*S%Y2EEHJZG%3234]73-+33,!)#)'+&2&1E
M8 CW7ND#B.D>M\+MNHVK3XG,5^,K=\;9[(R55N/>F^-V[DS&]]F9S:VX=K9_
M.;RW3N/,[OSE1@Z_9&(C@CJZZ:!:''046@T<8@]^Z]TE\?\ %OH?%+N)<=L*
M.D?=60[-RV:J(MQ;M%;-ENWMR;.W;O?+45<<\:W#Y23</7N#J,54T4E/-MS^
M$TL>(:ABA1![KW3A0_''IZ@HLE1)MC(5IS6/;&9W)YO>>^MP[BS],V?I-S"3
M<&Z<]N7);DSV0CRF/IA'5U=7-51TE-#2)(*2&.!?=>Z]2?''IZC&Z1'MC(2K
MO/(;ER>?2NWGOG)1S5.[]^S=G[ACQL61W+51[?Q]?ORIER0I,>*6E@EED6*-
M(W=#[KW0A;MV+M??0V_'NO%0YJCVUGO[R4&,K2TV)J<H,'F\!$V7Q;EJ#-4M
M-29^:6*"JCEBBK(X*E5$\$3I[KW33UCU5LCI_;?]U-AX_*46*>L_B%5/GMU;
MLWQN')5JT&/Q%/49G=^^LYN3=F;DQ^#Q%'CZ3[RMG^SQM%34D'CIJ>&)/=>Z
M$3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TG_[K8'^]
M7]]OL?\ ?S_W?_NM_$_NJS_BP_Q'^+?8_9?<?P__ (N'[GE\7F_LZ]/'OW7N
MDGN[I_KW?,VY*G<F&K*BLW9B^O\ #YK(8[<FZ-O9-J3JO=N;WWU[-B\GMW-8
MJOV]E-J[OW%5U]-78^2EK?.Z:Y6$4(C]U[H.\[\2^B]SU)J]Q;>W9G))<?DL
M?61Y7MON"NI,JV7ZNW!TKDLSG:"HWY)0Y_=E7U;NBMP[9JMCGR_V\B,*D2PP
M21^Z]T-6\MH8'?VU\WLS=-(V1VUN6ADQ.X,7YYJ>',86I95R>$KV@>.2;$YJ
MCUTM9#<+44DTD3>ES[]U[I,[*Z?Z]Z[W+OG=^T,+68S/=CUD-=NR>?<FZ,Q1
M5,T&<W9N<)B,-F\UD<+M6CGW-OO,Y*>GQ-/14]1D,G4U$J/-*SGW7NA,]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T'NT>KMG[
M(W!N[=6#BW%-N+?+8P;CRNY=\[XWM4RTF%J\[78;#XH[TW'N"/;6W<36;GR$
MM-C,8M'CX'K)2D*ES[]U[IAR?1'6>4R=+FSB]P8G-4>Y-P[JBS.UM_\ 86S<
MO)D]V2X6HW/2UF3VENG"5N0VWGZG;>.FJ\-422XB>:@IY'IB\,;+[KW3'BOC
M'TMA=Y5N_J';.8_O/6[@FW2:BNW_ -BY7%T.<JMX;BW_ %E7A-M97=E;MG;T
M==O+=F0R%1!04=-3SS5)\B,JQJONO="=NW8NU]]#;\>Z\5#FJ/;6>_O)08RM
M+38FIR@P>;P$39?%N6H,U2TU)GYI8H*J.6**LC@J543P1.GNO=-/6/56R.G]
MM_W4V'C\I18IZS^(54^>W5NS?&X<E6K08_$4]1F=W[ZSFY-V9N3'X/$4>/I/
MO*V?[/&T5-20>.FIX8D]U[H1/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=)?=^T,3OC#/@<U5[HHJ&2H@J6GVAO?>G7N9$E,Q:-4W'L'/[:W#%3L3^Y
M"M4(I1PZL /?NO=!72?&#HNAQF8PU'L2.FQ>>V'N#K+*4<.X=V)%/L;=.QNK
MNMLY@8K9[71QUFRNE]LT*SP&.J@&,\L4B3U%5)/[KW7J_P",W460GR-0U!OC
M'OD-Z5_8D<>W^XNX]L4V!WMF$W2F>W'LRCVWOW%4>PLAN;^^^8;+'")CTRLF
M2J'JUF>5V/NO=+C=/5&PMZY/;&9W1@Y,ME-G1TL6W:R;,YZ&6A6CWSUQV33F
M7[3)P)D9%WKU+M^N9ZH3.YH/$Q,$]3'-[KW2-J/C5TS4Y+)9-]KY*.7.T.\\
M7N:AI-[[^H<#O'%;_P!S;ZWCN;$[YVS1;HI]N[XQ,VY>S=P5='2Y>EK:?%/E
MJE:%*9'T^_=>Z16X_B%UMNG<_7V4S>5[$R^V]B;'[:V7)MK/=N=T9^MW72=L
MY_J+-96DW=NW*]EU&=W9L](.J5I:K;N8;)X?(Q5Q$D2I$8YO=>Z5]9\8^EZY
MZJ6IVYG#45&X-[;IIZN'L3LFEK<)GNQ-][-[.WC7;3K:7=\-7LW^+;_V#C,J
M(L2]%#2U4<[4Z1"MK14>Z]T\8[X_]28J!Z>BVK(HFDZ\J*N>HW%NJNKLC7=6
M=FY_N79F6RV2KLY4Y#+YRF[0W3D<U7U]5++69JLK)3DI:M6T^_=>Z?NP.I]A
M]I0I2;\PK;@QZ;=WMMA<;/D<E2T28_L' MM7<]7!'CZNDDH\]4;7J:O&P9*!
MHJ^CHLE6PP31I5SA_=>Z>MD;(VWUUMJAVCM.DK*/"4%1EJV-<EFLYN3*561S
M^8R&X<[E<ON'<V2S&X<[F,UG<K4UE765M545-34SO))(S,3[]U[I6>_=>Z][
M]U[HG_P0_P"R9MK_ /B0._\ _P""%[3]^Z]T<#W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T
M3_X(?]DS;7_\2!W_ /\ P0O:?OW7NC@>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NF.JW/MJBSV*VK6[AP=)NC.4>0R.$VW5
M9:@I\]F,?B/ ,K78K#RU"9#(4>,^ZB^XEAC=(?(NLC4+^Z]UQK]U;8Q6#RFZ
M,IN/ XW;6#7*OF]PU^8Q]'@\.F"JJFBS;93+5%1'08]<-6T4T-49I$%/+$Z2
M:65@/=>Z>*>HIZRG@JZ2>&JI:J&*HIJFGE2>GJ*>=%EAG@FB9HYH9HV#*RDJ
MRD$&WOW7NLWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[HG_P0_[)FVO_ .) [_\ _@A>T_?NO=' ]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%A[,Q.]-R]_=&8
M^CZIRU;USM&JRO8>Z^WJ.OZ\$%/NFCV]N[:.R=@28S([TQ'84>-IANROS%?7
MT6.JHDE2AHHXZF&ORCT'NO=%PW9TKVMB.FME]7; Z_W=@,=LOY-=A=PR4?6Z
M_'N=I-@GY)]C[IZ\P.S,;VQGIMDT.[L12;LP6\\<,CCOL:&' O&9HLLE+12^
MZ]T?_K]-W1[#V3'O]<2F_$VCMM-[)@%*X)-W+AJ)=R+A5(!7$KF1,*8?B'3[
M]U[I7>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NB?_!#_LF;:_\ XD#O_P#^"%[3]^Z]T<#W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3Q_-B^1W=?Q_P#] ?\
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MGJQ34=4BZ>Z;_P#3EB/]+?\ HL_NUN#[;^\']Q/[]_<;=_NW_I._T;_Z8_\
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M$\MM?LG;>/H\-N[(P29?K7>>'W7M?+5$VUXBK-@MY8&BK(Z>H9H99:=/)&Z
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M+5U=-'4T]*8:/P^<O4LRHP\\D4>E2O/-_>P*FG6B:"O1.=R9+XI[RG:JW?\
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M[H5FH\I5S44]%6RK4;R"&"GEI+L+,?IZ3S[TSANM@$= E_$_YP/_ #ZK+?\
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M /AFC^;Q_P \'BO_ $I7:_\ ]<_=M:^G6M)Z]_PS1_-X_P">#Q7_ *4KM?\
M^N?OVM?3KVD];3WQZSVPNM?A+6=N[SV%+O+'['W#\A\]FJ;!;6PVX=TS8;&?
M(3M%JV:CARLU!#)!BZ,O43-+4PQ04T4DC,%4^VZD<.KT'1B=Y]G]0=5=@87:
M]=UZ8:@UG55-E][87;^R:7 ;$K^\NP<AU-T[#FIJW-8G=574]@=D8Z3#THPF
M.RK4<[)+7?:4KB?WZI]>M4'5*?R1_P"9^]O_ /B0-R_^[*?VK3X!]G2=OB/V
M]#9\ /\ LHC&_P#AJ;H_]Q8/=9O@_/JT?Q= 1_PRIWU_S]7J'_J9O/\ ^Q?W
M7QE^?3FCJP;X&_"GLKX8/W'N+=67V[V+-NO;F"&$V_U_/-'F:^MVN=P5S8N&
M;>B[3P4-;EWR,<%*U36T]*LIO/-#'>0-R.'I3K86G0C]9=TU [\R,'8&^ZS:
M5=DX^V,3V!UCO/=VWH\9UCE_],G1_7?Q-V]_#8*^NPNW]R=N[5WW+58XT5;,
MVZLOFI8(I:XTE%#1-]6Z,1\:\AN/(]9Y%MU[IS&\\SCNY/DEMYMQ9Y<9'DZO
M&;6^1G:NVMOTLL6&Q^*QD%/B,!B:6CIXX:>-(Z>G1;$@L?=>Z'SW[KW5*'\Z
MWX8?(#YG=7])[9^/^UL9NG,;+W[N'.[@I\GNC;VUTI<;D-O1X^EFBGW#D,?#
M5.]4I4I&S,HY(M[NA .>JL*\.M=;_AB?^9+_ ,^AVI_Z-OK3_P"R7VYK7JND
M];S75.!R6UNKNMML9F%*?,;<V#L_ Y:GCFBJ(X,EB-O8['UT*3P,\,Z155.Z
MAT8JP%P2#[8Z<Z7WOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJZ_BQU'MOL?X?;FP-4:C$Y'M&
MC^4/5V7W#2233U5)@L]W=W3BQ+38^HJ#C348]LQ),A\:L[ *S%>![KW0Y;_^
M--'VCV!U[O/?.;V[F(.O-[4V]L:5Z[Q%/O21MM[MIMZ]?;7@WR<G,V.VKMC<
M6/HZNI2.@.0R%11QVJZ:":NIZSW7NJ6_DC_S/WM__P 2!N7_ -V4_M8GP#[.
MDS?$?MZ&SX ?]E$8W_PU-T?^XL'NLWP?GU:/XNCQ=@[HSF"^072VZ]SXS*8+
M([<V_P!D9KM_&=99'O;L/&4/7V%V#VQ7[9JLBE!LK [)W/M.LKJ:"22E7##/
MMNUL;2T7W2PEI4O3_0M])[5^V[>^3.^:3'Y;!8',[RVKL?"8RJ?.#&;AEV;@
MZO=F[>R**FSE3(U-79[?W:66P4QI88:*:EVO22P>1'#GW7NC.^_=>Z][]U[K
MWOW7N@O[:W[N+KK:.7W#MKK/>'9V0H<'N3(T^)VB,1-*E=A\'6Y/$T5?13Y.
M/<U9'N#)4\=#$,+C,S6)-,&:F\89A[KW5<$_R"B;X-]A9+=/?4E/W;M#<'R(
MJL9D]^[YRGQ1WIN');4[K[FP&S\A38;=F!IL]BL7%!M:3^"X2HQDF&R%7A5P
MU83215PC]U[JUG 5%15X+"U56]4]54XG'5%2]=C7PU:]1-1PR3/68>5GDQ54
MTC$R4S$M ]T))7W[KW3M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HG_P0_P"R9MK_ /B0._\
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M6_\ $/\ YE_\;_\ Q('S%_\ ?P=D^_=>ZL@]^Z]T7_;G_94_<O\ XK_\:/\
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B]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>j23251332_ba010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j23251332_ba010.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ D@'$ P$1  (1 0,1 ?_$ :(    & @,!
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M )],/_\ 5?OW7L]>_BN;_P">6K/_ #Z8?_ZK]^Z]GKW\5S?_ #RU9_Y],/\
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MRU9_Y],/_P#5?OW7L]>_BN;_ .>6K/\ SZ8?_P"J_?NO9Z]_%<W_ ,\M6?\
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M%1R4FZFKMKSTV*>?^(QU&)?<&:]^Z]TMNH>P,MM;?/6%1O;O3.;IRF/WGLK
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M=XY;/X2:CVKM:E2EP#9>79;XS-XVHDI<G%141K_=>Z;=N;PZH_TT=5ON#?>
MI*' TFS$W)B=R[6JZ&;9^YZ7K;YO5NQ\E#G*^N?#9JHRJ;DJ&IJ>@B?(4V0H
MZ=(C*]213^Z]T,F(V5A-A=>[PZTVC\GNE8L3+MCH??>6W%CL+DZC/TU!M7K3
MJ/8/\+7<&UMXO)18/M#96S$JL)68J>BW#0194RX\S?MU2^Z]T%6,Z#Z!PVP=
MI[:J_E)U!FL_M'M' ;URF2I-V;[V+1[HQ6[/C13]5[>VME\WL;M^AW^F-.P\
MM5Y[%QUN:RB-C';S-+$E17#W7NK?,-U]MS%5>U<KCZO<XDVKM>EVMAZ2+?\
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M$.IWK6;+B^1?4NWM\]&_W1VI#V+N;+;ZWQN#= S?5N>WW0)O$[9[#V?D^O\
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M_P 3NU:RDW=E*G#X@[\[#I=BMV!N_9>*R..SNX\#L;Y-=N]K9KK!\OV/T[V
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M;4W9MV.2@BV?083(OB8\=/''14T$WOU#U[H<^Y_CKOCL?';-BQ&\=\)D-G]
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M[-7^RP?W"VO_ !71_IJ_T3_Z(/XC]O\ W\_TE_PO_<9]GYON_P#2/Z?^+?\
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MXS-53X'./F=[4U2HH?!%Y_MD$<KR/&LC)&))]\.''K7^#J=#WY\@L1'!'5?
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M8[3J#??Y.BH])4L&!^XGCMI*D'^EC[]0]>Z;!O?;4@O1UU1E5Y]6#Q.8SZD
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M8FNJ>V-]Y"24$TR[9WAV!3=8[/H=R. ?\B;9^Y8@X*HTPLQV!Z5/7N@]/5V
MW_&9:CKGNGY15,L2$YWY5;IK]@].U=73RAHGK>GZ_!X3;:2V DBK<7UC-!*
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M_P"@7L+_ .MOOW=\^M4'2:JOCA\/:ZHFK*WH;XU5E74N9:BJJNKNKJBHGD(
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M J#_ (%5DQ]Z.H\>MXZ$7^\&!_YW>(_\^5'_ -?O?J'KW7O[P8'_ )W>(_\
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ME2?^<T/_ $9[]UZ@Z]_#Z#_E2I/_ #FA_P"C/?NO4'7OX?0?\J5)_P"<T/\
MT9[]UZ@Z]_#Z#_E2I/\ SFA_Z,]^Z]0=$OW'MW;]=\_^KZFMP6&K*C&_%3M.
MLQU158RBJ)J"LA[=ZD,-712RP/)2U,1<Z9(RK+<V//OW6^C9[SVAAM^[:R>T
M]P)428?+"D%8E+.U+.PHJZER,'CG4,T=JFD0GCD7'Y]^Z]T"U;\;,'%NJHW=
MM;>&[-MUU1N-LU#B'EH,UM?!T6Z>Q-K]B=U8K;F#KJ15HV[SJ]K)29J>KEK_
M +*"LK&Q<=#)6U;3^Z]TD/\ 9)^J?LOMO[Q=GBM_NP>LQG_[Y_[^)>BS1_PU
MNA!E3C#-_HW.-]'G(.Y?NO\ <A_%OXG_ );[]U[I2_[*KLG^(>/^]_9?]P?[
MV?WO_P!#?]Y,?_HK^]_OC_I(_AO\#_@/\8_@G^DC_<Q]O_$/T_[BM7\!_P!Q
M/OW7NC-^_=>ZZ(!!!%P000?H0>"#_K^_=>Z*=BM@;)JF[&^)O:.T]O;TZGW=
MA<KNC8FT]W8['YO;N>ZWS&1ACWKUY/AJZGDI:BCZUW9DX#31^-8:3#YG%T].
M+T;L+'.>M#TZ:HOY>/P2M$V3^('QSW554\<44&3WYU%LGL/-P0PQR1QP0YW?
M.'W#F8Z=1-(WC6<(7ED<C7([-7K?0[;)Z.Z5ZT,!ZXZ?ZMV :7Q_;'9/7^T]
MJFF\5,:*+P?P+$T'A\=&?$NFUHO2/3Q[]U[H4??NO=>]^Z]U&JZRDH*>2KKJ
MJFHJ6(7EJ:N>*FIX@38&2:9DC0$G\D>_=>Z"6K^0O1E+/+1KVUL#)9*$#R87
M;^YL7N;/W*%U5,!MZHR>:E>11Z52!BY( !) ][TGTZ]4=15[TP=>H_NQL3N7
M=4K)KC2FZEWKM6GF0H)8WI\OV5B]C8&IBFB]221U;1L.-5RH/M/V=:KUVN_.
MW\J/]P?0U9A7U,G_ !D_LG96W8_3(%\@?K67N5_#(AU(=&O@AE4VON@]>O9Z
M\L/R-RRJ[Y'I3837!>E3#;Y[9XNX:*/(/G>E[,RE2)#2D*01H:]QKM^?7L]=
M_P"CCLO(L9<[W_O.C9M.NAV'L_K+;>(<%2)4MNC:78.XHE)L4,>321.;LW!'
MJCTZ]UU_H$V;5DON#/\ :FZY7),RYWN'LW^%U%['3-MC$;HQ.T64278?[CQI
MU6%E"JOM1^76Z=.N)Z(Z3P57_$,1U%UK0Y.X+9:'9.W/XO(1)Y5:;+/CFR,[
M(_*EY6*V%OH/?JGU/7NA2@@@I88Z>FABIX(ET1001I##&H^BQQQA411?Z  >
M]=>ZR^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NB>YK_LOCKS_Q4OMC_P!^YU%[]U[HX7OW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H(.Y=I9S/;>QVX]EPK-V)USEXMZ[&I
MGJTQ\&:R5#2U5)D]G9"NDCFCI,3OG 5M5B9YG204HJUJ50RP1D;'&AX=>/4%
M.QNTLHBC"_'[=>*F9$99.Q-\=9[>H+R1&10TNQMT=HY2,1MZ)-5$'5B+*PN1
MZ@]>M=>#?([+*P:#I+K]KD+(*K??<"@#QD.T1H^CB2]F73K]-PVIK%3[M^?7
ML]<SL+MK*$/G.^<IB'#!_'UIUYL3;M*;%_VRG8E#V_5>%U8!K3B2Z@AUY!]4
M>G7NN#]%8+(:6W/OKN7=,XU:I:CMW?.U*:;R1B*5:G"]:Y?8VW:J*51S')1M
M&IY55N;^KZ4Z]3J71_'OHRCJ4K_]$O7]?E(W:1<WG-KXK<6?UO8NS9_/TV2S
M+EW&HWG-W9F/J9B?:F]>MTZ%FDHZ/'TT5'04M-0TD(80TM)!%34T09VD8100
MJD489W+&P%R2?>NO=2??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=$]S7_9?'7G_ (J7VQ_[]SJ+W[KW1PO?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]T3W-?]E\=>?^*E]L?^_<ZB]^Z]T<+W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$]S7_ &7Q
MUY_XJ7VQ_P"_<ZB]^Z]T8+L_L.AZMV?/N^NP6?W,JY[9>V*#;^UQ@SG<OG=_
M;TV_L+;E!0-N;.;:P$)GW!N:F$DM77TT,4.MV?TV/NO=(KL+O_;'5V)VUD=Y
M[;WK05N:VGGM_9W;]'C<-F<OU_L/95-M^?L?=V\)L/GZ[ S8SKM]U8^+(0X:
MMS%?525(_AM/7HDCI[KW2+?Y=]=O64N)Q>V>R,WG-RY"6DZMPN.VYCX:GNBB
MHQNB3+[@ZUKLMG<9@ZC 86DV5E:J>?+5>)9J*"GJ84E@RF'DR'NO=#1_I3V)
M_HK_ --G\=_XQE_H_P#]*7]Y?X9F/^/$_N[_ 'L_CG\&_A_]X/\ BP?Y1]K]
MI]Y_8\7D]'OW7NJ]OA]\8-C=M_$GXM]K=@=D_+O.;\[-^.G2786]LW#\]?G%
M@XLQN[>G6FV=R;DRD6%V]\A\5@,1'D,SDIIEI:&EIJ.G#^.&*.-50>Z]T8O_
M &1[IC_GM?E__P"G"?GU_P#=+>_=>Z]_LCW3'_/:_+__ -.$_/K_ .Z6]^Z]
MU[_9'NF/^>U^7_\ Z<)^?7_W2WOW7NO?[(]TQ_SVOR__ /3A/SZ_^Z6]^Z]T
M6#YM?%C8?6'PY^5'9&P^S?F+MW>VPOCUW!O#:.?IOY@7SNJ:C"[DVYL'/9;"
MY6"GK_D=5T,\M!D:2.54FBDB8K9E87'OW7NC/GX/],'G^^OR_P"?Z?S"/GR/
M]X'R6L/?NO=>_P!D>Z8_Y[7Y?_\ IPGY]?\ W2WOW7NO?[(]TQ_SVOR__P#3
MA/SZ_P#NEO?NO=>_V1[IC_GM?E__ .G"?GU_]TM[]U[KW^R/=,?\]K\O_P#T
MX3\^O_NEO?NO=%?^3?Q9V)L;_0*=J=F_,7#_ -[/DCU'LO</A_F!?.Z?^)[8
MW#GOM<SB)16?(ZH\<-=3^EGCT2J/TL#[]U[HT'^R/=,?\]K\O_\ TX3\^O\
M[I;W[KW7O]D>Z8_Y[7Y?_P#IPGY]?_=+>_=>Z]_LCW3'_/:_+_\ ].$_/K_[
MI;W[KW7O]D>Z8_Y[7Y?_ /IPGY]?_=+>_=>Z]_LCW3'_ #VOR_\ _3A/SZ_^
MZ6]^Z]T5_=7Q9V)0?+SJ'KND[.^8L.S-Q=,]L;DS6"7^8%\[FIZ_.8#<&Q:/
M#Y"2H?Y'-6I+0TV6J%54E5")#J4D*1[KW1H/]D>Z8_Y[7Y?_ /IPGY]?_=+>
M_=>Z]_LCW3'_ #VOR_\ _3A/SZ_^Z6]^Z]U[_9'NF/\ GM?E_P#^G"?GU_\
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M[KW1JO\ 9'^F/^>U^7__ *<)^?/_ -TM[]U[KW^R/=,?\]K\O_\ TX3\^O\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>j23251332_ga011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j23251332_ga011.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ & !G P$1  (1 0,1 ?_$ :(    & @,!
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MO@N\?YI7\H+X][IJ<AD-E4&+^?'R!WWLT5#P8+<=)M3H?;_3NVDRR1PRR35
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BV=S>5S^6S&,VY#2Q35U34?:T\DB1!05T>Z]T='W[KW7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tm2325133d1_ex6-001a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2325133d1_ex6-001a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X &<# 2(  A$! Q$!_\0
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M<Q9?\CA-_P!=+C_T7;41Y7?38'=6U-/^U;S_ * &H_\ ?RW_ /CM']JWG_0
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M[/Y!^[Y>-NWZ8XKMH8M48*,=[W?IV.>I0]I)M]M#@OA3JMOXC\*+!<3W1OK
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)** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>tm2325133d1_ex6-img001b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2325133d1_ex6-img001b.jpg
M1TE&.#=AA  < '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M!P" 61M#BAP9DHO'#])(JES)$F$7CR"FM9Q)LR$UAM5\  CPPUK-GT )6A*
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M!P:AG#.,*&=< ( *P0S$27BVG)'!8'W$IE Y,P#P D'@&((4 (? $P@ --0
M@ 8 H$'0.DW$6((&B! T"H<>26 #$%XDHL@?4FG_E 8 /QB$300 .&?0,A8
ML A!TD !@! #J6&?1P&L<5-#OX#%Q"_&D!*% 1YEP(A +P @ 0(C2,C'0-Y(
M 0 7[%B8HD![>+3 %*68P](/ "1BD#D*-!#.09WLQ Q!Z-P P!$"X<)I6$@T
MTU"_'D$@V 9"."/0+@L08,$$[:P!0","F4(% #B4 PP"+"P[2P%784)3#@"<
M8M M .B SD&H +##0-DD(RX%YYKBD0E4<+"7(0RY4X5'+3 QA!EWB/(.09D
M0)DC\+#)QCA6*%R$NYM <,5 ;6@[($/8@$.-BP]Q4\$!1A;4!P!6'%0.%@!\
M\,DC;NC@40P."Z2)1\O _Y,.)-$!, A#J020P=()17+>!N# LTV/%7@DQ(>)
M0)#%0%8- (Q!Z-"BBB-L1$$%#CH8T $%0(S'4"T!>-!X09( L,9!N=37P!.>
M?"C0*5<M"P\R/'C4Q>L(Q>Y G0DEX9$D QW"J008#Z0SL0)-L9,7!AFBL& !
M+$ !"T$(R9 M -QPT!OQ'N3-" # @<HJN+AK$#,0:%$0-O "D,(S"4W"\4)7
M"!/B!.(,0(RC(+S( , $P@H '"!&Q(-'["P@@B?$(1 +", GOI$AAK1B6 ?9
M @!,=I!L&4PAM@B FPQR",H@P OL.(@X(D"&A=R%!XI*R#=F, 2"R*$K,,!#
ME/\$$@SM#&05"VA!K!ZRMCE8@QO3P$4G7"$.$@#@#J]0Q"#H8 4MT 8&  @4
M"@%PN8/X8DM7H<00"7*.=2Q$A UJR HZ@#R!5.(Z'I'!%>0@"F+48AC-:(8N
M%$$R$CZ$#  @  <:$!B/^"%X@J' "J+$@@DM)!@ V$)"RB$'"UW(#,2(R#I,
M\;*&4 ( L"A(.^K0 \% (  %($  $!"8#0S0(:L800E*,(,EO $0T+!&,KYP
M!T@ PA+1H VVGE#*A&@C&9M3B#+J$#GF7*,EXK! %=1GBS2T  -HXM@P+O*R
M'#*D'=<<23L0D08I1* 7,Z$# $Z($&K4HA.?X$0<"A$BBV(T<S$DT8;N6+*.
8#G@@F@!-*%5D(0-:*/2A4QD.1#<2$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140386091726336">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>N-2 - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="24">3 Months Ended</th>
<th class="th" colspan="10">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 24, 2023</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><sup>[10]</sup></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><sup>[10]</sup></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><sup>[10]</sup></th>
<th class="th" colspan="2"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><sup>[10]</sup></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><sup>[10]</sup></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><sup>[10]</sup></th>
<th class="th" colspan="2"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><sup>[10]</sup></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><sup>[10]</sup></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><sup>[10]</sup></th>
<th class="th" colspan="2"><div>Sep. 30, 2023</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">0001635977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">N-CSR<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">abrdn
World Healthcare Fund<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_FeeTableAbstract', window );"><strong>Fee Table [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ShareholderTransactionExpensesTableTextBlock', window );">Shareholder Transaction Expenses [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:8pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:182">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Shareholder transaction expenses</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:8pt .7pt 0pt 0pt;vertical-align:bottom;width:133">&#160;</td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:182;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Sales load (as
        a percentage of offering price)<sup>(1)</sup></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:103;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.00</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:182">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Offering expenses (as
        a percentage of offering price)<sup>(2)</sup></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:103">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.19</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:182;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Dividend reinvestment and Stock Repurchase
        Plan Fees<sup>(3)</sup></span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:103;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">None</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  </table> </div>

<div>

<p style="margin:4pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(1) If Common Shares are sold
to or through underwriters, a prospectus or prospectus supplement will set forth any applicable sales load and the estimated offering
expenses borne by the Fund.</span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(2) Offering expenses payable
by the Fund will be deducted from the proceeds, before expenses, to the Fund.</span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(3) The
expenses of administering the Fund's Dividend Reinvestment and Stock Purchase Plan are included in "Other Expenses." You will pay brokerage
charges if you direct your broker or the plan agent to sell your Shares that you acquired pursuant to the Fund's Dividend Reinvestment
and Stock Purchase Plan. You may also pay a pro rata share of brokerage commissions incurred in connection with open-market purchases
pursuant to the Fund's Dividend Reinvestment and Stock Purchase Plan. For more details about the Dividend Reinvestment and Stock Purchase
Plan, see "Dividend Reinvestment and Stock Purchase Plan" in the Fund's Prospectus.</span></p> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SalesLoadPercent', window );">Sales Load [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_DividendReinvestmentAndCashPurchaseFees', window );">Dividend Reinvestment and Cash Purchase Fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_OtherTransactionExpensesAbstract', window );"><strong>Other Transaction Expenses [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_OtherTransactionExpensesPercent', window );">Other Transaction Expenses [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">0.19%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_AnnualExpensesTableTextBlock', window );">Annual Expenses [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%" width="100%">
  <tr>
    <td colspan="3" style="padding:8pt .7pt 0pt 0pt;vertical-align:bottom;width:182">&#160;</td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:8pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:133"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Annual
        expenses</strong></span><br/><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>(as a percentage of net<br/>assets</strong></span><br/><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>attributable
        to</strong></span><br/><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Common Shares)</strong></span></td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:90%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Advisory fee<sup>(4)</sup></span></p> </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:6%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.24</span></p>
        </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:90%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Interest expenses on bank borrowings<sup>(5)</sup></span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:6%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">1.45</span></p>
        </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:90%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Other expenses</span></p> </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:6%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.30</span></p>
        </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:90%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Total annual expenses</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:6%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2.99</span></p>
        </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:90%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Less: expense reimbursement<sup>(6)</sup></span></p>
        </td>
    <td colspan="1" style="width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:6%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.03</span></p>
        </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:0.5%">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:90%">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Total annual expenses after expense reimbursement</span></p>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:6%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">2.96</span></p>
        </td>
    <td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1.5%">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%">&#160;</td> </tr>
  </table> </div>

<div>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(4) The Advisory fee is charged
as a percentage of the Fund's average daily Managed Assets, as opposed to net assets. If leverage is used, Managed Assets will be greater
in amount than net assets, because Managed Assets includes borrowings for investment purposes.</span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(5) The percentage in the table
is based on total borrowings of $120,000,000 (the balance outstanding under the Fund's Credit Facility as of September 30, 2023, representing
approximately 21.2% of the Fund's Managed Assets) and an average interest rate during the fiscal year ended September 30, 2023, of 5.77%.
There can be no assurances that the Fund will be able to obtain such level of borrowing (or to maintain its current level of borrowing),
that the terms under which the Fund borrows will not change, or that the Fund's use of leverage will be profitable. The Fund currently
intends during the next twelve months to maintain a similar proportionate amount of borrowings but may increase such amount to 33 1/3%
of the average daily value of the Fund's total assets.</span></p> </div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(6) As of the close of business
on October 27, 2023, the Adviser has entered into a written contract with the Fund to limit the total ordinary operating expenses of the
Fund (excluding leverage costs, interest, taxes, brokerage commissions, acquired fund fees and expenses and any non-routine expenses)
from exceeding 1.51% of the average daily net assets of the Fund on an annualized basis for twelve months (the "Expense Limitation Agreement").The
Expense Limitation Agreement may not be terminated before October 27, 2025, without the approval of the Fund's trustees who are not "interested
persons" of the Fund (as defined in the 1940 Act).The Fund may repay any such reimbursement from the Adviser, within three years of the
reimbursement, provided that the following requirements are met: the reimbursements do not cause the Fund to exceed the lesser of the
applicable expense limitation in the contract at the time the fees were limited or expenses are paid or the applicable expense limitation
in effect at the time the expenses are being recouped by the Adviser. Because interest expenses and investment related expenses are not
subject to the reimbursement agreement, interest expenses and investment related expenses are included in the "Total annual expenses after
expense reimbursement" line item.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ManagementFeesPercent', window );">Management Fees [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">1.24%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_InterestExpensesOnBorrowingsPercent', window );">Interest Expenses on Borrowings [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">1.45%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_OtherAnnualExpensesAbstract', window );"><strong>Other Annual Expenses [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_OtherAnnualExpensesPercent', window );">Other Annual Expenses [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_TotalAnnualExpensesPercent', window );">Total Annual Expenses [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">2.99%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_WaiversAndReimbursementsOfFeesPercent', window );">Waivers and Reimbursements of Fees [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">0.03%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_NetExpenseOverAssetsPercent', window );">Net Expense over Assets [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ExpenseExampleTableTextBlock', window );">Expense Example [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<p style="margin:11pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Example</strong></span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following examples illustrate
the expenses you would pay on a $1,000 investment in common shares assuming that (i) all dividends and other distributions are reinvested
at NAV (ii) the percentage amounts listed under "Total annual expenses" above remain the same in the years shown and (iii) a 5% annual
portfolio total return.<sup>(1)</sup></span></p>

<div>

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following example does
not include the sales load:</span></p>

<table border="0" cellpadding="0" cellspacing="0">
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:60"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>1
        Year</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:63">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>3 Years</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:63">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>5 Years</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:67">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>10 Years</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:33;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">30</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:36;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">92</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:36;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">157</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:40;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">330</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  </table>

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following example assumes
a transaction fee of 1.19%, as a percentage of the offering price, as if it were borne solely by you, as purchaser<sup>(2)</sup>:</span></p>

<table border="0" cellpadding="0" cellspacing="0">
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:60"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>1
        Year</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:63">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>3 Years</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:63">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>5 Years</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:67">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>10 Years</strong></span></p> </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:33;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">41</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:36;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">103</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:36;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">167</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:40;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">338</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  </table>

<p style="margin:4pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(1) </span><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>The
examples above should not be considered representations of future expenses. Actual expenses may be higher or lower than those shown.</strong></span><span style="font-size:7pt;font-family:Arial, Helvetica">
The examples assume that all dividends and distributions are reinvested at net asset value. The Fund's actual rate of return may be greater
or less than the hypothetical 5% return shown in the examples. For more complete descriptions of certain of the Fund's costs and expenses,
see "Management of the Fund&#8212;Advisory Agreements" in the Fund's Prospectus.</span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(2) Notwithstanding this assumption,
in actuality, these fees will be indirectly borne by all holders of Common Shares.</span></p> </div> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_PurposeOfFeeTableNoteTextBlock', window );">Purpose of Fee Table , Note [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The purpose of the following
table and the example below is to help you understand the fees and expenses that holders of Common Shares ("Common Shareholders") would
bear directly or indirectly. The expenses shown in the table under "Other expenses," "Interest expenses on bank borrowings," "Total annual
expenses" and "Total annual expenses after expense reimbursement" are based on the Fund's capital structure as of September 30, 2023.
As of September 30, 2023, the Fund had $120,000,000 of leverage outstanding through bank borrowings which represented 21.2% of the Managed
Assets as of September 30, 2023. The table reflects Fund expenses as a percentage of net assets attributable to Common Shares. The following
table should not be considered a representation of the Fund's future expenses. Actual expenses may be greater or less than those shown
below.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_BasisOfTransactionFeesNoteTextBlock', window );">Basis of Transaction Fees, Note [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">as
        a percentage of offering price<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_OtherTransactionFeesNoteTextBlock', window );">Other Transaction Fees, Note [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">The
expenses of administering the Fund's Dividend Reinvestment and Stock Purchase Plan are included in "Other Expenses." You will pay brokerage
charges if you direct your broker or the plan agent to sell your Shares that you acquired pursuant to the Fund's Dividend Reinvestment
and Stock Purchase Plan. You may also pay a pro rata share of brokerage commissions incurred in connection with open-market purchases
pursuant to the Fund's Dividend Reinvestment and Stock Purchase Plan. For more details about the Dividend Reinvestment and Stock Purchase
Plan, see "Dividend Reinvestment and Stock Purchase Plan" in the Fund's Prospectus.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesTableTextBlock', window );">Senior Securities [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:67"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Fiscal
        Period&#160;</strong></span><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Ended</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Title of Security</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Total
        Principal</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Amount</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Outstanding</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Aggregate</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Liquidation</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Preference</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Liquidation</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Preference</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Per
        Share</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Asset
        Coverage</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Per
        $1,000</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">of
        Principal</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Amount</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Average</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Market
        Value</strong><strong style="margin-top:0pt;margin-bottom:0pt"><sup style="margin-top:0pt;margin-bottom:0pt">(2)</sup></strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2023</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">Loan
        Facility 2023</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">120,000,000</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">4,726</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><sup>(1)</sup></span></p>
        </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_121">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2022</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">Loan
        Facility 2022</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">120,000,000</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">4,786</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_221">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2021</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">Loan
        Facility 2021</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">120,000,000</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">5,714</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_321">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2020</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">Loan
        Facility 2020</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">120,000,000</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">4,554</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_421">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2019</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">Loan
        Facility 2019</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">120,000,000</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">4,396</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_521">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2018</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">Loan
        Facility 2018</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">120,000,000</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">4,861</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_621">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2017</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">Loan
        Facility 2017</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">120,000,000</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">4,999</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_721">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2016</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">Loan
        Facility 2016</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">120,000,000</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">5,160</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_821">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  </table>

<p style="margin:4pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(1) The asset coverage ratio
for the Loan Facility is calculated by dividing net assets plus the amount of any borrowings for investment purposes by the amount of
any senior securities, which includes the Loan Facility, and then multiplying by $1,000.</span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(2) Not applicable because
the senior securities are not registered for public trading.</span></p> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesNoteTextBlock', window );">Senior Securities, Note [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<p style="margin:11pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Senior Securities</strong></span></p>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following table sets forth
information about the Fund's outstanding senior securities as of the end of each of the Fund's last eight fiscal years. The Fund's senior
securities during this time period are comprised of borrowings which constitutes a "senior security" as defined in the 1940 Act. The information
in this table for the fiscal years ended 2022, 2021, 2020, 2019 and 2018 has been audited by a predecessor, independent registered public
accounting firm, and fiscal year ended 2023 has been audited by KPMG LLP, independent registered</span></p> </div>

<div>

<p style="margin:0pt 0pt 8pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">public accounting firm. The Fund's
audited financial statements, including the report of KPMG LLP thereon, and accompanying notes thereto, are included in this Annual Report.</span></p>


<div>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:67"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Fiscal
        Period&#160;</strong></span><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Ended</strong></span></td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica"><strong>Title of Security</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Total
        Principal</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Amount</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Outstanding</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Aggregate</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Liquidation</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Preference</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Liquidation</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Preference</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Per
        Share</strong></span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Asset
        Coverage</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Per
        $1,000</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">of
        Principal</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Amount</strong></span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Average</strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Market
        Value</strong><strong style="margin-top:0pt;margin-bottom:0pt"><sup style="margin-top:0pt;margin-bottom:0pt">(2)</sup></strong></span></p>
        </td>
    <td colspan="1">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2023</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">Loan
        Facility 2023</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">120,000,000</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">4,726</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><sup>(1)</sup></span></p>
        </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_121">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2022</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">Loan
        Facility 2022</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">120,000,000</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">4,786</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_221">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2021</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">Loan
        Facility 2021</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">120,000,000</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">5,714</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_321">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2020</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">Loan
        Facility 2020</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">120,000,000</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">4,554</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_421">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2019</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">Loan
        Facility 2019</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">120,000,000</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">4,396</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_521">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2018</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">Loan
        Facility 2018</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">120,000,000</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">4,861</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_621">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2017</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">Loan
        Facility 2017</span></p> </td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">120,000,000</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">4,999</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_721">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">September 30, 2016</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:7pt;font-family:Arial, Helvetica">Loan
        Facility 2016</span></p> </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">120,000,000</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">&#8212;</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">$</span></p> </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica">5,160</span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:7pt;font-family:Arial, Helvetica"><span style="-sec-ix-hidden:Fxbrl_20231202144904787_821">N/A</span></span></p>
        </td>
    <td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  </table>

<p style="margin:4pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(1) The asset coverage ratio
for the Loan Facility is calculated by dividing net assets plus the amount of any borrowings for investment purposes by the amount of
any senior securities, which includes the Loan Facility, and then multiplying by $1,000.</span></p>

<p style="margin:2pt 0pt 0pt 0pt;text-align:left"><span style="font-size:7pt;font-family:Arial, Helvetica">(2) Not applicable because
the senior securities are not registered for public trading.</span></p> </div>  </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_InvestmentObjectivesAndPracticesTextBlock', window );">Investment Objectives and Practices [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<p style="margin:9pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Objective of the Fund</strong></span></p>

<p style="margin:2pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">The Fund's investment objective is to seek
current income and long-term capital appreciation.</span></p> </div> <span>The
Fund's investment objective is to seek current income and long-term capital appreciation. The Fund invests primarily in equity and debt
securities of public and private U.S. and non-U.S. companies believed by the Fund's Investment Adviser, abrdn Inc. (as of October 27,
2023) (prior to October 27, 2023, Tekla Capital Management, LLC) (the Investment Adviser or the Adviser), to have significant potential
for above-average growth.</span><span>Forward
contracts may also be used for non-hedging purposes to pursue the Fund's investment objective. There is no requirement that the Fund hedge
all or any portion of its exposure to foreign currency risks.</span>

<div>

<p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>(5)&#160;&#160;At-the-Market
Offering</strong></span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund has a registration
statement on file with the SEC, initially effective on December 6, 2022, authorizing the Fund to issue shares through an At-the-Market
Offering (ATM) having an aggregate value of up to $150,000,000. The offering costs associated with the Fund's ATM offering are approximately
$278,586 of which $7,478 were charged to paid-in-capital upon the issuance of associated shares and $271,108 remains in prepaid expenses.</span></p>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">On December 14, 2022, the
Fund entered into a distribution agreement with Foreside Fund Services, LLC (Foreside), pursuant to which the Fund may offer and sell
up to $150,000,000 of shares from time to time, through Foreside as its agent, in transactions deemed to be at the market as defined in
Rule 415 under the Securities Act of 1933, as amended (the Offering). Under the Distribution Agreement, Foreside may enter into sub-placement
agent agreements with one or more selected dealers. Foreside has entered into a sub-placement agent agreement, dated December 14, 2022
(the Sub-Placement Agent Agreement), with UBS Securities LLC (UBS) relating to the shares to be offered under the Distribution Agreement.
During the year ended on September 30, 2023, 274,984 shares were sold under this agreement for $3,950,593 (net of commissions to Foreside
and UBS of $39,906).</span></p> </div>

<div>

<p style="margin:11pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Investment Objective
and Policies</strong></span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">There have been no changes
in the Fund's investment objective and policies since September 30, 2022 that have not been approved by shareholders.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's investment objective
is to seek current income and long-term capital appreciation.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Under normal market conditions,
the Fund expects to invest at least 80% of its Managed Assets in U.S. and non-U.S. companies engaged in the healthcare industries including
equity securities and debt securities. "Managed Assets" means the total assets of the Fund (including any assets attributable to borrowings
for investment purposes) minus the sum of</span></p> </div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">the Fund's accrued liabilities
(other than liabilities representing borrowings for investment purposes). The Fund's 80% policy may only be changed with 60 days' prior
notice to the Fund's shareholders (the "Shareholders"). The Fund will concentrate its investments in the healthcare industries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">A company will be deemed to
be a healthcare company if, at the time the Fund makes an investment in the company, 50% or more of such company's sales, earnings or
assets arise from or are dedicated to healthcare products or services or medical technology activities. healthcare companies may include
companies in one or more of the following sub-sectors: pharmaceuticals, biotechnology, managed care, life science and tools, healthcare
technology, healthcare services, healthcare supplies, healthcare facilities, healthcare equipment, healthcare distributors and Healthcare
REITs (as defined herein). The Investment Adviser determines, in its discretion, whether a company is a healthcare company.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Under normal market conditions,
the Fund expects to invest at least 40% of its Managed Assets in companies organized or located outside the United States or companies
that do a substantial amount of business outside the United States. The Fund may invest up to 5% of its Managed Assets in securities of
issuers located in emerging market countries ("Emerging Markets"). While the Fund may hedge its non-U.S. dollar exposure, it is currently
expected to do so from time to time rather than continuously. The Investment Adviser may hedge its non-U.S. dollar exposure from 0%-100%
at any given time, though it typically expects to do so between 0% and 50% of such exposure.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund expects to invest
60-90% of its Managed Assets in equity securities (which may include common stock, preferred stock and warrants or other rights to acquire
common or preferred stock). The Fund will invest in foreign securities and may buy and sell currencies for the purpose of settlement of
transactions in foreign securities. The Fund may invest up to 30% of its Managed Assets in convertible securities, which may include securities
that are noninvestment grade. The Fund may invest up to 20% of its Managed Assets as measured at the time of investment in non-convertible
debt securities, including corporate debt obligations and debt securities that are rated noninvestment grade (that is, rated Ba1 or lower
by Moody's Investors Service, Inc. ("Moody's"), BB+ or lower by Standard &amp; Poor's Ratings Group ("S&amp;P"), or BB+ by Fitch, Inc.
("Fitch") or comparably rated by another nationally recognized statistical rating organization ("NRSRO"), or, if unrated, determined by
the Investment Adviser to be of comparable credit quality) and not including convertible securities. The Fund may invest up to 15% of
its Managed Assets in non-convertible debt securities that are, at the time of investment, rated Caa1 or lower by Moody's and CCC+ or
lower by S&amp;P or Fitch, or comparably rated by another nationally recognized statistical rating organization, or, if unrated, determined
by the Investment Adviser to be of comparable credit quality. Such securities are subject to a very high credit risk. The Fund's investments
in noninvestment grade investments and those deemed to be of similar quality are considered</span></p> </div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">speculative with respect to
the issuer's capacity to pay interest and repay principal and are commonly referred to as "junk" or "high yield" securities.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund may invest in derivatives,
including but not limited to options, futures, options on futures, forwards, swaps (including credit default, index, basis, total return,
volatility and currency swaps), options on swaps and other derivatives. Initially, the Fund intends to employ a strategy of writing (selling)
covered call options on a portion of the common stocks in its portfolio, writing (selling) put options on a portion of the common stocks
in its portfolio and, to a lesser extent, writing (selling) covered call and writing (selling) put options on indices of securities and
sectors of securities generally within the healthcare industry. This option strategy is intended to generate current income from option
premiums as a means to enhance distributions payable to the Fund's shareholders and will be limited to 30% of the Fund's Managed Assets.
These option strategies are not always profitable. The sale of a covered call option exposes the Fund during the term of the option to
possible loss of opportunity to realize appreciation in the market price of the underlying security or to possible loss due to continued
holding of a security that might otherwise have been sold to protect against depreciation in the market price of the security. Therefore,
the Investment Adviser may choose to decrease its use of the option writing strategy to the extent that it may negatively impact the Fund.
Other than the Fund's option strategy and use of derivatives for hedging purposes, the Fund may invest up to 10% of its Managed Assets
in derivatives.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund may invest up to
10% of its Managed Assets in restricted securities, including private investments in public equity ("PIPEs") and venture capital investments.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund may invest up to
20% of its Managed Assets in healthcare REITs.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund may from time-to-time
lend its portfolio securities but has terminated its Securities Lending program effective July 18, 2023.</span></p> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskFactorsTableTextBlock', window );">Risk Factors [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<p style="margin:11pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Risk Factors</strong></span></p>

<p style="margin:8pt 0pt 10pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Investing in any investment company
security involves risk, including the risk that you may receive little or no return on your investment or even that you may lose part
or all of your investment. Investors should consider the following Risk Factors and special considerations associated with investing in
the Fund's shares.</span></p> <span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Portfolio</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
</span><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Market Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
As with any investment company that invests in equity securities, the Fund is subject to market risk&#8212;the possibility that the prices
of equity securities will</span> </div>

<div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">decline over short or extended
periods of time. As a result, the value of an investment in the Fund's shares will fluctuate with the market. You could lose some or all
of your investment over short or long periods of time.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Political and economic news
can influence market-wide trends and can cause disruptions in the U.S. or world financial markets. Other factors may be ignored by the
market as a whole but may cause movements in the price of one company's stock or the stock of companies in one or more industries. All
of these factors may have a greater impact on initial public offerings and emerging company shares.</span></p> </div>


<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Security Market Risk&#8212;Discount
to NAV.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Shares of closed-end investment companies frequently
trade at a discount from their NAV. This characteristic is a risk separate and distinct from the risk that the Fund's NAV per share could
decrease as a result of its investment activities and may be greater for investors expecting to sell their shares in a relatively short
period of time following completion of this offering. Although the value of the Fund's net assets is generally considered by market participants
in determining whether to purchase or sell shares, whether investors will realize gains or losses upon the sale of the shares will depend
entirely upon whether the market price of the shares at the time of sale is above or below the investor's purchase price for the shares.
Because the market price of the shares will be determined by supply of and demand for the shares which will be affected by factors such
as (i) NAV, (ii) dividend and distribution levels and their stability (which will in turn be affected by levels of dividend and interest
payments by the Fund's portfolio holdings, the timing and success of the Fund's investment strategies, regulations affecting the timing
and character of Fund distributions, Fund expenses and other factors), (iii) trading volume of the shares, (iv) general market, interest
rate and economic conditions and (v) other factors that may be beyond the control of the Fund. The Fund cannot predict whether the shares
will trade at, below or above NAV or at, below or above the initial public offering price.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Equity Securities
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund expects to invest 60-90% of its Managed Assets
in equity securities. Equity risk is the risk that equity securities held by the Fund will fall due to general market or economic conditions,
perceptions regarding the industries in which the issuers of securities held by the Fund participate, changes in interest rates, and the
particular circumstances and performance of particular companies whose securities the Fund holds. The price of an equity security of an
issuer may be particularly sensitive to general movements in the stock market, or a drop in the stock market may depress the price of
most or all of the equity securities held by the Fund. In addition, equity securities held by the Fund may decline in price if the issuer
fails to make anticipated distributions or dividend payments because, among other reasons, the issuer experiences a decline in its financial
condition. The Fund's expected investments in preferred stocks carries its own unique risks. Preferred stocks are typically subordinated
to bonds and other debt instruments in a company's capital structure, in terms of priority to corporate income, and therefore will be
subject to greater credit risk than those debt instruments. In addition, unlike interest payments on debt securities,</span></p>
</div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">preferred stock dividends
are payable only if declared by the issuer's board of directors. The prices of preferred stock also tend to move upwards slower than common
stock prices and the preferred stock may be substantially less liquid than common stock or other securities.</span></p>


<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Convertible Securities
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Convertible Securities generally offer lower interest
or dividend yields than nonconvertible debt securities of similar quality. The market value of convertible securities tends to decline
as interest rates increase and, conversely, tends to increase as interest rates decline. In addition, because of the conversion feature,
the market value of convertible securities tends to vary with fluctuations in the market value of the underlying common stock. When the
market price of the underlying common stock approaches or is greater than the convertible security's conversion price, the prices of the
convertible securities tend to rise as a reflection of the value of the underlying common stock. The conversion prior is defined as the
predetermined price at which the convertible security could be exchanged for the associated stock. Consequently, a unique feature of convertible
securities is that as the market price of the underlying common stock declines, convertible securities tend to trade increasingly on a
yield basis, and so may not experience market value declines to the same extent as the underlying common stock. Investments in convertible
securities generally entail less risk than investments in common stock of the same issuer but more risk than the issuer's debt obligations.</span></p>


<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Selection Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Different types of equity securities tend to shift into and out of favor with investors, depending on market and economic conditions.
The performance of funds that invest in healthcare industry equity securities may at times be better or worse than the performance of
funds that focus on other types of securities or that have a broader investment style.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Concentration in the
Healthcare Industries.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Under normal market conditions, the Fund
expects to invest at least 80% of its Managed Assets in securities of healthcare companies. As a result, the Fund's portfolio will likely
be more sensitive to, and possibly more adversely affected by, regulatory, economic or political factors or trends relating to the healthcare,
agricultural and environmental technology industries than a portfolio of companies representing a larger number of industries. The risk
is in addition to the risks normally associated with any strategy seeking capital appreciation by investing in a portfolio of equity securities.
As a result of its concentration policy, the Fund's investments may be subject to greater risk and market fluctuation than a fund that
has securities representing a broader range of investments. The healthcare industries can be volatile. The Fund may occasionally make
investments in a company with the objective of controlling or influencing the management and policies of that company, which could potentially
make the Fund more susceptible to declines in the value of the company's stock. The Investment Adviser may seek control in public companies
only occasionally and most often in companies with a small capitalization.</span></p>  </div>

<div>

<div>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare companies have in the
past been characterized by limited product focus, rapidly changing technology and extensive government regulation. In particular, technological
advances can render an existing product, which may account for a disproportionate share of a company's revenue, obsolete. Obtaining governmental
approval from U.S. governmental agencies such as the Food and Drug Administration (the "FDA"), and from non-U.S. governmental agencies
for new products can be lengthy, expensive and uncertain as to outcome. Such delays in product development may result in the need to seek
additional capital, potentially diluting the interests of existing investors such as the Fund. In addition, governmental agencies may,
for a variety of reasons, restrict the release of certain innovative technologies of commercial significance. These various factors may
result in abrupt advances and declines in the securities prices of particular companies and, in some cases, may have a broad effect on
the prices of securities of companies in particular healthcare industries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">A concentration of investments
in any healthcare industry or in healthcare companies generally may increase the risk and volatility of an investment company's portfolio.
Such volatility is not limited to the biotechnology industry, and companies in other industries may be subject to similar abrupt movements
in the market prices of their securities. No assurance can be given that future declines in the market prices of securities of companies
in the industries in which the Fund may invest will not occur, or that such declines will not adversely affect the NAV or the price of
the shares.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Intense competition exists
within and among certain healthcare industries, including competition to obtain and sustain proprietary technology protection, including
patents, trademarks and other intellectual property rights, upon which healthcare companies can be highly dependent for maintenance of
profit margins and market exclusivity. The complex nature of the technologies involved can lead to patent disputes, including litigation
that may be costly and that could result in a company losing an exclusive right to a patent.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">With respect to healthcare
industries, cost containment measures already implemented by national governments, state or provincial governments and the private sector
have adversely affected certain sectors of these industries. The implementation of the Affordable Care Act ("ACA") has created increased
demand for healthcare products and services, but potential changes to the ACA and future healthcare laws and regulations may impact demand
for healthcare products and services and has had or may have an adverse effect on some companies in the healthcare industries. Increased
emphasis on managed care in the United States and a shift toward value based payment models may put pressure on the price and usage of
products sold by healthcare companies in which the Fund may invest and may adversely affect the sales and revenues of healthcare companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Product development efforts
by healthcare companies may not result in commercial products for many reasons, including, but not limited to, failure to achieve acceptable
clinical trial results, limited effectiveness in treating the specified condition or illness, harmful side effects,</span></p> </div>
 </div>

<div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">failure to obtain regulatory
approval, and high manufacturing costs. Even after a product is commercially released, governmental agencies may require additional clinical
trials or change the labeling requirements for products if additional product side effects are identified, which could have a material
adverse effect on the market price of the securities of those healthcare companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Certain healthcare companies
in which the Fund may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing
and sale of pharmaceuticals, medical devices or other products. A product liability claim may have a material adverse effect on the business,
financial condition or securities prices of a company in which the Fund has invested.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">All of these factors as well
as others may cause the value of the Fund's shares to fluctuate significantly over relatively short periods of time.</span></p> </div>


<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Pharmaceutical Sector
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The success of companies in the pharmaceutical sector
is highly dependent on the development, procurement and marketing of drugs. The values of pharmaceutical companies are also dependent
on the development, protection and exploitation of intellectual property rights and other proprietary information, and the profitability
of pharmaceutical companies may be significantly affected by such things as the expiration of patents or the loss of, or the inability
to enforce, intellectual property rights.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The research and other costs
associated with developing or procuring new drugs and the related intellectual property rights can be significant, and the results of
such research and expenditures are unpredictable. There can be no assurance that those efforts or costs will result in the development
of a profitable drug. Pharmaceutical companies may be susceptible to product obsolescence. Pharmaceutical companies also face challenges
posed by the increased presence of counterfeit pharmaceutical products, which may negatively impact revenues and patient confidence. Many
pharmaceutical companies face intense competition from new products and less costly generic products. Moreover, the process for obtaining
regulatory approval by the FDA or other U.S. and non-U.S. governmental regulatory authorities is long and costly and there can be no assurance
that the necessary approvals will be obtained or maintained.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The pharmaceutical sector
is also subject to rapid and significant technological change and competitive forces that may make drugs obsolete or make it difficult
to raise prices and, in fact, may result in price discounting. Companies in the pharmaceutical sector may also be subject to expenses
and losses from extensive litigation based on intellectual property, product liability and similar claims. Failure of pharmaceutical companies
to comply with applicable laws and regulations can result in the imposition of civil and criminal fines, penalties and, in some instances,
exclusion of participation in government sponsored programs such as Medicare and Medicaid.</span></p> </div>  </div>

<div>

<div>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Companies in the pharmaceutical
sector may be adversely affected by government regulation and changes in reimbursement rates. The ability of many pharmaceutical companies
to commercialize and monetize current and any future products depends in part on the extent to which reimbursement for the cost of such
products and related treatments are available from third party payors, such as Medicare, Medicaid, private health insurance plans and
health maintenance organizations. Third-party payors are increasingly challenging the price and cost-effectiveness of many medical products.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Significant uncertainty exists
as to the reimbursement status of health care products, and there can be no assurance that adequate third-party coverage will be available
for pharmaceutical companies to obtain satisfactory price levels for their products.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The international operations
of many pharmaceutical companies expose them to risks associated with instability and changes in economic and political conditions, foreign
currency fluctuations, changes in foreign regulations and other risks inherent to international business. Additionally, a pharmaceutical
company's valuation can often be based largely on the potential or actual performance of a limited number of products. A pharmaceutical
company's valuation can also be greatly affected if one of its products proves unsafe, ineffective or unprofitable. Such companies also
may be characterized by thin capitalization and limited markets, financial resources or personnel, as well as dependence on wholesale
distributors. The stock prices of companies in the pharmaceutical industry have been and will likely continue to be extremely volatile.</span></p>
</div>

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Biotechnology Industry
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The success of biotechnology companies is highly dependent
on the development, procurement and/or marketing of drugs. The values of biotechnology companies are also dependent on the development,
protection and exploitation of intellectual property rights and other proprietary information, and the profitability of biotechnology
companies may be significantly affected by such things as the expiration of patents or the loss of, or the inability to enforce, intellectual
property rights.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The research and other costs
associated with developing or procuring new drugs, products or technologies and the related intellectual property rights can be significant,
and the results of such research and expenditures are unpredictable. There can be no assurance that those efforts or costs will result
in the development of a profitable drug, product or technology. Moreover, the process for obtaining regulatory approval by the FDA or
other U.S. and non-U.S. governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals
will be obtained or maintained.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The biotechnology sector is
also subject to rapid and significant technological change and competitive forces that may make drugs, products or technologies obsolete
or make it difficult to raise prices and, in fact, may result in price discounting. Companies in the biotechnology sector may also be
subject to expenses and losses from extensive litigation</span></p> </div>  </div>

<div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">based on intellectual property,
product liability and similar claims. Failure of biotechnology companies to comply with applicable laws and regulations can result in
the imposition of civil and/or criminal fines, penalties and, in some instances, exclusion of participation in government sponsored programs
such as Medicare and Medicaid.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Companies in the biotechnology
sector may be adversely affected by government regulation and changes in reimbursement rates. Healthcare providers, principally hospitals,
that transact with companies in the biotechnology industry, often rely on third party payors, such as Medicare, Medicaid, private health
insurance plans and health maintenance organizations to reimburse all or a portion of the cost of healthcare related products or services.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Biotechnology companies will
continue to be affected by the efforts of governments and third party payors to contain or reduce health care costs. For example, certain
foreign markets control pricing or profitability of biotechnology products and technologies. In the United States, there has been, and
there will likely continue to be, a number of federal and state proposals to implement similar controls.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">A biotechnology company's
valuation could be based on the potential or actual performance of a limited number of products and could be adversely affected if one
of its products proves unsafe, ineffective or unprofitable. Such companies may also be characterized by thin capitalization and limited
markets, financial resources or personnel. The stock prices of companies involved in the biotechnology sector have been and will likely
continue to be extremely volatile.</span></p> </div>

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Managed Care Sector
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Companies in the managed care sector often assume the
risk of both medical and administrative costs for their customers in return for monthly premiums. The profitability of these products
depends in large part on the ability of such companies to predict, price for, and effectively manage medical costs. Managed care companies
base the premiums they charge and their Medicare bids on estimates of future medical costs over the fixed contract period; however, many
factors may cause actual costs to exceed what was estimated and reflected in premiums or bids. These factors may include medical cost
inflation, increased use of services, increased cost of individual services, natural catastrophes or other large-scale medical emergencies,
epidemics, the introduction of new or costly treatments and technology, new mandated benefits (such as the expansion of essential benefits
coverage) or other regulatory changes and insured population characteristics. Relatively small differences between predicted and actual
medical costs or utilization rates as a percentage of revenues can result in significant changes in financial results.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Managed care companies are
regulated at the federal, state, local and international levels. Insurance and Health Maintenance Organization ("HMO") subsidiaries must
be licensed by and are subject to the regulations of the jurisdictions in which they conduct business. U.S. health plans and insurance
companies are also regulated under state insurance holding</span></p> </div>  </div>

<div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">company regulations, and some
of their activities may be subject to other health care-related regulations. The health care industry is also regularly subject to negative
publicity, including as a result of governmental investigations, adverse media coverage and political debate surrounding industry regulation.
Negative publicity may adversely affect stock price, damage the reputation of managed care companies in various markets or foster an increasingly
active regulatory environment, which, in turn, could further increase the regulatory burdens under which such companies operate and their
costs of doing business.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The evolution of the ACA and
other regulatory reforms could materially and adversely affect the manner in which U.S. managed care companies conduct business and their
results of operations, financial position and cash flows. The ACA includes guaranteed coverage and expanded benefit requirements, eliminates
pre-existing condition exclusions and annual and lifetime maximum limits, restricts the extent to which policies can be rescinded, establishes
minimum medical loss ratios, creates a federal premium review process, imposes new requirements on the format and content of communications
(such as explanations of benefits) between health insurers and their members, grants to members new and additional appeal rights, and
imposes new and significant taxes on health insurers and health care benefits.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">New laws or regulations could
drive substantial change to the way healthcare products and services are currently delivered and paid for in the United States. Health
plans and insurance companies could face meaningful disruption or disintermediation if the U.S. migrates to a single payer healthcare
system where the government acts as the sole payer of healthcare services for the entire population. A transformative overhaul of the
U.S. healthcare system could impact the financial viability of managed care companies in which the Fund may invest.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Managed care companies contract
with physicians, hospitals, pharmaceutical benefit service providers, pharmaceutical manufacturers, and other health care providers for
services. Such companies' results of operations and prospects are substantially dependent on their continued ability to contract for these
services at competitive prices. Failure to develop and maintain satisfactory relationships with health care providers, whether in-network
or out-of-network, could materially and adversely affect business, results of operations, financial position and cash flows.</span></p>
</div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Life Science and Tools
Industry Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Life sciences industries are characterized by
limited product focus, rapidly changing technology and extensive government regulation. In particular, technological advances can render
an existing product, which may account for a disproportionate share of a company's revenue, obsolete. Obtaining governmental approval
from agencies such as the FDA, U.S. Department of Agriculture and other U.S. and non-U.S. governmental agencies for new products can be
lengthy, expensive and uncertain as to outcome. Such delays in product development may result in the need to seek additional capital,
potentially diluting the interests of existing investors such as the Fund. In addition,</span></p>  </div>

<div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">governmental agencies may,
for a variety of reasons, restrict the release of certain innovative technologies of commercial significance, such as genetically altered
material. These various factors may result in abrupt advances and declines in the securities prices of particular companies and, in some
cases, may have a broad effect on the prices of securities of companies in particular life sciences industries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Intense competition exists
within and among certain life sciences industries, including competition to obtain and sustain proprietary technology protection. Life
sciences companies can be highly dependent on the strength of patents, trademarks and other intellectual property rights for maintenance
of profit margins and market share. The complex nature of the technologies involved can lead to patent disputes, including litigation
that could result in a company losing an exclusive right to a patent. Competitors of life sciences companies may have substantially greater
financial resources, more extensive development, manufacturing, marketing and service capabilities, and a larger number of qualified managerial
and technical personnel. Such competitors may succeed in developing technologies and products that are more effective or less costly than
any that may be developed by life sciences companies in which the Fund invests and may also prove to be more successful in production
and marketing. Competition may increase further as a result of potential advances in health services and medical technology and greater
availability of capital for investment in these fields.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">With respect to healthcare,
cost containment measures already implemented by national governments, state or provincial governments, international organizations and
the private sector have adversely affected certain sectors of these industries. Increased emphasis on managed care in the United States
may put pressure on the price and usage of products sold by life sciences companies in which the Fund may invest and may adversely affect
the sales and revenues of life sciences companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Product development efforts
by life sciences companies may not result in commercial products for many reasons, including, but not limited to, failure to achieve acceptable
clinical trial results, limited effectiveness in treating the specified condition or illness, harmful side effects, failure to obtain
regulatory approval, and high manufacturing costs. Even after a product is commercially released, governmental agencies may require additional
clinical trials or change the labeling requirements for products if additional product side effects are identified, which could have a
material adverse effect on the market price of the securities of those life sciences companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Certain life sciences companies
in which the Fund may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing
and sale of pharmaceuticals, medical devices or other products. There can be no assurance that a product liability claim would not have
a material adverse effect on the business, financial condition or securities prices of a company in which the Fund has invested.</span></p>
</div>  </div>

<div>

<div>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Technology
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Companies in the healthcare technology sector may
incur substantial costs related to product-related liabilities. Many of the software solutions, health care devices or services developed
by such companies are intended for use in collecting, storing and displaying clinical and health care-related information used in the
diagnosis and treatment of patients and in related health care settings such as admissions, billing, etc. The limitations of liability
set forth in the companies' contracts may not be enforceable or may not otherwise protect these companies from liability for damages.
Healthcare technology companies may also be subject to claims that are not covered by contract, such as a claim directly by a patient.
Although such companies may maintain liability insurance coverage, there can be no assurance that such coverage will cover any particular
claim that has been brought or that may be brought in the future, that such coverage will prove to be adequate or that such coverage will
continue to remain available on acceptable terms, if at all.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare technology companies
may experience interruption at their data centers or client support facilities. The business of such companies often relies on the secure
electronic transmission, data center storage and hosting of sensitive information, including protected health information, financial information
and other sensitive information relating to clients, company and workforce. In addition, such companies may perform data center and/or
hosting services for certain clients, including the storage of critical patient and administrative data and support services through various
client support facilities. If any of these systems are interrupted, damaged or breached by an unforeseen event or actions of a third party,
including a cyber-attack, or fail for any extended period of time, it could have a material adverse impact on the results of operations
for such companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The proprietary technology
developed by healthcare technology companies may be subject to claims for infringement or misappropriation of intellectual property rights
of others, or may be infringed or misappropriated by others. Despite protective measures and intellectual property rights, such companies
may not be able to adequately protect against theft, copying, reverse-engineering, misappropriation, infringement or unauthorized use
or disclosure of their intellectual property, which could have an adverse effect on their competitive position. In addition, these companies
are routinely involved in intellectual property infringement or misappropriation claims and it is expected that this activity will continue
or even increase as the number of competitors, patents and patent enforcement organizations in the healthcare technology market increases,
the functionality of software solutions and services expands, the use of open-source software increases and new markets such as health
care device innovation, health care transactions, revenue cycle, population health management and life sciences are entered into. These
claims, even if not meritorious, are expensive to defend and are often incapable of prompt resolution.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The success of healthcare
technology companies depends upon the recruitment and retention of key personnel. To remain competitive, such companies must attract,
motivate and retain</span></p> </div>  </div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">highly skilled managerial,
sales, marketing, consulting and technical personnel, including executives, consultants, programmers and systems architects skilled in
healthcare technology, health care devices, health care transactions, population health management, revenue cycle and life sciences industries
and the technical environments in which solutions, devices and services are needed. Competition for such personnel in the healthcare technology
sector is intense in both the United States and abroad. The failure to attract additional qualified personnel could have a material adverse
effect on healthcare technology companies' prospects for long-term growth.</span></p>

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Services
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The operations of healthcare services companies
are subject to extensive federal, state and local government regulations, including Medicare and Medicaid payment rules and regulations,
federal and state anti-kickback laws, the physician self-referral law ("Stark Law") and analogous state self-referral prohibition statutes,
Federal Acquisition Regulations, the False Claims Act and federal and state laws regarding the collection, use and disclosure of patient
health information and the storage, handling and administration of pharmaceuticals. The Medicare and Medicaid reimbursement rules related
to claims submission, enrollment and licensing requirements, cost reporting, and payment processes impose complex and extensive requirements
upon dialysis providers as well. A violation or departure from any of these legal requirements may result in government audits, lower
reimbursements, significant fines and penalties, the potential loss of certification, recoupment efforts or voluntary repayments. If healthcare
services companies fail to adhere to all of the complex government regulations that apply to their businesses, such companies could suffer
severe consequences that would substantially reduce revenues, earnings, cash flows and stock prices.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">A substantial percentage of
a healthcare services company's service revenues may be generated from patients who have state Medicaid or other non-Medicare government-based
programs, such as coverage through the Department of Veterans Affairs ("VA"), as their primary coverage. As state governments and other
governmental organizations face increasing budgetary pressure, healthcare services companies may in turn face reductions in payment rates,
delays in the receipt of payments, limitations on enrollee eligibility or other changes to the applicable programs.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Adverse economic conditions
could adversely affect the business and profitability of healthcare services companies. Among other things, the potential decline in federal,
non-U.S. government and state revenues that may result from such conditions may create additional pressures to contain or reduce reimbursements
for services from Medicare, Medicaid and other government sponsored programs. Increasing job losses or slow improvement in the unemployment
rate in the United States and elsewhere as a result of adverse or recent economic conditions may result in a smaller percentage of patients
being covered by an employer group health plan and a larger percentage being covered by lower paying Medicare and Medicaid programs. Employers
may also select more restrictive commercial plans with</span></p> </div>  </div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">lower reimbursement rates.
To the extent that payors are negatively impacted by a decline in the economy, healthcare services companies may experience further pressure
on commercial rates, a further slowdown in collections and a reduction in the amounts they expect to collect. In addition, uncertainty
in the financial markets could adversely affect the variable interest rates payable under credit facilities or could make it more difficult
to obtain or renew such facilities or to obtain other forms of financing in the future, if at all. Any or all of these factors, as well
as other consequences of the adverse economic conditions which cannot currently be anticipated, could have a material adverse effect on
a healthcare services company's revenues, earnings and cash flows and otherwise adversely affect its financial condition.</span></p>


<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Supplies
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> If healthcare supplies companies are unable to
successfully expand their product lines through internal research and development and acquisitions, their business may be materially and
adversely affected. In addition, if these companies are unable to successfully grow their businesses through marketing partnerships and
acquisitions, their business may be materially and adversely affected.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Consolidation of healthcare
providers has increased demand for price concessions and caused the exclusion of suppliers from significant market segments. It is expected
that market demand, government regulation, third-party reimbursement policies, government contracting requirements and societal pressures
will continue to change the worldwide healthcare industry, resulting in further business consolidations and alliances among customers
and competitors. This may exert further downward pressure on the prices of healthcare supplies companies' products and adversely impact
their businesses, financial conditions or results of operations.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Quality is extremely important
to healthcare supplies companies and their customers due to the serious and costly consequences of product failure. Quality certifications
are critical to the marketing success of their products and services. If a healthcare supplies company fails to meet these standards or
fails to adapt to evolving standards, its reputation could be damaged, it could lose customers, and its revenue and results of operations
could decline.</span></p> </div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Facilities
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> A healthcare facility's ability to negotiate favorable
contracts with HMOs, insurers offering preferred provider arrangements and other managed care plans significantly affects the revenues
and operating results of such healthcare facilities. In addition, private payers are increasingly attempting to control health care costs
through direct contracting with hospitals to provide services on a discounted basis, increased utilization reviews and greater enrollment
in managed care programs, such as HMOs and Preferred Provider Organizations ("PPOs"). The trend toward consolidation among private managed
care payers tends to increase their bargaining power over prices and fee structures. Non-government payers may increasingly demand reduced
fees. If a healthcare facility is unable to enter into and maintain managed care contractual arrangements on acceptable</span></p>
</div>

<div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">terms, if it experiences material
reductions in the contracted rates received from managed care payers, or if it has difficulty collecting from managed care payers, its
results of operations could be adversely affected.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Further changes in the Medicare
and Medicaid programs or other government health care programs could have an adverse effect on a healthcare facility's business. In addition
to the changes affected by the ACA, the Medicare and Medicaid programs are subject to other statutory and regulatory changes, administrative
rulings, interpretations and determinations concerning patient eligibility requirements, funding levels and the method of calculating
payments or reimbursements, among other things, requirements for utilization review, and federal and state funding restrictions. All of
these could materially increase or decrease payments from government programs in the future, as well as affect the cost of providing services
to patients and the timing of payments to facilities, which could in turn adversely affect a healthcare facility's overall business, financial
condition, results of operations or cash flows.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare facilities are
adversely affected by uninsured and underinsured patients, as well as a growing mix of Medicare and Medicaid patients that typically have
lower reimbursement rates than commercial managed care patients As a result, healthcare facilities continue to experience a shift in payer
mix and a high level of uncollectible accounts, which could worsen if there is an increase in unemployment. Healthcare facilities may
continue to experience significant levels of bad debt expense and may have to provide uninsured discounts and charity care for undocumented
immigrants who are not permitted to enroll in a health insurance exchange or government health care program. The trend of higher co-pays
and deductibles and a focus on migrating healthcare utilization to lower cost sites of care, may also pressure volumes and revenue at
certain healthcare facilities which could adversely impact the financial condition of hospitals and facilities with high fixed cost structures.</span></p>
</div>

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Equipment
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The medical device markets are highly competitive
and a healthcare equipment company many be unable to compete effectively. These markets are characterized by rapid change resulting from
technological advances and scientific discoveries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Development by other companies
of new or improved products, processes, or technologies may make a healthcare equipment company's products or proposed products less competitive.
In addition, these companies face competition from providers of alternative medical therapies such as pharmaceutical companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Medical devices and related
business activities are subject to rigorous regulation, including by the FDA, U.S. Department of Justice ("DOJ"), and numerous other federal,
state, and foreign governmental authorities. These authorities and members of Congress have been increasing their scrutiny of the healthcare
equipment industry. In addition, certain states have</span></p> </div>  </div>

<div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">passed or are considering
legislation restricting healthcare equipment companies' interactions with health care providers and requiring disclosure of certain payments
to them. It is anticipated that governmental authorities will continue to scrutinize this industry closely, and that additional regulation
may increase compliance and legal costs, exposure to litigation, and other adverse effects to operations.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare equipment companies
are substantially dependent on patent and other proprietary rights and failing to protect such rights or to be successful in litigation
related to such rights may result in the payment of significant monetary damages and/or royalty payments, may negatively impact the ability
of healthcare equipment companies to sell current or future products, or may prohibit such companies from enforcing their patent and other
proprietary rights against others.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Quality problems with the
processes, goods and services of a healthcare equipment company could harm the company's reputation for producing high-quality products
and erode its competitive advantage, sales and market share. Quality is extremely important to healthcare equipment companies and their
customers due to the serious and costly consequences of product failure. Quality certifications are critical to the marketing success
of goods and services. If a healthcare equipment company fails to meet these standards, its reputation could be damaged, it could lose
customers, and its revenue and results of operations could decline.</span></p> </div>

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Distributors
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Companies in the healthcare distribution sector
operate in markets that are highly competitive. Because of competition, many of these companies face pricing pressures from customers
and suppliers. If these companies are unable to offset margin reductions caused by pricing pressures through steps such as effective sourcing
and enhanced cost control measures, the financial condition of such companies could be adversely affected. In addition, the healthcare
industry has continued to consolidate. Further consolidation among customers and suppliers (including branded pharmaceutical manufacturers)
could give the resulting enterprises greater bargaining power, which may adversely impact the financial condition of companies in the
healthcare distribution sector.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Fewer generic pharmaceutical
launches or launches that are less profitable than those previously experienced may have an adverse effect on the profits of companies
in the healthcare distribution sector. Additionally, prices for existing generic pharmaceuticals generally decline over time, although
this may vary. Price deflation on existing generic pharmaceuticals may have an adverse effect on company profits. With respect to branded
pharmaceutical price appreciation, if branded manufacturers increase prices less frequently or by amounts that are smaller than have been
experienced historically, healthcare distribution companies may profit less from branded pharmaceutical agreements.</span></p> </div>
 </div>

<div>

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The healthcare industry is
highly regulated, and healthcare distribution companies are subject to regulation in the United States at both the federal and state level
and in foreign countries. If healthcare distribution companies fail to comply with these regulatory requirements, the financial condition
of such companies could be adversely affected.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Due to the nature of the business
of healthcare distribution companies, such companies may from time to time become involved in disputes or legal proceedings. For example,
some of the products that these companies distribute may be alleged to cause personal injury or violate the intellectual property rights
of another party, subjecting such companies to product liability or infringement claims. Litigation is inherently unpredictable, and the
unfavorable resolution of one or more of these legal proceedings could adversely affect the cash flows and balance sheets of healthcare
distribution companies. Pharmaceutical distributors currently face lawsuits related to the abuse of opioid medications in the United States.
The allegations include that pharmaceutical distributors failed to provide effective controls around the quantities of opioid medications
distributed to certain pharmacies, failed to properly prevent the diversion of medications and failed to report suspicious orders. Pharmaceutical
distributors are in discussions with federal, state and local jurisdictions related to their role in the distribution of opioid pharmaceuticals
and it is possible that they will be required to pay multi-billion dollar settlements related to the ongoing litigation.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare distribution companies
depend on the availability of various components, compounds, raw materials and energy supplied by others for their operations. Any of
these supplier relationships could be interrupted due to events beyond the control of such companies, including pandemics, epidemics or
natural disasters, or could be terminated. A sustained supply interruption could have an adverse effect on business.</span></p> </div>


<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Risks Associated with
Regulatory and Policy Changes.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> At any time after the date hereof,
U.S. and non-U.S. governmental agencies and other regulators may implement additional regulations and legislators may pass new laws that
affect the investments held by the Fund, the strategies used by the Fund or the level of regulation or taxation applying to the Fund.
These regulations and laws impact the investment strategies, performance, costs and operations of the Fund, as well as the way investments
in, and shareholders of, the Fund are taxed. In particular, changes to U.S. healthcare policy could affect the Fund and its investments.
The affordability of healthcare in the U.S. will remain a topic of debate, and proposals, laws and regulations to reduce the costs of
healthcare products and services could adversely impact healthcare companies that the Fund invests in.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Foreign Securities
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Foreign investments involve special risks that are not
typically associated with U.S. dollar denominated or quoted securities of U.S. issuers. Foreign investments may be affected by changes
in currency rates, changes in foreign or U.S. laws or restrictions applicable to such investments and changes in exchange control regulations
(e.g., currency blockage). A decline in the exchange rate of the currency (i.e., weakening of</span></p>  </div>

<div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">the currency against the U.S.
dollar) in which a portfolio security is quoted or denominated relative to the U.S. dollar would reduce the value of the portfolio security.
In addition, if the currency in which the Fund receives dividends, interest or other payments declines in value against the U.S. dollar
before such income is distributed as dividends to Shareholders or converted to U.S. dollars, the Fund may have to sell portfolio securities
to obtain sufficient cash to pay such dividends.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund may invest in foreign
securities which take the form of sponsored and unsponsored American depositary receipts ("ADRs"), global depositary receipts ("GDRs"),
European depositary receipts ("EDRs") or other similar instruments representing securities of foreign issuers (together, "Depositary Receipts").
ADRs represent the right to receive securities of foreign issuers deposited in a domestic bank or a correspondent bank. ADRs are traded
on domestic exchanges or in the U.S. over-the-counter ("OTC") market and, generally, are in registered form. EDRs and GDRs are receipts
evidencing an arrangement with a non-U.S. bank similar to ADRs and are designed for use in the non-U.S. securities markets. EDRs and GDRs
are not necessarily quoted in the same currency as the underlying security. To the extent the Fund acquires Depositary Receipts through
banks which do not have a contractual relationship with the foreign issuer of the security underlying the Depositary Receipts to issue
and service such unsponsored Depositary Receipts, there is an increased possibility that the Fund will not become aware of and be able
to respond to corporate actions, such as stock splits or rights offerings, involving the foreign issuer in a timely manner. In addition,
the lack of information may result in inefficiencies in the valuation of such instruments. Investment in Depositary Receipts does not
eliminate all the risks inherent in investing in securities of non-U.S. issuers. The market value of Depositary Receipts is dependent
upon the market value of the underlying securities and fluctuations in the relative value of the currencies in which the Depositary Receipts
and the underlying securities are quoted. However, by investing in Depositary Receipts, such as ADRs, which are quoted in U.S. dollars,
the Fund may avoid currency risks during the settlement period for purchases and sales. The issuers of Depositary Receipts may discontinue
issuing new Depositary Receipts and withdraw existing Depositary Receipts at any time, which may result in costs and delays in the distribution
of the underlying assets to the Fund and may negatively impact the Fund's performance.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Brokerage commissions, custodial
services and other costs relating to investment in international securities markets generally are more expensive than in the United States.
In addition, clearance and settlement procedures may be different in foreign countries and, in certain markets, such procedures have been
unable to keep pace with the volume of securities transactions, thus making it difficult to conduct such transactions.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Foreign issuers are not generally
subject to uniform accounting, auditing and financial reporting standards comparable to those applicable to U.S. issuers. There may be
less publicly available information about a foreign issuer than about a U.S. issuer. In addition, there is generally less government regulation
of foreign markets, companies and securities dealers</span></p> </div>  </div>

<div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">than in the United States,
and the legal remedies for investors may be more limited than the remedies available in the United States. Foreign securities markets
may have substantially less volume than U.S. securities markets and securities of many foreign issuers are less liquid and more volatile
than securities of comparable domestic issuers. Furthermore, with respect to certain foreign countries, there is a possibility of nationalization,
expropriation or confiscatory taxation, imposition of withholding or other taxes on dividend or interest payments (or, in some cases,
capital gains distributions), limitations on the removal of funds or other assets from such countries, and risks of political or social
instability or diplomatic developments which could adversely affect investments in those countries. At any time after the date hereof,
U.S. and non-U.S. governmental agencies and other regulators may implement additional regulations and legislators may pass new laws that
affect the investments held by the Fund, the strategies used by the Fund or the level of regulation or taxation applying to the Fund.
These regulations and laws impact the investment strategies, performance, costs and operations of the Fund, as well as the way investments
in, and shareholders of, the Fund are taxed. In particular, changes to U.S. healthcare policy could affect the Fund and its investments.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund may invest in securities
of issuers located in Emerging Markets. The risks of foreign investment are heightened when the issuer is located in an emerging country.
Emerging Markets are generally located in Africa, Asia, the Middle East, Eastern Europe and Central and South America. Investments in
securities of issuers located in Emerging Markets may be subject to heightened risks, including relative illiquidity, price volatility
and potential restrictions on repatriation of investment capital and income. The Fund's purchase and sale of portfolio securities in Emerging
Markets may be constrained by limitations relating to daily changes in the prices of listed securities, periodic trading or settlement
volume and/or limitations on aggregate holdings of foreign investors. Such limitations may be computed based on the aggregate trading
volume by or holdings of the Fund, the Investment Adviser, or its affiliates and respective clients and other service providers. The Fund
may not be able to sell securities in circumstances where price, trading or settlement volume limitations have been reached.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Foreign investment in the
securities markets of certain Emerging Markets is restricted or controlled to varying degrees which may limit investment in such countries
or increase the administrative costs of such investments. For example, certain Asian countries require governmental approval prior to
investments by foreign persons or limit investment by foreign persons to only a specified percentage of an issuer's outstanding securities
or a specific class of securities which may have less advantageous terms (including price) than securities of the issuer available for
purchase by nationals. In addition, certain countries may restrict or prohibit investment opportunities in issuers or industries deemed
important to national interests. Such restrictions may affect the market price, liquidity and rights of securities that may be purchased
by the Fund. The repatriation of both investment income and capital from</span></p> </div>  </div>

<div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">certain Emerging Markets is
subject to restrictions such as the need for governmental consents. In situations where a country restricts direct investment in securities
(which may occur in certain Asian and other countries), the Fund may invest in such countries through other investment funds in such countries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Many Emerging Markets have
experienced currency devaluations and substantial (and, in some cases, extremely high) rates of inflation. Other Emerging Markets have
experienced economic recessions. These circumstances have had a negative effect on the economies and securities markets of those Emerging
Markets.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Economies in Emerging Markets
generally are dependent heavily upon commodity prices and international trade and, accordingly, have been and may continue to be affected
adversely by the economies of their trading partners, trade barriers, exchange controls, managed adjustments in relative currency values
and other protectionist measures imposed or negotiated by the countries with which they trade.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Many Emerging Markets are
subject to a substantial degree of economic, political and social instability. Governments of some emerging countries are authoritarian
in nature or have been installed or removed as a result of military coups, while governments in other Emerging Markets have periodically
used force to suppress civil dissent. Disparities of wealth, the pace and success of democratization, and ethnic, religious and racial
disaffection, among other factors, have also led to social unrest, violence and/or labor unrest in some Emerging Markets. Unanticipated
political or social developments may result in sudden and significant investment losses. Investing in Emerging Markets involves greater
risk of loss due to expropriation, nationalization, confiscation of assets and property or the imposition of restrictions on foreign investments
and on repatriation of capital invested. As an example, in the past, some Eastern European governments have expropriated substantial amounts
of private property, and many claims of the property owners have never been fully settled. There is no assurance that similar expropriations
will not occur in other countries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's investment in Emerging
Markets may also be subject to withholding or other taxes, which may be significant and may reduce the return to the Fund from an investment
in issuers in such countries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Settlement procedures in Emerging
Markets are frequently less developed and reliable than those in the United States and may involve the Fund's delivery of securities before
receipt of payment for their sale. In addition, significant delays may occur in certain markets in registering the transfer of securities.
Settlement or registration problems may make it more difficult for the Fund to value its portfolio securities and could cause the Fund
to miss attractive investment opportunities, to have a portion of its assets uninvested or to incur losses due to the failure of a counterparty
to pay for securities the Fund has delivered or the Fund's inability to complete its contractual obligations because of theft or other
reasons.</span></p> </div>  </div>

<div>

<div>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The creditworthiness of the local
securities firms used by the Fund in Emerging Markets may not be as sound as the creditworthiness of firms used in more developed countries.
As a result, the Fund may be subject to a greater risk of loss if a securities firm defaults in the performance of its responsibilities.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The small size and inexperience
of the securities markets in certain Emerging Markets and the limited volume of trading in securities in those countries may make the
Fund's investments in such countries less liquid and more volatile than investments in countries with more developed securities markets
(such as the United States, Japan and most Western European countries). The Fund's investments in Emerging Markets are subject to the
risk that the liquidity of a particular investment, or investments generally, in such countries will shrink or disappear suddenly and
without warning as a result of adverse economic, market or political conditions or adverse investor perceptions, whether or not accurate.
Because of the lack of sufficient market liquidity, the Fund may incur losses because it will be required to effect sales at a disadvantageous
time and only then at a substantial drop in price. Investments in Emerging Markets may be more difficult to value precisely because of
the characteristics discussed above and lower trading volumes. In addition, the impact of the economic and public health crisis in emerging
market countries may be greater due to their generally less established healthcare systems and capabilities with respect to fiscal and
monetary policies, which may exacerbate other pre-existing political, social and economic tasks.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's use of foreign
currency management techniques in Emerging Markets may be limited. A significant portion of the Fund's currency exposure in Emerging Markets
may not be covered by these techniques.</span></p> </div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Forward Contract Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Forward contracts involve the purchase or sale of a specific quantity of a commodity, government security, foreign currency, or other
asset at a specified price, with delivery and settlement at a specified future date. Because it is a completed contract, a purchase forward
contract can be a cover for the sale of a futures contract. The Fund may enter into forward contracts for hedging purposes and non-hedging
purposes (i.e., to increase returns). Forward contracts may be used by the Fund for hedging purposes to protect against uncertainty in
the level of future foreign currency exchange rates, such as when the Fund anticipates purchasing or selling a foreign security. For example,
this technique would allow the Fund to "lock in" the U.S. dollar price of the security. Forward contracts may also be used to attempt
to protect the value of the Fund's existing holdings of foreign securities. There may be, however, an imperfect correlation between the
Fund's foreign securities holdings and the forward contracts entered into with respect to those holdings. Forward contracts may also be
used for non-hedging purposes to pursue the Fund's investment objective, such as when the Investment Adviser anticipates that particular
foreign currencies will appreciate or depreciate in value, even though securities denominated in</span></p>  </div>

<div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">those currencies are not then
held in the Fund's portfolio. There is no requirement that the Fund hedge all or any portion of its exposure to foreign currency risks.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Forward contracts, unlike
futures contracts, are not traded on exchanges and are not standardized; rather, banks and dealers act as principals in these markets,
negotiating each transaction on an individual basis. The principals who deal in the forward markets are not required to continue to make
markets in the currencies or commodities they trade and these markets can experience periods of illiquidity, sometimes of significant
duration. There have been periods during which certain participants in these markets have refused to quote prices for certain currencies
or commodities or have quoted prices with an unusually wide spread between the price at which they were prepared to buy and that at which
they were prepared to sell. Disruptions can occur in any market traded by the Investment Adviser due to unusually high trading volume,
political intervention or other factors. Arrangements to trade forward contracts may be made with only one or a few counterparties, and
liquidity problems therefore might be greater than if such arrangements were made with numerous counterparties. The imposition of controls
by governmental authorities might also limit such forward (and futures) trading to less than that which the Investment Adviser would otherwise
recommend, to the possible detriment of the Fund. Market illiquidity or disruption could result in major losses to the Fund. In addition,
the Fund will be exposed to credit risks with regard to counterparties with whom they trade as well as risks relating to settlement default.
Such risks could result in substantial losses to the Fund.</span></p> </div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Derivatives Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
The Fund may invest in derivative instruments including options, futures, options on futures, forwards, swaps (including credit default,
index, basis, total return, volatility and currency swaps), options on swaps and other derivatives, although suitable derivative instruments
may not always be available to the Investment Adviser for these purposes. The Fund intends to employ a strategy of writing (selling) covered
call options on a portion of the common stocks in its portfolio, writing (selling) put options on a portion of the common stocks in its
portfolio and, to a lesser extent, writing (selling) covered call and writing (selling) put options on indices of securities and sectors
of securities generally within the healthcare industry. This option strategy is intended to generate current income from option premiums
as a means to enhance distributions payable to the Fund's shareholders and will be limited to 30% of the Fund's Managed Assets. These
option strategies are not always profitable. The sale of a covered call option exposes the Fund during the term of the option to possible
loss of opportunity to realize appreciation in the market price of the underlying security or to possible loss due to continued holding
of a security that might otherwise have been sold to protect against depreciation in the market price of the security. To the extent the
Fund writes a covered put option, the Fund has assumed the obligation during the option period to purchase the security or securities
from the put buyer at the option's exercise price if the put buyer exercises its option, regardless of whether the value of the underlying
investment falls below the exercise price. This means that a Fund that writes a</span></p>  </div>

<div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">put option may be required
make payment for such investment at the exercise price. This may result in losses to the Fund and may result in the Fund holding securities
for some period of time when it is disadvantageous to do so. Therefore, the Investment Adviser may choose to decrease its use of the option
writing strategy to the extent that it may negatively impact the Fund. Other than the Fund's option strategy and use of derivatives for
hedging purposes, the Fund may invest up to 10% of its Managed Assets in derivatives. Derivative instruments can be illiquid, may disproportionately
increase losses, and may have a potentially large adverse impact on Fund performance.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Although both OTC and exchange-traded
derivatives markets may experience a lack of liquidity, OTC nonstandardized derivative transactions are generally less liquid than exchange-traded
instruments. The illiquidity of the derivatives markets may be due to various factors, including congestion, disorderly markets, limitations
on deliverable supplies, the participation of speculators or their withdrawal from the markets, government regulation and intervention,
and technical and operational or system failures. In addition, daily limits on price fluctuations and speculative position limits on exchanges
on which the Fund may conduct its transactions in derivative instruments may prevent the Fund from liquidating these positions at an advantageous
time or price, subjecting the Fund to the potential of greater losses. Losses from investments in derivative instruments can result from
a lack of correlation between changes in the value of derivative instruments and the portfolio assets (if any) being hedged, the potential
illiquidity of the markets for derivative instruments, the failure of the counterparty to perform its contractual obligations, or the
risks arising from margin requirements and related leverage factors associated with such transactions. Losses may also arise if the Fund
receives cash collateral under the transactions and some or all of that collateral is invested in the market. To the extent that cash
collateral is so invested, such collateral will be subject to market depreciation or appreciation, and the Fund may be responsible for
any loss that might result from its investment of the counterparty's cash collateral. The use of these derivatives trading techniques
also involves the risk of loss if the Investment Adviser is incorrect in its expectation of the timing or level of fluctuations in securities
prices, interest rates or currency prices. Investments in derivative instruments may be harder to value, subject to greater volatility
and more likely subject to changes in tax treatment than other investments. For these reasons, the Investment Adviser's attempts to hedge
portfolio risks through the use of derivative instruments may not be successful. Trading in derivative instruments can increase the Fund's
exposure to leverage. Thus, the leverage offered by trading in derivative instruments will magnify the gains and losses experienced by
the Fund and could cause the Fund's net asset value to be subject to wider fluctuations than would be the case if the Fund did not use
the leverage feature in derivative instruments.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Derivatives markets have been
subject to increased regulation over the past several years, which may continue, and consequently, may make derivatives trading more costly,
may limit the availability of and reduce the liquidity of derivatives or may otherwise adversely affect the</span></p> </div>
</div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">value or performance of derivatives.
Such potential adverse future developments could increase the risks reduce the effectiveness of the Fund's derivative transactions, and
cause the Fund to lose value. For instance, the SEC has adopted new regulations related to a registered investment company's use of derivatives
and related instruments. These regulations impose limits on the amount of derivatives a fund can enter into, eliminate the asset segregation
framework formerly used by funds to comply with Section 18 of the 1940 Act. These regulations may significantly impact the Fund's ability
to invest in derivatives and other instruments, limit the Fund's ability to employ certain strategies that use derivatives and/or adversely
affect the Fund's performance, efficiency in implementing its strategy, liquidity and/or ability to pursue its investment objectives.</span></p>


<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Risks Associated with
the Fund's Option Strategy.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The ability of the Fund to achieve
its investment objective is partially dependent on the successful implementation of its option strategy. There are several risks associated
with transactions in options on securities used in connection with the Fund's option strategy. For example, there are significant differences
between the securities and options markets that could result in an imperfect correlation between these markets, causing a given transaction
not to achieve its objectives. A decision as to whether, when and how to use options involves the exercise of skill and judgment, and
even a well-conceived transaction may be unsuccessful to some degree because of market behavior or unexpected events.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">As the writer of a call option
covered with a security held by the Fund, the Fund forgoes, during the option's life, the opportunities to profit from increases in the
market value of the security covering the call option above the sum of the premium and the strike price of the call but retains the risk
of loss should the price of the underlying security decline. As the Fund writes such covered calls over more of its portfolio, its ability
to benefit from capital appreciation becomes more limited. To the extent the Fund writes call options that are not fully covered by securities
in its portfolio (such as calls on an index or sector), it will lose money if the portion of the security or securities underlying the
option that is not covered by securities in the Fund's portfolio appreciate in value above the exercise price of the option by an amount
that exceeds the premium received on the option plus the exercise price of the option. The amount of this loss theoretically could be
unlimited. The writer of an option has no control over the time when it may be required to fulfill its obligations as a writer of the
option.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">When the Fund writes put options,
it bears the risk of loss if the value of the underlying stock declines below the exercise price minus the put premium. If the option
is exercised, the Fund could incur a loss if it is required to purchase the stock underlying the put option at a price greater than the
market price of the stock at the time of exercise plus the put premium the Fund received when it wrote the option. While the Fund's potential
gain as the writer of a</span></p> </div>  </div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">covered put option is limited
to the premium received from the purchaser of the put option, the Fund risks a loss equal to the entire exercise price of the option minus
the put premium.</span></p>

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Interest Rate Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Prices of fixed-income securities generally rise and fall in response to interest rate changes. Generally, the prices of fixed-rate instruments
held by the Fund will tend to fall as interest rates rise. Conversely, when interest rates decline, the value of fixed-rate instruments
held by the Fund can be expected to rise. Changing interest rates may have unpredictable effects on the markets, may result in heightened
market volatility and may detract from Fund performance. In addition, changes in monetary policy may exacerbate the risks associated with
changing interest rates. The longer the duration, or price sensitivity to changes in interest rates, of the security, the more sensitive
the security is to this risk. In typical market interest rate environments, the prices of longer-term fixed-rate instruments tend to fluctuate
more in price in response to changes in market interest rates than prices of shorter-term fixed-rate instruments. A 1% increase in interest
rates would reduce the value of a $100 note by approximately one dollar if it had a one-year duration. It is difficult to predict the
magnitude, timing or direction of interest rate changes and the impact these changes will have on the Fund's investments and the markets
where it trades.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The risks attendant to changing
interest rate environments have been, and continue to be, magnified in the current economic environment. To combat rising inflation, the
Board of Governors of the Federal Reserve System increased the federal funds rate several times in 2022 and 2023.</span></p> </div>


<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>REIT Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
REITs whose underlying properties are concentrated in a particular industry, such as the healthcare industry, or geographic region are
subject to risks affecting such industries or regions. The securities of REITs involve greater risks than those associated with larger,
more established companies and may be subject to more abrupt or erratic price movements because of interest rate changes, economic conditions
and other factors. Securities of such issuers may lack sufficient market liquidity to enable the Fund to effect sales at an advantageous
time or without a substantial drop in price.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Credit/Default Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Loans and other debt obligation investments are subject to the risk of non-payment of scheduled principal and interest. Changes in economic
conditions or other circumstances may reduce the capacity of the party obligated to make principal and interest payments on such instruments
and may lead to defaults. Such non-payments and defaults may reduce the value of the shares and income distributions. The value of loans
and other income investments also may decline because of concerns about the issuer's ability to make principal and interest payments.
In addition, the credit ratings of loans or other income investments may be lowered if the financial condition of the party obligated
to make payments with respect to such instruments changes. Because the Fund will invest in non-investment grade securities, it will be
exposed to a greater amount of credit risk than a fund which invests solely in investment grade securities. The prices of lower grade</span></p>
 </div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">instruments are generally
more sensitive to negative developments, such as a decline in the issuer's revenues or a general economic downturn, than are the prices
of higher grade instruments. Credit ratings assigned by rating agencies are based on a number of factors and do not necessarily reflect
the issuer's current financial condition or the volatility or liquidity of the security. In the event of bankruptcy of the issuer of loans
or other income investments, the Fund could experience delays or limitations with respect to its ability to realize the benefits of any
collateral securing the instrument. In order to enforce its rights in the event of a default, bankruptcy or similar situation, the Fund
may be required to retain legal or similar counsel and incur additional costs.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Non-Investment Grade
Securities Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund may invest in securities that are
rated, at the time of investment, non-investment grade quality (rated "Ba/BB+/BB+" or below by Moody's, S&amp;P or Fitch, respectively),
or securities that are unrated but determined to be of comparable quality by the Investment Adviser. The Fund may invest up to 15% of
its Managed Assets in non-convertible debt securities that are, at the time of investment, rated Caa1 or lower by Moody's and CCC+ or
lower by S&amp;P or Fitch, or comparably rated by another nationally recognized statistical rating organization, or, if unrated, determined
by the Investment Adviser to be of comparable credit quality. Such securities are subject to a very high credit risk. Securities of non-investment
grade quality are regarded as having predominantly speculative characteristics with respect to the issuer's capacity to pay interest and
repay principal, and are commonly referred to as "junk bonds." Non-investment grade securities and unrated securities of comparable credit
quality are subject to the increased risk of an issuer's inability to meet principal and interest payment obligations. The value of high
yield, lower quality bonds is affected by the creditworthiness of the issuers of the securities and by general economic and specific industry
conditions. These securities may be subject to greater price volatility due to such factors as specific corporate or municipal developments,
interest rate sensitivity, negative perceptions of the junk bond markets generally and less secondary market liquidity. Issuers of high
yield bonds are not as strong financially as those with higher credit ratings. These issuers are more vulnerable to financial setbacks
and recession than more creditworthy issuers, which may impair their ability to make interest and principal payments. Non-investment grade
securities may be particularly susceptible to economic downturns, specific corporate or municipal developments, interest rate sensitivity,
negative perceptions of the junk bond markets generally and less secondary market liquidity. An economic recession could disrupt severely
the market for such securities and may have an adverse impact on the value of such securities. In addition, any such economic downturn
could adversely affect the ability of the issuers of such securities to repay principal and pay interest thereon and increase the incidence
of default for such securities. Non-investment grade securities, though higher yielding, are characterized by high risk. They may be subject
to certain risks with respect to the issuing entity and to greater market fluctuations than certain lower yielding, higher rated securities.
The retail secondary market for non-investment grade securities may be less liquid than that for higher rated securities. Adverse conditions</span></p>
 </div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">could make it difficult at
times for the Fund to sell certain securities or could result in lower prices than those used in calculating the Fund's NAV. Because of
the substantial risks associated with investments in non-investment grade securities, you could lose money on your investment in shares
of the Fund, both in the short-term and the long-term.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Counterparty Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Many of the protections afforded to participants on some organized exchanges, such as the performance guarantee of a clearing house, might
not be available in connection with uncleared OTC transactions. Therefore, in those instances in which the Fund enters into uncleared
OTC transactions, the Fund will be subject to the risk that its direct counterparty will not perform its obligations under the transactions
and that the Fund will sustain losses. If a counterparty becomes bankrupt, the Fund may experience significant delays in obtaining recovery
(if at all) under the derivative contract in bankruptcy or other reorganization proceeding; if the Fund's claim is unsecured, the Fund
will be treated as a general creditor of such prime broker or counterparty and will not have any claim with respect to the underlying
security. The Fund may obtain only a limited recovery or may obtain no recovery in such circumstances. The counterparty risk for cleared
derivatives is generally lower than for uncleared OTC derivatives since generally a clearing organization becomes substituted for each
counterparty to a cleared derivative and, in effect, guarantees the parties' performance under the contract as each party to a trade looks
only to the clearing house for performance of financial obligations. However, there can be no assurance that the clearing house, or its
members, will satisfy its obligations to the Fund.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Regulation as a "Commodity
Pool".</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Investment Adviser has claimed an exclusion from
the definition of the term "commodity pool operator" with respect to the Fund pursuant to Regulation 4.5 promulgated by the U.S. Commodity
Futures Trading Commission (the "CFTC"). For the Investment Adviser to continue to qualify for the exclusion under CFTC Regulation 4.5
with respect to the Fund, the aggregate initial margin and premiums required to establish our positions in derivative instruments subject
to the jurisdiction of the Commodity Exchange Act of 1936, as amended ("CEA") (other than positions entered into for hedging purposes)
may not exceed five percent of the Fund's liquidation value or, alternatively, the net notional value of the Fund's aggregate investments
in CEA-regulated derivative instruments (other than positions entered into for hedging purposes) may not exceed 100% of the Fund's liquidation
value. In the event the Investment Adviser fails to qualify for the exclusion with respect to the Fund and is required to register as
a "commodity pool operator," it will become subject to additional disclosure, recordkeeping and reporting requirements with respect to
the Fund, which may increase the Fund's expenses.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Failure of Futures
Commission Merchants and Clearing Organizations.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund may
deposit funds required to margin open positions in derivative instruments subject to the CEA with a clearing broker registered as a "futures
commission merchant" ("FCM"). The CEA requires an FCM to segregate all funds received from customers with respect to any orders for the
purchase or sale of U.S. domestic futures contracts and cleared swaps from the FCM's</span></p>  </div>

<div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">proprietary assets. Similarly,
the CEA requires each FCM to hold in a separate secure account all funds received from customers with respect to any orders for the purchase
or sale of foreign futures contracts and segregate any such funds from the funds received with respect to domestic futures contracts.
However, all funds and other property received by a clearing broker from its customers are held by the clearing broker on a commingled
basis in an omnibus account and may be freely accessed by the clearing broker, which may also invest any such funds in certain instruments
permitted under the applicable regulation. There is a risk that assets deposited by the Fund with any swaps or futures clearing broker
as margin for futures contracts or cleared swaps may, in certain circumstances, be used to satisfy losses of other clients of the Fund's
clearing broker. In addition, the assets of the Fund may not be fully protected in the event of the clearing broker's bankruptcy, as the
Fund would be limited to recovering only a pro rata share of all available funds segregated on behalf of the clearing broker's combined
domestic customer accounts.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Similarly, the CEA requires
a clearing organization approved by the CFTC as a derivatives clearing organization to segregate all funds and other property received
from a clearing member's clients in connection with domestic futures, swaps and options contracts from any funds held at the clearing
organization to support the clearing member's proprietary trading. Nevertheless, with respect to futures and options contracts, a clearing
organization may use assets of a non-defaulting customer held in an omnibus account at the clearing organization to satisfy payment obligations
of a defaulting customer of the clearing member to the clearing organization. As a result, in the event of a default or the clearing broker's
other clients or the clearing broker's failure to extend its own funds in connection with any such default, the Fund would not be able
to recover the full amount of assets deposited by the clearing broker on its behalf with the clearing organization.</span></p> </div>


<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Liquidity Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Illiquid securities include securities the disposition of which is subject to substantial legal or contractual restrictions. The sale
of illiquid securities often requires more time and results in higher brokerage charges or dealer discounts and other selling expenses
than does the sale of securities eligible for trading on national securities exchanges or in the over-the-counter markets. Restricted
securities may sell at a price lower than similar securities that are not subject to restrictions on resale. The continued liquidity of
such securities may not be as well assured as that of publicly traded securities. During certain periods the liquidity of particular issuers
or industries, or all securities within particular investment categories, may shrink or disappear suddenly and without warning as a result
of adverse economic, market or political events, or adverse investor perceptions, whether or not accurate.</span></p>


<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Equity-Linked Notes.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Equity-linked notes ("ELNs") are hybrid securities with characteristics of both fixed income and equity securities. An ELN is a debt instrument,
usually a bond, that pays interest based upon the performance of an underlying equity, which can be a single stock, basket of stocks or
an equity index. The interest payment on an ELN may in some cases be leveraged so that, in percentage terms, it exceeds the relative performance
of the market.</span></p>  </div>

<div>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">ELNs generally are subject to
the risks associated with the securities of equity issuers, default risk and counterparty risk. Additionally, because the Fund may use
ELNs as an alternative or complement to its options strategy, the use of ELNs in this manner would expose the Fund to the risk that such
ELNs will not perform as anticipated, and the risk that the use of ELNs will expose the Fund to different or additional default and counterparty
risk as compared to a similar investment executed in an options strategy.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>PIPEs Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
PIPE transactions typically involve the purchase of securities directly from a publicly traded company or its affiliates in a private
placement transaction, typically at a discount to the market price of the company's common stock. In a PIPE transaction, the Fund may
bear the price risk from the time of pricing until the time of closing. Equity issued in this manner is often subject to transfer restrictions
and is therefore less liquid than equity issued through a registered public offering. In a PIPE transaction, the Fund may bear the price
risk from the time of pricing until the time of closing. The Fund may be subject to lock-up agreements that prohibit transfers for a fixed
period of time. In addition, because the offering of the securities in a PIPE transaction is not registered under the Securities Act,
the securities are "restricted" and cannot be immediately resold by the investors into the public markets. The Fund may enter into a registration
rights agreement with the issuer pursuant to which the issuer commits to file a resale registration statement allowing the Fund to publicly
resell its securities. Accordingly, PIPE securities may be deemed illiquid. However, the ability of the Fund to freely transfer the shares
is conditioned upon, among other things, the Commission's preparedness to declare the resale registration statement effective covering
the resale of the shares sold in the private financing and the issuer's right to suspend the Fund's use of the resale registration statement
if the issuer is pursuing a transaction or some other material non-public event is occurring. Accordingly, PIPE securities may be subject
to risks associated with illiquid securities.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Venture Capital Investments
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund may occasionally invest in venture capital opportunities.
While these securities offer the opportunity for significant capital gains, such investments also involve a degree of risk that can result
in substantial losses. Some of the venture capital opportunities in which the Fund may invest are expected to be companies that are in
a "start-up" stage of development, have little or no operating history, operate at a loss or with substantial variations in operating
results from period to period, have limited products, markets, financial resources or management depth, or have the need for substantial
additional "follow-on" capital to support expansion or to achieve or maintain a competitive position. Such additional investments may
dilute the interests of prior investors, such as the Fund. Some of these companies may be emerging companies at the research and development
stage with no marketable or approved products or technology. There can be no assurance that securities of start-up or emerging growth
companies will, in the future, yield returns commensurate with their associated risks.</span></p>  </div>

<div>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">These investments, which are considered
Restricted Securities, will be made primarily in convertible preferred stock. The Fund may also purchase non-convertible debt securities
in connection with its venture capital investments, and otherwise when the Investment Adviser believes that such investments would be
consistent with the Fund's investment objective. While these debt investments typically will not be rated, the Investment Adviser believes
that, in light of the risk characteristics associated with investments in emerging growth companies, if such investments were to be compared
with investments rated by S&amp;P or Moody's, they may be rated as low as "C" in the rating categories established by S&amp;P and Moody's.
Such securities are commonly referred to as "junk bonds" and are considered, on balance, as predominantly speculative.</span></p>


<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>ETFs Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
An investment in an ETF generally presents the same primary risks as an investment in a conventional fund (i.e., one that is not exchange-traded)
that has the same investment objectives, strategies and policies. In addition, an ETF may fail to accurately track the market segment
or index that underlies its investment objective. The price of an ETF can fluctuate, and the Fund could lose money investing in an ETF.
Moreover, ETFs are subject to the following risks that do not apply to conventional open-end funds: (i) the market price of the ETF's
shares may trade at a premium or a discount to their NAV; (ii) an active trading market for an ETF's shares may not develop or be maintained;
and (iii) there is no assurance that the requirements of the exchange necessary to maintain the listing of an ETF will continue to be
met or remain unchanged.</span></p>

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Leverage Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
The Fund intends to use financial leverage for investment purposes. The Fund may issue preferred shares, borrow money and/or issue debt
securities ("traditional leverage"). The Fund intends to use traditional leverage through a credit facility representing up to 20% of
the Fund's Managed Assets as measured at the time when leverage is incurred. In addition, the Fund may enter into reverse repurchase agreements,
swaps, futures, forward contracts, securities lending, short sales, and other derivative transactions, that have similar effects as leverage
(collectively referred to as "effective leverage"). Furthermore, at no time will the Fund's use of leverage, either through traditional
leverage or effective leverage, exceed 30% of the Fund's Managed Assets as measured at the time when leverage is incurred. Notwithstanding
the foregoing, effective leverage incurred through the Fund's option strategy and use of derivatives for hedging purposes will not be
counted toward the Fund's limit on the use of effective leverage or in the overall 30% leverage limitation.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's leveraged capital
structure creates special risks not associated with unleveraged funds having a similar investment objective and policies. These include
the possibility of greater loss and the likelihood of higher volatility of the NAV, market price and distributions of the Fund and the
asset coverage for preferred shares, if any. Such volatility may increase the likelihood of the Fund having to sell investments in order
to meet its obligations to make distributions on the preferred shares, or to redeem preferred shares when it may be disadvantageous to
do so. Also, if the Fund is utilizing leverage, a decline in NAV could affect</span></p> </div>  </div>

<div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">the ability of the Fund to
make distributions and such a failure to pay dividends or make distributions could result in the Fund ceasing to qualify as a regulated
investment company under the Code, as amended.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Other risks and special considerations
include the risk that fluctuations in interest rates on borrowings and short-term debt or in the interest or dividend rates on any leverage
that the Fund must pay will reduce the return to the shareholders; the effects of leverage in a declining market, which are likely to
cause a greater decline in the NAV of the shares than if the Fund were not leveraged, which may result in a greater decline in the market
price of the shares. If the Fund uses leverage, the amount of fees paid to the Investment Adviser for its services will be higher than
if the Fund did not use leverage because the fees paid are calculated based on Managed Assets, which includes assets purchased with leverage.
Therefore, the Investment Adviser has a financial incentive to use leverage, which creates a conflict of interest between the Investment
Adviser and common shareholders, as only the Fund's common shareholders would bear the fees and expenses incurred through the Fund's use
of leverage, including the issuance of Preferred shares, if any. Leverage may increase operating costs, which may reduce total return.</span></p>


<div>

<p style="margin:11pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Effects of Leverage</strong></span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Assuming that leverage will
represent approximately 20% of Managed Assets and that the Fund will bear expenses relating to that leverage at an annual cost of 1.00%,
Fund performance before leverage (net of expenses) must exceed .2% in order to cover the expenses specifically related to the Fund's use
of leverage. Actual leverage expenses will vary frequently and may be significantly higher or lower than the rate estimated above.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">As of September 30, 2023 and
the most recently signed line of credit agreement, the Fund projects an annual leverage expense of 6.57%. The Fund had $120,000,000 of
funds drawn on its line of credit which was 21.2% of Managed Assets as of September 30, 2023.</span></p>

<div>

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following table is furnished
in response to requirements of the SEC. It is designed to illustrate the effects of leverage on total returns from an investment in the
Fund assuming investment portfolio returns before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage
representing 20% of the Fund's Managed Assets and the Fund's currently projected annual leverage expense of 6.57%.</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:143;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">Assumed
        Fund Return Before Leverage</span><br/><span style="font-size:8pt;font-family:Arial, Helvetica">(Net of Expenses) </span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(10.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(5.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:29;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:33;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:143">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Assumed Fund Return Inclusive of Leverage </span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(14.14</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(7.89</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1.64</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:29">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4.61</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:33">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10.89</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  </table>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Assumed Fund performance before
and inclusive of leverage are hypothetical and are provided to assist investors in understanding the effects of leverage. Actual performance
experienced by the Fund may be lesser or greater than that shown above.</span></p> </div>  </div>  </div>
 </div>

<div>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Restricted Securities
and Valuation Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Some of the Fund's investments are subject
to restrictions on resale and generally have no established trading market or are otherwise illiquid with little or no trading activity.
The valuation process requires an analysis of various factors. The Fund's fair value methodology includes the examination of, among other
things, (i) the existence of any contractual restrictions on the disposition of the securities; (ii) information obtained from the issuer
which may include an analysis of the company's financial statements, the company's products or intended markets, or the company's technologies;
and (iii) the price of a security sold at arm's length in an issuer's subsequent completed round of financing. As there is typically no
readily available market value for some of the Restricted Securities in the Fund's portfolio, such Restricted Securities in the Fund's
portfolio are valued at fair value as determined in good faith by or under the direction of the Board pursuant to the Fund's valuation
policy and a consistently applied valuation process. Because of the inherent uncertainty of determining the fair value of investments
that do not have a readily available market value, the fair value of the Fund's investments determined in good faith by the Board may
differ significantly from the values that would have been used had a ready market existed for the investments, and the differences could
be material. There is no single standard for determining fair value in good faith. As a result, determining fair value requires that judgment
be applied to the specific facts and circumstances of each portfolio investment, while employing a consistently applied valuation process
for the types of investments the Fund makes.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Key Personnel Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
There may be only a limited number of securities professionals who have comparable experience to that of the Fund's existing portfolio
management team in the area of healthcare companies. If one or more of the team members dies, resigns, retires or is otherwise unable
to act on behalf of the Investment Adviser, there can be no assurance that a suitable replacement could be found immediately.</span></p>


<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Anti-Takeover Provisions
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund's Amended and Restated Declaration of Trust ("Declaration
of Trust"), dated March 5, 2015, as amended, has provisions that could have the effect of limiting the ability of other entities or persons
to (1) acquire control of the Fund, (2) cause it to engage in certain transactions, or (3) modify its structure. The By-Laws also contain
provisions regarding qualifications for nominees for Trustee positions, advance notice of Shareholder proposals, and requirements for
the call of special Shareholder meetings. These provisions may be considered "anti-takeover" provisions.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Related Party Transactions
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The majority of the Board is unaffiliated with the Investment
Adviser; nevertheless, the Fund may be subject to certain potential conflicts of interest. Although the Fund has no obligation to do so,
it may place brokerage orders with brokers who provide supplemental investment research and market and statistical information about healthcare
companies and the healthcare industries. In addition, other investment companies advised by the Investment Adviser may concurrently invest
with the Fund in restricted securities under certain conditions. The Fund also may invest, subject to</span></p>  </div>


<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">applicable law, in companies
in which the principals of the Investment Adviser or Trustees of the Fund have invested, or for which they serve as directors or executive
officers. The Investment Company Act prohibits the Fund from engaging in certain transactions involving its "affiliates," including, among
others, the Fund's Trustees, officers and employees, the Investment Adviser and any "affiliates" of such affiliates except pursuant to
an exemptive order or the provisions of certain rules under the Investment Company Act. In the view of the staff of the Commission, other
investment companies advised by the Investment Adviser may, in some instances, be viewed to be affiliates of the Fund. Such legal restrictions
and delays and costs involved in obtaining necessary regulatory approvals may preclude or discourage the Fund from making certain investments
and no assurance can be given that any exemptive order sought by the Fund will be granted.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Government Intervention.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Instability in the financial markets has led the U.S. government and certain foreign governments to take a number of unprecedented actions
designed to support certain financial institutions and segments of the financial markets that have experienced extreme volatility, and
in some cases a lack of liquidity, including through direct purchases of equity and debt securities. Federal, state, and foreign governments,
their regulatory agencies or self-regulatory organizations may take actions that affect the regulation of the issuers in which the Fund
invests in ways that are unforeseeable. Legislation or regulation may also change the way in which the Fund is regulated. Such legislation
or regulation could limit or preclude the Fund's ability to achieve its investment objective.</span></p>

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Market Disruption
and Geopolitical Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The value of your investment in the Fund
is based on the market prices of the securities the Fund holds. These prices change daily due to economic and other events that affect
markets generally, as well as those that affect particular regions, countries, industries, companies or governments. These price movements,
sometimes called volatility, may be greater or less depending on the types of securities the Fund owns and the markets in which the securities
trade. The increasing interconnectivity between global economies and financial markets increases the likelihood that events or conditions
in one region or financial market may adversely impact issuers in a different country, region or financial market. Securities in the Fund's
portfolio may underperform due to inflation (or expectations for inflation), interest rates, global demand for particular products or
resources, natural/environmental disasters, pandemics, epidemics, terrorism, cyber-attacks, regulatory events and governmental or quasi-governmental
actions. The occurrence of global events similar to those in recent years, such as terrorist attacks around the world, natural disasters,
social and political discord or debt crises and downgrades, among others, may result in market volatility and may have long term effects
on both the U.S. and global financial markets. A disruption of financial markets or other terrorist attacks could adversely affect Fund
service providers and/or the Fund's operations as well as interest rates, secondary trading, credit risk, inflation and other factors
relating to the shares. The Fund cannot predict the effects or likelihood of similar events in the future on the U.S. and world economies,
the value of the shares or the NAV of the Fund.</span></p>  </div>

<div>

<div>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Social, political, economic
and other conditions and events, such as natural/environmental disasters, health emergencies (e.g., epidemics and pandemics such as COVID-19,
avian influenza and HINI/09), cyber-attacks, terrorism, actual or threatened wars or other armed conflicts (such as the Russia/Ukraine
and Israel/Hamas conflicts), may occur and could significantly impact issuers, industries, governments and other systems, including the
financial markets. These impacts could negatively affect the Fund's investments in securities and instruments that are economically tied
to the applicable region, and include (but are not limited to) declines in value and reductions in liquidity. In addition, to the extent
new sanctions are imposed or previously relaxed sanctions are reimposed, complying with such restrictions may prevent the Fund from pursuing
certain investments, cause delays or other impediments with respect to consummating such investments or divestments, require divestment
or freezing of investments on unfavorable terms, render divestment of underperforming investments impracticable, negatively impact the
Fund's ability to achieve its investment objective, prevent the Fund from receiving payments otherwise due it, increase diligence and
other similar costs to the Fund, render valuation of affected investments challenging, or require the Fund to consummate an investment
on terms that are less advantageous than would be the case absent such restrictions. As global systems, economies and financial markets
are increasingly interconnected, events that once had only local impact are now more likely to have regional or even global effects. Events
that occur in one country, region or financial market will, more frequently, adversely impact issuers in other countries, regions or markets.
These impacts can be exacerbated by failures of governments and societies to adequately respond to an emerging event or threat. These
types of events quickly and significantly impact markets in the U.S. and across the globe leading to extreme market volatility and disruption.
The extent and nature of the impact on supply chains or economies and markets from these events is unknown, particularly if these types
of events persist for an extended period of time. These types of events, could reduce consumer demand or economic output, result in market
closures, travel restrictions or quarantines, and generally have a significant impact on the economies and financial markets and the Investment
Adviser's investment advisory activities and services of other service providers, which in turn could adversely affect the Fund's investments
and other operations. The value of the Fund's investments may decrease as a result of such events, particularly if these events adversely
impact the operations and effectiveness of the Investment Adviser or key service providers or if these events disrupt systems and processes
necessary or beneficial to the investment advisory or other activities on behalf the Fund.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">In March 2023, several financial
institutions experienced a larger-than-expected decline in deposits and two banks, Silicon Valley Bank ("SVB") and Signature Bank, were
placed into receivership. Given the interconnectedness of the banking system, the Federal Reserve invoked the systemic risk exception,
temporarily transferred all deposits-both insured and uninsured-and substantially all the assets of the two banks into respective bridge
banks and</span></p> </div>  </div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">guaranteed depositors' full
access to their funds. This type of systemic risk event and/or resulting government actions can negatively impact the Funds, for example,
through less credit being available to issuers or uncertainty regarding safety of deposits at other institutions. These risks also may
adversely affect financial intermediaries, such as clearing agencies, clearing houses, banks, securities firms, and exchanges, with which
the Fund interacts.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Potential Conflicts
of Interest Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Investment Adviser's investment team is
responsible for managing the Fund as well as three other closed-end investment companies. In the future, the investment team may manage
other funds and accounts, including proprietary accounts, separate accounts and other pooled investment vehicles, such as unregistered
hedge funds. In the future, a portfolio manager may manage a separate account or other pooled investment vehicle which may have materially
higher fee arrangements than the Fund and may also have a performance-based fee. The side-by-side management of these funds or accounts
may raise potential conflicts of interest relating to cross trading, the allocation of investment opportunities and the aggregation and
allocation of trades.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Special Purpose Acquisition
Company Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund may invest in SPACs. SPACs are collective
investment structures that pool funds in order to seek potential acquisition opportunities. Unless and until an acquisition is completed,
a SPAC generally invests its assets (less an amount to cover expenses) in U.S. Government securities, money market fund securities and
cash. SPACs and similar entities may be blank check companies with no operating history or ongoing business other than to seek a potential
acquisition. Certain SPACs may seek acquisitions only in limited industries or regions. If an acquisition that meets the requirements
for the SPAC is not completed within a predetermined period of time, the invested funds are returned to the entity's shareholders, unless
such shareholders approve alternative arrangements. Investments in SPACs may be illiquid and/or be subject to restrictions on resale.</span></p>
 </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_EffectsOfLeverageTextBlock', window );">Effects of Leverage [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<p style="margin:11pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Effects of Leverage</strong></span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Assuming that leverage will
represent approximately 20% of Managed Assets and that the Fund will bear expenses relating to that leverage at an annual cost of 1.00%,
Fund performance before leverage (net of expenses) must exceed .2% in order to cover the expenses specifically related to the Fund's use
of leverage. Actual leverage expenses will vary frequently and may be significantly higher or lower than the rate estimated above.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">As of September 30, 2023 and
the most recently signed line of credit agreement, the Fund projects an annual leverage expense of 6.57%. The Fund had $120,000,000 of
funds drawn on its line of credit which was 21.2% of Managed Assets as of September 30, 2023.</span></p>

<div>

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following table is furnished
in response to requirements of the SEC. It is designed to illustrate the effects of leverage on total returns from an investment in the
Fund assuming investment portfolio returns before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage
representing 20% of the Fund's Managed Assets and the Fund's currently projected annual leverage expense of 6.57%.</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:143;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">Assumed
        Fund Return Before Leverage</span><br/><span style="font-size:8pt;font-family:Arial, Helvetica">(Net of Expenses) </span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(10.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(5.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:29;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:33;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:143">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Assumed Fund Return Inclusive of Leverage </span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(14.14</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(7.89</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1.64</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:29">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4.61</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:33">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10.89</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  </table>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Assumed Fund performance before
and inclusive of leverage are hypothetical and are provided to assist investors in understanding the effects of leverage. Actual performance
experienced by the Fund may be lesser or greater than that shown above.</span></p> </div>  </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_AnnualDividendPayment', window );">Annual Dividend Payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">$ (1.4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="num">$ (1.4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1.4)<span></span>
</td>
<td class="num">$ (1.4)<span></span>
</td>
<td class="num">$ (1.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_EffectsOfLeverageTableTextBlock', window );">Effects of Leverage [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following table is furnished
in response to requirements of the SEC. It is designed to illustrate the effects of leverage on total returns from an investment in the
Fund assuming investment portfolio returns before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage
representing 20% of the Fund's Managed Assets and the Fund's currently projected annual leverage expense of 6.57%.</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:143;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">Assumed
        Fund Return Before Leverage</span><br/><span style="font-size:8pt;font-family:Arial, Helvetica">(Net of Expenses) </span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(10.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(5.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:29;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:33;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:143">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Assumed Fund Return Inclusive of Leverage </span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(14.14</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(7.89</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1.64</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:29">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4.61</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:33">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10.89</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  </table>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Assumed Fund performance before
and inclusive of leverage are hypothetical and are provided to assist investors in understanding the effects of leverage. Actual performance
experienced by the Fund may be lesser or greater than that shown above.</span></p> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ReturnAtMinusTenPercent', window );">Return at Minus Ten [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(14.14%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ReturnAtMinusFivePercent', window );">Return at Minus Five [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(7.89%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ReturnAtZeroPercent', window );">Return at Zero [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(1.64%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ReturnAtPlusFivePercent', window );">Return at Plus Five [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">4.61%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ReturnAtPlusTenPercent', window );">Return at Plus Ten [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">10.89%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_EffectsOfLeveragePurposeTextBlock', window );">Effects of Leverage, Purpose [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following table is furnished
in response to requirements of the SEC. It is designed to illustrate the effects of leverage on total returns from an investment in the
Fund assuming investment portfolio returns before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage
representing 20% of the Fund's Managed Assets and the Fund's currently projected annual leverage expense of 6.57%.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11.28<span></span>
</td>
<td class="nump">$ 11.72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7],[8]</sup></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.86<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.45<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7],[8]</sup></td>
<td class="nump">12.86<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16.45<span></span>
</td>
<td class="nump">14.33<span></span>
</td>
<td class="nump">13.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetAssetValuePerShare', window );">NAV Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11.44<span></span>
</td>
<td class="nump">$ 11.73<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7],[9]</sup></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.73<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7],[9]</sup></td>
<td class="nump">$ 12.11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">$ 15.18<span></span>
</td>
<td class="nump">$ 14.14<span></span>
</td>
<td class="nump">$ 13.51<span></span>
</td>
<td class="nump">$ 15.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_LatestPremiumDiscountToNavPercent', window );">Latest Premium (Discount) to NAV [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1.42%)<span></span>
</td>
<td class="num">(0.76%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[10]</sup></td>
<td colspan="2" class="nump">7.76%<span></span>
</td>
<td colspan="2" class="nump">7.93%<span></span>
</td>
<td colspan="2" class="nump">3.53%<span></span>
</td>
<td class="nump">6.91%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[10]</sup></td>
<td colspan="2" class="nump">12.90%<span></span>
</td>
<td colspan="2" class="num">(4.11%)<span></span>
</td>
<td colspan="2" class="nump">5.15%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[10]</sup></td>
<td colspan="2" class="num">(1.91%)<span></span>
</td>
<td colspan="2" class="num">(2.32%)<span></span>
</td>
<td colspan="2" class="nump">1.36%<span></span>
</td>
<td class="num">(0.09%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract', window );"><strong>Capital Stock, Long-Term Debt, and Other Securities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_OutstandingSecurityHeldShares', window );">Outstanding Security, Held [Shares]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">38,113,338<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_PortfolioMarketRiskMember', window );">Portfolio Market Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Portfolio</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
</span><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Market Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
As with any investment company that invests in equity securities, the Fund is subject to market risk&#8212;the possibility that the prices
of equity securities will</span>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">decline over short or extended
periods of time. As a result, the value of an investment in the Fund's shares will fluctuate with the market. You could lose some or all
of your investment over short or long periods of time.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Political and economic news
can influence market-wide trends and can cause disruptions in the U.S. or world financial markets. Other factors may be ignored by the
market as a whole but may cause movements in the price of one company's stock or the stock of companies in one or more industries. All
of these factors may have a greater impact on initial public offerings and emerging company shares.</span></p> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember', window );">Security Market Risk Discount To Net Asset Value [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Security Market Risk&#8212;Discount
to NAV.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Shares of closed-end investment companies frequently
trade at a discount from their NAV. This characteristic is a risk separate and distinct from the risk that the Fund's NAV per share could
decrease as a result of its investment activities and may be greater for investors expecting to sell their shares in a relatively short
period of time following completion of this offering. Although the value of the Fund's net assets is generally considered by market participants
in determining whether to purchase or sell shares, whether investors will realize gains or losses upon the sale of the shares will depend
entirely upon whether the market price of the shares at the time of sale is above or below the investor's purchase price for the shares.
Because the market price of the shares will be determined by supply of and demand for the shares which will be affected by factors such
as (i) NAV, (ii) dividend and distribution levels and their stability (which will in turn be affected by levels of dividend and interest
payments by the Fund's portfolio holdings, the timing and success of the Fund's investment strategies, regulations affecting the timing
and character of Fund distributions, Fund expenses and other factors), (iii) trading volume of the shares, (iv) general market, interest
rate and economic conditions and (v) other factors that may be beyond the control of the Fund. The Fund cannot predict whether the shares
will trade at, below or above NAV or at, below or above the initial public offering price.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_EquitySecuritiesRiskMember', window );">Equity Securities Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Equity Securities
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund expects to invest 60-90% of its Managed Assets
in equity securities. Equity risk is the risk that equity securities held by the Fund will fall due to general market or economic conditions,
perceptions regarding the industries in which the issuers of securities held by the Fund participate, changes in interest rates, and the
particular circumstances and performance of particular companies whose securities the Fund holds. The price of an equity security of an
issuer may be particularly sensitive to general movements in the stock market, or a drop in the stock market may depress the price of
most or all of the equity securities held by the Fund. In addition, equity securities held by the Fund may decline in price if the issuer
fails to make anticipated distributions or dividend payments because, among other reasons, the issuer experiences a decline in its financial
condition. The Fund's expected investments in preferred stocks carries its own unique risks. Preferred stocks are typically subordinated
to bonds and other debt instruments in a company's capital structure, in terms of priority to corporate income, and therefore will be
subject to greater credit risk than those debt instruments. In addition, unlike interest payments on debt securities,</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">preferred stock dividends
are payable only if declared by the issuer's board of directors. The prices of preferred stock also tend to move upwards slower than common
stock prices and the preferred stock may be substantially less liquid than common stock or other securities.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_ConvertibleSecuritiesRiskMember', window );">Convertible Securities Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Convertible Securities
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Convertible Securities generally offer lower interest
or dividend yields than nonconvertible debt securities of similar quality. The market value of convertible securities tends to decline
as interest rates increase and, conversely, tends to increase as interest rates decline. In addition, because of the conversion feature,
the market value of convertible securities tends to vary with fluctuations in the market value of the underlying common stock. When the
market price of the underlying common stock approaches or is greater than the convertible security's conversion price, the prices of the
convertible securities tend to rise as a reflection of the value of the underlying common stock. The conversion prior is defined as the
predetermined price at which the convertible security could be exchanged for the associated stock. Consequently, a unique feature of convertible
securities is that as the market price of the underlying common stock declines, convertible securities tend to trade increasingly on a
yield basis, and so may not experience market value declines to the same extent as the underlying common stock. Investments in convertible
securities generally entail less risk than investments in common stock of the same issuer but more risk than the issuer's debt obligations.</span></p>
<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_SelectionRiskMember', window );">Selection Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Selection Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Different types of equity securities tend to shift into and out of favor with investors, depending on market and economic conditions.
The performance of funds that invest in healthcare industry equity securities may at times be better or worse than the performance of
funds that focus on other types of securities or that have a broader investment style.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_ConcentrationInHealthcareIndustriesMember', window );">Concentration In Healthcare Industries [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Concentration in the
Healthcare Industries.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Under normal market conditions, the Fund
expects to invest at least 80% of its Managed Assets in securities of healthcare companies. As a result, the Fund's portfolio will likely
be more sensitive to, and possibly more adversely affected by, regulatory, economic or political factors or trends relating to the healthcare,
agricultural and environmental technology industries than a portfolio of companies representing a larger number of industries. The risk
is in addition to the risks normally associated with any strategy seeking capital appreciation by investing in a portfolio of equity securities.
As a result of its concentration policy, the Fund's investments may be subject to greater risk and market fluctuation than a fund that
has securities representing a broader range of investments. The healthcare industries can be volatile. The Fund may occasionally make
investments in a company with the objective of controlling or influencing the management and policies of that company, which could potentially
make the Fund more susceptible to declines in the value of the company's stock. The Investment Adviser may seek control in public companies
only occasionally and most often in companies with a small capitalization.</span></p>

<div>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare companies have in the
past been characterized by limited product focus, rapidly changing technology and extensive government regulation. In particular, technological
advances can render an existing product, which may account for a disproportionate share of a company's revenue, obsolete. Obtaining governmental
approval from U.S. governmental agencies such as the Food and Drug Administration (the "FDA"), and from non-U.S. governmental agencies
for new products can be lengthy, expensive and uncertain as to outcome. Such delays in product development may result in the need to seek
additional capital, potentially diluting the interests of existing investors such as the Fund. In addition, governmental agencies may,
for a variety of reasons, restrict the release of certain innovative technologies of commercial significance. These various factors may
result in abrupt advances and declines in the securities prices of particular companies and, in some cases, may have a broad effect on
the prices of securities of companies in particular healthcare industries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">A concentration of investments
in any healthcare industry or in healthcare companies generally may increase the risk and volatility of an investment company's portfolio.
Such volatility is not limited to the biotechnology industry, and companies in other industries may be subject to similar abrupt movements
in the market prices of their securities. No assurance can be given that future declines in the market prices of securities of companies
in the industries in which the Fund may invest will not occur, or that such declines will not adversely affect the NAV or the price of
the shares.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Intense competition exists
within and among certain healthcare industries, including competition to obtain and sustain proprietary technology protection, including
patents, trademarks and other intellectual property rights, upon which healthcare companies can be highly dependent for maintenance of
profit margins and market exclusivity. The complex nature of the technologies involved can lead to patent disputes, including litigation
that may be costly and that could result in a company losing an exclusive right to a patent.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">With respect to healthcare
industries, cost containment measures already implemented by national governments, state or provincial governments and the private sector
have adversely affected certain sectors of these industries. The implementation of the Affordable Care Act ("ACA") has created increased
demand for healthcare products and services, but potential changes to the ACA and future healthcare laws and regulations may impact demand
for healthcare products and services and has had or may have an adverse effect on some companies in the healthcare industries. Increased
emphasis on managed care in the United States and a shift toward value based payment models may put pressure on the price and usage of
products sold by healthcare companies in which the Fund may invest and may adversely affect the sales and revenues of healthcare companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Product development efforts
by healthcare companies may not result in commercial products for many reasons, including, but not limited to, failure to achieve acceptable
clinical trial results, limited effectiveness in treating the specified condition or illness, harmful side effects,</span></p> </div>


<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">failure to obtain regulatory
approval, and high manufacturing costs. Even after a product is commercially released, governmental agencies may require additional clinical
trials or change the labeling requirements for products if additional product side effects are identified, which could have a material
adverse effect on the market price of the securities of those healthcare companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Certain healthcare companies
in which the Fund may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing
and sale of pharmaceuticals, medical devices or other products. A product liability claim may have a material adverse effect on the business,
financial condition or securities prices of a company in which the Fund has invested.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">All of these factors as well
as others may cause the value of the Fund's shares to fluctuate significantly over relatively short periods of time.</span></p> </div>
<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_PharmaceuticalSectorRiskMember', window );">Pharmaceutical Sector Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Pharmaceutical Sector
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The success of companies in the pharmaceutical sector
is highly dependent on the development, procurement and marketing of drugs. The values of pharmaceutical companies are also dependent
on the development, protection and exploitation of intellectual property rights and other proprietary information, and the profitability
of pharmaceutical companies may be significantly affected by such things as the expiration of patents or the loss of, or the inability
to enforce, intellectual property rights.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The research and other costs
associated with developing or procuring new drugs and the related intellectual property rights can be significant, and the results of
such research and expenditures are unpredictable. There can be no assurance that those efforts or costs will result in the development
of a profitable drug. Pharmaceutical companies may be susceptible to product obsolescence. Pharmaceutical companies also face challenges
posed by the increased presence of counterfeit pharmaceutical products, which may negatively impact revenues and patient confidence. Many
pharmaceutical companies face intense competition from new products and less costly generic products. Moreover, the process for obtaining
regulatory approval by the FDA or other U.S. and non-U.S. governmental regulatory authorities is long and costly and there can be no assurance
that the necessary approvals will be obtained or maintained.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The pharmaceutical sector
is also subject to rapid and significant technological change and competitive forces that may make drugs obsolete or make it difficult
to raise prices and, in fact, may result in price discounting. Companies in the pharmaceutical sector may also be subject to expenses
and losses from extensive litigation based on intellectual property, product liability and similar claims. Failure of pharmaceutical companies
to comply with applicable laws and regulations can result in the imposition of civil and criminal fines, penalties and, in some instances,
exclusion of participation in government sponsored programs such as Medicare and Medicaid.</span></p> </div>

<div>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Companies in the pharmaceutical
sector may be adversely affected by government regulation and changes in reimbursement rates. The ability of many pharmaceutical companies
to commercialize and monetize current and any future products depends in part on the extent to which reimbursement for the cost of such
products and related treatments are available from third party payors, such as Medicare, Medicaid, private health insurance plans and
health maintenance organizations. Third-party payors are increasingly challenging the price and cost-effectiveness of many medical products.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Significant uncertainty exists
as to the reimbursement status of health care products, and there can be no assurance that adequate third-party coverage will be available
for pharmaceutical companies to obtain satisfactory price levels for their products.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The international operations
of many pharmaceutical companies expose them to risks associated with instability and changes in economic and political conditions, foreign
currency fluctuations, changes in foreign regulations and other risks inherent to international business. Additionally, a pharmaceutical
company's valuation can often be based largely on the potential or actual performance of a limited number of products. A pharmaceutical
company's valuation can also be greatly affected if one of its products proves unsafe, ineffective or unprofitable. Such companies also
may be characterized by thin capitalization and limited markets, financial resources or personnel, as well as dependence on wholesale
distributors. The stock prices of companies in the pharmaceutical industry have been and will likely continue to be extremely volatile.</span></p>
</div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_BiotechnologyIndustryRiskMember', window );">Biotechnology Industry Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Biotechnology Industry
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The success of biotechnology companies is highly dependent
on the development, procurement and/or marketing of drugs. The values of biotechnology companies are also dependent on the development,
protection and exploitation of intellectual property rights and other proprietary information, and the profitability of biotechnology
companies may be significantly affected by such things as the expiration of patents or the loss of, or the inability to enforce, intellectual
property rights.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The research and other costs
associated with developing or procuring new drugs, products or technologies and the related intellectual property rights can be significant,
and the results of such research and expenditures are unpredictable. There can be no assurance that those efforts or costs will result
in the development of a profitable drug, product or technology. Moreover, the process for obtaining regulatory approval by the FDA or
other U.S. and non-U.S. governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals
will be obtained or maintained.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The biotechnology sector is
also subject to rapid and significant technological change and competitive forces that may make drugs, products or technologies obsolete
or make it difficult to raise prices and, in fact, may result in price discounting. Companies in the biotechnology sector may also be
subject to expenses and losses from extensive litigation</span></p> </div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">based on intellectual property,
product liability and similar claims. Failure of biotechnology companies to comply with applicable laws and regulations can result in
the imposition of civil and/or criminal fines, penalties and, in some instances, exclusion of participation in government sponsored programs
such as Medicare and Medicaid.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Companies in the biotechnology
sector may be adversely affected by government regulation and changes in reimbursement rates. Healthcare providers, principally hospitals,
that transact with companies in the biotechnology industry, often rely on third party payors, such as Medicare, Medicaid, private health
insurance plans and health maintenance organizations to reimburse all or a portion of the cost of healthcare related products or services.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Biotechnology companies will
continue to be affected by the efforts of governments and third party payors to contain or reduce health care costs. For example, certain
foreign markets control pricing or profitability of biotechnology products and technologies. In the United States, there has been, and
there will likely continue to be, a number of federal and state proposals to implement similar controls.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">A biotechnology company's
valuation could be based on the potential or actual performance of a limited number of products and could be adversely affected if one
of its products proves unsafe, ineffective or unprofitable. Such companies may also be characterized by thin capitalization and limited
markets, financial resources or personnel. The stock prices of companies involved in the biotechnology sector have been and will likely
continue to be extremely volatile.</span></p> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_ManagedCareSectorRiskMember', window );">Managed Care Sector Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Managed Care Sector
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Companies in the managed care sector often assume the
risk of both medical and administrative costs for their customers in return for monthly premiums. The profitability of these products
depends in large part on the ability of such companies to predict, price for, and effectively manage medical costs. Managed care companies
base the premiums they charge and their Medicare bids on estimates of future medical costs over the fixed contract period; however, many
factors may cause actual costs to exceed what was estimated and reflected in premiums or bids. These factors may include medical cost
inflation, increased use of services, increased cost of individual services, natural catastrophes or other large-scale medical emergencies,
epidemics, the introduction of new or costly treatments and technology, new mandated benefits (such as the expansion of essential benefits
coverage) or other regulatory changes and insured population characteristics. Relatively small differences between predicted and actual
medical costs or utilization rates as a percentage of revenues can result in significant changes in financial results.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Managed care companies are
regulated at the federal, state, local and international levels. Insurance and Health Maintenance Organization ("HMO") subsidiaries must
be licensed by and are subject to the regulations of the jurisdictions in which they conduct business. U.S. health plans and insurance
companies are also regulated under state insurance holding</span></p> </div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">company regulations, and some
of their activities may be subject to other health care-related regulations. The health care industry is also regularly subject to negative
publicity, including as a result of governmental investigations, adverse media coverage and political debate surrounding industry regulation.
Negative publicity may adversely affect stock price, damage the reputation of managed care companies in various markets or foster an increasingly
active regulatory environment, which, in turn, could further increase the regulatory burdens under which such companies operate and their
costs of doing business.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The evolution of the ACA and
other regulatory reforms could materially and adversely affect the manner in which U.S. managed care companies conduct business and their
results of operations, financial position and cash flows. The ACA includes guaranteed coverage and expanded benefit requirements, eliminates
pre-existing condition exclusions and annual and lifetime maximum limits, restricts the extent to which policies can be rescinded, establishes
minimum medical loss ratios, creates a federal premium review process, imposes new requirements on the format and content of communications
(such as explanations of benefits) between health insurers and their members, grants to members new and additional appeal rights, and
imposes new and significant taxes on health insurers and health care benefits.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">New laws or regulations could
drive substantial change to the way healthcare products and services are currently delivered and paid for in the United States. Health
plans and insurance companies could face meaningful disruption or disintermediation if the U.S. migrates to a single payer healthcare
system where the government acts as the sole payer of healthcare services for the entire population. A transformative overhaul of the
U.S. healthcare system could impact the financial viability of managed care companies in which the Fund may invest.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Managed care companies contract
with physicians, hospitals, pharmaceutical benefit service providers, pharmaceutical manufacturers, and other health care providers for
services. Such companies' results of operations and prospects are substantially dependent on their continued ability to contract for these
services at competitive prices. Failure to develop and maintain satisfactory relationships with health care providers, whether in-network
or out-of-network, could materially and adversely affect business, results of operations, financial position and cash flows.</span></p>
</div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_LifeScienceAndToolsIndustryRiskMember', window );">Life Science And Tools Industry Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Life Science and Tools
Industry Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Life sciences industries are characterized by
limited product focus, rapidly changing technology and extensive government regulation. In particular, technological advances can render
an existing product, which may account for a disproportionate share of a company's revenue, obsolete. Obtaining governmental approval
from agencies such as the FDA, U.S. Department of Agriculture and other U.S. and non-U.S. governmental agencies for new products can be
lengthy, expensive and uncertain as to outcome. Such delays in product development may result in the need to seek additional capital,
potentially diluting the interests of existing investors such as the Fund. In addition,</span></p>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">governmental agencies may,
for a variety of reasons, restrict the release of certain innovative technologies of commercial significance, such as genetically altered
material. These various factors may result in abrupt advances and declines in the securities prices of particular companies and, in some
cases, may have a broad effect on the prices of securities of companies in particular life sciences industries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Intense competition exists
within and among certain life sciences industries, including competition to obtain and sustain proprietary technology protection. Life
sciences companies can be highly dependent on the strength of patents, trademarks and other intellectual property rights for maintenance
of profit margins and market share. The complex nature of the technologies involved can lead to patent disputes, including litigation
that could result in a company losing an exclusive right to a patent. Competitors of life sciences companies may have substantially greater
financial resources, more extensive development, manufacturing, marketing and service capabilities, and a larger number of qualified managerial
and technical personnel. Such competitors may succeed in developing technologies and products that are more effective or less costly than
any that may be developed by life sciences companies in which the Fund invests and may also prove to be more successful in production
and marketing. Competition may increase further as a result of potential advances in health services and medical technology and greater
availability of capital for investment in these fields.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">With respect to healthcare,
cost containment measures already implemented by national governments, state or provincial governments, international organizations and
the private sector have adversely affected certain sectors of these industries. Increased emphasis on managed care in the United States
may put pressure on the price and usage of products sold by life sciences companies in which the Fund may invest and may adversely affect
the sales and revenues of life sciences companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Product development efforts
by life sciences companies may not result in commercial products for many reasons, including, but not limited to, failure to achieve acceptable
clinical trial results, limited effectiveness in treating the specified condition or illness, harmful side effects, failure to obtain
regulatory approval, and high manufacturing costs. Even after a product is commercially released, governmental agencies may require additional
clinical trials or change the labeling requirements for products if additional product side effects are identified, which could have a
material adverse effect on the market price of the securities of those life sciences companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Certain life sciences companies
in which the Fund may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing
and sale of pharmaceuticals, medical devices or other products. There can be no assurance that a product liability claim would not have
a material adverse effect on the business, financial condition or securities prices of a company in which the Fund has invested.</span></p>
</div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_HealthcareTechnologySectorRiskMember', window );">Healthcare Technology Sector Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Technology
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Companies in the healthcare technology sector may
incur substantial costs related to product-related liabilities. Many of the software solutions, health care devices or services developed
by such companies are intended for use in collecting, storing and displaying clinical and health care-related information used in the
diagnosis and treatment of patients and in related health care settings such as admissions, billing, etc. The limitations of liability
set forth in the companies' contracts may not be enforceable or may not otherwise protect these companies from liability for damages.
Healthcare technology companies may also be subject to claims that are not covered by contract, such as a claim directly by a patient.
Although such companies may maintain liability insurance coverage, there can be no assurance that such coverage will cover any particular
claim that has been brought or that may be brought in the future, that such coverage will prove to be adequate or that such coverage will
continue to remain available on acceptable terms, if at all.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare technology companies
may experience interruption at their data centers or client support facilities. The business of such companies often relies on the secure
electronic transmission, data center storage and hosting of sensitive information, including protected health information, financial information
and other sensitive information relating to clients, company and workforce. In addition, such companies may perform data center and/or
hosting services for certain clients, including the storage of critical patient and administrative data and support services through various
client support facilities. If any of these systems are interrupted, damaged or breached by an unforeseen event or actions of a third party,
including a cyber-attack, or fail for any extended period of time, it could have a material adverse impact on the results of operations
for such companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The proprietary technology
developed by healthcare technology companies may be subject to claims for infringement or misappropriation of intellectual property rights
of others, or may be infringed or misappropriated by others. Despite protective measures and intellectual property rights, such companies
may not be able to adequately protect against theft, copying, reverse-engineering, misappropriation, infringement or unauthorized use
or disclosure of their intellectual property, which could have an adverse effect on their competitive position. In addition, these companies
are routinely involved in intellectual property infringement or misappropriation claims and it is expected that this activity will continue
or even increase as the number of competitors, patents and patent enforcement organizations in the healthcare technology market increases,
the functionality of software solutions and services expands, the use of open-source software increases and new markets such as health
care device innovation, health care transactions, revenue cycle, population health management and life sciences are entered into. These
claims, even if not meritorious, are expensive to defend and are often incapable of prompt resolution.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The success of healthcare
technology companies depends upon the recruitment and retention of key personnel. To remain competitive, such companies must attract,
motivate and retain</span></p> </div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">highly skilled managerial,
sales, marketing, consulting and technical personnel, including executives, consultants, programmers and systems architects skilled in
healthcare technology, health care devices, health care transactions, population health management, revenue cycle and life sciences industries
and the technical environments in which solutions, devices and services are needed. Competition for such personnel in the healthcare technology
sector is intense in both the United States and abroad. The failure to attract additional qualified personnel could have a material adverse
effect on healthcare technology companies' prospects for long-term growth.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_HealthcareServicesSectorRiskMember', window );">Healthcare Services Sector Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Services
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The operations of healthcare services companies
are subject to extensive federal, state and local government regulations, including Medicare and Medicaid payment rules and regulations,
federal and state anti-kickback laws, the physician self-referral law ("Stark Law") and analogous state self-referral prohibition statutes,
Federal Acquisition Regulations, the False Claims Act and federal and state laws regarding the collection, use and disclosure of patient
health information and the storage, handling and administration of pharmaceuticals. The Medicare and Medicaid reimbursement rules related
to claims submission, enrollment and licensing requirements, cost reporting, and payment processes impose complex and extensive requirements
upon dialysis providers as well. A violation or departure from any of these legal requirements may result in government audits, lower
reimbursements, significant fines and penalties, the potential loss of certification, recoupment efforts or voluntary repayments. If healthcare
services companies fail to adhere to all of the complex government regulations that apply to their businesses, such companies could suffer
severe consequences that would substantially reduce revenues, earnings, cash flows and stock prices.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">A substantial percentage of
a healthcare services company's service revenues may be generated from patients who have state Medicaid or other non-Medicare government-based
programs, such as coverage through the Department of Veterans Affairs ("VA"), as their primary coverage. As state governments and other
governmental organizations face increasing budgetary pressure, healthcare services companies may in turn face reductions in payment rates,
delays in the receipt of payments, limitations on enrollee eligibility or other changes to the applicable programs.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Adverse economic conditions
could adversely affect the business and profitability of healthcare services companies. Among other things, the potential decline in federal,
non-U.S. government and state revenues that may result from such conditions may create additional pressures to contain or reduce reimbursements
for services from Medicare, Medicaid and other government sponsored programs. Increasing job losses or slow improvement in the unemployment
rate in the United States and elsewhere as a result of adverse or recent economic conditions may result in a smaller percentage of patients
being covered by an employer group health plan and a larger percentage being covered by lower paying Medicare and Medicaid programs. Employers
may also select more restrictive commercial plans with</span></p> </div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">lower reimbursement rates.
To the extent that payors are negatively impacted by a decline in the economy, healthcare services companies may experience further pressure
on commercial rates, a further slowdown in collections and a reduction in the amounts they expect to collect. In addition, uncertainty
in the financial markets could adversely affect the variable interest rates payable under credit facilities or could make it more difficult
to obtain or renew such facilities or to obtain other forms of financing in the future, if at all. Any or all of these factors, as well
as other consequences of the adverse economic conditions which cannot currently be anticipated, could have a material adverse effect on
a healthcare services company's revenues, earnings and cash flows and otherwise adversely affect its financial condition.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_HealthcareSuppliesSectorRiskMember', window );">Healthcare Supplies Sector Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Supplies
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> If healthcare supplies companies are unable to
successfully expand their product lines through internal research and development and acquisitions, their business may be materially and
adversely affected. In addition, if these companies are unable to successfully grow their businesses through marketing partnerships and
acquisitions, their business may be materially and adversely affected.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Consolidation of healthcare
providers has increased demand for price concessions and caused the exclusion of suppliers from significant market segments. It is expected
that market demand, government regulation, third-party reimbursement policies, government contracting requirements and societal pressures
will continue to change the worldwide healthcare industry, resulting in further business consolidations and alliances among customers
and competitors. This may exert further downward pressure on the prices of healthcare supplies companies' products and adversely impact
their businesses, financial conditions or results of operations.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Quality is extremely important
to healthcare supplies companies and their customers due to the serious and costly consequences of product failure. Quality certifications
are critical to the marketing success of their products and services. If a healthcare supplies company fails to meet these standards or
fails to adapt to evolving standards, its reputation could be damaged, it could lose customers, and its revenue and results of operations
could decline.</span></p> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_HealthcareFacilitiesSectorRiskMember', window );">Healthcare Facilities Sector Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Facilities
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> A healthcare facility's ability to negotiate favorable
contracts with HMOs, insurers offering preferred provider arrangements and other managed care plans significantly affects the revenues
and operating results of such healthcare facilities. In addition, private payers are increasingly attempting to control health care costs
through direct contracting with hospitals to provide services on a discounted basis, increased utilization reviews and greater enrollment
in managed care programs, such as HMOs and Preferred Provider Organizations ("PPOs"). The trend toward consolidation among private managed
care payers tends to increase their bargaining power over prices and fee structures. Non-government payers may increasingly demand reduced
fees. If a healthcare facility is unable to enter into and maintain managed care contractual arrangements on acceptable</span></p>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">terms, if it experiences material
reductions in the contracted rates received from managed care payers, or if it has difficulty collecting from managed care payers, its
results of operations could be adversely affected.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Further changes in the Medicare
and Medicaid programs or other government health care programs could have an adverse effect on a healthcare facility's business. In addition
to the changes affected by the ACA, the Medicare and Medicaid programs are subject to other statutory and regulatory changes, administrative
rulings, interpretations and determinations concerning patient eligibility requirements, funding levels and the method of calculating
payments or reimbursements, among other things, requirements for utilization review, and federal and state funding restrictions. All of
these could materially increase or decrease payments from government programs in the future, as well as affect the cost of providing services
to patients and the timing of payments to facilities, which could in turn adversely affect a healthcare facility's overall business, financial
condition, results of operations or cash flows.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare facilities are
adversely affected by uninsured and underinsured patients, as well as a growing mix of Medicare and Medicaid patients that typically have
lower reimbursement rates than commercial managed care patients As a result, healthcare facilities continue to experience a shift in payer
mix and a high level of uncollectible accounts, which could worsen if there is an increase in unemployment. Healthcare facilities may
continue to experience significant levels of bad debt expense and may have to provide uninsured discounts and charity care for undocumented
immigrants who are not permitted to enroll in a health insurance exchange or government health care program. The trend of higher co-pays
and deductibles and a focus on migrating healthcare utilization to lower cost sites of care, may also pressure volumes and revenue at
certain healthcare facilities which could adversely impact the financial condition of hospitals and facilities with high fixed cost structures.</span></p>
</div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_HealthcareEquipmentSectorRiskMember', window );">Healthcare Equipment Sector Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Equipment
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The medical device markets are highly competitive
and a healthcare equipment company many be unable to compete effectively. These markets are characterized by rapid change resulting from
technological advances and scientific discoveries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Development by other companies
of new or improved products, processes, or technologies may make a healthcare equipment company's products or proposed products less competitive.
In addition, these companies face competition from providers of alternative medical therapies such as pharmaceutical companies.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Medical devices and related
business activities are subject to rigorous regulation, including by the FDA, U.S. Department of Justice ("DOJ"), and numerous other federal,
state, and foreign governmental authorities. These authorities and members of Congress have been increasing their scrutiny of the healthcare
equipment industry. In addition, certain states have</span></p> </div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">passed or are considering
legislation restricting healthcare equipment companies' interactions with health care providers and requiring disclosure of certain payments
to them. It is anticipated that governmental authorities will continue to scrutinize this industry closely, and that additional regulation
may increase compliance and legal costs, exposure to litigation, and other adverse effects to operations.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare equipment companies
are substantially dependent on patent and other proprietary rights and failing to protect such rights or to be successful in litigation
related to such rights may result in the payment of significant monetary damages and/or royalty payments, may negatively impact the ability
of healthcare equipment companies to sell current or future products, or may prohibit such companies from enforcing their patent and other
proprietary rights against others.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Quality problems with the
processes, goods and services of a healthcare equipment company could harm the company's reputation for producing high-quality products
and erode its competitive advantage, sales and market share. Quality is extremely important to healthcare equipment companies and their
customers due to the serious and costly consequences of product failure. Quality certifications are critical to the marketing success
of goods and services. If a healthcare equipment company fails to meet these standards, its reputation could be damaged, it could lose
customers, and its revenue and results of operations could decline.</span></p> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_HealthcareDistributorsSectorRiskMember', window );">Healthcare Distributors Sector Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Healthcare Distributors
Sector Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Companies in the healthcare distribution sector
operate in markets that are highly competitive. Because of competition, many of these companies face pricing pressures from customers
and suppliers. If these companies are unable to offset margin reductions caused by pricing pressures through steps such as effective sourcing
and enhanced cost control measures, the financial condition of such companies could be adversely affected. In addition, the healthcare
industry has continued to consolidate. Further consolidation among customers and suppliers (including branded pharmaceutical manufacturers)
could give the resulting enterprises greater bargaining power, which may adversely impact the financial condition of companies in the
healthcare distribution sector.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Fewer generic pharmaceutical
launches or launches that are less profitable than those previously experienced may have an adverse effect on the profits of companies
in the healthcare distribution sector. Additionally, prices for existing generic pharmaceuticals generally decline over time, although
this may vary. Price deflation on existing generic pharmaceuticals may have an adverse effect on company profits. With respect to branded
pharmaceutical price appreciation, if branded manufacturers increase prices less frequently or by amounts that are smaller than have been
experienced historically, healthcare distribution companies may profit less from branded pharmaceutical agreements.</span></p> </div>


<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The healthcare industry is
highly regulated, and healthcare distribution companies are subject to regulation in the United States at both the federal and state level
and in foreign countries. If healthcare distribution companies fail to comply with these regulatory requirements, the financial condition
of such companies could be adversely affected.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Due to the nature of the business
of healthcare distribution companies, such companies may from time to time become involved in disputes or legal proceedings. For example,
some of the products that these companies distribute may be alleged to cause personal injury or violate the intellectual property rights
of another party, subjecting such companies to product liability or infringement claims. Litigation is inherently unpredictable, and the
unfavorable resolution of one or more of these legal proceedings could adversely affect the cash flows and balance sheets of healthcare
distribution companies. Pharmaceutical distributors currently face lawsuits related to the abuse of opioid medications in the United States.
The allegations include that pharmaceutical distributors failed to provide effective controls around the quantities of opioid medications
distributed to certain pharmacies, failed to properly prevent the diversion of medications and failed to report suspicious orders. Pharmaceutical
distributors are in discussions with federal, state and local jurisdictions related to their role in the distribution of opioid pharmaceuticals
and it is possible that they will be required to pay multi-billion dollar settlements related to the ongoing litigation.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Healthcare distribution companies
depend on the availability of various components, compounds, raw materials and energy supplied by others for their operations. Any of
these supplier relationships could be interrupted due to events beyond the control of such companies, including pandemics, epidemics or
natural disasters, or could be terminated. A sustained supply interruption could have an adverse effect on business.</span></p> </div>
<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember', window );">Risks Associated With Regulatory And Policy Changes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Risks Associated with
Regulatory and Policy Changes.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> At any time after the date hereof,
U.S. and non-U.S. governmental agencies and other regulators may implement additional regulations and legislators may pass new laws that
affect the investments held by the Fund, the strategies used by the Fund or the level of regulation or taxation applying to the Fund.
These regulations and laws impact the investment strategies, performance, costs and operations of the Fund, as well as the way investments
in, and shareholders of, the Fund are taxed. In particular, changes to U.S. healthcare policy could affect the Fund and its investments.
The affordability of healthcare in the U.S. will remain a topic of debate, and proposals, laws and regulations to reduce the costs of
healthcare products and services could adversely impact healthcare companies that the Fund invests in.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_ForeignSecuritiesRiskMember', window );">Foreign Securities Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Foreign Securities
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Foreign investments involve special risks that are not
typically associated with U.S. dollar denominated or quoted securities of U.S. issuers. Foreign investments may be affected by changes
in currency rates, changes in foreign or U.S. laws or restrictions applicable to such investments and changes in exchange control regulations
(e.g., currency blockage). A decline in the exchange rate of the currency (i.e., weakening of</span></p>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">the currency against the U.S.
dollar) in which a portfolio security is quoted or denominated relative to the U.S. dollar would reduce the value of the portfolio security.
In addition, if the currency in which the Fund receives dividends, interest or other payments declines in value against the U.S. dollar
before such income is distributed as dividends to Shareholders or converted to U.S. dollars, the Fund may have to sell portfolio securities
to obtain sufficient cash to pay such dividends.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund may invest in foreign
securities which take the form of sponsored and unsponsored American depositary receipts ("ADRs"), global depositary receipts ("GDRs"),
European depositary receipts ("EDRs") or other similar instruments representing securities of foreign issuers (together, "Depositary Receipts").
ADRs represent the right to receive securities of foreign issuers deposited in a domestic bank or a correspondent bank. ADRs are traded
on domestic exchanges or in the U.S. over-the-counter ("OTC") market and, generally, are in registered form. EDRs and GDRs are receipts
evidencing an arrangement with a non-U.S. bank similar to ADRs and are designed for use in the non-U.S. securities markets. EDRs and GDRs
are not necessarily quoted in the same currency as the underlying security. To the extent the Fund acquires Depositary Receipts through
banks which do not have a contractual relationship with the foreign issuer of the security underlying the Depositary Receipts to issue
and service such unsponsored Depositary Receipts, there is an increased possibility that the Fund will not become aware of and be able
to respond to corporate actions, such as stock splits or rights offerings, involving the foreign issuer in a timely manner. In addition,
the lack of information may result in inefficiencies in the valuation of such instruments. Investment in Depositary Receipts does not
eliminate all the risks inherent in investing in securities of non-U.S. issuers. The market value of Depositary Receipts is dependent
upon the market value of the underlying securities and fluctuations in the relative value of the currencies in which the Depositary Receipts
and the underlying securities are quoted. However, by investing in Depositary Receipts, such as ADRs, which are quoted in U.S. dollars,
the Fund may avoid currency risks during the settlement period for purchases and sales. The issuers of Depositary Receipts may discontinue
issuing new Depositary Receipts and withdraw existing Depositary Receipts at any time, which may result in costs and delays in the distribution
of the underlying assets to the Fund and may negatively impact the Fund's performance.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Brokerage commissions, custodial
services and other costs relating to investment in international securities markets generally are more expensive than in the United States.
In addition, clearance and settlement procedures may be different in foreign countries and, in certain markets, such procedures have been
unable to keep pace with the volume of securities transactions, thus making it difficult to conduct such transactions.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Foreign issuers are not generally
subject to uniform accounting, auditing and financial reporting standards comparable to those applicable to U.S. issuers. There may be
less publicly available information about a foreign issuer than about a U.S. issuer. In addition, there is generally less government regulation
of foreign markets, companies and securities dealers</span></p> </div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">than in the United States,
and the legal remedies for investors may be more limited than the remedies available in the United States. Foreign securities markets
may have substantially less volume than U.S. securities markets and securities of many foreign issuers are less liquid and more volatile
than securities of comparable domestic issuers. Furthermore, with respect to certain foreign countries, there is a possibility of nationalization,
expropriation or confiscatory taxation, imposition of withholding or other taxes on dividend or interest payments (or, in some cases,
capital gains distributions), limitations on the removal of funds or other assets from such countries, and risks of political or social
instability or diplomatic developments which could adversely affect investments in those countries. At any time after the date hereof,
U.S. and non-U.S. governmental agencies and other regulators may implement additional regulations and legislators may pass new laws that
affect the investments held by the Fund, the strategies used by the Fund or the level of regulation or taxation applying to the Fund.
These regulations and laws impact the investment strategies, performance, costs and operations of the Fund, as well as the way investments
in, and shareholders of, the Fund are taxed. In particular, changes to U.S. healthcare policy could affect the Fund and its investments.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund may invest in securities
of issuers located in Emerging Markets. The risks of foreign investment are heightened when the issuer is located in an emerging country.
Emerging Markets are generally located in Africa, Asia, the Middle East, Eastern Europe and Central and South America. Investments in
securities of issuers located in Emerging Markets may be subject to heightened risks, including relative illiquidity, price volatility
and potential restrictions on repatriation of investment capital and income. The Fund's purchase and sale of portfolio securities in Emerging
Markets may be constrained by limitations relating to daily changes in the prices of listed securities, periodic trading or settlement
volume and/or limitations on aggregate holdings of foreign investors. Such limitations may be computed based on the aggregate trading
volume by or holdings of the Fund, the Investment Adviser, or its affiliates and respective clients and other service providers. The Fund
may not be able to sell securities in circumstances where price, trading or settlement volume limitations have been reached.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Foreign investment in the
securities markets of certain Emerging Markets is restricted or controlled to varying degrees which may limit investment in such countries
or increase the administrative costs of such investments. For example, certain Asian countries require governmental approval prior to
investments by foreign persons or limit investment by foreign persons to only a specified percentage of an issuer's outstanding securities
or a specific class of securities which may have less advantageous terms (including price) than securities of the issuer available for
purchase by nationals. In addition, certain countries may restrict or prohibit investment opportunities in issuers or industries deemed
important to national interests. Such restrictions may affect the market price, liquidity and rights of securities that may be purchased
by the Fund. The repatriation of both investment income and capital from</span></p> </div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">certain Emerging Markets is
subject to restrictions such as the need for governmental consents. In situations where a country restricts direct investment in securities
(which may occur in certain Asian and other countries), the Fund may invest in such countries through other investment funds in such countries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Many Emerging Markets have
experienced currency devaluations and substantial (and, in some cases, extremely high) rates of inflation. Other Emerging Markets have
experienced economic recessions. These circumstances have had a negative effect on the economies and securities markets of those Emerging
Markets.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Economies in Emerging Markets
generally are dependent heavily upon commodity prices and international trade and, accordingly, have been and may continue to be affected
adversely by the economies of their trading partners, trade barriers, exchange controls, managed adjustments in relative currency values
and other protectionist measures imposed or negotiated by the countries with which they trade.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Many Emerging Markets are
subject to a substantial degree of economic, political and social instability. Governments of some emerging countries are authoritarian
in nature or have been installed or removed as a result of military coups, while governments in other Emerging Markets have periodically
used force to suppress civil dissent. Disparities of wealth, the pace and success of democratization, and ethnic, religious and racial
disaffection, among other factors, have also led to social unrest, violence and/or labor unrest in some Emerging Markets. Unanticipated
political or social developments may result in sudden and significant investment losses. Investing in Emerging Markets involves greater
risk of loss due to expropriation, nationalization, confiscation of assets and property or the imposition of restrictions on foreign investments
and on repatriation of capital invested. As an example, in the past, some Eastern European governments have expropriated substantial amounts
of private property, and many claims of the property owners have never been fully settled. There is no assurance that similar expropriations
will not occur in other countries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's investment in Emerging
Markets may also be subject to withholding or other taxes, which may be significant and may reduce the return to the Fund from an investment
in issuers in such countries.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Settlement procedures in Emerging
Markets are frequently less developed and reliable than those in the United States and may involve the Fund's delivery of securities before
receipt of payment for their sale. In addition, significant delays may occur in certain markets in registering the transfer of securities.
Settlement or registration problems may make it more difficult for the Fund to value its portfolio securities and could cause the Fund
to miss attractive investment opportunities, to have a portion of its assets uninvested or to incur losses due to the failure of a counterparty
to pay for securities the Fund has delivered or the Fund's inability to complete its contractual obligations because of theft or other
reasons.</span></p> </div>

<div>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The creditworthiness of the local
securities firms used by the Fund in Emerging Markets may not be as sound as the creditworthiness of firms used in more developed countries.
As a result, the Fund may be subject to a greater risk of loss if a securities firm defaults in the performance of its responsibilities.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The small size and inexperience
of the securities markets in certain Emerging Markets and the limited volume of trading in securities in those countries may make the
Fund's investments in such countries less liquid and more volatile than investments in countries with more developed securities markets
(such as the United States, Japan and most Western European countries). The Fund's investments in Emerging Markets are subject to the
risk that the liquidity of a particular investment, or investments generally, in such countries will shrink or disappear suddenly and
without warning as a result of adverse economic, market or political conditions or adverse investor perceptions, whether or not accurate.
Because of the lack of sufficient market liquidity, the Fund may incur losses because it will be required to effect sales at a disadvantageous
time and only then at a substantial drop in price. Investments in Emerging Markets may be more difficult to value precisely because of
the characteristics discussed above and lower trading volumes. In addition, the impact of the economic and public health crisis in emerging
market countries may be greater due to their generally less established healthcare systems and capabilities with respect to fiscal and
monetary policies, which may exacerbate other pre-existing political, social and economic tasks.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's use of foreign
currency management techniques in Emerging Markets may be limited. A significant portion of the Fund's currency exposure in Emerging Markets
may not be covered by these techniques.</span></p> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_ForwardContractRiskMember', window );">Forward Contract Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Forward Contract Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Forward contracts involve the purchase or sale of a specific quantity of a commodity, government security, foreign currency, or other
asset at a specified price, with delivery and settlement at a specified future date. Because it is a completed contract, a purchase forward
contract can be a cover for the sale of a futures contract. The Fund may enter into forward contracts for hedging purposes and non-hedging
purposes (i.e., to increase returns). Forward contracts may be used by the Fund for hedging purposes to protect against uncertainty in
the level of future foreign currency exchange rates, such as when the Fund anticipates purchasing or selling a foreign security. For example,
this technique would allow the Fund to "lock in" the U.S. dollar price of the security. Forward contracts may also be used to attempt
to protect the value of the Fund's existing holdings of foreign securities. There may be, however, an imperfect correlation between the
Fund's foreign securities holdings and the forward contracts entered into with respect to those holdings. Forward contracts may also be
used for non-hedging purposes to pursue the Fund's investment objective, such as when the Investment Adviser anticipates that particular
foreign currencies will appreciate or depreciate in value, even though securities denominated in</span></p>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">those currencies are not then
held in the Fund's portfolio. There is no requirement that the Fund hedge all or any portion of its exposure to foreign currency risks.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Forward contracts, unlike
futures contracts, are not traded on exchanges and are not standardized; rather, banks and dealers act as principals in these markets,
negotiating each transaction on an individual basis. The principals who deal in the forward markets are not required to continue to make
markets in the currencies or commodities they trade and these markets can experience periods of illiquidity, sometimes of significant
duration. There have been periods during which certain participants in these markets have refused to quote prices for certain currencies
or commodities or have quoted prices with an unusually wide spread between the price at which they were prepared to buy and that at which
they were prepared to sell. Disruptions can occur in any market traded by the Investment Adviser due to unusually high trading volume,
political intervention or other factors. Arrangements to trade forward contracts may be made with only one or a few counterparties, and
liquidity problems therefore might be greater than if such arrangements were made with numerous counterparties. The imposition of controls
by governmental authorities might also limit such forward (and futures) trading to less than that which the Investment Adviser would otherwise
recommend, to the possible detriment of the Fund. Market illiquidity or disruption could result in major losses to the Fund. In addition,
the Fund will be exposed to credit risks with regard to counterparties with whom they trade as well as risks relating to settlement default.
Such risks could result in substantial losses to the Fund.</span></p> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_DerivativesRiskMember', window );">Derivatives Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Derivatives Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
The Fund may invest in derivative instruments including options, futures, options on futures, forwards, swaps (including credit default,
index, basis, total return, volatility and currency swaps), options on swaps and other derivatives, although suitable derivative instruments
may not always be available to the Investment Adviser for these purposes. The Fund intends to employ a strategy of writing (selling) covered
call options on a portion of the common stocks in its portfolio, writing (selling) put options on a portion of the common stocks in its
portfolio and, to a lesser extent, writing (selling) covered call and writing (selling) put options on indices of securities and sectors
of securities generally within the healthcare industry. This option strategy is intended to generate current income from option premiums
as a means to enhance distributions payable to the Fund's shareholders and will be limited to 30% of the Fund's Managed Assets. These
option strategies are not always profitable. The sale of a covered call option exposes the Fund during the term of the option to possible
loss of opportunity to realize appreciation in the market price of the underlying security or to possible loss due to continued holding
of a security that might otherwise have been sold to protect against depreciation in the market price of the security. To the extent the
Fund writes a covered put option, the Fund has assumed the obligation during the option period to purchase the security or securities
from the put buyer at the option's exercise price if the put buyer exercises its option, regardless of whether the value of the underlying
investment falls below the exercise price. This means that a Fund that writes a</span></p>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">put option may be required
make payment for such investment at the exercise price. This may result in losses to the Fund and may result in the Fund holding securities
for some period of time when it is disadvantageous to do so. Therefore, the Investment Adviser may choose to decrease its use of the option
writing strategy to the extent that it may negatively impact the Fund. Other than the Fund's option strategy and use of derivatives for
hedging purposes, the Fund may invest up to 10% of its Managed Assets in derivatives. Derivative instruments can be illiquid, may disproportionately
increase losses, and may have a potentially large adverse impact on Fund performance.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Although both OTC and exchange-traded
derivatives markets may experience a lack of liquidity, OTC nonstandardized derivative transactions are generally less liquid than exchange-traded
instruments. The illiquidity of the derivatives markets may be due to various factors, including congestion, disorderly markets, limitations
on deliverable supplies, the participation of speculators or their withdrawal from the markets, government regulation and intervention,
and technical and operational or system failures. In addition, daily limits on price fluctuations and speculative position limits on exchanges
on which the Fund may conduct its transactions in derivative instruments may prevent the Fund from liquidating these positions at an advantageous
time or price, subjecting the Fund to the potential of greater losses. Losses from investments in derivative instruments can result from
a lack of correlation between changes in the value of derivative instruments and the portfolio assets (if any) being hedged, the potential
illiquidity of the markets for derivative instruments, the failure of the counterparty to perform its contractual obligations, or the
risks arising from margin requirements and related leverage factors associated with such transactions. Losses may also arise if the Fund
receives cash collateral under the transactions and some or all of that collateral is invested in the market. To the extent that cash
collateral is so invested, such collateral will be subject to market depreciation or appreciation, and the Fund may be responsible for
any loss that might result from its investment of the counterparty's cash collateral. The use of these derivatives trading techniques
also involves the risk of loss if the Investment Adviser is incorrect in its expectation of the timing or level of fluctuations in securities
prices, interest rates or currency prices. Investments in derivative instruments may be harder to value, subject to greater volatility
and more likely subject to changes in tax treatment than other investments. For these reasons, the Investment Adviser's attempts to hedge
portfolio risks through the use of derivative instruments may not be successful. Trading in derivative instruments can increase the Fund's
exposure to leverage. Thus, the leverage offered by trading in derivative instruments will magnify the gains and losses experienced by
the Fund and could cause the Fund's net asset value to be subject to wider fluctuations than would be the case if the Fund did not use
the leverage feature in derivative instruments.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Derivatives markets have been
subject to increased regulation over the past several years, which may continue, and consequently, may make derivatives trading more costly,
may limit the availability of and reduce the liquidity of derivatives or may otherwise adversely affect the</span></p> </div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">value or performance of derivatives.
Such potential adverse future developments could increase the risks reduce the effectiveness of the Fund's derivative transactions, and
cause the Fund to lose value. For instance, the SEC has adopted new regulations related to a registered investment company's use of derivatives
and related instruments. These regulations impose limits on the amount of derivatives a fund can enter into, eliminate the asset segregation
framework formerly used by funds to comply with Section 18 of the 1940 Act. These regulations may significantly impact the Fund's ability
to invest in derivatives and other instruments, limit the Fund's ability to employ certain strategies that use derivatives and/or adversely
affect the Fund's performance, efficiency in implementing its strategy, liquidity and/or ability to pursue its investment objectives.</span></p>
<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_RisksAssociatedWithFundsOptionStrategyMember', window );">Risks Associated With Funds Option Strategy [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Risks Associated with
the Fund's Option Strategy.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The ability of the Fund to achieve
its investment objective is partially dependent on the successful implementation of its option strategy. There are several risks associated
with transactions in options on securities used in connection with the Fund's option strategy. For example, there are significant differences
between the securities and options markets that could result in an imperfect correlation between these markets, causing a given transaction
not to achieve its objectives. A decision as to whether, when and how to use options involves the exercise of skill and judgment, and
even a well-conceived transaction may be unsuccessful to some degree because of market behavior or unexpected events.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">As the writer of a call option
covered with a security held by the Fund, the Fund forgoes, during the option's life, the opportunities to profit from increases in the
market value of the security covering the call option above the sum of the premium and the strike price of the call but retains the risk
of loss should the price of the underlying security decline. As the Fund writes such covered calls over more of its portfolio, its ability
to benefit from capital appreciation becomes more limited. To the extent the Fund writes call options that are not fully covered by securities
in its portfolio (such as calls on an index or sector), it will lose money if the portion of the security or securities underlying the
option that is not covered by securities in the Fund's portfolio appreciate in value above the exercise price of the option by an amount
that exceeds the premium received on the option plus the exercise price of the option. The amount of this loss theoretically could be
unlimited. The writer of an option has no control over the time when it may be required to fulfill its obligations as a writer of the
option.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">When the Fund writes put options,
it bears the risk of loss if the value of the underlying stock declines below the exercise price minus the put premium. If the option
is exercised, the Fund could incur a loss if it is required to purchase the stock underlying the put option at a price greater than the
market price of the stock at the time of exercise plus the put premium the Fund received when it wrote the option. While the Fund's potential
gain as the writer of a</span></p> </div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">covered put option is limited
to the premium received from the purchaser of the put option, the Fund risks a loss equal to the entire exercise price of the option minus
the put premium.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_InterestRatesRiskMember', window );">Interest Rates Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Interest Rate Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Prices of fixed-income securities generally rise and fall in response to interest rate changes. Generally, the prices of fixed-rate instruments
held by the Fund will tend to fall as interest rates rise. Conversely, when interest rates decline, the value of fixed-rate instruments
held by the Fund can be expected to rise. Changing interest rates may have unpredictable effects on the markets, may result in heightened
market volatility and may detract from Fund performance. In addition, changes in monetary policy may exacerbate the risks associated with
changing interest rates. The longer the duration, or price sensitivity to changes in interest rates, of the security, the more sensitive
the security is to this risk. In typical market interest rate environments, the prices of longer-term fixed-rate instruments tend to fluctuate
more in price in response to changes in market interest rates than prices of shorter-term fixed-rate instruments. A 1% increase in interest
rates would reduce the value of a $100 note by approximately one dollar if it had a one-year duration. It is difficult to predict the
magnitude, timing or direction of interest rate changes and the impact these changes will have on the Fund's investments and the markets
where it trades.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The risks attendant to changing
interest rate environments have been, and continue to be, magnified in the current economic environment. To combat rising inflation, the
Board of Governors of the Federal Reserve System increased the federal funds rate several times in 2022 and 2023.</span></p> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_ReitRiskMember', window );">REIT Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>REIT Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
REITs whose underlying properties are concentrated in a particular industry, such as the healthcare industry, or geographic region are
subject to risks affecting such industries or regions. The securities of REITs involve greater risks than those associated with larger,
more established companies and may be subject to more abrupt or erratic price movements because of interest rate changes, economic conditions
and other factors. Securities of such issuers may lack sufficient market liquidity to enable the Fund to effect sales at an advantageous
time or without a substantial drop in price.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_CreditDefaultRiskMember', window );">Credit Default Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Credit/Default Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Loans and other debt obligation investments are subject to the risk of non-payment of scheduled principal and interest. Changes in economic
conditions or other circumstances may reduce the capacity of the party obligated to make principal and interest payments on such instruments
and may lead to defaults. Such non-payments and defaults may reduce the value of the shares and income distributions. The value of loans
and other income investments also may decline because of concerns about the issuer's ability to make principal and interest payments.
In addition, the credit ratings of loans or other income investments may be lowered if the financial condition of the party obligated
to make payments with respect to such instruments changes. Because the Fund will invest in non-investment grade securities, it will be
exposed to a greater amount of credit risk than a fund which invests solely in investment grade securities. The prices of lower grade</span></p>


<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">instruments are generally
more sensitive to negative developments, such as a decline in the issuer's revenues or a general economic downturn, than are the prices
of higher grade instruments. Credit ratings assigned by rating agencies are based on a number of factors and do not necessarily reflect
the issuer's current financial condition or the volatility or liquidity of the security. In the event of bankruptcy of the issuer of loans
or other income investments, the Fund could experience delays or limitations with respect to its ability to realize the benefits of any
collateral securing the instrument. In order to enforce its rights in the event of a default, bankruptcy or similar situation, the Fund
may be required to retain legal or similar counsel and incur additional costs.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_NonInvestmentGradeSecuritiesRiskMember', window );">Non Investment Grade Securities Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Non-Investment Grade
Securities Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund may invest in securities that are
rated, at the time of investment, non-investment grade quality (rated "Ba/BB+/BB+" or below by Moody's, S&amp;P or Fitch, respectively),
or securities that are unrated but determined to be of comparable quality by the Investment Adviser. The Fund may invest up to 15% of
its Managed Assets in non-convertible debt securities that are, at the time of investment, rated Caa1 or lower by Moody's and CCC+ or
lower by S&amp;P or Fitch, or comparably rated by another nationally recognized statistical rating organization, or, if unrated, determined
by the Investment Adviser to be of comparable credit quality. Such securities are subject to a very high credit risk. Securities of non-investment
grade quality are regarded as having predominantly speculative characteristics with respect to the issuer's capacity to pay interest and
repay principal, and are commonly referred to as "junk bonds." Non-investment grade securities and unrated securities of comparable credit
quality are subject to the increased risk of an issuer's inability to meet principal and interest payment obligations. The value of high
yield, lower quality bonds is affected by the creditworthiness of the issuers of the securities and by general economic and specific industry
conditions. These securities may be subject to greater price volatility due to such factors as specific corporate or municipal developments,
interest rate sensitivity, negative perceptions of the junk bond markets generally and less secondary market liquidity. Issuers of high
yield bonds are not as strong financially as those with higher credit ratings. These issuers are more vulnerable to financial setbacks
and recession than more creditworthy issuers, which may impair their ability to make interest and principal payments. Non-investment grade
securities may be particularly susceptible to economic downturns, specific corporate or municipal developments, interest rate sensitivity,
negative perceptions of the junk bond markets generally and less secondary market liquidity. An economic recession could disrupt severely
the market for such securities and may have an adverse impact on the value of such securities. In addition, any such economic downturn
could adversely affect the ability of the issuers of such securities to repay principal and pay interest thereon and increase the incidence
of default for such securities. Non-investment grade securities, though higher yielding, are characterized by high risk. They may be subject
to certain risks with respect to the issuing entity and to greater market fluctuations than certain lower yielding, higher rated securities.
The retail secondary market for non-investment grade securities may be less liquid than that for higher rated securities. Adverse conditions</span></p>


<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">could make it difficult at
times for the Fund to sell certain securities or could result in lower prices than those used in calculating the Fund's NAV. Because of
the substantial risks associated with investments in non-investment grade securities, you could lose money on your investment in shares
of the Fund, both in the short-term and the long-term.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_CounterpartyRiskMember', window );">Counterparty Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Counterparty Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Many of the protections afforded to participants on some organized exchanges, such as the performance guarantee of a clearing house, might
not be available in connection with uncleared OTC transactions. Therefore, in those instances in which the Fund enters into uncleared
OTC transactions, the Fund will be subject to the risk that its direct counterparty will not perform its obligations under the transactions
and that the Fund will sustain losses. If a counterparty becomes bankrupt, the Fund may experience significant delays in obtaining recovery
(if at all) under the derivative contract in bankruptcy or other reorganization proceeding; if the Fund's claim is unsecured, the Fund
will be treated as a general creditor of such prime broker or counterparty and will not have any claim with respect to the underlying
security. The Fund may obtain only a limited recovery or may obtain no recovery in such circumstances. The counterparty risk for cleared
derivatives is generally lower than for uncleared OTC derivatives since generally a clearing organization becomes substituted for each
counterparty to a cleared derivative and, in effect, guarantees the parties' performance under the contract as each party to a trade looks
only to the clearing house for performance of financial obligations. However, there can be no assurance that the clearing house, or its
members, will satisfy its obligations to the Fund.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_RegulationAsCommodityPoolMember', window );">Regulation As Commodity Pool [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Regulation as a "Commodity
Pool".</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Investment Adviser has claimed an exclusion from
the definition of the term "commodity pool operator" with respect to the Fund pursuant to Regulation 4.5 promulgated by the U.S. Commodity
Futures Trading Commission (the "CFTC"). For the Investment Adviser to continue to qualify for the exclusion under CFTC Regulation 4.5
with respect to the Fund, the aggregate initial margin and premiums required to establish our positions in derivative instruments subject
to the jurisdiction of the Commodity Exchange Act of 1936, as amended ("CEA") (other than positions entered into for hedging purposes)
may not exceed five percent of the Fund's liquidation value or, alternatively, the net notional value of the Fund's aggregate investments
in CEA-regulated derivative instruments (other than positions entered into for hedging purposes) may not exceed 100% of the Fund's liquidation
value. In the event the Investment Adviser fails to qualify for the exclusion with respect to the Fund and is required to register as
a "commodity pool operator," it will become subject to additional disclosure, recordkeeping and reporting requirements with respect to
the Fund, which may increase the Fund's expenses.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember', window );">Failure Of Futures Commission Merchants And Clearing Organizations [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Failure of Futures
Commission Merchants and Clearing Organizations.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund may
deposit funds required to margin open positions in derivative instruments subject to the CEA with a clearing broker registered as a "futures
commission merchant" ("FCM"). The CEA requires an FCM to segregate all funds received from customers with respect to any orders for the
purchase or sale of U.S. domestic futures contracts and cleared swaps from the FCM's</span></p>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">proprietary assets. Similarly,
the CEA requires each FCM to hold in a separate secure account all funds received from customers with respect to any orders for the purchase
or sale of foreign futures contracts and segregate any such funds from the funds received with respect to domestic futures contracts.
However, all funds and other property received by a clearing broker from its customers are held by the clearing broker on a commingled
basis in an omnibus account and may be freely accessed by the clearing broker, which may also invest any such funds in certain instruments
permitted under the applicable regulation. There is a risk that assets deposited by the Fund with any swaps or futures clearing broker
as margin for futures contracts or cleared swaps may, in certain circumstances, be used to satisfy losses of other clients of the Fund's
clearing broker. In addition, the assets of the Fund may not be fully protected in the event of the clearing broker's bankruptcy, as the
Fund would be limited to recovering only a pro rata share of all available funds segregated on behalf of the clearing broker's combined
domestic customer accounts.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Similarly, the CEA requires
a clearing organization approved by the CFTC as a derivatives clearing organization to segregate all funds and other property received
from a clearing member's clients in connection with domestic futures, swaps and options contracts from any funds held at the clearing
organization to support the clearing member's proprietary trading. Nevertheless, with respect to futures and options contracts, a clearing
organization may use assets of a non-defaulting customer held in an omnibus account at the clearing organization to satisfy payment obligations
of a defaulting customer of the clearing member to the clearing organization. As a result, in the event of a default or the clearing broker's
other clients or the clearing broker's failure to extend its own funds in connection with any such default, the Fund would not be able
to recover the full amount of assets deposited by the clearing broker on its behalf with the clearing organization.</span></p> </div>
<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_LiquidityRiskMember', window );">Liquidity Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Liquidity Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Illiquid securities include securities the disposition of which is subject to substantial legal or contractual restrictions. The sale
of illiquid securities often requires more time and results in higher brokerage charges or dealer discounts and other selling expenses
than does the sale of securities eligible for trading on national securities exchanges or in the over-the-counter markets. Restricted
securities may sell at a price lower than similar securities that are not subject to restrictions on resale. The continued liquidity of
such securities may not be as well assured as that of publicly traded securities. During certain periods the liquidity of particular issuers
or industries, or all securities within particular investment categories, may shrink or disappear suddenly and without warning as a result
of adverse economic, market or political events, or adverse investor perceptions, whether or not accurate.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_EquityLinkedNotesMember', window );">Equity Linked Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Equity-Linked Notes.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Equity-linked notes ("ELNs") are hybrid securities with characteristics of both fixed income and equity securities. An ELN is a debt instrument,
usually a bond, that pays interest based upon the performance of an underlying equity, which can be a single stock, basket of stocks or
an equity index. The interest payment on an ELN may in some cases be leveraged so that, in percentage terms, it exceeds the relative performance
of the market.</span></p>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">ELNs generally are subject to
the risks associated with the securities of equity issuers, default risk and counterparty risk. Additionally, because the Fund may use
ELNs as an alternative or complement to its options strategy, the use of ELNs in this manner would expose the Fund to the risk that such
ELNs will not perform as anticipated, and the risk that the use of ELNs will expose the Fund to different or additional default and counterparty
risk as compared to a similar investment executed in an options strategy.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_PrivateInvestmentInPublicEquityRiskMember', window );">Private Investment In Public Equity Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>PIPEs Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
PIPE transactions typically involve the purchase of securities directly from a publicly traded company or its affiliates in a private
placement transaction, typically at a discount to the market price of the company's common stock. In a PIPE transaction, the Fund may
bear the price risk from the time of pricing until the time of closing. Equity issued in this manner is often subject to transfer restrictions
and is therefore less liquid than equity issued through a registered public offering. In a PIPE transaction, the Fund may bear the price
risk from the time of pricing until the time of closing. The Fund may be subject to lock-up agreements that prohibit transfers for a fixed
period of time. In addition, because the offering of the securities in a PIPE transaction is not registered under the Securities Act,
the securities are "restricted" and cannot be immediately resold by the investors into the public markets. The Fund may enter into a registration
rights agreement with the issuer pursuant to which the issuer commits to file a resale registration statement allowing the Fund to publicly
resell its securities. Accordingly, PIPE securities may be deemed illiquid. However, the ability of the Fund to freely transfer the shares
is conditioned upon, among other things, the Commission's preparedness to declare the resale registration statement effective covering
the resale of the shares sold in the private financing and the issuer's right to suspend the Fund's use of the resale registration statement
if the issuer is pursuing a transaction or some other material non-public event is occurring. Accordingly, PIPE securities may be subject
to risks associated with illiquid securities.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_VentureCapitalInvestmentsRiskMember', window );">Venture Capital Investments Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Venture Capital Investments
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund may occasionally invest in venture capital opportunities.
While these securities offer the opportunity for significant capital gains, such investments also involve a degree of risk that can result
in substantial losses. Some of the venture capital opportunities in which the Fund may invest are expected to be companies that are in
a "start-up" stage of development, have little or no operating history, operate at a loss or with substantial variations in operating
results from period to period, have limited products, markets, financial resources or management depth, or have the need for substantial
additional "follow-on" capital to support expansion or to achieve or maintain a competitive position. Such additional investments may
dilute the interests of prior investors, such as the Fund. Some of these companies may be emerging companies at the research and development
stage with no marketable or approved products or technology. There can be no assurance that securities of start-up or emerging growth
companies will, in the future, yield returns commensurate with their associated risks.</span></p>

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">These investments, which are considered
Restricted Securities, will be made primarily in convertible preferred stock. The Fund may also purchase non-convertible debt securities
in connection with its venture capital investments, and otherwise when the Investment Adviser believes that such investments would be
consistent with the Fund's investment objective. While these debt investments typically will not be rated, the Investment Adviser believes
that, in light of the risk characteristics associated with investments in emerging growth companies, if such investments were to be compared
with investments rated by S&amp;P or Moody's, they may be rated as low as "C" in the rating categories established by S&amp;P and Moody's.
Such securities are commonly referred to as "junk bonds" and are considered, on balance, as predominantly speculative.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_ExchangeTradedFundsRiskMember', window );">Exchange Traded Funds Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>ETFs Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
An investment in an ETF generally presents the same primary risks as an investment in a conventional fund (i.e., one that is not exchange-traded)
that has the same investment objectives, strategies and policies. In addition, an ETF may fail to accurately track the market segment
or index that underlies its investment objective. The price of an ETF can fluctuate, and the Fund could lose money investing in an ETF.
Moreover, ETFs are subject to the following risks that do not apply to conventional open-end funds: (i) the market price of the ETF's
shares may trade at a premium or a discount to their NAV; (ii) an active trading market for an ETF's shares may not develop or be maintained;
and (iii) there is no assurance that the requirements of the exchange necessary to maintain the listing of an ETF will continue to be
met or remain unchanged.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_LeverageRiskMember', window );">Leverage Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<div>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Leverage Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
The Fund intends to use financial leverage for investment purposes. The Fund may issue preferred shares, borrow money and/or issue debt
securities ("traditional leverage"). The Fund intends to use traditional leverage through a credit facility representing up to 20% of
the Fund's Managed Assets as measured at the time when leverage is incurred. In addition, the Fund may enter into reverse repurchase agreements,
swaps, futures, forward contracts, securities lending, short sales, and other derivative transactions, that have similar effects as leverage
(collectively referred to as "effective leverage"). Furthermore, at no time will the Fund's use of leverage, either through traditional
leverage or effective leverage, exceed 30% of the Fund's Managed Assets as measured at the time when leverage is incurred. Notwithstanding
the foregoing, effective leverage incurred through the Fund's option strategy and use of derivatives for hedging purposes will not be
counted toward the Fund's limit on the use of effective leverage or in the overall 30% leverage limitation.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The Fund's leveraged capital
structure creates special risks not associated with unleveraged funds having a similar investment objective and policies. These include
the possibility of greater loss and the likelihood of higher volatility of the NAV, market price and distributions of the Fund and the
asset coverage for preferred shares, if any. Such volatility may increase the likelihood of the Fund having to sell investments in order
to meet its obligations to make distributions on the preferred shares, or to redeem preferred shares when it may be disadvantageous to
do so. Also, if the Fund is utilizing leverage, a decline in NAV could affect</span></p> </div>

<div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">the ability of the Fund to
make distributions and such a failure to pay dividends or make distributions could result in the Fund ceasing to qualify as a regulated
investment company under the Code, as amended.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Other risks and special considerations
include the risk that fluctuations in interest rates on borrowings and short-term debt or in the interest or dividend rates on any leverage
that the Fund must pay will reduce the return to the shareholders; the effects of leverage in a declining market, which are likely to
cause a greater decline in the NAV of the shares than if the Fund were not leveraged, which may result in a greater decline in the market
price of the shares. If the Fund uses leverage, the amount of fees paid to the Investment Adviser for its services will be higher than
if the Fund did not use leverage because the fees paid are calculated based on Managed Assets, which includes assets purchased with leverage.
Therefore, the Investment Adviser has a financial incentive to use leverage, which creates a conflict of interest between the Investment
Adviser and common shareholders, as only the Fund's common shareholders would bear the fees and expenses incurred through the Fund's use
of leverage, including the issuance of Preferred shares, if any. Leverage may increase operating costs, which may reduce total return.</span></p>


<div>

<p style="margin:11pt 0pt 2pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Effects of Leverage</strong></span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Assuming that leverage will
represent approximately 20% of Managed Assets and that the Fund will bear expenses relating to that leverage at an annual cost of 1.00%,
Fund performance before leverage (net of expenses) must exceed .2% in order to cover the expenses specifically related to the Fund's use
of leverage. Actual leverage expenses will vary frequently and may be significantly higher or lower than the rate estimated above.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">As of September 30, 2023 and
the most recently signed line of credit agreement, the Fund projects an annual leverage expense of 6.57%. The Fund had $120,000,000 of
funds drawn on its line of credit which was 21.2% of Managed Assets as of September 30, 2023.</span></p>

<div>

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">The following table is furnished
in response to requirements of the SEC. It is designed to illustrate the effects of leverage on total returns from an investment in the
Fund assuming investment portfolio returns before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage
representing 20% of the Fund's Managed Assets and the Fund's currently projected annual leverage expense of 6.57%.</span></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td colspan="3" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:143;background-color:#cceeff"><span style="font-size:8pt;font-family:Arial, Helvetica">Assumed
        Fund Return Before Leverage</span><br/><span style="font-size:8pt;font-family:Arial, Helvetica">(Net of Expenses) </span></td>
    <td colspan="1" style="background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(10.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(5.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">0.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:29;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">5.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:33;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10.00</span></p> </td>
    <td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8;background-color:#cceeff">&#160;</td> </tr>
  <tr>
    <td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:143">
        <p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Arial, Helvetica">Assumed Fund Return Inclusive of Leverage </span></p>
        </td>
    <td colspan="1">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(14.14</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(7.89</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">(1.64</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">)%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:29">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">4.61</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8">&#160;</td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:33">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">10.89</span></p>
        </td>
    <td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22">
        <p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:8pt;font-family:Arial, Helvetica">%</span></p> </td>
    <td colspan="1" style="width:8">&#160;</td> </tr>
  </table>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Assumed Fund performance before
and inclusive of leverage are hypothetical and are provided to assist investors in understanding the effects of leverage. Actual performance
experienced by the Fund may be lesser or greater than that shown above.</span></p> </div>  </div>  </div>
<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_RestrictedSecuritiesAndValuationRiskMember', window );">Restricted Securities And Valuation Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Restricted Securities
and Valuation Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> Some of the Fund's investments are subject
to restrictions on resale and generally have no established trading market or are otherwise illiquid with little or no trading activity.
The valuation process requires an analysis of various factors. The Fund's fair value methodology includes the examination of, among other
things, (i) the existence of any contractual restrictions on the disposition of the securities; (ii) information obtained from the issuer
which may include an analysis of the company's financial statements, the company's products or intended markets, or the company's technologies;
and (iii) the price of a security sold at arm's length in an issuer's subsequent completed round of financing. As there is typically no
readily available market value for some of the Restricted Securities in the Fund's portfolio, such Restricted Securities in the Fund's
portfolio are valued at fair value as determined in good faith by or under the direction of the Board pursuant to the Fund's valuation
policy and a consistently applied valuation process. Because of the inherent uncertainty of determining the fair value of investments
that do not have a readily available market value, the fair value of the Fund's investments determined in good faith by the Board may
differ significantly from the values that would have been used had a ready market existed for the investments, and the differences could
be material. There is no single standard for determining fair value in good faith. As a result, determining fair value requires that judgment
be applied to the specific facts and circumstances of each portfolio investment, while employing a consistently applied valuation process
for the types of investments the Fund makes.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_KeyPersonnelRiskMember', window );">Key Personnel Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Key Personnel Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
There may be only a limited number of securities professionals who have comparable experience to that of the Fund's existing portfolio
management team in the area of healthcare companies. If one or more of the team members dies, resigns, retires or is otherwise unable
to act on behalf of the Investment Adviser, there can be no assurance that a suitable replacement could be found immediately.</span></p>
<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_AntiTakeoverProvisionsRiskMember', window );">Anti Takeover Provisions Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Anti-Takeover Provisions
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund's Amended and Restated Declaration of Trust ("Declaration
of Trust"), dated March 5, 2015, as amended, has provisions that could have the effect of limiting the ability of other entities or persons
to (1) acquire control of the Fund, (2) cause it to engage in certain transactions, or (3) modify its structure. The By-Laws also contain
provisions regarding qualifications for nominees for Trustee positions, advance notice of Shareholder proposals, and requirements for
the call of special Shareholder meetings. These provisions may be considered "anti-takeover" provisions.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_RelatedPartyTransactionsRiskMember', window );">Related Party Transactions Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Related Party Transactions
Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The majority of the Board is unaffiliated with the Investment
Adviser; nevertheless, the Fund may be subject to certain potential conflicts of interest. Although the Fund has no obligation to do so,
it may place brokerage orders with brokers who provide supplemental investment research and market and statistical information about healthcare
companies and the healthcare industries. In addition, other investment companies advised by the Investment Adviser may concurrently invest
with the Fund in restricted securities under certain conditions. The Fund also may invest, subject to</span></p>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">applicable law, in companies
in which the principals of the Investment Adviser or Trustees of the Fund have invested, or for which they serve as directors or executive
officers. The Investment Company Act prohibits the Fund from engaging in certain transactions involving its "affiliates," including, among
others, the Fund's Trustees, officers and employees, the Investment Adviser and any "affiliates" of such affiliates except pursuant to
an exemptive order or the provisions of certain rules under the Investment Company Act. In the view of the staff of the Commission, other
investment companies advised by the Investment Adviser may, in some instances, be viewed to be affiliates of the Fund. Such legal restrictions
and delays and costs involved in obtaining necessary regulatory approvals may preclude or discourage the Fund from making certain investments
and no assurance can be given that any exemptive order sought by the Fund will be granted.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_GovernmentInterventionMember', window );">Government Intervention [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Government Intervention.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica">
Instability in the financial markets has led the U.S. government and certain foreign governments to take a number of unprecedented actions
designed to support certain financial institutions and segments of the financial markets that have experienced extreme volatility, and
in some cases a lack of liquidity, including through direct purchases of equity and debt securities. Federal, state, and foreign governments,
their regulatory agencies or self-regulatory organizations may take actions that affect the regulation of the issuers in which the Fund
invests in ways that are unforeseeable. Legislation or regulation may also change the way in which the Fund is regulated. Such legislation
or regulation could limit or preclude the Fund's ability to achieve its investment objective.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_MarketDisruptionAndGeopoliticalRiskMember', window );">Market Disruption And Geopolitical Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Market Disruption
and Geopolitical Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The value of your investment in the Fund
is based on the market prices of the securities the Fund holds. These prices change daily due to economic and other events that affect
markets generally, as well as those that affect particular regions, countries, industries, companies or governments. These price movements,
sometimes called volatility, may be greater or less depending on the types of securities the Fund owns and the markets in which the securities
trade. The increasing interconnectivity between global economies and financial markets increases the likelihood that events or conditions
in one region or financial market may adversely impact issuers in a different country, region or financial market. Securities in the Fund's
portfolio may underperform due to inflation (or expectations for inflation), interest rates, global demand for particular products or
resources, natural/environmental disasters, pandemics, epidemics, terrorism, cyber-attacks, regulatory events and governmental or quasi-governmental
actions. The occurrence of global events similar to those in recent years, such as terrorist attacks around the world, natural disasters,
social and political discord or debt crises and downgrades, among others, may result in market volatility and may have long term effects
on both the U.S. and global financial markets. A disruption of financial markets or other terrorist attacks could adversely affect Fund
service providers and/or the Fund's operations as well as interest rates, secondary trading, credit risk, inflation and other factors
relating to the shares. The Fund cannot predict the effects or likelihood of similar events in the future on the U.S. and world economies,
the value of the shares or the NAV of the Fund.</span></p>

<div>

<p style="margin:0pt 0pt 8pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">Social, political, economic
and other conditions and events, such as natural/environmental disasters, health emergencies (e.g., epidemics and pandemics such as COVID-19,
avian influenza and HINI/09), cyber-attacks, terrorism, actual or threatened wars or other armed conflicts (such as the Russia/Ukraine
and Israel/Hamas conflicts), may occur and could significantly impact issuers, industries, governments and other systems, including the
financial markets. These impacts could negatively affect the Fund's investments in securities and instruments that are economically tied
to the applicable region, and include (but are not limited to) declines in value and reductions in liquidity. In addition, to the extent
new sanctions are imposed or previously relaxed sanctions are reimposed, complying with such restrictions may prevent the Fund from pursuing
certain investments, cause delays or other impediments with respect to consummating such investments or divestments, require divestment
or freezing of investments on unfavorable terms, render divestment of underperforming investments impracticable, negatively impact the
Fund's ability to achieve its investment objective, prevent the Fund from receiving payments otherwise due it, increase diligence and
other similar costs to the Fund, render valuation of affected investments challenging, or require the Fund to consummate an investment
on terms that are less advantageous than would be the case absent such restrictions. As global systems, economies and financial markets
are increasingly interconnected, events that once had only local impact are now more likely to have regional or even global effects. Events
that occur in one country, region or financial market will, more frequently, adversely impact issuers in other countries, regions or markets.
These impacts can be exacerbated by failures of governments and societies to adequately respond to an emerging event or threat. These
types of events quickly and significantly impact markets in the U.S. and across the globe leading to extreme market volatility and disruption.
The extent and nature of the impact on supply chains or economies and markets from these events is unknown, particularly if these types
of events persist for an extended period of time. These types of events, could reduce consumer demand or economic output, result in market
closures, travel restrictions or quarantines, and generally have a significant impact on the economies and financial markets and the Investment
Adviser's investment advisory activities and services of other service providers, which in turn could adversely affect the Fund's investments
and other operations. The value of the Fund's investments may decrease as a result of such events, particularly if these events adversely
impact the operations and effectiveness of the Investment Adviser or key service providers or if these events disrupt systems and processes
necessary or beneficial to the investment advisory or other activities on behalf the Fund.</span></p>

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">In March 2023, several financial
institutions experienced a larger-than-expected decline in deposits and two banks, Silicon Valley Bank ("SVB") and Signature Bank, were
placed into receivership. Given the interconnectedness of the banking system, the Federal Reserve invoked the systemic risk exception,
temporarily transferred all deposits-both insured and uninsured-and substantially all the assets of the two banks into respective bridge
banks and</span></p> </div>

<p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica">guaranteed depositors' full
access to their funds. This type of systemic risk event and/or resulting government actions can negatively impact the Funds, for example,
through less credit being available to issuers or uncertainty regarding safety of deposits at other institutions. These risks also may
adversely affect financial intermediaries, such as clearing agencies, clearing houses, banks, securities firms, and exchanges, with which
the Fund interacts.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_PotentialConflictsOfInterestRiskMember', window );">Potential Conflicts Of Interest Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Potential Conflicts
of Interest Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Investment Adviser's investment team is
responsible for managing the Fund as well as three other closed-end investment companies. In the future, the investment team may manage
other funds and accounts, including proprietary accounts, separate accounts and other pooled investment vehicles, such as unregistered
hedge funds. In the future, a portfolio manager may manage a separate account or other pooled investment vehicle which may have materially
higher fee arrangements than the Fund and may also have a performance-based fee. The side-by-side management of these funds or accounts
may raise potential conflicts of interest relating to cross trading, the allocation of investment opportunities and the aggregation and
allocation of trades.</span></p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskAxis=ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember', window );">Special Purpose Acquisition Company Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">

<p style="margin:8pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Arial, Helvetica"><strong>Special Purpose Acquisition
Company Risk.</strong></span><span style="font-size:10pt;font-family:Arial, Helvetica"> The Fund may invest in SPACs. SPACs are collective
investment structures that pool funds in order to seek potential acquisition opportunities. Unless and until an acquisition is completed,
a SPAC generally invests its assets (less an amount to cover expenses) in U.S. Government securities, money market fund securities and
cash. SPACs and similar entities may be blank check companies with no operating history or ongoing business other than to seek a potential
acquisition. Certain SPACs may seek acquisitions only in limited industries or regions. If an acquisition that meets the requirements
for the SPAC is not completed within a predetermined period of time, the invested funds are returned to the entity's shareholders, unless
such shareholders approve alternative arrangements. Investments in SPACs may be illiquid and/or be subject to restrictions on resale.</span></p>
<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2023Member', window );">Loan Facility 2023 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[11]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,726<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,726<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred Stock Liquidating Preference</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[12]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract', window );"><strong>Capital Stock, Long-Term Debt, and Other Securities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SecurityTitleTextBlock', window );">Security Title [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">Loan
        Facility 2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2022Member', window );">Loan Facility 2022 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,786<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,786<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred Stock Liquidating Preference</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[12]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract', window );"><strong>Capital Stock, Long-Term Debt, and Other Securities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SecurityTitleTextBlock', window );">Security Title [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Loan
        Facility 2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2021Member', window );">Loan Facility 2021 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,714<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred Stock Liquidating Preference</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[12]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract', window );"><strong>Capital Stock, Long-Term Debt, and Other Securities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SecurityTitleTextBlock', window );">Security Title [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Loan
        Facility 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2020Member', window );">Loan Facility 2020 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred Stock Liquidating Preference</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[12]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract', window );"><strong>Capital Stock, Long-Term Debt, and Other Securities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SecurityTitleTextBlock', window );">Security Title [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Loan
        Facility 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2019Member', window );">Loan Facility 2019 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred Stock Liquidating Preference</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[12]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract', window );"><strong>Capital Stock, Long-Term Debt, and Other Securities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SecurityTitleTextBlock', window );">Security Title [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Loan
        Facility 2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2018Member', window );">Loan Facility 2018 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred Stock Liquidating Preference</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[12]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract', window );"><strong>Capital Stock, Long-Term Debt, and Other Securities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SecurityTitleTextBlock', window );">Security Title [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Loan
        Facility 2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2017Member', window );">Loan Facility 2017 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred Stock Liquidating Preference</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[12]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract', window );"><strong>Capital Stock, Long-Term Debt, and Other Securities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SecurityTitleTextBlock', window );">Security Title [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Loan
        Facility 2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2016Member', window );">Loan Facility 2016 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred Stock Liquidating Preference</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[12]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract', window );"><strong>Capital Stock, Long-Term Debt, and Other Securities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SecurityTitleTextBlock', window );">Security Title [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Loan
        Facility 2016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ck0001635977_ExampleDoesNotIncludeSalesLoadMember', window );">Example Does Not Include Sales Load [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_OtherAnnualExpensesAbstract', window );"><strong>Other Annual Expenses [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ExpenseExampleYear01', window );">Expense Example, Year 01</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[13]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ExpenseExampleYears1to3', window );">Expense Example, Years 1 to 3</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[13]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ExpenseExampleYears1to5', window );">Expense Example, Years 1 to 5</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[13]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ExpenseExampleYears1to10', window );">Expense Example, Years 1 to 10</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[13]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember', window );">Example Assumes Transaction Fee Of As Percentage Of Offering Price [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_OtherAnnualExpensesAbstract', window );"><strong>Other Annual Expenses [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ExpenseExampleYear01', window );">Expense Example, Year 01</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[14]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ExpenseExampleYears1to3', window );">Expense Example, Years 1 to 3</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[14]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ExpenseExampleYears1to5', window );">Expense Example, Years 1 to 5</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[14]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ExpenseExampleYears1to10', window );">Expense Example, Years 1 to 10</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[14]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 338<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="36"></td></tr>
<tr><td colspan="36"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">If Common Shares are sold to or through underwriters, a prospectus or prospectus supplement will set forth any applicable sales load and the estimated offering expenses borne by the Fund.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The expenses of administering the Fund's Dividend Reinvestment and Stock Purchase Plan are included in "Other Expenses." You will pay brokerage charges if you direct your broker or the plan agent to sell your Shares that you acquired pursuant to the Fund's Dividend Reinvestment and Stock Purchase Plan. You may also pay a pro rata share of brokerage commissions incurred in connection with open-market purchases pursuant to the Fund's Dividend Reinvestment and Stock Purchase Plan. For more details about the Dividend Reinvestment and Stock Purchase Plan, see "Dividend Reinvestment and Stock Purchase Plan" in the Fund's Prospectus.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Offering expenses payable by the Fund will be deducted from the proceeds, before expenses, to the Fund.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">The Advisory fee is charged as a percentage of the Fund's average daily Managed Assets, as opposed to net assets. If leverage is used, Managed Assets will be greater in amount than net assets, because Managed Assets includes borrowings for investment purposes.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">The percentage in the table is based on total borrowings of $120,000,000 (the balance outstanding under the Fund's Credit Facility as of September 30, 2023, representing approximately 21.2% of the Fund's Managed Assets) and an average interest rate during the fiscal year ended September 30, 2023, of 5.77%. There can be no assurances that the Fund will be able to obtain such level of borrowing (or to maintain its current level of borrowing), that the terms under which the Fund borrows will not change, or that the Fund's use of leverage will be profitable. The Fund currently intends during the next twelve months to maintain a similar proportionate amount of borrowings but may increase such amount to 33 1/3% of the average daily value of the Fund's total assets.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">As of the close of business on October 27, 2023, the Adviser has entered into a written contract with the Fund to limit the total ordinary operating expenses of the Fund (excluding leverage costs, interest, taxes, brokerage commissions, acquired fund fees and expenses and any non-routine expenses) from exceeding 1.51% of the average daily net assets of the Fund on an annualized basis for twelve months (the "Expense Limitation Agreement").The Expense Limitation Agreement may not be terminated before October 27, 2025, without the approval of the Fund's trustees who are not "interested persons" of the Fund (as defined in the 1940 Act).The Fund may repay any such reimbursement from the Adviser, within three years of the reimbursement, provided that the following requirements are met: the reimbursements do not cause the Fund to exceed the lesser of the applicable expense limitation in the contract at the time the fees were limited or expenses are paid or
                    the applicable expense limitation in effect at the time the expenses are being recouped by the Adviser. Because interest expenses and investment related expenses are not subject to the reimbursement agreement, interest expenses and investment related expenses are included in the "Total annual expenses after expense reimbursement" line item.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">Beginning with the year ended September 30, 2023, the Fund's financial statements were audited by KPMG LLP. Previous years were audited by a different independent registered public accounting firm.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">The closing price at which the Fund's shares were traded on the exchange.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top">Per-share dollar value of the Fund, calculated by dividing the total value of all the securities in its portfolio, plus any other assets and less liabilities, by the number of Fund shares outstanding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[10]</td>
<td style="vertical-align: top;" valign="top">Data presented are with respect to a short period of time and are not indicative of future performance.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[11]</td>
<td style="vertical-align: top;" valign="top">The asset coverage ratio for the Loan Facility is calculated by dividing net assets plus the amount of any borrowings for investment purposes by the amount of any senior securities, which includes the Loan Facility, and then multiplying by $1,000.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[12]</td>
<td style="vertical-align: top;" valign="top">Not applicable because the senior securities are not registered for public trading.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[13]</td>
<td style="vertical-align: top;" valign="top">The examples above should not be considered representations of future expenses. Actual expenses may be higher or lower than those shown. The examples assume that all dividends and distributions are reinvested at net asset value. The Fund's actual rate of return may be greater or less than the hypothetical 5% return shown in the examples. For more complete descriptions of certain of the Fund's costs and expenses, see "Management of the Fund&#8212;Advisory Agreements" in the Fund's Prospectus.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[14]</td>
<td style="vertical-align: top;" valign="top">Notwithstanding this assumption, in actuality, these fees will be indirectly borne by all holders of Common Shares.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_AnnualDividendPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br> -Subparagraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_AnnualDividendPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_AnnualExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_AnnualExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_BasisOfTransactionFeesNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_BasisOfTransactionFeesNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_DividendReinvestmentAndCashPurchaseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_DividendReinvestmentAndCashPurchaseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_EffectsOfLeveragePurposeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br> -Subparagraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_EffectsOfLeveragePurposeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_EffectsOfLeverageTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br> -Subparagraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_EffectsOfLeverageTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_EffectsOfLeverageTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_EffectsOfLeverageTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ExpenseExampleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ExpenseExampleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ExpenseExampleYear01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ExpenseExampleYear01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ExpenseExampleYears1to10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ExpenseExampleYears1to10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ExpenseExampleYears1to3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ExpenseExampleYears1to3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ExpenseExampleYears1to5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ExpenseExampleYears1to5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_FeeTableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_FeeTableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_FinancialHighlightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_FinancialHighlightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_GeneralDescriptionOfRegistrantAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_GeneralDescriptionOfRegistrantAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_InterestExpensesOnBorrowingsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_InterestExpensesOnBorrowingsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_InvestmentObjectivesAndPracticesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 2<br> -Paragraph b, d<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_InvestmentObjectivesAndPracticesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_LatestPremiumDiscountToNavPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 5<br> -Paragraph c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_LatestPremiumDiscountToNavPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ManagementFeesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 7<br> -Subparagraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ManagementFeesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_NetExpenseOverAssetsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_NetExpenseOverAssetsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OtherAnnualExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OtherAnnualExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OtherAnnualExpensesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OtherAnnualExpensesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OtherTransactionExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OtherTransactionExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OtherTransactionExpensesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OtherTransactionExpensesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OtherTransactionFeesNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OtherTransactionFeesNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OutstandingSecurityHeldShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 5<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OutstandingSecurityHeldShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_PurposeOfFeeTableNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_PurposeOfFeeTableNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ReturnAtMinusFivePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br> -Subparagraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ReturnAtMinusFivePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ReturnAtMinusTenPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br> -Subparagraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ReturnAtMinusTenPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ReturnAtPlusFivePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br> -Subparagraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ReturnAtPlusFivePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ReturnAtPlusTenPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br> -Subparagraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ReturnAtPlusTenPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ReturnAtZeroPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br> -Subparagraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ReturnAtZeroPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskFactorsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskFactorsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SalesLoadPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SalesLoadPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SecurityTitleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 1<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SecurityTitleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesAverageMarketValuePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br> -Paragraph 5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesAverageMarketValuePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesCvgPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br> -Paragraph 3<br> -Subparagraph Instruction 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesCvgPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br> -Paragraph Instruction 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 1<br> -Paragraph Instruction 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ShareholderTransactionExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ShareholderTransactionExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_TotalAnnualExpensesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_TotalAnnualExpensesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_WaiversAndReimbursementsOfFeesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_WaiversAndReimbursementsOfFeesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetAssetValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net asset value per share or per unit of investments in certain entities that calculate net asset value per share. Includes, but is not limited to, by unit, membership interest, or other ownership interest. Investment includes, but is not limited to, investment in certain hedge funds, venture capital funds, private equity funds, real estate partnerships or funds. Excludes fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 54B<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482134/820-10-35-54B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 59<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482134/820-10-35-59<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480737/946-205-50-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480737/946-205-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetAssetValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_PortfolioMarketRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_PortfolioMarketRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_EquitySecuritiesRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_EquitySecuritiesRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_ConvertibleSecuritiesRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_ConvertibleSecuritiesRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_SelectionRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_SelectionRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_ConcentrationInHealthcareIndustriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_ConcentrationInHealthcareIndustriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_PharmaceuticalSectorRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_PharmaceuticalSectorRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_BiotechnologyIndustryRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_BiotechnologyIndustryRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_ManagedCareSectorRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_ManagedCareSectorRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_LifeScienceAndToolsIndustryRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_LifeScienceAndToolsIndustryRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_HealthcareTechnologySectorRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_HealthcareTechnologySectorRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_HealthcareServicesSectorRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_HealthcareServicesSectorRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_HealthcareSuppliesSectorRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_HealthcareSuppliesSectorRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_HealthcareFacilitiesSectorRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_HealthcareFacilitiesSectorRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_HealthcareEquipmentSectorRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_HealthcareEquipmentSectorRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_HealthcareDistributorsSectorRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_HealthcareDistributorsSectorRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_ForeignSecuritiesRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_ForeignSecuritiesRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_ForwardContractRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_ForwardContractRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_DerivativesRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_DerivativesRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_RisksAssociatedWithFundsOptionStrategyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_RisksAssociatedWithFundsOptionStrategyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_InterestRatesRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_InterestRatesRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_ReitRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_ReitRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_CreditDefaultRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_CreditDefaultRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_NonInvestmentGradeSecuritiesRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_NonInvestmentGradeSecuritiesRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_CounterpartyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_CounterpartyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_RegulationAsCommodityPoolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_RegulationAsCommodityPoolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_LiquidityRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_LiquidityRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_EquityLinkedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_EquityLinkedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_PrivateInvestmentInPublicEquityRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_PrivateInvestmentInPublicEquityRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_VentureCapitalInvestmentsRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_VentureCapitalInvestmentsRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_ExchangeTradedFundsRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_ExchangeTradedFundsRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_LeverageRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_LeverageRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_RestrictedSecuritiesAndValuationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_RestrictedSecuritiesAndValuationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_KeyPersonnelRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_KeyPersonnelRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_AntiTakeoverProvisionsRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_AntiTakeoverProvisionsRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_RelatedPartyTransactionsRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_RelatedPartyTransactionsRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_GovernmentInterventionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_GovernmentInterventionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_MarketDisruptionAndGeopoliticalRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_MarketDisruptionAndGeopoliticalRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_PotentialConflictsOfInterestRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_PotentialConflictsOfInterestRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001635977_LoanFacility2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ck0001635977_ExampleDoesNotIncludeSalesLoadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ck0001635977_ExampleDoesNotIncludeSalesLoadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>tm2325133d1_ncsr_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cef="http://xbrl.sec.gov/cef/2023"
  xmlns:ck0001635977="http://www.teklacap.com/20230930"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ck0001635977-20230930.xsd" xlink:type="simple"/>
    <context id="C_20221001to20230930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977PortfolioMarketRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:PortfolioMarketRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleDoesNotIncludeSalesLoadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001635977:ExampleDoesNotIncludeSalesLoadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001635977:ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20230930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977SecurityMarketRiskDiscountToNetAssetValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:SecurityMarketRiskDiscountToNetAssetValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977EquitySecuritiesRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:EquitySecuritiesRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977ConvertibleSecuritiesRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:ConvertibleSecuritiesRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977SelectionRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:SelectionRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977ConcentrationInHealthcareIndustriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:ConcentrationInHealthcareIndustriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977PharmaceuticalSectorRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:PharmaceuticalSectorRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977BiotechnologyIndustryRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:BiotechnologyIndustryRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977ManagedCareSectorRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:ManagedCareSectorRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977LifeScienceAndToolsIndustryRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:LifeScienceAndToolsIndustryRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareTechnologySectorRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:HealthcareTechnologySectorRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareServicesSectorRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:HealthcareServicesSectorRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareSuppliesSectorRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:HealthcareSuppliesSectorRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareFacilitiesSectorRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:HealthcareFacilitiesSectorRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareEquipmentSectorRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:HealthcareEquipmentSectorRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareDistributorsSectorRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:HealthcareDistributorsSectorRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977RisksAssociatedWithRegulatoryAndPolicyChangesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:RisksAssociatedWithRegulatoryAndPolicyChangesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977ForeignSecuritiesRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:ForeignSecuritiesRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977ForwardContractRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:ForwardContractRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977DerivativesRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:DerivativesRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977RisksAssociatedWithFundsOptionStrategyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:RisksAssociatedWithFundsOptionStrategyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977InterestRatesRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:InterestRatesRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977ReitRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:ReitRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977CreditDefaultRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:CreditDefaultRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977NonInvestmentGradeSecuritiesRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:NonInvestmentGradeSecuritiesRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977CounterpartyRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:CounterpartyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977RegulationAsCommodityPoolMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:RegulationAsCommodityPoolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977LiquidityRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977EquityLinkedNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:EquityLinkedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977PrivateInvestmentInPublicEquityRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:PrivateInvestmentInPublicEquityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977VentureCapitalInvestmentsRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:VentureCapitalInvestmentsRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977ExchangeTradedFundsRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:ExchangeTradedFundsRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977LeverageRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:LeverageRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977RestrictedSecuritiesAndValuationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:RestrictedSecuritiesAndValuationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977KeyPersonnelRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:KeyPersonnelRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977AntiTakeoverProvisionsRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:AntiTakeoverProvisionsRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977RelatedPartyTransactionsRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:RelatedPartyTransactionsRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977GovernmentInterventionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:GovernmentInterventionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977MarketDisruptionAndGeopoliticalRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:MarketDisruptionAndGeopoliticalRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977PotentialConflictsOfInterestRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:PotentialConflictsOfInterestRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_cefRiskAxis_ck0001635977SpecialPurposeAcquisitionCompanyRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">ck0001635977:SpecialPurposeAcquisitionCompanyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_20211001to20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20181001to20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_20210401to20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20210701to20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20211001to20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_20220401to20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220701to20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_20221001to20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20230401to20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230701to20230930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20231124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <instant>2023-11-24</instant>
        </period>
    </context>
    <context id="C_20231124to20231124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2023-11-24</startDate>
            <endDate>2023-11-24</endDate>
        </period>
    </context>
    <context id="C_20221001to20230930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_20230930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_20211001to20220930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_20220930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_20201001to20210930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20210930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20191001to20200930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20200930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20181001to20190930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20190930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_20171001to20180930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_20180930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_20161001to20170930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2017Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="C_20170930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2017Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="C_20151001to20160930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_20160930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001635977:LoanFacility2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <unit id="Percent">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USD_Per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="C_20221001to20230930" id="F20231202043944553_0">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_20221001to20230930" id="F20231202043944554_1">0001635977</dei:EntityCentralIndexKey>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="C_20221001to20230930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2023Member"
      id="Fxbrl_20231202144904787_121"
      unitRef="USD_Per_Share"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="C_20211001to20220930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2022Member"
      id="Fxbrl_20231202144904787_221"
      unitRef="USD_Per_Share"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="C_20201001to20210930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2021Member"
      id="Fxbrl_20231202144904787_321"
      unitRef="USD_Per_Share"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="C_20191001to20200930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2020Member"
      id="Fxbrl_20231202144904787_421"
      unitRef="USD_Per_Share"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="C_20181001to20190930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2019Member"
      id="Fxbrl_20231202144904787_521"
      unitRef="USD_Per_Share"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="C_20171001to20180930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2018Member"
      id="Fxbrl_20231202144904787_621"
      unitRef="USD_Per_Share"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="C_20161001to20170930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2017Member"
      id="Fxbrl_20231202144904787_721"
      unitRef="USD_Per_Share"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="C_20151001to20160930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2016Member"
      id="Fxbrl_20231202144904787_821"
      unitRef="USD_Per_Share"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_20221001to20230930"
      id="Fxbrl_20231202101255345">N-CSR</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="C_20221001to20230930"
      id="Fxbrl_20231202101303401">abrdn World Healthcare Fund</dei:EntityRegistrantName>
    <dei:DocumentPeriodEndDate
      contextRef="C_20221001to20230930"
      id="Fxbrl_20231202161342701">2023-09-30</dei:DocumentPeriodEndDate>
    <cef:InvestmentObjectivesAndPracticesTextBlock
      contextRef="C_20221001to20230930"
      id="Fxbrl_20231212021220033">

&lt;div&gt;

&lt;p style="margin:9pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Objective of the Fund&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:2pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;The Fund's investment objective is to seek
current income and long-term capital appreciation.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; &lt;span&gt;The
Fund's investment objective is to seek current income and long-term capital appreciation. The Fund invests primarily in equity and debt
securities of public and private U.S. and non-U.S. companies believed by the Fund's Investment Adviser, abrdn Inc. (as of October 27,
2023) (prior to October 27, 2023, Tekla Capital Management, LLC) (the Investment Adviser or the Adviser), to have significant potential
for above-average growth.&lt;/span&gt;&lt;span&gt;Forward
contracts may also be used for non-hedging purposes to pursue the Fund's investment objective. There is no requirement that the Fund hedge
all or any portion of its exposure to foreign currency risks.&lt;/span&gt;

&lt;div&gt;

&lt;p style="margin:6pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;(5)&#160;&#160;At-the-Market
Offering&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt 0pt 8pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The Fund has a registration
statement on file with the SEC, initially effective on December 6, 2022, authorizing the Fund to issue shares through an At-the-Market
Offering (ATM) having an aggregate value of up to $150,000,000. The offering costs associated with the Fund's ATM offering are approximately
$278,586 of which $7,478 were charged to paid-in-capital upon the issuance of associated shares and $271,108 remains in prepaid expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt 0pt 8pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;On December 14, 2022, the
Fund entered into a distribution agreement with Foreside Fund Services, LLC (Foreside), pursuant to which the Fund may offer and sell
up to $150,000,000 of shares from time to time, through Foreside as its agent, in transactions deemed to be at the market as defined in
Rule 415 under the Securities Act of 1933, as amended (the Offering). Under the Distribution Agreement, Foreside may enter into sub-placement
agent agreements with one or more selected dealers. Foreside has entered into a sub-placement agent agreement, dated December 14, 2022
(the Sub-Placement Agent Agreement), with UBS Securities LLC (UBS) relating to the shares to be offered under the Distribution Agreement.
During the year ended on September 30, 2023, 274,984 shares were sold under this agreement for $3,950,593 (net of commissions to Foreside
and UBS of $39,906).&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:11pt 0pt 2pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Investment Objective
and Policies&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;There have been no changes
in the Fund's investment objective and policies since September 30, 2022 that have not been approved by shareholders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The Fund's investment objective
is to seek current income and long-term capital appreciation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Under normal market conditions,
the Fund expects to invest at least 80% of its Managed Assets in U.S. and non-U.S. companies engaged in the healthcare industries including
equity securities and debt securities. "Managed Assets" means the total assets of the Fund (including any assets attributable to borrowings
for investment purposes) minus the sum of&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;the Fund's accrued liabilities
(other than liabilities representing borrowings for investment purposes). The Fund's 80% policy may only be changed with 60 days' prior
notice to the Fund's shareholders (the "Shareholders"). The Fund will concentrate its investments in the healthcare industries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;A company will be deemed to
be a healthcare company if, at the time the Fund makes an investment in the company, 50% or more of such company's sales, earnings or
assets arise from or are dedicated to healthcare products or services or medical technology activities. healthcare companies may include
companies in one or more of the following sub-sectors: pharmaceuticals, biotechnology, managed care, life science and tools, healthcare
technology, healthcare services, healthcare supplies, healthcare facilities, healthcare equipment, healthcare distributors and Healthcare
REITs (as defined herein). The Investment Adviser determines, in its discretion, whether a company is a healthcare company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Under normal market conditions,
the Fund expects to invest at least 40% of its Managed Assets in companies organized or located outside the United States or companies
that do a substantial amount of business outside the United States. The Fund may invest up to 5% of its Managed Assets in securities of
issuers located in emerging market countries ("Emerging Markets"). While the Fund may hedge its non-U.S. dollar exposure, it is currently
expected to do so from time to time rather than continuously. The Investment Adviser may hedge its non-U.S. dollar exposure from 0%-100%
at any given time, though it typically expects to do so between 0% and 50% of such exposure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The Fund expects to invest
60-90% of its Managed Assets in equity securities (which may include common stock, preferred stock and warrants or other rights to acquire
common or preferred stock). The Fund will invest in foreign securities and may buy and sell currencies for the purpose of settlement of
transactions in foreign securities. The Fund may invest up to 30% of its Managed Assets in convertible securities, which may include securities
that are noninvestment grade. The Fund may invest up to 20% of its Managed Assets as measured at the time of investment in non-convertible
debt securities, including corporate debt obligations and debt securities that are rated noninvestment grade (that is, rated Ba1 or lower
by Moody's Investors Service, Inc. ("Moody's"), BB+ or lower by Standard &amp;amp; Poor's Ratings Group ("S&amp;amp;P"), or BB+ by Fitch, Inc.
("Fitch") or comparably rated by another nationally recognized statistical rating organization ("NRSRO"), or, if unrated, determined by
the Investment Adviser to be of comparable credit quality) and not including convertible securities. The Fund may invest up to 15% of
its Managed Assets in non-convertible debt securities that are, at the time of investment, rated Caa1 or lower by Moody's and CCC+ or
lower by S&amp;amp;P or Fitch, or comparably rated by another nationally recognized statistical rating organization, or, if unrated, determined
by the Investment Adviser to be of comparable credit quality. Such securities are subject to a very high credit risk. The Fund's investments
in noninvestment grade investments and those deemed to be of similar quality are considered&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;speculative with respect to
the issuer's capacity to pay interest and repay principal and are commonly referred to as "junk" or "high yield" securities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The Fund may invest in derivatives,
including but not limited to options, futures, options on futures, forwards, swaps (including credit default, index, basis, total return,
volatility and currency swaps), options on swaps and other derivatives. Initially, the Fund intends to employ a strategy of writing (selling)
covered call options on a portion of the common stocks in its portfolio, writing (selling) put options on a portion of the common stocks
in its portfolio and, to a lesser extent, writing (selling) covered call and writing (selling) put options on indices of securities and
sectors of securities generally within the healthcare industry. This option strategy is intended to generate current income from option
premiums as a means to enhance distributions payable to the Fund's shareholders and will be limited to 30% of the Fund's Managed Assets.
These option strategies are not always profitable. The sale of a covered call option exposes the Fund during the term of the option to
possible loss of opportunity to realize appreciation in the market price of the underlying security or to possible loss due to continued
holding of a security that might otherwise have been sold to protect against depreciation in the market price of the security. Therefore,
the Investment Adviser may choose to decrease its use of the option writing strategy to the extent that it may negatively impact the Fund.
Other than the Fund's option strategy and use of derivatives for hedging purposes, the Fund may invest up to 10% of its Managed Assets
in derivatives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The Fund may invest up to
10% of its Managed Assets in restricted securities, including private investments in public equity ("PIPEs") and venture capital investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The Fund may invest up to
20% of its Managed Assets in healthcare REITs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The Fund may from time-to-time
lend its portfolio securities but has terminated its Securities Lending program effective July 18, 2023.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; </cef:InvestmentObjectivesAndPracticesTextBlock>
    <us-gaap:SharePrice
      contextRef="C_20230930"
      decimals="2"
      id="Fxbrl_20231202152128342"
      unitRef="USD_Per_Share">11.72</us-gaap:SharePrice>
    <us-gaap:NetAssetValuePerShare
      contextRef="C_20230930"
      decimals="2"
      id="Fxbrl_20231202152137130"
      unitRef="USD_Per_Share">11.73</us-gaap:NetAssetValuePerShare>
    <cef:LatestPremiumDiscountToNavPercent
      contextRef="C_20221001to20230930"
      decimals="4"
      id="Fxbrl_20231202152140915"
      unitRef="Percent">-0.0009</cef:LatestPremiumDiscountToNavPercent>
    <cef:AnnualDividendPayment
      contextRef="C_20221001to20230930"
      decimals="2"
      id="Fxbrl_20231202152157339"
      unitRef="USD_Per_Share">-1.4</cef:AnnualDividendPayment>
    <cef:OutstandingSecurityHeldShares
      contextRef="C_20221001to20230930"
      decimals="INF"
      id="Fxbrl_20231202101640763"
      unitRef="Shares">38113338</cef:OutstandingSecurityHeldShares>
    <us-gaap:NetAssetValuePerShare
      contextRef="C_20220930"
      decimals="2"
      id="Fxbrl_20231202121140788"
      unitRef="USD_Per_Share">12.11</us-gaap:NetAssetValuePerShare>
    <us-gaap:NetAssetValuePerShare
      contextRef="C_20210930"
      decimals="2"
      id="Fxbrl_20231202122204823"
      unitRef="USD_Per_Share">15.18</us-gaap:NetAssetValuePerShare>
    <us-gaap:NetAssetValuePerShare
      contextRef="C_20200930"
      decimals="2"
      id="Fxbrl_20231202122207946"
      unitRef="USD_Per_Share">14.14</us-gaap:NetAssetValuePerShare>
    <us-gaap:NetAssetValuePerShare
      contextRef="C_20190930"
      decimals="2"
      id="Fxbrl_20231202122211075"
      unitRef="USD_Per_Share">13.51</us-gaap:NetAssetValuePerShare>
    <us-gaap:NetAssetValuePerShare
      contextRef="C_20180930"
      decimals="2"
      id="Fxbrl_20231202122215152"
      unitRef="USD_Per_Share">15.24</us-gaap:NetAssetValuePerShare>
    <cef:AnnualDividendPayment
      contextRef="C_20221001to20230930"
      decimals="2"
      id="Fxbrl_20231202122420675"
      unitRef="USD_Per_Share">-1.4</cef:AnnualDividendPayment>
    <cef:AnnualDividendPayment
      contextRef="C_20211001to20220930"
      decimals="2"
      id="Fxbrl_20231202122524761"
      unitRef="USD_Per_Share">-1.4</cef:AnnualDividendPayment>
    <cef:AnnualDividendPayment
      contextRef="C_20201001to20210930"
      decimals="2"
      id="Fxbrl_20231202122528993"
      unitRef="USD_Per_Share">-1.4</cef:AnnualDividendPayment>
    <cef:AnnualDividendPayment
      contextRef="C_20191001to20200930"
      decimals="2"
      id="Fxbrl_20231202122532689"
      unitRef="USD_Per_Share">-1.4</cef:AnnualDividendPayment>
    <cef:AnnualDividendPayment
      contextRef="C_20181001to20190930"
      decimals="2"
      id="Fxbrl_20231202122536477"
      unitRef="USD_Per_Share">-1.4</cef:AnnualDividendPayment>
    <us-gaap:NetAssetValuePerShare
      contextRef="C_20230930"
      decimals="2"
      id="Fxbrl_20231202122222386"
      unitRef="USD_Per_Share">11.73</us-gaap:NetAssetValuePerShare>
    <us-gaap:NetAssetValuePerShare
      contextRef="C_20220930"
      decimals="2"
      id="Fxbrl_20231202122231928"
      unitRef="USD_Per_Share">12.11</us-gaap:NetAssetValuePerShare>
    <us-gaap:NetAssetValuePerShare
      contextRef="C_20210930"
      decimals="2"
      id="Fxbrl_20231202122236013"
      unitRef="USD_Per_Share">15.18</us-gaap:NetAssetValuePerShare>
    <us-gaap:NetAssetValuePerShare
      contextRef="C_20200930"
      decimals="2"
      id="Fxbrl_20231202122240267"
      unitRef="USD_Per_Share">14.14</us-gaap:NetAssetValuePerShare>
    <us-gaap:NetAssetValuePerShare
      contextRef="C_20190930"
      decimals="2"
      id="Fxbrl_20231202122244532"
      unitRef="USD_Per_Share">13.51</us-gaap:NetAssetValuePerShare>
    <us-gaap:SharePrice
      contextRef="C_20230930"
      decimals="2"
      id="Fxbrl_20231202122946590"
      unitRef="USD_Per_Share">11.72</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_20220930"
      decimals="2"
      id="Fxbrl_20231202123346350"
      unitRef="USD_Per_Share">12.86</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_20210930"
      decimals="2"
      id="Fxbrl_20231202123354810"
      unitRef="USD_Per_Share">16.45</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_20200930"
      decimals="2"
      id="Fxbrl_20231202123359044"
      unitRef="USD_Per_Share">14.33</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_20190930"
      decimals="2"
      id="Fxbrl_20231202123402921"
      unitRef="USD_Per_Share">13.44</us-gaap:SharePrice>
    <cef:PurposeOfFeeTableNoteTextBlock
      contextRef="C_20221001to20230930"
      id="Fxbrl_20231202141321175">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The purpose of the following
table and the example below is to help you understand the fees and expenses that holders of Common Shares ("Common Shareholders") would
bear directly or indirectly. The expenses shown in the table under "Other expenses," "Interest expenses on bank borrowings," "Total annual
expenses" and "Total annual expenses after expense reimbursement" are based on the Fund's capital structure as of September 30, 2023.
As of September 30, 2023, the Fund had $120,000,000 of leverage outstanding through bank borrowings which represented 21.2% of the Managed
Assets as of September 30, 2023. The table reflects Fund expenses as a percentage of net assets attributable to Common Shares. The following
table should not be considered a representation of the Fund's future expenses. Actual expenses may be greater or less than those shown
below.&lt;/span&gt;&lt;/p&gt; </cef:PurposeOfFeeTableNoteTextBlock>
    <cef:ShareholderTransactionExpensesTableTextBlock
      contextRef="C_20221001to20230930"
      id="Fxbrl_20231202141330946">

&lt;div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:8pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:182"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Shareholder transaction expenses&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:8pt .7pt 0pt 0pt;vertical-align:bottom;width:133"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:182;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;Sales load (as
        a percentage of offering price)&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:103;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;1.00&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:182"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;Offering expenses (as
        a percentage of offering price)&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:103"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;0.19&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:182;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;Dividend reinvestment and Stock Repurchase
        Plan Fees&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:103;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;None&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:4pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;(1) If Common Shares are sold
to or through underwriters, a prospectus or prospectus supplement will set forth any applicable sales load and the estimated offering
expenses borne by the Fund.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:2pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;(2) Offering expenses payable
by the Fund will be deducted from the proceeds, before expenses, to the Fund.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:2pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;(3) The
expenses of administering the Fund's Dividend Reinvestment and Stock Purchase Plan are included in "Other Expenses." You will pay brokerage
charges if you direct your broker or the plan agent to sell your Shares that you acquired pursuant to the Fund's Dividend Reinvestment
and Stock Purchase Plan. You may also pay a pro rata share of brokerage commissions incurred in connection with open-market purchases
pursuant to the Fund's Dividend Reinvestment and Stock Purchase Plan. For more details about the Dividend Reinvestment and Stock Purchase
Plan, see "Dividend Reinvestment and Stock Purchase Plan" in the Fund's Prospectus.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; </cef:ShareholderTransactionExpensesTableTextBlock>
    <cef:BasisOfTransactionFeesNoteTextBlock
      contextRef="C_20221001to20230930"
      id="Fxbrl_20231202144737369">as
        a percentage of offering price</cef:BasisOfTransactionFeesNoteTextBlock>
    <cef:SalesLoadPercent
      contextRef="C_20221001to20230930"
      decimals="4"
      id="Fxbrl_20231202131712153"
      unitRef="Percent">0.01</cef:SalesLoadPercent>
    <cef:BasisOfTransactionFeesNoteTextBlock
      contextRef="C_20221001to20230930"
      id="Fxbrl_20231202144758996">as
        a percentage of offering price</cef:BasisOfTransactionFeesNoteTextBlock>
    <cef:OtherTransactionExpensesPercent
      contextRef="C_20221001to20230930"
      decimals="4"
      id="Fxbrl_20231202131721229"
      unitRef="Percent">0.0019</cef:OtherTransactionExpensesPercent>
    <cef:DividendReinvestmentAndCashPurchaseFees
      contextRef="C_20221001to20230930"
      decimals="0"
      id="Fxbrl_20231202131724023"
      unitRef="USD">0</cef:DividendReinvestmentAndCashPurchaseFees>
    <cef:AnnualExpensesTableTextBlock
      contextRef="C_20221001to20230930"
      id="Fxbrl_20231202141339022">

&lt;div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%" width="100%"&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:8pt .7pt 0pt 0pt;vertical-align:bottom;width:182"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:8pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:133"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Annual
        expenses&lt;/strong&gt;&lt;/span&gt;&lt;br/&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;(as a percentage of net&lt;br/&gt;assets&lt;/strong&gt;&lt;/span&gt;&lt;br/&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;attributable
        to&lt;/strong&gt;&lt;/span&gt;&lt;br/&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Common Shares)&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:90%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;Advisory fee&lt;sup&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:6%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;1.24&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1.5%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:0.5%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:90%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;Interest expenses on bank borrowings&lt;sup&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:6%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;1.45&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1.5%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:90%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;Other expenses&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:6%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;0.30&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1.5%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:0.5%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:90%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;Total annual expenses&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:6%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;2.99&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1.5%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:90%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;Less: expense reimbursement&lt;sup&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:6%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;0.03&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:1.5%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:0.5%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:90%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;Total annual expenses after expense reimbursement&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255);width:6%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;2.96&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt 0.7pt 0pt 0pt;text-align:left;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1.5%"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.5%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:2pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;(4) The Advisory fee is charged
as a percentage of the Fund's average daily Managed Assets, as opposed to net assets. If leverage is used, Managed Assets will be greater
in amount than net assets, because Managed Assets includes borrowings for investment purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:2pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;(5) The percentage in the table
is based on total borrowings of $120,000,000 (the balance outstanding under the Fund's Credit Facility as of September 30, 2023, representing
approximately 21.2% of the Fund's Managed Assets) and an average interest rate during the fiscal year ended September 30, 2023, of 5.77%.
There can be no assurances that the Fund will be able to obtain such level of borrowing (or to maintain its current level of borrowing),
that the terms under which the Fund borrows will not change, or that the Fund's use of leverage will be profitable. The Fund currently
intends during the next twelve months to maintain a similar proportionate amount of borrowings but may increase such amount to 33 1/3%
of the average daily value of the Fund's total assets.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;(6) As of the close of business
on October 27, 2023, the Adviser has entered into a written contract with the Fund to limit the total ordinary operating expenses of the
Fund (excluding leverage costs, interest, taxes, brokerage commissions, acquired fund fees and expenses and any non-routine expenses)
from exceeding 1.51% of the average daily net assets of the Fund on an annualized basis for twelve months (the "Expense Limitation Agreement").The
Expense Limitation Agreement may not be terminated before October 27, 2025, without the approval of the Fund's trustees who are not "interested
persons" of the Fund (as defined in the 1940 Act).The Fund may repay any such reimbursement from the Adviser, within three years of the
reimbursement, provided that the following requirements are met: the reimbursements do not cause the Fund to exceed the lesser of the
applicable expense limitation in the contract at the time the fees were limited or expenses are paid or the applicable expense limitation
in effect at the time the expenses are being recouped by the Adviser. Because interest expenses and investment related expenses are not
subject to the reimbursement agreement, interest expenses and investment related expenses are included in the "Total annual expenses after
expense reimbursement" line item.&lt;/span&gt;&lt;/p&gt; </cef:AnnualExpensesTableTextBlock>
    <cef:ManagementFeesPercent
      contextRef="C_20221001to20230930"
      decimals="4"
      id="Fxbrl_20231202131857489"
      unitRef="Percent">0.0124</cef:ManagementFeesPercent>
    <cef:InterestExpensesOnBorrowingsPercent
      contextRef="C_20221001to20230930"
      decimals="4"
      id="Fxbrl_20231202131859366"
      unitRef="Percent">0.0145</cef:InterestExpensesOnBorrowingsPercent>
    <cef:OtherAnnualExpensesPercent
      contextRef="C_20221001to20230930"
      decimals="4"
      id="Fxbrl_20231202131901664"
      unitRef="Percent">0.003</cef:OtherAnnualExpensesPercent>
    <cef:TotalAnnualExpensesPercent
      contextRef="C_20221001to20230930"
      decimals="4"
      id="Fxbrl_20231202131904127"
      unitRef="Percent">0.0299</cef:TotalAnnualExpensesPercent>
    <cef:WaiversAndReimbursementsOfFeesPercent
      contextRef="C_20221001to20230930"
      decimals="4"
      id="Fxbrl_20231202131906133"
      unitRef="Percent">0.0003</cef:WaiversAndReimbursementsOfFeesPercent>
    <cef:NetExpenseOverAssetsPercent
      contextRef="C_20221001to20230930"
      decimals="4"
      id="Fxbrl_20231202131908324"
      unitRef="Percent">0.0296</cef:NetExpenseOverAssetsPercent>
    <cef:OtherTransactionFeesNoteTextBlock
      contextRef="C_20221001to20230930"
      id="Fxbrl_20231202144846957">The
expenses of administering the Fund's Dividend Reinvestment and Stock Purchase Plan are included in "Other Expenses." You will pay brokerage
charges if you direct your broker or the plan agent to sell your Shares that you acquired pursuant to the Fund's Dividend Reinvestment
and Stock Purchase Plan. You may also pay a pro rata share of brokerage commissions incurred in connection with open-market purchases
pursuant to the Fund's Dividend Reinvestment and Stock Purchase Plan. For more details about the Dividend Reinvestment and Stock Purchase
Plan, see "Dividend Reinvestment and Stock Purchase Plan" in the Fund's Prospectus.</cef:OtherTransactionFeesNoteTextBlock>
    <cef:ExpenseExampleTableTextBlock
      contextRef="C_20221001to20230930"
      id="Fxbrl_20231202142243683">

&lt;div&gt;

&lt;p style="margin:11pt 0pt 2pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Example&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The following examples illustrate
the expenses you would pay on a $1,000 investment in common shares assuming that (i) all dividends and other distributions are reinvested
at NAV (ii) the percentage amounts listed under "Total annual expenses" above remain the same in the years shown and (iii) a 5% annual
portfolio total return.&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 8pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The following example does
not include the sales load:&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0"&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:60"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;1
        Year&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:63"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;3 Years&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:63"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;5 Years&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:67"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;10 Years&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:33;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;30&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:36;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;92&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:36;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;157&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:40;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;330&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin:8pt 0pt 8pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The following example assumes
a transaction fee of 1.19%, as a percentage of the offering price, as if it were borne solely by you, as purchaser&lt;sup&gt;(2)&lt;/sup&gt;:&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0"&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:60"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;1
        Year&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:63"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;3 Years&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:63"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;5 Years&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:67"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;10 Years&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:33;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;41&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:36;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;103&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:36;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;167&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:40;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;338&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin:4pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;(1) &lt;/span&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;The
examples above should not be considered representations of future expenses. Actual expenses may be higher or lower than those shown.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;
The examples assume that all dividends and distributions are reinvested at net asset value. The Fund's actual rate of return may be greater
or less than the hypothetical 5% return shown in the examples. For more complete descriptions of certain of the Fund's costs and expenses,
see "Management of the Fund&#x2014;Advisory Agreements" in the Fund's Prospectus.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:2pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;(2) Notwithstanding this assumption,
in actuality, these fees will be indirectly borne by all holders of Common Shares.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; &lt;/div&gt; </cef:ExpenseExampleTableTextBlock>
    <cef:ExpenseExampleYear01
      contextRef="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleDoesNotIncludeSalesLoadMember"
      decimals="0"
      id="Fxbrl_20231202141040228"
      unitRef="USD">30</cef:ExpenseExampleYear01>
    <cef:ExpenseExampleYears1to3
      contextRef="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleDoesNotIncludeSalesLoadMember"
      decimals="0"
      id="Fxbrl_20231202141050909"
      unitRef="USD">92</cef:ExpenseExampleYears1to3>
    <cef:ExpenseExampleYears1to5
      contextRef="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleDoesNotIncludeSalesLoadMember"
      decimals="0"
      id="Fxbrl_20231202141048194"
      unitRef="USD">157</cef:ExpenseExampleYears1to5>
    <cef:ExpenseExampleYears1to10
      contextRef="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleDoesNotIncludeSalesLoadMember"
      decimals="0"
      id="Fxbrl_20231202141045406"
      unitRef="USD">330</cef:ExpenseExampleYears1to10>
    <cef:ExpenseExampleYear01
      contextRef="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember"
      decimals="0"
      id="Fxbrl_20231202141100037"
      unitRef="USD">41</cef:ExpenseExampleYear01>
    <cef:ExpenseExampleYears1to3
      contextRef="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember"
      decimals="0"
      id="Fxbrl_20231202141102284"
      unitRef="USD">103</cef:ExpenseExampleYears1to3>
    <cef:ExpenseExampleYears1to5
      contextRef="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember"
      decimals="0"
      id="Fxbrl_20231202141104669"
      unitRef="USD">167</cef:ExpenseExampleYears1to5>
    <cef:ExpenseExampleYears1to10
      contextRef="C_20221001to20230930_usgaapStatementClassOfStockAxis_ck0001635977ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember"
      decimals="0"
      id="Fxbrl_20231202141106886"
      unitRef="USD">338</cef:ExpenseExampleYears1to10>
    <cef:SeniorSecuritiesNoteTextBlock
      contextRef="C_20221001to20230930"
      id="Fxbrl_20231202144429534">

&lt;div&gt;

&lt;p style="margin:11pt 0pt 2pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Senior Securities&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The following table sets forth
information about the Fund's outstanding senior securities as of the end of each of the Fund's last eight fiscal years. The Fund's senior
securities during this time period are comprised of borrowings which constitutes a "senior security" as defined in the 1940 Act. The information
in this table for the fiscal years ended 2022, 2021, 2020, 2019 and 2018 has been audited by a predecessor, independent registered public
accounting firm, and fiscal year ended 2023 has been audited by KPMG LLP, independent registered&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 8pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;public accounting firm. The Fund's
audited financial statements, including the report of KPMG LLP thereon, and accompanying notes thereto, are included in this Annual Report.&lt;/span&gt;&lt;/p&gt;


&lt;div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:67"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Fiscal
        Period&#160;&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Ended&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:62"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Title of Security&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Total
        Principal&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Amount&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Outstanding&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Aggregate&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Liquidation&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Preference&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Liquidation&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Preference&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Per
        Share&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Asset
        Coverage&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Per
        $1,000&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;of
        Principal&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Amount&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Average&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Market
        Value&lt;/strong&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;sup style="margin-top:0pt;margin-bottom:0pt"&gt;(2)&lt;/sup&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;September 30, 2023&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;Loan
        Facility 2023&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;120,000,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;4,726&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20231202144904787_121"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;September 30, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;Loan
        Facility 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;120,000,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;4,786&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20231202144904787_221"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;September 30, 2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;Loan
        Facility 2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;120,000,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;5,714&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20231202144904787_321"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;September 30, 2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;Loan
        Facility 2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;120,000,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;4,554&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20231202144904787_421"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;September 30, 2019&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;Loan
        Facility 2019&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;120,000,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;4,396&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20231202144904787_521"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;September 30, 2018&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;Loan
        Facility 2018&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;120,000,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;4,861&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20231202144904787_621"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;September 30, 2017&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;Loan
        Facility 2017&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;120,000,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;4,999&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20231202144904787_721"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;September 30, 2016&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;Loan
        Facility 2016&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;120,000,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;5,160&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20231202144904787_821"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin:4pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;(1) The asset coverage ratio
for the Loan Facility is calculated by dividing net assets plus the amount of any borrowings for investment purposes by the amount of
any senior securities, which includes the Loan Facility, and then multiplying by $1,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:2pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;(2) Not applicable because
the senior securities are not registered for public trading.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt; </cef:SeniorSecuritiesNoteTextBlock>
    <cef:SeniorSecuritiesTableTextBlock
      contextRef="C_20221001to20230930"
      id="Fxbrl_20231202144536403">

&lt;div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;vertical-align:bottom;width:67"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Fiscal
        Period&#160;&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Ended&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;vertical-align:bottom;width:62"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Title of Security&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Total
        Principal&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Amount&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Outstanding&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Aggregate&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Liquidation&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Preference&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Liquidation&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Preference&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Per
        Share&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Asset
        Coverage&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Per
        $1,000&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;of
        Principal&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Amount&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Average&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Market
        Value&lt;/strong&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;sup style="margin-top:0pt;margin-bottom:0pt"&gt;(2)&lt;/sup&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;September 30, 2023&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;Loan
        Facility 2023&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;120,000,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;4,726&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20231202144904787_121"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;September 30, 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;Loan
        Facility 2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;120,000,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;4,786&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20231202144904787_221"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;September 30, 2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;Loan
        Facility 2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;120,000,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;5,714&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20231202144904787_321"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;September 30, 2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;Loan
        Facility 2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;120,000,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;4,554&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20231202144904787_421"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;September 30, 2019&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;Loan
        Facility 2019&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;120,000,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;4,396&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20231202144904787_521"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;September 30, 2018&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;Loan
        Facility 2018&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;120,000,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;4,861&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20231202144904787_621"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;September 30, 2017&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;Loan
        Facility 2017&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;120,000,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;4,999&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20231202144904787_721"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:67"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;September 30, 2016&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:62"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;Loan
        Facility 2016&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:57"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;120,000,000&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:49"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:19"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;5,160&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:22"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:61"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20231202144904787_821"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:2pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin:4pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;(1) The asset coverage ratio
for the Loan Facility is calculated by dividing net assets plus the amount of any borrowings for investment purposes by the amount of
any senior securities, which includes the Loan Facility, and then multiplying by $1,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:2pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:7pt;font-family:Arial, Helvetica"&gt;(2) Not applicable because
the senior securities are not registered for public trading.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; </cef:SeniorSecuritiesTableTextBlock>
    <cef:SecurityTitleTextBlock
      contextRef="C_20221001to20230930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2023Member"
      id="Fxbrl_20231202144904787_12">Loan
        Facility 2023</cef:SecurityTitleTextBlock>
    <cef:SeniorSecuritiesAmt
      contextRef="C_20230930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2023Member"
      decimals="0"
      id="Fxbrl_20231202144904787_15"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmt>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="C_20230930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2023Member"
      decimals="0"
      id="Fxbrl_20231202144904787_113"
      unitRef="USD_Per_Share">0</us-gaap:PreferredStockLiquidationPreference>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="C_20230930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2023Member"
      decimals="0"
      id="Fxbrl_20231202144904787_117"
      unitRef="USD_Per_Share">4726</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SecurityTitleTextBlock
      contextRef="C_20211001to20220930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2022Member"
      id="Fxbrl_20231202144904787_22">Loan
        Facility 2022</cef:SecurityTitleTextBlock>
    <cef:SeniorSecuritiesAmt
      contextRef="C_20220930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2022Member"
      decimals="0"
      id="Fxbrl_20231202144904787_25"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmt>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="C_20220930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2022Member"
      decimals="0"
      id="Fxbrl_20231202144904787_213"
      unitRef="USD_Per_Share">0</us-gaap:PreferredStockLiquidationPreference>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="C_20220930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2022Member"
      decimals="0"
      id="Fxbrl_20231202144904787_217"
      unitRef="USD_Per_Share">4786</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SecurityTitleTextBlock
      contextRef="C_20201001to20210930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2021Member"
      id="Fxbrl_20231202144904787_32">Loan
        Facility 2021</cef:SecurityTitleTextBlock>
    <cef:SeniorSecuritiesAmt
      contextRef="C_20210930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2021Member"
      decimals="0"
      id="Fxbrl_20231202144904787_35"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmt>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="C_20210930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2021Member"
      decimals="0"
      id="Fxbrl_20231202144904787_313"
      unitRef="USD_Per_Share">0</us-gaap:PreferredStockLiquidationPreference>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="C_20210930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2021Member"
      decimals="0"
      id="Fxbrl_20231202144904787_317"
      unitRef="USD_Per_Share">5714</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SecurityTitleTextBlock
      contextRef="C_20191001to20200930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2020Member"
      id="Fxbrl_20231202144904787_42">Loan
        Facility 2020</cef:SecurityTitleTextBlock>
    <cef:SeniorSecuritiesAmt
      contextRef="C_20200930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2020Member"
      decimals="0"
      id="Fxbrl_20231202144904787_45"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmt>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="C_20200930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2020Member"
      decimals="0"
      id="Fxbrl_20231202144904787_413"
      unitRef="USD_Per_Share">0</us-gaap:PreferredStockLiquidationPreference>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="C_20200930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2020Member"
      decimals="0"
      id="Fxbrl_20231202144904787_417"
      unitRef="USD_Per_Share">4554</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SecurityTitleTextBlock
      contextRef="C_20181001to20190930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2019Member"
      id="Fxbrl_20231202144904787_52">Loan
        Facility 2019</cef:SecurityTitleTextBlock>
    <cef:SeniorSecuritiesAmt
      contextRef="C_20190930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2019Member"
      decimals="0"
      id="Fxbrl_20231202144904787_55"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmt>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="C_20190930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2019Member"
      decimals="0"
      id="Fxbrl_20231202144904787_513"
      unitRef="USD_Per_Share">0</us-gaap:PreferredStockLiquidationPreference>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="C_20190930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2019Member"
      decimals="0"
      id="Fxbrl_20231202144904787_517"
      unitRef="USD_Per_Share">4396</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SecurityTitleTextBlock
      contextRef="C_20171001to20180930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2018Member"
      id="Fxbrl_20231202144904787_62">Loan
        Facility 2018</cef:SecurityTitleTextBlock>
    <cef:SeniorSecuritiesAmt
      contextRef="C_20180930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2018Member"
      decimals="0"
      id="Fxbrl_20231202144904787_65"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmt>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="C_20180930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2018Member"
      decimals="0"
      id="Fxbrl_20231202144904787_613"
      unitRef="USD_Per_Share">0</us-gaap:PreferredStockLiquidationPreference>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="C_20180930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2018Member"
      decimals="0"
      id="Fxbrl_20231202144904787_617"
      unitRef="USD_Per_Share">4861</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SecurityTitleTextBlock
      contextRef="C_20161001to20170930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2017Member"
      id="Fxbrl_20231202144904787_72">Loan
        Facility 2017</cef:SecurityTitleTextBlock>
    <cef:SeniorSecuritiesAmt
      contextRef="C_20170930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2017Member"
      decimals="0"
      id="Fxbrl_20231202144904787_75"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmt>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="C_20170930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2017Member"
      decimals="0"
      id="Fxbrl_20231202144904787_713"
      unitRef="USD_Per_Share">0</us-gaap:PreferredStockLiquidationPreference>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="C_20170930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2017Member"
      decimals="0"
      id="Fxbrl_20231202144904787_717"
      unitRef="USD_Per_Share">4999</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SecurityTitleTextBlock
      contextRef="C_20151001to20160930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2016Member"
      id="Fxbrl_20231202144904787_82">Loan
        Facility 2016</cef:SecurityTitleTextBlock>
    <cef:SeniorSecuritiesAmt
      contextRef="C_20160930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2016Member"
      decimals="0"
      id="Fxbrl_20231202144904787_85"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmt>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="C_20160930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2016Member"
      decimals="0"
      id="Fxbrl_20231202144904787_813"
      unitRef="USD_Per_Share">0</us-gaap:PreferredStockLiquidationPreference>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="C_20160930_usgaapDebtInstrumentAxis_ck0001635977LoanFacility2016Member"
      decimals="0"
      id="Fxbrl_20231202144904787_817"
      unitRef="USD_Per_Share">5160</cef:SeniorSecuritiesCvgPerUnit>
    <cef:LatestPremiumDiscountToNavPercent
      contextRef="C_20201001to20201231"
      decimals="4"
      id="Fxbrl_20231202125337432"
      unitRef="Percent">0.0136</cef:LatestPremiumDiscountToNavPercent>
    <cef:LatestPremiumDiscountToNavPercent
      contextRef="C_20210101to20210331"
      decimals="4"
      id="Fxbrl_20231202131545225_323"
      unitRef="Percent">-0.0232</cef:LatestPremiumDiscountToNavPercent>
    <cef:LatestPremiumDiscountToNavPercent
      contextRef="C_20210401to20210630"
      decimals="4"
      id="Fxbrl_20231202131545225_423"
      unitRef="Percent">-0.0191</cef:LatestPremiumDiscountToNavPercent>
    <cef:LatestPremiumDiscountToNavPercent
      contextRef="C_20210701to20210930"
      decimals="4"
      id="Fxbrl_20231202131545225_523"
      unitRef="Percent">0.044</cef:LatestPremiumDiscountToNavPercent>
    <cef:LatestPremiumDiscountToNavPercent
      contextRef="C_20211001to20211231"
      decimals="4"
      id="Fxbrl_20231202131545225_723"
      unitRef="Percent">0.0515</cef:LatestPremiumDiscountToNavPercent>
    <cef:LatestPremiumDiscountToNavPercent
      contextRef="C_20220101to20220331"
      decimals="4"
      id="Fxbrl_20231202131545225_823"
      unitRef="Percent">-0.0411</cef:LatestPremiumDiscountToNavPercent>
    <cef:LatestPremiumDiscountToNavPercent
      contextRef="C_20220401to20220630"
      decimals="4"
      id="Fxbrl_20231202131545225_923"
      unitRef="Percent">0.129</cef:LatestPremiumDiscountToNavPercent>
    <cef:LatestPremiumDiscountToNavPercent
      contextRef="C_20220701to20220930"
      decimals="4"
      id="Fxbrl_20231202131545225_1023"
      unitRef="Percent">0.0691</cef:LatestPremiumDiscountToNavPercent>
    <cef:LatestPremiumDiscountToNavPercent
      contextRef="C_20221001to20221231"
      decimals="4"
      id="Fxbrl_20231202131545225_1223"
      unitRef="Percent">0.0353</cef:LatestPremiumDiscountToNavPercent>
    <cef:LatestPremiumDiscountToNavPercent
      contextRef="C_20230101to20230331"
      decimals="4"
      id="Fxbrl_20231202131545225_1323"
      unitRef="Percent">0.0793</cef:LatestPremiumDiscountToNavPercent>
    <cef:LatestPremiumDiscountToNavPercent
      contextRef="C_20230401to20230630"
      decimals="4"
      id="Fxbrl_20231202131545225_1423"
      unitRef="Percent">0.0776</cef:LatestPremiumDiscountToNavPercent>
    <cef:LatestPremiumDiscountToNavPercent
      contextRef="C_20230701to20230930"
      decimals="4"
      id="Fxbrl_20231202131545225_1523"
      unitRef="Percent">-0.0076</cef:LatestPremiumDiscountToNavPercent>
    <us-gaap:NetAssetValuePerShare
      contextRef="C_20231124"
      decimals="2"
      id="Fxbrl_20231202132832075"
      unitRef="USD_Per_Share">11.44</us-gaap:NetAssetValuePerShare>
    <us-gaap:SharePrice
      contextRef="C_20231124"
      decimals="2"
      id="Fxbrl_20231202132839890"
      unitRef="USD_Per_Share">11.28</us-gaap:SharePrice>
    <cef:LatestPremiumDiscountToNavPercent
      contextRef="C_20231124to20231124"
      decimals="4"
      id="Fxbrl_20231202132847426"
      unitRef="Percent">-0.0142</cef:LatestPremiumDiscountToNavPercent>
    <cef:RiskFactorsTableTextBlock
      contextRef="C_20221001to20230930"
      id="Fxbrl_20231202102330071">

&lt;div&gt;

&lt;p style="margin:11pt 0pt 2pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Risk Factors&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 10pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Investing in any investment company
security involves risk, including the risk that you may receive little or no return on your investment or even that you may lose part
or all of your investment. Investors should consider the following Risk Factors and special considerations associated with investing in
the Fund's shares.&lt;/span&gt;&lt;/p&gt; &lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Portfolio&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Market Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
As with any investment company that invests in equity securities, the Fund is subject to market risk&#x2014;the possibility that the prices
of equity securities will&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;decline over short or extended
periods of time. As a result, the value of an investment in the Fund's shares will fluctuate with the market. You could lose some or all
of your investment over short or long periods of time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Political and economic news
can influence market-wide trends and can cause disruptions in the U.S. or world financial markets. Other factors may be ignored by the
market as a whole but may cause movements in the price of one company's stock or the stock of companies in one or more industries. All
of these factors may have a greater impact on initial public offerings and emerging company shares.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;


&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Security Market Risk&#x2014;Discount
to NAV.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Shares of closed-end investment companies frequently
trade at a discount from their NAV. This characteristic is a risk separate and distinct from the risk that the Fund's NAV per share could
decrease as a result of its investment activities and may be greater for investors expecting to sell their shares in a relatively short
period of time following completion of this offering. Although the value of the Fund's net assets is generally considered by market participants
in determining whether to purchase or sell shares, whether investors will realize gains or losses upon the sale of the shares will depend
entirely upon whether the market price of the shares at the time of sale is above or below the investor's purchase price for the shares.
Because the market price of the shares will be determined by supply of and demand for the shares which will be affected by factors such
as (i) NAV, (ii) dividend and distribution levels and their stability (which will in turn be affected by levels of dividend and interest
payments by the Fund's portfolio holdings, the timing and success of the Fund's investment strategies, regulations affecting the timing
and character of Fund distributions, Fund expenses and other factors), (iii) trading volume of the shares, (iv) general market, interest
rate and economic conditions and (v) other factors that may be beyond the control of the Fund. The Fund cannot predict whether the shares
will trade at, below or above NAV or at, below or above the initial public offering price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Equity Securities
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The Fund expects to invest 60-90% of its Managed Assets
in equity securities. Equity risk is the risk that equity securities held by the Fund will fall due to general market or economic conditions,
perceptions regarding the industries in which the issuers of securities held by the Fund participate, changes in interest rates, and the
particular circumstances and performance of particular companies whose securities the Fund holds. The price of an equity security of an
issuer may be particularly sensitive to general movements in the stock market, or a drop in the stock market may depress the price of
most or all of the equity securities held by the Fund. In addition, equity securities held by the Fund may decline in price if the issuer
fails to make anticipated distributions or dividend payments because, among other reasons, the issuer experiences a decline in its financial
condition. The Fund's expected investments in preferred stocks carries its own unique risks. Preferred stocks are typically subordinated
to bonds and other debt instruments in a company's capital structure, in terms of priority to corporate income, and therefore will be
subject to greater credit risk than those debt instruments. In addition, unlike interest payments on debt securities,&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;preferred stock dividends
are payable only if declared by the issuer's board of directors. The prices of preferred stock also tend to move upwards slower than common
stock prices and the preferred stock may be substantially less liquid than common stock or other securities.&lt;/span&gt;&lt;/p&gt;


&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Convertible Securities
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Convertible Securities generally offer lower interest
or dividend yields than nonconvertible debt securities of similar quality. The market value of convertible securities tends to decline
as interest rates increase and, conversely, tends to increase as interest rates decline. In addition, because of the conversion feature,
the market value of convertible securities tends to vary with fluctuations in the market value of the underlying common stock. When the
market price of the underlying common stock approaches or is greater than the convertible security's conversion price, the prices of the
convertible securities tend to rise as a reflection of the value of the underlying common stock. The conversion prior is defined as the
predetermined price at which the convertible security could be exchanged for the associated stock. Consequently, a unique feature of convertible
securities is that as the market price of the underlying common stock declines, convertible securities tend to trade increasingly on a
yield basis, and so may not experience market value declines to the same extent as the underlying common stock. Investments in convertible
securities generally entail less risk than investments in common stock of the same issuer but more risk than the issuer's debt obligations.&lt;/span&gt;&lt;/p&gt;


&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Selection Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
Different types of equity securities tend to shift into and out of favor with investors, depending on market and economic conditions.
The performance of funds that invest in healthcare industry equity securities may at times be better or worse than the performance of
funds that focus on other types of securities or that have a broader investment style.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Concentration in the
Healthcare Industries.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Under normal market conditions, the Fund
expects to invest at least 80% of its Managed Assets in securities of healthcare companies. As a result, the Fund's portfolio will likely
be more sensitive to, and possibly more adversely affected by, regulatory, economic or political factors or trends relating to the healthcare,
agricultural and environmental technology industries than a portfolio of companies representing a larger number of industries. The risk
is in addition to the risks normally associated with any strategy seeking capital appreciation by investing in a portfolio of equity securities.
As a result of its concentration policy, the Fund's investments may be subject to greater risk and market fluctuation than a fund that
has securities representing a broader range of investments. The healthcare industries can be volatile. The Fund may occasionally make
investments in a company with the objective of controlling or influencing the management and policies of that company, which could potentially
make the Fund more susceptible to declines in the value of the company's stock. The Investment Adviser may seek control in public companies
only occasionally and most often in companies with a small capitalization.&lt;/span&gt;&lt;/p&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Healthcare companies have in the
past been characterized by limited product focus, rapidly changing technology and extensive government regulation. In particular, technological
advances can render an existing product, which may account for a disproportionate share of a company's revenue, obsolete. Obtaining governmental
approval from U.S. governmental agencies such as the Food and Drug Administration (the "FDA"), and from non-U.S. governmental agencies
for new products can be lengthy, expensive and uncertain as to outcome. Such delays in product development may result in the need to seek
additional capital, potentially diluting the interests of existing investors such as the Fund. In addition, governmental agencies may,
for a variety of reasons, restrict the release of certain innovative technologies of commercial significance. These various factors may
result in abrupt advances and declines in the securities prices of particular companies and, in some cases, may have a broad effect on
the prices of securities of companies in particular healthcare industries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;A concentration of investments
in any healthcare industry or in healthcare companies generally may increase the risk and volatility of an investment company's portfolio.
Such volatility is not limited to the biotechnology industry, and companies in other industries may be subject to similar abrupt movements
in the market prices of their securities. No assurance can be given that future declines in the market prices of securities of companies
in the industries in which the Fund may invest will not occur, or that such declines will not adversely affect the NAV or the price of
the shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Intense competition exists
within and among certain healthcare industries, including competition to obtain and sustain proprietary technology protection, including
patents, trademarks and other intellectual property rights, upon which healthcare companies can be highly dependent for maintenance of
profit margins and market exclusivity. The complex nature of the technologies involved can lead to patent disputes, including litigation
that may be costly and that could result in a company losing an exclusive right to a patent.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;With respect to healthcare
industries, cost containment measures already implemented by national governments, state or provincial governments and the private sector
have adversely affected certain sectors of these industries. The implementation of the Affordable Care Act ("ACA") has created increased
demand for healthcare products and services, but potential changes to the ACA and future healthcare laws and regulations may impact demand
for healthcare products and services and has had or may have an adverse effect on some companies in the healthcare industries. Increased
emphasis on managed care in the United States and a shift toward value based payment models may put pressure on the price and usage of
products sold by healthcare companies in which the Fund may invest and may adversely affect the sales and revenues of healthcare companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Product development efforts
by healthcare companies may not result in commercial products for many reasons, including, but not limited to, failure to achieve acceptable
clinical trial results, limited effectiveness in treating the specified condition or illness, harmful side effects,&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;
 &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;failure to obtain regulatory
approval, and high manufacturing costs. Even after a product is commercially released, governmental agencies may require additional clinical
trials or change the labeling requirements for products if additional product side effects are identified, which could have a material
adverse effect on the market price of the securities of those healthcare companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Certain healthcare companies
in which the Fund may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing
and sale of pharmaceuticals, medical devices or other products. A product liability claim may have a material adverse effect on the business,
financial condition or securities prices of a company in which the Fund has invested.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;All of these factors as well
as others may cause the value of the Fund's shares to fluctuate significantly over relatively short periods of time.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;


&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Pharmaceutical Sector
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The success of companies in the pharmaceutical sector
is highly dependent on the development, procurement and marketing of drugs. The values of pharmaceutical companies are also dependent
on the development, protection and exploitation of intellectual property rights and other proprietary information, and the profitability
of pharmaceutical companies may be significantly affected by such things as the expiration of patents or the loss of, or the inability
to enforce, intellectual property rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The research and other costs
associated with developing or procuring new drugs and the related intellectual property rights can be significant, and the results of
such research and expenditures are unpredictable. There can be no assurance that those efforts or costs will result in the development
of a profitable drug. Pharmaceutical companies may be susceptible to product obsolescence. Pharmaceutical companies also face challenges
posed by the increased presence of counterfeit pharmaceutical products, which may negatively impact revenues and patient confidence. Many
pharmaceutical companies face intense competition from new products and less costly generic products. Moreover, the process for obtaining
regulatory approval by the FDA or other U.S. and non-U.S. governmental regulatory authorities is long and costly and there can be no assurance
that the necessary approvals will be obtained or maintained.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The pharmaceutical sector
is also subject to rapid and significant technological change and competitive forces that may make drugs obsolete or make it difficult
to raise prices and, in fact, may result in price discounting. Companies in the pharmaceutical sector may also be subject to expenses
and losses from extensive litigation based on intellectual property, product liability and similar claims. Failure of pharmaceutical companies
to comply with applicable laws and regulations can result in the imposition of civil and criminal fines, penalties and, in some instances,
exclusion of participation in government sponsored programs such as Medicare and Medicaid.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Companies in the pharmaceutical
sector may be adversely affected by government regulation and changes in reimbursement rates. The ability of many pharmaceutical companies
to commercialize and monetize current and any future products depends in part on the extent to which reimbursement for the cost of such
products and related treatments are available from third party payors, such as Medicare, Medicaid, private health insurance plans and
health maintenance organizations. Third-party payors are increasingly challenging the price and cost-effectiveness of many medical products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Significant uncertainty exists
as to the reimbursement status of health care products, and there can be no assurance that adequate third-party coverage will be available
for pharmaceutical companies to obtain satisfactory price levels for their products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The international operations
of many pharmaceutical companies expose them to risks associated with instability and changes in economic and political conditions, foreign
currency fluctuations, changes in foreign regulations and other risks inherent to international business. Additionally, a pharmaceutical
company's valuation can often be based largely on the potential or actual performance of a limited number of products. A pharmaceutical
company's valuation can also be greatly affected if one of its products proves unsafe, ineffective or unprofitable. Such companies also
may be characterized by thin capitalization and limited markets, financial resources or personnel, as well as dependence on wholesale
distributors. The stock prices of companies in the pharmaceutical industry have been and will likely continue to be extremely volatile.&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Biotechnology Industry
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The success of biotechnology companies is highly dependent
on the development, procurement and/or marketing of drugs. The values of biotechnology companies are also dependent on the development,
protection and exploitation of intellectual property rights and other proprietary information, and the profitability of biotechnology
companies may be significantly affected by such things as the expiration of patents or the loss of, or the inability to enforce, intellectual
property rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The research and other costs
associated with developing or procuring new drugs, products or technologies and the related intellectual property rights can be significant,
and the results of such research and expenditures are unpredictable. There can be no assurance that those efforts or costs will result
in the development of a profitable drug, product or technology. Moreover, the process for obtaining regulatory approval by the FDA or
other U.S. and non-U.S. governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals
will be obtained or maintained.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The biotechnology sector is
also subject to rapid and significant technological change and competitive forces that may make drugs, products or technologies obsolete
or make it difficult to raise prices and, in fact, may result in price discounting. Companies in the biotechnology sector may also be
subject to expenses and losses from extensive litigation&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;based on intellectual property,
product liability and similar claims. Failure of biotechnology companies to comply with applicable laws and regulations can result in
the imposition of civil and/or criminal fines, penalties and, in some instances, exclusion of participation in government sponsored programs
such as Medicare and Medicaid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Companies in the biotechnology
sector may be adversely affected by government regulation and changes in reimbursement rates. Healthcare providers, principally hospitals,
that transact with companies in the biotechnology industry, often rely on third party payors, such as Medicare, Medicaid, private health
insurance plans and health maintenance organizations to reimburse all or a portion of the cost of healthcare related products or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Biotechnology companies will
continue to be affected by the efforts of governments and third party payors to contain or reduce health care costs. For example, certain
foreign markets control pricing or profitability of biotechnology products and technologies. In the United States, there has been, and
there will likely continue to be, a number of federal and state proposals to implement similar controls.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;A biotechnology company's
valuation could be based on the potential or actual performance of a limited number of products and could be adversely affected if one
of its products proves unsafe, ineffective or unprofitable. Such companies may also be characterized by thin capitalization and limited
markets, financial resources or personnel. The stock prices of companies involved in the biotechnology sector have been and will likely
continue to be extremely volatile.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Managed Care Sector
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Companies in the managed care sector often assume the
risk of both medical and administrative costs for their customers in return for monthly premiums. The profitability of these products
depends in large part on the ability of such companies to predict, price for, and effectively manage medical costs. Managed care companies
base the premiums they charge and their Medicare bids on estimates of future medical costs over the fixed contract period; however, many
factors may cause actual costs to exceed what was estimated and reflected in premiums or bids. These factors may include medical cost
inflation, increased use of services, increased cost of individual services, natural catastrophes or other large-scale medical emergencies,
epidemics, the introduction of new or costly treatments and technology, new mandated benefits (such as the expansion of essential benefits
coverage) or other regulatory changes and insured population characteristics. Relatively small differences between predicted and actual
medical costs or utilization rates as a percentage of revenues can result in significant changes in financial results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Managed care companies are
regulated at the federal, state, local and international levels. Insurance and Health Maintenance Organization ("HMO") subsidiaries must
be licensed by and are subject to the regulations of the jurisdictions in which they conduct business. U.S. health plans and insurance
companies are also regulated under state insurance holding&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;company regulations, and some
of their activities may be subject to other health care-related regulations. The health care industry is also regularly subject to negative
publicity, including as a result of governmental investigations, adverse media coverage and political debate surrounding industry regulation.
Negative publicity may adversely affect stock price, damage the reputation of managed care companies in various markets or foster an increasingly
active regulatory environment, which, in turn, could further increase the regulatory burdens under which such companies operate and their
costs of doing business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The evolution of the ACA and
other regulatory reforms could materially and adversely affect the manner in which U.S. managed care companies conduct business and their
results of operations, financial position and cash flows. The ACA includes guaranteed coverage and expanded benefit requirements, eliminates
pre-existing condition exclusions and annual and lifetime maximum limits, restricts the extent to which policies can be rescinded, establishes
minimum medical loss ratios, creates a federal premium review process, imposes new requirements on the format and content of communications
(such as explanations of benefits) between health insurers and their members, grants to members new and additional appeal rights, and
imposes new and significant taxes on health insurers and health care benefits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;New laws or regulations could
drive substantial change to the way healthcare products and services are currently delivered and paid for in the United States. Health
plans and insurance companies could face meaningful disruption or disintermediation if the U.S. migrates to a single payer healthcare
system where the government acts as the sole payer of healthcare services for the entire population. A transformative overhaul of the
U.S. healthcare system could impact the financial viability of managed care companies in which the Fund may invest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Managed care companies contract
with physicians, hospitals, pharmaceutical benefit service providers, pharmaceutical manufacturers, and other health care providers for
services. Such companies' results of operations and prospects are substantially dependent on their continued ability to contract for these
services at competitive prices. Failure to develop and maintain satisfactory relationships with health care providers, whether in-network
or out-of-network, could materially and adversely affect business, results of operations, financial position and cash flows.&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Life Science and Tools
Industry Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Life sciences industries are characterized by
limited product focus, rapidly changing technology and extensive government regulation. In particular, technological advances can render
an existing product, which may account for a disproportionate share of a company's revenue, obsolete. Obtaining governmental approval
from agencies such as the FDA, U.S. Department of Agriculture and other U.S. and non-U.S. governmental agencies for new products can be
lengthy, expensive and uncertain as to outcome. Such delays in product development may result in the need to seek additional capital,
potentially diluting the interests of existing investors such as the Fund. In addition,&lt;/span&gt;&lt;/p&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;governmental agencies may,
for a variety of reasons, restrict the release of certain innovative technologies of commercial significance, such as genetically altered
material. These various factors may result in abrupt advances and declines in the securities prices of particular companies and, in some
cases, may have a broad effect on the prices of securities of companies in particular life sciences industries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Intense competition exists
within and among certain life sciences industries, including competition to obtain and sustain proprietary technology protection. Life
sciences companies can be highly dependent on the strength of patents, trademarks and other intellectual property rights for maintenance
of profit margins and market share. The complex nature of the technologies involved can lead to patent disputes, including litigation
that could result in a company losing an exclusive right to a patent. Competitors of life sciences companies may have substantially greater
financial resources, more extensive development, manufacturing, marketing and service capabilities, and a larger number of qualified managerial
and technical personnel. Such competitors may succeed in developing technologies and products that are more effective or less costly than
any that may be developed by life sciences companies in which the Fund invests and may also prove to be more successful in production
and marketing. Competition may increase further as a result of potential advances in health services and medical technology and greater
availability of capital for investment in these fields.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;With respect to healthcare,
cost containment measures already implemented by national governments, state or provincial governments, international organizations and
the private sector have adversely affected certain sectors of these industries. Increased emphasis on managed care in the United States
may put pressure on the price and usage of products sold by life sciences companies in which the Fund may invest and may adversely affect
the sales and revenues of life sciences companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Product development efforts
by life sciences companies may not result in commercial products for many reasons, including, but not limited to, failure to achieve acceptable
clinical trial results, limited effectiveness in treating the specified condition or illness, harmful side effects, failure to obtain
regulatory approval, and high manufacturing costs. Even after a product is commercially released, governmental agencies may require additional
clinical trials or change the labeling requirements for products if additional product side effects are identified, which could have a
material adverse effect on the market price of the securities of those life sciences companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Certain life sciences companies
in which the Fund may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing
and sale of pharmaceuticals, medical devices or other products. There can be no assurance that a product liability claim would not have
a material adverse effect on the business, financial condition or securities prices of a company in which the Fund has invested.&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Healthcare Technology
Sector Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Companies in the healthcare technology sector may
incur substantial costs related to product-related liabilities. Many of the software solutions, health care devices or services developed
by such companies are intended for use in collecting, storing and displaying clinical and health care-related information used in the
diagnosis and treatment of patients and in related health care settings such as admissions, billing, etc. The limitations of liability
set forth in the companies' contracts may not be enforceable or may not otherwise protect these companies from liability for damages.
Healthcare technology companies may also be subject to claims that are not covered by contract, such as a claim directly by a patient.
Although such companies may maintain liability insurance coverage, there can be no assurance that such coverage will cover any particular
claim that has been brought or that may be brought in the future, that such coverage will prove to be adequate or that such coverage will
continue to remain available on acceptable terms, if at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Healthcare technology companies
may experience interruption at their data centers or client support facilities. The business of such companies often relies on the secure
electronic transmission, data center storage and hosting of sensitive information, including protected health information, financial information
and other sensitive information relating to clients, company and workforce. In addition, such companies may perform data center and/or
hosting services for certain clients, including the storage of critical patient and administrative data and support services through various
client support facilities. If any of these systems are interrupted, damaged or breached by an unforeseen event or actions of a third party,
including a cyber-attack, or fail for any extended period of time, it could have a material adverse impact on the results of operations
for such companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The proprietary technology
developed by healthcare technology companies may be subject to claims for infringement or misappropriation of intellectual property rights
of others, or may be infringed or misappropriated by others. Despite protective measures and intellectual property rights, such companies
may not be able to adequately protect against theft, copying, reverse-engineering, misappropriation, infringement or unauthorized use
or disclosure of their intellectual property, which could have an adverse effect on their competitive position. In addition, these companies
are routinely involved in intellectual property infringement or misappropriation claims and it is expected that this activity will continue
or even increase as the number of competitors, patents and patent enforcement organizations in the healthcare technology market increases,
the functionality of software solutions and services expands, the use of open-source software increases and new markets such as health
care device innovation, health care transactions, revenue cycle, population health management and life sciences are entered into. These
claims, even if not meritorious, are expensive to defend and are often incapable of prompt resolution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The success of healthcare
technology companies depends upon the recruitment and retention of key personnel. To remain competitive, such companies must attract,
motivate and retain&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;highly skilled managerial,
sales, marketing, consulting and technical personnel, including executives, consultants, programmers and systems architects skilled in
healthcare technology, health care devices, health care transactions, population health management, revenue cycle and life sciences industries
and the technical environments in which solutions, devices and services are needed. Competition for such personnel in the healthcare technology
sector is intense in both the United States and abroad. The failure to attract additional qualified personnel could have a material adverse
effect on healthcare technology companies' prospects for long-term growth.&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Healthcare Services
Sector Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The operations of healthcare services companies
are subject to extensive federal, state and local government regulations, including Medicare and Medicaid payment rules and regulations,
federal and state anti-kickback laws, the physician self-referral law ("Stark Law") and analogous state self-referral prohibition statutes,
Federal Acquisition Regulations, the False Claims Act and federal and state laws regarding the collection, use and disclosure of patient
health information and the storage, handling and administration of pharmaceuticals. The Medicare and Medicaid reimbursement rules related
to claims submission, enrollment and licensing requirements, cost reporting, and payment processes impose complex and extensive requirements
upon dialysis providers as well. A violation or departure from any of these legal requirements may result in government audits, lower
reimbursements, significant fines and penalties, the potential loss of certification, recoupment efforts or voluntary repayments. If healthcare
services companies fail to adhere to all of the complex government regulations that apply to their businesses, such companies could suffer
severe consequences that would substantially reduce revenues, earnings, cash flows and stock prices.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;A substantial percentage of
a healthcare services company's service revenues may be generated from patients who have state Medicaid or other non-Medicare government-based
programs, such as coverage through the Department of Veterans Affairs ("VA"), as their primary coverage. As state governments and other
governmental organizations face increasing budgetary pressure, healthcare services companies may in turn face reductions in payment rates,
delays in the receipt of payments, limitations on enrollee eligibility or other changes to the applicable programs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Adverse economic conditions
could adversely affect the business and profitability of healthcare services companies. Among other things, the potential decline in federal,
non-U.S. government and state revenues that may result from such conditions may create additional pressures to contain or reduce reimbursements
for services from Medicare, Medicaid and other government sponsored programs. Increasing job losses or slow improvement in the unemployment
rate in the United States and elsewhere as a result of adverse or recent economic conditions may result in a smaller percentage of patients
being covered by an employer group health plan and a larger percentage being covered by lower paying Medicare and Medicaid programs. Employers
may also select more restrictive commercial plans with&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;lower reimbursement rates.
To the extent that payors are negatively impacted by a decline in the economy, healthcare services companies may experience further pressure
on commercial rates, a further slowdown in collections and a reduction in the amounts they expect to collect. In addition, uncertainty
in the financial markets could adversely affect the variable interest rates payable under credit facilities or could make it more difficult
to obtain or renew such facilities or to obtain other forms of financing in the future, if at all. Any or all of these factors, as well
as other consequences of the adverse economic conditions which cannot currently be anticipated, could have a material adverse effect on
a healthcare services company's revenues, earnings and cash flows and otherwise adversely affect its financial condition.&lt;/span&gt;&lt;/p&gt;


&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Healthcare Supplies
Sector Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; If healthcare supplies companies are unable to
successfully expand their product lines through internal research and development and acquisitions, their business may be materially and
adversely affected. In addition, if these companies are unable to successfully grow their businesses through marketing partnerships and
acquisitions, their business may be materially and adversely affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Consolidation of healthcare
providers has increased demand for price concessions and caused the exclusion of suppliers from significant market segments. It is expected
that market demand, government regulation, third-party reimbursement policies, government contracting requirements and societal pressures
will continue to change the worldwide healthcare industry, resulting in further business consolidations and alliances among customers
and competitors. This may exert further downward pressure on the prices of healthcare supplies companies' products and adversely impact
their businesses, financial conditions or results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Quality is extremely important
to healthcare supplies companies and their customers due to the serious and costly consequences of product failure. Quality certifications
are critical to the marketing success of their products and services. If a healthcare supplies company fails to meet these standards or
fails to adapt to evolving standards, its reputation could be damaged, it could lose customers, and its revenue and results of operations
could decline.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Healthcare Facilities
Sector Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; A healthcare facility's ability to negotiate favorable
contracts with HMOs, insurers offering preferred provider arrangements and other managed care plans significantly affects the revenues
and operating results of such healthcare facilities. In addition, private payers are increasingly attempting to control health care costs
through direct contracting with hospitals to provide services on a discounted basis, increased utilization reviews and greater enrollment
in managed care programs, such as HMOs and Preferred Provider Organizations ("PPOs"). The trend toward consolidation among private managed
care payers tends to increase their bargaining power over prices and fee structures. Non-government payers may increasingly demand reduced
fees. If a healthcare facility is unable to enter into and maintain managed care contractual arrangements on acceptable&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;terms, if it experiences material
reductions in the contracted rates received from managed care payers, or if it has difficulty collecting from managed care payers, its
results of operations could be adversely affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Further changes in the Medicare
and Medicaid programs or other government health care programs could have an adverse effect on a healthcare facility's business. In addition
to the changes affected by the ACA, the Medicare and Medicaid programs are subject to other statutory and regulatory changes, administrative
rulings, interpretations and determinations concerning patient eligibility requirements, funding levels and the method of calculating
payments or reimbursements, among other things, requirements for utilization review, and federal and state funding restrictions. All of
these could materially increase or decrease payments from government programs in the future, as well as affect the cost of providing services
to patients and the timing of payments to facilities, which could in turn adversely affect a healthcare facility's overall business, financial
condition, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Healthcare facilities are
adversely affected by uninsured and underinsured patients, as well as a growing mix of Medicare and Medicaid patients that typically have
lower reimbursement rates than commercial managed care patients As a result, healthcare facilities continue to experience a shift in payer
mix and a high level of uncollectible accounts, which could worsen if there is an increase in unemployment. Healthcare facilities may
continue to experience significant levels of bad debt expense and may have to provide uninsured discounts and charity care for undocumented
immigrants who are not permitted to enroll in a health insurance exchange or government health care program. The trend of higher co-pays
and deductibles and a focus on migrating healthcare utilization to lower cost sites of care, may also pressure volumes and revenue at
certain healthcare facilities which could adversely impact the financial condition of hospitals and facilities with high fixed cost structures.&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Healthcare Equipment
Sector Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The medical device markets are highly competitive
and a healthcare equipment company many be unable to compete effectively. These markets are characterized by rapid change resulting from
technological advances and scientific discoveries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Development by other companies
of new or improved products, processes, or technologies may make a healthcare equipment company's products or proposed products less competitive.
In addition, these companies face competition from providers of alternative medical therapies such as pharmaceutical companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Medical devices and related
business activities are subject to rigorous regulation, including by the FDA, U.S. Department of Justice ("DOJ"), and numerous other federal,
state, and foreign governmental authorities. These authorities and members of Congress have been increasing their scrutiny of the healthcare
equipment industry. In addition, certain states have&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;passed or are considering
legislation restricting healthcare equipment companies' interactions with health care providers and requiring disclosure of certain payments
to them. It is anticipated that governmental authorities will continue to scrutinize this industry closely, and that additional regulation
may increase compliance and legal costs, exposure to litigation, and other adverse effects to operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Healthcare equipment companies
are substantially dependent on patent and other proprietary rights and failing to protect such rights or to be successful in litigation
related to such rights may result in the payment of significant monetary damages and/or royalty payments, may negatively impact the ability
of healthcare equipment companies to sell current or future products, or may prohibit such companies from enforcing their patent and other
proprietary rights against others.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Quality problems with the
processes, goods and services of a healthcare equipment company could harm the company's reputation for producing high-quality products
and erode its competitive advantage, sales and market share. Quality is extremely important to healthcare equipment companies and their
customers due to the serious and costly consequences of product failure. Quality certifications are critical to the marketing success
of goods and services. If a healthcare equipment company fails to meet these standards, its reputation could be damaged, it could lose
customers, and its revenue and results of operations could decline.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Healthcare Distributors
Sector Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Companies in the healthcare distribution sector
operate in markets that are highly competitive. Because of competition, many of these companies face pricing pressures from customers
and suppliers. If these companies are unable to offset margin reductions caused by pricing pressures through steps such as effective sourcing
and enhanced cost control measures, the financial condition of such companies could be adversely affected. In addition, the healthcare
industry has continued to consolidate. Further consolidation among customers and suppliers (including branded pharmaceutical manufacturers)
could give the resulting enterprises greater bargaining power, which may adversely impact the financial condition of companies in the
healthcare distribution sector.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Fewer generic pharmaceutical
launches or launches that are less profitable than those previously experienced may have an adverse effect on the profits of companies
in the healthcare distribution sector. Additionally, prices for existing generic pharmaceuticals generally decline over time, although
this may vary. Price deflation on existing generic pharmaceuticals may have an adverse effect on company profits. With respect to branded
pharmaceutical price appreciation, if branded manufacturers increase prices less frequently or by amounts that are smaller than have been
experienced historically, healthcare distribution companies may profit less from branded pharmaceutical agreements.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;
 &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The healthcare industry is
highly regulated, and healthcare distribution companies are subject to regulation in the United States at both the federal and state level
and in foreign countries. If healthcare distribution companies fail to comply with these regulatory requirements, the financial condition
of such companies could be adversely affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Due to the nature of the business
of healthcare distribution companies, such companies may from time to time become involved in disputes or legal proceedings. For example,
some of the products that these companies distribute may be alleged to cause personal injury or violate the intellectual property rights
of another party, subjecting such companies to product liability or infringement claims. Litigation is inherently unpredictable, and the
unfavorable resolution of one or more of these legal proceedings could adversely affect the cash flows and balance sheets of healthcare
distribution companies. Pharmaceutical distributors currently face lawsuits related to the abuse of opioid medications in the United States.
The allegations include that pharmaceutical distributors failed to provide effective controls around the quantities of opioid medications
distributed to certain pharmacies, failed to properly prevent the diversion of medications and failed to report suspicious orders. Pharmaceutical
distributors are in discussions with federal, state and local jurisdictions related to their role in the distribution of opioid pharmaceuticals
and it is possible that they will be required to pay multi-billion dollar settlements related to the ongoing litigation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Healthcare distribution companies
depend on the availability of various components, compounds, raw materials and energy supplied by others for their operations. Any of
these supplier relationships could be interrupted due to events beyond the control of such companies, including pandemics, epidemics or
natural disasters, or could be terminated. A sustained supply interruption could have an adverse effect on business.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;


&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Risks Associated with
Regulatory and Policy Changes.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; At any time after the date hereof,
U.S. and non-U.S. governmental agencies and other regulators may implement additional regulations and legislators may pass new laws that
affect the investments held by the Fund, the strategies used by the Fund or the level of regulation or taxation applying to the Fund.
These regulations and laws impact the investment strategies, performance, costs and operations of the Fund, as well as the way investments
in, and shareholders of, the Fund are taxed. In particular, changes to U.S. healthcare policy could affect the Fund and its investments.
The affordability of healthcare in the U.S. will remain a topic of debate, and proposals, laws and regulations to reduce the costs of
healthcare products and services could adversely impact healthcare companies that the Fund invests in.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Foreign Securities
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Foreign investments involve special risks that are not
typically associated with U.S. dollar denominated or quoted securities of U.S. issuers. Foreign investments may be affected by changes
in currency rates, changes in foreign or U.S. laws or restrictions applicable to such investments and changes in exchange control regulations
(e.g., currency blockage). A decline in the exchange rate of the currency (i.e., weakening of&lt;/span&gt;&lt;/p&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;the currency against the U.S.
dollar) in which a portfolio security is quoted or denominated relative to the U.S. dollar would reduce the value of the portfolio security.
In addition, if the currency in which the Fund receives dividends, interest or other payments declines in value against the U.S. dollar
before such income is distributed as dividends to Shareholders or converted to U.S. dollars, the Fund may have to sell portfolio securities
to obtain sufficient cash to pay such dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The Fund may invest in foreign
securities which take the form of sponsored and unsponsored American depositary receipts ("ADRs"), global depositary receipts ("GDRs"),
European depositary receipts ("EDRs") or other similar instruments representing securities of foreign issuers (together, "Depositary Receipts").
ADRs represent the right to receive securities of foreign issuers deposited in a domestic bank or a correspondent bank. ADRs are traded
on domestic exchanges or in the U.S. over-the-counter ("OTC") market and, generally, are in registered form. EDRs and GDRs are receipts
evidencing an arrangement with a non-U.S. bank similar to ADRs and are designed for use in the non-U.S. securities markets. EDRs and GDRs
are not necessarily quoted in the same currency as the underlying security. To the extent the Fund acquires Depositary Receipts through
banks which do not have a contractual relationship with the foreign issuer of the security underlying the Depositary Receipts to issue
and service such unsponsored Depositary Receipts, there is an increased possibility that the Fund will not become aware of and be able
to respond to corporate actions, such as stock splits or rights offerings, involving the foreign issuer in a timely manner. In addition,
the lack of information may result in inefficiencies in the valuation of such instruments. Investment in Depositary Receipts does not
eliminate all the risks inherent in investing in securities of non-U.S. issuers. The market value of Depositary Receipts is dependent
upon the market value of the underlying securities and fluctuations in the relative value of the currencies in which the Depositary Receipts
and the underlying securities are quoted. However, by investing in Depositary Receipts, such as ADRs, which are quoted in U.S. dollars,
the Fund may avoid currency risks during the settlement period for purchases and sales. The issuers of Depositary Receipts may discontinue
issuing new Depositary Receipts and withdraw existing Depositary Receipts at any time, which may result in costs and delays in the distribution
of the underlying assets to the Fund and may negatively impact the Fund's performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Brokerage commissions, custodial
services and other costs relating to investment in international securities markets generally are more expensive than in the United States.
In addition, clearance and settlement procedures may be different in foreign countries and, in certain markets, such procedures have been
unable to keep pace with the volume of securities transactions, thus making it difficult to conduct such transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Foreign issuers are not generally
subject to uniform accounting, auditing and financial reporting standards comparable to those applicable to U.S. issuers. There may be
less publicly available information about a foreign issuer than about a U.S. issuer. In addition, there is generally less government regulation
of foreign markets, companies and securities dealers&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;than in the United States,
and the legal remedies for investors may be more limited than the remedies available in the United States. Foreign securities markets
may have substantially less volume than U.S. securities markets and securities of many foreign issuers are less liquid and more volatile
than securities of comparable domestic issuers. Furthermore, with respect to certain foreign countries, there is a possibility of nationalization,
expropriation or confiscatory taxation, imposition of withholding or other taxes on dividend or interest payments (or, in some cases,
capital gains distributions), limitations on the removal of funds or other assets from such countries, and risks of political or social
instability or diplomatic developments which could adversely affect investments in those countries. At any time after the date hereof,
U.S. and non-U.S. governmental agencies and other regulators may implement additional regulations and legislators may pass new laws that
affect the investments held by the Fund, the strategies used by the Fund or the level of regulation or taxation applying to the Fund.
These regulations and laws impact the investment strategies, performance, costs and operations of the Fund, as well as the way investments
in, and shareholders of, the Fund are taxed. In particular, changes to U.S. healthcare policy could affect the Fund and its investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The Fund may invest in securities
of issuers located in Emerging Markets. The risks of foreign investment are heightened when the issuer is located in an emerging country.
Emerging Markets are generally located in Africa, Asia, the Middle East, Eastern Europe and Central and South America. Investments in
securities of issuers located in Emerging Markets may be subject to heightened risks, including relative illiquidity, price volatility
and potential restrictions on repatriation of investment capital and income. The Fund's purchase and sale of portfolio securities in Emerging
Markets may be constrained by limitations relating to daily changes in the prices of listed securities, periodic trading or settlement
volume and/or limitations on aggregate holdings of foreign investors. Such limitations may be computed based on the aggregate trading
volume by or holdings of the Fund, the Investment Adviser, or its affiliates and respective clients and other service providers. The Fund
may not be able to sell securities in circumstances where price, trading or settlement volume limitations have been reached.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Foreign investment in the
securities markets of certain Emerging Markets is restricted or controlled to varying degrees which may limit investment in such countries
or increase the administrative costs of such investments. For example, certain Asian countries require governmental approval prior to
investments by foreign persons or limit investment by foreign persons to only a specified percentage of an issuer's outstanding securities
or a specific class of securities which may have less advantageous terms (including price) than securities of the issuer available for
purchase by nationals. In addition, certain countries may restrict or prohibit investment opportunities in issuers or industries deemed
important to national interests. Such restrictions may affect the market price, liquidity and rights of securities that may be purchased
by the Fund. The repatriation of both investment income and capital from&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;certain Emerging Markets is
subject to restrictions such as the need for governmental consents. In situations where a country restricts direct investment in securities
(which may occur in certain Asian and other countries), the Fund may invest in such countries through other investment funds in such countries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Many Emerging Markets have
experienced currency devaluations and substantial (and, in some cases, extremely high) rates of inflation. Other Emerging Markets have
experienced economic recessions. These circumstances have had a negative effect on the economies and securities markets of those Emerging
Markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Economies in Emerging Markets
generally are dependent heavily upon commodity prices and international trade and, accordingly, have been and may continue to be affected
adversely by the economies of their trading partners, trade barriers, exchange controls, managed adjustments in relative currency values
and other protectionist measures imposed or negotiated by the countries with which they trade.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Many Emerging Markets are
subject to a substantial degree of economic, political and social instability. Governments of some emerging countries are authoritarian
in nature or have been installed or removed as a result of military coups, while governments in other Emerging Markets have periodically
used force to suppress civil dissent. Disparities of wealth, the pace and success of democratization, and ethnic, religious and racial
disaffection, among other factors, have also led to social unrest, violence and/or labor unrest in some Emerging Markets. Unanticipated
political or social developments may result in sudden and significant investment losses. Investing in Emerging Markets involves greater
risk of loss due to expropriation, nationalization, confiscation of assets and property or the imposition of restrictions on foreign investments
and on repatriation of capital invested. As an example, in the past, some Eastern European governments have expropriated substantial amounts
of private property, and many claims of the property owners have never been fully settled. There is no assurance that similar expropriations
will not occur in other countries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The Fund's investment in Emerging
Markets may also be subject to withholding or other taxes, which may be significant and may reduce the return to the Fund from an investment
in issuers in such countries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Settlement procedures in Emerging
Markets are frequently less developed and reliable than those in the United States and may involve the Fund's delivery of securities before
receipt of payment for their sale. In addition, significant delays may occur in certain markets in registering the transfer of securities.
Settlement or registration problems may make it more difficult for the Fund to value its portfolio securities and could cause the Fund
to miss attractive investment opportunities, to have a portion of its assets uninvested or to incur losses due to the failure of a counterparty
to pay for securities the Fund has delivered or the Fund's inability to complete its contractual obligations because of theft or other
reasons.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The creditworthiness of the local
securities firms used by the Fund in Emerging Markets may not be as sound as the creditworthiness of firms used in more developed countries.
As a result, the Fund may be subject to a greater risk of loss if a securities firm defaults in the performance of its responsibilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The small size and inexperience
of the securities markets in certain Emerging Markets and the limited volume of trading in securities in those countries may make the
Fund's investments in such countries less liquid and more volatile than investments in countries with more developed securities markets
(such as the United States, Japan and most Western European countries). The Fund's investments in Emerging Markets are subject to the
risk that the liquidity of a particular investment, or investments generally, in such countries will shrink or disappear suddenly and
without warning as a result of adverse economic, market or political conditions or adverse investor perceptions, whether or not accurate.
Because of the lack of sufficient market liquidity, the Fund may incur losses because it will be required to effect sales at a disadvantageous
time and only then at a substantial drop in price. Investments in Emerging Markets may be more difficult to value precisely because of
the characteristics discussed above and lower trading volumes. In addition, the impact of the economic and public health crisis in emerging
market countries may be greater due to their generally less established healthcare systems and capabilities with respect to fiscal and
monetary policies, which may exacerbate other pre-existing political, social and economic tasks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The Fund's use of foreign
currency management techniques in Emerging Markets may be limited. A significant portion of the Fund's currency exposure in Emerging Markets
may not be covered by these techniques.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Forward Contract Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
Forward contracts involve the purchase or sale of a specific quantity of a commodity, government security, foreign currency, or other
asset at a specified price, with delivery and settlement at a specified future date. Because it is a completed contract, a purchase forward
contract can be a cover for the sale of a futures contract. The Fund may enter into forward contracts for hedging purposes and non-hedging
purposes (i.e., to increase returns). Forward contracts may be used by the Fund for hedging purposes to protect against uncertainty in
the level of future foreign currency exchange rates, such as when the Fund anticipates purchasing or selling a foreign security. For example,
this technique would allow the Fund to "lock in" the U.S. dollar price of the security. Forward contracts may also be used to attempt
to protect the value of the Fund's existing holdings of foreign securities. There may be, however, an imperfect correlation between the
Fund's foreign securities holdings and the forward contracts entered into with respect to those holdings. Forward contracts may also be
used for non-hedging purposes to pursue the Fund's investment objective, such as when the Investment Adviser anticipates that particular
foreign currencies will appreciate or depreciate in value, even though securities denominated in&lt;/span&gt;&lt;/p&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;those currencies are not then
held in the Fund's portfolio. There is no requirement that the Fund hedge all or any portion of its exposure to foreign currency risks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Forward contracts, unlike
futures contracts, are not traded on exchanges and are not standardized; rather, banks and dealers act as principals in these markets,
negotiating each transaction on an individual basis. The principals who deal in the forward markets are not required to continue to make
markets in the currencies or commodities they trade and these markets can experience periods of illiquidity, sometimes of significant
duration. There have been periods during which certain participants in these markets have refused to quote prices for certain currencies
or commodities or have quoted prices with an unusually wide spread between the price at which they were prepared to buy and that at which
they were prepared to sell. Disruptions can occur in any market traded by the Investment Adviser due to unusually high trading volume,
political intervention or other factors. Arrangements to trade forward contracts may be made with only one or a few counterparties, and
liquidity problems therefore might be greater than if such arrangements were made with numerous counterparties. The imposition of controls
by governmental authorities might also limit such forward (and futures) trading to less than that which the Investment Adviser would otherwise
recommend, to the possible detriment of the Fund. Market illiquidity or disruption could result in major losses to the Fund. In addition,
the Fund will be exposed to credit risks with regard to counterparties with whom they trade as well as risks relating to settlement default.
Such risks could result in substantial losses to the Fund.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Derivatives Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
The Fund may invest in derivative instruments including options, futures, options on futures, forwards, swaps (including credit default,
index, basis, total return, volatility and currency swaps), options on swaps and other derivatives, although suitable derivative instruments
may not always be available to the Investment Adviser for these purposes. The Fund intends to employ a strategy of writing (selling) covered
call options on a portion of the common stocks in its portfolio, writing (selling) put options on a portion of the common stocks in its
portfolio and, to a lesser extent, writing (selling) covered call and writing (selling) put options on indices of securities and sectors
of securities generally within the healthcare industry. This option strategy is intended to generate current income from option premiums
as a means to enhance distributions payable to the Fund's shareholders and will be limited to 30% of the Fund's Managed Assets. These
option strategies are not always profitable. The sale of a covered call option exposes the Fund during the term of the option to possible
loss of opportunity to realize appreciation in the market price of the underlying security or to possible loss due to continued holding
of a security that might otherwise have been sold to protect against depreciation in the market price of the security. To the extent the
Fund writes a covered put option, the Fund has assumed the obligation during the option period to purchase the security or securities
from the put buyer at the option's exercise price if the put buyer exercises its option, regardless of whether the value of the underlying
investment falls below the exercise price. This means that a Fund that writes a&lt;/span&gt;&lt;/p&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;put option may be required
make payment for such investment at the exercise price. This may result in losses to the Fund and may result in the Fund holding securities
for some period of time when it is disadvantageous to do so. Therefore, the Investment Adviser may choose to decrease its use of the option
writing strategy to the extent that it may negatively impact the Fund. Other than the Fund's option strategy and use of derivatives for
hedging purposes, the Fund may invest up to 10% of its Managed Assets in derivatives. Derivative instruments can be illiquid, may disproportionately
increase losses, and may have a potentially large adverse impact on Fund performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Although both OTC and exchange-traded
derivatives markets may experience a lack of liquidity, OTC nonstandardized derivative transactions are generally less liquid than exchange-traded
instruments. The illiquidity of the derivatives markets may be due to various factors, including congestion, disorderly markets, limitations
on deliverable supplies, the participation of speculators or their withdrawal from the markets, government regulation and intervention,
and technical and operational or system failures. In addition, daily limits on price fluctuations and speculative position limits on exchanges
on which the Fund may conduct its transactions in derivative instruments may prevent the Fund from liquidating these positions at an advantageous
time or price, subjecting the Fund to the potential of greater losses. Losses from investments in derivative instruments can result from
a lack of correlation between changes in the value of derivative instruments and the portfolio assets (if any) being hedged, the potential
illiquidity of the markets for derivative instruments, the failure of the counterparty to perform its contractual obligations, or the
risks arising from margin requirements and related leverage factors associated with such transactions. Losses may also arise if the Fund
receives cash collateral under the transactions and some or all of that collateral is invested in the market. To the extent that cash
collateral is so invested, such collateral will be subject to market depreciation or appreciation, and the Fund may be responsible for
any loss that might result from its investment of the counterparty's cash collateral. The use of these derivatives trading techniques
also involves the risk of loss if the Investment Adviser is incorrect in its expectation of the timing or level of fluctuations in securities
prices, interest rates or currency prices. Investments in derivative instruments may be harder to value, subject to greater volatility
and more likely subject to changes in tax treatment than other investments. For these reasons, the Investment Adviser's attempts to hedge
portfolio risks through the use of derivative instruments may not be successful. Trading in derivative instruments can increase the Fund's
exposure to leverage. Thus, the leverage offered by trading in derivative instruments will magnify the gains and losses experienced by
the Fund and could cause the Fund's net asset value to be subject to wider fluctuations than would be the case if the Fund did not use
the leverage feature in derivative instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Derivatives markets have been
subject to increased regulation over the past several years, which may continue, and consequently, may make derivatives trading more costly,
may limit the availability of and reduce the liquidity of derivatives or may otherwise adversely affect the&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;
&lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;value or performance of derivatives.
Such potential adverse future developments could increase the risks reduce the effectiveness of the Fund's derivative transactions, and
cause the Fund to lose value. For instance, the SEC has adopted new regulations related to a registered investment company's use of derivatives
and related instruments. These regulations impose limits on the amount of derivatives a fund can enter into, eliminate the asset segregation
framework formerly used by funds to comply with Section 18 of the 1940 Act. These regulations may significantly impact the Fund's ability
to invest in derivatives and other instruments, limit the Fund's ability to employ certain strategies that use derivatives and/or adversely
affect the Fund's performance, efficiency in implementing its strategy, liquidity and/or ability to pursue its investment objectives.&lt;/span&gt;&lt;/p&gt;


&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Risks Associated with
the Fund's Option Strategy.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The ability of the Fund to achieve
its investment objective is partially dependent on the successful implementation of its option strategy. There are several risks associated
with transactions in options on securities used in connection with the Fund's option strategy. For example, there are significant differences
between the securities and options markets that could result in an imperfect correlation between these markets, causing a given transaction
not to achieve its objectives. A decision as to whether, when and how to use options involves the exercise of skill and judgment, and
even a well-conceived transaction may be unsuccessful to some degree because of market behavior or unexpected events.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;As the writer of a call option
covered with a security held by the Fund, the Fund forgoes, during the option's life, the opportunities to profit from increases in the
market value of the security covering the call option above the sum of the premium and the strike price of the call but retains the risk
of loss should the price of the underlying security decline. As the Fund writes such covered calls over more of its portfolio, its ability
to benefit from capital appreciation becomes more limited. To the extent the Fund writes call options that are not fully covered by securities
in its portfolio (such as calls on an index or sector), it will lose money if the portion of the security or securities underlying the
option that is not covered by securities in the Fund's portfolio appreciate in value above the exercise price of the option by an amount
that exceeds the premium received on the option plus the exercise price of the option. The amount of this loss theoretically could be
unlimited. The writer of an option has no control over the time when it may be required to fulfill its obligations as a writer of the
option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;When the Fund writes put options,
it bears the risk of loss if the value of the underlying stock declines below the exercise price minus the put premium. If the option
is exercised, the Fund could incur a loss if it is required to purchase the stock underlying the put option at a price greater than the
market price of the stock at the time of exercise plus the put premium the Fund received when it wrote the option. While the Fund's potential
gain as the writer of a&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;covered put option is limited
to the premium received from the purchaser of the put option, the Fund risks a loss equal to the entire exercise price of the option minus
the put premium.&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Interest Rate Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
Prices of fixed-income securities generally rise and fall in response to interest rate changes. Generally, the prices of fixed-rate instruments
held by the Fund will tend to fall as interest rates rise. Conversely, when interest rates decline, the value of fixed-rate instruments
held by the Fund can be expected to rise. Changing interest rates may have unpredictable effects on the markets, may result in heightened
market volatility and may detract from Fund performance. In addition, changes in monetary policy may exacerbate the risks associated with
changing interest rates. The longer the duration, or price sensitivity to changes in interest rates, of the security, the more sensitive
the security is to this risk. In typical market interest rate environments, the prices of longer-term fixed-rate instruments tend to fluctuate
more in price in response to changes in market interest rates than prices of shorter-term fixed-rate instruments. A 1% increase in interest
rates would reduce the value of a $100 note by approximately one dollar if it had a one-year duration. It is difficult to predict the
magnitude, timing or direction of interest rate changes and the impact these changes will have on the Fund's investments and the markets
where it trades.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The risks attendant to changing
interest rate environments have been, and continue to be, magnified in the current economic environment. To combat rising inflation, the
Board of Governors of the Federal Reserve System increased the federal funds rate several times in 2022 and 2023.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;


&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;REIT Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
REITs whose underlying properties are concentrated in a particular industry, such as the healthcare industry, or geographic region are
subject to risks affecting such industries or regions. The securities of REITs involve greater risks than those associated with larger,
more established companies and may be subject to more abrupt or erratic price movements because of interest rate changes, economic conditions
and other factors. Securities of such issuers may lack sufficient market liquidity to enable the Fund to effect sales at an advantageous
time or without a substantial drop in price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Credit/Default Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
Loans and other debt obligation investments are subject to the risk of non-payment of scheduled principal and interest. Changes in economic
conditions or other circumstances may reduce the capacity of the party obligated to make principal and interest payments on such instruments
and may lead to defaults. Such non-payments and defaults may reduce the value of the shares and income distributions. The value of loans
and other income investments also may decline because of concerns about the issuer's ability to make principal and interest payments.
In addition, the credit ratings of loans or other income investments may be lowered if the financial condition of the party obligated
to make payments with respect to such instruments changes. Because the Fund will invest in non-investment grade securities, it will be
exposed to a greater amount of credit risk than a fund which invests solely in investment grade securities. The prices of lower grade&lt;/span&gt;&lt;/p&gt;
 &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;instruments are generally
more sensitive to negative developments, such as a decline in the issuer's revenues or a general economic downturn, than are the prices
of higher grade instruments. Credit ratings assigned by rating agencies are based on a number of factors and do not necessarily reflect
the issuer's current financial condition or the volatility or liquidity of the security. In the event of bankruptcy of the issuer of loans
or other income investments, the Fund could experience delays or limitations with respect to its ability to realize the benefits of any
collateral securing the instrument. In order to enforce its rights in the event of a default, bankruptcy or similar situation, the Fund
may be required to retain legal or similar counsel and incur additional costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Non-Investment Grade
Securities Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The Fund may invest in securities that are
rated, at the time of investment, non-investment grade quality (rated "Ba/BB+/BB+" or below by Moody's, S&amp;amp;P or Fitch, respectively),
or securities that are unrated but determined to be of comparable quality by the Investment Adviser. The Fund may invest up to 15% of
its Managed Assets in non-convertible debt securities that are, at the time of investment, rated Caa1 or lower by Moody's and CCC+ or
lower by S&amp;amp;P or Fitch, or comparably rated by another nationally recognized statistical rating organization, or, if unrated, determined
by the Investment Adviser to be of comparable credit quality. Such securities are subject to a very high credit risk. Securities of non-investment
grade quality are regarded as having predominantly speculative characteristics with respect to the issuer's capacity to pay interest and
repay principal, and are commonly referred to as "junk bonds." Non-investment grade securities and unrated securities of comparable credit
quality are subject to the increased risk of an issuer's inability to meet principal and interest payment obligations. The value of high
yield, lower quality bonds is affected by the creditworthiness of the issuers of the securities and by general economic and specific industry
conditions. These securities may be subject to greater price volatility due to such factors as specific corporate or municipal developments,
interest rate sensitivity, negative perceptions of the junk bond markets generally and less secondary market liquidity. Issuers of high
yield bonds are not as strong financially as those with higher credit ratings. These issuers are more vulnerable to financial setbacks
and recession than more creditworthy issuers, which may impair their ability to make interest and principal payments. Non-investment grade
securities may be particularly susceptible to economic downturns, specific corporate or municipal developments, interest rate sensitivity,
negative perceptions of the junk bond markets generally and less secondary market liquidity. An economic recession could disrupt severely
the market for such securities and may have an adverse impact on the value of such securities. In addition, any such economic downturn
could adversely affect the ability of the issuers of such securities to repay principal and pay interest thereon and increase the incidence
of default for such securities. Non-investment grade securities, though higher yielding, are characterized by high risk. They may be subject
to certain risks with respect to the issuing entity and to greater market fluctuations than certain lower yielding, higher rated securities.
The retail secondary market for non-investment grade securities may be less liquid than that for higher rated securities. Adverse conditions&lt;/span&gt;&lt;/p&gt;
 &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;could make it difficult at
times for the Fund to sell certain securities or could result in lower prices than those used in calculating the Fund's NAV. Because of
the substantial risks associated with investments in non-investment grade securities, you could lose money on your investment in shares
of the Fund, both in the short-term and the long-term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Counterparty Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
Many of the protections afforded to participants on some organized exchanges, such as the performance guarantee of a clearing house, might
not be available in connection with uncleared OTC transactions. Therefore, in those instances in which the Fund enters into uncleared
OTC transactions, the Fund will be subject to the risk that its direct counterparty will not perform its obligations under the transactions
and that the Fund will sustain losses. If a counterparty becomes bankrupt, the Fund may experience significant delays in obtaining recovery
(if at all) under the derivative contract in bankruptcy or other reorganization proceeding; if the Fund's claim is unsecured, the Fund
will be treated as a general creditor of such prime broker or counterparty and will not have any claim with respect to the underlying
security. The Fund may obtain only a limited recovery or may obtain no recovery in such circumstances. The counterparty risk for cleared
derivatives is generally lower than for uncleared OTC derivatives since generally a clearing organization becomes substituted for each
counterparty to a cleared derivative and, in effect, guarantees the parties' performance under the contract as each party to a trade looks
only to the clearing house for performance of financial obligations. However, there can be no assurance that the clearing house, or its
members, will satisfy its obligations to the Fund.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Regulation as a "Commodity
Pool".&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The Investment Adviser has claimed an exclusion from
the definition of the term "commodity pool operator" with respect to the Fund pursuant to Regulation 4.5 promulgated by the U.S. Commodity
Futures Trading Commission (the "CFTC"). For the Investment Adviser to continue to qualify for the exclusion under CFTC Regulation 4.5
with respect to the Fund, the aggregate initial margin and premiums required to establish our positions in derivative instruments subject
to the jurisdiction of the Commodity Exchange Act of 1936, as amended ("CEA") (other than positions entered into for hedging purposes)
may not exceed five percent of the Fund's liquidation value or, alternatively, the net notional value of the Fund's aggregate investments
in CEA-regulated derivative instruments (other than positions entered into for hedging purposes) may not exceed 100% of the Fund's liquidation
value. In the event the Investment Adviser fails to qualify for the exclusion with respect to the Fund and is required to register as
a "commodity pool operator," it will become subject to additional disclosure, recordkeeping and reporting requirements with respect to
the Fund, which may increase the Fund's expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Failure of Futures
Commission Merchants and Clearing Organizations.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The Fund may
deposit funds required to margin open positions in derivative instruments subject to the CEA with a clearing broker registered as a "futures
commission merchant" ("FCM"). The CEA requires an FCM to segregate all funds received from customers with respect to any orders for the
purchase or sale of U.S. domestic futures contracts and cleared swaps from the FCM's&lt;/span&gt;&lt;/p&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;proprietary assets. Similarly,
the CEA requires each FCM to hold in a separate secure account all funds received from customers with respect to any orders for the purchase
or sale of foreign futures contracts and segregate any such funds from the funds received with respect to domestic futures contracts.
However, all funds and other property received by a clearing broker from its customers are held by the clearing broker on a commingled
basis in an omnibus account and may be freely accessed by the clearing broker, which may also invest any such funds in certain instruments
permitted under the applicable regulation. There is a risk that assets deposited by the Fund with any swaps or futures clearing broker
as margin for futures contracts or cleared swaps may, in certain circumstances, be used to satisfy losses of other clients of the Fund's
clearing broker. In addition, the assets of the Fund may not be fully protected in the event of the clearing broker's bankruptcy, as the
Fund would be limited to recovering only a pro rata share of all available funds segregated on behalf of the clearing broker's combined
domestic customer accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Similarly, the CEA requires
a clearing organization approved by the CFTC as a derivatives clearing organization to segregate all funds and other property received
from a clearing member's clients in connection with domestic futures, swaps and options contracts from any funds held at the clearing
organization to support the clearing member's proprietary trading. Nevertheless, with respect to futures and options contracts, a clearing
organization may use assets of a non-defaulting customer held in an omnibus account at the clearing organization to satisfy payment obligations
of a defaulting customer of the clearing member to the clearing organization. As a result, in the event of a default or the clearing broker's
other clients or the clearing broker's failure to extend its own funds in connection with any such default, the Fund would not be able
to recover the full amount of assets deposited by the clearing broker on its behalf with the clearing organization.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;


&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Liquidity Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
Illiquid securities include securities the disposition of which is subject to substantial legal or contractual restrictions. The sale
of illiquid securities often requires more time and results in higher brokerage charges or dealer discounts and other selling expenses
than does the sale of securities eligible for trading on national securities exchanges or in the over-the-counter markets. Restricted
securities may sell at a price lower than similar securities that are not subject to restrictions on resale. The continued liquidity of
such securities may not be as well assured as that of publicly traded securities. During certain periods the liquidity of particular issuers
or industries, or all securities within particular investment categories, may shrink or disappear suddenly and without warning as a result
of adverse economic, market or political events, or adverse investor perceptions, whether or not accurate.&lt;/span&gt;&lt;/p&gt;


&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Equity-Linked Notes.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
Equity-linked notes ("ELNs") are hybrid securities with characteristics of both fixed income and equity securities. An ELN is a debt instrument,
usually a bond, that pays interest based upon the performance of an underlying equity, which can be a single stock, basket of stocks or
an equity index. The interest payment on an ELN may in some cases be leveraged so that, in percentage terms, it exceeds the relative performance
of the market.&lt;/span&gt;&lt;/p&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;ELNs generally are subject to
the risks associated with the securities of equity issuers, default risk and counterparty risk. Additionally, because the Fund may use
ELNs as an alternative or complement to its options strategy, the use of ELNs in this manner would expose the Fund to the risk that such
ELNs will not perform as anticipated, and the risk that the use of ELNs will expose the Fund to different or additional default and counterparty
risk as compared to a similar investment executed in an options strategy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;PIPEs Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
PIPE transactions typically involve the purchase of securities directly from a publicly traded company or its affiliates in a private
placement transaction, typically at a discount to the market price of the company's common stock. In a PIPE transaction, the Fund may
bear the price risk from the time of pricing until the time of closing. Equity issued in this manner is often subject to transfer restrictions
and is therefore less liquid than equity issued through a registered public offering. In a PIPE transaction, the Fund may bear the price
risk from the time of pricing until the time of closing. The Fund may be subject to lock-up agreements that prohibit transfers for a fixed
period of time. In addition, because the offering of the securities in a PIPE transaction is not registered under the Securities Act,
the securities are "restricted" and cannot be immediately resold by the investors into the public markets. The Fund may enter into a registration
rights agreement with the issuer pursuant to which the issuer commits to file a resale registration statement allowing the Fund to publicly
resell its securities. Accordingly, PIPE securities may be deemed illiquid. However, the ability of the Fund to freely transfer the shares
is conditioned upon, among other things, the Commission's preparedness to declare the resale registration statement effective covering
the resale of the shares sold in the private financing and the issuer's right to suspend the Fund's use of the resale registration statement
if the issuer is pursuing a transaction or some other material non-public event is occurring. Accordingly, PIPE securities may be subject
to risks associated with illiquid securities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Venture Capital Investments
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The Fund may occasionally invest in venture capital opportunities.
While these securities offer the opportunity for significant capital gains, such investments also involve a degree of risk that can result
in substantial losses. Some of the venture capital opportunities in which the Fund may invest are expected to be companies that are in
a "start-up" stage of development, have little or no operating history, operate at a loss or with substantial variations in operating
results from period to period, have limited products, markets, financial resources or management depth, or have the need for substantial
additional "follow-on" capital to support expansion or to achieve or maintain a competitive position. Such additional investments may
dilute the interests of prior investors, such as the Fund. Some of these companies may be emerging companies at the research and development
stage with no marketable or approved products or technology. There can be no assurance that securities of start-up or emerging growth
companies will, in the future, yield returns commensurate with their associated risks.&lt;/span&gt;&lt;/p&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;These investments, which are considered
Restricted Securities, will be made primarily in convertible preferred stock. The Fund may also purchase non-convertible debt securities
in connection with its venture capital investments, and otherwise when the Investment Adviser believes that such investments would be
consistent with the Fund's investment objective. While these debt investments typically will not be rated, the Investment Adviser believes
that, in light of the risk characteristics associated with investments in emerging growth companies, if such investments were to be compared
with investments rated by S&amp;amp;P or Moody's, they may be rated as low as "C" in the rating categories established by S&amp;amp;P and Moody's.
Such securities are commonly referred to as "junk bonds" and are considered, on balance, as predominantly speculative.&lt;/span&gt;&lt;/p&gt;


&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;ETFs Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
An investment in an ETF generally presents the same primary risks as an investment in a conventional fund (i.e., one that is not exchange-traded)
that has the same investment objectives, strategies and policies. In addition, an ETF may fail to accurately track the market segment
or index that underlies its investment objective. The price of an ETF can fluctuate, and the Fund could lose money investing in an ETF.
Moreover, ETFs are subject to the following risks that do not apply to conventional open-end funds: (i) the market price of the ETF's
shares may trade at a premium or a discount to their NAV; (ii) an active trading market for an ETF's shares may not develop or be maintained;
and (iii) there is no assurance that the requirements of the exchange necessary to maintain the listing of an ETF will continue to be
met or remain unchanged.&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Leverage Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
The Fund intends to use financial leverage for investment purposes. The Fund may issue preferred shares, borrow money and/or issue debt
securities ("traditional leverage"). The Fund intends to use traditional leverage through a credit facility representing up to 20% of
the Fund's Managed Assets as measured at the time when leverage is incurred. In addition, the Fund may enter into reverse repurchase agreements,
swaps, futures, forward contracts, securities lending, short sales, and other derivative transactions, that have similar effects as leverage
(collectively referred to as "effective leverage"). Furthermore, at no time will the Fund's use of leverage, either through traditional
leverage or effective leverage, exceed 30% of the Fund's Managed Assets as measured at the time when leverage is incurred. Notwithstanding
the foregoing, effective leverage incurred through the Fund's option strategy and use of derivatives for hedging purposes will not be
counted toward the Fund's limit on the use of effective leverage or in the overall 30% leverage limitation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The Fund's leveraged capital
structure creates special risks not associated with unleveraged funds having a similar investment objective and policies. These include
the possibility of greater loss and the likelihood of higher volatility of the NAV, market price and distributions of the Fund and the
asset coverage for preferred shares, if any. Such volatility may increase the likelihood of the Fund having to sell investments in order
to meet its obligations to make distributions on the preferred shares, or to redeem preferred shares when it may be disadvantageous to
do so. Also, if the Fund is utilizing leverage, a decline in NAV could affect&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;the ability of the Fund to
make distributions and such a failure to pay dividends or make distributions could result in the Fund ceasing to qualify as a regulated
investment company under the Code, as amended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Other risks and special considerations
include the risk that fluctuations in interest rates on borrowings and short-term debt or in the interest or dividend rates on any leverage
that the Fund must pay will reduce the return to the shareholders; the effects of leverage in a declining market, which are likely to
cause a greater decline in the NAV of the shares than if the Fund were not leveraged, which may result in a greater decline in the market
price of the shares. If the Fund uses leverage, the amount of fees paid to the Investment Adviser for its services will be higher than
if the Fund did not use leverage because the fees paid are calculated based on Managed Assets, which includes assets purchased with leverage.
Therefore, the Investment Adviser has a financial incentive to use leverage, which creates a conflict of interest between the Investment
Adviser and common shareholders, as only the Fund's common shareholders would bear the fees and expenses incurred through the Fund's use
of leverage, including the issuance of Preferred shares, if any. Leverage may increase operating costs, which may reduce total return.&lt;/span&gt;&lt;/p&gt;


&lt;div&gt;

&lt;p style="margin:11pt 0pt 2pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Effects of Leverage&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Assuming that leverage will
represent approximately 20% of Managed Assets and that the Fund will bear expenses relating to that leverage at an annual cost of 1.00%,
Fund performance before leverage (net of expenses) must exceed .2% in order to cover the expenses specifically related to the Fund's use
of leverage. Actual leverage expenses will vary frequently and may be significantly higher or lower than the rate estimated above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;As of September 30, 2023 and
the most recently signed line of credit agreement, the Fund projects an annual leverage expense of 6.57%. The Fund had $120,000,000 of
funds drawn on its line of credit which was 21.2% of Managed Assets as of September 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 8pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The following table is furnished
in response to requirements of the SEC. It is designed to illustrate the effects of leverage on total returns from an investment in the
Fund assuming investment portfolio returns before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage
representing 20% of the Fund's Managed Assets and the Fund's currently projected annual leverage expense of 6.57%.&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:143;background-color:#cceeff"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;Assumed
        Fund Return Before Leverage&lt;/span&gt;&lt;br/&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(Net of Expenses) &lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(10.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(5.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;0.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:29;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;5.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:33;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;10.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:143"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;Assumed Fund Return Inclusive of Leverage &lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(14.14&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(7.89&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(1.64&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:29"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;4.61&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:33"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;10.89&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Assumed Fund performance before
and inclusive of leverage are hypothetical and are provided to assist investors in understanding the effects of leverage. Actual performance
experienced by the Fund may be lesser or greater than that shown above.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;
 &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Restricted Securities
and Valuation Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Some of the Fund's investments are subject
to restrictions on resale and generally have no established trading market or are otherwise illiquid with little or no trading activity.
The valuation process requires an analysis of various factors. The Fund's fair value methodology includes the examination of, among other
things, (i) the existence of any contractual restrictions on the disposition of the securities; (ii) information obtained from the issuer
which may include an analysis of the company's financial statements, the company's products or intended markets, or the company's technologies;
and (iii) the price of a security sold at arm's length in an issuer's subsequent completed round of financing. As there is typically no
readily available market value for some of the Restricted Securities in the Fund's portfolio, such Restricted Securities in the Fund's
portfolio are valued at fair value as determined in good faith by or under the direction of the Board pursuant to the Fund's valuation
policy and a consistently applied valuation process. Because of the inherent uncertainty of determining the fair value of investments
that do not have a readily available market value, the fair value of the Fund's investments determined in good faith by the Board may
differ significantly from the values that would have been used had a ready market existed for the investments, and the differences could
be material. There is no single standard for determining fair value in good faith. As a result, determining fair value requires that judgment
be applied to the specific facts and circumstances of each portfolio investment, while employing a consistently applied valuation process
for the types of investments the Fund makes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Key Personnel Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
There may be only a limited number of securities professionals who have comparable experience to that of the Fund's existing portfolio
management team in the area of healthcare companies. If one or more of the team members dies, resigns, retires or is otherwise unable
to act on behalf of the Investment Adviser, there can be no assurance that a suitable replacement could be found immediately.&lt;/span&gt;&lt;/p&gt;


&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Anti-Takeover Provisions
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The Fund's Amended and Restated Declaration of Trust ("Declaration
of Trust"), dated March 5, 2015, as amended, has provisions that could have the effect of limiting the ability of other entities or persons
to (1) acquire control of the Fund, (2) cause it to engage in certain transactions, or (3) modify its structure. The By-Laws also contain
provisions regarding qualifications for nominees for Trustee positions, advance notice of Shareholder proposals, and requirements for
the call of special Shareholder meetings. These provisions may be considered "anti-takeover" provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Related Party Transactions
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The majority of the Board is unaffiliated with the Investment
Adviser; nevertheless, the Fund may be subject to certain potential conflicts of interest. Although the Fund has no obligation to do so,
it may place brokerage orders with brokers who provide supplemental investment research and market and statistical information about healthcare
companies and the healthcare industries. In addition, other investment companies advised by the Investment Adviser may concurrently invest
with the Fund in restricted securities under certain conditions. The Fund also may invest, subject to&lt;/span&gt;&lt;/p&gt;  &lt;/div&gt;


&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;applicable law, in companies
in which the principals of the Investment Adviser or Trustees of the Fund have invested, or for which they serve as directors or executive
officers. The Investment Company Act prohibits the Fund from engaging in certain transactions involving its "affiliates," including, among
others, the Fund's Trustees, officers and employees, the Investment Adviser and any "affiliates" of such affiliates except pursuant to
an exemptive order or the provisions of certain rules under the Investment Company Act. In the view of the staff of the Commission, other
investment companies advised by the Investment Adviser may, in some instances, be viewed to be affiliates of the Fund. Such legal restrictions
and delays and costs involved in obtaining necessary regulatory approvals may preclude or discourage the Fund from making certain investments
and no assurance can be given that any exemptive order sought by the Fund will be granted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Government Intervention.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
Instability in the financial markets has led the U.S. government and certain foreign governments to take a number of unprecedented actions
designed to support certain financial institutions and segments of the financial markets that have experienced extreme volatility, and
in some cases a lack of liquidity, including through direct purchases of equity and debt securities. Federal, state, and foreign governments,
their regulatory agencies or self-regulatory organizations may take actions that affect the regulation of the issuers in which the Fund
invests in ways that are unforeseeable. Legislation or regulation may also change the way in which the Fund is regulated. Such legislation
or regulation could limit or preclude the Fund's ability to achieve its investment objective.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 8pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Market Disruption
and Geopolitical Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The value of your investment in the Fund
is based on the market prices of the securities the Fund holds. These prices change daily due to economic and other events that affect
markets generally, as well as those that affect particular regions, countries, industries, companies or governments. These price movements,
sometimes called volatility, may be greater or less depending on the types of securities the Fund owns and the markets in which the securities
trade. The increasing interconnectivity between global economies and financial markets increases the likelihood that events or conditions
in one region or financial market may adversely impact issuers in a different country, region or financial market. Securities in the Fund's
portfolio may underperform due to inflation (or expectations for inflation), interest rates, global demand for particular products or
resources, natural/environmental disasters, pandemics, epidemics, terrorism, cyber-attacks, regulatory events and governmental or quasi-governmental
actions. The occurrence of global events similar to those in recent years, such as terrorist attacks around the world, natural disasters,
social and political discord or debt crises and downgrades, among others, may result in market volatility and may have long term effects
on both the U.S. and global financial markets. A disruption of financial markets or other terrorist attacks could adversely affect Fund
service providers and/or the Fund's operations as well as interest rates, secondary trading, credit risk, inflation and other factors
relating to the shares. The Fund cannot predict the effects or likelihood of similar events in the future on the U.S. and world economies,
the value of the shares or the NAV of the Fund.&lt;/span&gt;&lt;/p&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 8pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Social, political, economic
and other conditions and events, such as natural/environmental disasters, health emergencies (e.g., epidemics and pandemics such as COVID-19,
avian influenza and HINI/09), cyber-attacks, terrorism, actual or threatened wars or other armed conflicts (such as the Russia/Ukraine
and Israel/Hamas conflicts), may occur and could significantly impact issuers, industries, governments and other systems, including the
financial markets. These impacts could negatively affect the Fund's investments in securities and instruments that are economically tied
to the applicable region, and include (but are not limited to) declines in value and reductions in liquidity. In addition, to the extent
new sanctions are imposed or previously relaxed sanctions are reimposed, complying with such restrictions may prevent the Fund from pursuing
certain investments, cause delays or other impediments with respect to consummating such investments or divestments, require divestment
or freezing of investments on unfavorable terms, render divestment of underperforming investments impracticable, negatively impact the
Fund's ability to achieve its investment objective, prevent the Fund from receiving payments otherwise due it, increase diligence and
other similar costs to the Fund, render valuation of affected investments challenging, or require the Fund to consummate an investment
on terms that are less advantageous than would be the case absent such restrictions. As global systems, economies and financial markets
are increasingly interconnected, events that once had only local impact are now more likely to have regional or even global effects. Events
that occur in one country, region or financial market will, more frequently, adversely impact issuers in other countries, regions or markets.
These impacts can be exacerbated by failures of governments and societies to adequately respond to an emerging event or threat. These
types of events quickly and significantly impact markets in the U.S. and across the globe leading to extreme market volatility and disruption.
The extent and nature of the impact on supply chains or economies and markets from these events is unknown, particularly if these types
of events persist for an extended period of time. These types of events, could reduce consumer demand or economic output, result in market
closures, travel restrictions or quarantines, and generally have a significant impact on the economies and financial markets and the Investment
Adviser's investment advisory activities and services of other service providers, which in turn could adversely affect the Fund's investments
and other operations. The value of the Fund's investments may decrease as a result of such events, particularly if these events adversely
impact the operations and effectiveness of the Investment Adviser or key service providers or if these events disrupt systems and processes
necessary or beneficial to the investment advisory or other activities on behalf the Fund.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;In March 2023, several financial
institutions experienced a larger-than-expected decline in deposits and two banks, Silicon Valley Bank ("SVB") and Signature Bank, were
placed into receivership. Given the interconnectedness of the banking system, the Federal Reserve invoked the systemic risk exception,
temporarily transferred all deposits-both insured and uninsured-and substantially all the assets of the two banks into respective bridge
banks and&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;guaranteed depositors' full
access to their funds. This type of systemic risk event and/or resulting government actions can negatively impact the Funds, for example,
through less credit being available to issuers or uncertainty regarding safety of deposits at other institutions. These risks also may
adversely affect financial intermediaries, such as clearing agencies, clearing houses, banks, securities firms, and exchanges, with which
the Fund interacts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Potential Conflicts
of Interest Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The Investment Adviser's investment team is
responsible for managing the Fund as well as three other closed-end investment companies. In the future, the investment team may manage
other funds and accounts, including proprietary accounts, separate accounts and other pooled investment vehicles, such as unregistered
hedge funds. In the future, a portfolio manager may manage a separate account or other pooled investment vehicle which may have materially
higher fee arrangements than the Fund and may also have a performance-based fee. The side-by-side management of these funds or accounts
may raise potential conflicts of interest relating to cross trading, the allocation of investment opportunities and the aggregation and
allocation of trades.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Special Purpose Acquisition
Company Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The Fund may invest in SPACs. SPACs are collective
investment structures that pool funds in order to seek potential acquisition opportunities. Unless and until an acquisition is completed,
a SPAC generally invests its assets (less an amount to cover expenses) in U.S. Government securities, money market fund securities and
cash. SPACs and similar entities may be blank check companies with no operating history or ongoing business other than to seek a potential
acquisition. Certain SPACs may seek acquisitions only in limited industries or regions. If an acquisition that meets the requirements
for the SPAC is not completed within a predetermined period of time, the invested funds are returned to the entity's shareholders, unless
such shareholders approve alternative arrangements. Investments in SPACs may be illiquid and/or be subject to restrictions on resale.&lt;/span&gt;&lt;/p&gt;
 &lt;/div&gt; </cef:RiskFactorsTableTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977PortfolioMarketRiskMember"
      id="Fxbrl_20231202103347060">&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Portfolio&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Market Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
As with any investment company that invests in equity securities, the Fund is subject to market risk&#x2014;the possibility that the prices
of equity securities will&lt;/span&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;decline over short or extended
periods of time. As a result, the value of an investment in the Fund's shares will fluctuate with the market. You could lose some or all
of your investment over short or long periods of time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Political and economic news
can influence market-wide trends and can cause disruptions in the U.S. or world financial markets. Other factors may be ignored by the
market as a whole but may cause movements in the price of one company's stock or the stock of companies in one or more industries. All
of these factors may have a greater impact on initial public offerings and emerging company shares.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977SecurityMarketRiskDiscountToNetAssetValueMember"
      id="Fxbrl_20231202103529052">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Security Market Risk&#x2014;Discount
to NAV.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Shares of closed-end investment companies frequently
trade at a discount from their NAV. This characteristic is a risk separate and distinct from the risk that the Fund's NAV per share could
decrease as a result of its investment activities and may be greater for investors expecting to sell their shares in a relatively short
period of time following completion of this offering. Although the value of the Fund's net assets is generally considered by market participants
in determining whether to purchase or sell shares, whether investors will realize gains or losses upon the sale of the shares will depend
entirely upon whether the market price of the shares at the time of sale is above or below the investor's purchase price for the shares.
Because the market price of the shares will be determined by supply of and demand for the shares which will be affected by factors such
as (i) NAV, (ii) dividend and distribution levels and their stability (which will in turn be affected by levels of dividend and interest
payments by the Fund's portfolio holdings, the timing and success of the Fund's investment strategies, regulations affecting the timing
and character of Fund distributions, Fund expenses and other factors), (iii) trading volume of the shares, (iv) general market, interest
rate and economic conditions and (v) other factors that may be beyond the control of the Fund. The Fund cannot predict whether the shares
will trade at, below or above NAV or at, below or above the initial public offering price.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977EquitySecuritiesRiskMember"
      id="Fxbrl_20231202103605676">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Equity Securities
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The Fund expects to invest 60-90% of its Managed Assets
in equity securities. Equity risk is the risk that equity securities held by the Fund will fall due to general market or economic conditions,
perceptions regarding the industries in which the issuers of securities held by the Fund participate, changes in interest rates, and the
particular circumstances and performance of particular companies whose securities the Fund holds. The price of an equity security of an
issuer may be particularly sensitive to general movements in the stock market, or a drop in the stock market may depress the price of
most or all of the equity securities held by the Fund. In addition, equity securities held by the Fund may decline in price if the issuer
fails to make anticipated distributions or dividend payments because, among other reasons, the issuer experiences a decline in its financial
condition. The Fund's expected investments in preferred stocks carries its own unique risks. Preferred stocks are typically subordinated
to bonds and other debt instruments in a company's capital structure, in terms of priority to corporate income, and therefore will be
subject to greater credit risk than those debt instruments. In addition, unlike interest payments on debt securities,&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;preferred stock dividends
are payable only if declared by the issuer's board of directors. The prices of preferred stock also tend to move upwards slower than common
stock prices and the preferred stock may be substantially less liquid than common stock or other securities.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977ConvertibleSecuritiesRiskMember"
      id="Fxbrl_20231202103613296">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Convertible Securities
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Convertible Securities generally offer lower interest
or dividend yields than nonconvertible debt securities of similar quality. The market value of convertible securities tends to decline
as interest rates increase and, conversely, tends to increase as interest rates decline. In addition, because of the conversion feature,
the market value of convertible securities tends to vary with fluctuations in the market value of the underlying common stock. When the
market price of the underlying common stock approaches or is greater than the convertible security's conversion price, the prices of the
convertible securities tend to rise as a reflection of the value of the underlying common stock. The conversion prior is defined as the
predetermined price at which the convertible security could be exchanged for the associated stock. Consequently, a unique feature of convertible
securities is that as the market price of the underlying common stock declines, convertible securities tend to trade increasingly on a
yield basis, and so may not experience market value declines to the same extent as the underlying common stock. Investments in convertible
securities generally entail less risk than investments in common stock of the same issuer but more risk than the issuer's debt obligations.&lt;/span&gt;&lt;/p&gt;
</cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977SelectionRiskMember"
      id="Fxbrl_20231202103619535">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Selection Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
Different types of equity securities tend to shift into and out of favor with investors, depending on market and economic conditions.
The performance of funds that invest in healthcare industry equity securities may at times be better or worse than the performance of
funds that focus on other types of securities or that have a broader investment style.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977ConcentrationInHealthcareIndustriesMember"
      id="Fxbrl_20231202103624052">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Concentration in the
Healthcare Industries.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Under normal market conditions, the Fund
expects to invest at least 80% of its Managed Assets in securities of healthcare companies. As a result, the Fund's portfolio will likely
be more sensitive to, and possibly more adversely affected by, regulatory, economic or political factors or trends relating to the healthcare,
agricultural and environmental technology industries than a portfolio of companies representing a larger number of industries. The risk
is in addition to the risks normally associated with any strategy seeking capital appreciation by investing in a portfolio of equity securities.
As a result of its concentration policy, the Fund's investments may be subject to greater risk and market fluctuation than a fund that
has securities representing a broader range of investments. The healthcare industries can be volatile. The Fund may occasionally make
investments in a company with the objective of controlling or influencing the management and policies of that company, which could potentially
make the Fund more susceptible to declines in the value of the company's stock. The Investment Adviser may seek control in public companies
only occasionally and most often in companies with a small capitalization.&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Healthcare companies have in the
past been characterized by limited product focus, rapidly changing technology and extensive government regulation. In particular, technological
advances can render an existing product, which may account for a disproportionate share of a company's revenue, obsolete. Obtaining governmental
approval from U.S. governmental agencies such as the Food and Drug Administration (the "FDA"), and from non-U.S. governmental agencies
for new products can be lengthy, expensive and uncertain as to outcome. Such delays in product development may result in the need to seek
additional capital, potentially diluting the interests of existing investors such as the Fund. In addition, governmental agencies may,
for a variety of reasons, restrict the release of certain innovative technologies of commercial significance. These various factors may
result in abrupt advances and declines in the securities prices of particular companies and, in some cases, may have a broad effect on
the prices of securities of companies in particular healthcare industries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;A concentration of investments
in any healthcare industry or in healthcare companies generally may increase the risk and volatility of an investment company's portfolio.
Such volatility is not limited to the biotechnology industry, and companies in other industries may be subject to similar abrupt movements
in the market prices of their securities. No assurance can be given that future declines in the market prices of securities of companies
in the industries in which the Fund may invest will not occur, or that such declines will not adversely affect the NAV or the price of
the shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Intense competition exists
within and among certain healthcare industries, including competition to obtain and sustain proprietary technology protection, including
patents, trademarks and other intellectual property rights, upon which healthcare companies can be highly dependent for maintenance of
profit margins and market exclusivity. The complex nature of the technologies involved can lead to patent disputes, including litigation
that may be costly and that could result in a company losing an exclusive right to a patent.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;With respect to healthcare
industries, cost containment measures already implemented by national governments, state or provincial governments and the private sector
have adversely affected certain sectors of these industries. The implementation of the Affordable Care Act ("ACA") has created increased
demand for healthcare products and services, but potential changes to the ACA and future healthcare laws and regulations may impact demand
for healthcare products and services and has had or may have an adverse effect on some companies in the healthcare industries. Increased
emphasis on managed care in the United States and a shift toward value based payment models may put pressure on the price and usage of
products sold by healthcare companies in which the Fund may invest and may adversely affect the sales and revenues of healthcare companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Product development efforts
by healthcare companies may not result in commercial products for many reasons, including, but not limited to, failure to achieve acceptable
clinical trial results, limited effectiveness in treating the specified condition or illness, harmful side effects,&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;


&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;failure to obtain regulatory
approval, and high manufacturing costs. Even after a product is commercially released, governmental agencies may require additional clinical
trials or change the labeling requirements for products if additional product side effects are identified, which could have a material
adverse effect on the market price of the securities of those healthcare companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Certain healthcare companies
in which the Fund may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing
and sale of pharmaceuticals, medical devices or other products. A product liability claim may have a material adverse effect on the business,
financial condition or securities prices of a company in which the Fund has invested.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;All of these factors as well
as others may cause the value of the Fund's shares to fluctuate significantly over relatively short periods of time.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;
</cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977PharmaceuticalSectorRiskMember"
      id="Fxbrl_20231202103631700">

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Pharmaceutical Sector
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The success of companies in the pharmaceutical sector
is highly dependent on the development, procurement and marketing of drugs. The values of pharmaceutical companies are also dependent
on the development, protection and exploitation of intellectual property rights and other proprietary information, and the profitability
of pharmaceutical companies may be significantly affected by such things as the expiration of patents or the loss of, or the inability
to enforce, intellectual property rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The research and other costs
associated with developing or procuring new drugs and the related intellectual property rights can be significant, and the results of
such research and expenditures are unpredictable. There can be no assurance that those efforts or costs will result in the development
of a profitable drug. Pharmaceutical companies may be susceptible to product obsolescence. Pharmaceutical companies also face challenges
posed by the increased presence of counterfeit pharmaceutical products, which may negatively impact revenues and patient confidence. Many
pharmaceutical companies face intense competition from new products and less costly generic products. Moreover, the process for obtaining
regulatory approval by the FDA or other U.S. and non-U.S. governmental regulatory authorities is long and costly and there can be no assurance
that the necessary approvals will be obtained or maintained.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The pharmaceutical sector
is also subject to rapid and significant technological change and competitive forces that may make drugs obsolete or make it difficult
to raise prices and, in fact, may result in price discounting. Companies in the pharmaceutical sector may also be subject to expenses
and losses from extensive litigation based on intellectual property, product liability and similar claims. Failure of pharmaceutical companies
to comply with applicable laws and regulations can result in the imposition of civil and criminal fines, penalties and, in some instances,
exclusion of participation in government sponsored programs such as Medicare and Medicaid.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Companies in the pharmaceutical
sector may be adversely affected by government regulation and changes in reimbursement rates. The ability of many pharmaceutical companies
to commercialize and monetize current and any future products depends in part on the extent to which reimbursement for the cost of such
products and related treatments are available from third party payors, such as Medicare, Medicaid, private health insurance plans and
health maintenance organizations. Third-party payors are increasingly challenging the price and cost-effectiveness of many medical products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Significant uncertainty exists
as to the reimbursement status of health care products, and there can be no assurance that adequate third-party coverage will be available
for pharmaceutical companies to obtain satisfactory price levels for their products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The international operations
of many pharmaceutical companies expose them to risks associated with instability and changes in economic and political conditions, foreign
currency fluctuations, changes in foreign regulations and other risks inherent to international business. Additionally, a pharmaceutical
company's valuation can often be based largely on the potential or actual performance of a limited number of products. A pharmaceutical
company's valuation can also be greatly affected if one of its products proves unsafe, ineffective or unprofitable. Such companies also
may be characterized by thin capitalization and limited markets, financial resources or personnel, as well as dependence on wholesale
distributors. The stock prices of companies in the pharmaceutical industry have been and will likely continue to be extremely volatile.&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977BiotechnologyIndustryRiskMember"
      id="Fxbrl_20231202103640523">

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Biotechnology Industry
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The success of biotechnology companies is highly dependent
on the development, procurement and/or marketing of drugs. The values of biotechnology companies are also dependent on the development,
protection and exploitation of intellectual property rights and other proprietary information, and the profitability of biotechnology
companies may be significantly affected by such things as the expiration of patents or the loss of, or the inability to enforce, intellectual
property rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The research and other costs
associated with developing or procuring new drugs, products or technologies and the related intellectual property rights can be significant,
and the results of such research and expenditures are unpredictable. There can be no assurance that those efforts or costs will result
in the development of a profitable drug, product or technology. Moreover, the process for obtaining regulatory approval by the FDA or
other U.S. and non-U.S. governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals
will be obtained or maintained.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The biotechnology sector is
also subject to rapid and significant technological change and competitive forces that may make drugs, products or technologies obsolete
or make it difficult to raise prices and, in fact, may result in price discounting. Companies in the biotechnology sector may also be
subject to expenses and losses from extensive litigation&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;based on intellectual property,
product liability and similar claims. Failure of biotechnology companies to comply with applicable laws and regulations can result in
the imposition of civil and/or criminal fines, penalties and, in some instances, exclusion of participation in government sponsored programs
such as Medicare and Medicaid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Companies in the biotechnology
sector may be adversely affected by government regulation and changes in reimbursement rates. Healthcare providers, principally hospitals,
that transact with companies in the biotechnology industry, often rely on third party payors, such as Medicare, Medicaid, private health
insurance plans and health maintenance organizations to reimburse all or a portion of the cost of healthcare related products or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Biotechnology companies will
continue to be affected by the efforts of governments and third party payors to contain or reduce health care costs. For example, certain
foreign markets control pricing or profitability of biotechnology products and technologies. In the United States, there has been, and
there will likely continue to be, a number of federal and state proposals to implement similar controls.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;A biotechnology company's
valuation could be based on the potential or actual performance of a limited number of products and could be adversely affected if one
of its products proves unsafe, ineffective or unprofitable. Such companies may also be characterized by thin capitalization and limited
markets, financial resources or personnel. The stock prices of companies involved in the biotechnology sector have been and will likely
continue to be extremely volatile.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977ManagedCareSectorRiskMember"
      id="Fxbrl_20231202103647195">

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Managed Care Sector
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Companies in the managed care sector often assume the
risk of both medical and administrative costs for their customers in return for monthly premiums. The profitability of these products
depends in large part on the ability of such companies to predict, price for, and effectively manage medical costs. Managed care companies
base the premiums they charge and their Medicare bids on estimates of future medical costs over the fixed contract period; however, many
factors may cause actual costs to exceed what was estimated and reflected in premiums or bids. These factors may include medical cost
inflation, increased use of services, increased cost of individual services, natural catastrophes or other large-scale medical emergencies,
epidemics, the introduction of new or costly treatments and technology, new mandated benefits (such as the expansion of essential benefits
coverage) or other regulatory changes and insured population characteristics. Relatively small differences between predicted and actual
medical costs or utilization rates as a percentage of revenues can result in significant changes in financial results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Managed care companies are
regulated at the federal, state, local and international levels. Insurance and Health Maintenance Organization ("HMO") subsidiaries must
be licensed by and are subject to the regulations of the jurisdictions in which they conduct business. U.S. health plans and insurance
companies are also regulated under state insurance holding&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;company regulations, and some
of their activities may be subject to other health care-related regulations. The health care industry is also regularly subject to negative
publicity, including as a result of governmental investigations, adverse media coverage and political debate surrounding industry regulation.
Negative publicity may adversely affect stock price, damage the reputation of managed care companies in various markets or foster an increasingly
active regulatory environment, which, in turn, could further increase the regulatory burdens under which such companies operate and their
costs of doing business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The evolution of the ACA and
other regulatory reforms could materially and adversely affect the manner in which U.S. managed care companies conduct business and their
results of operations, financial position and cash flows. The ACA includes guaranteed coverage and expanded benefit requirements, eliminates
pre-existing condition exclusions and annual and lifetime maximum limits, restricts the extent to which policies can be rescinded, establishes
minimum medical loss ratios, creates a federal premium review process, imposes new requirements on the format and content of communications
(such as explanations of benefits) between health insurers and their members, grants to members new and additional appeal rights, and
imposes new and significant taxes on health insurers and health care benefits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;New laws or regulations could
drive substantial change to the way healthcare products and services are currently delivered and paid for in the United States. Health
plans and insurance companies could face meaningful disruption or disintermediation if the U.S. migrates to a single payer healthcare
system where the government acts as the sole payer of healthcare services for the entire population. A transformative overhaul of the
U.S. healthcare system could impact the financial viability of managed care companies in which the Fund may invest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Managed care companies contract
with physicians, hospitals, pharmaceutical benefit service providers, pharmaceutical manufacturers, and other health care providers for
services. Such companies' results of operations and prospects are substantially dependent on their continued ability to contract for these
services at competitive prices. Failure to develop and maintain satisfactory relationships with health care providers, whether in-network
or out-of-network, could materially and adversely affect business, results of operations, financial position and cash flows.&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977LifeScienceAndToolsIndustryRiskMember"
      id="Fxbrl_20231202103654176">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Life Science and Tools
Industry Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Life sciences industries are characterized by
limited product focus, rapidly changing technology and extensive government regulation. In particular, technological advances can render
an existing product, which may account for a disproportionate share of a company's revenue, obsolete. Obtaining governmental approval
from agencies such as the FDA, U.S. Department of Agriculture and other U.S. and non-U.S. governmental agencies for new products can be
lengthy, expensive and uncertain as to outcome. Such delays in product development may result in the need to seek additional capital,
potentially diluting the interests of existing investors such as the Fund. In addition,&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;governmental agencies may,
for a variety of reasons, restrict the release of certain innovative technologies of commercial significance, such as genetically altered
material. These various factors may result in abrupt advances and declines in the securities prices of particular companies and, in some
cases, may have a broad effect on the prices of securities of companies in particular life sciences industries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Intense competition exists
within and among certain life sciences industries, including competition to obtain and sustain proprietary technology protection. Life
sciences companies can be highly dependent on the strength of patents, trademarks and other intellectual property rights for maintenance
of profit margins and market share. The complex nature of the technologies involved can lead to patent disputes, including litigation
that could result in a company losing an exclusive right to a patent. Competitors of life sciences companies may have substantially greater
financial resources, more extensive development, manufacturing, marketing and service capabilities, and a larger number of qualified managerial
and technical personnel. Such competitors may succeed in developing technologies and products that are more effective or less costly than
any that may be developed by life sciences companies in which the Fund invests and may also prove to be more successful in production
and marketing. Competition may increase further as a result of potential advances in health services and medical technology and greater
availability of capital for investment in these fields.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;With respect to healthcare,
cost containment measures already implemented by national governments, state or provincial governments, international organizations and
the private sector have adversely affected certain sectors of these industries. Increased emphasis on managed care in the United States
may put pressure on the price and usage of products sold by life sciences companies in which the Fund may invest and may adversely affect
the sales and revenues of life sciences companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Product development efforts
by life sciences companies may not result in commercial products for many reasons, including, but not limited to, failure to achieve acceptable
clinical trial results, limited effectiveness in treating the specified condition or illness, harmful side effects, failure to obtain
regulatory approval, and high manufacturing costs. Even after a product is commercially released, governmental agencies may require additional
clinical trials or change the labeling requirements for products if additional product side effects are identified, which could have a
material adverse effect on the market price of the securities of those life sciences companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Certain life sciences companies
in which the Fund may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing
and sale of pharmaceuticals, medical devices or other products. There can be no assurance that a product liability claim would not have
a material adverse effect on the business, financial condition or securities prices of a company in which the Fund has invested.&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareTechnologySectorRiskMember"
      id="Fxbrl_20231202103703595">

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Healthcare Technology
Sector Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Companies in the healthcare technology sector may
incur substantial costs related to product-related liabilities. Many of the software solutions, health care devices or services developed
by such companies are intended for use in collecting, storing and displaying clinical and health care-related information used in the
diagnosis and treatment of patients and in related health care settings such as admissions, billing, etc. The limitations of liability
set forth in the companies' contracts may not be enforceable or may not otherwise protect these companies from liability for damages.
Healthcare technology companies may also be subject to claims that are not covered by contract, such as a claim directly by a patient.
Although such companies may maintain liability insurance coverage, there can be no assurance that such coverage will cover any particular
claim that has been brought or that may be brought in the future, that such coverage will prove to be adequate or that such coverage will
continue to remain available on acceptable terms, if at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Healthcare technology companies
may experience interruption at their data centers or client support facilities. The business of such companies often relies on the secure
electronic transmission, data center storage and hosting of sensitive information, including protected health information, financial information
and other sensitive information relating to clients, company and workforce. In addition, such companies may perform data center and/or
hosting services for certain clients, including the storage of critical patient and administrative data and support services through various
client support facilities. If any of these systems are interrupted, damaged or breached by an unforeseen event or actions of a third party,
including a cyber-attack, or fail for any extended period of time, it could have a material adverse impact on the results of operations
for such companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The proprietary technology
developed by healthcare technology companies may be subject to claims for infringement or misappropriation of intellectual property rights
of others, or may be infringed or misappropriated by others. Despite protective measures and intellectual property rights, such companies
may not be able to adequately protect against theft, copying, reverse-engineering, misappropriation, infringement or unauthorized use
or disclosure of their intellectual property, which could have an adverse effect on their competitive position. In addition, these companies
are routinely involved in intellectual property infringement or misappropriation claims and it is expected that this activity will continue
or even increase as the number of competitors, patents and patent enforcement organizations in the healthcare technology market increases,
the functionality of software solutions and services expands, the use of open-source software increases and new markets such as health
care device innovation, health care transactions, revenue cycle, population health management and life sciences are entered into. These
claims, even if not meritorious, are expensive to defend and are often incapable of prompt resolution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The success of healthcare
technology companies depends upon the recruitment and retention of key personnel. To remain competitive, such companies must attract,
motivate and retain&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;highly skilled managerial,
sales, marketing, consulting and technical personnel, including executives, consultants, programmers and systems architects skilled in
healthcare technology, health care devices, health care transactions, population health management, revenue cycle and life sciences industries
and the technical environments in which solutions, devices and services are needed. Competition for such personnel in the healthcare technology
sector is intense in both the United States and abroad. The failure to attract additional qualified personnel could have a material adverse
effect on healthcare technology companies' prospects for long-term growth.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareServicesSectorRiskMember"
      id="Fxbrl_20231202103711415">

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Healthcare Services
Sector Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The operations of healthcare services companies
are subject to extensive federal, state and local government regulations, including Medicare and Medicaid payment rules and regulations,
federal and state anti-kickback laws, the physician self-referral law ("Stark Law") and analogous state self-referral prohibition statutes,
Federal Acquisition Regulations, the False Claims Act and federal and state laws regarding the collection, use and disclosure of patient
health information and the storage, handling and administration of pharmaceuticals. The Medicare and Medicaid reimbursement rules related
to claims submission, enrollment and licensing requirements, cost reporting, and payment processes impose complex and extensive requirements
upon dialysis providers as well. A violation or departure from any of these legal requirements may result in government audits, lower
reimbursements, significant fines and penalties, the potential loss of certification, recoupment efforts or voluntary repayments. If healthcare
services companies fail to adhere to all of the complex government regulations that apply to their businesses, such companies could suffer
severe consequences that would substantially reduce revenues, earnings, cash flows and stock prices.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;A substantial percentage of
a healthcare services company's service revenues may be generated from patients who have state Medicaid or other non-Medicare government-based
programs, such as coverage through the Department of Veterans Affairs ("VA"), as their primary coverage. As state governments and other
governmental organizations face increasing budgetary pressure, healthcare services companies may in turn face reductions in payment rates,
delays in the receipt of payments, limitations on enrollee eligibility or other changes to the applicable programs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Adverse economic conditions
could adversely affect the business and profitability of healthcare services companies. Among other things, the potential decline in federal,
non-U.S. government and state revenues that may result from such conditions may create additional pressures to contain or reduce reimbursements
for services from Medicare, Medicaid and other government sponsored programs. Increasing job losses or slow improvement in the unemployment
rate in the United States and elsewhere as a result of adverse or recent economic conditions may result in a smaller percentage of patients
being covered by an employer group health plan and a larger percentage being covered by lower paying Medicare and Medicaid programs. Employers
may also select more restrictive commercial plans with&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;lower reimbursement rates.
To the extent that payors are negatively impacted by a decline in the economy, healthcare services companies may experience further pressure
on commercial rates, a further slowdown in collections and a reduction in the amounts they expect to collect. In addition, uncertainty
in the financial markets could adversely affect the variable interest rates payable under credit facilities or could make it more difficult
to obtain or renew such facilities or to obtain other forms of financing in the future, if at all. Any or all of these factors, as well
as other consequences of the adverse economic conditions which cannot currently be anticipated, could have a material adverse effect on
a healthcare services company's revenues, earnings and cash flows and otherwise adversely affect its financial condition.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareSuppliesSectorRiskMember"
      id="Fxbrl_20231202103718987">

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Healthcare Supplies
Sector Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; If healthcare supplies companies are unable to
successfully expand their product lines through internal research and development and acquisitions, their business may be materially and
adversely affected. In addition, if these companies are unable to successfully grow their businesses through marketing partnerships and
acquisitions, their business may be materially and adversely affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Consolidation of healthcare
providers has increased demand for price concessions and caused the exclusion of suppliers from significant market segments. It is expected
that market demand, government regulation, third-party reimbursement policies, government contracting requirements and societal pressures
will continue to change the worldwide healthcare industry, resulting in further business consolidations and alliances among customers
and competitors. This may exert further downward pressure on the prices of healthcare supplies companies' products and adversely impact
their businesses, financial conditions or results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Quality is extremely important
to healthcare supplies companies and their customers due to the serious and costly consequences of product failure. Quality certifications
are critical to the marketing success of their products and services. If a healthcare supplies company fails to meet these standards or
fails to adapt to evolving standards, its reputation could be damaged, it could lose customers, and its revenue and results of operations
could decline.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareFacilitiesSectorRiskMember"
      id="Fxbrl_20231202103723901">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Healthcare Facilities
Sector Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; A healthcare facility's ability to negotiate favorable
contracts with HMOs, insurers offering preferred provider arrangements and other managed care plans significantly affects the revenues
and operating results of such healthcare facilities. In addition, private payers are increasingly attempting to control health care costs
through direct contracting with hospitals to provide services on a discounted basis, increased utilization reviews and greater enrollment
in managed care programs, such as HMOs and Preferred Provider Organizations ("PPOs"). The trend toward consolidation among private managed
care payers tends to increase their bargaining power over prices and fee structures. Non-government payers may increasingly demand reduced
fees. If a healthcare facility is unable to enter into and maintain managed care contractual arrangements on acceptable&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;terms, if it experiences material
reductions in the contracted rates received from managed care payers, or if it has difficulty collecting from managed care payers, its
results of operations could be adversely affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Further changes in the Medicare
and Medicaid programs or other government health care programs could have an adverse effect on a healthcare facility's business. In addition
to the changes affected by the ACA, the Medicare and Medicaid programs are subject to other statutory and regulatory changes, administrative
rulings, interpretations and determinations concerning patient eligibility requirements, funding levels and the method of calculating
payments or reimbursements, among other things, requirements for utilization review, and federal and state funding restrictions. All of
these could materially increase or decrease payments from government programs in the future, as well as affect the cost of providing services
to patients and the timing of payments to facilities, which could in turn adversely affect a healthcare facility's overall business, financial
condition, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Healthcare facilities are
adversely affected by uninsured and underinsured patients, as well as a growing mix of Medicare and Medicaid patients that typically have
lower reimbursement rates than commercial managed care patients As a result, healthcare facilities continue to experience a shift in payer
mix and a high level of uncollectible accounts, which could worsen if there is an increase in unemployment. Healthcare facilities may
continue to experience significant levels of bad debt expense and may have to provide uninsured discounts and charity care for undocumented
immigrants who are not permitted to enroll in a health insurance exchange or government health care program. The trend of higher co-pays
and deductibles and a focus on migrating healthcare utilization to lower cost sites of care, may also pressure volumes and revenue at
certain healthcare facilities which could adversely impact the financial condition of hospitals and facilities with high fixed cost structures.&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareEquipmentSectorRiskMember"
      id="Fxbrl_20231202103729901">

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Healthcare Equipment
Sector Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The medical device markets are highly competitive
and a healthcare equipment company many be unable to compete effectively. These markets are characterized by rapid change resulting from
technological advances and scientific discoveries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Development by other companies
of new or improved products, processes, or technologies may make a healthcare equipment company's products or proposed products less competitive.
In addition, these companies face competition from providers of alternative medical therapies such as pharmaceutical companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Medical devices and related
business activities are subject to rigorous regulation, including by the FDA, U.S. Department of Justice ("DOJ"), and numerous other federal,
state, and foreign governmental authorities. These authorities and members of Congress have been increasing their scrutiny of the healthcare
equipment industry. In addition, certain states have&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;passed or are considering
legislation restricting healthcare equipment companies' interactions with health care providers and requiring disclosure of certain payments
to them. It is anticipated that governmental authorities will continue to scrutinize this industry closely, and that additional regulation
may increase compliance and legal costs, exposure to litigation, and other adverse effects to operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Healthcare equipment companies
are substantially dependent on patent and other proprietary rights and failing to protect such rights or to be successful in litigation
related to such rights may result in the payment of significant monetary damages and/or royalty payments, may negatively impact the ability
of healthcare equipment companies to sell current or future products, or may prohibit such companies from enforcing their patent and other
proprietary rights against others.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Quality problems with the
processes, goods and services of a healthcare equipment company could harm the company's reputation for producing high-quality products
and erode its competitive advantage, sales and market share. Quality is extremely important to healthcare equipment companies and their
customers due to the serious and costly consequences of product failure. Quality certifications are critical to the marketing success
of goods and services. If a healthcare equipment company fails to meet these standards, its reputation could be damaged, it could lose
customers, and its revenue and results of operations could decline.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977HealthcareDistributorsSectorRiskMember"
      id="Fxbrl_20231202103736565">

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Healthcare Distributors
Sector Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Companies in the healthcare distribution sector
operate in markets that are highly competitive. Because of competition, many of these companies face pricing pressures from customers
and suppliers. If these companies are unable to offset margin reductions caused by pricing pressures through steps such as effective sourcing
and enhanced cost control measures, the financial condition of such companies could be adversely affected. In addition, the healthcare
industry has continued to consolidate. Further consolidation among customers and suppliers (including branded pharmaceutical manufacturers)
could give the resulting enterprises greater bargaining power, which may adversely impact the financial condition of companies in the
healthcare distribution sector.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Fewer generic pharmaceutical
launches or launches that are less profitable than those previously experienced may have an adverse effect on the profits of companies
in the healthcare distribution sector. Additionally, prices for existing generic pharmaceuticals generally decline over time, although
this may vary. Price deflation on existing generic pharmaceuticals may have an adverse effect on company profits. With respect to branded
pharmaceutical price appreciation, if branded manufacturers increase prices less frequently or by amounts that are smaller than have been
experienced historically, healthcare distribution companies may profit less from branded pharmaceutical agreements.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;


&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The healthcare industry is
highly regulated, and healthcare distribution companies are subject to regulation in the United States at both the federal and state level
and in foreign countries. If healthcare distribution companies fail to comply with these regulatory requirements, the financial condition
of such companies could be adversely affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Due to the nature of the business
of healthcare distribution companies, such companies may from time to time become involved in disputes or legal proceedings. For example,
some of the products that these companies distribute may be alleged to cause personal injury or violate the intellectual property rights
of another party, subjecting such companies to product liability or infringement claims. Litigation is inherently unpredictable, and the
unfavorable resolution of one or more of these legal proceedings could adversely affect the cash flows and balance sheets of healthcare
distribution companies. Pharmaceutical distributors currently face lawsuits related to the abuse of opioid medications in the United States.
The allegations include that pharmaceutical distributors failed to provide effective controls around the quantities of opioid medications
distributed to certain pharmacies, failed to properly prevent the diversion of medications and failed to report suspicious orders. Pharmaceutical
distributors are in discussions with federal, state and local jurisdictions related to their role in the distribution of opioid pharmaceuticals
and it is possible that they will be required to pay multi-billion dollar settlements related to the ongoing litigation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Healthcare distribution companies
depend on the availability of various components, compounds, raw materials and energy supplied by others for their operations. Any of
these supplier relationships could be interrupted due to events beyond the control of such companies, including pandemics, epidemics or
natural disasters, or could be terminated. A sustained supply interruption could have an adverse effect on business.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;
</cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977RisksAssociatedWithRegulatoryAndPolicyChangesMember"
      id="Fxbrl_20231202103742613">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Risks Associated with
Regulatory and Policy Changes.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; At any time after the date hereof,
U.S. and non-U.S. governmental agencies and other regulators may implement additional regulations and legislators may pass new laws that
affect the investments held by the Fund, the strategies used by the Fund or the level of regulation or taxation applying to the Fund.
These regulations and laws impact the investment strategies, performance, costs and operations of the Fund, as well as the way investments
in, and shareholders of, the Fund are taxed. In particular, changes to U.S. healthcare policy could affect the Fund and its investments.
The affordability of healthcare in the U.S. will remain a topic of debate, and proposals, laws and regulations to reduce the costs of
healthcare products and services could adversely impact healthcare companies that the Fund invests in.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977ForeignSecuritiesRiskMember"
      id="Fxbrl_20231202103747126">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Foreign Securities
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Foreign investments involve special risks that are not
typically associated with U.S. dollar denominated or quoted securities of U.S. issuers. Foreign investments may be affected by changes
in currency rates, changes in foreign or U.S. laws or restrictions applicable to such investments and changes in exchange control regulations
(e.g., currency blockage). A decline in the exchange rate of the currency (i.e., weakening of&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;the currency against the U.S.
dollar) in which a portfolio security is quoted or denominated relative to the U.S. dollar would reduce the value of the portfolio security.
In addition, if the currency in which the Fund receives dividends, interest or other payments declines in value against the U.S. dollar
before such income is distributed as dividends to Shareholders or converted to U.S. dollars, the Fund may have to sell portfolio securities
to obtain sufficient cash to pay such dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The Fund may invest in foreign
securities which take the form of sponsored and unsponsored American depositary receipts ("ADRs"), global depositary receipts ("GDRs"),
European depositary receipts ("EDRs") or other similar instruments representing securities of foreign issuers (together, "Depositary Receipts").
ADRs represent the right to receive securities of foreign issuers deposited in a domestic bank or a correspondent bank. ADRs are traded
on domestic exchanges or in the U.S. over-the-counter ("OTC") market and, generally, are in registered form. EDRs and GDRs are receipts
evidencing an arrangement with a non-U.S. bank similar to ADRs and are designed for use in the non-U.S. securities markets. EDRs and GDRs
are not necessarily quoted in the same currency as the underlying security. To the extent the Fund acquires Depositary Receipts through
banks which do not have a contractual relationship with the foreign issuer of the security underlying the Depositary Receipts to issue
and service such unsponsored Depositary Receipts, there is an increased possibility that the Fund will not become aware of and be able
to respond to corporate actions, such as stock splits or rights offerings, involving the foreign issuer in a timely manner. In addition,
the lack of information may result in inefficiencies in the valuation of such instruments. Investment in Depositary Receipts does not
eliminate all the risks inherent in investing in securities of non-U.S. issuers. The market value of Depositary Receipts is dependent
upon the market value of the underlying securities and fluctuations in the relative value of the currencies in which the Depositary Receipts
and the underlying securities are quoted. However, by investing in Depositary Receipts, such as ADRs, which are quoted in U.S. dollars,
the Fund may avoid currency risks during the settlement period for purchases and sales. The issuers of Depositary Receipts may discontinue
issuing new Depositary Receipts and withdraw existing Depositary Receipts at any time, which may result in costs and delays in the distribution
of the underlying assets to the Fund and may negatively impact the Fund's performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Brokerage commissions, custodial
services and other costs relating to investment in international securities markets generally are more expensive than in the United States.
In addition, clearance and settlement procedures may be different in foreign countries and, in certain markets, such procedures have been
unable to keep pace with the volume of securities transactions, thus making it difficult to conduct such transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Foreign issuers are not generally
subject to uniform accounting, auditing and financial reporting standards comparable to those applicable to U.S. issuers. There may be
less publicly available information about a foreign issuer than about a U.S. issuer. In addition, there is generally less government regulation
of foreign markets, companies and securities dealers&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;than in the United States,
and the legal remedies for investors may be more limited than the remedies available in the United States. Foreign securities markets
may have substantially less volume than U.S. securities markets and securities of many foreign issuers are less liquid and more volatile
than securities of comparable domestic issuers. Furthermore, with respect to certain foreign countries, there is a possibility of nationalization,
expropriation or confiscatory taxation, imposition of withholding or other taxes on dividend or interest payments (or, in some cases,
capital gains distributions), limitations on the removal of funds or other assets from such countries, and risks of political or social
instability or diplomatic developments which could adversely affect investments in those countries. At any time after the date hereof,
U.S. and non-U.S. governmental agencies and other regulators may implement additional regulations and legislators may pass new laws that
affect the investments held by the Fund, the strategies used by the Fund or the level of regulation or taxation applying to the Fund.
These regulations and laws impact the investment strategies, performance, costs and operations of the Fund, as well as the way investments
in, and shareholders of, the Fund are taxed. In particular, changes to U.S. healthcare policy could affect the Fund and its investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The Fund may invest in securities
of issuers located in Emerging Markets. The risks of foreign investment are heightened when the issuer is located in an emerging country.
Emerging Markets are generally located in Africa, Asia, the Middle East, Eastern Europe and Central and South America. Investments in
securities of issuers located in Emerging Markets may be subject to heightened risks, including relative illiquidity, price volatility
and potential restrictions on repatriation of investment capital and income. The Fund's purchase and sale of portfolio securities in Emerging
Markets may be constrained by limitations relating to daily changes in the prices of listed securities, periodic trading or settlement
volume and/or limitations on aggregate holdings of foreign investors. Such limitations may be computed based on the aggregate trading
volume by or holdings of the Fund, the Investment Adviser, or its affiliates and respective clients and other service providers. The Fund
may not be able to sell securities in circumstances where price, trading or settlement volume limitations have been reached.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Foreign investment in the
securities markets of certain Emerging Markets is restricted or controlled to varying degrees which may limit investment in such countries
or increase the administrative costs of such investments. For example, certain Asian countries require governmental approval prior to
investments by foreign persons or limit investment by foreign persons to only a specified percentage of an issuer's outstanding securities
or a specific class of securities which may have less advantageous terms (including price) than securities of the issuer available for
purchase by nationals. In addition, certain countries may restrict or prohibit investment opportunities in issuers or industries deemed
important to national interests. Such restrictions may affect the market price, liquidity and rights of securities that may be purchased
by the Fund. The repatriation of both investment income and capital from&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;certain Emerging Markets is
subject to restrictions such as the need for governmental consents. In situations where a country restricts direct investment in securities
(which may occur in certain Asian and other countries), the Fund may invest in such countries through other investment funds in such countries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Many Emerging Markets have
experienced currency devaluations and substantial (and, in some cases, extremely high) rates of inflation. Other Emerging Markets have
experienced economic recessions. These circumstances have had a negative effect on the economies and securities markets of those Emerging
Markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Economies in Emerging Markets
generally are dependent heavily upon commodity prices and international trade and, accordingly, have been and may continue to be affected
adversely by the economies of their trading partners, trade barriers, exchange controls, managed adjustments in relative currency values
and other protectionist measures imposed or negotiated by the countries with which they trade.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Many Emerging Markets are
subject to a substantial degree of economic, political and social instability. Governments of some emerging countries are authoritarian
in nature or have been installed or removed as a result of military coups, while governments in other Emerging Markets have periodically
used force to suppress civil dissent. Disparities of wealth, the pace and success of democratization, and ethnic, religious and racial
disaffection, among other factors, have also led to social unrest, violence and/or labor unrest in some Emerging Markets. Unanticipated
political or social developments may result in sudden and significant investment losses. Investing in Emerging Markets involves greater
risk of loss due to expropriation, nationalization, confiscation of assets and property or the imposition of restrictions on foreign investments
and on repatriation of capital invested. As an example, in the past, some Eastern European governments have expropriated substantial amounts
of private property, and many claims of the property owners have never been fully settled. There is no assurance that similar expropriations
will not occur in other countries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The Fund's investment in Emerging
Markets may also be subject to withholding or other taxes, which may be significant and may reduce the return to the Fund from an investment
in issuers in such countries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Settlement procedures in Emerging
Markets are frequently less developed and reliable than those in the United States and may involve the Fund's delivery of securities before
receipt of payment for their sale. In addition, significant delays may occur in certain markets in registering the transfer of securities.
Settlement or registration problems may make it more difficult for the Fund to value its portfolio securities and could cause the Fund
to miss attractive investment opportunities, to have a portion of its assets uninvested or to incur losses due to the failure of a counterparty
to pay for securities the Fund has delivered or the Fund's inability to complete its contractual obligations because of theft or other
reasons.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The creditworthiness of the local
securities firms used by the Fund in Emerging Markets may not be as sound as the creditworthiness of firms used in more developed countries.
As a result, the Fund may be subject to a greater risk of loss if a securities firm defaults in the performance of its responsibilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The small size and inexperience
of the securities markets in certain Emerging Markets and the limited volume of trading in securities in those countries may make the
Fund's investments in such countries less liquid and more volatile than investments in countries with more developed securities markets
(such as the United States, Japan and most Western European countries). The Fund's investments in Emerging Markets are subject to the
risk that the liquidity of a particular investment, or investments generally, in such countries will shrink or disappear suddenly and
without warning as a result of adverse economic, market or political conditions or adverse investor perceptions, whether or not accurate.
Because of the lack of sufficient market liquidity, the Fund may incur losses because it will be required to effect sales at a disadvantageous
time and only then at a substantial drop in price. Investments in Emerging Markets may be more difficult to value precisely because of
the characteristics discussed above and lower trading volumes. In addition, the impact of the economic and public health crisis in emerging
market countries may be greater due to their generally less established healthcare systems and capabilities with respect to fiscal and
monetary policies, which may exacerbate other pre-existing political, social and economic tasks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The Fund's use of foreign
currency management techniques in Emerging Markets may be limited. A significant portion of the Fund's currency exposure in Emerging Markets
may not be covered by these techniques.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977ForwardContractRiskMember"
      id="Fxbrl_20231202103822878">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Forward Contract Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
Forward contracts involve the purchase or sale of a specific quantity of a commodity, government security, foreign currency, or other
asset at a specified price, with delivery and settlement at a specified future date. Because it is a completed contract, a purchase forward
contract can be a cover for the sale of a futures contract. The Fund may enter into forward contracts for hedging purposes and non-hedging
purposes (i.e., to increase returns). Forward contracts may be used by the Fund for hedging purposes to protect against uncertainty in
the level of future foreign currency exchange rates, such as when the Fund anticipates purchasing or selling a foreign security. For example,
this technique would allow the Fund to "lock in" the U.S. dollar price of the security. Forward contracts may also be used to attempt
to protect the value of the Fund's existing holdings of foreign securities. There may be, however, an imperfect correlation between the
Fund's foreign securities holdings and the forward contracts entered into with respect to those holdings. Forward contracts may also be
used for non-hedging purposes to pursue the Fund's investment objective, such as when the Investment Adviser anticipates that particular
foreign currencies will appreciate or depreciate in value, even though securities denominated in&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;those currencies are not then
held in the Fund's portfolio. There is no requirement that the Fund hedge all or any portion of its exposure to foreign currency risks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Forward contracts, unlike
futures contracts, are not traded on exchanges and are not standardized; rather, banks and dealers act as principals in these markets,
negotiating each transaction on an individual basis. The principals who deal in the forward markets are not required to continue to make
markets in the currencies or commodities they trade and these markets can experience periods of illiquidity, sometimes of significant
duration. There have been periods during which certain participants in these markets have refused to quote prices for certain currencies
or commodities or have quoted prices with an unusually wide spread between the price at which they were prepared to buy and that at which
they were prepared to sell. Disruptions can occur in any market traded by the Investment Adviser due to unusually high trading volume,
political intervention or other factors. Arrangements to trade forward contracts may be made with only one or a few counterparties, and
liquidity problems therefore might be greater than if such arrangements were made with numerous counterparties. The imposition of controls
by governmental authorities might also limit such forward (and futures) trading to less than that which the Investment Adviser would otherwise
recommend, to the possible detriment of the Fund. Market illiquidity or disruption could result in major losses to the Fund. In addition,
the Fund will be exposed to credit risks with regard to counterparties with whom they trade as well as risks relating to settlement default.
Such risks could result in substantial losses to the Fund.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977DerivativesRiskMember"
      id="Fxbrl_20231202103828359">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Derivatives Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
The Fund may invest in derivative instruments including options, futures, options on futures, forwards, swaps (including credit default,
index, basis, total return, volatility and currency swaps), options on swaps and other derivatives, although suitable derivative instruments
may not always be available to the Investment Adviser for these purposes. The Fund intends to employ a strategy of writing (selling) covered
call options on a portion of the common stocks in its portfolio, writing (selling) put options on a portion of the common stocks in its
portfolio and, to a lesser extent, writing (selling) covered call and writing (selling) put options on indices of securities and sectors
of securities generally within the healthcare industry. This option strategy is intended to generate current income from option premiums
as a means to enhance distributions payable to the Fund's shareholders and will be limited to 30% of the Fund's Managed Assets. These
option strategies are not always profitable. The sale of a covered call option exposes the Fund during the term of the option to possible
loss of opportunity to realize appreciation in the market price of the underlying security or to possible loss due to continued holding
of a security that might otherwise have been sold to protect against depreciation in the market price of the security. To the extent the
Fund writes a covered put option, the Fund has assumed the obligation during the option period to purchase the security or securities
from the put buyer at the option's exercise price if the put buyer exercises its option, regardless of whether the value of the underlying
investment falls below the exercise price. This means that a Fund that writes a&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;put option may be required
make payment for such investment at the exercise price. This may result in losses to the Fund and may result in the Fund holding securities
for some period of time when it is disadvantageous to do so. Therefore, the Investment Adviser may choose to decrease its use of the option
writing strategy to the extent that it may negatively impact the Fund. Other than the Fund's option strategy and use of derivatives for
hedging purposes, the Fund may invest up to 10% of its Managed Assets in derivatives. Derivative instruments can be illiquid, may disproportionately
increase losses, and may have a potentially large adverse impact on Fund performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Although both OTC and exchange-traded
derivatives markets may experience a lack of liquidity, OTC nonstandardized derivative transactions are generally less liquid than exchange-traded
instruments. The illiquidity of the derivatives markets may be due to various factors, including congestion, disorderly markets, limitations
on deliverable supplies, the participation of speculators or their withdrawal from the markets, government regulation and intervention,
and technical and operational or system failures. In addition, daily limits on price fluctuations and speculative position limits on exchanges
on which the Fund may conduct its transactions in derivative instruments may prevent the Fund from liquidating these positions at an advantageous
time or price, subjecting the Fund to the potential of greater losses. Losses from investments in derivative instruments can result from
a lack of correlation between changes in the value of derivative instruments and the portfolio assets (if any) being hedged, the potential
illiquidity of the markets for derivative instruments, the failure of the counterparty to perform its contractual obligations, or the
risks arising from margin requirements and related leverage factors associated with such transactions. Losses may also arise if the Fund
receives cash collateral under the transactions and some or all of that collateral is invested in the market. To the extent that cash
collateral is so invested, such collateral will be subject to market depreciation or appreciation, and the Fund may be responsible for
any loss that might result from its investment of the counterparty's cash collateral. The use of these derivatives trading techniques
also involves the risk of loss if the Investment Adviser is incorrect in its expectation of the timing or level of fluctuations in securities
prices, interest rates or currency prices. Investments in derivative instruments may be harder to value, subject to greater volatility
and more likely subject to changes in tax treatment than other investments. For these reasons, the Investment Adviser's attempts to hedge
portfolio risks through the use of derivative instruments may not be successful. Trading in derivative instruments can increase the Fund's
exposure to leverage. Thus, the leverage offered by trading in derivative instruments will magnify the gains and losses experienced by
the Fund and could cause the Fund's net asset value to be subject to wider fluctuations than would be the case if the Fund did not use
the leverage feature in derivative instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Derivatives markets have been
subject to increased regulation over the past several years, which may continue, and consequently, may make derivatives trading more costly,
may limit the availability of and reduce the liquidity of derivatives or may otherwise adversely affect the&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;value or performance of derivatives.
Such potential adverse future developments could increase the risks reduce the effectiveness of the Fund's derivative transactions, and
cause the Fund to lose value. For instance, the SEC has adopted new regulations related to a registered investment company's use of derivatives
and related instruments. These regulations impose limits on the amount of derivatives a fund can enter into, eliminate the asset segregation
framework formerly used by funds to comply with Section 18 of the 1940 Act. These regulations may significantly impact the Fund's ability
to invest in derivatives and other instruments, limit the Fund's ability to employ certain strategies that use derivatives and/or adversely
affect the Fund's performance, efficiency in implementing its strategy, liquidity and/or ability to pursue its investment objectives.&lt;/span&gt;&lt;/p&gt;
</cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977RisksAssociatedWithFundsOptionStrategyMember"
      id="Fxbrl_20231202103835215">

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Risks Associated with
the Fund's Option Strategy.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The ability of the Fund to achieve
its investment objective is partially dependent on the successful implementation of its option strategy. There are several risks associated
with transactions in options on securities used in connection with the Fund's option strategy. For example, there are significant differences
between the securities and options markets that could result in an imperfect correlation between these markets, causing a given transaction
not to achieve its objectives. A decision as to whether, when and how to use options involves the exercise of skill and judgment, and
even a well-conceived transaction may be unsuccessful to some degree because of market behavior or unexpected events.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;As the writer of a call option
covered with a security held by the Fund, the Fund forgoes, during the option's life, the opportunities to profit from increases in the
market value of the security covering the call option above the sum of the premium and the strike price of the call but retains the risk
of loss should the price of the underlying security decline. As the Fund writes such covered calls over more of its portfolio, its ability
to benefit from capital appreciation becomes more limited. To the extent the Fund writes call options that are not fully covered by securities
in its portfolio (such as calls on an index or sector), it will lose money if the portion of the security or securities underlying the
option that is not covered by securities in the Fund's portfolio appreciate in value above the exercise price of the option by an amount
that exceeds the premium received on the option plus the exercise price of the option. The amount of this loss theoretically could be
unlimited. The writer of an option has no control over the time when it may be required to fulfill its obligations as a writer of the
option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;When the Fund writes put options,
it bears the risk of loss if the value of the underlying stock declines below the exercise price minus the put premium. If the option
is exercised, the Fund could incur a loss if it is required to purchase the stock underlying the put option at a price greater than the
market price of the stock at the time of exercise plus the put premium the Fund received when it wrote the option. While the Fund's potential
gain as the writer of a&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;covered put option is limited
to the premium received from the purchaser of the put option, the Fund risks a loss equal to the entire exercise price of the option minus
the put premium.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977InterestRatesRiskMember"
      id="Fxbrl_20231202103841443">

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Interest Rate Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
Prices of fixed-income securities generally rise and fall in response to interest rate changes. Generally, the prices of fixed-rate instruments
held by the Fund will tend to fall as interest rates rise. Conversely, when interest rates decline, the value of fixed-rate instruments
held by the Fund can be expected to rise. Changing interest rates may have unpredictable effects on the markets, may result in heightened
market volatility and may detract from Fund performance. In addition, changes in monetary policy may exacerbate the risks associated with
changing interest rates. The longer the duration, or price sensitivity to changes in interest rates, of the security, the more sensitive
the security is to this risk. In typical market interest rate environments, the prices of longer-term fixed-rate instruments tend to fluctuate
more in price in response to changes in market interest rates than prices of shorter-term fixed-rate instruments. A 1% increase in interest
rates would reduce the value of a $100 note by approximately one dollar if it had a one-year duration. It is difficult to predict the
magnitude, timing or direction of interest rate changes and the impact these changes will have on the Fund's investments and the markets
where it trades.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The risks attendant to changing
interest rate environments have been, and continue to be, magnified in the current economic environment. To combat rising inflation, the
Board of Governors of the Federal Reserve System increased the federal funds rate several times in 2022 and 2023.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977ReitRiskMember"
      id="Fxbrl_20231202103847054">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;REIT Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
REITs whose underlying properties are concentrated in a particular industry, such as the healthcare industry, or geographic region are
subject to risks affecting such industries or regions. The securities of REITs involve greater risks than those associated with larger,
more established companies and may be subject to more abrupt or erratic price movements because of interest rate changes, economic conditions
and other factors. Securities of such issuers may lack sufficient market liquidity to enable the Fund to effect sales at an advantageous
time or without a substantial drop in price.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977CreditDefaultRiskMember"
      id="Fxbrl_20231202103851303">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Credit/Default Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
Loans and other debt obligation investments are subject to the risk of non-payment of scheduled principal and interest. Changes in economic
conditions or other circumstances may reduce the capacity of the party obligated to make principal and interest payments on such instruments
and may lead to defaults. Such non-payments and defaults may reduce the value of the shares and income distributions. The value of loans
and other income investments also may decline because of concerns about the issuer's ability to make principal and interest payments.
In addition, the credit ratings of loans or other income investments may be lowered if the financial condition of the party obligated
to make payments with respect to such instruments changes. Because the Fund will invest in non-investment grade securities, it will be
exposed to a greater amount of credit risk than a fund which invests solely in investment grade securities. The prices of lower grade&lt;/span&gt;&lt;/p&gt;


&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;instruments are generally
more sensitive to negative developments, such as a decline in the issuer's revenues or a general economic downturn, than are the prices
of higher grade instruments. Credit ratings assigned by rating agencies are based on a number of factors and do not necessarily reflect
the issuer's current financial condition or the volatility or liquidity of the security. In the event of bankruptcy of the issuer of loans
or other income investments, the Fund could experience delays or limitations with respect to its ability to realize the benefits of any
collateral securing the instrument. In order to enforce its rights in the event of a default, bankruptcy or similar situation, the Fund
may be required to retain legal or similar counsel and incur additional costs.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977NonInvestmentGradeSecuritiesRiskMember"
      id="Fxbrl_20231202103857346">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Non-Investment Grade
Securities Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The Fund may invest in securities that are
rated, at the time of investment, non-investment grade quality (rated "Ba/BB+/BB+" or below by Moody's, S&amp;amp;P or Fitch, respectively),
or securities that are unrated but determined to be of comparable quality by the Investment Adviser. The Fund may invest up to 15% of
its Managed Assets in non-convertible debt securities that are, at the time of investment, rated Caa1 or lower by Moody's and CCC+ or
lower by S&amp;amp;P or Fitch, or comparably rated by another nationally recognized statistical rating organization, or, if unrated, determined
by the Investment Adviser to be of comparable credit quality. Such securities are subject to a very high credit risk. Securities of non-investment
grade quality are regarded as having predominantly speculative characteristics with respect to the issuer's capacity to pay interest and
repay principal, and are commonly referred to as "junk bonds." Non-investment grade securities and unrated securities of comparable credit
quality are subject to the increased risk of an issuer's inability to meet principal and interest payment obligations. The value of high
yield, lower quality bonds is affected by the creditworthiness of the issuers of the securities and by general economic and specific industry
conditions. These securities may be subject to greater price volatility due to such factors as specific corporate or municipal developments,
interest rate sensitivity, negative perceptions of the junk bond markets generally and less secondary market liquidity. Issuers of high
yield bonds are not as strong financially as those with higher credit ratings. These issuers are more vulnerable to financial setbacks
and recession than more creditworthy issuers, which may impair their ability to make interest and principal payments. Non-investment grade
securities may be particularly susceptible to economic downturns, specific corporate or municipal developments, interest rate sensitivity,
negative perceptions of the junk bond markets generally and less secondary market liquidity. An economic recession could disrupt severely
the market for such securities and may have an adverse impact on the value of such securities. In addition, any such economic downturn
could adversely affect the ability of the issuers of such securities to repay principal and pay interest thereon and increase the incidence
of default for such securities. Non-investment grade securities, though higher yielding, are characterized by high risk. They may be subject
to certain risks with respect to the issuing entity and to greater market fluctuations than certain lower yielding, higher rated securities.
The retail secondary market for non-investment grade securities may be less liquid than that for higher rated securities. Adverse conditions&lt;/span&gt;&lt;/p&gt;


&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;could make it difficult at
times for the Fund to sell certain securities or could result in lower prices than those used in calculating the Fund's NAV. Because of
the substantial risks associated with investments in non-investment grade securities, you could lose money on your investment in shares
of the Fund, both in the short-term and the long-term.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977CounterpartyRiskMember"
      id="Fxbrl_20231202103903478">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Counterparty Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
Many of the protections afforded to participants on some organized exchanges, such as the performance guarantee of a clearing house, might
not be available in connection with uncleared OTC transactions. Therefore, in those instances in which the Fund enters into uncleared
OTC transactions, the Fund will be subject to the risk that its direct counterparty will not perform its obligations under the transactions
and that the Fund will sustain losses. If a counterparty becomes bankrupt, the Fund may experience significant delays in obtaining recovery
(if at all) under the derivative contract in bankruptcy or other reorganization proceeding; if the Fund's claim is unsecured, the Fund
will be treated as a general creditor of such prime broker or counterparty and will not have any claim with respect to the underlying
security. The Fund may obtain only a limited recovery or may obtain no recovery in such circumstances. The counterparty risk for cleared
derivatives is generally lower than for uncleared OTC derivatives since generally a clearing organization becomes substituted for each
counterparty to a cleared derivative and, in effect, guarantees the parties' performance under the contract as each party to a trade looks
only to the clearing house for performance of financial obligations. However, there can be no assurance that the clearing house, or its
members, will satisfy its obligations to the Fund.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977RegulationAsCommodityPoolMember"
      id="Fxbrl_20231202103908123">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Regulation as a "Commodity
Pool".&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The Investment Adviser has claimed an exclusion from
the definition of the term "commodity pool operator" with respect to the Fund pursuant to Regulation 4.5 promulgated by the U.S. Commodity
Futures Trading Commission (the "CFTC"). For the Investment Adviser to continue to qualify for the exclusion under CFTC Regulation 4.5
with respect to the Fund, the aggregate initial margin and premiums required to establish our positions in derivative instruments subject
to the jurisdiction of the Commodity Exchange Act of 1936, as amended ("CEA") (other than positions entered into for hedging purposes)
may not exceed five percent of the Fund's liquidation value or, alternatively, the net notional value of the Fund's aggregate investments
in CEA-regulated derivative instruments (other than positions entered into for hedging purposes) may not exceed 100% of the Fund's liquidation
value. In the event the Investment Adviser fails to qualify for the exclusion with respect to the Fund and is required to register as
a "commodity pool operator," it will become subject to additional disclosure, recordkeeping and reporting requirements with respect to
the Fund, which may increase the Fund's expenses.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember"
      id="Fxbrl_20231202103913035">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Failure of Futures
Commission Merchants and Clearing Organizations.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The Fund may
deposit funds required to margin open positions in derivative instruments subject to the CEA with a clearing broker registered as a "futures
commission merchant" ("FCM"). The CEA requires an FCM to segregate all funds received from customers with respect to any orders for the
purchase or sale of U.S. domestic futures contracts and cleared swaps from the FCM's&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;proprietary assets. Similarly,
the CEA requires each FCM to hold in a separate secure account all funds received from customers with respect to any orders for the purchase
or sale of foreign futures contracts and segregate any such funds from the funds received with respect to domestic futures contracts.
However, all funds and other property received by a clearing broker from its customers are held by the clearing broker on a commingled
basis in an omnibus account and may be freely accessed by the clearing broker, which may also invest any such funds in certain instruments
permitted under the applicable regulation. There is a risk that assets deposited by the Fund with any swaps or futures clearing broker
as margin for futures contracts or cleared swaps may, in certain circumstances, be used to satisfy losses of other clients of the Fund's
clearing broker. In addition, the assets of the Fund may not be fully protected in the event of the clearing broker's bankruptcy, as the
Fund would be limited to recovering only a pro rata share of all available funds segregated on behalf of the clearing broker's combined
domestic customer accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Similarly, the CEA requires
a clearing organization approved by the CFTC as a derivatives clearing organization to segregate all funds and other property received
from a clearing member's clients in connection with domestic futures, swaps and options contracts from any funds held at the clearing
organization to support the clearing member's proprietary trading. Nevertheless, with respect to futures and options contracts, a clearing
organization may use assets of a non-defaulting customer held in an omnibus account at the clearing organization to satisfy payment obligations
of a defaulting customer of the clearing member to the clearing organization. As a result, in the event of a default or the clearing broker's
other clients or the clearing broker's failure to extend its own funds in connection with any such default, the Fund would not be able
to recover the full amount of assets deposited by the clearing broker on its behalf with the clearing organization.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;
</cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977LiquidityRiskMember"
      id="Fxbrl_20231202103919110">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Liquidity Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
Illiquid securities include securities the disposition of which is subject to substantial legal or contractual restrictions. The sale
of illiquid securities often requires more time and results in higher brokerage charges or dealer discounts and other selling expenses
than does the sale of securities eligible for trading on national securities exchanges or in the over-the-counter markets. Restricted
securities may sell at a price lower than similar securities that are not subject to restrictions on resale. The continued liquidity of
such securities may not be as well assured as that of publicly traded securities. During certain periods the liquidity of particular issuers
or industries, or all securities within particular investment categories, may shrink or disappear suddenly and without warning as a result
of adverse economic, market or political events, or adverse investor perceptions, whether or not accurate.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977EquityLinkedNotesMember"
      id="Fxbrl_20231202103923782">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Equity-Linked Notes.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
Equity-linked notes ("ELNs") are hybrid securities with characteristics of both fixed income and equity securities. An ELN is a debt instrument,
usually a bond, that pays interest based upon the performance of an underlying equity, which can be a single stock, basket of stocks or
an equity index. The interest payment on an ELN may in some cases be leveraged so that, in percentage terms, it exceeds the relative performance
of the market.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;ELNs generally are subject to
the risks associated with the securities of equity issuers, default risk and counterparty risk. Additionally, because the Fund may use
ELNs as an alternative or complement to its options strategy, the use of ELNs in this manner would expose the Fund to the risk that such
ELNs will not perform as anticipated, and the risk that the use of ELNs will expose the Fund to different or additional default and counterparty
risk as compared to a similar investment executed in an options strategy.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977PrivateInvestmentInPublicEquityRiskMember"
      id="Fxbrl_20231202103930930">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;PIPEs Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
PIPE transactions typically involve the purchase of securities directly from a publicly traded company or its affiliates in a private
placement transaction, typically at a discount to the market price of the company's common stock. In a PIPE transaction, the Fund may
bear the price risk from the time of pricing until the time of closing. Equity issued in this manner is often subject to transfer restrictions
and is therefore less liquid than equity issued through a registered public offering. In a PIPE transaction, the Fund may bear the price
risk from the time of pricing until the time of closing. The Fund may be subject to lock-up agreements that prohibit transfers for a fixed
period of time. In addition, because the offering of the securities in a PIPE transaction is not registered under the Securities Act,
the securities are "restricted" and cannot be immediately resold by the investors into the public markets. The Fund may enter into a registration
rights agreement with the issuer pursuant to which the issuer commits to file a resale registration statement allowing the Fund to publicly
resell its securities. Accordingly, PIPE securities may be deemed illiquid. However, the ability of the Fund to freely transfer the shares
is conditioned upon, among other things, the Commission's preparedness to declare the resale registration statement effective covering
the resale of the shares sold in the private financing and the issuer's right to suspend the Fund's use of the resale registration statement
if the issuer is pursuing a transaction or some other material non-public event is occurring. Accordingly, PIPE securities may be subject
to risks associated with illiquid securities.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977VentureCapitalInvestmentsRiskMember"
      id="Fxbrl_20231202103936730">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Venture Capital Investments
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The Fund may occasionally invest in venture capital opportunities.
While these securities offer the opportunity for significant capital gains, such investments also involve a degree of risk that can result
in substantial losses. Some of the venture capital opportunities in which the Fund may invest are expected to be companies that are in
a "start-up" stage of development, have little or no operating history, operate at a loss or with substantial variations in operating
results from period to period, have limited products, markets, financial resources or management depth, or have the need for substantial
additional "follow-on" capital to support expansion or to achieve or maintain a competitive position. Such additional investments may
dilute the interests of prior investors, such as the Fund. Some of these companies may be emerging companies at the research and development
stage with no marketable or approved products or technology. There can be no assurance that securities of start-up or emerging growth
companies will, in the future, yield returns commensurate with their associated risks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;These investments, which are considered
Restricted Securities, will be made primarily in convertible preferred stock. The Fund may also purchase non-convertible debt securities
in connection with its venture capital investments, and otherwise when the Investment Adviser believes that such investments would be
consistent with the Fund's investment objective. While these debt investments typically will not be rated, the Investment Adviser believes
that, in light of the risk characteristics associated with investments in emerging growth companies, if such investments were to be compared
with investments rated by S&amp;amp;P or Moody's, they may be rated as low as "C" in the rating categories established by S&amp;amp;P and Moody's.
Such securities are commonly referred to as "junk bonds" and are considered, on balance, as predominantly speculative.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977ExchangeTradedFundsRiskMember"
      id="Fxbrl_20231202103942470">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;ETFs Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
An investment in an ETF generally presents the same primary risks as an investment in a conventional fund (i.e., one that is not exchange-traded)
that has the same investment objectives, strategies and policies. In addition, an ETF may fail to accurately track the market segment
or index that underlies its investment objective. The price of an ETF can fluctuate, and the Fund could lose money investing in an ETF.
Moreover, ETFs are subject to the following risks that do not apply to conventional open-end funds: (i) the market price of the ETF's
shares may trade at a premium or a discount to their NAV; (ii) an active trading market for an ETF's shares may not develop or be maintained;
and (iii) there is no assurance that the requirements of the exchange necessary to maintain the listing of an ETF will continue to be
met or remain unchanged.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977LeverageRiskMember"
      id="Fxbrl_20231202103947774">

&lt;div&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Leverage Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
The Fund intends to use financial leverage for investment purposes. The Fund may issue preferred shares, borrow money and/or issue debt
securities ("traditional leverage"). The Fund intends to use traditional leverage through a credit facility representing up to 20% of
the Fund's Managed Assets as measured at the time when leverage is incurred. In addition, the Fund may enter into reverse repurchase agreements,
swaps, futures, forward contracts, securities lending, short sales, and other derivative transactions, that have similar effects as leverage
(collectively referred to as "effective leverage"). Furthermore, at no time will the Fund's use of leverage, either through traditional
leverage or effective leverage, exceed 30% of the Fund's Managed Assets as measured at the time when leverage is incurred. Notwithstanding
the foregoing, effective leverage incurred through the Fund's option strategy and use of derivatives for hedging purposes will not be
counted toward the Fund's limit on the use of effective leverage or in the overall 30% leverage limitation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The Fund's leveraged capital
structure creates special risks not associated with unleveraged funds having a similar investment objective and policies. These include
the possibility of greater loss and the likelihood of higher volatility of the NAV, market price and distributions of the Fund and the
asset coverage for preferred shares, if any. Such volatility may increase the likelihood of the Fund having to sell investments in order
to meet its obligations to make distributions on the preferred shares, or to redeem preferred shares when it may be disadvantageous to
do so. Also, if the Fund is utilizing leverage, a decline in NAV could affect&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;the ability of the Fund to
make distributions and such a failure to pay dividends or make distributions could result in the Fund ceasing to qualify as a regulated
investment company under the Code, as amended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Other risks and special considerations
include the risk that fluctuations in interest rates on borrowings and short-term debt or in the interest or dividend rates on any leverage
that the Fund must pay will reduce the return to the shareholders; the effects of leverage in a declining market, which are likely to
cause a greater decline in the NAV of the shares than if the Fund were not leveraged, which may result in a greater decline in the market
price of the shares. If the Fund uses leverage, the amount of fees paid to the Investment Adviser for its services will be higher than
if the Fund did not use leverage because the fees paid are calculated based on Managed Assets, which includes assets purchased with leverage.
Therefore, the Investment Adviser has a financial incentive to use leverage, which creates a conflict of interest between the Investment
Adviser and common shareholders, as only the Fund's common shareholders would bear the fees and expenses incurred through the Fund's use
of leverage, including the issuance of Preferred shares, if any. Leverage may increase operating costs, which may reduce total return.&lt;/span&gt;&lt;/p&gt;


&lt;div&gt;

&lt;p style="margin:11pt 0pt 2pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Effects of Leverage&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Assuming that leverage will
represent approximately 20% of Managed Assets and that the Fund will bear expenses relating to that leverage at an annual cost of 1.00%,
Fund performance before leverage (net of expenses) must exceed .2% in order to cover the expenses specifically related to the Fund's use
of leverage. Actual leverage expenses will vary frequently and may be significantly higher or lower than the rate estimated above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;As of September 30, 2023 and
the most recently signed line of credit agreement, the Fund projects an annual leverage expense of 6.57%. The Fund had $120,000,000 of
funds drawn on its line of credit which was 21.2% of Managed Assets as of September 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 8pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The following table is furnished
in response to requirements of the SEC. It is designed to illustrate the effects of leverage on total returns from an investment in the
Fund assuming investment portfolio returns before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage
representing 20% of the Fund's Managed Assets and the Fund's currently projected annual leverage expense of 6.57%.&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:143;background-color:#cceeff"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;Assumed
        Fund Return Before Leverage&lt;/span&gt;&lt;br/&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(Net of Expenses) &lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(10.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(5.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;0.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:29;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;5.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:33;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;10.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:143"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;Assumed Fund Return Inclusive of Leverage &lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(14.14&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(7.89&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(1.64&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:29"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;4.61&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:33"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;10.89&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Assumed Fund performance before
and inclusive of leverage are hypothetical and are provided to assist investors in understanding the effects of leverage. Actual performance
experienced by the Fund may be lesser or greater than that shown above.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;
</cef:RiskTextBlock>
    <cef:EffectsOfLeverageTextBlock
      contextRef="C_20221001to20230930"
      id="Fxbrl_20231202112444499">

&lt;div&gt;

&lt;p style="margin:11pt 0pt 2pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Effects of Leverage&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Assuming that leverage will
represent approximately 20% of Managed Assets and that the Fund will bear expenses relating to that leverage at an annual cost of 1.00%,
Fund performance before leverage (net of expenses) must exceed .2% in order to cover the expenses specifically related to the Fund's use
of leverage. Actual leverage expenses will vary frequently and may be significantly higher or lower than the rate estimated above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;As of September 30, 2023 and
the most recently signed line of credit agreement, the Fund projects an annual leverage expense of 6.57%. The Fund had $120,000,000 of
funds drawn on its line of credit which was 21.2% of Managed Assets as of September 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;

&lt;p style="margin:8pt 0pt 8pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The following table is furnished
in response to requirements of the SEC. It is designed to illustrate the effects of leverage on total returns from an investment in the
Fund assuming investment portfolio returns before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage
representing 20% of the Fund's Managed Assets and the Fund's currently projected annual leverage expense of 6.57%.&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:143;background-color:#cceeff"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;Assumed
        Fund Return Before Leverage&lt;/span&gt;&lt;br/&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(Net of Expenses) &lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(10.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(5.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;0.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:29;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;5.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:33;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;10.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:143"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;Assumed Fund Return Inclusive of Leverage &lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(14.14&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(7.89&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(1.64&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:29"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;4.61&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:33"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;10.89&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Assumed Fund performance before
and inclusive of leverage are hypothetical and are provided to assist investors in understanding the effects of leverage. Actual performance
experienced by the Fund may be lesser or greater than that shown above.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt; </cef:EffectsOfLeverageTextBlock>
    <cef:EffectsOfLeverageTableTextBlock
      contextRef="C_20221001to20230930"
      id="Fxbrl_20231202112644218">

&lt;div&gt;

&lt;p style="margin:8pt 0pt 8pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The following table is furnished
in response to requirements of the SEC. It is designed to illustrate the effects of leverage on total returns from an investment in the
Fund assuming investment portfolio returns before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage
representing 20% of the Fund's Managed Assets and the Fund's currently projected annual leverage expense of 6.57%.&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:143;background-color:#cceeff"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;Assumed
        Fund Return Before Leverage&lt;/span&gt;&lt;br/&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(Net of Expenses) &lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:35;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(10.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(5.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:31;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;0.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:24;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:29;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;5.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;vertical-align:bottom;width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:right;vertical-align:bottom;width:33;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;10.00&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 4pt 0pt;text-align:left;vertical-align:bottom;width:22;background-color:#cceeff"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8;background-color:#cceeff"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="3" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:143"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;Assumed Fund Return Inclusive of Leverage &lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:35"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(14.14&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(7.89&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:31"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;(1.64&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:24"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;)%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:29"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;4.61&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;vertical-align:bottom;width:8"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;vertical-align:bottom;width:33"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;10.89&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:left;vertical-align:bottom;width:22"&gt;
        &lt;p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"&gt;&lt;span style="font-size:8pt;font-family:Arial, Helvetica"&gt;%&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="width:8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Assumed Fund performance before
and inclusive of leverage are hypothetical and are provided to assist investors in understanding the effects of leverage. Actual performance
experienced by the Fund may be lesser or greater than that shown above.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; </cef:EffectsOfLeverageTableTextBlock>
    <cef:EffectsOfLeveragePurposeTextBlock
      contextRef="C_20221001to20230930"
      id="Fxbrl_20231202113204920">

&lt;p style="margin:8pt 0pt 8pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;The following table is furnished
in response to requirements of the SEC. It is designed to illustrate the effects of leverage on total returns from an investment in the
Fund assuming investment portfolio returns before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage
representing 20% of the Fund's Managed Assets and the Fund's currently projected annual leverage expense of 6.57%.&lt;/span&gt;&lt;/p&gt; </cef:EffectsOfLeveragePurposeTextBlock>
    <cef:ReturnAtMinusTenPercent
      contextRef="C_20221001to20230930"
      decimals="4"
      id="Fxbrl_20231202112722028_13"
      unitRef="Percent">-0.1414</cef:ReturnAtMinusTenPercent>
    <cef:ReturnAtMinusFivePercent
      contextRef="C_20221001to20230930"
      decimals="4"
      id="Fxbrl_20231202112722028_17"
      unitRef="Percent">-0.0789</cef:ReturnAtMinusFivePercent>
    <cef:ReturnAtZeroPercent
      contextRef="C_20221001to20230930"
      decimals="4"
      id="Fxbrl_20231202112722028_111"
      unitRef="Percent">-0.0164</cef:ReturnAtZeroPercent>
    <cef:ReturnAtPlusFivePercent
      contextRef="C_20221001to20230930"
      decimals="4"
      id="Fxbrl_20231202112722028_115"
      unitRef="Percent">0.0461</cef:ReturnAtPlusFivePercent>
    <cef:ReturnAtPlusTenPercent
      contextRef="C_20221001to20230930"
      decimals="4"
      id="Fxbrl_20231202112722028_119"
      unitRef="Percent">0.1089</cef:ReturnAtPlusTenPercent>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977RestrictedSecuritiesAndValuationRiskMember"
      id="Fxbrl_20231202104054873">

&lt;p style="margin:8pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Restricted Securities
and Valuation Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; Some of the Fund's investments are subject
to restrictions on resale and generally have no established trading market or are otherwise illiquid with little or no trading activity.
The valuation process requires an analysis of various factors. The Fund's fair value methodology includes the examination of, among other
things, (i) the existence of any contractual restrictions on the disposition of the securities; (ii) information obtained from the issuer
which may include an analysis of the company's financial statements, the company's products or intended markets, or the company's technologies;
and (iii) the price of a security sold at arm's length in an issuer's subsequent completed round of financing. As there is typically no
readily available market value for some of the Restricted Securities in the Fund's portfolio, such Restricted Securities in the Fund's
portfolio are valued at fair value as determined in good faith by or under the direction of the Board pursuant to the Fund's valuation
policy and a consistently applied valuation process. Because of the inherent uncertainty of determining the fair value of investments
that do not have a readily available market value, the fair value of the Fund's investments determined in good faith by the Board may
differ significantly from the values that would have been used had a ready market existed for the investments, and the differences could
be material. There is no single standard for determining fair value in good faith. As a result, determining fair value requires that judgment
be applied to the specific facts and circumstances of each portfolio investment, while employing a consistently applied valuation process
for the types of investments the Fund makes.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977KeyPersonnelRiskMember"
      id="Fxbrl_20231202104059334">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Key Personnel Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
There may be only a limited number of securities professionals who have comparable experience to that of the Fund's existing portfolio
management team in the area of healthcare companies. If one or more of the team members dies, resigns, retires or is otherwise unable
to act on behalf of the Investment Adviser, there can be no assurance that a suitable replacement could be found immediately.&lt;/span&gt;&lt;/p&gt;
</cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977AntiTakeoverProvisionsRiskMember"
      id="Fxbrl_20231202104107262">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Anti-Takeover Provisions
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The Fund's Amended and Restated Declaration of Trust ("Declaration
of Trust"), dated March 5, 2015, as amended, has provisions that could have the effect of limiting the ability of other entities or persons
to (1) acquire control of the Fund, (2) cause it to engage in certain transactions, or (3) modify its structure. The By-Laws also contain
provisions regarding qualifications for nominees for Trustee positions, advance notice of Shareholder proposals, and requirements for
the call of special Shareholder meetings. These provisions may be considered "anti-takeover" provisions.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977RelatedPartyTransactionsRiskMember"
      id="Fxbrl_20231202104111657">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Related Party Transactions
Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The majority of the Board is unaffiliated with the Investment
Adviser; nevertheless, the Fund may be subject to certain potential conflicts of interest. Although the Fund has no obligation to do so,
it may place brokerage orders with brokers who provide supplemental investment research and market and statistical information about healthcare
companies and the healthcare industries. In addition, other investment companies advised by the Investment Adviser may concurrently invest
with the Fund in restricted securities under certain conditions. The Fund also may invest, subject to&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;applicable law, in companies
in which the principals of the Investment Adviser or Trustees of the Fund have invested, or for which they serve as directors or executive
officers. The Investment Company Act prohibits the Fund from engaging in certain transactions involving its "affiliates," including, among
others, the Fund's Trustees, officers and employees, the Investment Adviser and any "affiliates" of such affiliates except pursuant to
an exemptive order or the provisions of certain rules under the Investment Company Act. In the view of the staff of the Commission, other
investment companies advised by the Investment Adviser may, in some instances, be viewed to be affiliates of the Fund. Such legal restrictions
and delays and costs involved in obtaining necessary regulatory approvals may preclude or discourage the Fund from making certain investments
and no assurance can be given that any exemptive order sought by the Fund will be granted.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977GovernmentInterventionMember"
      id="Fxbrl_20231202104119954">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Government Intervention.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;
Instability in the financial markets has led the U.S. government and certain foreign governments to take a number of unprecedented actions
designed to support certain financial institutions and segments of the financial markets that have experienced extreme volatility, and
in some cases a lack of liquidity, including through direct purchases of equity and debt securities. Federal, state, and foreign governments,
their regulatory agencies or self-regulatory organizations may take actions that affect the regulation of the issuers in which the Fund
invests in ways that are unforeseeable. Legislation or regulation may also change the way in which the Fund is regulated. Such legislation
or regulation could limit or preclude the Fund's ability to achieve its investment objective.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977MarketDisruptionAndGeopoliticalRiskMember"
      id="Fxbrl_20231202104126191">

&lt;p style="margin:8pt 0pt 8pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Market Disruption
and Geopolitical Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The value of your investment in the Fund
is based on the market prices of the securities the Fund holds. These prices change daily due to economic and other events that affect
markets generally, as well as those that affect particular regions, countries, industries, companies or governments. These price movements,
sometimes called volatility, may be greater or less depending on the types of securities the Fund owns and the markets in which the securities
trade. The increasing interconnectivity between global economies and financial markets increases the likelihood that events or conditions
in one region or financial market may adversely impact issuers in a different country, region or financial market. Securities in the Fund's
portfolio may underperform due to inflation (or expectations for inflation), interest rates, global demand for particular products or
resources, natural/environmental disasters, pandemics, epidemics, terrorism, cyber-attacks, regulatory events and governmental or quasi-governmental
actions. The occurrence of global events similar to those in recent years, such as terrorist attacks around the world, natural disasters,
social and political discord or debt crises and downgrades, among others, may result in market volatility and may have long term effects
on both the U.S. and global financial markets. A disruption of financial markets or other terrorist attacks could adversely affect Fund
service providers and/or the Fund's operations as well as interest rates, secondary trading, credit risk, inflation and other factors
relating to the shares. The Fund cannot predict the effects or likelihood of similar events in the future on the U.S. and world economies,
the value of the shares or the NAV of the Fund.&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;

&lt;p style="margin:0pt 0pt 8pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;Social, political, economic
and other conditions and events, such as natural/environmental disasters, health emergencies (e.g., epidemics and pandemics such as COVID-19,
avian influenza and HINI/09), cyber-attacks, terrorism, actual or threatened wars or other armed conflicts (such as the Russia/Ukraine
and Israel/Hamas conflicts), may occur and could significantly impact issuers, industries, governments and other systems, including the
financial markets. These impacts could negatively affect the Fund's investments in securities and instruments that are economically tied
to the applicable region, and include (but are not limited to) declines in value and reductions in liquidity. In addition, to the extent
new sanctions are imposed or previously relaxed sanctions are reimposed, complying with such restrictions may prevent the Fund from pursuing
certain investments, cause delays or other impediments with respect to consummating such investments or divestments, require divestment
or freezing of investments on unfavorable terms, render divestment of underperforming investments impracticable, negatively impact the
Fund's ability to achieve its investment objective, prevent the Fund from receiving payments otherwise due it, increase diligence and
other similar costs to the Fund, render valuation of affected investments challenging, or require the Fund to consummate an investment
on terms that are less advantageous than would be the case absent such restrictions. As global systems, economies and financial markets
are increasingly interconnected, events that once had only local impact are now more likely to have regional or even global effects. Events
that occur in one country, region or financial market will, more frequently, adversely impact issuers in other countries, regions or markets.
These impacts can be exacerbated by failures of governments and societies to adequately respond to an emerging event or threat. These
types of events quickly and significantly impact markets in the U.S. and across the globe leading to extreme market volatility and disruption.
The extent and nature of the impact on supply chains or economies and markets from these events is unknown, particularly if these types
of events persist for an extended period of time. These types of events, could reduce consumer demand or economic output, result in market
closures, travel restrictions or quarantines, and generally have a significant impact on the economies and financial markets and the Investment
Adviser's investment advisory activities and services of other service providers, which in turn could adversely affect the Fund's investments
and other operations. The value of the Fund's investments may decrease as a result of such events, particularly if these events adversely
impact the operations and effectiveness of the Investment Adviser or key service providers or if these events disrupt systems and processes
necessary or beneficial to the investment advisory or other activities on behalf the Fund.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;In March 2023, several financial
institutions experienced a larger-than-expected decline in deposits and two banks, Silicon Valley Bank ("SVB") and Signature Bank, were
placed into receivership. Given the interconnectedness of the banking system, the Federal Reserve invoked the systemic risk exception,
temporarily transferred all deposits-both insured and uninsured-and substantially all the assets of the two banks into respective bridge
banks and&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;

&lt;p style="margin:0pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;guaranteed depositors' full
access to their funds. This type of systemic risk event and/or resulting government actions can negatively impact the Funds, for example,
through less credit being available to issuers or uncertainty regarding safety of deposits at other institutions. These risks also may
adversely affect financial intermediaries, such as clearing agencies, clearing houses, banks, securities firms, and exchanges, with which
the Fund interacts.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977PotentialConflictsOfInterestRiskMember"
      id="Fxbrl_20231202104134933">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Potential Conflicts
of Interest Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The Investment Adviser's investment team is
responsible for managing the Fund as well as three other closed-end investment companies. In the future, the investment team may manage
other funds and accounts, including proprietary accounts, separate accounts and other pooled investment vehicles, such as unregistered
hedge funds. In the future, a portfolio manager may manage a separate account or other pooled investment vehicle which may have materially
higher fee arrangements than the Fund and may also have a performance-based fee. The side-by-side management of these funds or accounts
may raise potential conflicts of interest relating to cross trading, the allocation of investment opportunities and the aggregation and
allocation of trades.&lt;/span&gt;&lt;/p&gt; </cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="C_20221001to20230930_cefRiskAxis_ck0001635977SpecialPurposeAcquisitionCompanyRiskMember"
      id="Fxbrl_20231202104141560">

&lt;p style="margin:8pt 0pt 0pt 0pt;text-align:left"&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt;&lt;strong&gt;Special Purpose Acquisition
Company Risk.&lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial, Helvetica"&gt; The Fund may invest in SPACs. SPACs are collective
investment structures that pool funds in order to seek potential acquisition opportunities. Unless and until an acquisition is completed,
a SPAC generally invests its assets (less an amount to cover expenses) in U.S. Government securities, money market fund securities and
cash. SPACs and similar entities may be blank check companies with no operating history or ongoing business other than to seek a potential
acquisition. Certain SPACs may seek acquisitions only in limited industries or regions. If an acquisition that meets the requirements
for the SPAC is not completed within a predetermined period of time, the invested funds are returned to the entity's shareholders, unless
such shareholders approve alternative arrangements. Investments in SPACs may be illiquid and/or be subject to restrictions on resale.&lt;/span&gt;&lt;/p&gt;
</cef:RiskTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fxbrl_20231202131712153"
          xlink:label="Fxbrl_20231202131712153"
          xlink:type="locator"/>
        <link:footnote id="FN20231202141707772" xlink:label="FN20231202141707772" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">If Common Shares are sold to or through underwriters, a prospectus or prospectus supplement will set forth any applicable sales load and the estimated offering expenses borne by the Fund.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202131712153"
          xlink:to="FN20231202141707772"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202131721229"
          xlink:label="Fxbrl_20231202131721229"
          xlink:type="locator"/>
        <link:footnote id="FN20231202141718378" xlink:label="FN20231202141718378" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Offering expenses payable by the Fund will be deducted from the proceeds, before expenses, to the Fund.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202131721229"
          xlink:to="FN20231202141718378"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202131724023"
          xlink:label="Fxbrl_20231202131724023"
          xlink:type="locator"/>
        <link:footnote id="FN20231202141728748" xlink:label="FN20231202141728748" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The expenses of administering the Fund's Dividend Reinvestment and Stock Purchase Plan are included in "Other Expenses." You will pay brokerage charges if you direct your broker or the plan agent to sell your Shares that you acquired pursuant to the Fund's Dividend Reinvestment and Stock Purchase Plan. You may also pay a pro rata share of brokerage commissions incurred in connection with open-market purchases pursuant to the Fund's Dividend Reinvestment and Stock Purchase Plan. For more details about the Dividend Reinvestment and Stock Purchase Plan, see "Dividend Reinvestment and Stock Purchase Plan" in the Fund's Prospectus.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202131724023"
          xlink:to="FN20231202141728748"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202131857489"
          xlink:label="Fxbrl_20231202131857489"
          xlink:type="locator"/>
        <link:footnote id="FN20231202141747132" xlink:label="FN20231202141747132" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Advisory fee is charged as a percentage of the Fund's average daily Managed Assets, as opposed to net assets. If leverage is used, Managed Assets will be greater in amount than net assets, because Managed Assets includes borrowings for investment purposes.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202131857489"
          xlink:to="FN20231202141747132"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202131859366"
          xlink:label="Fxbrl_20231202131859366"
          xlink:type="locator"/>
        <link:footnote id="FN20231202141759866" xlink:label="FN20231202141759866" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The percentage in the table is based on total borrowings of $120,000,000 (the balance outstanding under the Fund's Credit Facility as of September 30, 2023, representing approximately 21.2% of the Fund's Managed Assets) and an average interest rate during the fiscal year ended September 30, 2023, of 5.77%. There can be no assurances that the Fund will be able to obtain such level of borrowing (or to maintain its current level of borrowing), that the terms under which the Fund borrows will not change, or that the Fund's use of leverage will be profitable. The Fund currently intends during the next twelve months to maintain a similar proportionate amount of borrowings but may increase such amount to 33 1/3% of the average daily value of the Fund's total assets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202131859366"
          xlink:to="FN20231202141759866"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202131906133"
          xlink:label="Fxbrl_20231202131906133"
          xlink:type="locator"/>
        <link:footnote id="FN20231202141817796" xlink:label="FN20231202141817796" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of the close of business on October 27, 2023, the Adviser has entered into a written contract with the Fund to limit the total ordinary operating expenses of the Fund (excluding leverage costs, interest, taxes, brokerage commissions, acquired fund fees and expenses and any non-routine expenses) from exceeding 1.51% of the average daily net assets of the Fund on an annualized basis for twelve months (the "Expense Limitation Agreement").The Expense Limitation Agreement may not be terminated before October 27, 2025, without the approval of the Fund's trustees who are not "interested persons" of the Fund (as defined in the 1940 Act).The Fund may repay any such reimbursement from the Adviser, within three years of the reimbursement, provided that the following requirements are met: the reimbursements do not cause the Fund to exceed the lesser of the applicable expense limitation in the contract at the time the fees were limited or expenses are paid or
                    the applicable expense limitation in effect at the time the expenses are being recouped by the Adviser. Because interest expenses and investment related expenses are not subject to the reimbursement agreement, interest expenses and investment related expenses are included in the "Total annual expenses after expense reimbursement" line item.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202131906133"
          xlink:to="FN20231202141817796"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202141040228"
          xlink:label="Fxbrl_20231202141040228"
          xlink:type="locator"/>
        <link:footnote id="FN20231202141602793" xlink:label="FN20231202141602793" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The examples above should not be considered representations of future expenses. Actual expenses may be higher or lower than those shown. The examples assume that all dividends and distributions are reinvested at net asset value. The Fund's actual rate of return may be greater or less than the hypothetical 5% return shown in the examples. For more complete descriptions of certain of the Fund's costs and expenses, see "Management of the Fund&#x2014;Advisory Agreements" in the Fund's Prospectus.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202141040228"
          xlink:to="FN20231202141602793"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202141045406"
          xlink:label="Fxbrl_20231202141045406"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202141045406"
          xlink:to="FN20231202141602793"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202141048194"
          xlink:label="Fxbrl_20231202141048194"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202141048194"
          xlink:to="FN20231202141602793"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202141050909"
          xlink:label="Fxbrl_20231202141050909"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202141050909"
          xlink:to="FN20231202141602793"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202141100037"
          xlink:label="Fxbrl_20231202141100037"
          xlink:type="locator"/>
        <link:footnote id="FN20231202141541386" xlink:label="FN20231202141541386" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Notwithstanding this assumption, in actuality, these fees will be indirectly borne by all holders of Common Shares.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202141100037"
          xlink:to="FN20231202141541386"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202141102284"
          xlink:label="Fxbrl_20231202141102284"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202141102284"
          xlink:to="FN20231202141541386"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202141104669"
          xlink:label="Fxbrl_20231202141104669"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202141104669"
          xlink:to="FN20231202141541386"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202141106886"
          xlink:label="Fxbrl_20231202141106886"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202141106886"
          xlink:to="FN20231202141541386"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202152128342"
          xlink:label="Fxbrl_20231202152128342"
          xlink:type="locator"/>
        <link:footnote id="FN20231204153347876" xlink:label="FN20231204153347876" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The closing price at which the Fund's shares were traded on the exchange.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202152128342"
          xlink:to="FN20231204153347876"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202152137130"
          xlink:label="Fxbrl_20231202152137130"
          xlink:type="locator"/>
        <link:footnote id="FN20231204153401745" xlink:label="FN20231204153401745" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Per-share dollar value of the Fund, calculated by dividing the total value of all the securities in its portfolio, plus any other assets and less liabilities, by the number of Fund shares outstanding.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202152137130"
          xlink:to="FN20231204153401745"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202121140788"
          xlink:label="Fxbrl_20231202121140788"
          xlink:type="locator"/>
        <link:footnote id="FN20231202124019444" xlink:label="FN20231202124019444" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Beginning with the year ended September 30, 2023, the Fund's financial statements were audited by KPMG LLP. Previous years were audited by a different independent registered public accounting firm.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202121140788"
          xlink:to="FN20231202124019444"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202122222386"
          xlink:label="Fxbrl_20231202122222386"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202122222386"
          xlink:to="FN20231202124019444"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202122420675"
          xlink:label="Fxbrl_20231202122420675"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202122420675"
          xlink:to="FN20231202124019444"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202122946590"
          xlink:label="Fxbrl_20231202122946590"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202122946590"
          xlink:to="FN20231202124019444"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202125337432"
          xlink:label="Fxbrl_20231202125337432"
          xlink:type="locator"/>
        <link:footnote id="FN20231202132818615" xlink:label="FN20231202132818615" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Data presented are with respect to a short period of time and are not indicative of future performance.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202125337432"
          xlink:to="FN20231202132818615"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202131545225_323"
          xlink:label="Fxbrl_20231202131545225_323"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202131545225_323"
          xlink:to="FN20231202132818615"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202131545225_423"
          xlink:label="Fxbrl_20231202131545225_423"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202131545225_423"
          xlink:to="FN20231202132818615"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202131545225_523"
          xlink:label="Fxbrl_20231202131545225_523"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202131545225_523"
          xlink:to="FN20231202132818615"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202131545225_723"
          xlink:label="Fxbrl_20231202131545225_723"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202131545225_723"
          xlink:to="FN20231202132818615"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202131545225_823"
          xlink:label="Fxbrl_20231202131545225_823"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202131545225_823"
          xlink:to="FN20231202132818615"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202131545225_923"
          xlink:label="Fxbrl_20231202131545225_923"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202131545225_923"
          xlink:to="FN20231202132818615"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202131545225_1023"
          xlink:label="Fxbrl_20231202131545225_1023"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202131545225_1023"
          xlink:to="FN20231202132818615"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202131545225_1223"
          xlink:label="Fxbrl_20231202131545225_1223"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202131545225_1223"
          xlink:to="FN20231202132818615"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202131545225_1323"
          xlink:label="Fxbrl_20231202131545225_1323"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202131545225_1323"
          xlink:to="FN20231202132818615"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202131545225_1423"
          xlink:label="Fxbrl_20231202131545225_1423"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202131545225_1423"
          xlink:to="FN20231202132818615"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202131545225_1523"
          xlink:label="Fxbrl_20231202131545225_1523"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202131545225_1523"
          xlink:to="FN20231202132818615"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202144904787_117"
          xlink:label="Fxbrl_20231202144904787_117"
          xlink:type="locator"/>
        <link:footnote id="FN20231202150552498" xlink:label="FN20231202150552498" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The asset coverage ratio for the Loan Facility is calculated by dividing net assets plus the amount of any borrowings for investment purposes by the amount of any senior securities, which includes the Loan Facility, and then multiplying by $1,000.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202144904787_117"
          xlink:to="FN20231202150552498"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202144904787_121"
          xlink:label="Fxbrl_20231202144904787_121"
          xlink:type="locator"/>
        <link:footnote id="FN20231202150602254" xlink:label="FN20231202150602254" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Not applicable because the senior securities are not registered for public trading.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202144904787_121"
          xlink:to="FN20231202150602254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202144904787_221"
          xlink:label="Fxbrl_20231202144904787_221"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202144904787_221"
          xlink:to="FN20231202150602254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202144904787_321"
          xlink:label="Fxbrl_20231202144904787_321"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202144904787_321"
          xlink:to="FN20231202150602254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202144904787_421"
          xlink:label="Fxbrl_20231202144904787_421"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202144904787_421"
          xlink:to="FN20231202150602254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202144904787_521"
          xlink:label="Fxbrl_20231202144904787_521"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202144904787_521"
          xlink:to="FN20231202150602254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202144904787_621"
          xlink:label="Fxbrl_20231202144904787_621"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202144904787_621"
          xlink:to="FN20231202150602254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202144904787_721"
          xlink:label="Fxbrl_20231202144904787_721"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202144904787_721"
          xlink:to="FN20231202150602254"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20231202144904787_821"
          xlink:label="Fxbrl_20231202144904787_821"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20231202144904787_821"
          xlink:to="FN20231202150602254"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>24
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M[]B5O_[(3/!0$M^._P'3 !X3,Y>J$PQQE#VM%(>7N& 1V8"&P!^)H^^][&.
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MX"E-%'J*W^Q_;\27+H-DFCW BG4I(2J]IZ?UPB[@A)2+*?L29U@D%Q^R3LI
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MC(>61(^%SI!ROE=B$QQ:PG,(=ID#_8!?LH@HA]P)K=0LIY-;6KSY7+C<=L5
M1F+61"U7"S0LL6G#U12P$4"U)'5B+]IV4F9H,=?:^P3!C+$?N/D,W=\X8<S8
M(:\4'2T_OH?3"*)[<UQY 2C%8K)N/_^=#-B$E[1R5JH0H?>%%-8.F\&H1953
M2&S 9K?-S)CCW%GV-"#[<<RGTK53L2S+Z+5DM/5"=)GI^F+1=($UX%!)A[L4
MDGV ,H5K4^0QI:;AV$7/(MBX?BH50$6<5&0U2HH-G,=JYJPRI'<D"3[>"[$
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MQ0LU3KA,$JLPY[AA]WSE(D=M%"["FN"&8!9']VF&THJ4,.-OU2IX;%VO%"#
M4/XG8BMT"KTUES2,."@*7@M8M80FK<HIJ]C$:YT9V5)@4"BR&I %5X<O64N6
ML34YN8&GD2-UN31S;O_B^F6:[I@LJ?TV)MG2(WU<9O8:%36*:PV%VI(FQK&
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M*-I8%.U&%.U6%.U.% W$FRB<[+D?RAY\$&^RA4QDX<YEX609$XBW;U'(Y/C
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M0#DASNS)GI6"VNN0J3@\V7_UEGO0H,.FWGPF:,L/Z8=Z%/(0Q47#6[29\+'
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M?COZF2<P%]]C,U,3S)6"-:GL#"(OJ6>J*[WB ].RRE6/2$+E2SI+L/89D2%
M3[-\E9'7)DX!0-E3DG,7+>V+"[Q$,N/TG:+SI;2\ VD.CT5S<@U2J8#K?5'N
M;-H-S%)^U4]E:RRKW?8BP 6#5ZEM5Y;"F@$IX5Y&+D=*;SBLQR0#9L->O%R1
MU\D[HGI)Z@-%29&%F,U&Y(A^H6KU""!%6"39(WF:,,4K6P*Q!?R*!C,-OYJ(
M^I3#.B*W0?=2@OY%.(T)4$8\\Q%=5A;OM\>]V^\RLA4T9>$^RL+)*I1PEY&M
MH"D+]TD*KGZ7<14TC[LK:+[/@,V!6,)3]BP/E&@)35&T4U&T,U&T"U&T2U&T
M*U&TD2C:M2C:6!3M1A3M5A3M3A0-KC>B<++G?BA[\$&LR5;9E(4[EX6394P@
MUKY%E<UC5V7S^/6W]4")UMP413L513L31;L01;L41;L211N)HEV+HHU%T6Y$
MT6Y%T>Y$T4"\R=;<E(63/?@@WF1K;LK"G<O"R3(F$&_?HN;FL:NY>=Q9]&Q'
M#Y1H84U1M%-1M#-1M M1M$M1M"M1M)$HVK4HVE@4[484[584[4X4#618-^MH
M-_AH-]06:Y!+JJ% ^9 -I#8EP+?6KV.5S HV=:99.O4 &[9?\OG$RQ@=+W^O
M(DS88)NM=F?87!\?P_?(4"VN,C,&?LP9J?N#T."M,Y_264_C%"I9]]S+[I&-
MMS5NP[JMO1#&D:)!\7XQ5Q%9XH/R=WS$0Y2ON?"9J8/F%Q1KHN'OJG2F\F2M
M$ZBL3;D?_G6A4K^"6"V!9\M;8;1:Y5DT72AROF BE?8!:+N_:OL"\D2X!:"!
M>EY].3UHT/'Q^.UY[)+3Y@GFOIA,,+7C)X_K.T'N#_R(F9K'F)P4%>P6S)67
ML<3K$I6>.[+M&W7EN8D*U5=V/;JDIJ@HLFE,#BP]$SA!A<D![,$7::^0IHT&
M)03>8L0Z3X:GVII\M6WO-*$6O2XJPX7F9!E-\@"#!QIH.Z!#&T[@=]J'6F3D
MS< $'.=,JU.A&91P*<-MJ;@^H/V&K=MU7G>M;5D1QW7@P2A.V)?BG%%Q$\5W
MK,S=I+17D*KGH</+=V=Y+B1B3]DDB>_Y[&UQQ,C6&9:%^R@+)ZM7@4HO6V=8
M%NZ3%%Q=I7=UAH^[BX5^5H;S/>U[$:TV+(IV*HIV)HIV(8IV*8IV)8HV$D6[
M%D4;BZ+=B*+=BJ+=B:*!8B\*)WONA[(''R29;(%56;AS63A9Q@22[%L46#UQ
M!59/]K^I[^5$M*:J*-JI*-J9*-J%*-JE*-J5*-I(%.U:%&TLBG8CBG8KBG8G
MBC9\)PLG>^Z'L@=_^%$63I:1#,]EX609T_"3%%Q=O+F:JB>=1>UV\[UT8SQ;
MAHD63A5%.Q-%NQ!%NQ1%NQ)%&XFB78NBC471;D31;D71[D310(9ULXZZC:<?
M?(C1G8(6TW*]8G/Y9IZ%,=X6BWB.8??P3\H3J*B(VSQZP$8CZ#BP-<EZNJP8
M&EYA+--(I+UF4S^@./EZ3LR\2F>%WXD&#:P+%27E8AJY)B'KENFBW1@KD\5+
M57#!IY(J5E$W%*HLI@VO]2$#;\AY-JTH6X!CX^W:^+ZCG!_5C4@F>1;-5*T+
M3%&NDRV5G&0W79:?@FH@6X]6%NY<%DZ6WX-J\"WJT9X<.-6@NZCD^PR(.<6R
M;GC&S]/PS!V9<Y<!UV7;[1[AV8J#:+5:4;0S4;0+4;1+4;0K4;21*-JU*-I8
M%.U&%.U6%.U.% T4!U$XV7,_E#WX(.%D:Q7*PIW+PLDR)I!PWZ)6X8FK57AR
M^&UMNZ*%"T713D71SD31+D31+D71KD311J)HUZ)H8U&T&U&T6U&T.U$T$&^R
MA0MEX60//H@WV<*%LG#GLG"RC G$V[<H7'CB"A?"/_]YVVXGQK-EF"3:J2C:
MF2C:A2C:I2C:E2C:2!3M6A1M+(IV(XIV*XIV)XH&,JR;==1M/QRW';3:?_KA
M7S P-DS1^FEK*GEUE&Q)G6"S&E14AHF*X!]OMM6$PK'K4?:>X=96.&KIV+W1
MVH JPV MEV0=3!0'S_IEBSA6F/N+)VO^>S33,?9^EP7;WR#+X=_6")WE\++I
MPVV:!:!EE]ML<P,1[C&"\W.?T0NB^QPK*955;EIXIP]QGJ5H^H7?E&JZ2+,D
MNU_[E:?(]!QY'UCK@YU3Z23LQ($-',(DRN]QDRHTU=%*>QLXUA6U@I@K\^CL
M #-3J@&D]Q=7PD6)V\;O!3=_0-.Y^D(1TKJB#P;B*WP:\2:F0SP^$6],?K/T
M5S#<[/$RK5$FKOAT7=MQ/Y#:%;%I%@.BL&GN#$,$Z^4IF)5%&S[9Y8-%5/A$
MV%A;8Z[/,9J>U];.@!=WT]> ,-AT'2;WD"%A),HKFX;3SJ;3",/_:<VQP%30
MB!"W!91<A_F,/A/)F2/SL2%%0GZ3W/: -S7,EG3,N%<.T3TL9&R2'"+3!FC=
MT_D$G#:PRC BGFH!!53TRI7+HN-4%50Q#0/V72J+S?NH93\T6KKSU[M0^G X
M>X@+76T,J<HVV,#J5=SGPE)[0!65:BM&6TN5PN8P91U1;\JA$=F&!=*SH=3X
M'[3W?9_)N3?(,:.YX KYU40!J.MU] _=?B5>QB7E8F2S:JI=/\ N8(@9]O#!
M? M:?W>@Z;1CGD&!VW:? ;^A8^_U4*&4'5=MK>=>1U83 (_B:G!(3\AK8-&P
MA-O7F ^:GHS92/)H374')R[!%A?P#!Y%7+Q2=R2AFF_>+N7J0:65Z@&1%5FB
M2J#77R=EQ,V&W+QQ0IA\\X!,$)L[_:7_N5_[>PADEQ*I86\<DUUQFF7<J^9#
M7MW#YF,7H\*<\A?XQ-[IA^'>2^;2A)QFZ:OMZ %^7*H>S??;\Y:H]+Y<(.>F
MUC*X[ A9P1KF^#TTHPP]DEA?K!]^QEG.@'NO=>4TWML9MMK)5K17N*::2VE2
M3Y5B-R=0;F 8:F2IK>>?)-B I"I=;4%.VV+_J=E$UZ&IMFB;E>W:5QHFV MX
MMQ\B8#Y<TL]6F\/Q<NQ+0^Q>)91"ABQ$KTB<IK"A+"<M[>D>8MERJ7*L0!<6
M\7T:SX$F827I.!>*1LNJPLI#F$C@5BJ:Y-6J#"T%<Z.E.M/P^*Y7_JRMRB&E
MQ:&Z -L&"UU@"A'NC.]5#17)\3!+@WIB5UW'<*"Q?_3:&3DH'PVI5)<!6-82
MV72;QYD8<ZM*XR4,X4?8S#Y;_A(72\L.6Z)QLX_;VM>!^@$1L_=67%!:E&%<
M6N)/XFQ3YUCST:LM3:;;AUF9MBEP35*DWFM;$S*H)P/64NSB6@FY\"I#I0.4
M(W2NZU-\#\28:@=[1<EH3<+9 -ZRQ68BVXIZ6HFL=5;2(W'10-Y4><\Z[POF
M$WH2]JFF"DF8NIU3K:ZEU[@,CC1*!*8&5;(V1KP ^T25"R*HF:X<:0YI*VWB
M@9@FU<PTIC-@R. FS.VHN5=!_T8Q@-P!LS<] H!?EQSIX<$%6.D2]K''>7BX
MVG[)1V1C"<:'5-B7"G!AEEC#]7Z!K^C&<+C$K;2O-WD!CR=K'?^AM,!:1HB=
MFD@+P)['R(+S^S@M?)5.?86I%M@%<&UR*K$SW]<PM=F+U)+,YVBPQUGRH*AA
M%UY-Z$CPEY*<K,KZFJ*^SQEV@=\7; J:AU9"M#*%VI/'^*SNEF0%MUBSTU6\
M2CAPI(?NAW]%E07>7^E3Y58M\#<;QR5%"=:()1/P#/A66)<$V,<,B!B7 /_$
M&DL::<'DY ;  #64U'0/!7E,]47]![R:D?$#*0Q4I#)@1KMY93(4RH^90U[4
M>2AND)U<Y"?-#N>P[3.JG/D>R60(2_!B;_@>M($0-?,IJ?0SRR*Q1Z1MUN>1
MEU4$B.3AAHR,H4>9E%8:VW*\FA/"**QP,(_QT)+HD9'\9G?$)F!C23_ .02[
MS(%^P"]9 +UEN2>T4K.<3FYI\>9SX7+;%0,9B5D3M5PM,"668ZCXBJT?)X"_
MI"0!/I>4+4[L10=IE1E6$M7:^P3!3!%4X.8S[#>($UY5U-X.^316./5X&VE7
M171OCBLO "B11(&MY[^3 9M^GJV<%?M&FGTAA;7#9C!J4>44$ANPV6TS,XG$
M[BQ[&I#]..93Z=JI6)9E,,'5A6XOQ%+"N'!XZ*>+6.'F3_$NA60?H$PALP+L
M:I3HL0'4(#!QH$3$G&+<4#P21J-$I@%Z&>ZWL<J0WI$D^'@/2"U?SBO4WV:&
MSHI>X,U(2PIG]; J/JL$R*;Q<RO4\JJ<94V!E]^?44A'<[QP1U9SQBZQ=LV2
MM5$X9QW*:XB=:&,RR#A56B]*0(M"IA8^O/312311=/75;S+CFC-/XTV*YSZ<
MF9V_"E3F&"M!E+1^];NP5BN7:$Z(^1[6.*E;VX[6%!&N0MQ.H>\W97M-;]E^
M2+0@@CL.]O@E*69YG/G4)#:M1=G$PQG[Q!(6',BI>4/)-IM>?9-[^N-,0T_3
M%7:%!!5-546F,%3"L>EEA.UAF=W9.L%F*U"#WIS4-(GBI:_!FZ5N88JDM8+T
M)(H.;%7L.L6W7B6<*-Y<ST5DS$EJAKU[$R>ZS(4&GG@$10?+== W,;FZMK-M
M/7YU\UC8$V-U4M[E"14'/ <;+8=#;CE<F)[#6\)!1>W$LBZ8X4=9.%F7SO!<
M%D[6133\) 57]R:Z/C$GW<T>1K5CC05UX  \G=[?C?IL_Z)HYQA1M#-1M M1
MM$M1M"M1M)$HVK4HVE@4[484[584[4X4;?A.%D[VW ]E#SY(-=F. ;)PY[)P
MLHP)I-JWZ!APXCH&G)Q\VQ!0T<X!HFBGHFAGHF@7HFB7HFA7HF@C4;1K4;2Q
M*-J-*-JM*-J=*!J(-]G. ;)PL@<?Q)MLYP!9N'-9.%G&!.+M6W0..'&= TXZ
M2S?O& (JVAY %.U4%.U,%.U"%.U2%.U*%&TDBG8MBC861;L11;L51;L310,9
MULTZ6NT]7H//HII.T=W0#)<@QT_]7>T?C(M-CZZVW7HN&.RBETVKW,6F63,S
MM<3+JWOM+B3;:K%I<O9C0M!G@+WQ[(C!EA&UAUL'9*V2+"Z]8([MSFS/Y^V[
MS^.4R@&PT]SY2]%7K>W;0=>\31Q%S2KLQ:!RM %& MP7)AH(9AV[ !3MGC=A
M!DE&6]4S/\>IF4:9A0HG.Z6NB]L_5,>) F%%.88@V<\F7T_0# O5ZZNC#WE+
M\0<,R:(]M*M"=F[RWW:LLHX(\!:DYP&0/PS=B[0LM3E2E-<L+MD+GF,=WQ4V
M@IR2:XT^*K=1):D?:4+N$/;.:*\@^9CP:SF\HQ[RY1%40'X%L]M8+!P^N!^.
MGMKM>OBD\8APP!W\B>*JMH(0F<\C#)%91 E&N:DB8.^/Z2]IG,$AQZ].=9QH
MA2%G<Q6737HT_AD_=C!5]\8KH3W=UM%*<:3P1XX^2N?H.<,I_Q*EZV KJ=.4
MXY: %P[R\R/X<  JFZSC*RA$*IYZ?J1?LERA\\34[<Z(1:';+S/!BH'S8X8V
M5-%T?OTP=-XIBBW$(=L##7V8"LC$5;Y.,HKHF-7#0+:06:#)#&,&<;*1-ZW"
MM#/5LU<Z/"!.^2?=%70;LR6*\$*Q* Z5(P_<,:I'DQH7JHGTHKUX4"'Q!^TA
M1"J@X%\^QB8>E*>&K5(Q5&8^IXCV@(;%BNBNW2@%Z:'_K-<(G&0GZ2PNB"1A
MJ[  ^2Z2A<,!\&OKL6<<X0G'@ @'.""2&U*5B[AU 3PZM"%+VQE1K\5#R4O)
M\6WDK00*/-5^\P[N'E ?V^4JT:';L-T)/(''OC6JA -[?5X#)R\K8L/JI_%#
MS'D#TQQF@]YL+!2/_6@5_%!N!$=BMUN*N.P%.NK(R S3F%IG?7CQR,4*II+E
M'-U\GT=+%XKZ"_EW<Z8:_B&>]8,G]B[P]FZR)=6B/2":/]7US<Y5O)Q4\#(_
MAP$L?#+,/L&G433&$QNB0Q+B?R@=/IX"^<,/(+ERHXL@C X&LFR)=0L;*VIT
M&ET^'K"9>]:G:8KN3SE(G18SJ'$Z(Q<IF$,'7N$B/P"%$;$0*8,.D'-+\36&
MY5#!I.;&].RN]&S,%H<4("EH<;=*(HZ?"_2?:H%V^3VLU#]T+7E87!CTE3^H
MCAOP:O$;*63"4%PP$'[RJWK,BMDA$RK@./IGCU79&&T85H=#1C94J[Z\&,)6
M>;$_82W\JM?-DW4DQ$S]G7SSI?>U4R1(C&4RG-EN!X5Z;95R+HRF@$4L.'Q@
MK1<E0=6A,"01^X$18Q,2;B/UD!WQ/@1/T;4._T#0I6Y-@4&:#4V-N(''T;R3
M99.;3(J(&<!E=V'7;=BB@ _)=%WK^%%K;Z^?K+$VIT7RW&SD">6(^9]MHCOZ
MX= &[7!3B@9;<7'/>#]@AH%[S(D@$Q/"1AE1W#*"J--&QV"4O&;]]3)BD8VW
M<FE4M0B6W>9AY!1E(OGL+I[#9)3)<[*L %4!6, J+:(YJ>CVY.!449LU:J;.
M5:BKA($)26TFJU 8<3W[A14L_9%\Z\(=MM$T((2R*M<A/+ Z19:F"H/ . @&
M_VON65,* GQ<H.8:P>&8H3LEGE2NF7FM"_D.ET@;,T_10)2 @]/UTOHH\C4&
M512IAX*?2KQ%_C_LO5MS&U>:)?J>OR)#<7HLQ4!L2W*5[5,1)P*2#9$T#>/0
M&!:#;PD@068)R$3EA13KU\_^+ON62(!4U^+TRSQTETP *_?UVSN_RUKF U=C
M->Q]Q0K;8>$^8^&P+K#Q&18.ZU(;_X:"B[VO7MCNK\?5J3Y&=11G=@$_G3,#
MU;J#HDV@:*=0M',HV@44;0I%FT'1+J%H<RC:%13M&HIV T4;?\3"8??]&+OQ
MS;&&%7?"PIUAX;"&R1QK+R'N]%<O[O37GU\V9P:J^ 1%FT#13J%HYU"T"RC:
M%(HV@Z)=0M'F4+0K*-HU%.T&BF:.-ZSB$Q8.N_'-\895?,+"G6'AL(;)'&\O
MH?CTHU=\^O&HY,;S<F:.8WSK&09%FT#13J%HYU"T"RC:%(HV@Z)=0M'F4+0K
M*-HU%.T&BC;^^(3I&';X#"?-Q"0;@?=S/TOF4,Y*F"7SGQQ*>RI1YM!#]_-D
MAC)SDO^./)F]9B?_'6DRZ:$TF>2%TV1&/A) ;0K)*O[=!)ID/X$F_6](H$GV
M$VC2H00:'X$/!^+Q64D?Z9-)'\G_R:2/]%C21_*<I(]X(VLHO3#KZ_]$SL>1
M-6FS09*A;) 4G0TR. I!,D@RD R2/B<9)'DB&23YYF200Y;WW\D%28[D@M!Y
M\,WI(.F_D0Z2'$\'>6+R7C@;Y#2B8+DO5GG-JYC(;7;,0F',%(="FY%F9)F-
MVE!Z&T_+7G#R$$661)EK%UG^=Y(SDH'DC/2IY S>8W8(4F(X9-HWI??S[(N2
M=1(02]A3)-S:EJ'F)/UX8/F2K4IZ<==PROC$M<9_/< BU!\@V1!LZZ@%9H5U
MRSQ*XE!ND8GY-/^:$670R%(,)3;'0(/7CC22C(D_8X]<+N)DP]"T,='>'E/.
M2(T\44503)HO,8G\[7!HFM(6?!+!.E_EEOE5J)>8C[&A!$#*@["L2-Z\2*\X
MZV#(KCQ^UR1!T@'3E;C$!TS"@YX6BCRP726;(0%F,X1)?M^:S9 \.YOAZ>0$
M90@[=@0=3%'H;Y7GIBA@7V.P'H+Q9RP<UN,P/L/"83T8X]]0<+&SR^N__GA<
MQ-&R;3.SVG,Y/8YC?K/S"ZH'"T4[A:*=0]$NH&A3*-H,BG8)19M#T:Z@:-=0
MM!LHVO@C%@Z[[\?8C6_.-*QP*1;N# N'-4SF3'L)X=(?W_LS[?V+YB?\"%4M
MA:)-H&BG4+1S*-H%%&T*19M!T2ZA:',HVA44[1J*=@-%,\<;5K44"X?=^.9X
MPZJ68N'.L'!8PV2.MY=0+?W1JY;^>%0V[IGY"5!I4BC:!(IV"D4[AZ)=0-&F
M4+09%.T2BC:'HEU!T:ZA:#=0-'.&'3<= ]X>34[8B\Y$'/'JUI3@!D4QMUQ4
MF+ 0";G0*PI):.TFE\D& C[WZK(/ZAN77=-66V)+YH!-V]6E<*9794N9#Z:O
MVZ+;:C!]SV,O%,S6IYP$];=<U1=5X08_:V)_,E,L<"![I,%&TP1)0G!.:59?
MH8%PO=/HP^_A\/A"XH65:+$]H/_@6MA:(ZPR "Y&MBA63,E/#-M;IMZG@( 4
M&$>/%$YH@EX77X7+G=]@E!7Z;^E=]9!S$)Q*0I- <$?9J-7'+V <#UV22-$#
M!;L>LL:U8*4QQ_5&'?FE[XR9(FJP5?<)'R($]W&C$Q(=RYQPB))/="(N9&-+
MX4<V+%64J^*^6'5<X6^_QK(=K*'49F9E5;N[D$N<9_YMLR02<MN&W"PQ99$?
M)?FN6)EN+%61L* 0"JT??3NDA O-3C"3'M9<AW&@QQ%_D:0=>*@6YE5S30&.
MUZ$N4_[5+ <;1<V;1@,M]LN)+2)^XYL?)!;86"8]F". %)2K=C;<Z4,?9L*6
M9BXN YYPEC2C>#M5T5+L8I&W#Q2'T)6NLRMK(>DML#KM2!9(HR>U"$&0 I]9
M8J1N)!(.GN\CYB4(\PO"JM\PWD)9)H?V#N666&X.:J;D1VAL3#5)1JFY\*B)
MB<N#I82:8G0V9$K?D;"O>: /EOX1!$O3UZ].?__CU1M*F&B*59&)AI$Q3J00
MN3'+KE3Z%!ZT.B*7D,09'YG7R.H_.C,Q--3\QY!3GH. G#3@:YDYPT2#FS[&
MZ^*^R4"&EA^BCK7>)&+H0\5WU8;U>2RM?=!&,6X4\T^<T%)&=DZR6/;%FV1M
M!L'7MS9*'*"&&H=I+&]E24CDVS6M4 ]NF602D?,KB&/#*^MDL?1CE(6C*I*W
MKE>J!T#K.?,E^G'1^BI?,-%^5]>5&3E15=-V!F)[R52;E;IF#:N-!"'"4;K*
MMIDJ3]3YKO,I<=OAM6[6A95&LZ%JL_W69A^*>E_(I)!D$A\-3$2@#ZK</)S-
M0>?H2*.RZZY6(:90.,Q#++IZ99:W+B)9I+T#4I@&@F,K44.Q3E<5C9]?Q[0"
M\ON*=.P"X1X1STGV+)PY7*IZVVA+K:R#)DT-RKJ882RY,]I2WC<'QK:_RX+V
M!XENGD8AC F[5!H.;V?-7;K>5 _:0>J/'G-->MMEY$K,^=0*%AS;_I4_&B(!
MDE&:;S@EIR5N)K.=G,"?%ZIP*3BJPE.6G5J\3;'.2?C!=/QKL>VV$MP.]/OL
MZ1/SCCAI3TU$,]]>%M3$$9WYF5GDC3E)$[JP$:@]%#@5DH>(:!Q88XFVI$U6
MT#L!G0:%<#0M64V&TY',-^F8C+17]#XFZ9Z:/E"VFNQ'["L=R;D(L84[32G#
M-"N]A;5'Z!MWL(4\)G2A]'>L+0<P39-N::+XSJ-_XL;)6G/Z+]ENE],AI0IE
MM&[#KNQET&5?<^[3T/-#6VA;?)).#0SG=%5UG-)%NR!9U;3'Z2!JLU"*RAXU
M#]GC,X2D:L=6P_G#&X-9ZYF_RPJ1Q!H2?+(94LG (11M+38MYGV$E,4HL9*$
M@U9%0]I^JK)B_HN/9C;&DCDFYD#V;'$K%PN6-V,#1_?UQSR4R4J:1V,(MV;]
M4AH-_3;(_,JXU[+4*==0?QTG,[D1L30[= 6C87/W*,J=X1POS3^F!!3SC+NL
MLRHO27 X"ZBT2@9!R<_D0F[-QWT14PX=,/T'97L.WHWL;9_E_]+=W6-CMG1&
MMLOGK?4),ZP!TK&($M_B;WI9'_[4YRSWN'/DYS2FB<\,B[-TODL';:RLP+IJ
M=DY7*5CJ XR01>U2IE9ID(/M7GMT8IL\\:N_C?)7)7O')V&R(C&G&"NKI&34
MQH0\(KIC6GQ7[%0I>' 0Z-C-]8!]6QI;5-5?*.>UZMJWU=K^9?3,(\Y)%PV/
MWG-.J&$?--2[@'7<C3]CX;".P/$9%@[K6!S_AH*+?= _>!_T#T<=21?F*I+^
M:6X5=#Z,S4J<5]6F^0:*D^/XW^R?1J)-H&BG4+1S*-H%%&T*19M!T2ZA:',H
MVA44[1J*=@-%&W_$PF'W_1B[\<WY!H7#&A)SOD'AL(;)G&\@N/A\\V)W/_[E
M95.(H*IW4+0)%.T4BG8.1;N HDVA:#,HVB44;0Y%NX*B74/1;J!HYGC#JMYA
MX; ;WQQO6-4[+-P9%@YKF,SQ]A*J=S]ZU;L?C\H./3.%""IM!T6;0-%.H6CG
M4+0+*-H4BC:#HEU"T>90M"LHVC44[0:*9LZPXZ8C\OQDUO.31)Z?DY2_U<BW
M&AMGM6'L?O%F8LM,;5']NEIVY LE[H*-)D0PC;POM)10FRW<'RP,YX)=J6&G
MX/.HQWJ0K>ZYZ%W3&"@,FF1EZB)RVIA0^R1;,A<!^YXS"G1PG2X75G-HF73=
M(TWY[QJ;+3%RS @GZ1^.E2**:EL"B(19"3)-7$G#Q)+)+^.1Q%%^R:EGEBMC
M?%LSP4*G5??/XK)P3Z#N1#HK$BA,B+V_O7L<*74"#32A.1;^5,CWJZXUW;7U
MNJM\DSV*%H+.9LCK$5,\" $&21Q4:9/G7\)XG-;RCA)7J$Q1@H(BS"HHP%&F
M7 /2;MHDD$)92=' =>6*UX-]PB@9'@O3P%$B\TL!^EQ".11!9S^\C;1:WA6.
MK%/\4D>D*$LSA1Q^B&DQUH' 1!!(I-P!VTY2L^%X#,4%-M0W*EN6P('-N+))
M V'FE1_/;$%Q.+^R:;96^9*VL,OK:W)BF.%\#U_>['=)F(\3<$0D2]/11B@Z
MN+@Y2Q=UE=E,.5=4[A"#Q_2YW8.';0Z8"9JJ?4$@E7R@H$PA\8]L2ZPK=O /
MH85I)2&>UV3@(*KY=B;+UK$3Q;P 2GTDUBUQ#PJB=!)@/R1R9EK#.RK@'1I1
M#'*54PY(R)!TE,EG;>E@)*,ID:I\BO09&&,GFT T36R2I"\PS4C^5?+H<IND
M$2U35]Q./3&+FW>F-)7-7=?&HQD0IC!IAD2[@@5I#2%E$W!6C\MOH(06ZH\$
M@N49DH9*TT-KVS0PGM&8"H"781Q$9$D%8\8':OS-TJWJ/#@R(BXM'P UC1P%
M/%I!=)TLD@0B>4GQ\I.LPSK@1_BGF3&SM5D_@2*YM'D3ET(HVB:>:L#%3FV?
MJ6/,$2:)EP$[U![SD[/6(E9"^:+<PY!/(13+,E\K$YH*1^BS<*,@26Z'1GL_
M8BU&UBXTI65@:@?E->"F*-D9I0CXXX#62B3JYR>=]J2FDDK*DLUAZN6">>H*
M9^D*EXCAH\'T$,UEZ5T<[#I1[187L=<S1[,DJ(M\:(GEI/84^8:R7_].86'3
MGIUFLOD<@1&G2%D"$SGR3%>$.VMC'KMZ]'P>,NHNA3'@1M%T1Z4KN2]D,4=?
MZ(G"1!0P2D'BZ&1"5HH!J@YK/^5K-I.QR7L&V2;IYMO=7=84G/T2Y3@,)9:P
M_(BQ&RPYU[#="8X*N4\TFECJ5K2Y*'WC@O0I%'Y-]CK*(T):))942;-8#YN9
MDW0V<(51-IOD2/M8)Z]J T,8'/ZNEV+'.4-3;Q?.L([2A1DR@K!7X[8:F4/?
M)3)DR[LBI]E<DF(@RP_1,2^+O0ZR;4<.(19<HKFB76 O4[26Q6[Y3#3:!9N-
MY"50P@AMY*9861O31"V2DW1(7$]L)1V*L9VUJ?2_WE-1P9HS']VEL6B",=L\
MVKN6N9$<O+?9=+/@%MD;%.&?T[0J8OO+%OE&V.&"1+5UY068*'<IN)3:UH6C
M(,I7=,[S^-GW!3D*9<NY:YS+5(VO37I6RY;0<SF^0 F+WL%U^FGP!N3+$HYN
M&#T*1"M*3GQG8/=ISD2GR9TY3K!)-W^;\S7\\)'*QI^VX;Y"'AW2:K#-ABN6
M87I_I(AU5+5KH,U,QY8^\(S0IJ)92;+TB5GQ23G^/A%MCL&KM+_R[ \ZD43)
MH.>K PD[6"%X+-QG+!S6[38^P\)AW7CCWU!PL<?7"\'_>%S-.2# F_O+T+,)
M?Z *\5"T"13M%(IV#D6[@*)-H6@S*-HE%&T.1;N"HEU#T6Z@:../6#CLOA]C
M-[XYW+ Z>UBX,RP<UC"9P^TE=/9^]#I[/_[TLMDZ4+T]*-H$BG8*13N'HEU
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M@WI=*F*)!W.O1)%FBW\]<],SL]/S1U0[^/K5;/9'\^J-%!>W-;'0MA6'2*(
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M_KHKF8U@0[%[%^]+MWE[)R3ZRVRS[$0$(;$%N1)PC&O>LX'JUCWM]GVK-#I
MEF#;5=N210YGCKGR++$9 %(-YZ+PSE!PH;_^V[695W-H!^P,]>K=M(Z-BT9]
MU1X3%T@XT]B]4*N!%DJD)</TRL5692O<\\W7_*$2,\O;6NF]$K-#*Y:KO$T;
M!W30$Q<7'@W'%;F0T!6Y1>HA0:D@;\>]+4R+OROEV)8J7ZY6M'^PPQ /(F=A
MT&ALBZ_4E$.D(#J$0E3_N*- L'DT"\(?+$NE;T>EH#USI9AC7P \&C[EHYR#
MH/(T2YN[8MUJV7I>)]0)*2,E[G'9-]2KKK26DPX%8]"YI#2>YX?*-+[4'!:Z
M.-""\<NV**/RYD-30SI/!UH;YGSHCC9-6V1D(Q:M<L3G>DC)V(;7"S^U]FJA
MH?V[K.:0/;>$5156U;*C1IJ3LMANBUMRFPHY@I4(VI%-:E5T2JX;4DCMJ$RL
M9D_^59,\JJ=L?'BMH-P*,P-<:/K6S(U<[E9R."XLLTQFVKOL^)#E5O+!%JR
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MMG]&NI%Z2#?6)\DQD6)A\%V&&I],B.S*5XE1=</UP"H0+=-,G3;#FGM9W9B
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M4*UP8XN"N9#:_HA*KKGDGP(L[%Q/@B!/4=[G32M>\[M\XQC&)QW),'/9(]&
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M4'>T1QBZR70(_8$\T++$RFH?>&Z=ZRX^24^KA_R>C//B,1ZDP>5L%Q;9&4L
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M]><D\-GDUD(QM9U:))Y#LZ<.A=_ W.Y8O,]@//#UF%[1P-SN6+S?8'B]5[2
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MQ0:A"8YO[)^CA_'JG\;FL_EX<6\#]=O'T?S7X7(YO/G3-;98O^DIKP9V9C.
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M7"^W_WNO3X-:^Q.I7$LKYVOEVEJY4"L7:>5BK5Q/*Y=JY3*M7*Z5NWXI=OQ
M&A3;GVCU/HCUQ&$%:5"J]V-QBJZ_"V2[]B175AQ2&N=[IY>\P7JYAM8Y12K7
MU,JUM'*^5JZME0NU<I%6+M;*];1RJ58NT\KE6CFD0+%SBE9/' 60 L7.*5H]
M3ZPGCE/(@V_BL=*H>*PT7O)8>>5Z.:TOBE2NJ95K:>5\K5Q;*Q=JY2*M7*R5
MZVGE4JU<II7+M7)(<F)?%*V>. H@R8E]4;1ZGECOI3BU>_W=^8X<]R;>*(V*
M-TIC[ZKSY^OESEY8+Z<U/I'*-;5R+:V<KY5K:^5"K5RDE8NU<CVM7*J5R[1R
MN58..4YL?*+5$T<!Y#BQ\8E6SQ/KB>,4DMR;&)\<5XQ/CH_V/M#\D?5RQUKS
M$ZE<4RO7TLKY6KFV5B[4RD5:N5@KU]/*I5JY3"N7:^4LT6GUQ$'@6AP%+-%I
M]<1AQ1*=5D\<IRS1J?2>)+J*^\GQ?O>35ZV7VZ_U^@RGM3Z1RK6T<KY6KJV5
M"[5RD58NULKUM'*I5B[3RN5:.60XL?6)5D\<!9#AQ-8G6CU/K">.4\APA=[^
M]7=/TE>CDK[V+BC_X?5R^V5?G\FTWB92N996SM?*M;5RH58NTLK%6KF>5B[5
MRF5:N5PKATPF]C;1ZHFC #*9V-M$J^>)]<1Q"IFL\2R3G=I?[TIB%<^2X_V>
M)=&/KY?;K_SZ/*9U,)'*M;1ROE:NK94+M7*15B[6RO6T<JE6+M/*Y5HYY#&Q
M@XE63QP%D,?$#B9:/4^L)XY3R&.%WH[U=T^R6,6ZQ/[]RB>)KUXO]\(F=JZ7
MV_^]UZ=!I5Q3*]?2ROE:N;96+M3*15JY6"O7T\JE6KE,*Y=KY:Y?BAT_D :E
M>N(H@#0HU1.'%:1!J9XX3B$-_H#>D_5W3W)EQ2'E^'3O])(W6"]WK'5.D<HU
MM7(MK9ROE6MKY4*M7*25B[5R/:U<JI7+M'*Y5@XI4.R<HM431P&D0+%SBE;/
M$^N)XQ12X)MXK!Q7/%:.7_)8>=UZN?URKT]R6E\4J5Q+*^=KY=I:N5 K%VGE
M8JU<3RN7:N4RK5RNE4.2$_NB:/7$40!)3NR+HM7SQ'KB.(4DMS\%[5Q_=[8W
MQU6\48[WKCK_S[__-;Q_L.3VQ\Q^Q(6S9<V;WDP>;T>U9#BQ3VS[M_L7T.W7
M?WW2TSJA2.5:6CE?*]?6RH5:N4@K%VOE>EJY5"N7:>5RK1R2GM@)1:LGC@)(
M>F(G%*V>)]83QRDDO3=Q0CFN.*$<7^Q]PED\OKR>3A^'D]K?_WH831??\0Q3
M:X<BE6MJY5I:.5\KU];*A5JY2"L7:^5Z6KE4*Y=IY7*M'#*=V Y%JR>. LAT
M8CL4K9XGUA/'*62Z-_%#.:[XH1SO]T,IDUNM_)UW6!N,AO/:49U/<-FO]<_Z
M\8[,J#51D<HUM7(MK9ROE6MKY4*M7*25B[5R/:U<JI7+M'*Y5NYZ'3NJ\\^/
MG_KFBV_M:_&]C7PGMD;1ZGEB/7'T0;Y[$VN4DXHURLG>->D\WRUJ]=IR5CNF
M2>\%P9U);__W7IWTI')-K5Q+*^=KY=I:N5 K%VGE8JU<3RN7:N4RK5RNE;M>
MQXZMR>J7C6=93[M9\<UM64^K)XX6EO6T>N+P8UE/I?<DZU5\4D[V^Z3LRWJG
M/.OM%]R=];0F*U*YIE:NI97SM7)MK5RHE8NT<K%6KJ>52[5RF58NU\I=KV/'
M5M:KGYX_3WMB\Q2MW@>QGCA<(.V)S5.T>H%,[TG::U32WGY_E7UIKW[$\]Y^
MQ=UY3VO)(I5K:N5:6CE?*]?6RH5:N4@K%VOE>EJY5"N7:>5RK=SU.G9LY;UC
M\I!3NUWQW8V\)[9:T>IY8CUQ_$'>$^D]R7L52Y:3_98LJTF;UXO%X_UH4>O-
MA]/%\&8YGDUKS=&HUKDS5(M&\YO1=(DU[O9!Y^YN-"\\6\8WH_US.O=O_O7)
M3NO;(I5K:>5\K5Q;*Q=JY2*M7*R5ZVGE4JU<II7+M7)(=F+?%JV>. H@*8I]
M6[1ZGEA/'*>0%$5Z3Y)BQ>'%_HTM2.=TEIJR3*>4:VKE6EHY7RO7ULJ%6KE(
M*Q=KY7I:N50KEVGE<JT<,IU43QP$KL51 )E.JB<.*\AT4CUQG$*F$^D]R705
M?Y:3O2O?7S>G\P6M?]9/=F1&K6.+5*ZIE6MIY7RM7%LK%VKE(JU<K)7K:>52
MK5RFE<NU<M?KV+'UP/.D_OQYI]B(1:OW0:PGCA9(>&(C%JU>(--[DO J1BPG
M^U?!_\"DSOV"N[.>UL)%*M?4RK6T<KY6KJV5"[5RD58NULKUM'*I5B[3RN5:
MN>MU[-B>WG)T_#SMB:U9M'H?Q'KB<(&T)[9FT>H%,KTG::_BS7+RDC?+JV=U
M[A?<G?:T)BY2N:96KJ65\[5R;:U<J)6+M'*Q5JZGE4NU<IE6+M?*7:]CQW;:
M.R.S.L7F+%J]#V(]<;A VA.;LVCU IG>D[17,6<YV;LH_H=F=>Y7W)WWM)8N
M4KFF5JZEE?.U<FVM7*B5B[1RL5:NIY5+M7*95B[7REVO8\?6PO7CB^=I3^S4
MHM7[(-831PND/;%3BU8OD.D]27MP:MG^Z+2RF/WTI;7G__+N:K_/[N]GTUKR
M>6@;KMG_JRUFDUMDP]F\MOP\GSU^^EQ[G-Z.YE_GX^5HOCBL#6L/\]GB872S
M?%S@KRK_:_'X8$GU?C1=UKZ.)Y/:8K2LW<WFR\^UX?1;;6AP?#/\.+&-. /0
M"0Q T?%A^7E4&RV6X_OA<G1;FZUFDXY6$VT^SN;34>WC-_>'3=N=]_]L_*N'
M+ZW^8G97&][>CZ?CQ;+X[NHO_WU1^V/\97P[LLW$H_'TBVW'[2"V6S0=C![G
M-Y^'5A1$D^'4G8-QX5-Z:_^HO2OF_JPF_;Q_5QO,'HO#>QA^JWV<S_XL>CV9
MQOR3[<KXKO;-_N)V/+>3@G_.RS\J3NFH]N V\PD[8>=Y,3(E]U?E15A^'KJO
MU88W__,X1F_$A\?YXG%8_/F/'M=[M]OWML?#R6+F=MU=R-I\N!S6%M@T3F+E
M<&QDC!>+\6RZP/EX=%T:[7S<S*;343$=^.O8KNS,SLNO]T6?JX=RBPO1+C?M
MC-W/;,]N1\OA>&(#]./L<>D$7Z5T:&=Y5'OWJN^\P\%6=CU:#_/W_SS^5^?9
M&+4SZH9V9906H^0C=O_V\09#^VX^NR_&P'QV,QK=VNWT<72'(USI'%;/V/M_
MGKAA?GW[9;R8S;_5[NPPQHMRJ-F]L\!%W$S%M@M8V>-AV83LUD[=M]H_AM,A
MOG.]L+L2M['=- \/L\7(W>U3NWI#1][7+"Q,1N5W;6./]B>'3[Z^/K)/\Y'=
MLW.<J^'][!$7_+.-[HT<#O!F:!I/%<I[S-W<%K[L7"X0*VJ5*V.#"#MH)_S4
MG8;*D9;79NE.N>WDQR$.Q,;D<H;N,A5-.R?_5F\<'1X=N?_4?L;W/@[M"M_8
M"7M<+I8V ' E792KGK_?;<2/EQMGY*$32T8/2S>]O79\=%AK'#6.#VOSD8O;
M4]>WU,+<?/:7BV5VVAOU]XV?GER8[3/QBQN!" FK<SZU,VKG +>F7;W'=3R[
M&R]N[."^84:&#6-T324[8]LZ?7]^_M/[FITS&UDW)FU7:CK#%7F<X[C+(/-L
MG+JSB=C_T6ZWJ87SF\]N*$Q<:%B=T]K/"&0S"R:VI_B[L5U.%R#LFCW_\U\.
M-UNS [M?E&?ZZ^>QR:_WH?C[<F1-9TL,\NDG^X7FHF9E;__=#4EL8CU*5_MO
M)_YN[,:$._A"N-PSNQ8XL=/;1?643M%V8?EU-/DRLD@S77Y>;!V91<;Q_7@R
M=%GNP3*9A3U<E'*L5P_3QJ"%)@18&]EV5]@NNO.WNBUFM>/C6OUOQ^O!L'U[
M?G$M K?'23&6R]ORGV?_NEZL_N!F,BM.P<?'A>7UQ0)#OW.SG&$H-,Y70V&Y
MBAWVJ04V&S0860CCMCO#&E*ZG1&$=#>-M0CHZRMB?S.QHR^OG-N7V=QNE:$%
M(HOZ\Z)-;S4%K[_Z\^@OW-W@ZXMT,UL@'*Q&M^W=\"_$.YIR#C?9[PZ"%O@6
M[CY9;ZZX:;[94)G^:F6*[<LFB/Y2!%K;"8NQV(GZ^]/ZCA._"55;1V#G$[>D
MF_$[_E_;#8LPXR)";0\7%T_>K9XKM''"ABX[7EML=+70NU_>8S#N^Q,W;C#H
M/Q;WR'CJ*J$R-SRYL*>'[D*M,J&+-U^&DZ>#9_YHM9"=J*^?9ZZH@?R[U=E'
M56'5G)WI=]L7SD;)[>C.3N;M*L;6+T^.:M<WR^(HW%]A;RWFH8:P*^"&^7PT
MOO]H2;\XG'6>*T=?L<=.T([81;#UZ=[ZYB%N-&3IV\U-?S>;3(K ,Q^Y,8$_
M+(K5^]'RZKF('<*L""$N\50'=#$DW$=6@>*^6 V*37%:CJ)B\!<7JCP5ZQME
M%<[&]X6\&YY?$6W=EY"*YI6A:I\_#,?X<.VW7_V_[]K^R"H.LN6MC7P<%6?I
M9O;X@.'SK7H-WM=^*S/Q.L%LW4R5Q#L?3=SXVQ+'"5T\?OQO[$59HVQ?].%J
M-!_^X!:J9;>[JWI% "RFW6_^] X5Q^HL;>W#NQI^YEA"&MV__^?YOWX;?1I/
MIS@GZ\CV0O*LW$!V$UBN'-N6K418E@/+7>.A1;9E<7Z#Z!\?:NUV]![MRK^,
M9_8CJ!C<3_]P:#\([EP_\Z4=WNWH ?O@3L0G]YO%E?D?;0A8X+M!QL!>WXWG
M=AP7KOA!R,=G#VZ)G0V#[?QI.[PH?C^X+=LPO2T+(C=(BF3Z_I^7_XI&\U^+
M<O_6[BL[&<\RSZ'=-Y.;Q^("V:[?HFQ>)<PB#ZR_,[3$BX\7FVY]94& ;&EW
M[GAFM_3D<>$BQ<S]E"JC+48$[D&[9,./J+#&+AL48W;ZZ"Z,;<'=N>6A5<JU
M]_^L'_WK#_QV*4LOE,/S47&A[9.'<ICBMXWM":+=>';K#A.WCLL>Y:"VRV%W
MWG+\Q1W1W>/R<>YJ38N]]ZB6;%-U=PG<CEL0*/,'$N"LR @&T4UC4RNB2.<G
ML9)OW'EQ-_^ZG,!9>KD@7IVE[>\MBC;$FTMQ6(Z1=:G];#\/5S^_I[7[Q\ER
M_##YAGTT^7^KHUI^C[[#Z-Q1"4^K>KZX[$\VN3ZIE7&-@RC'-H9E<?&.R]_O
M[C&\^V%GI]\NU>/D=I4(+=HN+!- 8EU@NW"XJ%RG551XCQ2U%2:0I$SE\_C3
MY^*WMR415^ /<5.@?K+-?9T6E>)F1]RRUR+Y8'#?EK\9B_%Z:\<T'UNAY_8"
MQSHO?TIB^"TW%[>X0S95*'Z.%?OGBGK;__G(]G^ZVLO5[RCL)NZ)<B]M][\]
MX*Y9CE'YG_ZT^IK;]56<7.U\Y0>SE5+V"7X^C!8W\_'#^K3=C.:NLMTN%EQM
MME5?E3^9BY\J;O!5OO'__C\7C7KC/]8_2]=US&+?K^;Z"882;M#U;RZK"<I3
M[O;PT/V.=.?)#4X36JR2:UGBXV;%@Y7)M\U3(5RGS[.)#15WB%O/M-ZS)VA_
M6WP>C9:('O_Y?^Y']E/Z]]%D@K-@=]/_?==H-+ R; WLG-_]WW?7]:O?&N_^
M]NSS/^I7U]=U JY_,Q(P\D?CZN],JMVX^@?[O->X^B_V^?5OC:OKWRFQ35S3
M;32/KSX<D\];QU<>^]P_O@K8Y^'Q58=]'AU?==GG\?%5PCY/CZ_Z[//L^&K
M/L^/[70ST#RY^G#"#NSDRF.?^R=7 ?L\/+GJL,^CDZLN^SP^N4K8Y^G)59]]
MGIU<#=CG^8D=& /-TZL/I^S 3J\\]KE_>A6PS\/3JP[[/#J]ZK+/X].KA'V>
MGE[UV>?9Z=6 ?9Z?VH$QT#R[^G#&#NSLRF.?^V=7 ?L\/+OJL,^CLZLN^SP^
MNTK8Y^G959]]GIU=#=CG^9D=& /-\ZL/Y^S SJ\\]KE_?A6PS\/SJP[[/#J_
MZK+/X_.KA'V>GE_UV>?9^=6 ?9Z?VX$QT+RX^G#!#NSBRF.?^Q=7 ?L\O+CJ
ML,^CBZLN^SR^N$K8Y^G%59]]GEU<#=CG^84=& /-RZL/E^S +J\\]KE_>16P
MS\/+JP[[/+J\ZK+/X\NKA'V>7E[UV>?9Y=6 ?9Y?VH$QT*P?77VH'[%#,^)1
MXAL)* F-="B)C'0IB8TDE*1&^I1D1@:4Y$8LW3+4K-?M4%F^;1GQ*/&-!)2$
M1CJ41$:ZE,1&$DI2(WU*,B,#2O*ZJRP8:M8;=J@LO;>,>)3X1@)*0B,=2B(C
M74IB(PDEJ9$^)9F1 26Y$3M46J_4K6"ITXK%B$>);R2@)#32H20RTJ4D-I)0
MDAKI4Y(9&5"2UU' 4-2L6PE3IS6,$8\2WTA 26BD0TEDI$M);"2A)#72IR0S
M,J DKZ.DH:A9MZ*F3JL:(QXEOI& DM!(AY+(2)>2V$A"26JD3TEF9$!)7D>1
M0U&S;F5.G=8Y1CQ*?",!):&1#B61D2XEL9&$DM1(GY+,R("2O(ZRAZ)FW0J?
M.JU\C'B4^$8"2D(C'4HB(UU*8B,)):F1/B69D0$E>1V%$$7-NI5"=5H+&?$H
M\8T$E(1&.I1$1KJ4Q$822E(C?4HR(P-*\CI*(XJ:=2N.ZK0Z,N)1XAL)* F-
M="B)C'0IB8TDE*1&^I1D1@:4Y'442Q0U&U8M-6BU9,2CQ#<24!(:Z5 2&>E2
M$AM)*$F-]"G)C PHR1NHEBAJ-JQ::M!JR8A'B6\DH"0TTJ$D,M*E)#:24)(:
MZ5.2&1E0DC=0+5'4;%BUU*#5DA&/$M](0$EHI$-)9*1+26PDH20UTJ<D,S*@
M)&^@6J*HV;!JJ4&K)2,>);Z1@)+02(>2R$B7DMA(0DEJI$])9F1 2=Y M411
MLV'54H-62T8\2GPC 26AD0XED9$N);&1A)+42)^2S,B DKR!:HFB9L.JI0:M
MEHQXE/A& DI"(QU*(B-=2F(C"26ID3XEF9$!)7D#U1)%S8952PU:+1GQ*/&-
M!)2$1CJ41$:ZE,1&$DI2(WU*,B,#2O(&JB6*F@VKEAJT6C+B4>(;"2@)C70H
MB8QT*8F-))2D1OJ49$8&E.0-5$L4-1M6+35HM63$H\0W$E 2&NE0$AGI4A(;
M22A)C?0IR8P,*,D;J)8H:C:L6FK0:LF(1XEO)* D--*A)#+2I20VDE"2&NE3
MDAD94)(W4"U1U#RV:NF85DM&/$I\(P$EH9$.)9&1+B6QD822U$B?DLS(@)+\
M&-421<UCJY:.:;5DQ*/$-Q)0$AKI4!(9Z5(2&TDH28WT*<F,#"C)CU$M4=0\
MMFKIF%9+1CQ*?",!):&1#B61D2XEL9&$DM1(GY+,R("2_!C5$D7-8[P,XV_#
M\#J,OP_#"S'^1@ROQ/@[,;P4XV_%\%J,OQ?#BS'^9@ROQOB[,?=RC%9+QU8M
M'=-JR8A'B6\DH"0TTJ$D,M*E)#:24)(:Z5.2&1E0DA^C6J*H>6S5TC&MEHQX
ME/A& DI"(QU*(B-=2F(C"26ID3XEF9$!)?DQJB6*FL=6+1W3:LF(1XEO)* D
M--*A)#+2I20VDE"2&NE3DAD94)(?HUJBJ'ELU=(QK9:,>)3X1@)*0B,=2B(C
M74IB(PDEJ9$^)9F1 27Y,:HEBIK'5BT=TVK)B$>);R2@)#32H20RTJ4D-I)0
MDAKI4Y(9&5"2'Z-:HJAY;-72,:V6C'B4^$8"2D(C'4HB(UU*8B,)):F1/B69
MD0$E^3&J)8J:)U8MG=!JR8A'B6\DH"0TTJ$D,M*E)#:24)(:Z5.2&1E0DI^@
M6J*H>6+5T@FMEHQXE/A& DI"(QU*(B-=2F(C"26ID3XEF9$!)?D)JB6*FB=6
M+9W0:LF(1XEO)* D--*A)#+2I20VDE"2&NE3DAD94)*?H%JBJ'EBU=()K9:,
M>)3X1@)*0B,=2B(C74IB(PDEJ9$^)9F1 27Y":HEBIHGF$S$9Q-A.A&?3X0)
M17Q&$:84\3E%F%3$9Q5A6A&?5X2)17QF$:86\;E%;G(1K99.K%HZH=62$8\2
MWTA 26BD0TEDI$M);"2A)#72IR0S,J D/T&U1%'SQ*JE$UHM&?$H\8T$E(1&
M.I1$1KJ4Q$822E(C?4HR(P-*\A-42Q0U3ZQ:.J'5DA&/$M](0$EHI$-)9*1+
M26PDH20UTJ<D,S*@)#]!M411\\2JI1-:+1GQ*/&-!)2$1CJ41$:ZE,1&$DI2
M(WU*,B,#2O(35$L4-4^L6CJAU9(1CQ+?2$!):*1#262D2TEL)*$D-=*G)#,R
MH"0_0;5$4?/4JJ536BT9\2CQC024A$8ZE$1&NI3$1A)*4B-]2C(C TKR4U1+
M%#5/K5HZI=62$8\2WTA 26BD0TEDI$M);"2A)#72IR0S,J D/T6U1%'SU*JE
M4UHM&?$H\8T$E(1&.I1$1KJ4Q$822E(C?4HR(P-*\E-42Q0U3ZU:.J75DA&/
M$M](0$EHI$-)9*1+26PDH20UTJ<D,S*@)#]%M411\]2JI5-:+1GQ*/&-!)2$
M1CJ41$:ZE,1&$DI2(WU*,B,#2O)35$L4-4\Q&9O/QL9T;#X?&Q.R^8QL3,GF
M<[(Q*9O/RL:T;#XO&Q.S^<QL3,WF<[/=Y&Q:+9U:M71*JR4C'B6^D8"2T$B'
MDLA(EY+82$)):J1/269D0$E^BFJ)HN:I54NGM%HRXE'B&PDH"8UT*(F,="F)
MC224I$;ZE&1&!I3DIZB6*&J>6K5T2JLE(QXEOI& DM!(AY+(2)>2V$A"26JD
M3TEF9$!)?HIJB:+FJ55+I[1:,N)1XAL)* F-="B)C'0IB8TDE*1&^I1D1@:4
MY*>HEBAJGEFU=$:K)2,>);Z1@)+02(>2R$B7DMA(0DEJI$])9F1 27Z&:HFB
MYIE52V>T6C+B4>(;"2@)C70HB8QT*8F-))2D1OJ49$8&E.1GJ)8H:IY9M71&
MJR4C'B6^D8"2T$B'DLA(EY+82$)):J1/269D0$E^AFJ)HN:954MGM%HRXE'B
M&PDH"8UT*(F,="F)C224I$;ZE&1&!I3D9ZB6*&J>6;5T1JLE(QXEOI& DM!(
MAY+(2)>2V$A"26JD3TEF9$!)?H9JB:+FF55+9[1:,N)1XAL)* F-="B)C'0I
MB8TDE*1&^I1D1@:4Y&>HEBAJGF$Q&U_-AN5L?#T;%K3Q%6U8TL;7M&%1&U_5
MAF5M?%T;%K;QE6U8VL;7MKG%;;1:.K-JZ8Q62T8\2GPC 26AD0XED9$N);&1
MA)+42)^2S,B DOP,U1)%S3.KELYHM63$H\0W$E 2&NE0$AGI4A(;22A)C?0I
MR8P,*,G/4"U1U#RS:NF,5DM&/$I\(P$EH9$.)9&1+B6QD822U$B?DLS(@)+\
M#-421<USJY;.:;5DQ*/$-Q)0$AKI4!(9Z5(2&TDH28WT*<F,#"C)SU$M4=0\
MMVKIG%9+1CQ*?",!):&1#B61D2XEL9&$DM1(GY+,R("2_!S5$D7-<ZN6SFFU
M9,2CQ#<24!(:Z5 2&>E2$AM)*$F-]"G)C PHR<]1+5'4/+=JZ9Q62T8\2GPC
M 26AD0XED9$N);&1A)+42)^2S,B DOP<U1)%S7.KELYIM63$H\0W$E 2&NE0
M$AGI4A(;22A)C?0IR8P,*,G/42U1U#RW:NF<5DM&/$I\(P$EH9$.)9&1+B6Q
MD822U$B?DLS(@)+\'-421<USJY;.:;5DQ*/$-Q)0$AKI4!(9Z5(2&TDH28WT
M*<F,#"C)SU$M4=0\AQD =P. '0#W X A '<$@"4 ]P2 *0!W!8 M /<%@#$
M=P: -0#W!G#F +1:.K=JZ9Q62T8\2GPC 26AD0XED9$N);&1A)+42)^2S,B
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M ,SCS <+. O!.IQ%8%W.8K"$LQ2LSUD&-N LK[NF !S:P:/"XWT!P#S.?+"
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M <SCS <+. O!.IQ%8%W.8K"$LQ2LSUD&-N LK[N&"!S:P:/"XST1P#S.?+"
MLQ"LPUD$UN4L!DLX2\'ZG&5@ \[RNFN1P*$=/"H\WB4!S./,!PLX"\$ZG$5@
M7<YBL(2S%*S/608VX"RONZ8)'-K!H\+C?1/ /,Y\L("S$*S#6036Y2P&2SA+
MP?J<96 #SO*Z:Z/ H1T\*CS>20',X\P'"S@+P3J<16!=SF*PA+,4K,]9!C;@
M+*^[Q@H<VL&CPN.]%< \SGRP@+,0K,-9!-;E+ 9+.$O!^IQE8 /.\KIKM<!A
MLXYF"W7>;0',X\P'"S@+P3J<16!=SF*PA+,4K,]9!C;@+*^[Y@L<VL&CPN/]
M%\ \SGRP@+,0K,-9!-;E+ 9+.$O!^IQE8 /.\KIKQ\"A'3PJ/-Z1 <SCS <+
M. O!.IQ%8%W.8K"$LQ2LSUD&-N LK[L&#1S:P:/"XST:P#S.?+" LQ"LPUD$
MUN4L!DLX2\'ZG&5@ \[RNFO9P*$=/"H\WK4!S./,!PLX"\$ZG$5@7<YBL(2S
M%*S/608VX"RONR8.'-K!H\+C?1S /,Y\L("S$*S#6036Y2P&2SA+P?J<96 #
MSO*Z:^O H1T\*CS>V0',X\P'"S@+P3J<16!=SF*PA+,4K,]9!C;@+*^[1@\<
MVL&CPN.]'L \SGRP@+,0K,-9!-;E+ 9+.$O!^IQE8 /.\KIK_<"A'3PJ/-[]
M <SCS <+. O!.IQ%8%W.8K"$LQ2LSUD&-N LK[MF$!S:P:/"X_T@P#S.?+"
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MPNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " "4BHM7!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M )2*BU=K*9C_[0   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( )2*BU>97)PC$ 8  )PG   3
M  "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ E(J+5Q3[
M$X<<30$ +0X* !@              ("!# @  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( )2*BU=29XY[*P,  .H2   -
M  "  5Y5 0!X;"]S='EL97,N>&UL4$L! A0#%     @ E(J+5Y>*NQS
M$P(   L              ( !M%@! %]R96QS+RYR96QS4$L! A0#%     @
ME(J+5[9"5R8R 0  ( (   \              ( !G5D! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( )2*BU<D'INBK0   /@!   :              "
M ?Q: 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( )2*
MBU=ED'F2&0$  ,\#   3              "  >%; 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     )  D /@(  "M= 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>85</ContextCount>
  <ElementCount>47</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="tm2325133d1_ncsr.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995470 - Disclosure - N-2</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cef/role/N2</Role>
      <ShortName>N-2</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ck0001635977-20230930.xsd</File>
    <File>ck0001635977-20230930_def.xml</File>
    <File>ck0001635977-20230930_lab.xml</File>
    <File>ck0001635977-20230930_pre.xml</File>
    <File doctype="N-CSR" isDefinitelyNotFs="true" isNcsr="true" isUsgaap="true" original="tm2325133d1_ncsr.htm">tm2325133d1_ncsr.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>j23251332_ab001.jpg</File>
    <File>j23251332_ac002.jpg</File>
    <File>j23251332_ac003.jpg</File>
    <File>j23251332_ac004.jpg</File>
    <File>j23251332_ba007.jpg</File>
    <File>j23251332_ba008.jpg</File>
    <File>j23251332_ba009.jpg</File>
    <File>j23251332_ba010.jpg</File>
    <File>j23251332_ga011.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="131">http://xbrl.sec.gov/cef/2023</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>29
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2325133d1_ncsr.htm": {
   "nsprefix": "ck0001635977",
   "nsuri": "http://www.teklacap.com/20230930",
   "dts": {
    "schema": {
     "local": [
      "ck0001635977-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/2006/xbrldi-2006.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/cef/2023/cef-2023.xsd",
      "https://xbrl.sec.gov/cef/2023/cef-2023_pre.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_lab.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "ck0001635977-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ck0001635977-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ck0001635977-20230930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2325133d1_ncsr.htm"
     ]
    }
   },
   "keyStandard": 47,
   "keyCustom": 0,
   "axisStandard": 3,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 52,
   "hidden": {
    "total": 10,
    "http://xbrl.sec.gov/cef/2023": 8,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 85,
   "entityCount": 1,
   "segmentCount": 52,
   "elementCount": 251,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/cef/2023": 131,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://fasb.org/us-gaap/2023": 27
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/cef/role/N2",
     "longName": "995470 - Disclosure - N-2",
     "shortName": "N-2",
     "isDefault": "true",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_20221001to20230930",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "strong",
       "span",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2325133d1_ncsr.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20221001to20230930",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "strong",
       "span",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2325133d1_ncsr.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "cef_InterestExpensesOnBorrowingsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "InterestExpensesOnBorrowingsPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expenses on Borrowings [Percent]"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "cef_RiskFactorsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RiskFactorsTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk Factors [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "cef_OtherMasterFundExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherMasterFundExpensesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Master Fund Expenses [Percent]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "cef_OtherTransactionExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionExpensesPercent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expenses [Percent]"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "ck0001635977_PotentialConflictsOfInterestRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "PotentialConflictsOfInterestRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Potential Conflicts of Interest Risk.",
        "label": "Potential Conflicts Of Interest Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ProspectusTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ProspectusTable",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89"
     ]
    },
    "ck0001635977_PrivateInvestmentInPublicEquityRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "PrivateInvestmentInPublicEquityRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Investment In Public Equity Risk [Member]",
        "documentation": "This member stands for private investments in public equity (\"PIPEs\") Risk."
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualExpensesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Expenses [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "ck0001635977_RegulationAsCommodityPoolMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "RegulationAsCommodityPoolMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information of regulation as commodity pool.",
        "label": "Regulation As Commodity Pool [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "cef_PrimaryShelfFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "PrimaryShelfFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary Shelf [Flag]"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "cef_ManagementFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ManagementFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Fees [Percent]"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "cef_InvestmentObjectivesAndPracticesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "InvestmentObjectivesAndPracticesTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Objectives and Practices [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "cef_RegisteredClosedEndFundFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RegisteredClosedEndFundFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registered Closed-End Fund [Flag]"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ck0001635977_LeverageRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "LeverageRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Leverage Risk.",
        "label": "Leverage Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_PrimaryShelfQualifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "PrimaryShelfQualifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary Shelf Qualified [Flag]"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "cef_BusinessDevelopmentCompanyFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "BusinessDevelopmentCompanyFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Development Company [Flag]"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "ck0001635977_LiquidityRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "LiquidityRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Liquidity Risk.",
        "label": "Liquidity Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r17",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r53",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r176"
     ]
    },
    "cef_DividendAndInterestExpensesOnShortSalesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "DividendAndInterestExpensesOnShortSalesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend and Interest Expenses on Short Sales [Percent]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ck0001635977_LifeScienceAndToolsIndustryRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "LifeScienceAndToolsIndustryRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Life Science and Tools Industry Risk.",
        "label": "Life Science And Tools Industry Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_DividendReinvestmentAndCashPurchaseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "DividendReinvestmentAndCashPurchaseFees",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Reinvestment and Cash Purchase Fees"
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "cef_GeneralDescriptionOfRegistrantAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "GeneralDescriptionOfRegistrantAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Description of Registrant [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "cef_IncentiveFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "IncentiveFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Fees [Percent]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "cef_DistributionServicingFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "DistributionServicingFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution/Servicing Fees [Percent]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "cef_IntervalFundFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "IntervalFundFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interval Fund [Flag]"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "cef_OtherAnnualExpense1Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherAnnualExpense1Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 1 [Percent]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ck0001635977_LoanFacility2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "LoanFacility2016Member",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility 2016 [Member]",
        "documentation": "Loan Facility 2016 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001635977_AntiTakeoverProvisionsRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "AntiTakeoverProvisionsRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Anti-Takeover Provisions Risk.",
        "label": "Anti Takeover Provisions Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_NetExpenseOverAssetsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "NetExpenseOverAssetsPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Expense over Assets [Percent]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ck0001635977_LoanFacility2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "LoanFacility2017Member",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility 2017 [Member]",
        "documentation": "Loan Facility 2017 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cef_LoanServicingFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LoanServicingFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Servicing Fees [Percent]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "cef_NewCefOrBdcRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "NewCefOrBdcRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New CEF or BDC Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "ck0001635977_LoanFacility2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "LoanFacility2018Member",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility 2018 [Member]",
        "documentation": "Loan Facility 2018 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherFeederFundExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherFeederFundExpensesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Feeder Fund Expenses [Percent]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "cef_FeeTableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "FeeTableAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Table [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "ck0001635977_LoanFacility2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "LoanFacility2019Member",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility 2019 [Member]",
        "documentation": "Loan Facility 2019 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_DividendExpenseOnPreferredSharesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "DividendExpenseOnPreferredSharesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Expenses on Preferred Shares [Percent]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "cef_RiskTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RiskTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "cef_ShareholderTransactionExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ShareholderTransactionExpensesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Transaction Expenses [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "ck0001635977_LoanFacility2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "LoanFacility2020Member",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility 2020 [Member]",
        "documentation": "Loan Facility 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherAnnualExpense2Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherAnnualExpense2Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 2 [Percent]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ck0001635977_LoanFacility2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "LoanFacility2021Member",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility 2021 [Member]",
        "documentation": "Loan Facility 2021 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherAnnualExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherAnnualExpensesAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expenses [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r7",
      "r8",
      "r10",
      "r11",
      "r17",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r53",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r176"
     ]
    },
    "cef_OtherTransactionExpense3Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionExpense3Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 3 [Percent]"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001635977_LoanFacility2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "LoanFacility2022Member",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility 2022 [Member]",
        "documentation": "Loan Facility 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SalesLoadPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SalesLoadPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Load [Percent]"
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ck0001635977_LoanFacility2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "LoanFacility2023Member",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility 2023 [Member]",
        "documentation": "Loan Facility 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherAnnualExpense3Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherAnnualExpense3Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 3 [Percent]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualDividendPayment": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualDividendPayment",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r174",
      "r175",
      "r177"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "ck0001635977_ManagedCareSectorRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "ManagedCareSectorRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Managed Care Sector Risk.",
        "label": "Managed Care Sector Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_UnderwritersCompensationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "UnderwritersCompensationPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriters Compensation [Percent]"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherAnnualExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherAnnualExpensesPercent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expenses [Percent]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ck0001635977_PortfolioMarketRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "PortfolioMarketRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portfolio Market Risk [Member]",
        "documentation": "This member stands for Portfolio Market Risk."
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionExpensesAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expenses [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001635977_NonDiversificationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "NonDiversificationRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Diversification Risk [Member]",
        "documentation": "This member stands for Non-Diversification Risk."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ck0001635977_MarketDisruptionAndGeopoliticalRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "MarketDisruptionAndGeopoliticalRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Market Disruption and Geopolitical Risk.",
        "label": "Market Disruption And Geopolitical Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionExpense1Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionExpense1Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 1 [Percent]"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionExpense2Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionExpense2Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 2 [Percent]"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001635977_PharmaceuticalSectorRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "PharmaceuticalSectorRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Pharmaceutical Sector Risk.",
        "label": "Pharmaceutical Sector Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001635977_NonInvestmentGradeSecuritiesRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "NonInvestmentGradeSecuritiesRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Non-Investment Grade Securities Risk.",
        "label": "Non Investment Grade Securities Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "cef_LongTermDebtTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Title [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "cef_OtherSecurityDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherSecurityDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Security, Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "cef_LongTermDebtPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtPrincipal",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Principal"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "cef_SecurityPreemptiveAndOtherRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityPreemptiveAndOtherRightsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Preemptive and Other Rights [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ck0001635977_HealthcareSuppliesSectorRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "HealthcareSuppliesSectorRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Healthcare Supplies Sector Risk.",
        "label": "Healthcare Supplies Sector Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_DistributionsMayReducePrincipalTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "DistributionsMayReducePrincipalTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributions May Reduce Principal [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ck0001635977_InterestRatesRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "InterestRatesRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Rates Risk [Member]",
        "documentation": "Interest Rates Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SecurityObligationsOfOwnershipTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityObligationsOfOwnershipTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Obligations of Ownership [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ck0001635977_KeyPersonnelRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "KeyPersonnelRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Key Personnel Risk.",
        "label": "Key Personnel Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "cef_PreferredStockRestrictionsArrearageTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "PreferredStockRestrictionsArrearageTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Restrictions, Arrearage [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "cef_PreferredStockRestrictionsOtherTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "PreferredStockRestrictionsOtherTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Restrictions, Other [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "cef_RightsSubjectToOtherThanMajorityVoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RightsSubjectToOtherThanMajorityVoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Subject to Other than Majority Vote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ck0001635977_HealthcareTechnologySectorRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "HealthcareTechnologySectorRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Healthcare Technology Sector Risk [Member]",
        "documentation": "This member stands for Healthcare Technology Sector Risk."
       }
      }
     },
     "auth_ref": []
    },
    "cef_RightsLimitedByOtherSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RightsLimitedByOtherSecuritiesTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Limited by Other Securities [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "cef_LongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ck0001635977_ConvertibleSecuritiesRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "ConvertibleSecuritiesRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Securities Risk [Member]",
        "documentation": "This member stands for Convertible Securities Risk."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001635977_ConcentrationInHealthcareIndustriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "ConcentrationInHealthcareIndustriesMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Concentration in the Healthcare Industries.",
        "label": "Concentration In Healthcare Industries [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r161"
     ]
    },
    "ck0001635977_CounterpartyRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "CounterpartyRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Counterparty Risk.",
        "label": "Counterparty Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LongTermDebtStructuringTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtStructuringTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Structuring [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Involuntary Liquidating Preference per Unit (Deprecated 2023-01-31)"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ck0001635977_CreditDefaultRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "CreditDefaultRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Credit/Default Risk.",
        "label": "Credit Default Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r161"
     ]
    },
    "cef_OtherSecurityTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherSecurityTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Security, Title [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ck0001635977_DerivativesRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "DerivativesRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Derivatives Risk.",
        "label": "Derivatives Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "cef_SeniorSecuritiesAveragingMethodNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesAveragingMethodNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Averaging Method, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "cef_LongTermDebtIssuanceAndSubstitutionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtIssuanceAndSubstitutionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Issuance and Substitution [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "cef_LongTermDebtDividendsAndCovenantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtDividendsAndCovenantsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Dividends and Covenants [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r140"
     ]
    },
    "ck0001635977_EquityLinkedNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "EquityLinkedNotesMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Equity-Linked Notes.",
        "terseLabel": "Equity-linked Notes [Member]",
        "label": "Equity Linked Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LongTermDebtRightsLimitedByOtherSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Rights Limited by Other Securities [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "cef_SeniorSecuritiesCvgPerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesCvgPerUnit",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Coverage per Unit"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "cef_OtherSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherSecuritiesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Securities [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ck0001635977_EquitySecuritiesRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "EquitySecuritiesRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities Risk [Member]",
        "documentation": "This member stands for Equity Securities Risk."
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesHighlightsAnnualizedNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesHighlightsAnnualizedNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Highlights Annualized, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r133",
      "r140"
     ]
    },
    "ck0001635977_ExampleDoesNotIncludeSalesLoadMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "ExampleDoesNotIncludeSalesLoadMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Example Does Not Include Sales Load [Member]",
        "documentation": "It represents as a example does not include the sales load.",
        "terseLabel": "Example does not include the sales load [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001635977_ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "ExampleAssumesTransactionFeeOfAsPercentageOfOfferingPriceMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Example Assumes Transaction Fee Of As Percentage Of Offering Price [Member]",
        "documentation": "It represents as a example assumes transaction fee of as percentage of offering price.",
        "terseLabel": "Example assumes transaction fee of percentage of offering price [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "cef_SeniorSecuritiesCoveragePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesCoveragePerUnit",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Coverage per Unit (Deprecated 2023-01-31)"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "cef_WarrantsOrRightsCalledPeriodDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "WarrantsOrRightsCalledPeriodDate",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Period [Date]"
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ck0001635977_ExchangeTradedFundsRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "ExchangeTradedFundsRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for ETFs Risk.",
        "terseLabel": "Exchange-Traded Funds Risk [Member]",
        "label": "Exchange Traded Funds Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_WarrantsOrRightsCalledAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "WarrantsOrRightsCalledAmount",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Amount"
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "cef_WarrantsOrRightsCalledTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "WarrantsOrRightsCalledTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Title"
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ck0001635977_ForeignSecuritiesRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "ForeignSecuritiesRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Securities Risk [Member]",
        "documentation": "This member stands for Foreign Securities Risk."
       }
      }
     },
     "auth_ref": []
    },
    "cef_ProspectusLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ProspectusLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prospectus [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "ck0001635977_FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "FailureOfFuturesCommissionMerchantsAndClearingOrganizationsMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Failure Of Futures Commission Merchants And Clearing Organizations [Member]",
        "documentation": "Represents information of failure of futures commission merchants and clearing organizations."
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesHighlightsAuditedNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesHighlightsAuditedNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Highlights Audited, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r134",
      "r140"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "cef_WarrantsOrRightsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "WarrantsOrRightsExercisePrice",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "cef_SeniorSecuritiesAverageMarketValuePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesAverageMarketValuePerUnit",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Average Market Value per Unit"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ck0001635977_ForwardContractRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "ForwardContractRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Forward Contract Risk.",
        "label": "Forward Contract Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OutstandingSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OutstandingSecuritiesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Securities [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_NetAssetValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetAssetValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NAV Per Share",
        "documentation": "Net asset value per share or per unit of investments in certain entities that calculate net asset value per share. Includes, but is not limited to, by unit, membership interest, or other ownership interest. Investment includes, but is not limited to, investment in certain hedge funds, venture capital funds, private equity funds, real estate partnerships or funds. Excludes fair value disclosure."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r61",
      "r68",
      "r69",
      "r71",
      "r72",
      "r75",
      "r85"
     ]
    },
    "cef_OutstandingSecurityAuthorizedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OutstandingSecurityAuthorizedShares",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Authorized [Shares]"
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ck0001635977_GovernmentInterventionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "GovernmentInterventionMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Government Intervention.",
        "label": "Government Intervention [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OutstandingSecurityTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OutstandingSecurityTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Title [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "cef_SeniorSecuritiesHeadingsNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesHeadingsNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Headings, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ck0001635977_HealthcareServicesSectorRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "HealthcareServicesSectorRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Healthcare Services Sector Risk.",
        "label": "Healthcare Services Sector Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OutstandingSecurityNotHeldShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OutstandingSecurityNotHeldShares",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Not Held [Shares]"
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "cef_OutstandingSecurityHeldShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OutstandingSecurityHeldShares",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Held [Shares]"
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "ck0001635977_HealthcareEquipmentSectorRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "HealthcareEquipmentSectorRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Healthcare Equipment Sector Risk [Member]",
        "documentation": "This member stands for Healthcare Equipment Sector Risk."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ck0001635977_HealthcareDistributorsSectorRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "HealthcareDistributorsSectorRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Healthcare Distributors Sector Risk [Member]",
        "documentation": "This member stands for Healthcare Distributors Sector Risk."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001635977_HealthcareFacilitiesSectorRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "HealthcareFacilitiesSectorRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Healthcare Facilities Sector Risk [Member]",
        "documentation": "This member stands for Healthcare Facilities Sector Risk."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001635977_BiotechnologyIndustryRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "BiotechnologyIndustryRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Biotechnology Industry Risk [Member]",
        "documentation": "This member stands for Biotechnology Industry Risk."
       }
      }
     },
     "auth_ref": []
    },
    "cef_BdcFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "BdcFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BDC File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001635977_RelatedPartyTransactionsRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "RelatedPartyTransactionsRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Related Party Transactions Risk.",
        "label": "Related Party Transactions Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001635977_ReitRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "ReitRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "REIT Risk [Member]",
        "documentation": "This member stands for REIT Risk."
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualDividendPaymentInitial": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualDividendPaymentInitial",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment, Initial"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ck0001635977_RestrictedSecuritiesAndValuationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "RestrictedSecuritiesAndValuationRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Restricted Securities and Valuation Risk.",
        "label": "Restricted Securities And Valuation Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001635977_RisksAssociatedWithFundsOptionStrategyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "RisksAssociatedWithFundsOptionStrategyMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Risks Associated with the Fund's Option Strategy.",
        "label": "Risks Associated With Funds Option Strategy [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001635977_RisksAssociatedWithRegulatoryAndPolicyChangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "RisksAssociatedWithRegulatoryAndPolicyChangesMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks Associated With Regulatory And Policy Changes [Member]",
        "documentation": "This member stands for Risks Associated with Regulatory and Policy Changes."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001635977_SecurityMarketRiskDiscountToNetAssetValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "SecurityMarketRiskDiscountToNetAssetValueMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Market Risk Discount To Net Asset Value [Member]",
        "terseLabel": "Security Market Risk-discount To Net Asset Value [Member]",
        "documentation": "This member stands for security market risk-discount to net asset value."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001635977_SelectionRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "SelectionRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selection Risk [Member]",
        "documentation": "This member stands for Selection Risk."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001635977_VentureCapitalInvestmentsRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "VentureCapitalInvestmentsRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Venture Capital Investments Risk.",
        "label": "Venture Capital Investments Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001635977_SpecialPurposeAcquisitionCompanyRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.teklacap.com/20230930",
     "localname": "SpecialPurposeAcquisitionCompanyRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Special Purpose Acquisition Company Risk.",
        "label": "Special Purpose Acquisition Company Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualDividendPaymentCurrent": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualDividendPaymentCurrent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment, Current"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "cef_LatestSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LatestSharePrice",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Share Price (Deprecated 2023-01-31)"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "cef_AcquiredFundTotalAnnualExpensesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AcquiredFundTotalAnnualExpensesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Total Annual Expenses, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "cef_FinancialHighlightsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "FinancialHighlightsAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Highlights [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "cef_HighestPriceOrBid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "HighestPriceOrBid",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid"
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "cef_ReturnAtMinusFivePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ReturnAtMinusFivePercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Minus Five [Percent]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "cef_WaiversAndReimbursementsOfFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "WaiversAndReimbursementsOfFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Waivers and Reimbursements of Fees [Percent]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "cef_ExpenseExampleYears1to3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ExpenseExampleYears1to3",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 3"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "cef_SeniorSecuritiesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesAmount",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Amount (Deprecated 2023-01-31)"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "cef_LowestPriceOrBidNav": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LowestPriceOrBidNav",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid, NAV"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "cef_SeniorSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "cef_ExpenseExampleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ExpenseExampleTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "cef_EffectsOfLeverageTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "EffectsOfLeverageTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r91",
      "r158",
      "r159",
      "r160"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "cef_TotalAnnualExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "TotalAnnualExpensesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Annual Expenses [Percent]"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "cef_SeniorSecuritiesAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "cef_HighestPriceOrBidNav": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "HighestPriceOrBidNav",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid, NAV"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "cef_AcquiredFundFeesAndExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AcquiredFundFeesAndExpensesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees and Expenses [Percent]"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "cef_IncentiveAllocationMinimumPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "IncentiveAllocationMinimumPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation Minimum [Percent]"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Liquidating Preference",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r9",
      "r175",
      "r178"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "cef_ExpenseExampleYear01": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ExpenseExampleYear01",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Year 01"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "cef_HighestPriceOrBidPremiumDiscountToNavPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "HighestPriceOrBidPremiumDiscountToNavPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid, Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r91",
      "r158",
      "r159",
      "r160"
     ]
    },
    "cef_SecurityTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Title [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "cef_AnnualInterestRateInitialPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualInterestRateInitialPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate, Initial [Percent]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "cef_LatestNav": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LatestNav",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest NAV (Deprecated 2023-01-31)"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "cef_EffectsOfLeverageTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "EffectsOfLeverageTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "cef_ExpenseExampleYears1to5": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ExpenseExampleYears1to5",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 5"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "cef_SharePricesNotActualTransactionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SharePricesNotActualTransactionsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Prices Not Actual Transactions [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "cef_LowestPriceOrBidPremiumDiscountToNavPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LowestPriceOrBidPremiumDiscountToNavPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid, Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "cef_AnnualCoverageReturnRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualCoverageReturnRatePercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Coverage Return Rate [Percent]"
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "cef_AnnualInterestRateCurrentPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualInterestRateCurrentPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate, Current [Percent]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "cef_ReturnAtMinusTenPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ReturnAtMinusTenPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Minus Ten [Percent]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "cef_NoPublicTradingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "NoPublicTradingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Public Trading [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "cef_ExpenseExampleYears1to10": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ExpenseExampleYears1to10",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 10"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "cef_RiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RiskAxis",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_PurposeOfFeeTableNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "PurposeOfFeeTableNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purpose of Fee Table , Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "CapitalStockLongTermDebtAndOtherSecuritiesAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock, Long-Term Debt, and Other Securities [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "cef_ReturnAtZeroPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ReturnAtZeroPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Zero [Percent]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "cef_NoTradingHistoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "NoTradingHistoryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading History [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "cef_LatestPremiumDiscountToNavPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LatestPremiumDiscountToNavPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Fee not based on Net Assets, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "cef_BasisOfTransactionFeesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "BasisOfTransactionFeesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Transaction Fees, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "cef_SecurityLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityLiabilitiesTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Liabilities [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "cef_ReturnAtPlusFivePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ReturnAtPlusFivePercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Plus Five [Percent]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "cef_AllRisksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AllRisksMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Risks:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "cef_SecurityDividendsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityDividendsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Dividends [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "cef_OtherTransactionFeesBasisNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionFeesBasisNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "cef_OtherTransactionFeesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionFeesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "cef_CapitalStockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "CapitalStockTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "cef_ReturnAtPlusTenPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ReturnAtPlusTenPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Plus Ten [Percent]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r174",
      "r175",
      "r177"
     ]
    },
    "us-gaap_InterestRateRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestRateRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Rate Risk [Member]",
        "documentation": "The risk associated with changes in interest rates that effect the value of an interest-bearing asset or liability, and a servicing asset or liability."
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionFeesBasisMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionFeesBasisMaximum",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Maximum"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "cef_OtherTransactionFeesBasisMaximumPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionFeesBasisMaximumPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Maximum [Percent]"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "cef_AnnualInterestRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualInterestRatePercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate [Percent]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "cef_OtherExpensesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherExpensesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "cef_EffectsOfLeveragePurposeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "EffectsOfLeveragePurposeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage, Purpose [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "cef_SecurityVotingRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityVotingRightsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Voting Rights [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "cef_AcquiredFundFeesEstimatedNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AcquiredFundFeesEstimatedNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees Estimated, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "cef_LowestPriceOrBid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LowestPriceOrBid",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid"
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "cef_AcquiredFundFeesAndExpensesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AcquiredFundFeesAndExpensesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees and Expenses, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "cef_IncentiveAllocationMaximumPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "IncentiveAllocationMaximumPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation Maximum [Percent]"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "cef_AcquiredFundIncentiveAllocationNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AcquiredFundIncentiveAllocationNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Incentive Allocation, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "cef_SecurityLiquidationRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityLiquidationRightsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Liquidation Rights [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "cef_SharePriceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SharePriceTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "cef_IncentiveAllocationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "IncentiveAllocationPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation [Percent]"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482134/820-10-35-54B"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "59",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482134/820-10-35-59"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "a"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "a",
   "Subparagraph": "4"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "a",
   "Subparagraph": "5"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "a",
   "Subparagraph": "6"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "a",
   "Subparagraph": "Instruction 2"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "b",
   "Subparagraph": "1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "b",
   "Subparagraph": "2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "c"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "d"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "2"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "2",
   "Paragraph": "a"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "2",
   "Paragraph": "b"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "2",
   "Paragraph": "c"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "2",
   "Paragraph": "e"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "3"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "5"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "5",
   "Paragraph": "1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "5",
   "Paragraph": "2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "5",
   "Paragraph": "3"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "5",
   "Paragraph": "4"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 10",
   "Subparagraph": "a"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 10",
   "Subparagraph": "a, g, h"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 10",
   "Subparagraph": "f"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 10",
   "Subparagraph": "g"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 10",
   "Subparagraph": "i"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 11"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 4"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 5"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 7",
   "Subparagraph": "a"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 7",
   "Subparagraph": "b"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 8"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 9"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "1",
   "Paragraph": "Instruction 2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "1",
   "Paragraph": "Instruction 3"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "1",
   "Paragraph": "Instruction 8"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "3"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "3",
   "Paragraph": "2"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "3",
   "Paragraph": "3",
   "Subparagraph": "Instruction 2"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "3",
   "Paragraph": "4",
   "Subparagraph": "Instruction 3"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "3",
   "Paragraph": "5"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "3",
   "Paragraph": "Instruction 1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "3",
   "Paragraph": "Instruction 4"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "3",
   "Paragraph": "Instruction 5"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "2",
   "Paragraph": "b, d"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "3",
   "Paragraph": "a"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "3",
   "Paragraph": "b"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "3",
   "Paragraph": "b",
   "Subparagraph": "1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "3",
   "Paragraph": "b",
   "Subparagraph": "2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "3",
   "Paragraph": "b",
   "Subparagraph": "3"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "5",
   "Paragraph": "b"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "5",
   "Paragraph": "b",
   "Subparagraph": "4"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "5",
   "Paragraph": "b",
   "Subparagraph": "Instruction 2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "5",
   "Paragraph": "b",
   "Subparagraph": "Instruction 3"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "5",
   "Paragraph": "b",
   "Subparagraph": "Instruction 4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "5",
   "Paragraph": "b",
   "Subparagraph": "Instructions 4, 5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "5",
   "Paragraph": "c"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "5",
   "Paragraph": "e"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>30
<FILENAME>0001104659-23-125049-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-125049-xbrl.zip
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MPQI#F'(B%S\]M&>.U\+#/,PC7+U]$:1>)D)E-R*S[FI,-V(S3&AG!K,)<+M
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MV0S2E0WT1CC<B9$I#F_>)#G_ZHH?G27Q- J#/+N>KCZ6,$A;)XHWPF',_6+
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MQ\8XC,*QQ_R8$^EMZN2)M-(_:?7]85\&G/#&8ETLD3B\EYFS.QP$\P(G &\
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M>+9Z&![1D0(A"@APQ4Z:"!=U3?7]\JK.+A!Y51<UB+RS&EQ%WAFIH0+9KXY
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MTXK&@SGC(E+F<@=N@8L3EQB08[  XGW;NIBX3V1NO*_-PG!,8JN.48[2\J!
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M.FQ_I.N.111$?EW&Z:S6,*Y$"/UR5XA6 ?N]P"@3X2 \X_'$?]#3LS1657M
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MJOH\K,HTD<8;51E0XIKP;&QLNW^CNXR[;]!DF$I!PC"ZM%RG74$T6J)U&89
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MH%%)1M[(L_3 ZM; 0-M5%K>"!,5L313RXB82T\QRV=^D1$'YH=W'B')!TBQ
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M.$1Y%QI710VMMOB"C+YJ?V/CDXL@W+50*>MB;>IOZ:4M2E97=/0&;MR0[[X
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M!M*^#H[L@6U-O(YI9/8[^B8%/0V)79@>TM64$I%. 0O_[?GQ0]K,*>\;#Q
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M(),ZFQR>1/(Q.2!^Y@T2$4RC ZJ:9:M[=(G6M(W\^*L,]6,\DG$8D+)-7^6
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M%#B::0,# NL6'N!_J(5PP/602UBOD-<,HZ:*)L;KOH -W'I SZBIQP12$/O
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M(SH6O%$K=>E^?(K7@R&I+'M( ^T^![2]Q/AC>WY>IE<Z<P/S6L-O@?W@/8/
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MF"?3.=\><<6CWZ$<HMN5>FV,6G:+&V0'+:OXK4A"C*.!*?R&S#!PD2?Y"9E
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MCHH@>RFW12-FU"'I5KK\M%6@^X*X"?U^.WUE8J  GE&EEVEA:D.GO^S5ZE,
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M5_M<06Q(8Q^5RUJ%#\6X6/-CRV.3Y*CPC2E._CY)K"%=N# --)4[JO#]^K0
MR*)X<TN-Q!;5Q833Z]$9&G#6"(_SV[.;_^/I=U]7C&!QDJ$ #$47?TG"N5<G
M#,;!R(Y*,,G2Z!%/R2W$L%S;*KY69Z15\ZYA@8/F9VJM#T].M(PE!5<]#?)]
M3[EOBVE7TD0]&^$MDM<9FKG+'Z\,4LMPR:0"QA [/9LH997!O/GA+T6RT6^
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MHVG.D2_=$CBHINE+TFB8+.;L<>%QP329?[0Z\1SKSZ]R*_!;P6=8]/Y+^!C
M=7C>Q*3?_!CG<!9-7#6*)0JIP[AKHHO.56^?Z'XDU;3K>8!O($9-FDW3)(R+
M8R;/K'NW#=X?VN5\)^50NKI_^>D2UA-, 4=UC%0HW7,TO;PZ:.>FA+W*Q<T
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MP7J#B%B#M8\J*GR>7716 +B3^A.IT&#I!")03O@$]1[1K<-^Z? \-V"?NIC
M7!^4+S#B#YILU!I03]=,\(P(TN<*%("_SS#2(U);G*QFFYY;\F[*!]LTT&BD
M E*HXXBQ,6JJI$-5RA5A':SK=%6F#C9T[99]=_R?;M^^F*!$>_H&=+0"A;NG
MM%?YR*)0]\\;;%7PH6N$XH,6G<D7=TM9!*[@>XU?>OV6G<6Z:+4S+E,C3;@;
M*3*(-_?'C 6UHMDV!55G)@A"#%[U98D4AI2#1P$YOK^]KJE.5;2&;T \O[]L
M',NCXB#EVDC[1PJ@ECJJ)8+'3BRK_,VO3XV0$L&1P,JJO[B@AX!8A'&2C7ZB
M]DFQP#-2F3-PT:TUV4P L>!,?_1ETG4P[*(&&V)^D>Z+*9;O=T6@$+X(O^A.
MH0MOA@W7M559I '?N*T,$@6I3.TY@AA5U(/-@'%GHFU6I(,,=$3L1L'#>G4R
MU0KTR7F5HW'[G'<PA#>!<]OMT_F3_OZ^_/)F64%%LWV* SS;0_J\'*(\7TT)
M?#$RY9]S2)ZH $)AAL7DFD98&2T6#^L<&M;/(0H;TGJI,*OV3THH^3U;B/73
M=*TS2I^@L?T50!U4ADQLRP\OLHAKK?1>?_#DQ=L-MVPIEFO@ B/NU=N>B+T6
M00[[5@&>_G*0 Q @0Q'?(0TB6PXL@R' =<"'HKKWODT#V5475%<?A?5MV!,"
M5OB>\$*+ZYV7GNE\I_QONAZ#2!)=W/_CK4M']4]<EVB]'R,&30SD6$^FDQ%O
M<7G3"9?5J,C($\DQFE5;2)3]UE A+."%YT?WY_GDMGNJ\C^YUEE9J;_-)XS+
MUQG_!F?[Z8M\>J'!C;]?Y$859G,&<(N(D+MM8?WR'WX> -JR_*+&_!NH5(67
M[]&/B+'R'*_'N_D-U=4R_2SVE3#M\JM6)C("'KY2_<<&9&CG@9KVQKP8U&#(
M9E^9_\@$TE"QJ_+)3EJSN9H!C?#,HU<]\[R0&+UP,3QN9,GB(?]Q<+6#KM*.
M:X .L=W*: GA$EF?'EX*F@(NW%BMUW,(+%(OWT0,2L04E,AG^FO$FM-77B2:
M:RG?ZF\WR%, &1V&E$?)J]*B(?#OYVS(3%O7OBXB2FWG78L'28SH(.H08O_O
M""N2/]\JSSBH[%%BEZ3Q*8Y&J72]I*2O3U\!?.6>X@.A#3ML*_S4-V_U5SGJ
M@U7*AG,]+(<ZCA]J\7H=64T^-KSCO.%3P!0E,O$T53;2DK+@L\)S)]Y.Y'9$
MK[6]1/N(9,.IL= X!Z846M0]AY[++2>C.^\45/FC79L)I]R;L+(=\?6#5ZZ]
M9HZYA4;Y3/0593@WU1E<#0U;DENL(8O3&TZBXP$*RRE,T[Z$$=LNH[Y:A^N'
M7V/'QO+J#7T?*KN#'(VL30TC5K]W<R2(_VW3)]IF:3;S*(#/N]F,<K^[%SK"
M8JJ>M3-L38,BPJFG_:))].7KJ1+9DER# 5D)'^O-56_D;%"^X)S!60<2FXVG
M91:K]N*DB>-.EUW/G)60J8RAD;M:[":6F&4XDU0W,S!708C \BF$$GHIFT8D
M$V;)C4E,)\U=:W[Y:K+E=TBOVWQ93>9U Q)9=5W$(Q-&UV%623>\*YZ:P<A4
M95YC2=)35RX;:4>Y5U.YS"_C<X/@GQ](>?D:=X:O&/C<PZ6&(,G;"QRN)IM]
MHY1Y]+'O\:EM+#@$FKJ>1 2OMBY(6.)F%NY[.\F=^BBJ03YAB)!.(7-[*O/M
M3)Y1\Y5O@7)*"F<,[)TQY'6A3\ PBY].]YF0T[Y[D:=F#[V(I=Y@0ZSC_$S7
ML%$!1^:4#O-+FSVL#\\P!:M-7XY(PA3 X3PKUM 0EL7<,VBC(0,^S<'S[RTN
M*%0Z(!&8"3AX PR<B^7W#HV<%4X_QN1'="8W&0F9ZYT([<EXY[7X?L- 8KW2
M:.9A]3S!/K$)S?X5PI!5FG_+RG'%JZPT*4?.)MI2@WSY2'*U]I[_X[9*X0:4
MPS/Y8?T,9?O&0 %G8%1 3((98C/[/\_P?1..8CS3:&^]4W W=-]>/MBB_"^#
M5\V@R1X@76/G[=9WSW$.4S!U4P ;\YF]._.R/[@20T68T_7&[*6_G@)8PLEU
MAM_,D<IKWP[:,R3O::ZAW4VJ,+1R<\72VD:;\)@(DN_4Q=N8/#3E/GAE6D9
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M-R(+'8+\D$+MV""WR1FWW6_?R*FC2"-$_ \>5N!8LT0[TH6OOZU?_CU+GE6
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MMK3*&VI276*+,+.WT3 P'A^S *M^L :?[5!QU&_@#>((%OQ0DG=!F1+ROQ@
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M&W&JZ/ \/W2AKQ7]> V =^3QX$5E[Q@+>CLI@V7[ KRSM*<9%<1V .U[#CV
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M08;L)1F1S3KSGWG3[>]OF?KM<N^83'I7NS>Z^N5@T,"IV]4^U351?Q=L]-5
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M*=6I'/!0N([=)3M9#?F8(DZ)+G'FM?U2W]>UB3HQD878G6D49G%WSV :6HB
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M"9<ZN&()=]Z-#NK*3&RY:TV4\*Z]@R!4SG\ABZLHVSSCV_.L\XT5;3?DN>9
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M9YIE$4$Z,2 VIJ-$L1X"&?U+8\F237$\H8K=MM,TA--(3#$]Z=!N)J V&6Q
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M<BJVG8FN5U@W+15-#A5+%_6GXV/>3M$.FC/'P\-/Z*3WX$U)&8U@%N=Q[/I
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M:?S:Q,J\)]90M(Q227U[K>O"4G#D<O?6(.-3--&57 "3Q<BX'P/]J.[AOU4
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MN*2PH90AZP(YU"F?VMJQY!)5%4SV441."K9\$K^>REJ3R?&4.[BR1$C31"C
MC<87X_L3'[NSFG,$NOI]L2^H380'D_6]_/?UXHK*ZJGK3?[EVG8B2E,CA"[1
M:]J"4&C_7%4K**6@(Y$C"BV0AJH[U;$G1!XLE3_#/W\IU08E^*I 3NB2GOS3
MG5N%E+C].2:;;L-CH._XPB:JX18>JGXW'^5JX")??<@Z([?T2.%\*R4[U/#/
M833:=>UB:X,*_!<U[$7Q9^-'RG:KPCS5L0Y*M$!Y(Z#S4DQH>]>,%IQ8[TJ'
M!%/"MF1N+U%OOE1K];,^9YEEK#:'J-G\C(FNNC 1/73%S,3H5=?F<SQOJ_+6
MDSB5T*%;[[^<-GH4'VKM0K"ZS%-[8R]&VZY4PN#/D]V7+BMSO?^&7EW9&C,4
M5;#4<3,?294[^/!MSP=/2W%E4KJAMHQVN+,]!1'#+%,JF'1,E53/TH-,7W\O
MTZ<JX2;LH1_[*X6NYW3[^T2(Z&EM8=L$.9/<:C2H?N?H%3B(],.W$S.]R9W0
M$_()UV0K)8NK'5U\Z38?K\3"W4^MMS5*H!_C&_-U$#DZO]=(WX9\PO":[T,"
M$0J&X0^)I?&NU8DB^7:#,B\"3N=6EB1'RGU[QKDR%9LXCZT+[B)E5<J5E>4Z
MER4O9*E'+*49WIOQ,'9RO&4]OZC>(GF*L;,Y ZO^<#K3.E8 [D]<_,.N#'83
MK@>644Z4IH=J]KU4\2%VE&2F>.U2L**B(A<-;O0QK3+JO7AFYK_E3X0_"K(D
MC_DTMZBSD=A.(59UVC?'X#PO5&<S48F78='II$!='F]$=_I^;=N>I<][U\>A
M$:,:K)VL84ADR& 7FK#S!^C.9;]EEQ?-'WL0RF(;-JU>\107%,,G1@=.P-@W
M[R,&2D"QYE#Y/78Y_2+"QP=#U 5@NMH!.9,<Z3]PF:#BC'1+E"*ZG2IPAAM1
M=J?"YE9SK'H-)J=O--4P*KMC@_:%&<U[GC56.N5CKG@MT>S]I8GL@0 )SGW
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MRJKP\I>PA/&"-;MBVV2^.=?=)H!1U!FDG7F:*F_(B-,-TB5:D>B.:G/Y_<+
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M0+[<QA/W .2Q@.E8^0A;/IDZ0II.OAO@+%3Z7<5K# NVO$%+26/- 1V!:C6
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M1\462? RXH:_(8K*;HKH=$V,VHLP&Q5-]:&Q)/2N!XNZW#I;(3!O,SC!N8D
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MZI0UXD;4%@)&Q/4[M*5_;)&UD I1!&<E+XT;9S)T%4+@K:P7<"1^.64POBM
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M0H;V]F1>)D6>=8*.I>N(A1V3^CL)==3X:R8EN?T6<0/VYBXNDCM%I8_3)BU
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MH_S>0=-F24\I =E:G2-E4X_Z#-M-UO>$8OI<K\=D=TF=O*.X\_S<'G$V"9\
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MYR;DJP A<T?9P)"AB\=\/P).36?#95!>\A39"_'[*;OCT\2!*&2MII#:[@.
ME]7NUC;[C&\U<E_@_#VAV;&J%Q5C@//BW<;^NQ)NSDB29;O=M^=MWJ3VHX87
MZ-%,-)MI)9[BOHB['8!'_\;/P^L076S=!4RH&[V;AD=+)0=!;+AG/QT D&P]
M3<$7AGJD*7.XI4MGL]?%@*VDN4/K<.2DMHO3:Z/%Q>9 ]8 0%L>D'$]Q4G G
MJ>FA&^6WC]D#ZR%0A >+] 1Q'@"L<'#>40(^F@8[ANAAL,X"VUS7US[_B&(W
M@"9!PQ.YTR ]J'7BC&]E$'+O,+"V1J(GPS00%\'0_C=<1Y7)+\!*I7_;/13V
MNU?P*99]!A'E"H=8X!H ="J)/'SK=AYRF1%&9]OWF%TK:-/1E(_!)#,LOQ<O
MMPPNDIEL@B2ZLW<J<[1 R?=2>F7BJ!F-,Z '6<^UP6X;Z:RT U>F5;OTHQI\
M.7PS29[5-/<Y=H#.>UCQ,#$V@'/:[>$AYZ:&TUC5BO!KZ/T +79O5:C"XQK'
M7>_RL:Y?NG(?Z9*:8MQ3ZZKLV3&5!XK@+)( ";!Y_K;E%^'0Y=,U$,B_S)3<
MXW;AZFY\R^)B#,U&'9DC+;L0JW_&Z Y2\T(4 ;@C[5UZ^7*(_?(8<X,!QY!G
M(*JF1]4@<VB;BID 9\$C5N6LE>P0.Q#T!]3E+JO\.FY/Q<GFL$J]XC(#\3N0
MQ;0D59UGBZYD:%,XNY+/:K9W1-D"V;,?]:$B]ZK5W!=>+I^KFK"A!!W>;J2!
M-I@)K*MKH.=5F,*XONE@W#)\A#O#\'0;CM(&^K5V*[!@3=XAB(!+%+_=ZJ!B
MM4B.=$/M@.S8E&GJHG5-1DRO$FXY&%%>$>GBC"S0@2+79;;#T?KN<+BS2 1A
M#![F'73<O2^LC8MM;-DQ;/4R,\'?Q.;,=#:HG'08<(QW%X%<G DG&,#-+0:H
MW#]W]#(I]!#ML6WJ:NUHB*.\M8IEC5XK(#.PG-+V>_K1+K7N _@%=,.3*2[W
MD4#T1?0!L; /E._:\RD]*AG&!E+]IZ#I71JV@?U86%4H408JEV9IGHVSL+*-
M]KGMFNAXDNC(+VPODWC\4@R7F\?&-K6SXV8-<2_@7LZME?8=R^M1MFO2K_+Z
MH_Q+YH,WDN@1,@ 5:=<)FC!P8O9OAPUF,F]>3?4J8LYQAT.'\@J+?"65=79.
MS&T6U_/BZU&$LYE\39$\+45ON1OIODFV*/-USC :M*'(NN-I;C[M[/[G6C6Q
MKD5R_;P7 C2\Y2ORJ7#W7\Y[!G;[S%SFME3^E76K<8]-]FY-CH8X749_'I%0
MF2A[MB-!D2G/8H/F*5C7!YNAV1<S2I4=]?$-,IK' -:'>J"H9<^UF0<T6*O3
MYI^_W%_\GUGR9PKZG*T<L8F)T4GC%.MN'X,#YT$;5/0O]PJML2(A^AR8$G0K
MKT6SYF)VK*ZA37)5&J?(ZL,UFZ/OXUJ+HJ?(%<G,0XRE9[J!0U7^_$Y+&+\O
M P#77B5?)4=->1JB/B!RK9:26 *0EA7DJ1:$W>J,F?L1->8[Q7J2G%\E-[3_
M)J&QN\EN@K276X_Z]T%#&*IY+=9%QU9:&%RN:-9\7H,X87[+&;IT/B)BG3PC
MT,;_CL_%T,;I<&A\V9&%!X#4:VF-376=7)<\,@QH?)N1D[ ZI/N7F3SOJR;\
MH:(;JN:?JE55+?H$KK6W*\L]YM\)X%-2AFY:=DQ5"8T8[+F3Y[ML:UX\6]-9
ML!;C"*@JN<!)M>HG+J_6XG*+E-(%%NYU%C+R+:/$:3D\_0PD+R,! POXD.'L
M$@W6Q\XGJXX[1YE0_J7]L+=[BB]IOU1_KF)4AS #&7-K%'NRWCC_/2R&:M?P
MU/5OF6M&@B2?F9.-LI&%1(;D-_D*_<+.!)N&N4A$*8.639XYP6_SUW$@M5GK
M:QS\5S6LO.1330CY;HC0G9"CSW__6?A)-,5N4SW=92)]I<)M BV[@9\ZRO/)
M%>>8Q!9TEL69/R=^/E_H7_FI?1/57)%S!HH#R\>*Y<7+3@,ZJ>M(E.O)?;!:
MGO*]'.<[CY]DO[7(?'SO\:DW.1H2@UA99N0XK#/UV&C>3K%"Y/&'8HI.%3%
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M_KZ;'-?\?241=6P"J "KVZSY,55\,K>X(OQA);ER,<ETLNZ5=[J;F&R&=P@
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MTVJ E  0Y2 [!ISM"Y(4QK?=)J8PV[/LF_EM:#A5C7W !8./0C#^NYKBLC%
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ME (*SS 42D*MA9(^=967].B^R7UE8'ZJ/'1%X.Y(\=Y.I@N36A.=%9K$KLW
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M\-+J?'L,["HR;1JV VRMO=HA2[@&?__4G4_NW-W8H%_#[M.?*++.+65O C!
M'*&J4E/2/0XYN$1T4?;^74VJ^==(F;7NIQP%!J;I7L*)Y\%F?.GK!(5U"PKT
MC1B/5C  ) 4V-C?BZ-MQG/ S-Y:O+<,JTY6&&59BR,<Q>BX?I'9P[8^;XDWT
MI69 HB&G][""P]NAPC&XFO3GM.AC0$*K<HD5U*D!<B!37[ VF]B:+SAO7R:W
MUVVB3\#:A'J*_HHV,QU*W5,EZ\670+0T1U1;9!][K1 \'/G/C?&-]"4_*C9T
M"YU2DTI6^)!:JC:WM3X-+17"P?VU#38-(7: L.9&F2.=-H8^Z%DCDE]427J@
M>M-%WR=-'#NP?<;!^N4KP\_%FQI+.>W&\TN$3%^>!B_MT*$J?4M6^N0WG*\?
MB,T5]#[#PL>Q,MP@E$!?IV<[QXF.E[5><(E$GY-5.,D:4^"PPF)$#\D+QX#:
M62="5>T[FAXK'+ZB6353$*+,88 [4H16TX/"^])+C[>#UP)^]+S64SO1'56$
M',#([ 1U4XF#U2$NHA?^#*QSH>\4%CM\4"]"%K\2NCR7>[GBGO(9A8\#QD4V
M2$&U9#L"JJ=IY46(;TB@:._69___?B!MER8C,")CW*=S%E,22P3-BWH_/\YX
M4]39"'3&M/A[A4"[L.]0<?<\U5+^EKB?<AEP.Q>377/XZKP=D)PZV)*GK:YY
M:W8G4-$O3.W(?M9Y4XU<U3@Z84L=<_$KQ (S=_'+1EH19"=MKL-KD/-,33)&
MC5B\F0W+,-L^!R5BUEH')1Q9)'_#W+[3=%TPDR!^=3?M9"UP)']3I$FS^E;E
MV8PSM5!CHM!+(=.^]-Y3@D>@&3\&M<TS0ISHA'J?Z7I.JJW53'3@/V+JT"'C
M6NZ;BEK[$(WTV4P=[_RP$ JW0^04VLJ=,"Q,A32S*0!&7$"3WM61*+;)AKR6
MF+#E"H)<J;>XMZG) ["BXAV%,&;#8OU@7YEMY9)TFJ8VM!#7Y/[X[WN\AXUE
MQ,=6YO-OQ%.'0QEQ1K-FN?_(YF#D-UI4C5];ZD'.CX:!O(?-7/7.M@IOA"Z\
M^?+%:]4B R''&U)/I[6CA].1X6/:FK^K$>U&)%BO: D[Q.]OZ0+RL?4U.[DR
M0@H8J!IW3>%-2][=)/,_'7(&*(L/ZB$;C872.PESB]@U$1O+D#4Z9KL>;JFG
MK:]Z/S%+,GPX\>>;L>++_59WUPBL,7T\8JLW:Y>P39&YWN[-#0U!_WD0&_;^
M?,P'OL'<_V5E"1;^?C];[H(RY9.FZ4L*/?8X(9UUFA_6C87:4Y[%G:L^O3N,
M*/]3B64_VNF2K4]^B4;[$Z?"Q]%SRKW[:CHW11L^7SCC56@H+JLUE_%-ZED8
MQ+H3U5V]/S^S&I$P6/[L4IXC)"4"ZJIV7\RN.%'HY=)+WA!;R^Y.P=&&1Y@1
M:D++:.Q8T]9*='O@,\?2;W_E&CU^8ZY=D_7$E\0E]K4;N*"_9(_!ANDA)Z)Y
MG7]GI6"$HQP.D[[9>Z[O5__9\[^E="M3M"\=I0$D<.3[R-$?3^Y_NF#+YGOC
M=>:ME8E.G8*V-ZJU:E;' . >C8QK(@7DGWFZ"^_R-7/Q>(^(?QLH-2_H 8):
MR7["GE,[)7(]\@202(V<<@NYC?D[MK8K$#?Q>[G)W6AE-$7Q $\YP]&0GVHC
MHHF+6)K%]/WPH$Q'D/U<%S*$V@8<#M0]YR\M#U_0ZM.)!0O*;&$D)U^XH!Z+
MC)17EKU[$3%UYGX!;K<N?^T!^A.L"@P<H:/(6[#[(P/OID.?A=VR*6XX<3]#
MPSI-L5*O+EL2'A750*[%5(LU/-SO_");]K@,]E"N$\PW7AYMK!!>!1))BB71
MT. GKF/GPG9=;P+Y?BNXZTM=D:2.POX#L\=MC_:$T$;%CP&N\-KZM?5/'!5B
M%:"GS_2G=JO?_FR_E)?E]=][O'M<<9:DDC'3U^(B&[5 (]=UDJBMMK0FOHA=
MI\KKQ]^/)<4ZQ>F 41?)78X_=CO0-5@-/6Q5:<NU FO$)T,W_H3^=Z:\-%[J
MKMG/_M(K+=?J>QI5M8![C&P>NG_U\VSXWOJ?U1_=6LWG-;OX5:S._BPLS"7K
M1'&<IX2&9$E4B*:4Y'B0 .UV2!>C<T&)(8_&'CUKG,G<XW#?8R>FS[OU_B>'
M1V1<&A,VP^/ON;-\'5 TN=9K<A>AEGTKJBAY_=E=S?&59F_ULKRI\$%6WE(>
M).W%))'$CB&NHR!E[WYZ23;^Z3@B+"2Q:Z*K<408P1LR';KK'3X>XSD5R UG
M\8;S=@]JU1P#'OF%D0/&PK4A[,[W%+@.;GW=4U/UMHM1X?DXCZ5$:D^6BU7*
MXW4D%1_\/G1JA+IOV\F]=#N[Y([I5S!?W+Q26?A,U8(M0[TXQN#-^:E8J?MZ
M%DSN7BC9O+:V\+K[4[_/^'T8T';B+LQP7$ON,+=Q5QV^X9W9_RC'_AUA^T:M
M[/:8]=<AS7/#]E9BF<&G()9ZVX2N(PK[U>BO+=)BJJD6US2S0MS^I'>-?V3S
MT:, 2\E^7S19;V(BA\U<5CQI"W((!41%BNGNS-=OE'%8+<,XLD]S1*S"[_2/
MD,,8GUCUQY_@M^J[^^5EM3*+XBNB3J*. >/.Y2%/@#R>2Z9O31TU-55\!C43
M4$<^@OI) # @,JK]=V;J?66#]>=5Y6 2$$S&X2<5QUHL1WA#U.8\U? T VB4
MJ%WPJD[^!GH^C-S>^(^ ;&P= R*/ <*,U'UAHQA7/W@(JQZB,<2)WGL9%"%W
MEZCD0PP]&UAM$6321-2!^1T,U7/GDM8#1AFE+G7FS2SU-U/CTNYH:M0V<?HQ
M/JU"I^+ZE1K6\<RG0/ @MR5\DIH@-KN"DB1ZA0A/!72O*@A\/0:4;B)F8V$E
MA\!P8N0EN4LMF1&9KOX^MZ: AE);5$,\)4J;6!W\KNR]@<C5BX8"S7Y0?Y\"
M>(I..PG7XI$^&A0I05X @!ZPD/B;:?%XZ@8=CMCQ;_3*1ZG3[XT([;?'$S%:
MDPQC$T.+J.PF0<AT]=,EDE@8E#Q%SUE$<4O2V"YT=?LD,$67^1B0SABLK\R>
M0R: S)^,_:R8"HR*I;[\A\_@R;:-"$Y.,4/(5(Q&K21E:Y"!<D9MF?<TFRUF
M;_O[*"EVLE+IF8O$7UUB#HREP$0(K)"\DZ U]#_3=6D K$II*M=V_D\PI=K5
MU<_@D#%T,7KRW',7G9*=H%T*S\#^$4/*((0_KBHJ=F5JG->%+4$*:-@X0H<@
MLW/$N/9LR12V[HXFEEV:GT[L#J,,I&^D@,['2#W?K<6G<>#^]:KDR HV2=J.
MAB-[.3(?ZB3D#V 81H8M8<5T8E:PE*>3J"=(=6"L,\:C_AU.?+N%B FE,Z J
MIOIU'LKL*@>.,>-M+,]7KHNG3/%UG+'++Y7*]-YDC+#+/'S')93P::0TJBKD
M2D.TGX_R0,+A-)U_"/D'QN))SD[Y:SP$Q..%B37ZODPMF>]"!BN[7&J(N2W,
M,M#T!]  OX)/ MS:&MS?0)X=QF8'%+ @J&#)C$B=HCE!>7_]#0PZI.K-J&5[
M/:H^1I#B( 9] MD9. 9@J QG-SOS,3N>445O9*72>:>)^#1#21I7-W)CVKN(
M7U'74>9!?7?.BDXTUQVG"3V*W3C5-X#^?"4JY2W/$:F&K]G$A7E*+2/4!5@R
M=(\!/'1,=P-GY<@)YWNA+&VHH,+,B4J<I< 8)C%#$5GE?^/6Z2 .;/HF'=HK
ME0TL@G51&%SA1M^H_VP2.^7-+@T>:,AF:SNRNR+#H+O3[.\]OV?HKVM+@P7&
M"!(_SD\Y4[:@96BQE:Z")6GU^KCXBLEEO;JTOI.HOD;@2"J1T;>%4S8#/+$H
M  ZS!+F81@^?SP,/?Z,S+"?4T.WLC-6O4QFF35)\)IPU**H,G-MTC7')K-*"
M_-9#W9J:1D'T\#$ 2ZYGC*SMBF(UI'8.I!X@*<G=U;U+1-@_S0C1Y,'Y8T#Q
M,<!)CXZS(QEEGMJ96>S\WAS5UR],K HTR5@NK3/D8X!#!@P01-NA,9K"*_N(
MM'HT#CT*1+X2/ 9$,,H/ZZ<"P!D?TW@1/]+3!Z+3WJW[(J9>_;M>VS?L"/6T
MM@PHNJ.L.#\8LK= E/L^IY!UZ!?2X_HK%0%X,QIX^2@#NT1<7\LB5'&-A1\#
MM$1?CO.D'\J'(;Q%=7:("Y^> FA__<9[!UA?'W'FU_=]50?I@KJF.;BK-!&+
M<[-YO@<+D*V@1QV@5=^-R/#<P-.VQ Z!IOI.*6<"[",+0[X\TLVF(;][X  U
M0"N(TF5A;(T2.0\U9Y)F7/(K-1)! (V#IVY1(/2-Y*!Y+5]8[6+'$X\S!_;2
MI14I?+>9RG+?%+!Z4IHI5 !];40X:7LVA33;WEXHG$&I[O)=^UG]VDVPEDND
MQE.+>7ZVF:'>8=,5\K$+>;O=;+4L_+ ]0M[[B].-DJF0>JM?R&/ G'1PG55Q
MG*8AP!A6RI):@/[?T67[@1*@66OG&, F.UAJO^>=2@]XKA[L?^R$@9LCWDY_
MXY $[V/ RR/&9!O8+L%<G*KE<(7%W*S/0"9#(7^CO9W1(+E5=\6,Q8&B5!X5
MFY04U_#1=?<HT@"%1P9_Y*.<$$D)+F5U@"6(T-?NIN2R[T949$0QI>R$R*1I
M>R)WQJTRB4YHB),"X @>,19.-OJDGEC,CD9*WP7,T,,P)&GEM#X:N#:(<X16
M2.[G?!Z#.J8[I=W[*I3;F9+QT>6:P<KD!:]/)YXZ\PD,59=3<'KR_J;5?\?
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MLFW;$_"]$C'B3LV3Y(?(&QV!9/7TF4T>1/^HO/C7)]+4)\7FCDU&CCGR-E=
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M<13.B,T5E-_53>608F</RZ'WUMA[D=D_3DCT_()G2\--ML$R,PNDE8HQB6.
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M3^G!-<[!T2!F.S52#6@T"KI+=E]!8H=!0%<.S_^PQ*<IA7OU<7^D8GM!$\<
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MJX6%Y9[F-FL5QLP%40H@D=\=5\>\Q_[;R,^N/[2MK;WYR7=0*JPR./&5BL*
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MS:Q>SIU-S!TT'P;>N:0RI/^6PK,EH$:Q@T3#RFB,@1<+\^&,D]XI?DJF25<
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M0LEIA[>!=G9\Z-%L 5:J+F?GOR'20V2P--[-.ME'MP8BQET! 'P..* $04M
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MG1Q)*[I>R_7,X5B_H-M/TX;9Q=7VIQ1B-,73J* H$X9_G!\3V^=0>^W11OE
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M]HMPSIU>*EX]5U>)YYV83CMV6,M+J[OV-XLVTM1S\>7S$TK @A28-\S@L%;
M*$<M:O+<UQOJD3JGJO0$??DLZC,)#':W9M2*)GP\&A"\<V.N_[['?V%+SHX#
MYP_QVVC;N<BPCJ%,B7BI! ?O'[_: [_$*:HKB]EV[ -Z$Z.QBZ6'83Z@V1!T
M;T<3UD+D]_A%%_>R3%R8J7)NN\"BS8WO L(*MY*SH2-[H'QZ5;TNS5%F5>)/
M)ZE 0=LY] AD*+IF-E'F$LXK<"(J'XC'\IO>A%2\JUNJ)$?\'6OTTO.T *[*
M4X:;%@P;ZPA?0CQA+,G!!WM(T)3A+NX_QM?*O)BH]!W>D% +/&DNG8679Y*V
MPSZ-I2E5>1U8.G:.ZXFO_7VF1?,JD]T4UBAF^0\>"_OG*0R8E?<6&\^PBC6Z
MZQIG@)35"(J[9]]G@M\LXQTB86C<NMW-34<!#24:C.Y.ZM,M+*63E&[U=F;,
M3*1HP@*XA5GU/!2.VFC&T*48D92_6PU2 :YSD@V#BPKHFZ+;G)$J[ZNW&,?>
MB^;K:+362C_.XFEK;E: )&ZBPZLRPC)*C?4_,"VD/ 3*2$="S6=I2#CG)B1(
MOU([1?V*7XWVS 1 RJ-*F+@+W.*LB+@,#*>5C_ _JN6WJ1D0Y2UK[L7!B=L8
M-C  #9($!67&>FZ'ZBFI(;FG2#/H&B DJCH<M&KZ3*(L&N".69@=FLBUKNY-
MV.5ALY$2\K?X5CL4WH<&O67;XT==;/!F<DS6V!RBST*?W!-SMT%*PU?[=C K
M*Z6UC+L]#4ZC5^$'+BC:D<(/GXVJ:ZVIH1D.30_ZJ,0PM;;9('Y [82=N7I)
M&[ILS^T4*SJXAS:[%PA'HN.JPYYV]01/52 M8SSAY -$<QT"%;B*HI$8QC[*
MO U *.Y%RL68SYN][1(L*2EY=J@*AX8FW="$P]S8/))*K67G,D?W$2)WHJ)(
M=C-DAZ,*P*^C ,U%4-!W+5XG=<]EK9G-><RP.!,UR&MSJ2SMYB<$$*:-<QV1
M ,I">Z *IJ/UE/<!8 Y5?B=RL*Y[#VD\RW#!4. <@>IWQ?'54:+5V_=W:OG_
M&6;8#2;FYJL>VD-&-#;N[0-:V"RU*A.BB2N[/^11(.E\3KRT>$4DUOHIM6&&
M0U>\5Y'W:'AT*W+HM<8\OOPYKK"&(0J[HZ+_DFCD?=?)_O8&_P!_YKW9GO(T
M"T^I-5WZW5\>61Z&MF:;0:,][UCW5I\.G#@":>>IUPE=M!98-51OL$R0Y/Y3
M'@P.!=6MU)56.\LY*2Y*,5SN^\Q&&V7">WC8D*Q:HP7?S"KY^WE+6S[+!0T9
MY:3SS9+;I1ZSS$:F<=;HV.]]@,T_V3Y;>SV!1\%F!IO;4O"^?G%6^Q1CY K<
M<5YD>GH\2EEIO;3BF9[P]NF!\I0Q:VI\P#[@*G9SU1OC:J _D?#+B>Q.'(&V
MWWEKP;+..Y'N3OU2KGY(6]H8/\CFKMCCU8[0FW4XEL\N8$GK1=: 8\E9VQ6[
MUTW!8JKF?;L77L 44,6\FS20!W)IC1^77-'IC/_QRB7-1.C0G,=7T2(=%2:A
M.3RHQ*;W 6]6*NKJV09!(K\%$$SAN&6L3OHW']3=>1S?.,.R.NNER07@ Q8E
MKM/PG!G()ANE]FA9F436^U*,N3I /7./(QX!:VD>.>[+"^GNB)F-O_V 9X"/
MR4$XG.'1E5>J<XTZ 6()))=+))+7-RZJ1,>V#@/- </ ZNBAW[ =R&5<!]#M
M@<$7L?"OTY\W^=1YIK0="8..JT&:AJ/AA<.S87$GPW4^-V1>?^X $W!:DPS=
MO)@=8N]PQ_,K\NQ!ZF@*7 &$0= H4]F."9OH5DIA0;<JUR_<%8^1&J@RP<;N
M<]N+F*@0*IW0/I+006H) N7C58:)*NL[/&QT'[;XO3;O!)'*2MB$K\V(,T&<
M0Z\C]:_T?\U'VZR!<-$Z!O^<#)$.U+OU?[Z9FREQ19V5/- 3RE4+81F]'9\B
MNBY<+U%N>[FX:%,<I+$H2CO$KH>*E"!=HV524W#449@Q@BL@5IVKD8WKLZ:(
MUO%+J-AQ=B/U6$S&W\PQGQ-TJ0$ENLE;"!-Y@_G:C-AY*'I!X>#H^LZ,W/4O
M]\E*<2%]VRZ;JXYR\#R)T)A(&$K0__UEP:QLI4TJ#UFX)8="(IH(^^QA<PX=
MF)E 6F^?G*(-)US_^&O#5.7N+R=C7. +V35X6;[-Q7-<56#:S#X U\'FI2@Y
M6(CC4^+@LK3^FQ\R5UZ\6+=K_06>'.X[K'Z.UZN)U?1D3P2V,MSGL$%QA_XU
M&:/*O*^I&><15;4V>9>?6EYDK2]S0KNH*3&^]FYJHVS%F<:9W4&@9F5A7_FH
M%0JD@ 01XWJ)PDPCPBJ*W3LR'W%UTQ FDMHSTV1=PNXT1X/DT_K0L(%HV0Q^
MD%G7AE= 6NP#GG%H@PT9$5\\I>M'BRYSYQM%.NBMO_2,5.!A33-GVS&NE[ 0
M!>K6<L)N;?+5\XEVQL7A*KR?N:2N.+-+RBSS_O* ?D#"M8KY9-<<_%'N +YG
M<<=Y&:9O4T@GE[18RE_<Q*EEOT@CF&M7?QOD&/W(M_6RANDIN$WLO!)<0V&9
M":!EZB?$QV *7#1)*2+49NS+@'WM@;%FAPIT'H/C)5](*UXHA'VRO+JA]J&B
MR$9@SCW\TG)??/RK9 W6+F/W_II(N9%F@ONB74;$,W/3\>OO/8,T)US;*4@G
MP$14*9EHZ*PYT,%,GI]\RW>)F93Z(I=FF9Z(@2J=2:?T;4LL]VF6#7\.?TMH
MK\^VN"YH0!7[$5,Z>>)-9W[U(M5 _,7MD'9V+0VL!]\,+W/NF_QZ'JU$__!!
M9-,6.6AF?NOI@R+_L;H21K#&@42 .D!^"=&_<&4;:FTO.=_I=&%A\Z)K74 #
M][7F5FUJRD%EUE*S7]/'JA_YF-#EJ5<_:??[9"-1XV.-_@NQ9NH7O.I]-*W"
MATU31!Q;B"OK+]J>"(6_XV%47?J+H+^T9UDX[@,BUWY*1_K;%;R1(@ZV2>("
MQ&+?%/BIV^?XO-T'Q"^S65X>UM5[6!-N>0+3-:+D$Y:03H4L6'@%.N1:B8$'
M4_N,EA!K"Q7PZ &BUE"L%<^#DULZ1N](DI#<TEEF0I,\KO]2O79QT,)D! R?
M]+PG=4+OFY,H\'#:M^%(U^W3?HXVPH$#UN=CO&DSF'#*?_I3B?YW:H#R+>?@
M B7F7ATT G2HO./F+U(Z;$FXYLRY[:XY1].1HZ=D<"^CC8&8,+T@O-M_C $S
MY(KZX_GO\_2@T/NV&1.OWY9$G;%7?)GV7[)7/8+1*%A?[T63J.5E'MF]CPN/
MA'X5E5*7@S=MIG5:KK@S7GUU!^$60QH8V@^ 11^N($H(,^)$*7IA.RZ2>O(_
M[.@EY)^-+:N!9@]@58VNX?L;<O+^]RKF@9WO1.6J8@@])Z[7S'1RL7*6/@C:
MDY("3'ZLD+\7$@,GK"]B3(_8*:D"SBF<>B%8RX!2IR=O59!:L>#=Z',9H]QE
MPL,HPDCB>B]S%T=U:+FZNH[7WST131P^AI=D'H89J)^M?.?(]<(QOZHT5CJT
M3LE,V/QICN)<]/=3P(+.5@=:(50SQ^C4TH3V6!I!T=3J6'Z'_N^:C>XSKW!W
M@HLU+<V+O3Y;6*F9J6T<XDI01^XP]0=H=UZYKI$/_K..!.%6:?N I*B BO#S
MU9>V5D,93EM*^/Y-IBZ=C)K"#RVA?B7; 5+0-;>)( H[6!'%^C0D0CR8]ANI
MZ*+#PK'PV[ME-,J$OILQ8Y:?P:ZL1^@MU23.Q?#M5^Y:S(-[HEO[@"$@9XK)
M0?[8_1T&,D(2"/[?')/SB58O5"Z41@"M&BWI<F2FKGPWVG!H8-J@^^L4&4SD
M:D]U>+Z(U;"U2@KZ*E5;/B62@43E4C99'YL#\ACV11E>!YN3>N-7+.9XMN>9
MA/FI)KJ-DJ?)'W/62R'!$"I!OX$ 7/HG"=LI8Q5K(EN>NGU@IIJ',?6%,W#B
M?-,$ZQ('M7=G]\4,?)%&!P'HH<4T8V.4C(O'9A0W$J'@H5A^R>:$4\;[@"#1
MH5TV"FUJ%%8O!A6B;7>\-/4::U6B0?S3GQCT&X/.&-4*G8. .;=H"R'-!&HP
MN']JBEWZ7XM9Q"_3X+W1U,.!G<0TOF7X-L?0Y-Y02E-CTW1JUP'2K&,W:.UV
MWRSG=L,T5Y9VOC4U*=1*X8F@F$M7FW/TH0;"X/\&AX:'_XL<N^N_])^A473R
MO5\/E8X:7<7:2DGR0ADLC>4?[25]\@D$]3!:*GA;Y6HM*#%:QKI+"J_(;)S;
MI;LN-.R]GA \I7V93RCF3:B_CTL7KVK6R1<C\+YM,?3H.#'!R:-B-]CFT$R:
M-O<W3#!V[6KBZ.&V9^M8AN@6S1!2<+5A40;XLB(ZD4?I>>'BHN:W8T<'0XHC
M9EF*D_KX&[<3M$&8UOH2=D<<VP= 4!POPF_F1B]EIZ-A*--M-L_@9_.XES>W
MFWZ>4?V5 301JHA*!A@DZTES')1DJ?JS]R\=;I-[=NXT7^O -ZW;9,8TZQ)+
MGNY1-]3TTJ\0>4TJQ6-.!W"B@3>.J"#:RUFM?Z+N69;*7_(-G:?OT6ZK)'X?
MOE:W#VAG1P"8ZGB C'5*IYZ(GIN.M@@0C"/^9;%!OX/=L"#/[8YH 4'_7S;!
M!_F2VMC8GOYKI,G.SGEL(DN<D5$= G,%Z\<!B?_L3VK9/*'_#A]A)"#M"[!O
MYC!?E19':$7\W^13QB5T80(@22'%K&3NJ$'6:%P7:,P@S7 5%[8K#"\*Q0L%
M"=Z3/0/)K)VI'H8Q@V#_=@/08@<NOG=)$>Z-[WUZ<BKK?++HR"#GK' PW#18
M03 QI$C-=2Q&94@S*/ 0&RTG#+ HDRKE_JM4?'_P6"-#Y)!GN0Q9NCUWJWT2
M7E1_Y3Z6B3;G%>^K'&>6BFE1 ;L_*).*%7>YLFQI@F??QQHZURB-ANI*S;-4
M/-RCBI*OY"%:BD2[>-U>#'V9CFGEV0--<=;"8[JMVH5=P_VEC'(.?)2HC.E,
MI0%SPRG( S\/F?@J,,%S:ZC<WY=<9-!0.H'-"A35(+$FO/>91MA%UDE*1P=G
M;C G>X7(Q !GVQCHFKIF]JN/6P#A$H:@Y B\=AW[786/RK);R)+P$\8ZBHO
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M5V4T-S_@2X$O[G7 CA@VN;K-(DX2VDE-R-@R=E9]22].O%^:8C)T$) )QW$
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MN*SLWLX<MP/:!SH[DN*C9:,V0R@![7E!ZH<O$0)1*:C8"4$DJ&RX31:X-1.
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MMQY"E*F%T\^=]%92 $P<*P=KLSD/F\S(V=49^A(MLZ[^?N@T<,\_O&^%\5I
M-V+R]Q=O7^)3(5C!#];GE$#37B+_-$'JSPA&M"__+C9 X:BX7RKR-G@(E1FD
M)QNW/1^+W&G:H(855#S]92P;_$Q=^(DVZY/@/J!^:WI\F.'?Y=QF?:1:Z4F^
M^"@CNL91:93%ET"PKPXSHRO_.<I\*M"A6:@4?=0.=)- 1@^5S>Z9,:8F9?7A
M?15GR'Z'.@?0;1+,/T=0("GYGT'9<C)"E]T5#>X7H?$\&-KJ,L&H7I=:1&_!
M#;&+U/NVWW^WM(%6]ZF<Q=D;Z8G3,0Q([A8_QZNZB7:5F%>-&-HN+5%(,=?&
MDWZ!#=AH=[8ZS-CK^[DE_=F*C+(.8^G?4[6O0LT)>^/\3/3:UO)E1'6N:X#-
M766B%%=7LJET_/AC:>O*+Q)4V75B<WA0+>GOG;?G-$)'5"P\P=3FJGH52M^N
MZ+]Y7O<WU]0#B0F\BSR)T%28SBQ+B;,%*J=D;6]@@UL94 VM#!?AUSXYEPS[
M-TS;,I7DI :H^7T&G+RA=-"C?:'CZKU&2:'BA!$R.^S*AA%'ZS5E__HDIUW\
M./:M* 5/N_7L]+MSS:RWN&B5S=LC&$ODR(B_<IA+C-HQ'4'?YAB^<7/ .9!5
M>L F41[KRE^0,3KN5'A(U3&BZPGY0)?IL\2C#*U!FSTN;Z;A_W%TW?%L?VTT
M]AY=J!5%J]3H4.LG0M6N/6L7'7:-M$8C1I4V)4;14GO'"#6"(EJ[K=J)VD6+
MQ*Q$"(DWWO_S2;ZYR3W/.<^]SSDCR=5\VK.X!Y=?+W7'-B^O(^=3>F;/P%!'
M/]L6[E=<AMB;5SDP!!C]"?M3:W0"<*:R'1S1R_- U&W_5MD@F[2;J9>=@TRO
M3964?]-=5YVLCD!P1N5O=K2T:_BW_0=Y=_;RN7Q9W>469D1M2K.PSF*RN?19
M-8F%N3:4;?&__F#L4B4LIC[M4"S J^Y2\;\+]0'*=0W \E7*4;%X;5Q1_N3]
MA?I!$U/4\3I188"O8H]B*$7=H416X%>+96VS]!,C:LTYA7M:)D+3;-_\Y_MW
MP9+6JHH&-B")O-O9\<C""EVH-'_)PEI?MUF14XH:!4[7MTYK-=]Z'S[43/GA
MA <T;>GUMDC1:]C/B'^8H]XM/S7,[\Z/IQTMDH+X$AFL0Z?!0+>ASO)Y"LK<
MP0?#8JBZF$HZ3J>CJF,_!7@Z_(^XDW'9KLE5,0JCQP2?GPV"[=0+T'D>SIEP
M^=^=A70\V'R=RF ESW=:[);G(DO>W&,NU<IT9X1'^1E)LRP;=73&Y>]K$:":
MXQ.\8$-F> ["R(YILL*!1:7I!  VB:*S^XCR2G"LD6@Z'B,#G]T=/ &(T/Y_
M ]MJ&<]6:#$EL')6376RA,_TW;D@(OUY(X%:36.=F05G(FGL6K5:"0.*[+1Q
MJ%XB-W1[%=MFH6.)G^!,XU!M%9V%BRBF\"W.Q%"5MJ&1Y;<K 4I'1BU,>#ZY
M\.8T/Z/%6-C_\^Y$&^#GGJJ+KK<>^TC!;Y7&U$OE5_S?!D!/;T#BZ4_31K@(
MPH(YQMV$5XV2#"5L$.9D?,J)*8::(AF+M'CI:) TWYH"K#>!OB_2(=9G'10&
M6^PNF=/%+ XO=(8:CNF ='Z@:W$<KJ,@?D C6F7<X\[\?*XD#DR8/G5N2[*M
MV[.6??1Z0G5L](8%VPH_.^,0K!^WQH>Q(.&)73FL2)GVNGI5 -70RGA*A"FX
M.'V0C(2T$:M[-H;NO7D@R )F6X-]4F0;6W#BA8F3S9I<X^7U!V5_7[LP"%FA
M*K<(2+"P]IGQ3<R? !:A&[Q-HU4$K::TSC!^G1)DI4HRI589X6!OJM]S)BK
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M8U_I]+S*4R3SPP_CJ@#%+$%[H!G/1A@P#38%C"IWK=6X]4OL_<3[?]\Y*9<
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M$4_H(=HTJRQ"^W^EIDHI!Z5><K&7<OJEUWV6M2A<)KV?2/:<-+"WGY3U@TH
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M]QF5,V22%B//>/1Y 9>T\O,C=//S734U9.I>A):$ 92S $^5X?D5+/X>/"<
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M$:48,"X?@I^[R//R07ZW>^G[0HN7P384<\VSZ@)+7<#3VROB29W3?>-&_/*
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MLN/5(]J_%?-]3$>+;1.=J2U>@=*R84L*!W01==CF.URCYZAM\/<OUK)_WR_
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MVG+FC$X [M!U4SXG38T)W;H(BCAF _HE.I:!^PRVH2_V/ZX/1AY(3GAL>!V
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M\QR<>FLY]+:NO%%Y^TW;CKY&4]/]AM( -J;T_X<6K'7NU_[V>>MO\[!6:*
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M4M<?<97"G2:T3P!G!BC  (9)CG([^XDCCN SX^OEO!?>140_=(IG%MGQX\
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M?_^UQ%X-Z1];)53R!)"S&UA*'6U[&JI"(ME '(QES=)>&/(D,N\^8F;1T'6
MU?1/ "/%GA!W6[RH'\ZSU D#V%Z-*<.OLB2L4QAHIX'Q1;F_WOFJ*#;6S!@W
MPKLLO^B3N$2"0@Y;@8A0D$.H QN.0&.&*CTX 5P2UR:[HK"V@20:Q@36+,$"
MC*/MG!KJ-$U[K]0D->ZP=WP9IX:KB*?YP\H[2-8CA_>T$=3(#(^B?:"I0=)=
M6$U@%,'EYNIE#O/+21B_V70B$0Z/!DBS+"ZLTTXE.W<=Y#NOR\7AS4$UZ9U
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M1]1-UPH#ZQO*/IX//_'(_5T,;N<U[0?N6M/HK..51N"WASR<:H\4*+3L>(P
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M\.C^[[>&_.<\>N7]N!SR43+'H+5CR@Z^]]ED@T-BMI.K80(ORZ&%$FEQ8<9
MS*E(\-\)8.G9S 85G9W9QFS<8&(M?:Y(_Y,\\NWH@/35'Z+7*<D&GXOMV1)L
MI7X$$1R@@SA;)X,PK_T.GP:CY,JPN!:IP3/@YA, W/DJ:W>L0I?6;+DKRJQN
MLS$-I'7S0NBK<0B0,,760DLX!D\EC:/L*YW*>=]WH!IN+-[L?;]PL=[J[*;T
M:T3OYEW.JD++Z'O%KAM\1%JQ04VH[]%^ :JGLS7YJM9?453(5F/9A5OO'=5+
M-GCFS"\8__PNW#,Z\.U;N0%7:75!ZE9'7DUQD]R#\K5<JMXYPVL/\(G%N]>M
MHBTGB =:JOJ7,R=QEPU4%W= N-THV"HARBW+!)QP4_KHNKY%^=$ANG7,7K?2
MGY _D795VC?IM15,YE@>M-X7L?-[=&00\3OA>Z1"-Q,1O3(SQQH&Z<QT"KF9
M\50Q@3OJ+8- 1PQE=]MMD0 %VQIW": G8*@'AZ=^3AC([_ZRQ@%F]])H6OYO
MVC16G(1+TDC9*_E.9P&4>3*V"R1359BAJ_R(#O=1!H"<$"KH %(D.VYSGT/J
MLBM=M@22, +D3QHX:Q+U*X_T=;"9CM3Z%PK#MDMDV6'0V8& (GR /_VCPNER
M/[*"$ JZ->G_Z[R J3%,(DTKBS+U%#Q#!5$Z?$M<W8"6>MSI9U<D\_B88JCF
M8[1]-=(6$O='P'SX\^[YGW<#[<TUM6."1R?'&_V4KPM7V^0I!:*69[YW(U7%
M6P/$8DE4O28T%\>59 U@_7OUCI=>[]_SHZ7,@19^:DP+5=D0I$>'/=]#4KLM
MPDI 01)+G+JYWEE8PFI5NF'4@0'G1TIV^(F_85W\]>^!H]O9!O9:=<G9?V'<
M)<X.*?ZG!R:%8DXECV[)@$ .=DJ5SA("<H;B:=%1(#D#H-NN%FD52[GM8MN2
MK=FG $&JSNI"'R9]\0)P5:HL1O'19<FL.-+ [J&1TMSO-/W+,YM9:>;'P<!I
MC6XQYS.>=%FW8+.6L_]*7?JG=>-+V;W"50N%\&@53]H8CO:JFPJ+(G@6BS3?
M/1^)?MPCU2#]KF_:DK'2=C6>F]_!\?\V>'.^5>>SPV4C16HO:C_Y<UTO!-G5
M>+6+(1B )@&MJ>'["[]!SKMB#F^_><U, C=M$A"49^8K>YNUJ,EK#PL<S7KG
MSC\!^S>T7JSE& \O>1S8Q;H]C,6I JTW#;),Q4%\+DZ2BJ[9EW^_^.ZA-%PQ
M"QQLHDZV0-PC_IO)FFS\"W3[9TW5*E,YAC7OCRQ/MDV"5V^\24!?DV: 7&:O
M(XD(9)HRXH[SS,?HX+6+KQK5Q?_RS&_4V/@!98-N*JG+G_?^[U7T@,UNU0B[
M:#(+=2*(\#C![F']F&-4]FP&Q&Q0>%_\1PGGQ;?![Y^A'V'#Q1+;?S1IRS)B
M6T2IT-;527.;!>L;5;,?7HM@AS,'U#U)5XS;$C2JS16=TF'EI/V%?/NU$<C/
M>9LW>4WCKX2CY=0I%QY9*-<Q^'N$=6P&ED;O$0R*K1MV^6]UA/0!;$;95-@R
M-,PG;PLP3IL?1;K-M57BO[1990KSY+;.F_.GKI4]MG-1I!DN.WQ@]QJ[G4\@
M4<YL&]3P(IY#)VZ#74B4\//2D=\_%08$5A;,WD[E8M3+"$V)^AA#TYK12=_G
MK9W50'7.5I=D)PC]P/(/IB#Y@M;3N$&PQ%2B>'D=A2L5MKXY.JGQ&[-'>I\?
M#WI0[_UE-&_J9H!<TX1FB5%+D$?J:ZVB-"KQ)<R*;03JP^*05^/HB>R.97N=
M(2WU2GL^5SOW[OS2/C.C&G@D?PB-:SMS/=+""[_XW/]&O!W78:L*-T\F^<K"
MKHG;/*42Q#%B::WS<F&*Y,5C[S)YQ,H5;9N,7W""_8R][<4[IL?\T;4W,&C;
M ,7[[L,W8?\O+<&MAA#9ZF]V]F>>.F0C6WU$72P$4TV<<WAA6')GQ\@PCKWQ
M0M#7I;Y%KJE<>XL>_KAQVDP,Z?C4RWAWTQ@9?G5L6H<3)(C9CRH^EE<_[2%]
M34"8\;8&L'"GP5SEU23@3'C*"<#WF+V%_!N'T.6S&Y%-5K@&U;5\0&OYN]]B
M3<.0R'8TJ%]H</-/4*;:"4"@7H6N2A#+,UZ'I,[X-W*/SB3[]\;7?%G>@8XU
MXA<AERHY_BY".6@OY\E@$[=CK3QJ!:0SN\IGJ7?0C,3-;&7XQBD>\#E#<!6>
M'[G<C4PWRVJDJ;L;24F9<$6W!=@M8+O38/,@7(UXJT,T3. O[@1PAH1F(] P
M&$AM_6OHO?Q\@Z-OF.5U7[XH0FAOQ&%<6.L)0&3*V?MO%U/@,/W1>C).NU(W
M#G;?"-$Z^PU'?R&/FS02+6N<#'EZ,Q*9*(@=P?VE'7P"PMPEQT6,=?[;Q*7Z
M5\FE7U0XRW7&3%C<U04U=[?[$QQ%(Y 1ZN:[7I4>)D:WZJ7A-Q1_F -B@C8[
M/Z[UCMF= -)T\1VC"D1YP'CO5C,/"3B"V%V%^A;>\C,4?\22<,.[J55B*LF9
M'VQT?,[##[0!J<T.N=NO28"-^WLQH@-LDJ2O+\WRE0-33[-S!,6.I(3<=NXE
M^:;IL)*OS,)SJ##4P5$EOANAG5D%_-*"45U\5<\\]2\*\WO;Q:G\H[%RQAD1
MUW]\O0>>OC"WWHZC&O%DUJ]VAFLK$S9].VG[C^JL@RJFHL$S"W,)MOBYMF<M
MDYL:%EKU7P5P#2)%#BV>%'/2L=-Z %.N2AAQIG/QWSW;=U%9K>.^:]RS-?T2
MJM)1YD?^I-JJ_!56H0_")9=^?Y_MLX [W%#A9EA:I<":M=:ZRP7+ LIJ<$D^
MP0Z#YZX#^-6"18CQQ#G'!6VE;=T$5Y#\WO\X.N]XMMXOCD=1JZC6*$74:$NI
M+S5:1>Q1(_;>JJU-T1(EI4518G>H/1.[2HP&K3U:,Z)V18W$)D)(_.+W_WV]
M[GT]]S[G\WG?<YYSTFEIEJ/M5@[IZN^^UO[V>CKN9 %%V'KM^P> *(1KT.<^
M^)#)LRA3SXY^3E-+FB5'3!#:XI=QKI_UAOGXHT&*ET(IW\\ J/ ::_P[/_!A
MM:\_'(3?8Q\_+]\R_O7N^$VJ:[@@DX040922 CX"UJ"2$1#>@B<<KQF; 9>E
MW'OR[ZI<.%QT6EK("\>A1%\J#PM((I\XZQ[60$T5O*__)Q0) MCO]\#L!>@M
MQC*_J'00<-0OB=:5,AX /9^-B2T*&WDX,K+E$"%ON%'W_5TBO,^,MAR0I%5W
M9QT(.TH4'[9TG?SES(>4EYN!)!H.XI*%],.O7QO);%>JG&4!$O/*\A U9;KN
M E;C<AXVJ;V$E95)TE1BN']%L/"81;%>F0GWA<,S0.K\+#OD.&0K!]M?U1/;
M?N$,@#\#Q"F?$)2(8/T,;=A$6 .E\+Q!>'OO/'P2/_8P$!._WJ=S!K \4#AW
MF-NOE#!J@D_>6MXCJ;<35@Y%WQP0(U$CTDT*4R]2*E\*;Y+ W'04^NXH2A;1
M!0(7H*W1.Y RX50\QC!'4_*K?1J%;!*A=<C6D.HW*K\,E%-!=("[P3O01F3S
MJOZM]:/__P6Q+@R:^MB/ED@(8_G:!Z!_IWB)+1N@AN3/?4#<:E2JC)POZ%-Q
MV+Z=@N"Q, &78D C-)W.)(<9DEW2^)O"@1I3(_-E'K-J^>L<'7[2+T@72>$U
M]FO_#K*(*;\T-<4TN=__3*Q6NW^0([20U=#=+CP;_C67*MWX\=8>!\^R-+X*
MB!ME/OLUYSJ?8P-W$PF*6I@CE;%5V9>? +?%"^P28&91$>#A0_ 1&PW5\/C*
M$@*\E!0.KG]-L^'\-$;2)GOY]X)RI:"^XQ76F-+3TO7HVW^R"@"DA3XJU=;X
M#[?38"I&'38%]SHV(79Q%7VEQ3I*5[2>/EFFKW6#6A\PX$"8PZ6J(+1^F67<
MGS. Z-X?A_=QO*+KQE]E8 ZQPB9]%SCMIZ(KI:$EPR<, %K$52?$AQ7*:G:H
M7U5=TZILQ*R]1')NF " SFV?<+7"(4M2XS$[;8IJ.SC$KQ(%?#3[/GMA,7:P
M7ROQULZER =7S#AF^Q/2[+S>93C4:2?+G0$<@.%G $6G?1Q.E7,K9FZ!GS0N
M)7/QR?3]<M$PUF)I72,!>77OY\RA?:=DE<932.TZN%'"VO-5]F=VB^#L!7>Y
M'\TVCVNZ)PIEV0OE6H2MD)(AX;L#(36JR?G52=C:E C5-V143?<VU-=<Q;[X
MMSF1VP!8#LK; >65$_U0_T9H43R&X(JUNT:O:[F!L*KS,H;R].."5>TGTSV^
M2GS=">X&IJF?:-^L[57JB=+$O$T0HZK,@> LD-WNU-%BM7,S[3CY1VF65^9[
M=R]L3NKR[K&R?W5/1ZV0N ALN/WVL+V?@//D_+$,4L$R@FTDFV_?4OW2#0E;
M]_\".$(>_!O\X]L+C!I&9=98,%2(X2A3$9UQL6T)1=VL*95Z'=',XCR--56]
M1^$^54I-]]<]VF2;+_V>*T_-R3:4Q3GI*5H) ?O,*81M-1/"5D/?L6<CO-:Q
M[M34W0(F;AC*K/')+=U&T8PY2\?;?@>$H=FJ&-%]W:6;(</XVO+).&+:C\OJ
M=']-41%+N7F"MURO;Y%QO]JL9,]P EG]/6&E;PCU]>!U2+X8_]G\=TR&VT]'
M'^.H/B%@B+*NDV#$)9"H.FSI@Y99MX2<?$Y.YA>4G(=[@O[+6#N/\5LR=_32
M%.D$[*JA9:B0.O37%SYP2[3 )SIAKY;0%F>E^#OCJGFM\4JI9P"OMM#,QRG7
M;'/< ]R9*X/E/WH/[Y\!0/9[-0;L<>FA=<U**M(\B9#MOYS^U]Y5WH+Z@0$V
M'0<ZPHVY4J63_T^1P 2/RU[\M##@(A0;#KI&:F2U<Y/LYQ@$JR,@TN2G?P*A
MG.5=: L:97FVI.M-YBX,0E?N4U=L:P-E IP9[2J"Q]W0JXZQMW!)#"(X[QPN
M6*WS?+&%,Z5*>^<-+RW@V2,%0@\PFDV6V3UCK)HGDGK4F,0R322VG(_I)<C\
M+NPV.@,4G %HMHI#7"(@_VXJ\>55NBWGY=>=!D%WD*CD[VIXL;L<A2FRWN/0
M,7#I0BIEZN00;-=K8.?C\$1>2;NC762?(HAW-D;U5LK;O+VM9\(.3"0S+,V>
M$"(@1#VIX2CV1(2@3.#U/]^H89._O'U\+@H_A4NC6/E.3RG&3@XU9ZZOX27@
M)6J,230OTJX<+JT7M"LLV^=Y\<09(063%!U&S;=^1]_O&^5S\-4:J;6OOV@E
M6=/!BK!9-CO_F;,5QSK9VSDJNYE<_SF7.S<M3X^CGHO#P2'Z)U9[&TX-CT!B
M'$V-90F[9<Y4DRVWUS<9#N%^65F;'<VTKC>!X<G@Y5W_'Z-X]\(%\[?^<FF(
MRR;']U=.=_25G?493EG;VO#H%@N?5]\G_IR:>>V> ;)TKHDOST8]69SR4IXF
M(@\6?0+QO7'6[+7_>"]QW6B*L.@KW@EE6A,BWY4F2ZHLE))H3A(9;_3]$'K'
MM7=1-<V'4T"M5HBFH.8'<$/ZO!M_6Z=5<>O,,XG:R4WM<B!\3T,:NA8*A$7B
M'6T:E^!4B9_PY",5]YGT=,V<F'A^)7W 500=84DG_GV$H*X0]Y!TQL;Q["B(
M]_P98-^?:A3K#C'6N.P@SHUPS1?<9%!76<BY>]1'509'.P!W;Y'#;_,K/=M=
ML\335@3^E/:]5]ZR[RW?S+U\/H*50"S]BXX3A/DM$GR]$E-='W7MZ=-JQXND
M@4_8?=E4[*N,VC^JF)X!#-/&Q04_/WEN81L55D*C>?%&T\W),T XZHNJX[-@
MDQ;"P'9$A?AS5<P][327[M>CR4%.RU]3!N3,D(K8^3C!1DC#%PVQ6QI#HWT.
MCUN9/]9%T'?9_*I)K?CW0WNO8&CJM=1)%@73>DPPAA=Y=CRW;8DOYBLZZ;_Y
MTJ7;YMO0M-]/S',J=J>!IN9S' Z"_FLX.)CXCWY7IZZ'2_UK)HV?]*\^$M2Y
MAJ#L$%(=ZYO7E(_X_/FS^ <M;2='2>8LX5[+W\E,("=_*"&9!!>P(1H^]&C\
MO?(LZ6_9&RZ6-/GH*I,M7"C9N!P 4@\D8.=AU$C!MYUB6P+'_ZJB,^;-W_3;
M*=8HCOPLM9\5VYGNRQ!%ECLI?.6<@O?M1!QL&+ZY*2*Y]2,WT=O/KD_^S8V]
M7GI1/9[=JK>3#+O#*_.SN)S'&X_Z=2;Q.<TV,/[0X>0([WOCJOF#"O;RN9G)
MB5R +T(W*84,HKO;FL,5@N^2_]9$9PL)O[U9_[ &%L/PIAC Q"V\--DNNMM/
M;&M4XFHL<:C0\7"1_^[]8J)CBM7+BB@:JT@5I!.BI0K(K:3HVA>'ABN#8D^<
MFW;\N1[<KM-I97CF)S4GU^U?-60^5B,:H-I>'DZT7Y_QM6;\8QLOT?'@7^3K
M'.TH'A(;8UOZ^12H%@?SK:.Z9C[750NQ=C3$9T /*3R;##Z?[.Y=)-WP4"/K
M&D=N560B(1T\]I\=);^8#30#=8:4V5_,81[UKXQ\KO1,_+&\O#E7_(T2<^6A
MR3K+A(=]O]:5 =#..4_C*KN#X):6V.JLZ%S( '.+D>D=3WAIUF<-'];HH;KL
MV9G3B&]S]D5<VJWB<*$4,_,&P]I$6;TE 4G=8EG;XCH)-85Z^\03N"#*OXS9
MZ7??3[7R;O./*-%BLT>B)FJW)KH29_:]H7$H+@%_T_67L?-'#L<GH;?D&O(=
MRW%ZR1HT=3)7- :81-:'C\(G/P?^14<Q5#_,33_*4@V]G"=<7>PZZ"V8KZM\
M!C#=CO!L&?QZ#V:NE9%Y!9HY1G.I'(.&7\S1$HQ0<Y[_&$;X^T7PP]>)^V:K
M*=]3*;4-PQ.[6RB_-Y476K)[T$I9TVGW^LF0Q[5( BD[G,#NU*UTG*$+1MAT
MM&\I>Q]1QLM7%K*AIN2(<ER>OQ5F<JJDV\='0*QR=&FM,Z9E]J/($S[]25N#
M2$;DV +Z_U,EHX"IO,"_,PJH*YH(A%:I.5G=9:APEM5EM[])]6!6:0K7),PG
M(>*A4!\0V6[E/LS_7 4YGL-ZU/P)#O?QL[Q, BO7TL:L$I)](_6(5$GM_]IW
M$D_C:Q73U@*E8^6O]>8"0.W/ %%+V*H08) (D^@25A^;R]JG +3G7GPS3%IP
MAJB$%_YJ8UV?LD\77TP_8L75+6V4$DD4*?\0%9O -4$90?!10(1#6BB20*RN
M&FOU&_UTR;<4._0]DP[ 3)'NQ<R31M<6?1)D)P))>B)@U5*ZFLF>GN4@Z!J[
M*)6'+' #I)M-4,:3<!S=A8H O^!"T$2LOPDWB<WWB!A9'GI0-2_#*R9JA_&N
MK1?.VV6PB@%0_7<9Z72[*MCXI,B_P4^P.B _,T$#H*&VC)/\.0@4/B39G0$,
M=LV4FE2XJVNEP+;.CTYA/.GZ_@2I)Q*A"F*Z8SVK<[I6:QK#5[$28>Y5C-Q"
MSUJRKP/A(&=B#"G\#]Z1]E.HX_H_2R&2#1"<3TEDTW[GJP7M.C?*):N!7W]D
M5FJ4Z&8TYH)QBMR+5]V@,X%;*+NBTC5QN=H)=1+ -^@'S_)YRO+\=+W&[_'B
M4>9^DC[!!F:YT2B\+*A+ZB2OSI/@:X]@(_D<B XX:N+U-8<Z*NZX0!LHR/$(
M[V+!=7T!#9:Z)T)YW1W*L\_]H" 8!!]Q8[$W^\VO+77AKNR]L#IE\OUS(CL_
MHW.W<0QM8JUNS2*K#Q8>Y$4JFD'Y9W$,B;OG58 P:]]=T+(E,_:93$.#F_C2
MZ"7$7D^+@*4C#)X1Y7I NJTZNZ3DLXBI>#?E6/2^;]Q<R:*"(8F1\%I=@A&I
MU"ZR-XD<GV/.K62%\%Y_V3'BE6SZG/LG-J]<L9:2NVZ,Q"A;K:4/>FK25$33
M]P(B[M.F4]I1XS7!%;Z#M#UJX2P1]YNY@0;S2^?S6!\C?O\<<'_:DNL/+2!=
MWV-8#NP]O_1]O_6/*_?B&<9-"0#&Y1TU'FZ%Y9,%IS6AV>LQC\#\QI5; IIT
M=-$Z:7?537Z> 3![H"D?MF]@=;G:[VD,WE_;1Z9@P^O\3EW[D6%G -\MLG7I
M1ND<5PK>4>+17!0W/XM4=](1:/.(B"/4W'VMLE#G]LF+@/B3F2&@%"]TF3Z#
MU=!^G:!(]&L8O;1YM^2D"9$I=%'GJ="ZOWX]&Z.)/ /0WM;?OUQA5, &Z/3N
MX@K^D8_8X\Y;)FO\67I+=7?Z48.-V6S2!PHB>;ZIQC5.^3X#H8&V3<6]$P]#
MI_Z$297$CQ5?T.X7QBA?):!0)U'X7A5;H.76EPS/1X[@R?]8IG;T;L26+)/9
M1\-("U&;/]#L5NRU)U=*$W*%11\+ 22#SP#PIH9?KT\CH;T+\,FH,HT>S64C
M'>;+=L73<JO[B [Z,?]P#BB\%CDVCR\.03G>A*OJ/U;T23,U,Z;$-+MT..2H
M!4&IIL\3FWK<CEJGK?%2N3A3G;I/J+#-REDQR-QIY:4SZ+OT X9OS4Y<(".O
M<^)0M ^Q-9ZRP5=^)7^=Z/JJS_V:A5O[YK0:NTM80Q5ERG[./\ZR8<_?__&-
M3M\67/$R-#3P;IFIZXV2DO)W /^0FSGO2&GJRX (=,O7 TBDD''V^-^+RS_Z
M*+8R8;[=6HANWI0&!9!05(T+X.0-%%\^O6#^]Q\&9G7UM+G5VG<1<GE)4=4N
M6X#\9V@U<!"L'(.PB\XJ#8--FW<)AJ7=9U2F]:9$MN%^?E>:@_ IMK_RD>J>
M0FDWOTC2\:HX\H,4PL1-36-JNL<TWP^)28I=.F9TL87-2P#@ 58KV,0C\8(:
M.U%K 1NOR6O!:=.I$TJURY[>GLJIW:@&]%$(=[U$K@(-3$+[5TQ[+QF[ ,=4
MC-SX7C'1*=N\]*M[VU]?D40!K,[UVN'M82MQ;_LU6U^LK$3KQ] ;J_H8:<2E
MW$[U\O@LJW:0IH^<R(66M>:>%Y"W1XIO]70<EG")]'4\QF'?X10(K2GR$=(O
M_$#S_ML&O56UO<,5(IN(!W79,*Y/12F/B,E/+0(8C5^]#;C\#)"=JT=G/Q-7
MVEMF);7KWO)BS+=I'8]_:Z[)^B]!USZ>4WCM7_^3=L5EB@HZ2EEI2@X[@FR-
M=-M$A/SV_>[!Y>&AK<3(_:SH7<>X7LFC(B86A?1CP/1"^E:!,FF^QA@.^L?P
M>')+JC\)WJ=UT*;TR=!3Z/'8>U:T22R]!>"N/V47^E(E%'+P!1^!-F[(2-@C
M.P((XC<W&NLF?LOAE*,E(W,/E7;7U6>X)H[GR>MVD(@GGS_[?FSX3/?>T+)U
M+,<K$\WQ*<5,,#)Z=C:O%";X_7[P_5>?O%Y!>]O??]-7ZAGW__:AGUG9DFYB
M-9*2F\63:KMH,'D[\U$RI_2X/K$:A<Y[(<]941_N#.22<^,3C)E?UZ?/.96;
M:+J;S71;2&O>4QPK=$\^<R+%XB+:&8P\)?M7@]B\/LNDZGOL#;STV\M<9BTW
M'/=W_"&3D:ED8/!O8A90^0@6&?E-Z1M_P^WJGWT(VJLT2UUG@,=4#3QWTUGA
M%1 K H.GE/UQ84$E(F'CXL<SP'"M:B&74484%3!\O=MN6Y?^9K>"CJG$Z[8<
M;MW]RC3VN+PD*LJ*E6"BU^3NQ][XT800F!O'CY)%C]\#/*#= V& ?P^(3LB]
MM8O#9H/Z)L.\=]PBXW*92,##,\#F.<.7NA Y1^4\[WB;Z(I"C1E),^35_>V)
M?8'P@CB.C#(X2_@;UX!.<A(%23JI84/:)7_(B.8Q43=AISX0BL*(G0,+HL:'
M/,Q3CQJJ#I C"_-Q]IP"3U0?W 4LDD%5[1@L+!R+KH7H;]5SJ=XL;HC!!E%
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M!P3S3V\D9>(-ZEYPFQAMNWL[8>B<LR,=> 5,$@)PHX?<2Q4#Q3IA3!/1'74
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MWND05+.J(EV=" '23TH\>5E*JF^;C5]@F$2KJ_WWI'']DEJMJ[DAC4(S]QG
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MB&-1'TVM9]5>P RRFZ5[TU$.J,Z7CB+D !&M#=%PQ&Y7^4E3HZ#&ZS- RAE
M< .#XO"H: ?AV]8*<>>WP#TRR/Z0O08(I4T(-TU=Q,ZDDT6+=<ZM]LXWJJ,J
MTB#AKN[<21<TT&%CQQO=(-CRG>(4EEW;MFU&S^-1-FR5H>*TGAFAU4%O3^Q*
M&<%D"/BUY%_=%!!MI;<3VHS2=!E4VZ,1P<(9<90V%,'E5S%V3/!1O'AJ5?3T
M?/S30?'>IO:.FX>G--O?)Z'-@LG#H-?S;RX[W<B(^EASK;H\*Y.O6KA) L+L
M/W@&\%R;)Q43L#].F"H^VB^5%-=F,ANK5$6Z,Z2I3/S*N=EKG=?&B#LFFL"@
M33QHG4^R^.^>$P(&2:F 9)681XX,:BG"P<[ WJ0S0%NKGL7ZYP/T,Z< ,S5S
MSBVZ1\XTZ2G?I3QRFX3,O&=Q%,)V'70&?WS@_O*:6$+"NYNK%\5%<6$7K<&D
MVQUM1\';T;4%-=P^*V69MP1L'EY7=A9Y(""R(5)U(VXICTR- X@VE'>MQ-9[
M\XQ-Y@;;MCL&5M$%WW_D7"]2/M@K-1XZ ] =D\)\0PG!7\J) :N/\\&ZQ8/R
MIN-%@*1]@3=7!S"%U6U=M[=QS^-TS@ ,'.-;V23:;_<O8&1H;JTSBE$8@>G;
M:(3%WOIJR#7&U$1&8=H9,/7S#(,S@!V8W/-QL38UF6OUADLZB+>ZPH'P*'R6
MR;8_'#8*^8!&PL,?.N&O'E[XZ[F:JNR5('[CO8>&[ILY9GILTVH!4,BA)/U+
M12=)G+U"TB=&1YH_YFW08+8(L]1GWOG:;CD<=U6*SEI-<MHK*H('EDZ=HCRV
M[E]1]W]J5:$.X1$5<P:*?*UKE[1^GAY7%S_EP6= S\9,*:&<GG=RJMF8?5K8
M%?7<L2Y9YOO&&> %G3^:]I :@D($K ^4)BPDQW,2;]3&6-)'ADE"K3;<+[,J
MG5^ S@=.H3(G@K\I4SK>3/=#O,38F8H8M(1,>;^> >S]6#7^E[V*?-\M/OIU
M@BS96^,U-&D9F@4%)='D,_1HE/P(/I*&5XXOO,?CM$N,,K[!V8^_[Z7>-06U
MSMU/-8\*>?7BHYRVPT$,CS/CB8EW6/,N#EW)$AW_K]M]*[[4%)<P-QMWRVS]
M*;NXX#@2_;#F6W<E*SL[ZZAB]T?BOR/HZ,JH:%9"T/V%L?K+;DFW9@70&1%1
MUC%Y;42"9,>83:[M:*I&$5.X7E>J0"A^';5CZ&0$,FVRO?7*.L?I9M&O!&MF
MN\:.)N5V;YJ#FR<XER+O(-=[QU=2:!0_2$TP/<P:X6,3D2AVEK3VTF$.]"Y$
M;I&]O*=(AB\^GBP(-/UN<MZ?3'B65#+H]*(S](]1NT2U?=*%@S>K-LO]Y!;V
M8;=*=ZFZOTGA12K$!E7('TU5^47Q/?G)%Q=NIM/J&$7-9G%R'J1?B+VL,FO&
M(U+A_K*"J9<\))XWIMBAQ.0R%<<2A8(V[I9(D!HF%!&C?/8K&7R[.L?$[;:Q
M$28[@+F8G8V_?Y$(\8HAMKV';L._8>V\LH=N2;9;#B-_=NCTM"*!%B@.@3M4
MG\Z=$&U%:R77H<GAH(OM_T6D&MI^@]/OJK]U>UC\I/6/OJ\P59;0F$*HOWUG
M=_XC+'^L4>D#AT!"R/"X[V_7Z^0NM6W0R>NASI*"N_TE3149C#'Q_&^&>KH$
M_]AW]9ZB^+KU(5N,GI!#7>#E(=.6X(DQ^8CAS/@"_:A=F&H>*4 'C6JHM!0=
MJ5$;\+V2(O[$B$%1+,K+,.ZAF#!T*>U.5X'P/_DD)W_B)X0?Q!0J0&K[\("Q
MIEFA]00L*Q6H(_/NG432D+%\U9BI/H$FC&^!A""(+L97X>98=3\$/SU@'>95
MP31Y"KD<&IDBI1[4LN,_;\E76U/^VHC%AC[*<4Y5H9YU.*287P72Z/WKZI;#
MWQ\+>?P_<J8;35^XS\K8OJNDN^M3,Y[6JZC#)\_ES[.F15]8M#8?$ KI3M*1
M-2+>_KQV-ZZ.6/6M^]],70NPMUG0W0.?-\0?>4B1CQ^KR83ST >[P,-'P.MU
M3MORTWL *<EB)2ZNOW[7ZLTSJ# PV$BL[_K57_6V)W9@($N3%FNJU9QBU>$4
M)-U'*=Q4[YB$WE%/YTP",PE-R(0Z:S8"YI)H0U?6]8#GF9[KHE5)HVB2$*&A
M:OX'IK"8D8Q;0"T:OVEQ:P#0&G+ ":T W0R8I1J5 Z@;XU?ZM*2B$4P8$)=J
M';$6<^%K;^2/[L)-::=)Z#,_9P::[O1PF??,MEH?TZJ8T2)SU@@"^8A0GR2#
MOS48]75F;CJ3'$K*?WA(Z41 U*U#$"667E61W!^2PEFQ2[.%8U2?SAL"5?5[
MD\@V$%[T3*>55H%!V5DZS"X:+907AB*8_7IK3AO/X5).54+>R.8(JU_>E%#^
MV538;,V!59A(W4!Z>IRJD03 &O D#6AS86B(;F.$H(&%-FX(<6UD%+S+5JLT
MC)*ZR!_1UBC,=^]NS^ITH']]+0:UT1;27>)&JFY_WO6CCB&:PSOCU?(A$4O8
MCMSZDJMX3?[C!Y?:O*M]W%P BA1HZ@P0$4JL;QM'6S\_ \19#:NA(/K).BFQ
M3?Y;G/0(K'['&2!T5SWT *KTTUVU)E0L$9(W5E?4%.:@28JZ3]CW/]389K58
MMZY IDH&*XQ)!0[P/4N:YI/E=H(HCU.4@ 6PG9H#4^7M(-Y\M*USSO(6>[XM
M0;B)5SK@0@Y74QMI 1M*"/Q2-")J$JLT9M NFF<7!6SARPRZQ$^UI,_"BEX&
M#[._>RZNTV=VU+XJ'K\D--3#?0Z+V@9I'N5N&/^GM_+(ET2QS*U7SP"BQ&WD
M88C($O%"BMS;5UQJ*K?P!&[1#'^*('FJ>A2AD_T*B?LW1VN\<T"7H2X&TYM8
M7,!-H=YCBR'LMHMIFERK<%-]I5,$E@$Q/A]6=M/A489*$,JNT3LICZQU664U
MDG *!_U$$;7R(9)Z)CR>]!G?M+B?!I>_:EHYU6PEG]3"XTI+\?!/8#HPU^PW
M*S93YPGY'W)_;12..#]$XMJ$4H&SOT&YYDYKDZL0X'-3\_$Q_5:/@7XK#4?-
M=E/FUB#6\3WXLHP.M$AA'>M+7KSF&LCPUIJMC< 2RIN+(YP!''VWFE7;U2]F
M(:[99W)4*Q&"@'29%"$\"(J#J1@9L>3)<3N&1P2P G&V% (&Y8[\W*?P>,:J
MP+C7:80?'\!\!I@]H4*BIN[13,#W*Z]U EW\]?V_..#1MS+)&O]?SY.-Y3LN
M^RU.:"NR*3.?GV]Q3)NI#1,%@1L%;Y.MXAYYO_#E3;Q<37][M"VK!2KSFLTX
M*OX@.DQ01>DT*;!$M5']@<_PO^594]&)$<O&NBKZ%-&%_@)^CD#T_Q*T7?Y,
MI89"G 4\9YY:F3R-:[CRZ"FRO]3ZH$J9)II+#-[4<\2QXVJ%#%B?WA)8S]YN
MJELF:=Y9G?2&,4=SC6DMD5E/A""BR.C122:U"=)*YM,QT%$>W?'*>3?3L$JK
MC:OMKE7Z9;E&\^:%3TJ=V\3XDJSI1KI26Z!NLQV]/-@TK*5&CK+P7%"-P8T$
M1@16?3.UU3YV3N8OHF\E&]E'>YH$4R%%,/2H%4(J-['S3B-N53/O3&D_E@7<
M!Y,OWL(1A/ :IW<PJ :9M=^3#U+K)K2O5&1??YMM,<=WAX_/4_@:OU ?X_Y6
MW\;X<X2Y4]KL\947.S._>3P+T:?.!067LNYKCC_9?P1)^WP3WW]1R&&=%75,
M"/]X>V'V&?$,H.];\XOS@X**FKW..T6,A/S*']DBF$VY3&AKPQ$I;%H=C7P%
M<5Z\?M,32O0;^Y2SN^SIV&3:9KW\B,R?K09CU9CYCV,*S1(K\_TW4\=AJZW9
M0V1F<:A\"&_N1.OTAEI3Z!!]\3OUIQG IAM"A2%F!<@G:7RWE'BSY13]N$H*
MKDKS.++]2(5IJ$O"6Q_]%''C'D-=^AOWZ>H4RL9"[7&Y :/)RL9YI\,O^^<G
ML@WB,E9RZ>%T1EGP@7([51ZLA5[@YJUN#5%*RS9]TPO[S,>D6ID-S"?<2NF/
M_Y-GN]K"Q8 839J>QOO[L8)D:F#0R?$ WSKT,_]C/&$B<T#CCFB90I*(=^0M
M1WXOVBFZ0KP@H9?@5W>O[@61.C4< LZ]-W.@5C' '_E7PHLJTO2]R;*!6WV3
M+*R6HGBK924'.O5G+U:@B5+ANA;O>'B.(E.UZ^^]L "LY^X6-9R@41F,+.K^
M"$$D!PT^J6XC4'Y"0R:GOGKRG8%;RO7A&-H,WKZ(,955_%:7[]1!(L2\4/8V
MRGMET6ES?C*;D]W*6?#9%\3,5WG\JFA9;651"?)[V:4[IDY5>Y.!#P:QM2*]
M^-)7EVOM>)/Q./-*EO0>[K"PL/_J%AV$/]'=SVPH]#9UPBK)+)R$ND<SLG@W
MWT)O_D=/%3(WN2D3WV285SZO@"F21LIN<9)?=?$(^F%A&H?8@?N=NO8//!$=
MV)*:<@F=$AFOW#;;Z@2OK$M$/_PV6"KW]"KA@H[<-0!7#RIZQ@"W !-\'WO7
M;%(G(^6Z:4;2I3?R-;^%DWS=,Z"3$U)<MLF6IB&4<DY$WR<8N*1GKW#EXX/
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MB$O-:RQ4+;.7!-XX)H(W?!/[)Q, [FFM$TVKD0<RQCW-K&)\\#;B=NMH==R
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MK2H!-@"184EA>*KH"]9^<%_I^6;4..GB?WRQT2RL/B\<7GE^1WG_U^NR/MB
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M35U1*?8B.D*1[0(2X("U_-H_1]'HG#WO7G3L.X,TZ;]D;R%](,P 9I>%CQ\
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MT6"%*-/G^IN:IHMC?#[B;)KY59D? /37<E?,#=TO#_B63'XA5@\E8KRE_DO
MZZ5^3A<:O)(;IYB'D&2[U\(Z+>)>E0E?+++,Z/\Q65"&_A2R=!#2SQ>_:AZ
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MU<77Y<]B*+=+&KYJ7C72D[8./49M$P[73<+&U*D\)+#N!\+T;(]M1J_KEGK
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M R#"5L>$:X3U#>GH>.+E!$YE2G5I+Z0:!:$%<7)!;(:7AE7:TD%> ">**MR
M<A=>N2,^Z! (B\8Y:\+?%XN]S3YI;^J89236R:&)%S39P?B/X^.@8_]]>GH
M9]=?-/'@_CH,@IWS2!2[UQBH>0X E(,.HM__(]%=X%OA;3CACEO_9%?#$9&E
M2H5X#H!=CM$9'<U"6$M:QWJ= QCC[G<1U[H$CC#1SEY9H81V43*%^(&L;/^W
M2>29W4+'PD.;D B0]A2;(3&$YO5B$?JRU\=^^ZWE[9JSQ&S)K*#(J7T_6BZB
MZP&PJ@M<-A+G\\(<785/.A:>#O"+#7BH'2=#NL'R#.<L_I$W&<&3N/T76E_7
MO:E:3]0BLNE/GM'AC^#DWZAA] 1_UEN]5XX?M_CZ5FU5[(+&N4$N:4[7"8*P
MP__HZJ]A7A$0 >[_?-C$#'R<.5R$!Z[$?.\X>[X$(()22!J)<S@,?97>$%5>
M6>9BC;;B0)1)\)=L-ZAM0399<.NRB")C^+ZJYJ55NPO /$JH\?.UOAW-QC/H
MEW^[SHXHX4]OMS3T[M?4"KTR^&OK;,J>KL5E:<9)#1LZQ2 +FR$-G9L;$,<7
M+_]\:%?SGAWPV>)H80H$7+%=A VL8V707=<FOA(V>*8%)9Z+FWN)?%WSJLY*
M?N?*D&P3;"D626OI=?6^A8<<FNO(<0P&J@@'^W<)1#NXJZ 4A7D("C>Z]_)2
M%>*7J&SS&:-8)@O-!%>P5)F3M0\%:G?>M19X739<+K&K9O.C/A'NW] )"5_.
M,]ELK0GY]RE+\=@T!*XK%&V70E+?<"-\RL1<_$3L^XB89*^8=01_GF8)XUZU
M:25![V?/ON?)ZF5S<7$KPN^C5W&&WD;S1JYH">,5*<58;0<KD-2!IC+R]#<.
M ['T_]5]++.>^%WIP<^G$?[16M_Z]?,H[ Y;TM>Q8*N'9I03@JZ0^^PX3[J*
M!@_5G!..-KK,Y;1/GXXS,\V4\(T_&"8F:40AF7B:ANC2>;P&,_*X0V6N(#W[
M+B9_6N=*C1DLN<++QE7AA]ER9MSM1C=!"^)!,2P T8>!,5='?@[V>_/;$S<A
MR)FJPYX5)]L[-HYA/8B[%G]C#9#NKZ7FQ!)D!;<KEFE=9I<*D"X)VT=HXF'C
MO3YNT8FDR[Y;W'BJP#=N_[@'7I)#ST"\3D! $QNU](T%0HA9EQ7"KK3@@,7'
M<MMDY3!-E]I'^NG/T4WJ@>SK%?E=5O<(C+/3\QO?$FNI+(;!8Z?QI[53F>BK
M*7SW%3(I#:ZXZ"VKVVDR5W;A.8]*XB=^0YK0,'7D7D&>;:YH?R#D7HVUE/Q-
M>*U$;TID26=&X 6:4@6JMV. /<.,&;$BM26ZYGW%\,P=+L/GA9H +H"!(1]5
M8'C[44/]2,*Q'R5P@$<WER']*A/83VE":RV>/Z^0DROTT0%[&QW^NM]L_$XS
MI-6D)"O16RO+8<E*+-!3SNJAKX68C2%\WO!6G*7DB^1IQ(T+=&!X$/(#;DTH
M&2L4";;9>?^#6YJ:;:Q$ N# O9;R0[S*JO9^"AX+H@' HBOH7&BKJJ,J7L6+
M(U5:=#X>3_).405] V]D>JO(<M&H[=Z0R/@N4,MR6]0Y;6#U;N3PR@EXA>Q2
M ROS>\/X\52$RHXEW3?P>TS&SSIJFQM;']&\+WEDA&(RRC8 9PMSB2Z!ZK>]
M*O>5='6DP0[?%9K&:6OK8:(UR-496-\%#NQ4+BJT8'*;<T+:&?^FWI%=TQ?*
M^.Z@V]V^RG@1]GK!@<ZZ3:V_'US7Y;#AX'>R'$-#A:7J8C9M5:"U2H/KN""P
MYT0WOP0RJ*^A:#;KX>/I>P4_B/,2EAKVH0&4W71GP?>.G/6'ZL=*%]HUF,#4
M'G85WRI$8ASWK<=E=@<:%7*=Q2]B!DN5P!8]SF'CQN#9O6G%NNC^TG &_#F@
M.Q&(]2\>: UD.P=D056Z4(0Z_.N:X^+&'V3]G- G(,INUZS2O_+?"QBG%DC+
MISB,NN0>E!_)>7_%6_+/,+_3EUHWL\E<:4 7G@]TD0+\Q$MVKR&1M$/EUX=L
M1.C1 J7=&8R@!\*-*H(Q^D#7Z&K<W*V/'[9M7J>7YI6V+?3;.#2SEK0U$2I2
MH/6[UOR0JM)-95SY/&^R\G42YL&@V#F@I=PP,DYV(L0JLX]<>#314=?U_C/7
M[41XHJC/E3&U)1?-/%N 8:4QM2@M2! Q'!4UDEAD>A/;^B&M_E=G$2B;K)9]
M?&3Z?K-?PD3'@*UW-AJJ?,8XFP6<O,@*P]F?-E)#=?KB)14^":*O,A<AU)""
MDR0DBE"&F<8'/7&34-;3R*O\HF,CXLJ.\$CUA)U>-1C]+M>WZR<XA-1G?B>B
M?N/]D\<!WSO4$A0=>#1];W^P2*TN_$CE%.^)1QX&2D.G3N%X;<F:713R[FWM
M6V0IH1;\V]X#RF\_ A3D@#CF0"84KO8DC/55XZB!AFJ-U:A^,0,+-:PA3@.I
M? X04,=MXZ(>]/4^F6W[$5T&8LZP2^?#$JZ#&\\!_$"KXY4>F NV5QXC)\#A
MR=46G_8PJ-NR3DDUJ[Q:4#/\*+I@PP!G;ZNJYQGB:&F2)/I*W)#H(Y )[3ON
M4FGM.-)#>G,H*=H*N7@W6$=%$,GZ(VT7Z J#J*E.K8R,P4-I)XRC;Y\T+2]K
MR!HBQTB[,]%1]T=\>JPT6]J_M!A))3E?\%(=M9$A?I-J;!!Y'(H_"OWVP1Q"
M,"=U(;VF>:>SDH-8&\C[ ;1PQ9?A\Z5>/3_,'RF$KD5\M>-4]1K7@+.@5A!A
M]U] L%%?L[ [7V<C/\#7BUX<*ILV)+=62DZ50_AL39T"^-4L;*1X5!UY_$-&
MOO(]&:.19*FBNGAL=2D%Y_M_[O57-F!_[8(^W57,CICV54UNXVQ9L11V\(HW
M_E:J M9X8\D71Z]\]&DB4?N68&?76Q47JY=U)EU_V/<D=1R-'&^;3>N@;?-O
M__[3D%?=D$LS&NIF5@/K\+'"U(Y^9'D#PK5(A/**-$*X!)%'8E'\FTC&I8HQ
M6);#]_P)A%12>OAJH:@4>]/#%1M\EBXZ;G@<O/QTI'5F3(-E23\08ZLOY'O&
MN5V5R1$SC'E;+7_46?+(-C(E6B/F=(0\#%[:(^@7'-RNOCG_7S),T-PGM$M4
M]8C?)"?Y?8L:AXU]&L%5\:YU![UC986\/(VMVYKUE(-N V3XQ@;AK*>,8TYI
M?]U[=+R'#Q]V@H51-K&(/;8,0$TJ-B;UU\2C:(GU>8=4:,;TH#[-0770CQ)$
MB\?U;6FO/6V8 3Z\[JE"Z^LK2QNWFZXE<*Z)L;\(D9:FTSC\ JE9PLC:F6)X
MLY]C=/1>_I@\=K#/M:)^1R'SG.9U\F(A4U<]::8>+_BWY]?;_OR@96<FQ=AB
M 3V>.EB#;604R_+ZI7MS9[WQRLXR8OJSNL^FA!1.I,:[2L&R#F(N+5$25DT5
M<PXP^]4UU3J L*Y7Y5[?@K=[T>PYW,*XE?^!B<JK:K8T&"#%2>Z[UCC,IDG*
M?.Y5FP4FEQ3TQ)W)];WO:-C>^@9PRO=#((I^"K7MU'IM)43"-/:G1S>S7)3'
M(54V^LS.&N=6-%354=@/>6P/K\%:S%(--%DRI9>&\PDB4%;UDS\JW_T>^C8J
M8NQ@W>2#\9JHZTM2U:3I["J )@H<E1.P)WC^)__%ATQ\L_-;43#C>[/_:S'3
M\V:*1&3*!YZD52KH(><12F0(GO6B0P8J=/CD25!G[I;A/X_RD96]T/51RH9[
M7W._?^;7^O,RV+(EAN ZOV\$WII4-U<+6Y-Z 2SFIFS9F7C\F <!%LBU\L1?
M:-/&*KO-9W^,.NP+$^D<U&55KW'GE"F09O=R'T=02G1P6;B9U-%Q$7?KPW9!
MGP_R7U;![G+PC37D<)A;ZM-H\=%TQ23-)@0-W%K8)A$[49"<3:A!LZ(X/]-_
M@W_S\B6?,%<7)TK7/#',[WZD0DR)IAN.1#*C1K(K!PW)J?^NG92/D99G DCU
M F9+_]71,9#ALP)!%]E^IS:]-KMR0GPVIZF)\ZY04PN>RT0W:!-/<VF)38)U
M,*L[$1KET!!W?AKJ.%N&Y9<<75SF*7A."B,*/Y),T!Z7NO(]_ N?/G[;6Z6
MLK<#&+_,1^V,D;,<:E#CTZHBTPBP<Y>P,H8B_N9-2LMKL1V($<008_4=ZGGT
M/AF)I&,N4(.4$;\+,J_]U-:B\*N5J8WYL2H%)VK2!PU1I=\[,D4,HYIN)WDK
M9H%-V9W. ?Y31558*7Q+#-V9_F>*29A>9R*EGZU"TQ2O?8RAN\<7A(K;3UDH
MXC0H$OM!=VB;?IYSM/R351OMX2,Q4)&A6D&Z1AX0=WKD0E>:_CD$(M,C*3'R
MO&VM$XY.X95O6C^09H+A&R!=>G?]=*7#A RLV:\5,!D!A0^7_H +S@&)8Z1(
ML-6PP_0_(Y'J]*UR*1#6D/J.G\RN1Z#9\H+KY6%T;:3)VH><=)VT7[O?6EH<
M9YET"NE6(X-J"477C2J51N,WHZWGUW1AAZ]7H6;1.,Q&!/9G[]3T89FEW2]1
M'6>4<<G;1I 3Y0\/L_6YQ OJ&YP=,N)W7%NACNF5$ OL33?-I=L< H[]BZY%
MPW2'FCN7;DMJ:23JV::ZK-D[]J]C6?#*[8)CE\Y'UZ^^MLF(\Y^&+6*%,KX=
M$:]#P["D*R@PJZZ>JF:T$6S#;)BD/QX%[3F3V?6$O\=[R:<]PU=3=C/&:!?L
M!T>),KW()B _OR!..B#3;*J%$P(9';&FM;DV?$@A8IV_1A6IJTL ->S,?R,;
MQ!BGZ=>:(3N=ML4B'99-%L?MM.&B;H6PVSX77B6%$WW6WO6,^<633_<OP,RQ
M,T'Q+D?@@^M?N2A,M@P H7U="*#%I2M9E]B-M#\R!%3?T*(+>D__=/AHIQZ]
MM4GE0/7EI\'*YM.@BD%RD=:N<U#5%QW:>R-)RFV-2/']7UOW+];I0L<^V?DV
M>4W;_AJ:H-R.I%TI8(G$.2O]'TE7'=?D][9'B9(JI72)D@H2.DF1[NY&E X9
M(@@C!"1'J_ EI+?1-4)*8H!!,Z0;MB$E8S#8>.'W_G\^9\_NYSSWN:YSW^>Z
M7$74X_@B:^4,3<,9)W+?^!Y?"1[C[;<?!TGI;HP =[4(1)6K?IO+6:'^ZLV4
M<_\\+V<+"UZ^A&D+3[X7J#J*>[X)#]XBD*ZT[-',?Z^SZ^'L43YZW6RRCLJ;
M_S\;]AEJ<)F*,Y?XI..4-TQ#L #:=<4ATS3(,K$N)$I;8GBA[1(:3@A=LD:[
MZ 1G68D'STB1%/.KE,,!':0N[,'>PNNC]J(%G>,A*KNX9._JM3,^;[!AQP5@
MNNM*"^:2*-^3N[96RGK0L8@G(<:]%'CW#=@06T1(%Z@6")J=BQ$MM!1TKE</
MC)$3 _ N*,L%!"NMD)0@H+71JIB%IW9=AEF99@84WWT 074V\)L*NJXV/%5#
MR^"XCFA]^%C!'QY)C#\HL&6G44NJ)EF^UL.*;/7WH&M@6G 7;NU_C:OE$_ ;
M,\0_S8^/,D%#&9#S0H'K):FB$'X/XKT(&ADR'$5!$*91@09W5G#+[H6U2*:%
M2,_+!#61'8W1""W'OHAN(B/G5=3_.S;?K;:&);C^)^]B:2$8H5X&J(&=+_TC
M]2ZU[6.^M;M]=/-8?*O4.<YC9)/W\K_H$?XU[$ &.-!'P39PHOZMXNH,2^JT
M(]RM/(>_+6IP>AD^.ZA!!:Y0PMX..V$'K0+MN[S6_UT"%51><B8MM\;M,P_@
MG\"Y8<FGUK$2T\ OL]EFSU'+C,@N\[*.D,^%6*?8O,-_X\&NIMH)U.E/;_KM
MB7DLQTHHLZ7,AU\76"34:'%.27\EG_S9MU@J\UV;R#QX([3]IB#Y-._,P9O=
MWBKNZ$I7D,RS+\)"GPOS/R'UA^_(EYN(2O$9!A(F+?\AK_J,U>\'F)']:7^K
M).WC]LOY.$C_P5BD\XB:?G4VJYQ[(:_M;5^BPN1[09"O8HJW7IB$@<?+@T[9
M("\SX\A 8&29F^&2#:^+9W[P!8 CU#<20S3I7.V^A(EW&R?>[?^978<*$OI
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MX]WH75_6V=@HC[-M&YPP%OY/PN;%_8;7QGK]UL[/H8+#&(G@=@]OV4G?Z@N
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MK# A/GR /-DW0.73$*]*3SLNO+;^I/*C>5HF',&V9G-ISQX_%>(-A3X2O6W
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M._E8Y'QCL*V'=M:?I%AC.*/9-:#(AX\?7Z]DPU[0OW(C7T?C,6\M:BSN8O*
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MGOF6$ZS.N1QJ90ML?YD4B73\G7%XTQ[*)'K+QUI>C1-WNF0C/@Z$)5BF,@@
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MVWU\]. (A 3M@R]>X>9,9BD5L9H>:QF_Q?[25?S\Y4[6LFZ_>LX8M#811K\
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M7R+,\=/%B'CGQWMCAJ:"3OP-_=:6E#G>R.M\S#"+-UDZ#^0 ID]><UKLKM>
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MO;9]*OJ?U.Q',>>:#/N4'^$,M)4YYP"[]QW$ NUI10CA[RWUH:FUI3@=T7/
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M"RJ6,TEV,E-K7<%^K=!.TJ0BA?LH]<[/QIC:EKRW^O6"']4T]#6(X.&/6*W
M?7&GUEI),ELX_0K<!_G.:CP\>5QFU:M-SL7: ZC#_U>1\YQF-&2,,RB BVCF
M6K#I'ALJ;Z>SZ\- H"-PX_?)7(<TM@H>[7N=E=8!-.6.F&"3F9GM50^*07X
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MZ<;EO6PE<U&]A'M$.*$+5-%2.-31%ODX39C'4&>IHBE/,9!>58/QAN>3 &R
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M0B>QZL]4@I+>R_HR/D]O!S/R^QOCZD*Y_  _LFK%GO9V=!2WTN^52<N_DG+
MFC>L6TPM<]< IY>8ACB ,7[;\[ZA'V3I1;@SF*-2YVS3HF.%@LCT@J3=[?D
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MN\J<JAZ)W8C5LIQO.#,)6<E[R!AT_"EP +^Y4.-<%UVK**PQ5O=8;SR-E"2
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MN\FM(.PM@:VNSM7*G'FY>Y\V,\&T0J'!+[K[-/: J&F,& ,V?'?_W'QG8**
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M3O$20,C-,N7N9.^G,DKCER9 $UPR4PM3;=^+W8;,"D+X<\:!,$%P!9%AF+A
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M63^G(WV^B0YIM7]\C^V\&<8&"S57Y_8TQL^ XR <5NY/ V?LC*%IGQ%MN<%
MA 3C5(@7X>S&.0"VV=Q?;L$E=_,HTVN)5YCNYA/)U)O5TI'6G'3*?I21CISY
MY:<]/1&$HJ GN8_AOL\JBICVBZNKR*9!L30[X.Y@KQCSJW"&CG['$(258$^4
M? W=\3E )A!##"[ (=%5F9[_F87$M*Z/=LFG,=<A1L+8E^PLVBC3$4K)FQJ9
M>H$'@4'^YX#DL7?]R-%'")(J$HSW,SC>WRS#84HU_(0Z.^;X*'H4'/Y.V2<E
MAL9 D(B'M]$0^J9W..)JP<F-*>E8*X'<O7"U7Q$NZ0__I&B.H2_M+" \\UP&
MIDH,YA0M)97EUY>?MQ)A%5"HHUULQZT S*4#R9%W]1CXPQKN70BD[ELJH)I;
M7>;^'9/09=3))\OM8"N: H;",[+WU?:I]=YS@+0[T5TA9IQ-/$](NT9/W;B^
M^6.4HBIO8@42-68\-CY&*^IW>R Y,.IEV#>;,/%GLG3E^18*@.=?'W]\V&_H
MI5;;VY\#ZUGZV[7LGB-HTEH._?//,8.]OM=R'EO^8O"7))=V74[];C!/HYR>
MIZJ#AIK#UUG"[3<-IFQ5[C<7G<U,-7CFD&5RSSX&<];\9_13QR"VN-9(AUF-
MZ[91=V")U1J_YH=)B-F-I&$+[S\C\\]P<=:!]>PSLX-[K(*,A6Y_2=-/'D=%
M4 %20VF(9&PW ?C@,^EV>IWT!.J>E1C;YQT*5IO;ZX[>%F<4,N> &XO00'1Q
M5AB,O'H@X>)+RN@W#[C=11VL==?AI]V'U[TY/L^$D M$F/IVP;[JW4^E=V$!
M3H+ 7TT9:WL&$^]((:CV*<QH3SETM_NS%D"BCXH,1A)#P-T7JVPKUZ'2H[7@
M]OK-GN-O++*R3377KAY>^I%6HMNCVT2SI_^[;WF5_U!IT[Q-=%&%C%SL# DN
M%//N;9Q1D?6[6J14V70.J,3L'AR9Y,%'VG1D3QY1)5V?>D=F:5TC[1S5PL=L
M9,)Z![V0&'Q/[%GDR>7XN$^\0$V.#-<)=\>$/@2+4W7RCP/8Z7 '; \'1=F]
MUV50-3*R*AJ$W9OWU!*8F5&NHTP^4$+/YIJ4#>5W"H<7!@AZ&4E)WM1J,RY.
M"?UO"@+C30S9AAYXO3]R_2=U2XW;-L5(O]"L*<(Q*9Z<\F# !N_A.ZR(UX?;
MQQWM4Z9$?CC(?>)%$>@\,YL8*3#^Z,H$RN.!W*OOJ>6_11D?#F/R@^YQ6W(1
M=%J)O:XIS^?N.E.F(NEPLM]D>?-_G ,<YN5:7I2*GP.VN__D*N9O/QC'Y%D<
MFQ\ 2[=+9'D-"LF=1^CVAV;<U9FGOAJ\KPX=QZ:B(FSAMLG\OBXC3;3-WR@A
M/RX-PLWP_B?T*82<6O>^0>/MH<E=1I"@;=/8@XPV0:@QA>PR2:7M@C^U?VS_
M&3\_[<FTX/G@'-!O.& 4[A*T'M?"=WO%D9;/$C)\RAN*GSI8URT\$9FWG&+Y
M%-]4;9T]\U%*X?D-'G'%?RDOF)+!,/0"+F@R>4Q)89ISUE\\^4V+/'.1HU4D
M*:_YK;#9O%M/S-A?2U]@4*6"=V0)BNFT+.V:Y*XIJN=/,9T 2 =98=-[*]D'
MK 0)Q<\%&9H H?NQ(6]OH@WIRG^B*4!B+D)R/0@:_#$"\19FZ \K/[G=N6ZA
M:SEP721=.L::JT3O3Y*E1T:Q'G)R\H+* 8,G+EYE-!:[F T/;!1E*6\.TB^O
MKS)JTA (1HO$ASM36^E^P0UZA7"&70-84H0J*9*J8<SKJ^ NI"<W7%ER'KR+
MX&PJNE' _MC4ZDI,$N]+RPV?]V;W"#P,O/B@3KB'0;D:L%XI*]$C9$A!MY6C
M-_O%KZ>E*8FB'""^>;ZR\JQ[% %<.*&N?!@<1QEC/?*1*&8UG)'3\82S6^K)
MU!>7M@#70K.#=+ZIDHV!<B-Y>H:#(ZA&M2LW%0@>1_^F?#CMC[,H6XI5E9H*
M?.BX'HZ4H<0>$X-10?-R]EZ;*XUGH<_V34?;;!BD#)B'?E!EQ *\-=:()"5%
M_$N>=,/5P[3QZEHP@R/UE\FN:PX%5#$-MU\?KYX#XH,7Y":#P"55/P:[NC*Z
M42*OL;I1%_"^9&Z (@O'Y\.ND/'S=%-:A[G43" KT4%=(RH*:_.RMV\;'?NY
MU*H$WP,W*IS R(Y7-PFUT7J5N^CFCBI+BYIV#Q^T$TY\<>$S6:*Y<S91IOT:
M=:B^:& 5AB]"_G;_#SAI?1SF[_+(8>#TS>:GEW_.,K8V6$83./MF/=[JZ1+4
M OC3)M%J1D:/^Z@;>VB!/\C%#F^""$%;[9F%07*!+NM-T*X>W0CV#][+4*WJ
MO;*\E3?6;TW?:]PSRS(%-\;;S/?2F#T1+EI"=, <O=$5J?Y:#IV/C3L*WU16
MGEI&#5?1=F]\:A8^?0D( /ANH^R;*=:_3VQLT&]4/6%BB_YE'&9FJ)^B"7SM
MQ\%,$<XJ*]M*!&N/P6TJQD'TU%_*JG*$41.]#X/#/7J5.RRG'/)+8Q"&(!QA
MW-_\JLN!V?+MJ/X; N)EW3?F7B;\<, #CV#!8W*$(-?J]3G@?UUG^HUN*R")
MOK4,^=(PX?R=<X!M\&0>W#Z5F9LCD\_970DEFLH_J_7M52ER@JP$)>$-[&&Z
M3;F2A[LGX%C=OU/3+AE/9/E"K,\!J2<84@+I\K!&R'DJ8$YW<27PBF!NA$GW
M7EQ523"1,?O+^,G;Y%J F;E CDU^4+D-3$.X+)3Q_9M_F<SPCANL\&96H^_?
MS"U6&_P/<L""=O$>VOT1);\Q"^J5%<:=4CO8L8?#E/-AE?B7(_ZB1Q9Z'TUF
MTR9:.]NFI[U[!M5Y=*.='K8N?%IEHHIS^VNMPC1V#FAD21C&RG,"-<N'H5<^
MMOJK']&/SD[4,2O8)/2,Q;$G"8:J6U%/.* %;:.:?%C'3RXQ+2 0U)YOGVRX
M,?=R5#82YO)5YUU5MFXD5N+$W%H[)YYT#4."*)+T6TPFG[U7Y+D;&(3FBQZ@
ML$TTY[]FP_C"Z2Y"2>?6PPNE")?N1$_/'$QX?OVNS$+3U;K*Z-Y ;5@?7G C
MPOM:RRE#$!YU@!?U4FQ*[16:Y3QVF%CC;?5-_/3P595P[^1SN\#6ELFYW>TI
M/$I!KJP?>S@>%+I40,'46"W$V)$3T6/XNK)+M+*=V ;P>P@.1@[#3,_:@TIG
MN!4AC*I3\_!(8YKD?" &9\9F&R%OQ?5.+O;'F0CB%!CZ_T_Z<WM-@I8;P?P?
M))[;3K_C%&V;D*B5+\OQ_?/$-E=5!_!,"8-CL&\RP4X\'K6Q$=C+9DB:M7Y/
M_^/FG_DYME70DM'G"*XPJE;BC1QZ<#G",(C0GJ\+$LW$< ?N9RM.8.5WVA*?
M0.>"8^X(56P9)*AS)-%9 #*]E(S(BB2#!IC[:=!%%+^#R"R[TV[2L!=2W+YK
MHT/=X./?],5Z/JK=5<JQLVW/M8E@)?HUC3T[2%Y(Z0X7]%ZC&[^6@#?82X!F
M M\#E[NO,#L"4I!%E,U,! YP8R(K%76OKO:RD8?Y;Y*OU6V*=BB?R%U/E]2.
M15H11..Q//RY 1P'8I[Y_W&7MDM*=V1^T(C'DDJ?LSOX'\Z[3?N#I/4PIX$[
MK=JM0@OL_8)77EQQ*B[WN25^EBM7;HT:K<)#$A'TAT,OKRK\M)B?C0ZK7A:K
M;_K=T+[*CG&1&J+GO</]9F-P[!>Z_;<#DU_%"@ S'Y'8:'D@!50D34_!X3S]
MTQK,T3^1KAZ^"N_B]=+C7+'_]<7=/(BJ!SGXV9XX9[^A$LV517F\\L&U/5L_
M!YSY;N;F3^5ZH)_."4WV>'U-G(J1J*]_A&'6/<G\N3DSV+!:[U>W-V%N/K'F
M+%CJ)#R2X9'BKH*9W%U#29_-)=Q9(4N97E5Y,(;?KP$4#=R_:ZS?$,BD_HQ:
M#5&.04)LN.3P$HGN(2W9V7D?/C7KJJOQW_^KE*(M]]_NHN%+*TKFY:8)LD;'
M90H_GT=6=UK;HA2:YU;6*T1O"=*\TL7U#CVV/J'*;"I=3?1Z)WC2UIE&6.7F
M^1JZE.#FF/W,R%XNGQ.NI7:3]W E3EE/>]#?\O80&A?(BLN]T6K]J;W/Z79L
M,N,SW%NU-!I^C:@(_LR;V.N/T*%6;>> BUTQSZ9??6MT;:DL"L>2TEQ-8UW/
MF%*5_5W_7Z]S8[KRJH,01Y2M1&)TVU^*+2@JL^@<L&]P@YD'D^C\2:9<^G&C
M<L;$IMBZ5+2(O&8X>T2D7WM4YW\/T#'V\D%0NZ_)CATWV)J>2(D:+Z\75CC=
MENPQ$'21,Z_NILN]KO*&)VF=5O[)91[/KFAVL^F#?;#7!"OS\^!GF3]-*0N_
M#GWJ,W4JVV,&,K8&>3#2-='3D29 G=%GGL7:5/<B\BM2U),FC3GC)8[AL>>
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MXURD>NX"TEL!T=0U7N]Z+D\G7B.+/!K=R0ME@JN[$P]EK_Q@HJYYX#4\\NZ
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MJYL3T[/I>TG6PKF1UH=R6\QA\'Y#E98SR&S(LVY_YYVQ!J-L8!]DW,O\H+9
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ME;AOIQZAXEIM+$0'[&;=[H4DJ<*MGZ@9.+HD$!I0@^ &'RC?9Q*MO0[XVSF
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M7->IG<,G=="N?RTNK-X12]MAG;GN>M#%/5\NZ^H?OO8L3V&-U$PXUDS9;**
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M3[]0>0AX-U I=.FAF\^NOS0Y)H*S 2U< 4\;JJA*C83F)H=*%+J&E'"<8?M
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MJ&DB8T(NPLZ'4")=$?3XXN3'.(C+G6=-CD'I/YS699B^Y'V0QCTD#.:&2C8
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M1&/XO?EE"_<C_%"_0UJJ=:'$G[Q\ON G9%E(ELZ3(A$WP<'3#<2)IK8J-FQ
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MC8'%RR]7W%Q6^!]8<)4*BHG=YOP(F D8*"K8)KS=!,,@?T[Z%MFT;PBL].;
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M;  W!^8 F-\(1!3,Q@!MX!/ZN?WG "V0G%3:/7Y$6$H*.3==LLB/8RA[K&J
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M3,H>7>%1_$&7<T0:"O7)%Z_JG,]6WXX(S7[X:4RE]+I04]M(:$N1>O>F=DY
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M4-][G4\"B_@KH$&%N 'MK9C&,\6.T/PVJXI;UK;3AR'F@QG=.4:S'5RNPP9
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M!G%#>H\;0FL(HG\M:=W0D[HD?T,M:IJ<&<T@4&E(#.]2T[2X'4T_^U70[%5
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MD9@:B78AJ]F!3Z1&I['>'VZ:4T' ,V!VCNO!'4"11+Z*VNYK;[*R<C_YWI8
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MC@[= J;7>,+4X'&O%I"&Q [6>-""VN_IBV+Q\:)#"1SREE@<[2^7@R='FR<
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M!>/P&.Z",CVGA@XX.X$3$L1]5O)T(_SUWQ-%U/_,'/5. )L>>ROZZW.6JOU
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M3CO)(]GHW'/-+Z@C)QS/$\T,FL58%JDU4III7YVW=-*&M"_46["?%*","6(
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M]E!O"IY'*X@ KW#AF*Z27(:Y_!-P#TY)@;R:0OR7=)" A;&Q29W)DUCA5.V
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MU:T/U7G/O5T22IHQ\M](!P-,FY4&\/!2]<IL&FC$3>9@(V_ARX1)P(9&5M'
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MX\_\FXTA_Z?POUWX.?L_ %!+ P04    " "4BHM7#NMG/J]M   N>P  $P
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M+6KLG5[;5]:S=G_Y/JVXJ0^[?B"NHF_C$1297M+</[-QR)@!G&>FYR07"Q=
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M61_1&8!NPJM4G/G^!Y*@3NYL$_L0[ZT[FFZ>)8O,V6$UCY"$&7$X>+NZ-3,
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MQNE3:1Y)E>_4'@TF73!C1B6PE;FK?QKV]E12ZZC&_G4&P&FHG@'8_A/& #
MIZ3=:<PT_/BG[++"MZ"@MKI-HXY9V]=@J=62]18P#$%\ZN8QO5& -ZC?I=F$
MQX?E"<4.8$PQKFX-VL9WAA,A+E=*\4=2VLSE DQW7Z;;"&82.)9Q<%T/BDG
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MQ<?8[6/J+\2>+=WVR&S$NY4!$*&%:+0S49JS]"_=XF92#B&*(<Z! ;C(AF
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M_)8EIB@O;,0+Y+OH"V,/%]UPS!'*IK&35?@Z],@1Z]>&Q[DV*7)H5,.2 IX
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MEC1J490I7'V&JIB15B*R;,#<^PAH:/SCK^G#_9(W6=R53+3>UZ6VTX="%A@
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MZ++>Y\>;W\,4)M^Q\_[EW-,*E)+K4&JF&B((F23O P9 -9O>ZWB<T+Z/<F$
MEE88@.Q=!D!HZRB8 =@;8@!8VC?6?Y_DP[>1/^>=R;&FIH09C?>M$:V^^\-=
M6[71^,#0@?5@>U55+8U>CM'X:X=>8$20XZ[\[>6:_8WK,7]9Q;T 3HO=R"N_
MR*:CRK8;U4#EL'E]+GI?;\;(+NZ3V?B=5O0V_?9@V=6_7W(^NQ#&U*6+;\YF
MM3X*.@/SWC6:Q8GZKZ)B8 L.?KIIN#3]074C,;12CKC8&"K<)0P2#B'\6:MS
MT\Q%R)3T5>E&7H2%U.?Q LXG"%D[*@Y7(I!1&\H#)1PTK97*<O5\)*J'?4;*
M3YRN,><V%7U6$W'VZ]=9VKA.OW@@I.I+.D?D_)&&^A@#T**XM77,KB+* * T
M6O=-INHY/J3TF*Q 6M0?6Y)*.)#[%K,*27R**=Q6&5?;OJ_=$>_A\+#9=S-2
M-9E^?#;<M<>@Z)P[ .$ <9+H*0_CY(A6.H0>R#$ @4K30H>J="""$D)J]<ZM
MWE4(M3M*6&,?G\BP6LA:^;)2BP56VYK$SPK,CPI?/A\([(@=F+C9(]"RZ4$>
M^H-/W/U#M)-]9S949PP#=(N,*;:B\TD<O$?,W?O1OO<2XLT V!VW+DGG;*1S
M6HK%'Q#;$4E677/OL.TBZD+0Z ?QYF"! LVD:8&,45Q\9+MXVAW46F*9G'=9
MB#-0+? H7:I8V+8W_X2G$$B0<A,2R@(\J;''C=!&S D=)3$ (PR +H+23R6R
M,Z,1-K\"^K6YZK K0A!,WQ+\O-_#^GTFT4XFXIN67CNZH=B]AIPGG3%(.A2?
M_MRQ6GM!F\41=DI\X&;4C?XRR6=G9JJ>"M9I KF&D^B&B,&>,EIL,5I8\CM:
MJOWRU'%:%;5-/T)@+L3/C[?QN+C9UWJC7Y_+S/8/Y;)BY&>GJ-ZU]&F/9U(A
MA%ZQU<FP+-0/!L!X7@2QQ4IC^>UB3R5]I+4><TC]5R'_#>&03]^.OO2[U%Z]
M%\H/OKW8^U.6=U17%+;G$"=<6IJ><]%(M2_%INQOOHO2Q-$_3V::Z:U;3:5Q
MIMH*HGV<K!:ZUQ72!(J3.E^L%I!(;UWR^BV&M(&\7J6F+6%7Q'[FH\_)' :9
MJ.\-\Y7_K?M7RK;&*M,C]5(F(<WS7F+*)7,XJJ@]HF3,Q'1\[D<AW3&#NL1T
M$*+A= 0>(I5W33>*&^I\'^B;Q;,917U9CUNN5):N'OZ.D;>X4QV7*Y;J=A3J
M6<QR,C?S"6M.I07SJ^Q)1]_:M_A]' [5FIF,LH(^NYWRG6S'EI=FMPU;-;+J
M.)+N6MXOVD17MZ*EGP\T\K4$>=.:1&3U@^MN1,HJ7>\[WO<@JWT1KLFV&MO;
M9FVU-]^8D$<^&/G7J)KO=M#"! C&N/9Q1K6KP/,*U$7)R6R+>8LU^!/5NS0'
M/ZN?M)[";E4%J^0>@OY#C[LNL7[F$^EN\QZ&MB/\DNX7OQR6:W\4$YTJ3Y)G
MR77]G[B^Q<3MI@VGP<C*JZ-61*K&L'>\.7!\JOV:#%R7Q6 2[N"D+O$2EF(N
M95=SY0YJI=?<HNBK2TT=PE7^92-&6JKUX=0C22CF"P_P29B)=O8B<N<=W0E_
M9L<@CX;T/0J=>?F)TPKJ,CYW$&S)W7(X\7/GRG%[,K+7?,Q1._1^_(=)(_Y;
MCCL#USS4J@0I3[D,R9\+6]6.>NEF#H,1RQ']'.M;P/+M3<\?**J+MTKYP/MO
M8([=39FTSP59\3&9SWH_0/51;\Q9D3?W?\9YZ:H?50"0]N)Z:X;TIPS @.[!
MNR.% [MJ&C4DV+N#%-U0_PN'X[,.GPGYB8G.*$KQ)ZJAYO/C4UUD]_LY!8#&
MFO9&9F+;Q6-GJJB%/MHJTX\Y;6\BD-X)&M37(:^84&I?FF( 7.=P&WB%5=6\
M99+9N=1NK5_PT!XIW<L?<R+U5-N75J-OEN:G9PH:J6YGW*_[.^,D:,N1M96)
M_F/<P?O?D,MF $;G1[./4^'^WP28(%\*< QU6 WBJU+)S5YH6XR00]>D7MNX
M\P$_/^K0*9;W;55QY;%3B5A+5NG3CPOY%J-\[(8-54W7.!3"=P0"B\=T'\0>
M)VYEME,CYVG\04P)7*,!WA]8"T*&STO%L(M8':201WI(39O&\?O5FF'SMJX*
M62E^*U28UUZR(WCYKK+7\,_!+H.H<.#4+2?(]H2S>[WJMRBWV9-@J5%GESN:
M2&/ 7TA-*G7W@( 8B=HP.>90@3/7X PM"XVHA 4WGU?W#D8<4'>&T<C=1 1O
M E<FUA8 .EY2-VL^],B*E6SR*"PLZUN^^]&Q0=([XK+DBX>.UL'@DB_NU#J?
M^LUOW*.JV.R!E(.WQ/*%>B4!A^[!!WN-[ -A0Q,=)G- "RJWV6)-8OVX-EN"
M;-Q!?LS)RV9_3&CW"A*<>7X$32:,AAUD;)];C>A39P#PP(;ZT#N%;.<RNT&1
MXL'@'UN"V5<?.G40CT)OY*Q<(7;9ZN6ZKV$3#-^LW:"HP<<>\KI/]L<':1V!
M]A5V=PO04V5H,^!V>*Q$!)8O^?R<EL"[+<$\9?'FP.*-YS*FD8-D2>G4NB_1
M?C>F0T(."DYQ&=?QO+:/;J,1MO8?">CLSYF1V[OGH_;I:"9+$$/QLA+F^>PK
M(8\(3;+DV/HBJH*E4G6*@%FC6!7HI&6?\2G.QQ5F8[HHFMJF?3E^9^W!FA26
M#KV'W[0SVW%8;'\(!KTZGA[0C>DF"SD2U$1^TJEU$Z)G3*UMF^!G/;C^CN$M
MXA6/=+W3:[86LK^^4QY$"3[T90!<SAU,(^;:VN09@/5'CNUK#$ H\8!,V%/8
MHX8B9*T1+0Y,??K#?N+S^)$P#4F/:-,B%]H.(!81/>TM#O-&'6]H"(&BMG%B
M2_.64H)1@F6T6O.\EL._;N9V\,^[M32^GXH',S4_F.N>@=4+&";50>Y[#&^M
M<0+T75T@ZNSD.^FI2ORV^,3O4^5<IL91WE3O%='CA4G$[TFA@Z \)]'_W&@V
M,<K^$PH;C,%/9UK7W\WF]$^=&8HX\MR/-C9K4;EG9HG@CA6,"TF9 1^F(;S&
M%"MO("=LZ$?Q?]S,5F_I?RC LT4Q:X,RN:0$@N"[/D_O/6[Z/82S^(*;:UKG
MYQP&O87,PG,VYE_A_!I8]!JV]\B[WEL?6Y]KIBCWWBP.+S+M;( )ZD17ZT2+
M#7J1:J\:_EWT*+\:MVJ?.6+8:$RGN[O*O>.+_:%DV],08_RW:_[7X)CI!!>S
M\QZ+5W6_:3FDA84_3?]^P*XRN,YMD*_Z1Q.5-)]M/V+ANY.WH#$2<[!%[R4R
M"590!N?;N30U9Q"KDL(<\(%L8O5WXI'.C0>E/,J'S4;>ZLJI;G'AX9=7?MRK
M^<,&\C@_ZU/;G\R^M;Z-6S:QAPFN[C=Q^+/5,IEQ>TC4%VKL(_YR*^IK1S"H
MW(B2=[W1C9EGEUHE_M@*[>,Z3[LRSJR_!HQ;F.A\Q;YZU(1(M?\YQU?I.Q;L
M]4W3('NV:18OSRNPA''P95>W$K.P.V^VORLME'YO]41=M=U?TW%;+TR-V2K=
M@==,(C2NM(4$N_;#+CG>VHZL0 JW-R-\O02J/\Z$[$Z8)^VS]R44Y99TK=XJ
MS?9W7"V($ +^Z2NI*K^V8/U'5Y?]7U^SU5&?8]XIT80=?N5R'M#LF*VS@)S)
M !#FY^M%D39Y07L^BI>[*U<VLL^T/0[V([6F3 LTS @,?9R1)0_3\0A)1=3.
M9^P5@J 96US_(Z-$?$8WTF=QL9??Z8VN)G<WZ4=KTXV"E$?"$;8Y!6J'I0S
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MZ&4AN++M1:9Q-<ZGG"$T3>WR4O*[AM^N@^;_WOQ;!0#P0O2)NNL398H3$F!
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M]A^31^>#TT^P]_5_S3PAQ^/_ U!+ P04    " "4BHM78Z8W^V)G  !I>
M$P   &HR,S(U,3,S,E]B83 Q,"YJ<&?LNG=8DUVT+QAL* KH1U,0^!11 0%I
M08' IP@("$COH%3I4A)** H* @+2FX#4T#L$$@(BO?<2DH "TE(0) D0(#>>
M.>?>.W/.S'/NS)W[S\SF><B3O?/N=ZWU6VO]UMKO2Y^G?P=<UE+75 <PG0(
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MK<B%&GUX!YA QIF^)HIR.U8->VBIJT:Q-5G2 0Y3]?S?]J1>G+[@^]1H_=;
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M.TNBZ9MSLRR7I=O%]X2J8\MV:J\*=/R'O#IVT&O@=]\=X(.1LY!K+J7+,->
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M6L[VOC3WS",$=^GR<X\MJS1(3#R"]WIU:$F;KJL46#,>1F:WV1C_+KP$E6E
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M<J(&:?W&Q\9*&C;Y_#K=1XLX2X/ZZ\S]>3&"-Q$PD%(DKU+NP'R@Y_%\J[G
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M7&>V26XQP\1,8[_5X_$[O_/G>7W^>[\>C_?G^?B\/Y_71SPD'@5^.6]E8P6
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MEO15[:M(KCD-]A2[1$3G.25-$XEX!,P2&</2FFPW)W)"F,C\WA0E2P*@"#M
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MS\<OM\FF;;RV7IZ$:]FW<?.IW'Q._Q=02P,$%     @ E(J+5U@#X-:;"
MIR4  !\   !T;3(S,C4Q,S-D,5]E>#DY+6EN9'!U8F%C8W0N:'1M[5IM;]NV
M%OZN7\$96) ,?G>:+;%KP+&=-5B:!K%WBWX::(FVV4JD2E)Q?'_]/8>49/FM
M2=84UQA6%$XLOIW7YSR'2N?=^/U-U^N\&_8&78_@O\[X>GPS['9J[J?7J;G!
MSN6'P2<R&G^Z&;XM3:4P%Z11CPT9\XAI<LL6Y%Y&5)3=@S(9,<6GI6[GITJ%
M7%(AF+KB(7M;,E&SU7S3:+6"QE_L\?R\PD40)Q/J^Z8Z-U$)1%A-OZ-F_K94
MHW&L:U/XGGU^CG33_3:3^%/5\FTKC>+O?PE?*\V^-FJ)9DJ72*4"JMQE>D14
MS;BX(/52]TA,=-SNU.ZZ7F&"88^F0D,^@TF*S^:F30IK.I?=X>.<3[AQJ\_/
MJYVK#[?CM=5&4:&G4D471$C!2MWKVP&Y^_.2]/K]<:>&\\':E]W-HY]KXX)$
M,'53DW'O\F9(^L.;F]%=KW]]^_O;4KUDO]_U!H/L^XN/7/# S'%J_><2!DYG
M?)]M\L"4X3X-,[,9&9=<;'7&@VQ2NO[\+'YL$SRVHOE_F3L;[%HTHAV=THB'
MRXNGQ-K>:<-#C5;UF)X<GYXXBZ?&'P^V!-S8J4V*D? YT89/EZ\L:'].Q0P6
M<4'NV8QK#!QSI/371+8UZ:-9ITLN9J3G^S(1!D:KFVK Q[WU1\TZOOOJ\?3]
MVXWG3#&RH)I0XEN546,S9T1M:PW@P&(&'\(00(F0^X3FVGM!HM >;FTLP4#P
M+89395 EERR4"\*U'>8",Y :+@6!V Q9 "Y09+(DUX9%Y)3(*;F"&4[7WRI_
ME,EBSOVYE9,+/TP"6)+*>96(()?03Y0"Z3PG (']U_8A"$\!Y(N9V[4C!@NX
MX6 P*@(R?$Q-T)=1Q+5&^8Z/P@#W'@W[1\K^=H+;CE@,HDZ82B.Y62;->K-5
M_1<W?@QNN,"HUAO_0L7_"RI T\YU%P#;[7O/--C4)3'D:Q$;''0 L 0;, %&
M\*9<19W:]0^LLM^_W8>M!#]S^5TF P R;@QSCX]H%+?)6"8^H ED8PX7 SLR
MSB"C[#G<>YZ-"-K(0B*N&K,O(24?I0H#\H[1T,Q]JASND6.<D![I@# ]#_9'
M]\#N0<(@>P'?X#^D-(^I88&W$L4'N;2&251QC8?;6@#+D]"@8RG!>1;9D3M1
MWWI\PLR",9$*UZ<Q-S0D[ZF@,Q:A?C<W?8NI=*("0:Z%7R7;5OVU[#FKHAJ]
M).#&02_8E^'9^/A24A7@E[&"[&7@Q:+2=G0%S-.\)!"@J4H^@ %R5Z0)J5:!
M^X/@^E7*<EI$-2J5JH"%9ZOD3;F@PN=@?6W M6A\<*#VT'4BR*/(+"2)I,;
M\]$_4ZX!WLF24:4)!D*PZ9Q6W<9\TVZS>ZQ! AX D3;$!TTI%S;, B@>&OP7
M<P$V]D  "O.T'U)06:$^Z5 9EBJR0 :B(8-RC;\F@-=3#B+!<"0#]SO$)<1Q
M @&K\"BLVF5";=!H7\8,)Q=R* 8V M$.;<G!>GFP8DQK+OVFKX[W.<M[REDG
M=A!/T\D$VK $]P9#@FQ12M1@5,ED-M\+?\;Q1?P0,DM"<"Z=*>9B+TU&[QA9
M5LK1(D8%:@JNMX6\53]%XM\X.>8/:3F!(2B>2>@*R@BX6B:L8B%"%D@*E36Q
M\*,A# *F-CE<SM]ZOH6NQGGKM.PAGD7.:$7D*$[. .0DQ[45C(B@F'Y4+,&+
M@$\VCG>&&\9AK! G?71]GI]>GI\N&Z1.E M:C&'<(P]C0"Z? 9]F&?%=LW"9
M\*E-.D R&2+$05Y8MX+Q]#1%Z!5LP"8R@>(QIP\,^#;TWH&7J00K(_H%C3P%
MGV(QR/9*)I\9F'&E+#Y=DP,)#S=Z!53.;#L!J8C,"$DVWVU 'VQV]D(M2=[4
M0.NB(8S2/-F3",X2=!(RPAY>G@S?G0O%F#XY6,..LT"80VIBD>;!JDR[Y@R:
M41DOLZB!@&$SB39;)8[VG-IY8[#=[$%*8O&3V/7A8B@4>>?W9W54_;OM'TU%
M5PBA&MF4F5.3*S!-E.!ZGB62U315*F0VF6@0@ )ZE;BPNTT6E'(Q9QA;**U-
M-;T2NI!/$0T8-LSY"5QX-DCWVZ-*>KE5-SF1$ZQ, AM=>YK;,O;O  <4R*XM
MQ^N7.6?5!NCCI-C3?Q]H2-K/2KWZAHNT7^26I,,P/LM;GTF:GT,QRV@NV%+
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MR?^Q7*39)A]BRT,OR V%+N= J,D/(PJI26KXUU;VCZ_P#[3^!U!+ P04
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M/H!7E>8IS5,+AQ)?);[%IQ K>-A: 7@=*NS=3OG9KP_ 2VF-TAJE-57;8BF
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M-[/^]<(J$QO;S$Q"-!7X66UF9VP90HOQJ%E!@J'YH.A;LD5H.[PK]6%JX6M
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M8IE+XRZ;PO9<K3,*QL>T''034K'CILUF:1=)XT&AS/!X-$>)="1D;VJ.,?G
MAV6%?'HO?B6>TQFG%J8/9B61 853!E(E.0I"/@1A!^\-__(QHX024A:SAR@
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MFW@]%?,NX<P *6'V$2,@<WJ9YE#:+1/:F&Q!2A IK<"_!XD,40>R#-V!17"
M*Y&STJA7JW/(F:&87,&(]!A,%I$K:%;XU(],-SLVH.U/T+@&X /_ 3Z']]JF
MBWB1 <\A<D030.P"V74 +&X[$?MD6H[K1$.B?(>U^" " P >+14UVGTU%O !
MR#<,#=N!;2#P'TC7P_(9 ._?3"SP.$7?$9^BXDC6#G "-!>A  ,7Q*G6ZSBA
M!9,;<C, RP6UV*S!0%^50JWVIL" 9B!A%C0-*^[YN+)Q@/.6JFA*^1,U<6]L
M@U!ZL-U9/6(IEQ1(0E/V%M6=#RH'1HK/.< 6I$9@[:<??Z>->H.)]4-)Z?N>
M \VG8Q#/2PX%YD!A\;I<$[HU,]I_$FMC%RFW)^,'PG<<X@F:O&A8C@S6 @GK
MV6&6I!Y@,1;=<_>.@S[RHEXX-C/0GT[?<4U" 0/8Z4$YXJ)(F<E.$W@0%!BJ
M89 0D"X8(M$O$2^?E4I,/RZES# NYG>F&T\J L'+4KR7EZ6Z7JLU9LE2,TPZ
MLEQ?D+(=AV!6A"&*T)45^<A21BUAJ2C19? IJ%%@/N10W#1@6B9#Z 24)80;
MF%8DMH]T9>$9%Z@H.8#FY <@<B8H1MAC$'MGT4F&!NPM?T!M@]^GBVWY(:JG
M1$I@=.8#@I&9&YPVVFL[V" HXI#D+>U."-\06,[+ QR$L8S QSN!@F 0 (!P
M$'JAHL]9P)'J')L!T!-%V_-BTW7^1J^!&3I"8XZS'>FE(PE&V%<D&!DEK FZ
MFC#GT;L",O5CCQ#_H?"TA:PY'B%."=PF%K:BT4(E^R[IK3O3G63"( ;D!82Z
M[_D$H;#YHX3ZB&$ -0.EC\87#KC$YAT@IIWH:KU1+K*F%8E9T%,X6M"=B%A@
M!4A< N[TVP QQ'12$"JY3XR8&H09DR9,R3WVIH8"BYC 'BF/CN^Z0H$%G'@"
M'Q1& 9AN)].-P!1\H8IH(\PRM& )^@B0/LI%PA0C(T!RD6!^L5"2%*F@)&K1
MZ8OFB3WO46O32[BE!1E6A<\'IH,?DOA/_F^A_CF8 S-Z'NNDS065+#\>"$=7
M9@T*[*-$!NE&-29,&2 0<)?X;ZQQ)&@8M__$44@,.;[H9L+-VHH]9$$^2=6M
M4*0DA)E'.XB $BJ-C>&(H9<%-C;>7T'Q5HM&K5&::]B8_0%:AX!X0?I#D#\P
M2*7, F.$P+2HKE),(5P3R%^=.(HS]E<!I6EL1BA/T$K/Z?:$40+\3IC&1$*@
MJH?N[CVQ.8X& K" N !XPH2-U)9@6A ;+/4H<&!OHU$@>0.)L1'(1B.])[:P
MT<:+2%:,CW ,C#_@,'XO&64"07&8N//(4<+PAP,??D8.@IW*F^0U&GJRI,G@
M,Y8$NEE=CHB)AU;@#%*R63R@S7Q<K]$V,K852%M"H#/BKLP;__6/NJ$;/Z>(
M/E6YX5K-B4I9+]5G[=F7?H2J+T6KH 7ERM%$-4+R1&Z JK1CAXDZD>#(\83A
M"GM5ZF_ Y>[Y+G <46K,6S)W]+!37J+/S+&89_;1F<.=DR;0PD9Z?'+-KG1V
M/40WZ!P\_0.=<WJQJ$?^R+U'4T]F7BR7&N5RI5+Z [[YT %#EE/OHZX^/-[]
M.6#O:'C*4:^Z%X O'W[EPY6'4?Y#AV&,W)5SQS)[(6$92Z5RK5Z;9\@@[,)%
M'$!C'(5H' L#$X7"8T!; 4S)EL8-<;X QDLR%XZI7 1SM3)C3-<\R M'@0U[
M)*#=*32JP1[H6K%0ML XI",2$"TP7?H.,A5^''* WD[DH.=$& F(H&$7=GS8
MGMTXI%W?)R>,1$XHCJ0,7,=LH]7E$+(3^X\7DZ4#/= N+$F4,>&6EC<#* (+
M7IY!DH^\ZW@>SC %LT_879G5 ]P#9I8#1(&A11)+T%J: &8E"7^]_O:9??UZ
M70"-P>\<'^@A\,SD@R90&WUXJ)% B/D QT![7Y><8N1':L.N#PJ _/TXZHX3
M++]UE8RZ7J_JLUCD#)U)<D="Q1]P01CX9"!W<G0VP0(C('1\F[@'T04!;+GO
MHPZR8$.[XYG]#)ZGXQ P3!_3.9\0,2&($5)O\<Y)BWN.'[12/FL*1/Z-?%:_
M(3\"9W_WG.AI3?!''*)7_XRWHPL/=KP8%ZWYX(1_9,\MOOJFE_@#\,UOQ 12
MB^ 1PQ\C75YN%%$'_*$;H$QB& 3U_;UU]@<,Z@_2L4#GT#GQ'/>7(^B1'WU(
M%$TRUP\O2  ])8"Q,@&,10A@["@!BBD!])4)H"]"@-)N$D!OI 0HKDR XB($
M*.\H >H) ?3&J@30&XL0H+*C!*BE!*BO3(#Z(@2H[B@!JBD!:BL3H+8( 6H[
M2H!*2H#JR@2H+D* ^EH(, ^Y5(J5BE%NS#M-% :JY4N/'1WW"Q\<?(FS&7GY
M\9AF-M3->/@(O9*[)74$(Y9]^D@DP;+C[X6T@!G K$F+(#ULF1JGEAPL@ST=
MNY$S<(<X1FC^)QW/.9;&?I5B%?;SRBPL#+9GUJ^4' P)C#\Q\A3J9= ITD(B
M5+1EYB+UX]&Q/Y-1  $GX&OQ\ -[CX%$)R&%" $3,0HL.L'HCU^.0@>-_R/Y
M62] 'LMR;#[!>86'T#XZSO:8Z2+M5$9J2;ZC\*,3*3I$MYFVY ?IE)//<S))
M94^9S]&W$CD=!XP'F@N?&75T>O'KT9@%.OGRAU&[QV,=CH]"@/'I48!A$D0
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M(:1G5N_C>^ML7@=.Z)<-O78"CSRK_3^ 5'_07(X^R*]MYPZX<Z)??.<2>"K
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M-;^^/\:F/[QO!^QX?=VPRQC=="<,]J%*OEBI%5^@G_.'@0/\?)+.J<4'D7!
MEHH: QFHO$2O8>3T,2D_,T4M(]:.@:D]U@/!"MF !^EX8' #$&/.:H5Z,I)%
MF H$4S [_$2Q0?D93,A84<I8<9JET,.(WN(Y\]6-Y2;\_?+B]OR,M6Z;M^<M
M0<G6^>GWFXO;B_-6KGEYQL[_??JE>?GYG)U>??MVT6I=7%V*YWXW08=YW<B'
M1L\*IP58DTJYD9)B,&MB>F7UF94G9M8,'-/5V!?NWG$4,'PS"GRO^^'3U<TW
M4K:@U,COYUCD>9Q0LD6P0< V!'O),]&/;G/GY,RWR(=].QQP4%O"W0O:=_95
MQZ,/E_G3U@VIVE%?,'DYD">((37&3-7Q%#7TY=8Y(<WI^<WMQ:>+\[-<ZTOS
MYOS+U=>S\QMV<WY]=7/+KC[!;Y\O6K?G-^=G8I&_-2^;G\^_G5_>LHO+W\Y;
MM_0KL,)U\Q(X9,&9)BN.W#E+1\Z?9G&Y:8XJ(#*9YCG7M"+6<6![\DAKL3I>
MB"T52[7%AKP&1GUJ:19@5!@O&-I91CVG<X\;WG5@!4PONH1O%F%8LQW87NYW
M/W!M$!W3C7J6&7"&M?YFL/&*:_H4A99<U;?G#R:L(DX^YW= \R:39F;(0LSS
MW7% 93L>LWIF #V_&Q_ZYN')#*YY$@L8H_0>T-$3_+@VVB8[4THOMGYHM HU
M]$9Q&^2 ;HM,U+U@K2C@/-)8*W8B#KM;44O'<]US7$#6[J#GF+M'NTIM*Z0K
MZ<72TL08P:&E38 YF\DK%;*5R+$E*7O;M&W SR$#;3X(',]R!J;+^ .WXLBY
MX^F _$[' 7/VW0Y2KE;:"N'^QQG G&R^/$E>V.Y8<B)X^.][[!,/ C-PM!S!
M$G;A605- ,_'%?&8 H:_F@SOUY5V![$@'&.F9^?,$:>#.0F0I>,'^-0=,/:[
M'4'-(Q3YSS 7<9</>KZ7 &8-<)7EQB@R#)"B2>QWPO1\O5C,5PPC7RE7*SLR
M$8SK0DIWG!#$-C?D9L"X9Y^,.0]V;*P!'_B@9KQN3H0<G; K*_)QJ#JY.0P6
M^0L8LU6]5#9JXS9"8LQ>4\/G(NYM 2,!>;1O1K\<.0_1B0WOY/OP2@\;SMOF
M,(]TS7,/I#@A:T[Z9$J/V!!,.!?9^UXP4L5=GF\#4_W(FQV0OQ/3O3>'X<\]
M[G1[T4EI\# MHR//V9N?VZ;UHQOX8+OD0>OYP4DW,(='H#T6]EPNH0$?7?TE
M_4R).7YQ>_Z-Z86<,,!;[/:*M6ZO3G\5=GFKL*@GH?[DL)T^B*\+:_JG43(J
M>JED_&&V8=D+?PZZL#4&UIQOCK>Q=E/S,R:D<LZ$K&+1F#VAT3?'<XFX>">E
MN9V4)CK9+!?JU=78\!&G 'M[^^7W=TOZ>98>]Y)>RV3<;S^!HN*!.\S=\A^N
MR6;.8-'!5PI5C%C=\!2:GA?#5G5#N\#42!]S;2_;XY0#O32MG-?%L?/)5'\&
MAQ8LOS]S,?=I9ZDNRUB36\NTWUN YSD^O4DJ;5XI30*C^8[[,X2A3CO& U*&
M=4:MX<G4@J_<2^ZV)W5:SPR9TQ^X'-$1'O8P8#W@&)O9TR-@;R-X[YI^?\>B
MGAF!S>IC3&](8)ZPD3L<>S5D\)3) L1X(5@P[2'#1C[Z9F"C"_,VB,.(\[#
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M 3D/< 7L4AR[!5%&<?90MYJA[\$LAJA1><@YS<AR BONX]U$V'YRI);[:+C
MY $3C#,*\F'"%5F.VYHXIK$FDDMP4##HP E_A(!L<)Y2^O 89GWXGC5# 990
M]C/B;4GH0&04GX< .!GPN1,-88\$_.A$#EJ=(R489K==R:\X@__Z1]W0C9^)
MZ_TP=-ITIU7NG/AAX$C$,-5\ @XLV$1 J.YXD .M%1 C ?7%YB2<P$)[ +<4
M<%*F1.1B?"#6,<DDD"DSRW&():XJBAX[;HS0!KB#J$,X6$RHRSW<P-UA3F@;
M^A &'/E"O0],/ !#E5%@J&2%F+@HZ@))XR18.@G<RJ8G@.Q(QVA"/8#N\/N.
M!3CY'A0)S0$&2%!(#""/0I6+ K)YA,![DN]!HH)X('20G._W0JM DDC6[Z2*
M 35PA?+&.J:8E-2HP.; A:G2E3,WD=3WH$(Q["_"9W.BWS[,$XF<]DJKC%/$
M<Q+)7TCUR >;04(K^4='?H\, &_C"V0TDA#8,:HL1*#-U$B!_K*C):5DLBXJ
M(I@(F*T8"^,CW8"L,--!#%N(A6>EI) %S6"X*.;=E/D%0Q38F8//(<-$P\$\
M1D5>%-N]TT'.@E_Q+ MW&3Q=,>](]0$O"?[ST0H4H!>[A+$E!,TN./RTG8QN
MSNZZV&I,-NY(1MDL$47XU!NY.$:D15*A")(["5:XS2."/,09I#)-N71SN^WX
M5ASBZ'UBF90^V=XE1I:+T@Y\C*_.BB$IKL*^'GN\@'/J=^X*ZP!X"/U4^^&1
M.D-SJ#5"5-KCNVGCY49R3EC$N0-F)\4K N!0)^?:@&T].ESVTD-#HY:8-$1M
MC<[4<3L#@RY I9ME5M.^<T(.RGUT_ Y*,(S[W$[BFY,-+C$8A:.,WD;I@49S
M'7+",^&"/Y7H[%OZG,:^?CT5@[?SJ%A(Y$YDGQE_Y46B3-C;6\?Z@1'F7_[[
MRSMR[9"77W8QZY4D@N"KT^&L99%I'<YN\>MTBW/>TJ;'>#5 8P@O[Z,ZD <D
MLNG;+__]3LO-'^R,=\E=,=][FVW[]^EASWSG"=SW@IQZ>^]G0;"$IV)3(]<:
M$/1? *T#  X? ;MS86+\:H*MC=;09Y]'?VO"C/[3!\ZF_;DC^1;=/.A,0T-T
MO&TFVX:=6[PLK!_Q^J33$]8_*RZE1%JF'T7FRSZJI\_BJ&<\#^M/7\%:C4ED
M)7F/MDQN6KU<8I])'Q6>R,-/%"IT&@F6 #P!CP$=I*R&(W'%[1-%.24$+GXK
MX@-T>WYT EMC-Z@KSIQOB. \7V.G!?8[@$''[(-H]C"L W?T6]^VV0UW(DD]
MX3,*0-E =Z<]TTF=!N2Z?LJM\X+,]1WI0AZK1 LFVB\W4_MYG.S<C.\WH_<B
M#F1(%1S O=G:+>6MA!W%*53J8Y/X6JQ>#)C51^21'"6@^]Q"#SM!C01Z.\%(
M1C(C\LG6 "TO'8\1&MY=U!,2HH884$3CAH%]]$$_>7GA!<PZ,@*_ Q0!C&6Z
M88X\%8F)3N]G'^TY0$A_T!M*O#AP_>'<AP,?G=H)]@D%C]@9 MUS($34 U#2
M%18&^MM"N;'DG%#@WHYTRP5=Q'<36X(D',A2U_7;:)70R.!=L(N !Z0+*K7(
M1XXS81'A&J*N /,*H?KV6+5)VN!?,<QXY&"\3QDC1T;33]6BP=HHD03E<=L%
M<P7U1IOW3+>#36!V(B<B?X:TG@(>@>),IBB,'C270+@1\L+'=URL$E)"T!$(
MXT<898D.%\Q8(]8Q=R^<$ )[2K$"^F9(F/J$+!B1R\GS#'\.T3Z!+EO"Y4:>
M8A-5!I@9?\5HUM-Y5.IP"[A%9CAYL7"N8U)&#I>.T.!R!<FF$U'^'*TTX@[@
M01OL6'AJX'(3C4'?^R=P(P\!;T0T=!1$-([BD.CA^OX/Y(I[T%QDS6#4'3 .
M'NALC3E&Y_YH5XDY(0M$?BZ!QXL$*[S@"']/1!]IUN/N(,L2.1(_3O9K@7U#
M*]9/8<U0?C+P(TS+A>Y'^EO8K+0F9*5.G81$#CH/K< ''8,:^P=" Q0(Z!9_
M)MY0,NE9Z.=2%D\X5?@(!E$<C"NN9"1X(AAP%#P'MM+ H5.?C^CXZ[<=\N#-
M,EE! ,GK)I0WMWH>F%M=H9? 9 %=Q3%J#Z^@D.XF,4_8#@B#IU+0-<I70LO4
M8F:>>>=T$Y]=)Z:AR_-/*]DJ1OZ,K@\J77J#@/_)T);R393*2>V98-:5U28[
MG4#J0KC)7VW2V^B6%.&@J)[[N/KH#T=G$9YM8V,=)^@#?DFV: &9[D<J2KA1
MG&!J-/ %DHDV(I_U>7I*#!3[)VSJ'# (^\T!F:=^$JC.3LE(QG> .(&7(_^*
M4$&"'C@ ? /9(4#'L",<VWI5J)M)^R1E1QA8X'"P@-#CEN7)O37R7U"K92QF
M6!L11@K:;?M*K1D2?](B2G -HM]W1/3!5$C#/6D19!'<W>#K.V*Y$=Z18/2>
MM]'KA*D7J=G>7ST,4M*RG[@3GT2]O_ 3(1*C#^_QPT+N"\<#1>P551H>TJ2G
MD>@5A'&"3, (_XKIIIM+*@PG809#;3PD 3O(>KN<T8((@11^+C(TP<;']'B@
M@[:W-9ZFV_?)"X49/CT&=.\;U9^%BCEAF%HSE+DUTQ"T8^[EX_#8XIU$-0GI
MW?J@S_L #D]2I5BX27)-_+]T[#_G_.V/\Q3V^,D;!+FWD8]G%0'G6=?^NP79
M<6G'Y4*GRK!+PP9F@4BZPR<\@$^3;4XL<7EN+''YB8#E%SS".^T%:*/"V]=.
M!*K%%I&HUV \4 [9 PJ^?.KFS],>[J_BJ &#F#*;R./'F<O>%W ^Y-Y^]\S8
M!CV-$<W.C)L5NP@,)OWHX?8<Z5^RQT;"8T.PO(TG.6"^@.DJ@;T\(7,(.XOC
MT,1W(4P#&<XAOR*STZ%P-]2W=Z LF.=[>6L(F-JBT)P.!B'<B?,JWT.<K:5'
MB4"</MC3,9V1TD'LP!SB);&X+8]BQX(;"UF'+]@$OKR?!9/I@7BY>/3M^7<T
MD%'X!,60TA!&S<*F_P,@N>-G+!LRK !YY"1PP%'2<3690'Y E^QAOH$9IA$P
MA+5'<QP_1A:40I>'*5QEH0@OX6BAI*?FF2,]\9Y&_LX<'<9J!(62 <T]V*/#
M.-G[Q'&D*>V\-/0#(;Y)J,E-;$N ^[..*G>!73&T$;^'M06#1A*"V[G)6<O0
M+4/$ E.P"07"XN(':- '%"/9)]]X/P8K$SD&B/E7[%@_W#0&*.#"CR[T-??H
M-,@2CD76$8Z]JW0@B"US][!< XQ2Z%,LBQWSA#M&C.$1OJ035>H[L^8CGH1V
MKL<D0JS/-^E4/371[]#R 0P'2:2:)H-K,&* 8JO(T =K#GD/CY-E8,<8J?"Y
M.73-C*S KJ75(#T.V4DSG#0PDA^W05&X0^GLPDB-G%07S0MV9 7FW_R(H3_:
M(=]'ZA_5*,S@?L)SA_8]V)?DE" G8$>@.'%8Q$+7OQ?.8]&?#- :6V-4"1A9
MQ+7<B)5EE"+*DCC!IU7(T!W5@#Q^@6&@DXU.'= >[\04]SU&0=.^0RJ@%&U/
M2BYP>3-."!BDYT>"DCGR1)@B3D%XGE-O@_2W .$R;!CP/NEQ8:R2ORK9*<1&
MD75>X,JC_4617KSO T89 (&3X 9_(&-RT?EM8B@&\!+W08%CQA+4..0[\[+]
MF]*]V@7JTFY98$T*R!3Z'.,J?#HAP+1NT'_;OT<FGW3]DL=V7-]16 GH"XH/
MH4,+_=W8W,@W%>,1D[BN''M]&$2?/$BN\+O0)C2 )L7V9;P#>MDQB %"0ADR
M)X-/'D0 "5*<CC3PFK]\D8Z=2O@NN64SLT_]/%L\P23=AQ+2IN@\N=?(G5<(
MM=BVO*QGVP;2N_X@>VP4^GD+?>8V^_SU.J\+GY&04Y!,(#NS@[@;RO,_BO-'
M?8E..@ @)G0LG9Y^&QW< #AN2+%@#%&.!D%WL4>NN2B(*:P3A1-#"(%U1O*)
M+-O4+;%S^Z[TQI%KTT4G%ZZLZ!48&-F0CG-(I?L=/Y[QM.-16OL8SYG:9A11
M7+0<ZVA4!'+(ZY;&NVMIO.H J8?&!' PGCVF(9@,OX?>-/9GC"H(MIQ[<9X$
M@N1KB9:\YQSW+%L<!P*&0XJ*$#5-!*;1Z^0]P5,#\K7SL9G >AC%-W28Z-M#
M^940.J)QNFIBL7I"0#->990<'#%MIC(:*)>XNR]D@%88 6SG&%#8I7,O'#\@
M>Z</ZVEZW(]EV&)F9-J(3W _-@=)B*J\S0 \&M@.:(60HO.DW]BC V6/=YRH
MD$//.U)!2P/%9HU#!IQ1:H(P$P:;F:.,.*/;0'C6!)P7F$,9%(R;3)A-$8 [
M&@9ANTX?315TK?EMK PB8EA"E_,!,P<>-P'6]4#/8NA:Y@%0F[!B&%,N6V=O
M3Z^NS]X1"+2XF.KI92OM7*#8IOLWH)4^#_XI%+",L,7C+CQ:P8"PN#](X_=H
M'Y,W+S <,PU/%"XQCL[H5'D*"18L\%9LHG3O** ?XJ8)1LEC^*XG;[M0M(V,
MQ<2]J>.[CI\S91PPVA,BQ@RMO'<"!PB'>(;NM*^A-@:Z(.8!./<[@FB1#@.&
M:[K#,!*'_\ 7=( \.LA G2?/M:<XF:)?'RR9E^(G,+H_0@>FR^D:&;W@HDZ3
M0HD4!DFCRV>SY,+L^_+@N.\#7P&NP*81,[P5]W&Z,:'"] F>Q#2]RXD6T"V+
M!\@8,#K3L$TW@24L=_0S/&)CL^N6-+.G[.[T2N75S=<S]N6\^?7VRVGSYCSW
MZ?OE&?M?UKR\_-[\FJ3-T\=&O ]ND!?8.EM\8"+T=(?D/4]!F A5(EAN HZ)
M089M&>49C5W" $O5I%@S)SWNR\9BI *5/8ZRP'"18;R9!#*@IT <^@[:V>Q[
MX=>"O"XU=DY&L D!T0_!T@[%_CI>7OX#^8F$"I@&6"+ZBJ:4V-QHV'.4W&E$
M,SZ[X<\4#I5<9Q-FB+!M1E,DIZ,DD,4'8A27(J*%O!#B$$N,@X)"DLLZ&*A"
M1W-)I(H3TF$<FQF"(<*^42)QP\__\/Q[;RHLX^WI^:=WC&)E9%@XG7Q0[!EY
M*WP\#4--#,JJCR8.O) \/[:L1$F$ I;<?)*@&,R2XV2O98B9B:,6J7)'RQ[P
M/*8BH=M58MGIP7?)T:>DA8@Z[=$J ]),HDZR@QN/G\"#VUPF7@"^_8&T%'<*
MTE/$!;#V.#.G8=W1O8\GNIQ61.+P$(3/Z8 (>9$[3';O7/8T"H $05*\ET<'
M0WCBC!$A;G*E05BS1)NVCV.5Z!H'G[EI*.S'00# S>5=GH1$\!'C+8B\]?6K
MCX^<6/#93O;5'9481NZRFP*[ZH<@4M+C_9MC\5SJ]B827B?;N71*!#NQ81EL
MB2WK$#:L91/D/I(N&+7<.;I<$'>%N05O)"WOPG_,@_]X@B=9B*58Q$)2(L&3
MQ3LGH_O15VG\(!@OUWC?$Z\AW0*Y/KJ^]6.1I$^).\!N1M!YIM]RL=&HE8\8
M#T&M(4<',3_*9)/?0O14.MULF.:"40;&^/#F#F<R4\GL>_#3MTG34$[R<*..
MY3]R27*'3)Z#Z8N_&!7,+4>@CEG1)1/)M6:>^PAY+-??_-QQ?3,2F0S%U/.1
M/Q!4EG\'0J[?;"W?![!4X PR.V=N*POY: C^T>V7WX_>"8 H@KXHW7!N$B?A
MM4]Y*1_X O7 ?P! @+6&U\#.'V3X8YSF^X@HM!^CQ0L4,BY"<"GB"/H )G Y
M VUZ3Q<:[81SQJX:49#P,)=>ILS&T,UQKR,&2"*;1A?7P%9S4S84QCB&@M"X
MY(W)D4^X+%PFS>_?Z(K60UX$4"57L7)D<Z)7AH 3=HZN68<R?.9E;.<=Q^.W
M[=]1S628N$XCHK>B2#(C:8HX_^0$!=E02V"GN W\0@$R3X]4AG"(O*+BO\WN
MI N<S K3]E/!QKL*B2\YB>,5<>XB$::XOI?XMD:*$8.=P1:3ON=9]_YVB YC
MUWOPKB3YQ2F0Q<,]'S2!.'X35U!)$:0:GPM;"AT@[G"')C7BREPFSI=A#\(7
MBC&H/.O_RQXG:]DURW[LXH6K,+EP15:H9 ^;$T/L$ ENLQY?M ]EJ*J(J*7+
MKD-QIT,<CB<W4LD4<^@*O(P^G<<1PJ$MV!IV=HSW=?Y&8GH^.N%2PDWP^WIV
M_^+CN_^<JC;KT+VTO5[=H0K@]W0N=)HF3PGI)&)]N0%,,L,;QZ7BL3&1)GAC
MU0%POU@YIWN],FU>_<.R..]TUI&(^FG)D+F8K_'F^_LP'GQ MR?\6"@1==+A
M_"DLF;R;]MXQ8LXFWE2'0;?]UBB6-6:4ZO"?2N7=,VB2</)/"S+JXBU*>_ 3
M67)X0V@ZX^^HE*HP")-B[!1M1<LTP^J3MAYJ<?IPO!@WPU1)G)C<AFVI#];P
M+T?&>#Y@+^[G;3_*RP>./NAZH68DIDDRX!DU<-;!&DM7"WBFS&U&M"Z;OY%$
M&4M(U L)S!X+@RP /"X,ESQJHMO_-]RR@=$EGV]*+DJKR\4VV7[+6\TUGB/$
M_>.W9S*#TF+5#@Y\D\DO)@;E8D.O9)V$7Q%C1I*F"45O_4OS#A@<O:B+. =3
MP4C?D2*1-[(R47Y<)NBT ]XY^E L%!M/R\9S2?9&[4*+$ZTI*QZ6BNP,+)K?
M?#?N\SW?B_22KI4KAE*Z"X 0 />T589*V;X$B"F7:YJNU[2J459::1FS4P1'
M+,&:NZN.UL]5E>KR7/6*E=Q7+C>YJSA*KK$K=?<2C EP5"L6Z9]2=TN<!&&.
M:9:RZ0UZF,DW4)KR#8R&LW^*T- +>G6+</\5JT"146Y[2F]ERC4:JU)N#0Q[
M^^7W6:?":Z+=8>JRR^9O; ENVS SO3S/_!N8YM_+<<V.ZJ6527%*N4G$):1,
M5==%REL]W?C5 %.6T-5&+&RX5G1QV-JLBN>@>N6@--K*1/DDBH4F)/\/%4+Q
MQUCJ>7QZ-EX_@LN$",M@E-U";]LZX:G42J5&UK4MBN>=X4U$[MG7YK"_K#O[
M^><\(Y\V5H59]WG/_%K-Y37%P#P=MCQ^VN]0,I);F8E55%C"9/AXG8,N:LRH
M0H#7\<;#([F,ARQ,!$*_8+#/@A,UQB<*S)$7Q7=LW\6KEFGYA5%H'C -7L.4
M15GH8FR2295J!F5*-E"65)Y-*>]X=-$GO22(^2WQ(K8WE'<$1690BJG#Q #,
M==*K)5J2'5:4:L8>Q/TA07=_Y.38/3J7QNE,B0T'XG )+5^82G(ORI2NOWW)
M>9,HM2^^:].%^PRS+'JY8'FBOH4-R\0HY;0VF$<E+9!VD]<-UA0ZMEC@^'..
MI"C?8M-U?4NFP)@?QO7T*&8DX&J;Q6)M9@*NS#?'\QEN[>%VSZ=92R0E.DLB
MU5^0<O6YE*L_2;F-7 *J+2U%=&'2!DG*C5< DM'[E$O(-K&V(XB9$TZJU?VX
ML#Q>^'<3][_&.& +2GOQRV!?Y3715'FWA[F+,(QA=]W"O;"G;QVL7*%^/@G>
MGC_(A&(MK.R4O^5!/S<*! ]?NAKX\@04&=?3NHZY48'K26IN+-@766[<H!6=
MHG' Y>]Y89&=A(#[L&"G9_OW2"2\8+N4_6L8SS& T[LPQ.8O!E!2"YM*J.D_
M,[%3C:W1FDSA=1)?JKG'R%^KKH'Z;S+^,:#C<K7@%^\F/4=?WBI=UJ53?(Y+
M!UAZ>8?DXCKN7W[/"WTOPY.E^L],?OIBBCYE_8D4=XO(P#/=E_K3R_.HA^V1
MQ7ANOQFV((S\Z$#*:SD_^_F^!]MM'A4]!Z5P'YB#9S!5K=#([#)K(<33\E':
M/3J\688*2_'5IE7/&C2,N.(E;A.GZ_$9)CH0-=E>7LF(OBEE)KL6=RN#4&BZ
M=$ M>0'S^;OP<Q7,QO7(%M5%;0OJ8J^TPL'BCG/729?AJX,I? 3R./4WH! 4
MZC@DU%$ME!3J4*ACTKR+ O-_N,<M,UV.@6NQYMG-3NH7A2G6(P1EA2E>+::X
M[L#S@98NQ6:L"P4F#@E,E ME!284F)@(>N[QH.^G*_')"3$>A>JD1WBRO"E'
MQEAY]G0XMSX03YI/RHVQ#96Q#?MCKS3#P4*.&]_J\70AY%DY:W[>63M#08\=
MAA[*CZ&@QX2"N?3O1L#CT@]L)_S!FL>MG54P"E6L2QL4%:IXI:CB&P^L'Q,A
M&:=^85-FAH(5AP0K2EOQB.X>'12LR!Z/M+'1T0FLV?8#,_(#D5EW@_$8YW_%
MCB@8.!&/$0\&KJ,<&9O5%%4%.5XIY "%\)O#-WUV\C&;)%WAC#W'&=O0'KM'
M!X4SLFJEW^7>SFL5!2#6I0*V<7BZ5Y)^L #BS/3,'@_2I3CU@\$&9/V;+)=R
M)LJE4(&1,\?L>CY5SE"88L\QQ3:<H+M'!X4IQD+'^1V60!\=NY(_0=TF>>W@
M0QV8O%;PT3(]OS.Z4+*K9Z,*:>PLTC *%84T%-(85RL?P8C(W(T?!7QNT;I)
M1[.DE:-@QKH4A8(9KQ5F?(DQ%=^FW9F/&!Q+&1H*?>PL^M!5X@R%/J;0ASG,
M^%.;GW?2I%&P8I\UP%X)^L'"BM/6UU$D5F3OX@FIP@X[C!WJ"CLH[#"N4K[Z
MWM^CQ!>4;6LC"&+LAJJZF;IU4*&28:P$*N97FYB<@$P)K=<Q4W/2U&8S[-8F
ME^L%$^SJU<8:4KR>7GV_O+WYS\B5>?';^4WKXM/%:?/VXNKR61E?ETZ2S&8F
M25Y3 MXUKHW*O[N[A&^LG?"RW._N$7^C8 C4S8M6B7QZ3Q'92UDK,B,>+K._
M*$MIYRR$:KU@*%/I14VEPV7HZ@XR=$7=[3PHVY_0]<9W-?;VWHEZ6.0'BZ1%
M\"SC#_GOA18+^!WW8OYN$>HJFWU-\04-9;0O9;3O/;-5M\ALZL;.<LSVRJR?
M%NP,?_/ -3U;V3Y[;?O4U.U<9?H<D.E353?#E.6SNN7S*XS8]OO*L-F@LT+9
M-<JNV1#QRUNYS;._O/;*S)HS[D&;/Y1)L]<FC2K5H$R:0S)I2NH*JC)I5J#7
MIP"S82A39I.2JBMXJ4R9 TY,L+^\]LI,F<\\Z)O>4)DR>VW*J#L\RI0Y)%-&
M5Z:Y,F56H%<SQK+-KF,J:^;0-Y^]DLG#XK4M6C/;V1CVE]=>F37S+Q->5+;,
MGMLRZDZ"LF64+:/X^77;,I<\ZHG0Z87NC1X4PMRJ-:/\Y<J:V12O;>,^\?[R
MVBNS9BX"KF[.[+T]4U1G,\J>.2![IJAN@BE[9@5ZG?8<3YW+;%10%;I4EHSB
MM5WDM==FR82!R5UER.RY(:.RGRE#YI ,F6U$X>\>'90ALZ0A8WJFK2R9C4JJ
MJIFF+!G%:[O(:^\G<MZ_/[:=N[',]U.IL.<.5R\-'AY+QLZN6S(?^U2"]J,/
M96:V ]MCOU_=?#UC7\Z;7V^_G#9OSG.?OE^>L?]ES<O+[\VO[.;\^NKF-COK
M7C!:S"[/MP-N_LB;'1CHB>G>F\,P2=*/HYO.ZRUWGV+QS?2FV W,X1$[1G(
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M6.F)YF9++JFW#)E,XF0I+N-"%7#4!!:RT>C]<?'M@MX+4(T@(L96@'>.X-$
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MPZ2],/!!)CF>SK VF,"@!K#DHB8JW]*YKZ@L3Z*$-K>%5;#!FA]B6Z 4>3@
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M'"^4A5!.??(.U*1W0#?HYNARW@&%@W<7!Y>,ND+!"@6O@9'TAM;0U7W1_<'
M@1-&OIO_-L0*)ZV_8J?=3M1]>91\RP!$W%!P>#N&95DY@P\?$.N:4:UKY>I&
MSLX4)%YB94Y_:Z5E3OQ@@,E4"G5Y ZAH'!OUXY*ND/"!(&%,^JJPL,+":]'H
M]6I-*U=4-,3>H.&S+^P\QEI1:?:LBPO6,@,7X; QNO^!IX *#F]%JAKUC1W8
M*3"\K46NE1I:47F'=PX*G[N<BEDG!;W3"(E*$AU<(MVH\/"AX.&-WL-0>/B0
M\;"A51J&5JLMEEU.X>$=P,/GW\ZR>;FS*!@U?>/8J*398Z<RQRI0O#'1*JN
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M^>P2H(P3_F#-XQ;J>>7TV&P855DK5937XZ"]'GI-J];*6D.O*L^'\GSL@\=
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MDOY&Q^-%.QZ%]"?19+QJ_H(=#X4J&L[_0,>C>(/E.IZ57#2WK8 MUEVM7O1
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M$0N <6[]@-@\N^!/8SY\B),*U>V!Y0[,$=[>B-U:,S=:6-)O;T?./5<AJ__
M<N&?I06;R6+-%--LMRD;SI4%/]V6\7QY[^<>Z9Z?7WZ]ZO;_>='_1/J7P]Z
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M,IFR(*YMH&3FN0Z@!O#WO=GD!EZ'KQ!_ @PQB\9^P.M?*4FI?!.0M[NOUIK
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MU&:W[R[G>'W [%G@1(^PO%'LJYR(.W) C&MV^_O).?\F^!9)CGS^G5)'E4[
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MHTM4+RK(TOP:!XRY[\I*__$W4Y&57X^0D8XTPMW[,65>R$)>Z&?[GL?$P#]
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M7 9WEN?\FY?->"W07V0 #W-NX2.@.KIS37SE@VIV6+BV,][/-V(6OY%$9OS
M'<'+EAN-;5!@PFBU3E/S]9HX(9B<KU886O9X%K((;-<-U]Q"!0:S,"*W?C !
M=>Y[\+; 'A.='ZFL$TZ%G%6";P,MR;_X8C[-FAL#RWL$"D6\P9W<T21BA<+(
M@5T(@8!LU+)=/V2C-[P)'C 42&DR"#O[%CO^EC,R3);-7X&_V'Q9H)O%J81\
MA?\Y\UC"=+)^1GYS?KRS?7XR,_$>XHQ^/_G(&5)69/A'UJ1.IZV=D.1-;-2-
MEMZ@JAU)3L[A/3R_E5C]W/+\F_]E=@0;XL0$&0L9^T[L61#DYGES8KG #V^
M6!-B6U,G AFTIF!S0!KYVG*[B[\[)-/  3Z!XX57"/O73 1JX>\C=A.U<I=N
M@+(I)H"_PJ?N0;3)M[/!F7C!\[TWXI>8COP3-\QUV'V,.')0)G=RW=&] R)-
M2<Q'%YY]1DXM\:Q+._(Y&E+:M,5)]9J<PC/]@.\]][<$*0W9=]<BY\F.OV8'
M3 $.G<-'ES@F>2[Q8UY*?GTMA@6, 4R0,"=X4U!K<'"6VP(FA97Z]^Q-"CA
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M0$<!T;) 5R:79$$NSTAW(?X?XRGA"GN/\Z!Q\E3.H'%V(H[3K'YRS?,FH"A
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MG\FYD*M<F$5P(W]^^GU"@?$7D@M9:V,R>>#.=YW@. %UQ?JM&-JVN"\2P6[
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M?R>O++!=$$>#P;D<Q7Y*XJYR%2?>S6YO$T9?IO"\#"4Q=,R[=T"A"'O1RLN
M4(_\Y.FR['%G('G%N@=_1G )]^+_?_;>_*EQ)%L8_5U_10:W^QN8$"Y)WJOO
M5#P74-4U30$7J.XW\>+%A&REL:9DR:T%RAWWC__.R4QMMC&VD2W99$1W ;:4
MR\FSYUG,&?PKGX/>,3S/B),;WP/5>EP^&P4I_]6$164\M3%Z*(DOEB.S2Y],
M9X$*,>%[88P8V^ZD))27R]$$/]"YDQ0Y'V I^O,LKMLA^XO=!QZ8> (S6.R'
M"0*3GC(&RIDT$8HV=S0WF*.YD7% AR/FE&1+QGY"Z28-=8:2EFR2LZ=T"TJ1
M6UUY7W5.M<\NAO4_"KE#G?5_&F'@88[^N1K)KFD\IG<Q#RJ[^J+BWHQ?X@%#
M"9^H<-$)TF2Q0#-!'&(/*&LSG[(63RR<B$U8GMOG/$KX$0(WF+T_4I+[(X3)
MW+62D1$#EFTQ#2]K#X Z*0 0NWT6DT1%X@\Z,OY@PYA!:C&#Y!YOI"O JUDP
M78;>A-X7>LK&J@?R/Q@DEIU<(YBY]N;7,?$]#CR5:E#X%_/V9?0WY=E[F@6J
M''[L9ANCYX2\BHY+=A/$HJHP0D#%N*KX8.)[<Q^U/CM@NC;7?%'EYS$/7/<K
MT07]3%\\-75<X"4,["H)_>/;\ ([8X#P\&BQG8S^%"0.)=29'UR;&]4^8^D.
MBR%+K6; F:$ '4XAXAA9&'VV@^ /D]WQXD!"\9S#G3OJ/Z)8X%),""^&:& G
M<Z9;OMJ5-5PK0+]9#SI8-P$CC9RFJLR90L(),Q,U4R-W&.(Y8V5A]"WE%_2,
M@%$WA_,98Y0PXPR"7/C1,T+'%^-KW#'3FT%E]Q7FF/K<Z]TPU FH^!PO&I)F
MBP0C/CW?%('!@ (@=! /L\^R@<0=*>SE">\_61!OUHNBSI@5]#0.TF'?*G,Q
M-OF-JZ#Q@XG_2),(HOFKY)GYYB(J'V8BL=09V.(^%.11S"H+L_<4,#2HDBP"
M'E0W! <.D43,"R6+^2Y9],0LAV-N:NX(AL?Q775!S#+J8J>A=\IU,E41\5CY
M."T1T"6NJ#WO.U.%X;33(XDO[<;4?Z ^NKC8W65R1<71:(R1:L*U&+L[8U-K
MP*.]N+1@44U*AI\+0";VV)!SHO1TN<6]&!-KI!<NXI2I-N8GRP4,/_[)Z*CU
M3DLUFHT3?D2PNF@L)%A.K."Z$ ,SY\:CA#IJMVZH6E?'#<$4J7. #9!SS7$S
ME+L4^;> 7-S /?ZIV6BJG7K[!,7QQ+0Y 7*@L0--G"B"6>+YO,L?3LDA7K@8
M=MF7WF^@[%(2F+ 3Q9LV%K8=6^GX&KN;?K8#[!-&1*.OC+5E+;4;:ZV]=M*X
MT&*;QKP2^U^# :7#X8YZ@8O[_VQ8* N'0&5!^)PW*K7]_+;63(==!N!E6: <
MPH9>!(#72?Q<H:_W1BF?KX-#LU$].+0,36UHAMINK-?B_%F(+"6USA( K(B2
M?*05!UJ[L*OQ2DZR&X;!N[XB>XC<1!"BOXL.>,_O]0JAK\D,EL%H%6:P9S3_
MNNTVURE\7>QV&VVU:33A_\UJ<\WM>SEEKTO Y=)IR1)_(0%;=$,"+ES<OY;"
MJR?FCLNA_>H!0M=TM=[LJ"VC63A$7B:\96*[)("L5Y)):A]'V.UEF>Z1-\;7
M,US>C"I2$C\J;;_-NMJIUU6MVRZ#Z^P7<WG3FM&E&8I[\[S7U:)#ZONF4[(C
M1&I&!ZL9&6JGU53;#4WJ13O3BYXO.[;%PD&9%#GD*W'6.(MMGKD<\OS<]?;"
MD!.2"SG!(),*>,1;L^BXQ39S>FL=/>H5]:X6WOX2=B6#=T3O-^P#N%0$;!6T
M*W1.:[=W"UM$Y"([S[U!^!G;ZSA7L-AI%:*/O$+(7,<ZGK@V/K;C<G:9E"!Q
MUYJL!V]\7UE(N1SU3^]63\R7HOUIU8/#:PK!KN4IW_45F$3KMXS6NJ'6M;9J
M=%N'A]D[%Y8[\H D^4_9>+(BF@ 73O=OC+Q+VRY8F-VFKM9U?0=4_*J+7(EU
MAX-U>D=MMPS5*.JF<'M8]];,IMLD;OJ,BPAI#>TSA5</#H:A:O6&VN[6#T]M
ME)C]IC%;5XU60ZT;NU"E2C.(Q+W*GA2]RD<>[T-JZA9NI9** MDZ4F=F,%(^
MX452-9+<6)G+7,\:GM>OS*V:L%7'::WB%>'=M>)J "(#*?=RCY?\Q+NT2]OL
MVTY::#13GYE76:8LE9*5(9G/ "\_2Y'5J(G+?+N\0PDP$>H.["ID':=58,0Y
M>/Z#Z8J4,]-1+&_ >^JHO-+!<&@/,'41MY)461"U2K(E/>.&%W'.JS-SC%C"
MT&6=.7R;-ZJ(DE(B$^IC8B.K<\ _LGW%BN(BPO%B:Z27U QVIFJ,3RZ^BH5_
M(S]@[_>QH#H-@DRB&>,2 :\ME=8&X[E?@<A]Y25V6(EBS-#%/6+"'FQ&F2G\
MB 5"HX &N4S<L?F#E95)6CTDQ6AR]<B0."+WNXMDA 68L;(%3P86W6+BSBLP
MASW.K*5/%9;'%P,ZK56!3[#ZD5C88(KYAP.6G 8 ^]5[HH]8'ZMOBCI5:8W)
M+'A8?<E@KJRF*+'CT[$7KEK_88ND=>FA .)MILJGI$SM,INA"982_$DWFJJF
M:?B_X@ :LCQ7. L[TTSJH^DR$%]YCR:Y&WBA;?)J3Y?BA3/VPHG(Y(73L7V>
M<?M/TXWPYLQHQ352GLU'3ZLG8CZZY9N <!9B'2Q1BY>8UJS+3QTG$;,:X:QV
M"$=N7HM3D&]2 L5*ZW/P;$CL&,0+CUP/0@^7I:L*"Y*(*VPD&VG/)87BG(,1
M'%^FUAT156M9C2)8I59K-W\F$R="F-]=?[H%UH#M#I@\81_SL@D.?<2B8NP)
M?+>&,LMGJ;G)"N;KFMNK+*"[V0(2EH'E#%BWFG@JWO:)BPXL<QEGBULFX!_P
M#-Z#R'0R;)+,8-C<(G7M9W(\845MW6A\4B,W@OGGCUM94!.1AU@ ;4030))X
M23@HUBP7:V/U^F=7(=:8J2?>IZP>'T]NIM9S6-#(5#SG#?0")H06=QT0J)FM
MY1M7D\ZO9R+VC.[UI'Q&LF-^(D],N\13X$UOE.3@&3#CY%CQ;0[[L2HT$<WO
MDB6(K&!&7BD-\$ A8*K/9=4V:^WVSSR5.4.EF#.?:7C ZP>%+'QI8/K^5 "7
M]^99B!=8%0DHF#6+0H@.33LN(\0E0S01)YK);'=-)HB\;+%A3!5."GKE8!2?
M\LQXHNH0@SU?>3I0I@W?+*N,NP?&]<AXJXU+UCK+B/7/S"Y&-AR,/QA-R?$=
MX.D5R"M2/\GIB*0Z.B+O,@.H<A=-L'YR7'^C OKA.2S,-V,7(W"U1SOP0">Z
MO#Q3COF7<35"FN&8\88"L2&A5 6B;H5+>4W21 3"'CTF1N*:N=F*5)FZH(P)
MB369C 6!.F:ZC)^E':F2XJF".0USQ)KV.N&L=%$;LZ^B$*,P1":9<I1A4L=Z
MP?Y2SEF-ZE!U35:'VHPFCXT3[E7A_Z:-H!1! [PPRC4KC=L#LP@L'.3 GV@5
MR#8A&'887''!6OYDT3Z2BM!<ZYS__"0E5/8EEA:YF2&)G#2='V)6D<B,I9A)
M85$DZ*S2PCI+<-IFB@(,K]< I69)>E5"KLT2]IB:;I"J+HKH-9(9 ^N#1KFZ
M7%E3-M/IB(FMC.RO0/N/_.$G4D69/?#-SWG!\?K4'O?1]LX=,J^1(IP!";>,
MNW"QY<UT#@ PQNZ@ #3(N!!17/Z+6?:\@4LP4\SF#*3_$(L#3^"H4#N^YEZ+
M&IFI',BCN)5GK*4@64,@! M?Z4^8(:"U>!,?G\XYM#A+&,#&'I $8)V)L\->
M6B9>54+O@;*W14&G(/+9!G JCFJ9H;A1SPO;F"D#8OV(63.$B[EG9^58B@C8
M3Y1B2=P@/B4EF8H'5V/=[&GN2''S6"AS$)]A1OXCK\%J9CS8?6@&(U;"*%.1
M<[;H+;:LC;U+&?I3GD:>F F,H]DG$C1%+8\]<1?U UZSF5RPXN9,]VM5@!H!
MF8)<@PNL!_8%,'"":,BZ( I0"#1!)QCOARL:'/@J:\7J6@PIAG&IX+1U5KY_
M!@S_T<-"4]SOB,8D#(\&INT#T@6L)A,L3^&E,#W*&[],F*<K,XYE^Z"O\=XQ
M+QT76>FX2M>XC^LYZ?X)(*+\SL3'5VJBNZXB#1(2Y(F8KY07X#L%\O:5U,1A
M;7EM#^W@O[@2#F(LPG+HK!R:S[+F!)=%Y)I$Z,YE_@/ -)2: E_H8.3:0#N\
MXC<'1,8VY'IXNH34RE)8X2(<%\U[F!L@PP2VP&1>-[#O>Z;%^QT#XG'C32=)
MM/>?D1?&S:EYB75FX0J3423BL(:8 U8<,LDNCL<RE&0L,4BF8![OJAFW,'_@
MWEO6VQ>ED2A<R79PG/98R"^)-5@2W<\STZLSAJ^J"*L57:<JH>&@=L)!9V>(
M'<?$*8!'63 NNG1C ]S]SA0)3MPS_0)8S7)@K?S4D(W:8GW(4"F(/(_9_[Q1
M*&C;#_"2PGS"46BC%H5@C=+2W/G2>;R/PBF:-0ZZ\1/DX+7KWR5]Q7/CBP0J
MCF*B9^DT:^[S=GH,?EC9,,CWCIO[S,\9^GDKGRRR\F,,J),7,2!S]DKD+CW]
M[*T(<\\G1,4;.?"1XR<SZ\J7\3J)RRR*&;PL]*:,#AEH\-V9?E!Q XJX$#UJ
MN:R9GA5?/<0%N]%+#POT!EP)$/H#KH%WK(&GL&Y[OE?2G,A4JB$R/RUI#JKD
M/=K<XYCQ=B$Z#U'DQ+6N8\Q@EXF"Y[ FT[K:UG6UH>LQ<29>1>;F%@,A!B:M
MT)*VDI.H[]@#8'M#7AL_=H'Q\T]<G,(]D&H[V:+;U? 0K'-)7]?WSD.P)9G,
M,SL9::%8YA)O&C<UXR*.2]AGRR8"0G%LR;"9K% K*6FT$0>W& )R6TP:[;9V
M$RH9:WUQ6$%(F*ZWFU31 @&Z0JICMY!4Q]5!*CCJ=K-%=PS"9AD@?$7":/5
MV%FGVDIA(-QRSO*.L7#'(+SW> CY=I*6]6ZQX?>-;B'5,@J VY7GPO0N6RR*
M:-2=%SL.7I0L:\7F[S;=85>2^A/S=U8PS\U8IZ[: 41MKZ-&[&D2]BO+E>X
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M9K.E&LV=E)&MF"TMO6+RD*573'K%]HJ2=\FPI5]LC8.Y>[+#O[@.([UC>VY
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MB<DP,S^;,--< '<0N9D/%E9(CJ]/:W>PQ(^^^9?M<,$'2[/$_;*@8+P=RX6
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MYIOEUN9<,)MN3+E/FU2+('+*0\CGP\>7!8YCXD:25L23^M)41$P&YAMEF9T
M"![//=,;6)GI#0QPF$XP9ITA,D:'B]=R#:OCQ6<RQP<>?H(YI#08^/8D@?\
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ME(_PVF<NQ.O2,]VX?CF^&4=NY>]*\*D$2$FY<XX*RZK];P<U]C] \F5T*2-
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MVC*FZ*!BBEHRIF@%5UAG,U=8,W&%M386+*TU76$M&5-4-8UJ3V**.AOXK0K
MZX/Q6[WM.S\94R2/N")\K"A_3\',;;_]/3*FJ$HJQ9[$%'5>X8LIE_H6U(R&
M%<F8(AE3M)J?I+/O,47O0K/OT ^*,@?KQ@RL9VS[5P#Z6#\A]R-*S""@(2P9
M]FD^4.*CJ%: .DD(7R*QIQ:O'1  Q"!RS)!:I#\EEOUH(]2("T.P@0(R<:*
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M#UB],6?>L:^F@FC4KAE:&5Z<ZH%B(W6M*KA518"6XQ"J'ASTAF35$JOWJ]G
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MP^C,PP- P"D ."KL^_^;<*GQSA)BX_]',D L K"LMMM&NV&T7BV.$ !<',V
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M R"$D\_<O_>Z6&E5JS-^+U^41\63((5!'&.KV?I<I7SE#4?=QO+H)Q?N*'
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M@5*GAMX\=.+<<-4NP!5Q_XVZ(Z'\\7RA:6;^4WM@>\4.5CEM4-?CLL9XL-)
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MP$.-1IP,-U!U8\[0L%M"[DK,,S:+&")],M98 K,SI3#Q:MH@4I@:<T:H0_J
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M&0\Y6MS=_FR'?+2.WZ;^17B1SI G5O,*CK$4EG-G#>I0H<U (D<A]-XP\FO
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MXG>G0:J$\2&*9]O:A_OMH[K.HU(ED9].T*&HJ8XQ^#:*'!>$4W:4_J)X]Y2
M6'M4YX(W>/M-2+"<5C$2='+Z2Q%RYYPIKJZH_2'993[J!E8JY,8_T#%C?QR>
M:K98B4IL&5ERX;(R)AW%)<X<>Z_4OAKD[&+\N6H)W*$3=@E1.?^60VLE\1+
M!9U&$3F!_07G#*H \77"4V*0,@LY:+*&Z5L<5<UH-2-/:H241]G(6\B'IUF=
M+#M%4=G#>_*CZYTJ2/9MCU1_#?B"1BBAMV^K-NPK3B=*6EZ(KU1_!-F%DJIB
M6H,P86(Z]T]]%P=7*NKQ=K0< \^F1QE(:>EA[&3H+,(AM-6.G[&@-<*52I &
M<-8)N(P>,//3F1???92!KU'>;TX.$W,ZM)&P:=M5J%=-NH2K)6+_%.MT2/[(
M[T=$2F?=]UXN+CC_<,U#13GQ4B'':BL3L8A?9 -NNCEX8B#BG\L%\^>?4YWK
MKG2U3GJ<;H$5L51$!(G5!\S$U0NRHJMYV'8!%VVRV'7:KR:*D%Q2\AZ@-?6^
MU4@E9A_0;?0U!-Z6C1R.$G&:);^0 %;:T\Y;"YV&L3->GYSQG:,%=3')6N>$
M"%%;Y*@AY_T?!#F^$ZK)V7<+<C"&L07D.#DZ.CVY#\C!&,9FD./H\/CX?%=4
MDRU&WR5U86:#:5(%N=E2\K6)A864A*3%2*11\T72%U%=V7#95F7K.V=%-(O/
MH]6K1_ZO%K9FHV]A>K%'+SK4#>/7)Z>0IFWE]V80'(3W?K!#Z32*L7LO"P*L
MMO@U)*U\?*]Y2RU=CZURGVL"P& 61FZ$:@I?B(8K)TPY3CW(?L4\W3Z,T NM
M*;5YD,JDI<X63K+K@C0/-774*<662_7!8^/!,";1=<9W][+>AC$/[#"7)H.B
M[I&/GS]3/( $+26GZC'KRH1L5)IG AF$<SF4>4!;<Y0\!U=4LW)6N\IP/8V(
ML)QR<;)#RQGU@+4Y5B[WO2R:IL*_NZQ-B!VQTF\Q_NO*8$<AM O+%(EC::>Q
M%*&G);<V],Y@4(N0EN1P0D-7D(#(Q/T,3#%DG-<\U*>V:=$B/)K8(MF:[$S3
M].L>R@VRART :"\ST-Y!]D?3[)F<&MK6'?Q \^DJ;$8M&^=$\=72TR91)_07
MAY\/0N\,HIF=MK8SNC<WGUXM.,D^3=M.AXZ,@P8CQ+)(IP%A(U4J(0HOH#KB
MK87?$@2@MA!=_K'R[R)ZL3= G*2M<:&)T=@T:>Q'/J*(XN]&-JU<7L]I5AL(
MOJL64E, ,*52)ZX[Q->-7GMH"LE\'E(;ECA(7LAJ3J=:CDK64K*TB,*+2Z@R
M-WH$T<OIPT?_,3>"=&X S$TAVS21WZ[&8]GO5IW,'&C<ZEC!'*%.] ]_YJ8'
M(1)'Z R@"/_S4&5F(?:\!\%'Q%T<9$&PM=@"Q;R"GZ8H?!?$Z8-H8BGZ^(YZ
MVOQ55*2!RA0"Q2#C1J^(7T$"@A7S9.GB)<<'+=/S4V0I',2RI(V//%DN1I?T
MQ%!8;(JFY=%OYMQV[S-Y423P@2W'K0H99!AKDK<BXA!-H*AQ(T11&EWR'J1W
M'8$=P4_J>$6[!UF?M1U';Q _P]Y*\<+-^1E+;+E,1=;U]#.TYJ9$#P'+7$%B
MI;"+S)G8] EY@!\&"1]#DPA9\RBE J! C(<P=LGV=<5R-C8V%P\:12N&S3/V
MU_"K=]V)HIF0[80C:KH[F)I7@E4[F()]<4)&&O3Y9\%2!::JTK+ ')DP<S(.
MZ,"9B<-I=B4P$^E,JHA@T'KN-2'68?-J >Q%7#="*0=181;6H[P':QWH3XD,
M270C:NP%:=//28HG04=R8.3,&P5?1$!L>K=L3*D; %LZ$;FLYC11TM#>Z/V)
MB!_+'PH3&+H)3CCI$T";!@21)T6K'7[%9<AWA4ULNK1!KX/4QUGM,+)<_=16
MJ@-P&47/_'4FD?/O" +L4'V^,Q+(R]\%"83ACVWXR/GAZ_LHZMP.?[QZO-.(
M>Y'?^+UUS:KC<DI#:\'BY).*,-5>_G=3FDN3#2UIX<W'BI8,W<Y<F>P:C$XP
MTO&\<4E_E 362,_((JC')4X;]3K/.@]$<F$%]"[5+8I)934T3-P6KL7.O0?H
M?F7T"PF$(]J@!-4!:,"<&_TH3*D\PM")'$:->%,"=I_Z$ \-RJWT_)L!YV$[
MG4:)H,D%.K%M9YD,D(.>6Y0NI2]E_UXL!#";D2;C?Y8=#S@":$E*M#.DP32T
M68@T&UB"H6(@@N\XAB*)P%R:<W_F3J8TI3^1<';;:W_V?V)B2ULL_",T$@E)
M'W&:,J(WWA3<ZJL3P089BA!I2\Z ,A@A $L['>MO-%W*B9Z%L%QOKE%!!)C"
M6X*"O!>2F'0_).=?J$4P=6)R:Y/R[D"8YGS7T[1:#NJT"( F$L-+[O!I,T6.
MR3H(I::P:G/^7H)$^$5!,P_\J<L"V)CD[SA/P5^"*"!#36$JP+J/34F(*]:J
M(@XYJI?U9U7 (75(W9?2VV= ^E/8,S+) 81$Y F*;)"1]W>KN.18G6>9_W1W
M^P=2HQI]JJKI4F%+@F*F57M=)M)K[=KOKYFV35\4ETE?($-]0[@,=,<%0?'8
MSSP&.#Z:]?;L$C7-@I:5^Z$$("S97!$#P!TZ"\NB_?0T8D#9"%IN&,! 1@WA
M#J,1B]\*PQ"JOANQW9"?,?&#<9F-TQIN$S3UA\!9<XBCL4TX]\F5#X-Z0"WH
M5\?'K\Y?/9)" S7,?2,N^9WT&8Z.ST]/7S\9?08T_-4'>&BE9Z<WB#VE;9@;
M,N%U$WA )D,O F1KC:P$KL\M+UYK]_)(:I5%F,< "!&=F-]('^"L-0Q%"+0[
M91^=GT@G )8T_B&>$*#-:I 6'S:G@U@?<<(S$;IK9U3!>\D9.T*H- :.\\!W
MBP%?=!C84L5.QI/>+-/5O*G$OO-#(&2_#?10^<"%#T2MP39P9AB'O)3^*Q33
MT//8!V]J^D9H@?EJ+BXCU=+/7<+RE"GNOLQ4;L)4GP6.G_ >%=\-++- +9JB
MC44LT8C5J(D*([1_@QF2LGU_#M4W"42Q1Y;#CWZO6RXO-+I.:>FF:50@#G-)
M$0:W)'=FUI9=K0 QMN%0&J*:&7 F*6;)_;>ER(\<X1E%)=S3O-&*6?^MY4W)
MLZHN=_^R\:[JY?<7(58H8B_!%^V!S)Z^7N66^0FY"[M^TS6V:MI5 IY9Y(?5
M*S^7 ^NF3Y%+5A&K*@9OVG469G"4@R:SM'T-_U)YA1S2<1DK3*<5.E% HIK_
MMU9).?]^H1D@+UN@F=.3D^-[-!57+V!7Y3>(LN,2UMH["E,<J/K5W.ZE ,.F
M61,C%=RI7:<MRC78%-"1TGF*L=JF2SU;#[[R3LF=J27*_8DUK3Z5KGLBMWF<
M.<A&L#1\Z-4MW'[Z7&L1J2_D'^@0@PH&:QEP=3#J]*AN'XT%?=A-)FBJ^%'L
M,YD[3<^CM4&1%G2"A4P0!RIJ"".^]&>@$';-5:E5+=U37[1:;]O,DL9M@U[+
M<2!0QAD0:)E6I8/)ROZ:0-[K2*9(GP>.D&GBRSEKIL58>CIE%)>P0FF#*#=>
M-<*=X;49<^QZ*2DLEQJ<T+2L83,?JF[LH'"1IISHP8RJ=MMJ(# TPT.[SD-K
MNE\*XN6W+-M!K8Y7[0KQ[0U)\;;^P"C&]NQ5L?^E95O<,'&:NB[RN"Y7:],)
M3;[KAK]+/A 2_"(9RE,?\C_<^!0ANJQF<>X&CD@)U>-#H 5O"A_D)L4.6@U)
MITKY3I+P]\%EU#7AHG<LE;Y'H0@(?8J)!+@B8M#>M?/'DTG : &7B^!8R$;1
M_5G7: 9Y&0-#,$8HO.C"CNR&'2F]>>ALF=Y3) F2O+OR=HCKNK$)'H^$>0_@
M1&,$.@O/4>;,%NA%F&IJ6D?XB&09[6H9>F_LSF+V;_P?*(=(S<-1+\#9K"!4
M/"Z73:4-V2(_EZ-XNS4%'4QU:"-Q8E;\M0ZPFBW2ZNN'1-F3RY*/"#$\P/:E
M]$<<R2N:$Q@E._=*3ZIGB<V)%5I\#5LA8L(]P>P/'#.?\=7NXUC\;N"A'A*U
M>'5R]OHQ4(L?2S J2"SL;HC%Z>OCDR>B*&G&_N!@Q89"M7&X969UKV(-0*W8
MM.S.7/\"AHW^3?8QQ:XWQ2(I(I#U+<LOIZ9*Y9><3V[:F$N47U% GIOZ+ 8]
MU6G"15\DM^;[1.)??) V-KO)2):>BXD'GS/ =>R3 [((Y0RR\@<,C< 9;1FB
M- -?T&D@4G$^VIW6J.O@ DR /3<-"SL\EZC]A0*%;@27,CYBT44B<0#/6>V(
M2R LBR ?N/1BM;SW%5WD)11B.PO8X;(14:NA.RG:B8> QLQM@R$W3BK5.OP'
M;H4$?I3Y)(+F9 ?[W91B<^./!'/PG>+4 Z^G5\-FEZ^V+$,S3*F[ )]'?NO]
MBUFUFK4.B9]967"QCG0F2^NRB0QAEXT$%TEA;&%.@%#97V<GA__<@3]^%O[K
M!=@:0GUVZ1/9T$:6;^QBQ>LQPFW)VY'K\!ED*!M&HHA*@71,\G7"(>3X=,@,
MHS. LD[6S/8G&E_:PTG]9UM.LUDM:BUTE'!06^)@[, FR(JK37):%,;8SPA.
M@'&86_^C(<0NX!FWC':+PIOCP]U_6K9FMN."-]DX(L80(V]6,K04:2[V!>@*
M9'THQH 8:[5#R1+RC>.N+<">E^0\$]RS-)<#L%8VE$B31Q/ES?A]_;R%;='!
MLT<R%>:!9BE[X%U\G\[60O@U1Z954<9T"+);97/!T1<<$OZ>3.GWAAR]?/6[
M(/4P,+0%.3H[.3Z\1Q_RX(UM=M?.SEX=OMQ5H_*PGS584P3!@<=AF8J=PE/=
MB,.+/R%C]QUO0T6U/:79G BMU9H!<+YGBC9@=U+"'K P9W0Z"7T4DQ,376"&
M"116-G@_J BYK@EEHY^5DE0A>V$H"CQ/3KV < PO.[;3STNUO$7[30N'@@J.
M')/=(QYBLCP$XPZB+K4+JP]7>*T6-+XC/H_I@=*#.'68_;G\X[#W+-DO#2-S
MU>A#KP#X7WZ\T[4+"2E^Y7EXSX&[*?H$1!3PJ[N,]!%A*LSY$9Z$,MZ%.MVH
M:/WUXQOF#PABN"_:L_;%S$PZWH!D1>"W&(2,KC<G680(-5JGWLJ^=74M#&D*
M*Z@[I$2/$_#&-&$<T4K9-&P2RV/O1+O[A$(/$P+5!)GR4>J7 ?H[3=<!\[1"
M -#FY80MO$GIXM-JD8K >D%/=%&.5.@FT*-5W5$JAXU#T^;#LFNQ.DQ@+)&J
M0J90"X>"1(Q4E8"=H@3A+IV&I2GP8'#VV=U(1$#AZ<OXZ14&2"G^*L#--"T=
M27 I3(/R'WT]60&;(UMNUQF[=$42/[]S@4XXNI,1B11FUN= U8VFVDT7.9M*
M9=1)94;\&U,@3@MJ_LS6'B/H$.4V/ %9%SD(Z%<N;I>A1&=''23X:QLNK@E/
M$P.RZ7M.1-#Y^H6_,/*RE ,1(8[P?&Y@X^AFF=3-AGOF7:+Y4FORA&H.]Y<M
MW#:2>"X[P#&V51!'RX\4,QOZ5,?VCUK(@-PDI>@AZBF[M]<XHZ\MJ6\N9'+I
MAL&C!F4_J-9#Q'U$*?0E6E_"48Y%!\%NH3R/EQ4"M0D?D.:7E>9^HS(USW _
M*BE8/-ZEOV[K<('0^3%\KL&I86-*))0$232\I$VOKAI++0X$8%&&( 0>T9P)
MT\PR[D@Z#:V#9[V)9',=O8XV-=0!1P[$*X<W%<K4Z Y=MO,&KP<3CPTV6BKT
M0F?6:!F,,=XG231?<4=,97UTE(^-I\9I$]/*0(JFFPA]\5=Z_,DMUNV2@MX&
M"ZS6]+QYH6J .EI((C?XB=PO\VUK/HHO?D;]CS4E.N_5O8N\RE($RE"9L<F/
M?-8J(:1E22=O4 STI&UMN,!^&5_SEB<7XIU4<$Y6M#XB&7N+.4VD9-BY=#:+
MJ^:!UMM*GBB8#*B,2T+IUKMAA\T*2O!Q_HDE_IBE"GMBZ^ OUS%UL*DPZ!F)
MU"W93(MY7_;KWV@Y) L1[^\F].*[YCI^:[Z\JS+&E/J[N>2))R77_&Y\S!WV
MQ!WPTZ(*L9F2*%)OM?<^BUFF.D^_43_#*JY+=/.(/%J-3G-Y*?-6B^7R2.H?
M,D389*1-Y+_IHM(1W;';+))/IU!YF)RK]M(U!V01\!IJ"'NGQ(U[@L51]V+@
MO/YN<12&23;C*/[3PY?W$8\Q,,DWQ$?$N6RZ]4 V9N;T8W2)-:)5^JDM4F=S
MEQAG37&&C1':_-HRK%!B.A@?<MX\M:*P\@1IX!GX&(.* 70RZ5L?WKYA['9<
MHV<J*8-:#4[3N+:P75"L=""$K->1PFXFQEEWM!N1=N0^6<W"Q$DP("@J[YJ'
M E(T3$,)G-H\BZTD\%.<'6W)0GP$VTR:8E;>U,TG-'%!M*J,6):VZ31:_\"2
M!]G1*WT%1Z]/#[,+(?9VQD\&RY!<!L7^Q12Z();? 5],ZB^)):)%32]D\G'*
M;C&)%/BDJX[[* (,P:"ZCA)IVI(@ST+W#W2P"IJS+%G?!IBJ(R:&6\0Q"M>S
MZPTKR3,]6K\V^WYR=GQT]HU:V]),M;\"J?L@,W!K4O[XZ/STY>E 4O[V2L]O
MV_O6+ 5^Q$R?\2';0%*08UP#:[.*T77E3:;;M%[0GIM0(T!A42Q(C$9TE>-Z
MC:*GRQ[$JC0TE">)>R3A=I@9QWT=.G",3=W'G*Z6K_J5,!<3$KI"#(.\'0''
M91R.50"0_A7^V9QEG77RS#HF=10EV$XY,7>ADAL"([QS)N-?52!%QXEP(%.&
ME\83''<V]Z&LT#*^@(F53%O.T'T!N/\&W+2V#*-/HMF07R!P\%,EN?B_KL97
M7"1))Q^XV@580]ZAF0.C&"<\2RV"F)OU :6:6:D*0Z8B7R""R]([VB2,";D:
MCHU)R^OS;B.""U&NIDQB(]GPF 5WFJN5CF,ALSJLZ:VE(%<UA>V]?.TS IHG
MXC"D@I6<>)Y4BG:(4Z/ G-8/)OG4,!@,4F]E<_A<X\@[.23LA;804!EB*7PJ
MTV0V+G*Y(@AFB0A4G2NG4$A[C8VPO"YO3]I+OT6HYH1IDMRM8$R1?]!RF(58
M2*R,X;! I"*>_9?>KPN3%J27+;^ &XBU2;^$C4W89$P)T\:VSA49'5.Z9]":
M+N$F"[72\EC*3BZ_2&)^63<O\E!F"_^2"C37(>^>LG&&T_J=SFU* ^'4&3J#
M#8]W$\W=EG-4H3]F6$@=AD!* KE< P>'J^DP@O++J"S';;+P!/<,$L]*9IBN
MVEMOP9!>=&91LB2X8>E?\5(Z&X\$NG!$7]>7GNYS/73@ML_KT!4X1/E)5K23
MT05Y?S6=T(MC.QW52$ 'BC>*+V5W5NX_DU(Q6>:&<)5[#\$_7M%L!CTW-G)#
M<[W04G43D2/S 86\7[JOK(6#[%V2#ZXB!<6:U!#IK8CJK*/B7+5](RD+!@/K
M]#4T.7IP27AL"?W9F-N4X(/K2:*>TSL3\Y#3_M/%!PA+7I?3#;&,DG7]G]<L
MTF!VI.9-KM!@OG=0;8)M[D1^V1UH<W[X>R"_"":S#;1Y^?+D/HHV$O5\:R7?
M'ED-O238ICI-878MNZ&:\8X,#4<'26\2(_#.]ONYF 8BB)^0YI93!Y;%=2U+
MCQ/V%8'PZ=$IJ1(]?"#\3C(ZOU%"QQ+1GU!(JV/,:) /3CA_'_I03*HOY7A?
M^+6#A%YD3E$"0HX9$K5('I:,U)ODF":D#K(_1GV7X*.:VS7LWD2J=]>A9Y^,
M",$XZ@LNH>ADXFA@!Z0@(!"01&*=;\G9F*?'Z%W'(6RA$# M:[TM/2JGDY+;
M!8;0:KX@<OV(*>Z,A 8\, 2D*7$LMDX)(4=*N@=7J>0R?NSR'L.HH^8?,X2I
M^,BZJSD2\=M.=MV-AI^4/;HIL6>D*Y14P^6!>.'7TYQ(&I]532Z.)KU6WG6R
M^6TA:M!K<)HK>.&5D/ JKJS!<R_7"Q!B9.[2M5G./U=^]QA6@VG&@J?8![%Z
M>&7$M2AY.N^EU)QE$[)NNB_LQ ^,1E)\<00^H&N6VX= $,31/T?$W<RBXVO>
M"#H2\/>PW(OLG[QMI' $S1_0+.-+-0/3#55L(B' ?AUK=OL_[U-V+8MECN^$
MGV@4@&21B]]VY0/JU9@V6TBULPB\HE9#YB+$PA%H;N.'L 384742,ED^CEY
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M\6@'C*2WR($+TO)M)VQ0,Q"_SR0Z6RR@UT0GRKS;N+[-;,M4@ SH_^*W6'3
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MRAB:RH)N]1SB1>>YJG9W=_B-9W-CD>[IW;1YAP!]3-K%\C(Z7_CY.5;GP@.
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M;]2D]=1L17A1TE.2<SW-U.@\QTUIOMZHC;4NK6D4AG*@KBN7WIRHOF>&T]5
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M)B]B7^S[PPB'Q'VS?8B_?MT7)O)UMO_-1+W$.N<MR)!&9Z29;J&V0=YRS;7
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MM4]A$G@';]:OM@+>WL9C/Q]7 '/>K$TW=5;5R^) %R/*@S17.6GX>!:IZ#6
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M!C1*R4H365#!@S\ Z<:ON8Q2;%.DW)?AB"\E3%,O77Y@XG 1-(](0^'8E=<
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M8Q0-BT6RT=1WKA3I/8S*/OD@8T\02=Z)'AT]E]^6:$61$>FFNM-R20'T WB
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M:]@4;W?0LP9_9E(6WN<X[8)>N,>F 5BKG<[YWH9=7K72 ^C^.\)F&P5+>:.
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M7V1E9BYX;6Q02P$"% ,4    " "4BHM7@[$TK%X2  "/&P$ '0
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M,S,R7V%C,# T+FIP9U!+ 0(4 Q0    ( )2*BU?K\=G7"DL  -%/   3
M          "  5N-! !J,C,R-3$S,S)?8F$P,#<N:G!G4$L! A0#%     @
ME(J+5Q3#.Z5V;0  9W8  !,              ( !EM@$ &HR,S(U,3,S,E]B
M83 P."YJ<&=02P$"% ,4    " "4BHM7#NMG/J]M   N>P  $P
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M97)T+FAT;5!+ 0(4 Q0    ( )2*BU>"S/9$T@@  .M+   9
M  "  5,K!@!T;3(S,C4Q,S-D,5]E>#DY+6-E<G0N:'1M4$L! A0#%     @
ME(J+5W5:L2PO!@  XA\  !X              ( !7#0& '1M,C,R-3$S,V0Q
M7V5X.3DM:6YD<'5B86-C+FAT;5!+ 0(4 Q0    ( )2*BU=8 ^#6FP@  *<E
M   ?              "  <<Z!@!T;3(S,C4Q,S-D,5]E>#DY+6EN9'!U8F%C
M8W0N:'1M4$L! A0#%     @ E(J+5Y1B\5&()P  688" !P
M ( !GT,& '1M,C,R-3$S,V0Q7V5X.3DM<V5C,3EX82YH=&U02P$"% ,4
M" "4BHM7#;R]J)0' @"E%Q< %               @ %A:P8 =&TR,S(U,3,S
A9#%?;F-S<BYH=&U02P4&     !, $P G!0  )W,(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
